broad_name	smiles	status	target	moa	diseaseArea	indication
(R)-(-)-apomorphine	CN1CCc2cccc-3c2[C@H]1Cc1ccc(O)c(O)c-31	Launched	ADRA2A|ADRA2B|ADRA2C|CALY|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
(R)-(-)-rolipram	COc1ccc(cc1OC1CCCC1)[C@@H]1CNC(=O)C1	Phase 1	PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	phosphodiesterase inhibitor		
(R)-baclofen	NC[C@H](CC(O)=O)c1ccc(Cl)cc1	Phase 3	GABBR1|GABBR2	benzodiazepine receptor agonist		
(S)-(+)-rolipram	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1	Phase 1	PDE4B|PDE4D	phosphodiesterase inhibitor		
[sar9,met(o2)11]-substance-p	CC(C)C[C@H](NC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O	Preclinical	TACR1	tachykinin antagonist		
A-1070722	COc1ccc2c(NC(=O)Nc3cccc(n3)C(F)(F)F)ccnc2c1	Preclinical	GSK3A|GSK3B	glycogen synthase kinase inhibitor		
A-1120	OC(=O)c1ccccc1NC(=O)N1CCC(CC1)c1ccccc1C(F)(F)F	Preclinical	RBP4	retinoid receptor ligand		
A-317491	OC(=O)c1cc(C(O)=O)c(cc1C(O)=O)C(=O)N(Cc1cccc(Oc2ccccc2)c1)[C@H]1CCCc2ccccc12	Preclinical	P2RX3	purinergic receptor antagonist		
A-33903	CC(=O)N[C@@H]1N=C(c2ccccc2)c2ccccc2NC1=O |&1:4	Phase 2				
A-366	COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1 |t:19|	Preclinical	EHMT1|EHMT2	histone lysine methyltransferase inhibitor		
A-381393	Cc1ccc(cc1C)N1CCN(Cc2nc3ccccc3[nH]2)CC1	Preclinical		dopamine receptor antagonist		
A-412997	Cc1cccc(NC(=O)CN2CCC(CC2)c2ccccn2)c1	Preclinical	DRD4	dopamine receptor agonist		
A-438079	Clc1cccc(-c2nnnn2Cc2cccnc2)c1Cl	Preclinical	P2RX7	purinergic receptor antagonist		
A-485	CNC(=O)Nc1ccc2c(CC[C@@]22OC(=O)N(CC(=O)N(Cc3ccc(F)cc3)[C@@H](C)C(F)(F)F)C2=O)c1	Preclinical		histone acetyltransferase inhibitor		
A-582941	CN1C[C@H]2CN(C[C@H]2C1)c1ccc(nn1)-c1ccccc1	Preclinical	CHRNA7	nicotinic receptor agonist		
A-61603	CS(=O)(=O)Nc1c(O)ccc2[C@H](CCCc12)C1=NCCN1 |&1:11	Preclinical	ADRA1A|ADRA1B|ADRA1D	adrenergic receptor agonist		
A-674563	Cc1[nH]nc2ccc(cc12)-c1cncc(OC[C@@H](N)Cc2ccccc2)c1	Preclinical	AKT1|PKIA|PRKACA	AKT inhibitor		
A-7	NCCCCCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	Preclinical		calmodulin antagonist		
A-769662	Oc1ccccc1-c1ccc(cc1)-c1csc2[nH]c(=O)c(C#N)c(O)c12	Preclinical		AMPK activator		
A-784168	FC(F)(F)c1cccnc1N1CCC(=CC1)C(=O)Nc1ccc(cc1)S(=O)(=O)C(F)(F)F |c:14|	Preclinical	TRPV1	transient receptor potential channel antagonist		
A-803467	COc1cc(NC(=O)c2ccc(o2)-c2ccc(Cl)cc2)cc(OC)c1	Preclinical	SCN10A	sodium channel blocker		
A-804598	C[C@H](N\C(NC#N)=N/c1cccc2ncccc12)c1ccccc1	Preclinical	P2RX7	purinergic receptor antagonist		
A-839977	Clc1cccc(c1Cl)-n1nnnc1NCc1ccccc1Oc1ccccn1	Preclinical	P2RX7	purinergic receptor antagonist		
A-867744	CCC(=O)c1cc(-c2ccc(Cl)cc2)n(c1C)-c1ccc(cc1)S(N)(=O)=O	Preclinical	CHRNA3|CHRNA4|CHRNA7	acetylcholine receptor allosteric modulator		
A-887826	CCCCOc1ccc(cc1Cl)-c1cncc(c1)C(=O)NCc1cccnc1N1CCOCC1	Preclinical	SCN10A	sodium channel blocker		
A-922500	OC(=O)[C@@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	Preclinical	DGAT1	diacylglycerol O acyltransferase inhibitor		
A-939572	CNC(=O)c1cccc(NC(=O)N2CCC(CC2)Oc2ccccc2Cl)c1	Preclinical	SCD	stearoyl-CoA desaturase inhibitor		
A-967079	CC\C(=N/O)\C(\C)=C\c1ccc(F)cc1	Preclinical	TRPA1	transient receptor potential channel antagonist		
A-987306	Nc1nc(N2CCNCC2)c2CCC3=C([C@@H]4CCCC[C@@H]4O3)c2n1 |t:14|	Preclinical	ADORA1|AVPR1A|CCR1|CHRM1|CHRM2|CHRM3|CHRM4|DRD3|HTR1A|HTR1B|HTR2A|HTR2B|HTR3A|TACR2	histamine receptor antagonist		
AA-29504	CCOC(=O)Nc1ccc(NCc2c(C)cc(C)cc2C)cc1N	Preclinical	GABRA1|GABRA4|GABRB3	GABA receptor positive allosteric modulator		
AAI101	[H][C@@]12CC(=O)N1[C@@H](C(O)=O)[C@](C)(Cn1cc[n+](C)n1)S2(=O)=O	Phase 3		lactamase inhibitor		
AB-423	CC[C@@H](C)NS(=O)(=O)c1ccc(F)c(c1)C(=O)Nc1ccc(F)c(F)c1	Preclinical		HBV capsid assembly inhibitor		
abacavir	Nc1nc(NC2CC2)c2ncn([C@@H]3C[C@H](CO)C=C3)c2n1 |c:18|	Launched		nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
abafungin	Cc1ccc(Oc2ccccc2-c2csc(NC3=NCCCN3)n2)c(C)c1 |t:18|	Phase 3		sterol methyltransferase inhibitor		
abamectin	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C(C)C)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4	Launched	GABBR1|GABBR2	benzodiazepine receptor agonist	infectious disease	gastrointestinal parasites
abametapir	Cc1ccc(nc1)-c1ccc(C)cn1	Phase 3	MMP9	metalloproteinase inhibitor		
abarelix	CC(C)C[C@H](NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	Phase 3	GNRHR	gonadotropin releasing factor hormone receptor antagonist		
ABBV-744	CCNC(=O)c1cc2c(cn(C)c(O)c2n1)-c1cc(ccc1Oc1c(C)cc(F)cc1C)C(C)(C)O	Phase 1		bromodomain inhibitor		
ABC-294640	Clc1ccc(cc1)[C@]12C[C@H]3C[C@H](C[C@](C3)(C1)C(=O)NCc1ccncc1)C2 |&1:7	Phase 2	SPHK2	sphingosine kinase inhibitor		
abemaciclib	CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1	Launched	CDK4|CDK6	CDK inhibitor	oncology	breast cancer
abiraterone	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c1cccnc1 |c:21	Launched	CYP11B1|CYP17A1	androgen biosynthesis inhibitor	oncology	prostate cancer
abiraterone-acetate	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC=C4c4cccnc4)[C@@H]3CC=C2C1 |c:16	Launched	CYP17A1	androgen biosynthesis inhibitor	oncology	prostate cancer
ABT-072	COc1c(\C=C\c2ccc(NS(C)(=O)=O)cc2)cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O	Phase 2		RNA polymerase inhibitor		
ABT-202	N[C@H]1CCN(C1)c1cccnc1 |&1:1|	Phase 1		acetylcholine receptor agonist		
ABT-239	C[C@@H]1CCCN1CCc1cc2cc(ccc2o1)-c1ccc(cc1)C#N	Phase 1	HRH1|HRH2|HRH3	histamine receptor antagonist		
ABT-491	CN(C)C(=O)n1cc(C(=O)c2ccc(Cn3c(C)nc4cnccc34)c(F)c2)c2c(cccc12)C#C	Phase 1	PTAFR	platelet activating factor receptor antagonist		
ABT-639	Fc1ccccc1NS(=O)(=O)c1cc(C(=O)N2CCN3CCC[C@@H]3C2)c(Cl)cc1F	Phase 2	CACNA1G|CACNA1H|CACNA1I	calcium channel blocker		
ABT-702	Nc1ncnc2nc(cc(-c3cccc(Br)c3)c12)-c1ccc(nc1)N1CCOCC1	Preclinical	ADK	adenosine kinase inhibitor		
ABT-724	C(N1CCN(CC1)c1ccccn1)c1nc2ccccc2[nH]1	Phase 2	DRD4	dopamine receptor agonist		
ABT-737	CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(cc1[N+]([O-])=O)S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1	Phase 1/Phase 2	BCL2|BCL2L1|BCL2L2	BCL inhibitor		
ABT-751	COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1	Phase 2	TUBB	tubulin polymerization inhibitor		
ABX-1431	FC(F)(F)C(OC(=O)N1CCN(Cc2ccc(cc2N2CCCC2)C(F)(F)F)CC1)C(F)(F)F	Phase 2		monoacylglycerol lipase inhibitor		
ABX464	FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1	Phase 2		antiviral		
AC-186	Oc1ccc(cc1)C1(CCC(F)(F)CC1)c1ccccc1F	Preclinical	ESR2	estrogen receptor agonist		
AC-261066	CCCCOCCOc1nc(sc1C)-c1ccc(C(O)=O)c(F)c1	Preclinical	RARB	retinoid receptor agonist		
AC-264613	C\C(=N/NC(=O)[C@H]1[C@@H](CNC1=O)c1ccccc1)c1cccc(Br)c1	Preclinical	F2RL1	PAR agonist		
AC-55541	C\C(=N/NC(=O)[C@@H](NC(=O)c1ccccc1)c1n[nH]c(=O)c2ccccc12)c1cccc(Br)c1 |&1:6	Preclinical	PARP2	PARP inhibitor		
AC-55649	CCCCCCCCc1ccc(cc1)-c1ccc(cc1)C(O)=O	Preclinical	RARA|RARB	retinoid receptor agonist		
AC-710	CCN1C(C)(C)CC(CC1(C)C)Oc1ccc(nc1)C(=O)Nc1ccc(NC(=O)Nc2cc(on2)C(C)(C)C)cc1	Preclinical	CSF1R|FLT3|KIT|PDGFRA|PDGFRB	PDGFR tyrosine kinase receptor inhibitor		
AC-7954-(+/-)	CN(C)CC[C@]1(Cc2ccccc2C(=O)O1)c1ccc(Cl)cc1 |&1:5|	Preclinical	UTS2R	urotensin receptor agonist		
acadesine	NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1N	Phase 3		AMPK activator		
acalabrutinib	CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(cc2)C(=O)Nc2ccccn2)c2c(N)nccn12	Launched	BTK	Bruton's tyrosine kinase (BTK) inhibitor	hematologic malignancy	mantle cell lymphoma (MCL)
acalisib	C[C@H](Nc1ncnc2nc[nH]c12)c1nc2ccc(F)cc2c(=O)n1-c1ccccc1	Phase 1	PIK3CB|PIK3CD	PI3K inhibitor		
acamprosate	CC(=O)NCCCS(O)(=O)=O	Launched	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM5	glutamate receptor antagonist	neurology/psychiatry	abstinence from alcohol
acarbose	C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O |t:37|	Launched	AMY2A|MGAM	glucosidase inhibitor	endocrinology	diabetes mellitus
ACDPP	CN(C)c1nc(N)c(nc1Cl)C(=O)Nc1cccnc1	Preclinical	GRM5	glutamate receptor antagonist		
acebilustat	[H][C@]12CN(Cc3ccc(cc3)C(O)=O)[C@]([H])(CN1Cc1ccc(Oc3ccc(cc3)-c3ncco3)cc1)C2	Phase 2		leukotriene inhibitor		
acebutolol	CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O	Launched	ADRB1	adrenergic receptor antagonist	cardiology	hypertension, ventricular arrhythmias
acecainide	CCN(CC)CCNC(=O)c1ccc(NC(C)=O)cc1	Phase 3	SCN5A	polarization inhibitor		
aceclidine	CC(=O)O[C@H]1CN2CCC1CC2 |&1:4	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor agonist	ophthalmology	glaucoma
aceclofenac	OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Launched	PTGS2	prostanoid receptor antagonist	rheumatology	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, periarthritis, lumbago, ischiadynia
acedapsone	CC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(NC(C)=O)cc1	Launched			infectious disease	leprosy
acedoben	CC(=O)Nc1ccc(cc1)C(O)=O	Phase 2				
acefylline	Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O	Launched	ADORA1	adenosine receptor agonist	pulmonary	asthma
aceglutamide	CC(=O)N[C@@H](CCC(N)=O)C(O)=O	Launched			gastroenterology	peptic ulcer disease (PUD)
acelarin	C[C@H](N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1 |a:1	Phase 2/Phase 3		anticancer agent		
acemetacin	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OCC(O)=O)c2c1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology	osteoarthritis
aceneuramic-acid	CC(=O)N[C@@H]1[C@@H](O)C[C@](O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O	Phase 3	CES1|SELE|SELP			
acenocoumarol	CC(=O)C[C@@H](c1ccc(cc1)[N+]([O-])=O)c1c(O)c2ccccc2oc1=O |&1:4	Launched	VKORC1	vitamin K antagonist	hematology	deep vein thrombosis (DVT)
acepromazine	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(C)=O	Launched	ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A	dopamine receptor antagonist	neurology/psychiatry	sedative
acesulfame-potassium	CC1=CC(=O)NS(=O)(=O)O1 |t:1|	Phase 3				
acetanilide	CC(=O)Nc1ccccc1	Preclinical		hydrogen peroxide decomposition inhibitor		
acetarsol	CC(=O)Nc1cc(ccc1O)[As](O)(O)=O	Launched			gastroenterology	diarrhea
acetazolamide	CC(=O)Nc1nnc(s1)S(N)(=O)=O	Launched	AQP1|CA1|CA12|CA14|CA2|CA3|CA4|CA7	carbonic anhydrase inhibitor	ophthalmology	glaucoma
acetohexamide	CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	ABCC8|KCNJ1|KCNJ10|KCNJ11	ATP channel blocker	endocrinology	diabetes mellitus
acetohydroxamic-acid	CC(=O)NO	Launched	MMP12	urease inhibitor	infectious disease	urinary tract infections
acetophenazine	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(CCO)CC3)c2c1	Launched	DRD1|DRD2	dopamine receptor antagonist	neurology/psychiatry	psychosis
acetriazoic-acid	CC(=O)Nc1c(I)cc(I)c(C(O)=O)c1I	Preclinical				
acetyl-farnesyl-cysteine	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC[C@H](NC(C)=O)C(O)=O	Launched	PPARG	methyltransferase inhibitor	dermatology	acne vulgaris (AV)
acetyl-l-leucine	CC(C)C[C@H](NC(C)=O)C(O)=O	Launched			neurology/psychiatry	vertigo
acetyl-11-keto-beta-boswellic-acid	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |a:1	Phase 2	HSD11B1|HSD11B2	lipoxygenase inhibitor		
acetylcholine	CC(=O)OCC[N+](C)(C)C	Launched	ACHE|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2	acetylcholine receptor agonist	neurology/psychiatry, gastroenterology, pulmonary	drowsiness, fatigue, headache, indigestion, chest congestion
acetylcysteine	CC(=O)N[C@@H](CS)C(O)=O	Launched	ACY1|CHUK|GRIN1|GRIN2A|GRIN2B|GRIN2D|GRIN3A|GSS|IKBKB|RELA|SLC7A11	mucolytic agent	gastroenterology	acetaminophen overdose, hepatic injury
acetylsalicylsalicylic-acid	CC(=O)Oc1ccccc1C(=O)Oc1ccccc1C(O)=O	Preclinical		cyclooxygenase inhibitor		
acetylspiramycin	[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@@]3([H])CC[C@@H]([C@@H](C)O3)N(C)C)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:42	Preclinical		other antibiotic		
acexamic-acid	CC(=O)NCCCCCC(O)=O	Launched	GAST	5 alpha reductase inhibitor	dermatology	wound healing
acifran	C[C@]1(OC(=CC1=O)C(O)=O)c1ccccc1 |&1:1	Phase 3	HCAR2|HCAR3	cholesterol inhibitor		
acipimox	Cc1cnc(c[n+]1[O-])C(O)=O	Launched	HCAR2	cholesterol inhibitor	endocrinology	hyperlipidemia
acitazanolast	OC(=O)C(=O)Nc1cccc(c1)-c1nn[nH]n1	Launched		mediator release inhibitor	allergy	allergic rhinitis
acitretin	COc1cc(C)c(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)c(C)c1C	Launched	RARA|RARB|RARG|RBP1|RXRA|RXRB|RXRG|STAT3	retinoid receptor agonist	dermatology	psoriasis
acivicin	N[C@H]([C@@H]1CC(Cl)=NO1)C(O)=O |c:5|	Phase 2	CTPS1	gamma glutamyltransferase inhibitor		
aclarubicin	CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc2[C@H]1C(=O)OC	Launched	TOP1|TOP2A	topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
aclidinium	OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1cccs1)c1cccs1	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	pulmonary	bronchitis, emphysema, chronic obstructive pulmonary disease (COPD)
acolbifene	CC1=C([C@@H](Oc2cc(O)ccc12)c1ccc(OCCN2CCCCC2)cc1)c1ccc(O)cc1 |t:1|	Phase 3		estrogen receptor antagonist		
acoziborole	CC1(C)OB(O)c2cc(NC(=O)c3ccc(F)cc3C(F)(F)F)ccc12	Preclinical		antitrypanosomal		
ACPC	NC1(CC1)C(O)=O	Phase 1		glutamate receptor antagonist		
acriflavine	Nc1ccc2cc3ccc(N)cc3nc2c1.C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	Launched	HIF1A	hypoxia inducible factor inhibitor	infectious disease	fungal infection
acriflavinium	C[n+]1c2cc(N)ccc2cc2ccc(N)cc12	Launched	HIF1A	hypoxia inducible factor inhibitor	infectious disease	fungal infection
acrisorcin	CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12	Launched		other antifungal	infectious disease	fungal infection
acrivastine	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1cccc(\C=C\C(O)=O)n1	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis
acrylate	[Na].OC(=O)C=C	Phase 3		mucus protecting agent		
ACT-132577	NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Launched	EDNRA|EDNRB	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
ACT-462206	COc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1C(=O)Nc1cc(C)cc(C)c1	Phase 1	HCRTR1|HCRTR2	orexin receptor antagonist		
actarit	CC(=O)Nc1ccc(CC(O)=O)cc1	Launched		interleukin receptor agonist	rheumatology	rheumatoid arthritis
ACTB-1003	COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1	Phase 1	KDR|TEK	FGFR inhibitor, VEGFR inhibitor		
actinomycin-d	CC(C)[C@@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	Launched		RNA polymerase inhibitor	oncology	Wilm's tumor, Ewing's sarcoma, rhabdomyosarcoma, testicular carcinoma
actinoquinol	CCOc1ccc(c2cccnc12)S(O)(=O)=O	Preclinical				
acumapimod	Cc1ccc(cc1-n1ncc(C(=O)c2cccc(c2)C#N)c1N)C(=O)NC1CC1	Phase 1		p38 MAPK inhibitor		
ACY-1215	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1	Phase 1/Phase 2	HDAC1|HDAC2|HDAC3|HDAC6|HDAC8	HDAC inhibitor		
acyclovir	Nc1nc(=O)c2ncn(COCCO)c2[nH]1	Launched	PNP	DNA polymerase inhibitor	infectious disease	genitial herpes, shingles, chicken pox
AC1NDSS5	CCCCCCCCCCCCCCCCCC[S+](CCC)c1ccccc1C(=O)OCC	Phase 1				
AC260584	CCCCC1CCN(CCCN2C(=O)COc3cc(F)ccc23)CC1	Preclinical		cholinergic receptor agonist		
AD-5467	CC(C)[C@H]1Oc2c(cccc2N(CC(O)=O)C1=S)C(C)C |&1:3	Phase 2	AKR1B1	aldose reductase inhibitor		
adapalene	COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O	Launched	RARA|RARB|RARG|RXRA|RXRB|RXRG	retinoid receptor agonist	dermatology	acne vulgaris (AV)
adaprev	O[C@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O |a:3	Phase 3	AKR1B1|GPI|HK1|M6PR|PYGM	TGF beta receptor inhibitor		
adaptavir	C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](C)N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(N)=O	Phase 2	CCR5	CC chemokine receptor antagonist		
adarotene	OC(=O)\C=C\c1ccc(cc1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Phase 1	RARB|RARG	retinoid receptor agonist		
adatanserin	O=C(NCCN1CCN(CC1)c1ncccn1)C12CC3CC(CC(C3)C1)C2	Phase 2	HTR1A|HTR2A	serotonin receptor agonist, serotonin receptor antagonist		
adavivint	CC(C)CC(=O)Nc1cncc(c1)-c1ccc2[nH]nc(-c3nc4cncc(-c5cccc(F)c5)c4[nH]3)c2c1	Phase 1		WNT pathway inhibitor		
ADD-233089	Clc1ccc(cc1)-n1cc([nH]c1=O)N1CCOCC1	Phase 1		benzodiazepine receptor agonist		
adefovir	Nc1ncnc2n(CCOCP(O)(O)=O)cnc12	Launched		DNA polymerase inhibitor	infectious disease	hepatitis B
adefovir-dipivoxil	CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc12)OCOC(=O)C(C)(C)C	Launched		DNA polymerase inhibitor	infectious disease	hepatitis B
adelmidrol	OCCNC(=O)CCCCCCCC(=O)NCCO	Launched		anti-inflammatory agent	dermatology	dermatitis
ademetionine	C[S+](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Launched		methyltransferase stimulant, phosphodiesterase inhibitor	neurology/psychiatry	depression, attention-deficit/hyperactivity disorder (ADHD)
adenine	Nc1ncnc2nc[nH]c12	Preclinical	ACACB|ACP1|APRT|MTAP|PECR|SRPK2	protein synthesis stimulant		
adenosine	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Launched	ADORA1|ADORA2A|ADORA2B|ADORA3|PI4K2A|PI4K2B|TRPM4	adenosine receptor agonist	cardiology	Wolff-Parkinson-White Syndrome (WPW)
adenosine-phosphate	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O	Launched	ACSL1|ACSS1|ACSS2|ADCY1|ADK|CREB1|FBP1|HINT1|PDE4B|PDE4D|PIM1|PRKAA1|PRKAB1|PRKAB2|PYGL|TRPM4	adenosine receptor agonist		
adenosine-triphosphate	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O	Phase 2	ABCA1|ABCB1|ABCB11|ABCC2|ABCC8|ABCC9|ABCG1|ABL1|ABL2|ACSL1|ACSS1|ACSS2|ACVR1|ACVR1B|ACVRL1|ADCY1|ADRBK1|ADRBK2|AFG3L2|AKT1|ALK|AMHR2|APAF1|ARAF|ASNA1|ASNS|ASS1|CDK15|GPR17|ITPR1|NAE1|NT5C2|P2RY1|P2RY11|P2RY13|P2RY2|P2RY4|PRKAA1|RYR1|RYR2|RYR3|SLC25A4|TNK2|TRPM4|TRPM7	adenosine receptor agonist		
adiphenine	CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1	Launched	CHRNA1	acetylcholine receptor antagonist	neurology/psychiatry	spasms
adipic-acid	OC(=O)CCCCC(O)=O	Preclinical	SLC22A6	solute carrier family member inhibitor		
adiporon	O=C(COc1ccc(cc1)C(=O)c1ccccc1)NC1CCN(Cc2ccccc2)CC1	Preclinical	ADIPOR1|ADIPOR2	adiponectin receptor agonist		
ADL5859	CCN(CC)C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2cccc(O)c12 |t:14|	Phase 2	OPRD1	opioid receptor agonist		
adomeglivant	Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-c1ccc(cc1)C(C)(C)C	Preclinical		glucagon receptor antagonist		
adoprazine	Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1	Phase 2	DRD2|HTR1A	dopamine receptor antagonist, serotonin receptor agonist		
adrafinil	ONC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1 |r|	Launched		adrenergic receptor agonist	neurology/psychiatry	fatigue
adrenalone	CNCC(=O)c1ccc(O)c(O)c1	Launched	ADRA1A	adrenergic receptor agonist	hematology	hemorrhage
adrenosterone	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	Preclinical	HSD11B1|HSD11B2	11-beta hydroxysteroid dehydrogenase inhibitor		
ADX-10059	Cc1cc(C)c(N)c(n1)C#Cc1cccc(F)c1	Phase 2	GRM5	glutamate receptor negative allosteric modulator		
ADX-47273	Fc1ccc(cc1)C(=O)N1CCC[C@@H](C1)c1nc(no1)-c1ccc(F)cc1	Preclinical	GRM5	glutamate receptor modulator		
AEE788	CCN1CCN(Cc2ccc(cc2)-c2cc3c(N[C@H](C)c4ccccc4)ncnc3[nH]2)CC1	Phase 1/Phase 2	EGFR|ERBB2|ERBB4|FGFR2|FGFR3|KDR	EGFR inhibitor, VEGFR inhibitor		
AEG3482	NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1	Preclinical		HSP inducer		
afalanine	CC(=O)N[C@@H](Cc1ccccc1)C(O)=O	Phase 3	DRD2	dopamine receptor agonist		
afamelanotide	CCCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(N)=O	Launched		melanocyte-stimulating hormone mimetic		
afatinib	CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1	Launched	EGFR|ERBB2|ERBB4	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
afimoxifene	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	Phase 2	ESR1|ESR2|ESRRG|PLD1|PRKCD|PRKCE|PRKCQ|PRKCZ	estrogen receptor antagonist		
afloqualone	Cc1ccccc1-n1c(CF)nc2ccc(N)cc2c1=O	Launched		acetylcholine receptor antagonist	neurology/psychiatry	sedative
AFN-1252	CN(Cc1oc2ccccc2c1C)C(=O)\C=C\c1cnc2NC(=O)CCc2c1	Phase 2		FABI inhibitor		
afobazole	CCOc1ccc2nc(SCCN3CCOCC3)[nH]c2c1	Launched		anxiolytic	neurology/psychiatry	anxiety
AF38469	Cc1cccc(NC(=O)c2ccc(cc2C(O)=O)C(F)(F)F)n1	Preclinical	SORT1	sortilin inhibitor		
AG-1024	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O	Preclinical	IGF1R	insulin growth factor receptor inhibitor		
AG-14361	CN(C)Cc1ccc(cc1)-c1nc2cccc3C(=O)NCCn1c23	Preclinical	PARP1	PARP inhibitor		
AG-490	Oc1ccc(\C=C(/C#N)C(=O)NCc2ccccc2)cc1O	Preclinical	EGFR|JAK2|JAK3	EGFR inhibitor, JAK inhibitor		
AG-555	Oc1ccc(\C=C(/C#N)C(=O)NCCCc2ccccc2)cc1O	Preclinical	CDK2	tyrosine kinase inhibitor		
AG-556	Oc1ccc(\C=C(/C#N)C(=O)NCCCCc2ccccc2)cc1O	Preclinical		tyrosine kinase inhibitor		
AGI-5198	Cc1nccn1CC(=O)N([C@@H](C(=O)NC1CCCCC1)c1ccccc1C)c1cccc(F)c1 |&1:10	Preclinical	IDH1	isocitrate dehydrogenase inhibitor		
AGI-6780	FC(F)(F)c1cccc(NC(=O)Nc2cc(ccc2-c2ccsc2)S(=O)(=O)NC2CC2)c1	Preclinical	IDH2	isocitrate dehydrogenase inhibitor		
AGM-1470	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl |a:2	Phase 2	METAP2	cell cycle inhibitor		
agmatine	NCCCCNC(N)=N	Phase 3	ADRA2C|ASIC3|CACNA1B|CHRNA1|GRIN1|KCNJ1|NISCH	nitric oxide synthase inhibitor		
AGN-192403	CC(C)[C@@H]1[C@H]2CC[C@@H](C2)[C@H]1N |a:3	Preclinical	NISCH	imidazoline receptor ligand		
AGN-194310	CCc1ccc(cc1)C1=CC(C)(C)Sc2ccc(cc12)C#Cc1ccc(cc1)C(O)=O |t:9|	Phase 3	RXRA|RXRB|RXRG	retinoid receptor antagonist		
AGN-195183	CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc1cc(F)c(C(O)=O)c(F)c1	Phase 1/Phase 2	RARA	retinoid receptor agonist		
agomelatine	COc1ccc2cccc(CCNC(C)=O)c2c1	Launched	HTR2A|HTR2B|HTR2C|MTNR1A|MTNR1B	melatonin receptor agonist, serotonin receptor antagonist	neurology/psychiatry	depression
AGP-103	CCCCCCCCCCCCCCCCCCCCCC(O)=O	Launched		membrane permeability inhibitor		
AH-7614	Cc1ccc(cc1)S(=O)(=O)NC1c2ccccc2Oc2ccccc12	Preclinical	FFAR4	free fatty acid receptor antagonist		
AH11110	O[C@@H](COc1ccccc1-c1ccccc1)CC(=N)N1CCCCC1 |&1:1|	Preclinical	ADRA1B	adrenergic receptor ligand		
AH6809	CC(C)Oc1ccc2c(c1)oc1ccc(cc1c2=O)C(O)=O	Preclinical	PTGDR|PTGER1|PTGER2|PTGER3	prostanoid receptor antagonist		
AI-10-49	FC(F)(F)Oc1ccc2nc([nH]c2c1)-c1ccc(OCCOCCOc2ccc(nc2)-c2nc3ccc(OC(F)(F)F)cc3[nH]2)cn1	Preclinical	CBFB	core binding factor inhibitor		
AIM-100	C(Nc1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1)[C@@H]1CCCO1	Preclinical	TNK2	tyrosine kinase inhibitor		
ajmaline	[H][C@]12C[C@]34[C@H](O)[C@@]1([H])[C@]1([H])C[C@]([H])(N2[C@H](O)[C@@]1([H])CC)[C@]3([H])N(C)c1ccccc41	Launched		sodium channel blocker	cardiology	Wolff-Parkinson-White Syndrome (WPW)
AJ76-(+)	CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical	DRD2|DRD3|DRD4	dopamine receptor antagonist		
AK-7	Brc1cccc(NC(=O)c2cccc(c2)S(=O)(=O)N2CCCCCC2)c1	Preclinical	SIRT2	SIRT inhibitor		
AKBA	C[C@@H]1CC[C@]2(C)CC[C@]3(C)C(=CC(=O)[C@@H]4[C@@]5(C)CC[C@@H](OC(C)=O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@H]1C |c:10|	Phase 3	ALOX5	lipoxygenase inhibitor		
aklomide	NC(=O)c1ccc(cc1Cl)[N+]([O-])=O	Launched			infectious disease	coccidiosis
AL-8697	Cc1c(F)cc(cc1-c1c(F)cn2c(nnc2c1F)C(C)(C)C)C(=O)NC1CC1	Preclinical	MAPK14	p38 MAPK inhibitor		
alacepril	C[C@H](CSC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension
alafosfalin	C[C@H](N)C(=O)N[C@@H](C)P(O)(O)=O	Phase 1		bacterial cell wall synthesis inhibitor		
alagebrium	Cc1sc[n+](CC(=O)c2ccccc2)c1C	Phase 2/Phase 3		glycosylation inhibitor		
alanine	C[C@@H](N)C(O)=O |&1:1	Launched				
alanosine	N[C@@H](CN(O)[N+][O-])C(O)=O	Phase 2		antimetabolite		
alantolactone	C[C@H]1CCC[C@]2(C)C[C@H]3OC(=O)C(=C)[C@H]3C=C12 |t:16|	Preclinical	STAT3	apoptosis stimulant, STAT inhibitor		
alaproclate	C[C@@H](N)C(=O)OC(C)(C)Cc1ccc(Cl)cc1 |&1:1|	Phase 2	SLC6A4	serotonin receptor antagonist		
alarelin	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	Launched	GNRH1	gonadotropin releasing factor hormone receptor antagonist		
albendazole	CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1	Launched	TUBA1A|TUBB|TUBB4B	tubulin polymerization inhibitor	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis
albendazole-oxide	CCC[S@@](=O)c1ccc2nc(NC(=O)OC)[nH]c2c1 |r|	Launched		anthelmintic agent	infectious disease	cystic hydatid disease, parenchymal neurocysticercosis
albuterol	CC(C)(C)NC[C@@H](O)c1ccc(O)c(CO)c1 |&1:6|	Launched	ADRB2	adrenergic receptor agonist	pulmonary	asthma
alcaftadine	CN1CCC(CC1)=C1c2ncc(C=O)n2CCc2ccccc12	Launched	HRH1	histamine receptor antagonist	allergy	allergic conjunctivitis
alclofenac	OC(=O)Cc1ccc(OCC=C)c(Cl)c1	Launched	PTGS1	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis
alclometasone-dipropionate	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@H]2[C@H]3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |a:14	Launched	CYP3A4|NR3C1|SERPINA6	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
alcuronium	OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2[C@@H]5\C(=C/N([C@@H]31)c1ccccc41)[C@H]1C[C@H]3[C@@]5(CC[N@@+]3(CC=C)C\C1=C/CO)c1ccccc21 |a:5	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRNA7	muscle relaxant	neurology/psychiatry	muscle relaxant
alda-1	Clc1cccc(Cl)c1C(=O)NCc1ccc2OCOc2c1	Preclinical	ALDH2	aldehyde dehydrogenase activator		
aldoxorubicin	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(\CO)=N\NC(=O)CCCCCN1C(=O)C=CC1=O |c:55|	Phase 3	TOP2A	topoisomerase inhibitor		
alectinib	CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1	Launched	ALK|MET	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
alendronate	NCCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	ATP6V1A|FDPS|PTPN4|PTPRE|PTPRS	bone resorption inhibitor	orthopedics	osteoporosis
alexidine	CCCC[C@H](CC)CNC(=N)N=C(N)NCCCCCCNC(N)=NC(=N)NC[C@H](CC)CCCC |&1:29	Preclinical	PTPMT1	phosphatidylglycerophosphatase inhibitor		
alfacalcidol	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched	CYP27B1|VDR	vitamin D receptor agonist	endocrinology	vitamin D deficiency
alfadolone-acetate	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	Phase 2		benzodiazepine receptor agonist		
alfuzosin	COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)[C@H]1CCCO1 |&1:23|	Launched	ADRA1A|ADRA1B|ADRA1D|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
algestone-acetophenide	CC(=O)[C@@]12O[C@@](C)(O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]21C)c1ccccc1 |t:15|	Launched			endocrinology	contraceptive
alibendol	COc1cc(CC=C)cc(C(=O)NCCO)c1O	Launched		antispasmodic	gastroenterology	bile stimulation
alimemazine	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccccc12 |&3:1|	Launched	HRH1	histamine receptor agonist, histamine receptor antagonist	neurology/psychiatry, allergy, pulmonary	sedative, urticaria, itching, cough suppressant
alinidine	Clc1cccc(Cl)c1N(CC=C)C1=NCCN1 |t:13|	Phase 3		bradycardic effect 		
alisertib	COc1cc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2OC)ccc1C(O)=O |c:11|	Phase 3	AURKA	Aurora kinase inhibitor		
aliskiren-hemifumarate	COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)ccc1OC	Launched	REN	renin inhibitor	cardiology	hypertension
alisporivir	[H][C@]1(C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	Phase 3		cyclophilin inhibitor		
alizapride	COc1cc2[nH]nnc2cc1C(=O)NC[C@H]1CCCN1CC=C |&1:15	Launched		dopamine receptor antagonist	gastroenterology	nausea
alizarin	Oc1ccc2C(=O)c3ccccc3C(=O)c2c1O	Preclinical				
allantoin	NC(=O)N[C@H]1NC(=O)NC1=O |r|	Launched		cosmetic	dermatology	skin protectant
allicin	C=CCS[S@@](=O)CC=C |&1:4	Phase 2	TRPA1|TRPV1	cytokine production inhibitor		
allopurinol	O=c1nc[nH]c2n[nH]cc12	Launched	XDH	xanthine oxidase inhibitor	rheumatology, urology	gout, kidney stones
allopurinol-riboside	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ncc2c(O)ncnc12	Phase 2		anti-leishmanial agent, phosphorylase inhibitor		
allylestrenol	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)CC=C |t:8|	Launched	ESR1|PGR|SLC6A9	steroidal progestin	obstetrics/gynecology	premature labor
allylisothiocyanate	C=CCN=C=S	Preclinical	TRPA1	TRPV agonist		
allylthiourea	NC(=S)NCC=C	Preclinical		nitrification inhibitor		
almitrine	Fc1ccc(cc1)C(N1CCN(CC1)c1nc(NCC=C)nc(NCC=C)n1)c1ccc(F)cc1	Launched	ATP1A1	neurotransmitter agonist	pulmonary	chronic obstructive pulmonary disease (COPD)
almorexant	CNC(=O)[C@H](N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(cc1)C(F)(F)F)c1ccccc1	Phase 3	HCRTR1|HCRTR2	orexin receptor antagonist		
almotriptan	CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12	Launched	HTR1B|HTR1D	serotonin receptor agonist	neurology/psychiatry	migraine headache
aloe-emodin	OCc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Preclinical	CASP8	anticancer agent		
alogliptin	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
aloin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc12	Preclinical		angiogenesis inhibitor		
aloperine	C1CCN2C[C@H]3C[C@H](C=C4CCCN[C@@H]34)[C@H]2C1 |t:8|	Preclinical				
alosetron	Cc1nc[nH]c1CN1CCc2c(C1=O)c1ccccc1n2C	Withdrawn	HTR3A	serotonin receptor antagonist		
alovudine	Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O	Phase 2		DNA synthesis marker		
aloxistatin	CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C	Phase 3	CTSG	protease inhibitor		
alpelisib	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F	Launched	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor	oncology	breast cancer
alpha-asarone	COc1cc(OC)c(\C=C\C)cc1OC	Preclinical	HMGCR	cytochrome P450 inhibitor, HMGCR inhibitor		
alpha-D-glucopyranose	OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical				
alpha-glucosyl-hesperidin	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O)cc2O1	Preclinical		antioxidant		
alpha-linolenic-acid	CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O	Phase 3	ELOVL4|FADS1|FADS2|FFAR1|FFAR4|PTGS2|SLC8A1|TRPV1	omega 3 fatty acid stimulant		
alpha-methylhistamine-dihydrobromide-(R)-(-)	C[C@@H](N)Cc1cnc[nH]1	Preclinical	HRH3	histamine receptor agonist		
alpha-methylhistamine-dihydrobromide-(S)-(+)	C[C@H](N)Cc1cnc[nH]1	Preclinical	HRH3	histamine receptor agonist		
alpha-methylserotonin	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	Preclinical	HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR4	serotonin receptor agonist		
alpha-tochopherol	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 |&1:6	Launched		antioxidant	endocrinology	vitamin E deficiency
alpha-tochopheryl-acetate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@]1(C)CCc2c(C)c(OC(C)=O)c(C)c(C)c2O1 |&1:6	Launched		antioxidant	endocrinology	vitamin E deficiency
alpidem	CCCN(CCC)C(=O)Cc1c(nc2ccc(Cl)cn12)-c1ccc(Cl)cc1	Withdrawn	GABRA1	benzodiazepine receptor agonist		
alprenolol	CC(C)NC[C@@H](O)COc1ccccc1CC=C |&1:5	Launched	ADRB1|ADRB2	adrenergic receptor antagonist	cardiology	angina pectoris
alprostadil	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched	CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGER1|PTGER2|PTGER4|PTGIR	prostanoid receptor agonist	cardiology	congenital heart defects
alrestatin	OC(=O)CN1C(=O)c2cccc3cccc(C1=O)c23	Preclinical	AKR1B1	aldose reductase inhibitor		
ALS-8112	Nc1ccn([C@@H]2O[C@@](CO)(CCl)[C@@H](O)[C@H]2F)c(=O)n1	Phase 1				
ALS-8176	CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O	Phase 1		RNA polymerase inhibitor		
altanserin	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1	Phase 2	HTR2A	serotonin receptor antagonist		
althiazide	NS(=O)(=O)c1cc2c(N[C@@H](CSCC=C)NS2(=O)=O)cc1Cl |&1:9	Launched		diuretic	cardiology	hypertension
altinicline	CN1CCC[C@H]1c1cncc(c1)C#C	Phase 2	CHRNA4|CHRNB2	nicotinic receptor agonist		
altiratinib	Fc1ccc(NC(=O)C2(CC2)C(=O)Nc2cc(F)c(Oc3ccnc(NC(=O)C4CC4)c3)cc2F)cc1	Phase 1	KDR|MET|TEK	MET inhibitor, VEGFR inhibitor		
altrenogest	C[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC=C |c:2	Launched	PGR	progestogen hormone	endocrinology	estrus
altretamine	CN(C)c1nc(nc(n1)N(C)C)N(C)C	Launched		DNA synthesis inhibitor	oncology	ovarian cancer
alverine	CCN(CCCc1ccccc1)CCCc1ccccc1	Launched	HTR1A	muscle relaxant	gastroenterology	irritable bowel syndrome, diverticular disease
alvespimycin	CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7	Phase 2	HSP90AA1	HSP inhibitor		
alvimopan	C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(O)=O)CC[C@@]1(C)c1cccc(O)c1	Launched	OPRD1|OPRK1|OPRM1	opioid receptor antagonist	gastroenterology	postoperative ileus
alvocidib	CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2	CDK1|CDK2|CDK4|CDK5|CDK6|CDK7|CDK8|CDK9|EGFR|PYGM	CDK inhibitor		
ALX-40-4C	CC(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(N)=O	Preclinical		CC chemokine receptor antagonist		
ALX-5407	CN(CC[C@@H](Oc1ccc(cc1)-c1ccccc1)c1ccc(F)cc1)CC(O)=O	Phase 1	SLC6A9	glycine transporter inhibitor		
AM-1241	CN1CCCC[C@@H]1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12 |&1:6	Preclinical	CNR1|CNR2	cannabinoid receptor agonist		
AM-24	Oc1c(I)cc(I)cc1I	Phase 2	ALOX5	lipoxygenase inhibitor		
AM-251	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical	CNR1|GPR18|GPR55	cannabinoid receptor antagonist		
AM-281	Cc1c(nn(c1-c1ccc(I)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCOCC1	Preclinical	CNR1|CNR2|GPR55	cannabinoid receptor antagonist		
AM-404	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)Nc1ccc(O)cc1	Preclinical	CNR1|CNR2|FAAH|TRPV1	cyclooxygenase inhibitor, FAAH inhibitor, TRPV antagonist		
AM-580	CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O	Preclinical	RARA	retinoid receptor agonist		
AM-630	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2cc(I)ccc12	Preclinical	CNR1|CNR2	cannabinoid receptor antagonist		
AM-92016	CN(CCc1ccc(Cl)c(Cl)c1)C[C@@H](O)COc1ccc(NS(C)(=O)=O)cc1 |&1:13|	Preclinical	GRIN1	potassium channel blocker		
amantadine	NC12CC3CC(CC(C3)C1)C2	Launched	DRD2|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A	glutamate receptor antagonist	infectious disease, neurology/psychiatry	influenza A virus infection, Parkinson's Disease
ambazone	NC(=S)NNc1ccc(cc1)N=NC(N)=N	Phase 1		DNA damage inducer		
ambenonium	CC[N+](CC)(CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc1ccccc1Cl)Cc1ccccc1Cl	Launched	ACHE	cholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
ambrisentan	COC([C@H](Oc1nc(C)cc(C)n1)C(O)=O)(c1ccccc1)c1ccccc1	Launched	EDNRA|EDNRB	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
ambroxol	Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 |r|	Launched	CYP3A4	sodium channel blocker	pulmonary	bronchitis
amcasertib	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2\C(=O)Nc3ccc(cc23)-c2csc(n2)-c2ccccc2)c1C	Phase 2		kinase inhibitor		
amcinonide	CC(=O)OCC(=O)[C@@]12OC3(CCCC3)O[C@@H]1C[C@H]1[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |a:7	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
AMD-3465	C(NCc1ccccn1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	Preclinical	CXCR4	CC chemokine receptor antagonist		
amdinocillin	CC1(C)S[C@@H]2[C@H](\N=C\N3CCCCCC3)C(=O)N2[C@H]1C(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections, gram-negative bacterial infections
AMD11070	NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc12	Phase 3	CCR5|CXCR4	CC chemokine receptor antagonist		
ameltolide	Cc1cccc(C)c1NC(=O)c1ccc(N)cc1	Preclinical		anticonvulsant		
amenamevir	Cc1cccc(C)c1N(CC(=O)Nc1ccc(cc1)-c1ncon1)C(=O)C1CCS(=O)(=O)CC1	Phase 1		helicase primase inhibitor		
ametantrone	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3ccccc3C(=O)c12	Preclinical		anticancer agent		
amezinium	COc1cc(N)cn[n+]1-c1ccccc1	Launched	ADRB2	adrenergic receptor agonist	cardiology	hypotension
amfenac	Nc1c(CC(O)=O)cccc1C(=O)c1ccccc1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
amflutizole	Nc1c(snc1-c1cccc(c1)C(F)(F)F)C(O)=O	Phase 2	XDH	xanthine oxidase inhibitor		
AMG-PERK-44	Cc1ccc2cc(ccc2n1)-c1c(C)ccc(C(=O)c2c(-c3ccccc3)n(C)n(-c3ccccc3)c2=O)c1N	Preclinical	EIF2AK4	PERK inhibitor		
AMG-176	CO[C@H]1\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3OC[C@]4(CCCc5cc(Cl)ccc45)CN(C[C@@H]4CC[C@@H]14)c3c2 |t:3|	Phase 1		MCL1 inhibitor		
AMG-208	COc1ccc2c(OCc3nnc4ccc(nn34)-c3ccccc3)ccnc2c1	Phase 1	MET	tyrosine kinase inhibitor		
AMG-232	CC(C)[C@@H](CS(=O)(=O)C(C)C)N1[C@@H]([C@H](C[C@](C)(CC(O)=O)C1=O)c1cccc(Cl)c1)c1ccc(Cl)cc1	Phase 2	MDM2	MDM inhibitor		
AMG-319	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1	Phase 2	PIK3CD	PI3K inhibitor		
AMG-337	COCCOc1cnc2ccn([C@H](C)c3nnc4c(F)cc(cn34)-c3cnn(C)c3)c(=O)c2c1	Phase 2	MET	MET inhibitor		
AMG-487	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1	Phase 2		CC chemokine receptor antagonist		
AMG-487-(+/-)	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(OC(F)(F)F)cc1 |&1:20	Phase 2	CXCR3	CC chemokine receptor antagonist		
AMG-510	CC(C)c1nccc(C)c1-n1c2nc(c(F)cc2c(nc1=O)N1CCN(C[C@@H]1C)C(=O)C=C)-c1c(O)cccc1F	Phase 1/Phase 2		K-Ras inhibitor		
AMG-517	CC(=O)Nc1nc2c(Oc3cc(ncn3)-c3ccc(cc3)C(F)(F)F)cccc2s1	Phase 1	TRPV1	TRPV antagonist		
AMG-548	Cn1c(NC[C@@H](N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O	Phase 1	MAPK11|MAPK12|MAPK13|MAPK14	MAP kinase inhibitor		
AMG-837	CC#C[C@@H](CC(O)=O)c1ccc(OCc2cccc(c2)-c2ccc(cc2)C(F)(F)F)cc1	Phase 1	FFAR1	free fatty acid receptor agonist		
AMG-925	C[C@H]1CC[C@@H](CC1)n1c2cnccc2c2cnc(Nc3ccc4CN(CCc4n3)C(=O)CO)nc12 |r|	Phase 1	CDK4|CDK6|FLT3	CDK inhibitor, FLT3 inhibitor		
AMG-9810	CC(C)(C)c1ccc(\C=C\C(=O)Nc2ccc3OCCOc3c2)cc1	Preclinical	TRPV1	TRPV antagonist		
AMG319	C[C@@H](Nc1ncnc2nc[nH]c12)c1cc2ccc(F)cc2nc1-c1ccccn1 |&1:1	Phase 2	PIK3CD	PI3K inhibitor		
AMG458	COc1ccc2c(Oc3ccc(NC(=O)c4c(C)n(CC(C)(C)O)n(-c5ccccc5)c4=O)nc3)ccnc2c1	Preclinical	MET	MET inhibitor		
AMG900	Cc1csc(c1)-c1nnc(Nc2ccc(Oc3ncccc3-c3ccnc(N)n3)cc2)c2ccccc12	Phase 1	AURKA|AURKB|AURKC	Aurora kinase inhibitor		
AMI-1	Oc1cc(cc2cc(NC(=O)Nc3ccc4c(O)cc(cc4c3)S(O)(=O)=O)ccc12)S(O)(=O)=O	Preclinical	PRMT1	protein arginine N-methyltransferase inhibitor		
amibegron	CCOC(=O)COc1ccc2CC[C@@H](Cc2c1)NC[C@H](O)c1cccc(Cl)c1	Phase 3	ADRB3	adrenergic receptor agonist		
amidopyrine	CN(C)c1c(C)n(C)n(-c2ccccc2)c1=O	Launched		analgesic agent	dermatology	dermatitis herpetiformis (DH)
amifampridine	Nc1ccncc1N	Launched		potassium channel blocker	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)
amiflamine	C[C@@H](N)Cc1ccc(cc1C)N(C)C |&1:1	Phase 1	MAOA|SLC6A2	monoamine oxidase inhibitor		
amifostine	NCCCNCCSP(O)(O)=O	Launched	ALPPL2|ENPP1	reducing agent	nephrology	renal toxicity
amikacin	NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections
amiloride	NC(=N)NC(=O)c1nc(Cl)c(N)nc1N	Launched	AOC1|ASIC1|ASIC2|ASIC3|PKD2|PKD2L1|PLAU|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC9A1|TRPC7|TRPV2	sodium channel blocker	cardiology	hypertension, congestive heart failure
amineptine	OC(=O)CCCCCCNC1c2ccccc2CCc2ccccc12	Withdrawn	SLC6A2|SLC6A4	dopamine receptor agonist		
aminocaproic-acid	NCCCCCC(O)=O	Launched	LPA|PLAT|PLG	plasminogen activator inhibitor	hematology	fibrinolytic bleeding
aminoglutethimide	CC[C@]1(CCC(=O)NC1=O)c1ccc(N)cc1 |&1:2	Launched	CYP11A1|CYP19A1	glucocorticoid receptor antagonist	endocrinology, oncology	Cushing's syndrome, breast cancer
aminoguanidine	NN=C(N)N	Phase 3	AKR1B1|NOS2|TIMP3	nitric oxide synthase inhibitor		
aminohydroxybutyric-acid	NC[C@@H](O)CC(O)=O |&1:2	Launched			neurology/psychiatry	epilepsy
aminolevulinic-acid-benzyl-ester	NCC(=O)CCC(=O)OCc1ccccc1	Phase 1				
aminomethyltransferase	C[C@H]1CCN=C(N)S1 |&1:1	Preclinical	NOS2	nitric oxide synthase inhibitor		
aminopentamide	CC(CC(C(N)=O)(c1ccccc1)c1ccccc1)N(C)C	Launched	CHRM1	acetylcholine receptor antagonist	gastroenterology	acute abdominal visceral spasm, hypertrophic gastritis (GHG), nausea
aminophylline	Cn1c2nc[nH]c2c(=O)n(C)c1=O	Launched	ADORA1|ADORA2A|ADORA2B|ADORA3|HDAC2|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	adenosine receptor antagonist	pulmonary	asthma, bronchitis, emphysema
aminopterin	Nc1nc(N)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1	Phase 3	DHFR|SLC46A1	dihydrofolate reductase inhibitor		
aminopurvalanol-a	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical	CDK1|CDK2|CDK5	CDK inhibitor, tyrosine kinase inhibitor		
aminosalicylate	Nc1ccc(C(O)=O)c(O)c1	Launched	ALOX5|CHUK|PLA2G2E|PTGS1|PTGS2	cyclooxygenase inhibitor	gastroenterology	inflammatory bowel disease, ulcerative colitis
aminothiadiazole	Nc1nncs1	Phase 2	ADORA3|IMPDH1	inosine monophosphate dehydrogenase inhibitor		
aminothiazole	Nc1nccs1	Preclinical	NOS2	cyclin D inhibitor		
amiodarone	CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1	Launched	ADRB1|CACNA1H|CACNA2D2|KCNA7|KCNH2	potassium channel blocker	cardiology	ventricular arrhythmias
amiprilose	CN(C)CCCO[C@H]1[C@H](O[C@@H]2OC(C)(C)O[C@H]12)[C@H](O)CO	Phase 3		CD antagonist		
amiselimod	CCCCCCCOc1ccc(CCC(N)(CO)CO)cc1C(F)(F)F	Phase 2		sphingosine 1-phosphate receptor modulator		
amisulpride	CCN1CCC[C@@H]1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC |&1:6	Launched	DRD2	dopamine receptor antagonist	neurology/psychiatry	psychosis, bipolar disorder, schizophrenia
amitifadine	Clc1ccc(cc1Cl)[C@@]12C[C@@H]1CNC2 |&1:8	Phase 3	SLC6A2|SLC6A3|SLC6A4	serotonin transporter (SERT) inhibitor		
amitraz	CN(\C=N\c1ccc(C)cc1C)\C=N\c1ccc(C)cc1C	Launched	ADRA1A|ADRA2A	adrenergic receptor agonist	infectious disease	generalized demodicosis
amitriptyline	CN(C)CCC=C1c2ccccc2CCc2ccccc12	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2C|HTR6|HTR7|KCNA1|KCND2|KCND3|KCNQ2|KCNQ3|NTRK1|NTRK2|OPRD1|OPRK1|OPRM1|SIGMAR1|SLC6A2|SLC6A4	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
amlexanox	CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O	Launched	FGF1|IL3|PDE4A|PDE4B|PDE4C|PDE4D|S100A12|S100A13	histamine receptor modulator	dental, pulmonary, ophthalmology, allergy	aphthous ulcers, asthma, conjunctivitis, allergic rhinitis
amlodipine	CCOC(=O)C1=C(COCCN)NC(C)=C([C@H]1c1ccccc1Cl)C(=O)OC |&1:16	Launched	CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNA2D1	calcium channel blocker	cardiology	hypertension, chronic stable angina, vasospastic angina, coronary artery disease (CAD)
ammonium-glycyrrhizinate	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C(O)=O)C(O)=O |t:18|	Launched	HSD11B1|HSD11B2|SLCO1B1|SLCO1B3	thrombin inhibitor	dermatology	cosmetic
ammonium-lactate	N.C[C@@H](O)C(O)=O |&1:2	Launched	HCAR1		dermatology	xerosis cutis, ichthyosis vulgaris
ammonium-perfluorocaprylate	OC(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	Phase 1	PIM1	Pim kinase inhibitor		
AMN-082	C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1	Preclinical	GRM7	glutamate receptor modulator		
amodiaquine	CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O	Launched	HNMT	histamine receptor agonist	infectious disease	malaria
amonafide	CN(C)CCN1C(=O)c2cccc3cc(N)cc(C1=O)c23	Phase 3	TOP2A|TOP2B	topoisomerase inhibitor		
amorolfine	CCC(C)(C)c1ccc(C[C@@H](C)CN2C[C@H](C)O[C@H](C)C2)cc1 |a:15	Launched		membrane integrity inhibitor	infectious disease	onychomycosis
amoxapine	Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1 |t:13|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH4|HTR1A|HTR1B|HTR2A|HTR2B|HTR2C|HTR3A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4	norepinephrine reputake inhibitor	neurology/psychiatry	depression
amoxicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(O)=O	Launched	CYP2C19|SLC15A1|SLC15A2|SLC22A6	penicillin binding protein inhibitor	infectious disease, gastroenterology	skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections
AMPA-(RS)	Cc1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:8|	Preclinical	GRIN1	glutamate receptor agonist		
AMPA-(S)	Cc1o[nH]c(=O)c1C[C@H](N)C(O)=O	Preclinical	GRIA2|GRIN1	glutamate receptor agonist		
ampalex	O=C(N1CCCCC1)c1ccc2nccnc2c1	Phase 2	GRIA1|GRIA2|GRIA3|GRIA4	glutamate receptor agonist		
amperozide	CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Launched	FAAH|HTR2A	dopamine receptor antagonist	neurology/psychiatry	psychosis
amphotericin-b	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46	Launched		membrane permeability enhancer	infectious disease	fungal infection
ampicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	respiratory tract infections, meningitis, bacterial septicemia, endocarditis, urinary tract infections, gastrointestinal infections
ampiroxicam	CCOC(=O)O[C@@H](C)OC1=C(N(C)S(=O)(=O)c2ccccc12)C(=O)Nc1ccccn1 |&1:6	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
amprenavir	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Launched		HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
amprolium	CCCc1ncc(C[n+]2ccccc2C)c(N)n1	Launched		thiamine uptake blocker	infectious disease	coccidiosis
ampyrone	Cc1c(N)c(=O)n(-c2ccccc2)n1C	Preclinical		cyclooxygenase inhibitor		
amrinone	Nc1cc(c[nH]c1=O)-c1ccncc1	Launched	PDE3A|PDE3B|PDE4B|TNF	phosphodiesterase inhibitor	cardiology	congestive heart failure
amrubicin	CC(=O)[C@@]1(N)C[C@H](O[C@H]2C[C@H](O)[C@H](O)CO2)c2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c2C1	Launched	TOP2A|TOP2B	topoisomerase inhibitor	oncology	small cell lung cancer
amsacrine	COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12	Launched	KCNH2|TOP2A	topoisomerase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
amthamine	Cc1nc(N)sc1CCN	Preclinical	HRH2	histamine receptor agonist		
amtolmetin-guacil	COc1ccccc1OC(=O)CNC(=O)Cc1ccc(C(=O)c2ccc(C)cc2)n1C	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis, osteoarthritis
amuvatinib	S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12	Phase 2	KIT|MET	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor		
amygdalin	OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@@H](C#N)c3ccccc3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	CASP3	caspase activator		
amyl-nitrite	CCCCCO[NH2+][O-]	Preclinical		atrial natriuretic peptide receptor agonist		
amyleine	CC[C@@](C)(CN(C)C)OC(=O)c1ccccc1 |&1:2|	Preclinical		local anesthetic		
amylene-hydrate	CCC(C)(C)O	Preclinical		local anesthetic		
AMZ30	[O-][N+](=O)c1cccc(c1)S(=O)(=O)n1cccc1\C=C(/C#N)S(=O)(=O)c1ccc(F)cc1	Preclinical		protein phosphatase inhibitor		
AM095	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(CC(O)=O)cc1)c1ccccc1	Preclinical		lysophosphatidic acid receptor antagonist		
AM211	CCN(Cc1cc(ccc1-c1cc(CC(O)=O)ccc1OC)C(F)(F)F)C(=O)NCc1ccccc1	Preclinical		prostaglandin inhibitor		
AM679	COc1cnc(nc1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OC[C@@H]4Cc5ccccc5N4C(C)=O)ccc23)cc1	Preclinical	ALOX5AP|CNR1|CNR2	cannabinoid receptor agonist, lipoxygenase inhibitor		
ANA-12	O=C(Nc1ccccc1C(=O)N[C@H]1CCCCNC1=O)c1cc2ccccc2s1 |&1:12	Preclinical	NTRK2	tropomyosin receptor kinase inhibitor		
anabasine	C1CC[C@@H](NC1)c1cccnc1 |&1:3	Preclinical		acetylcholine receptor agonist		
anacetrapib	COc1cc(F)c(cc1-c1ccc(cc1CN1[C@@H](C)[C@H](OC1=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C	Phase 3	CETP	cholesteryl ester transfer protein inhibitor		
anagliptin	Cc1cc2ncc(cn2n1)C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
anagrelide	Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl |t:5|	Launched	PDE3A	phosphodiesterase inhibitor	hematology, hematologic malignancy	thrombocythemia, myeloproliferative neoplasms
anamorelin	CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N	Phase 3	GHSR	growth hormone secretagogue receptor agonist		
anandamide	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO	Phase 2	CACNA1G|CACNA1H|CACNA1I|CNR1|CNR2|GLRA1|GPR18|GPR55|KCNA2|KCNK3|KCNK9|TRPM8|TRPV1	cannabinoid receptor agonist		
anastrozole	CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N	Launched	CYP19A1	aromatase inhibitor	oncology	breast cancer
andarine	CC(=O)Nc1ccc(OC[C@](C)(O)C(=O)Nc2ccc(c(c2)C(F)(F)F)[N+]([O-])=O)cc1	Phase 1	AR	androgen receptor modulator		
andrographolide	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](C\C=C3/[C@H](O)COC3=O)C(=C)CC[C@H]12	Phase 2	IL1B|IL6|NFKB1|NFKB2|TNF	tumor necrosis factor production inhibitor		
androstenone	C[C@@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]34C)[C@@H]1CC=C2 |&1:1	Preclinical		steroid		
androsterone	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical		androgen receptor agonist		
anecortave-acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@]12C |c:25	Launched		angiogenesis inhibitor	ophthalmology	macular degeneration
anethole	COc1ccc(\C=C\C)cc1	Launched		glutathione transferase stimulant		
anethole-trithione	COc1ccc(cc1)-c1cc(=S)ss1	Launched		glutathione transferase stimulant	dental	xerostomia
anguidine	CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1 |c:9|	Phase 2	SLC5A1	protein synthesis inhibitor		
anidulafungin	CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O |r|	Launched		fungal 1,3-beta-D-glucan synthase inhibitor	infectious disease	candidemia, fungal infection, esophageal candidiasis
aniracetam	COc1ccc(cc1)C(=O)N1CCCC1=O	Launched	DRD2|GRIA1|GRIA2|GRIA3|GRIA4|HTR2A	glutamate receptor agonist		
anisindione	COc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Launched	GGCX	vitamin K antagonist	hematology	deep vein thrombosis (DVT)
anisodamine	CN1[C@H]2C[C@H](O)[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c1ccccc1 |a:4	Phase 3	ADRA1A	lipid peroxidase inhibitor		
anisomycin	COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1	Preclinical	NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1	DNA synthesis inhibitor		
anisotropine	CCCC(CCC)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C	Launched		acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
anlotinib	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1	Launched	KDR|PDGFRB	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
anpirtoline	Clc1cccc(SC2CCNCC2)n1	Phase 1	HTR1B	serotonin receptor agonist		
ANR-94	CCOc1nc2c(N)ncnc2n1CC	Preclinical	ADORA2A	adenosine receptor antagonist		
ansamitocin-p-3	[H][C@@]12O[C@@]1(C)[C@H](CC(=O)N(C)c1cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@]([H])(OC(=O)N3)[C@H]2C)cc(OC)c1Cl)OC(=O)C(C)C |t:17	Preclinical		apoptosis stimulant		
antagonist-g	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	Phase 1	MAPK8	neuropeptide receptor antagonist		
antalarmin	CCCCN(CC)c1nc(C)nc2n(c(C)c(C)c12)-c1c(C)cc(C)cc1C	Preclinical	CRHR1	corticotropin releasing factor receptor antagonist		
antazoline	C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1 |t:17|	Launched	HRH1	antihistamine	ophthalmology, otolaryngology	conjunctivitis, nasal congestion
anthralin	Oc1cccc2Cc3cccc(O)c3C(=O)c12	Launched		DNA synthesis inhibitor	dermatology	psoriasis
anthraquinone	O=C1c2ccccc2C(=O)c2ccccc12	Preclinical	CDC25B	CDC inhibitor		
antimony-potassium	[H][C@]12O[SbH]3(OC1=O)OC(=O)[C@]([H])(O3)[C@@]1([H])O[SbH]3(OC(=O)[C@]2([H])O3)OC1=O |r|	Phase 2				
antimonyl	O=C1O[SbH]23OC1C1O[SbH]4(OC(C(O2)C(=O)O3)C(=O)O4)OC1=O	Phase 1				
antimycin-A	CCCCCC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@@H](NC(=O)c2cccc(NC=O)c2O)[C@@H](C)OC1=O	Preclinical	CYCS	ATP synthase inhibitor		
antioxine	CC(C)c1ccc(C)c(O)c1	Launched				
AN2718	OB1OCc2cc(Cl)ccc12	Phase 1		leucyl-tRNA synthetase inhibitor		
AP-18	C\C(=C/c1ccc(Cl)cc1)\C(\C)=N\O	Preclinical	TRPA1	transient receptor potential channel antagonist		
apabetalone	COc1cc(OC)c2c(c1)[nH]c(nc2=O)-c1cc(C)c(OCCO)c(C)c1	Phase 3	BRD3	apolipoprotein expression enhancer		
apafant	Cc1nnc2CN=C(c3cc(CCC(=O)N4CCOCC4)sc3-n12)c1ccccc1Cl |c:6|	Phase 3	PTAFR	platelet activating factor receptor antagonist		
apalutamide	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F	Launched		androgen receptor antagonist	oncology	prostate cancer
apararenone	CC1(C)Oc2cc(NS(C)(=O)=O)ccc2N(C1=O)c1ccc(F)cc1	Preclinical		mineralocorticoid receptor antagonist		
apatinib	O=C(Nc1ccc(cc1)C1(CCCC1)C#N)c1cccnc1NCc1ccncc1	Phase 3	CSK|KDR|KIT|RET	RET tyrosine kinase inhibitor		
APC-100	Cc1c(C)c2OC(C)(C)CCc2c(C)c1O	Phase 1/Phase 2	AR	androgen receptor antagonist, anti-inflammatory agent		
APcK-110	COc1cc(OC)cc(c1)-c1ccc2c([nH]nc2n1)-c1ccc(F)cc1	Preclinical	KIT|STAT3	KIT inhibitor		
APD597	COc1c(Nc2ccc(nc2C)S(C)(=O)=O)ncnc1OC1CCN(CC1)C(=O)OC(C)C	Phase 1	GPR119	glucose dependent insulinotropic receptor agonist		
APD668	CC(C)OC(=O)N1CCC(CC1)Oc1ncnc2n(ncc12)-c1ccc(cc1F)S(C)(=O)=O	Phase 1	GPR119	glucose dependent insulinotropic receptor agonist		
aphidicolin	C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@H]1C[C@@H]3C[C@]21CC[C@]3(O)CO	Phase 1		RNA synthesis inhibitor		
API-001	Cc1cc(OCCN2CCOCC2)nn1-c1ccc2ccccc2c1	Phase 2	SIGMAR1	sigma receptor antagonist		
API-1	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c2c1=O	Preclinical	AKT1|AKT2|AKT3	AKT inhibitor		
apigenin	Oc1ccc(cc1)-c1cc(=O)c2c(O)cc(O)cc2o1	Preclinical	AKR1B1|AR|CDK6|CFTR|CYP19A1|CYP1B1|HSD17B1	casein kinase inhibitor, cell proliferation inhibitor		
apixaban	COc1ccc(cc1)-n1nc(C(N)=O)c2CCN(C(=O)c12)c1ccc(cc1)N1CCCCC1=O	Launched	F10	coagulation factor inhibitor	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, pulmonary embolism (PE), atrial fibrillation (AF), deep vein thrombosis (DVT)
apocynin	COc1cc(ccc1O)C(C)=O	Phase 1	NOX4	NADPH oxidase inhibitor		
apoptosis-activator-II	Clc1ccc(CN2C(=O)C(=O)c3ccccc23)cc1Cl	Preclinical	BCHE|CES1	carboxylesterase inhibitor		
APR-246	COC[C@@]1(CO)N2CCC(CC2)C1=O |&1:3	Phase 3	TP53	p53 activator		
apraclonidine	Nc1cc(Cl)c(NC2=NCCN2)c(Cl)c1 |t:7|	Launched	ADRA1A|ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	ophthalmology	glaucoma, intraocular pressure
apramycin	CN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections
apratastat	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(OCC#CCO)cc1	Phase 2	ADAM17|MMP1|MMP13|MMP9	matrix metalloprotease inhibitor, tumor necrosis factor production inhibitor		
apremilast	CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1C(=O)c2cccc(NC(C)=O)c2C1=O	Launched	PDE4A|PDE4B|PDE4C|PDE4D	phosphodiesterase inhibitor	dermatology, rheumatology	psoriasis, psoriatic arthritis
aprepitant	C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Launched	TACR1	tachykinin antagonist	gastroenterology	nausea, vomiting
apricitabine	Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1	Phase 3		nucleoside reverse transcriptase inhibitor		
aprindine	CCN(CC)CCCN(C1Cc2ccccc2C1)c1ccccc1	Launched	CALM1|SCN5A	voltage-gated sodium channel blocker	cardiology	cardiac arrythmia
apronal	CC(C)[C@H](CC=C)C(=O)NC(N)=O |&1:3	Preclinical		cytochrome P450 modulator		
aptiganel	CCc1cccc(c1)N(C)C(=N)Nc1cccc2ccccc12	Phase 3	GRIN1	glutamate receptor antagonist		
APTO-253	Cc1[nH]c2ccc(F)cc2c1-c1nc2c([nH]1)c1cccnc1c1ncccc21	Phase 1	KLF4	krÃ¼ppel-like factor expression enhancer		
APY-29	C1CC1c1cc(Nc2ccnc(Nc3ccc4nc[nH]c4c3)n2)[nH]n1	Preclinical	ERN1	serine/threonine kinase inhibitor		
apyramide	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)Oc3ccc(NC(C)=O)cc3)c2c1	Preclinical		cyclooxygenase inhibitor		
APY0201	Cc1cccc(\C=N\Nc2cc(N3CCOCC3)n3nc(cc3n2)-c2ccncc2)c1	Preclinical	IL12A|IL12B|PIKFYVE	phosphoinositide dependent kinase inhibitor		
AP1903	CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc(c2)[C@@H](CCc2ccc(OC)c(OC)c2)OC(=O)[C@@H]2CCCCN2C(=O)[C@@H](CC)c2cc(OC)c(OC)c(OC)c2)c1)c1cc(OC)c(OC)c(OC)c1	Phase 1/Phase 2	MTOR			
AP26113	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N(C)C	Phase 2	ALK|EGFR	ALK tyrosine kinase receptor inhibitor		
AQ-RA741	CCN(CC)CCCCC1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	Preclinical	CHRM2	acetylcholine receptor antagonist		
AQ-13	CCN(CC)CCCNc1ccnc2cc(Cl)ccc12	Phase 2		antimalarial agent		
AQW-051	Cc1ccc(cc1)-c1ccc(O[C@H]2CN3CCC2CC3)cn1	Preclinical		nicotinic receptor agonist		
AR-A014418	COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1	Preclinical	GSK3B	glycogen synthase kinase inhibitor		
AR-C155858	CC(C)Cn1c2sc(Cc3c(C)n[nH]c3C)c(C(=O)N3C[C@H](O)CO3)c2c(=O)n(C)c1=O	Preclinical	SLC16A1|SLC16A7	monocarboxylate transporter inhibitor		
AR-12	NCC(=O)Nc1ccc(cc1)-n1nc(cc1-c1ccc2c(ccc3ccccc23)c1)C(F)(F)F	Phase 1	PDPK1	phosphoinositide dependent kinase inhibitor		
AR-42	CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1	Phase 1	HDAC1	HDAC inhibitor		
arachidonic-acid	CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Phase 1	CLCN2|KCNJ4|KCNK10|KCNK18|KCNK2|PRKCZ|PTGS1|TRPC6|TRPM2	cytochrome P450 inhibitor		
aramchol	CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@@]2(C)[C@H](C[C@@H](O)[C@H]3[C@@H]4CC[C@H]([C@H](C)CCC(O)=O)[C@@]4(C)[C@@H](O)C[C@H]23)C1	Phase 2/Phase 3		stearoyl-CoA desaturase inhibitor		
arbidol	CCOC(=O)c1c(CSc2ccccc2)n(C)c2cc(Br)c(O)c(CN(C)C)c12	Launched	CYP3A4	cytochrome P450 inhibitor	infectious disease	influenza A virus infection
arbutin	OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2/Phase 3	TYR	melanin inhibitor		
ARC-239	COc1ccccc1N1CCN(CCN2C(=O)c3ccccc3C(C)(C)C2=O)CC1	Preclinical	ADRA2A|ADRA2B|ADRA2C	adrenergic receptor antagonist		
arctigenin	COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc2ccc(O)c(OC)c2)cc1OC	Preclinical	CHUK|MAP2K1	MEK inhibitor		
arcyriaflavin-a	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3ccccc3c21	Preclinical	CCND1|CDK4	CDK inhibitor		
ardeparin	CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O	Withdrawn	SERPIND1	thrombin inhibitor		
arecaidine-but-2-ynyl-ester	CC#CCOC(=O)C1=CCCN(C)C1 |t:7|	Preclinical	CHRM2	acetylcholine receptor agonist		
arecaidine-propargyl-ester	CN1CCC=C(C1)C(=O)OCC#C |c:4|	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor agonist		
arecoline	COC(=O)C1=CCCN(C)C1 |t:4|	Phase 1	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor agonist		
argatroban	C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2C[C@@H](C)CNc12 |a:1	Launched	F2	thrombin inhibitor	hematology	heparin-induced thrombocytopenia (HIT)
argireline	CSCC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O	Phase 3		neurotransmitter release inhibitor		
arglabin	CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13 |t:1|	Launched	FNTA|NFKB1	farnesyltransferase inhibitor		
aripiprazole	Clc1cccc(N2CCN(CCCCOc3ccc4CCC(=O)Nc4c3)CC2)c1Cl	Launched	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7	serotonin receptor agonist, serotonin receptor antagonist	neurology/psychiatry	depression, schizophrenia, bipolar disorder
aripiprazole-lauroxil	CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(CC3)c3cccc(Cl)c3Cl)cc12	Launched		serotonin receptor agonist	neurology/psychiatry	schizophrenia
arofylline	CCCn1c(=O)n(-c2ccc(Cl)cc2)c2nc[nH]c2c1=O	Phase 3	PDE4A	phosphodiesterase inhibitor		
arotinolol	CC(C)(C)NC[C@@H](O)CSc1nc(cs1)-c1ccc(s1)C(N)=O |&1:6	Launched	ADRB3	adrenergic receptor antagonist	cardiology, neurology/psychiatry	hypertension, tremors
ARQ-092	Nc1ncccc1-c1nc2ccc(nc2n1-c1ccc(cc1)C1(N)CCC1)-c1ccccc1	Phase 1	AKT2	AKT inhibitor		
ARQ-621	NCCCN([C@H](CC#C)c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)C(=O)c1cccc(Cl)c1F	Phase 1	KIF11	kinesin-like spindle protein inhibitor		
ARRY-334543	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 |c:34|	Phase 2/Phase 3	ERBB2	EGFR inhibitor		
arsanilic-acid	Nc1ccc(cc1)[As](O)(O)=O	Phase 1	LYZ			
arsenic-trioxide	O=[As]O[As]=O	Launched	AKT1|CCND1|IKBKB|JUN|MAPK1|MAPK3|TXNRD1	apoptosis stimulant	gastroenterology	diarrhea
artemether	CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	Launched	ATP1A1	antimalarial agent	infectious disease	malaria
artemisinin	C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched	CYP2B6	DNA synthesis inhibitor	infectious disease	malaria
artemotil	CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@@]24OO3	Launched			infectious disease	malaria
artesunate	C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(O)=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched		DNA synthesis inhibitor	infectious disease	malaria
articaine	CCCN[C@@H](C)C(=O)Nc1c(C)csc1C(=O)OC |&1:4|	Launched		local anesthetic	neurology/psychiatry	local anesthetic
arundic-acid	CCCCCC[C@@H](CCC)C(O)=O	Phase 2/Phase 3	PTGS2|S100B	astrocyte modulating agent		
ARV-825	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(OCCOCCOCCOCCNc3cccc4C(=O)N([C@H]5CCC(=O)NC5=O)C(=O)c34)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |a:9	Preclinical	BRD4	bromodomain inhibitor		
AS-1269574	Cc1cc(NCCO)nc(n1)-c1ccc(Br)cc1	Preclinical	GPR119	glucose dependent insulinotropic receptor agonist		
AS-1892802	OC[C@@H](NC(=O)Nc1ccc(cc1)-c1ccncc1)c1ccccc1	Preclinical	ROCK1	rho associated kinase inhibitor		
AS-1949490	C[C@H](NC(=O)c1sccc1OCc1ccc(Cl)cc1)c1ccccc1	Preclinical	INPP5D	SHIP2 phosphatase inhibitor		
AS-2034178	OC(=O)CCc1ccc(NCc2cccc3N(CCOc4ccccc4)CCCc23)cc1F	Preclinical	FFAR1	free fatty acid receptor agonist		
AS-2444697	Cc1cc(ccn1)-c1nc(co1)C(=O)Nc1cn(nc1C(N)=O)C1CCOCC1	Preclinical	IRAK4	interleukin inhibitor		
AS-252424	Oc1cc(F)ccc1-c1ccc(\C=C2/SC(=O)NC2=O)o1	Preclinical	PIK3CG	PI3K inhibitor		
AS-604850	FC1(F)Oc2ccc(\C=C3/SC(=O)NC3=O)cc2O1	Preclinical	PIK3CA|PIK3CG	PI3K inhibitor		
AS-703026	OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F	Phase 2	MAP2K1|MAP2K2	MEK inhibitor		
AS-77	O=c1ccc2c(OCCCCOc3ccccc3)c3ccoc3cc2o1	Phase 1	KCNA3|KCNA5|KCNN4	potassium channel blocker		
ASA-404	Cc1ccc2c(oc3c(CC(O)=O)cccc3c2=O)c1C	Phase 3		angiogenesis inhibitor		
asapiprant	CC(C)Oc1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(-c2ncco2)c(OCC(O)=O)c1	Preclinical		prostaglandin inhibitor		
asaraldehyde	COc1cc(OC)c(C=O)cc1OC	Preclinical	PTGS2	cyclooxygenase inhibitor		
ASC-J9	COc1ccc(\C=C\C(O)=CC(=O)\C=C\c2ccc(OC)c(OC)c2)cc1OC	Phase 2	AR	androgen receptor enhancer		
asciminib	O[C@@H]1CCN(C1)c1ncc(cc1-c1cc[nH]n1)C(=O)Nc1ccc(OC(F)(F)Cl)cc1	Phase 2		Bcr-Abl kinase inhibitor		
ascomycin	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@@H](O)[C@@H](C1)OC |c:3|	Preclinical	FKBP1A	calcineurin inhibitor		
ascorbic-acid	OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:2	Launched	SLC23A1|SLC23A2	antioxidant	endocrinology	scurvy
asenapine	[H][C@]12CN(C)C[C@]1([H])c1cc(Cl)ccc1Oc1ccccc21 |&1:1	Launched	DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia, bipolar disorder
asiatic-acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	Preclinical	PYGM	apoptosis stimulant		
asimadoline	CN([C@H](CN1CC[C@H](O)C1)c1ccccc1)C(=O)C(c1ccccc1)c1ccccc1	Phase 3	OPRK1	opioid receptor agonist		
asivatrep	CCCc1nc(ccc1\C=C\C(=O)N[C@H](C)c1cc(F)c(NS(C)(=O)=O)c(F)c1)C(F)(F)F	Phase 3		transient receptor potential channel antagonist		
ASP-2535	CC(C)c1nnc(-c2ccc(nc2)-c2ccccc2)n1-c1cccc2nonc12	Phase 1	SLC6A9	glycine transporter inhibitor		
ASP-6537	COc1nc(-c2ccc(OC)cc2)n(n1)-c1ccc(OC)cc1	Preclinical		cyclooxygenase inhibitor		
ASP-9521	COc1ccc2[nH]c(cc2c1)C(=O)N1CCC(CC(C)(C)O)CC1	Preclinical		aldo-keto reductase inhibitor		
aspartame	COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](N)CC(O)=O	Launched	TAS1R2|TRPV1			
aspirin	CC(=O)Oc1ccccc1C(O)=O	Launched	AKR1C1|ASIC3|EDNRA|HSPA5|IKBKB|NFKB1|NFKB2|NFKBIA|PRKAA1|PRKAA2|PRKAB1|PRKAB2|PRKAG1|PRKAG2|PRKAG3|PTGS1|PTGS2|RPS6KA3|TP53	cyclooxygenase inhibitor	neurology/psychiatry, endocrinology, dental	headache, fever, toothache, muscle pain
ASP3026	COc1cc(ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Phase 1	ALK	ALK tyrosine kinase receptor inhibitor		
AST-1306	Fc1cccc(COc2ccc(Nc3ncnc4ccc(NC(=O)C=C)cc34)cc2Cl)c1	Phase 1	EGFR|ERBB2	EGFR inhibitor		
astaxanthin	C\C(\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C(=O)[C@@H](O)CC1(C)C |c:9	Launched		antioxidant		
astemizole	COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1	Withdrawn	HRH1|KCNH1|KCNH2	histamine receptor antagonist		
astilbin	C[C@@H]1O[C@@H](O[C@@H]2[C@H](Oc3cc(O)cc(O)c3C2=O)c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Preclinical		nuclear factor erythroid derived, like (NRF2) activator		
astragaloside-a	CC(C)(O)[C@H]1CC[C@](C)(O1)[C@H]1[C@@H](O)C[C@@]2(C)[C@@H]3C[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O)C4(C)C	Preclinical		anti-inflammatory agent		
ASTX660	C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1	Phase 1/Phase 2		apoptosis inhibitor		
asunaprevir	COc1cnc(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)c2cc(Cl)ccc12	Phase 3		HCV inhibitor		
asymmetrical-dimethylarginine	CN(C)C(=N)NCCC[C@H](N)C(O)=O	Phase 1	NOS2|NOS3	nitric oxide synthase inhibitor		
AT-1015	O=CN1CCC(CC1)C(=O)NCCN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:29|	Preclinical	HTR2A	serotonin receptor antagonist		
AT-406	CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C	Phase 1		IAP antagonist 		
AT-7519	Clc1cccc(Cl)c1C(=O)Nc1cn[nH]c1C(=O)NC1CCNCC1	Phase 2	CDK1|CDK2|CDK4|CDK5|CDK6|CDK9	CDK inhibitor		
AT-9283	O=C(NC1CC1)Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1	Phase 2	AURKA|AURKB|JAK2|JAK3|RPS6KA6|STK17A	Aurora kinase inhibitor, JAK inhibitor		
ataluren	OC(=O)c1cccc(c1)-c1noc(n1)-c1ccccc1F	Launched	DMD	CFTR channel agonist, dystrophin stimulant	genetics, pulmonary	duchenne muscular dystrophy (DMD), cystic fibrosis
atazanavir	COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(cc1)-c1ccccn1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C	Launched		HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ATB-346	COc1ccc2cc(ccc2c1)[C@@H](C)C(=O)Oc1ccc(cc1)C(N)=S |&1:12	Phase 2	PTGER2	cyclooxygenase inhibitor		
atenolol-(+)	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1	Preclinical		adrenergic receptor antagonist		
atenolol-(+/-)	CC(C)NC[C@@H](O)COc1ccc(CC(N)=O)cc1 |&1:5	Launched	ADRB1|ADRB2|LTF|PLA2G2E	adrenergic receptor antagonist	cardiology	hypertension, angina pectoris
atenolol-(-)	CC(C)NC[C@H](O)COc1ccc(CC(N)=O)cc1	Launched		adrenergic receptor antagonist	cardiology	hypertension
atglistatin	CN(C)C(=O)Nc1cccc(c1)-c1ccc(cc1)N(C)C	Preclinical		adipose triglyceride lipase inhibitor		
aticaprant	Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(Oc2ccc(cc2F)C(N)=O)cc1	Phase 2		opioid receptor antagonist		
atipamezole	CCC1(Cc2ccccc2C1)c1cnc[nH]1	Launched		adrenergic receptor antagonist	neurology/psychiatry	reverse sedative
atiprimod	CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1	Phase 2	JAK2|STAT3	JAK inhibitor, STAT inhibitor		
atizoram	COc1ccc(cc1O[C@H]1C[C@@H]2CC[C@H]1C2)C1CNC(=O)NC1	Phase 2	PDE4A|PDE4B|PDE4C|PDE4D	phosphodiesterase inhibitor		
ATN-161	CC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(N)=O	Phase 2	ITGA5|ITGAV|ITGB1|ITGB3	integrin antagonist		
atomoxetine	CNCC[C@@H](Oc1ccccc1C)c1ccccc1	Launched	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|SLC6A2|SLC6A3|SLC6A4	norepinephrine transporter inhibitor	neurology/psychiatry	attention-deficit/hyperactivity disorder (ADHD)
atorvastatin	CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1	Launched	AHR|DPP4|HMGCR	HMGCR inhibitor	neurology/psychiatry, cardiology	stroke, heart attack
atosiban	CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@@H](C)CC)[C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)cc1 |a:8	Launched	AVPR1A|AVPR1B|AVPR2|OXTR	oxytocin receptor antagonist	neurology/psychiatry, cardiology, endocrinology	stroke, angina pectoris, myocardial infarction, hyperlipidemia
atovaquone	Clc1ccc(cc1)[C@H]1CC[C@@H](CC1)[C@H]1C(=O)C(=O)c2ccccc2C1=O |a:7	Launched		mitochondrial electron transport inhibitor	infectious disease	pneumonia
ATPA	CC(C)(C)c1o[nH]c(=O)c1C[C@@H](N)C(O)=O |&1:11	Preclinical	GRIK1	glutamate receptor agonist		
atractylenolide-i	[H][C@@]12CC3=C(C)C(=O)OC3=C[C@@]1(C)CCCC2=C |c:3	Preclinical		JAK inhibitor		
atracurium	COc1ccc(C[C@H]2c3cc(OC)c(OC)cc3CC[N@@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@@H]2Cc2ccc(OC)c(OC)c2)cc1OC |&1:7	Launched		acetylcholine receptor antagonist	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant
atrasentan	CCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(OC)cc1)C(O)=O)c1ccc2OCOc2c1	Phase 3	EDNRA	endothelin receptor antagonist		
atropine	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:2	Launched	CHRM1|CHRM2|CHRM3	acetylcholine receptor antagonist	ophthalmology	cycloplegia, mydriasis, amblyopia
atropine-oxide	C[N@@+]1([O-])[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1 |&1:3	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist		
atuveciclib	COc1cc(F)ccc1-c1ncnc(Nc2cccc(C[S@](C)(=N)=O)c2)n1	Phase 1		CDK9 inhibitor		
AT13148	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(cc1)-c1cn[nH]c1	Phase 1	AKT1|AKT2|AKT3|ROCK1|ROCK2|SGK3	protein kinase inhibitor		
AT13387	CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O	Phase 2	HSP90AA1	HSP inhibitor		
AT7867	Clc1ccc(cc1)C1(CCNCC1)c1ccc(cc1)-c1cn[nH]c1	Preclinical	AKT2|GSK3B|PKIA|PRKACA	AKT inhibitor		
auranofin	CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O	Launched	IKBKB|PRDX5|TRPA1	NFkB pathway inhibitor	rheumatology	rheumatoid arthritis
aurora-a-inhibitor-i	CCN1CCN(CC1)C(=O)Cc1ccc(Nc2ncc(F)c(Nc3ccc(cc3)C(=O)Nc3ccccc3Cl)n2)cc1	Preclinical	AURKA	Aurora kinase inhibitor		
aurothioglucose	OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O	Launched	PRKCI	PKC inhibitor	rheumatology	rheumatoid arthritis
AUT-1	CC[C@H]1NC(=O)N(C1=O)c1ccc(Oc2ccc(C)c(OC)c2)nc1	Preclinical		potassium channel activator		
autotaxin-modulator-1	C[C@@H](N1[C@H]2CC[C@@H]1C[C@@H](C2)C(O)=O)c1ccc2ccc(O[C@H]3CC[C@H](CC3)C(F)(F)F)c(c2c1)C(F)(F)F |a:1	Preclinical	ENPP2	autotaxin inhibitor		
AV-412	CN1CCN(CC1)C(C)(C)C#Cc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)C=C	Phase 1	EGFR|ERBB2	protein tyrosine kinase inhibitor		
AV-608	FC(F)(F)c1cc(cc(c1)C(F)(F)F)C(=O)N1CC[C@@H](C[C@H]1Cc1ccc(Cl)cc1)NC(=O)c1ccnc2ccccc12	Phase 2	TACR1	tachykinin antagonist		
avacopan	Cc1ccc(NC(=O)[C@H]2CCCN([C@H]2c2ccc(NC3CCCC3)cc2)C(=O)c2c(C)cccc2F)cc1C(F)(F)F	Phase 2		complement inhibitor		
avadomide	Cc1nc2cccc(N)c2c(=O)n1[C@H]1CCC(=O)NC1=O |&1:13	Phase 2		antitumor agent		
avagacestat	NC(=O)[C@@H](CCC(F)(F)F)N(Cc1ccc(cc1F)-c1ncon1)S(=O)(=O)c1ccc(Cl)cc1	Phase 2	PSEN1	gamma secretase inhibitor		
avanafil	COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl	Launched	PDE5A	phosphodiesterase inhibitor	urology	erectile dysfunction
avapritinib	Cn1cc(cn1)-c1cc2c(ncnn2c1)N1CCN(CC1)c1ncc(cn1)[C@@](C)(N)c1ccc(F)cc1	Launched		KIT inhibitor		
avasimibe	CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C	Phase 3	CES1	ACAT inhibitor		
avatrombopag	OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1	Launched	MPL	thrombopoietin receptor agonist	hematology	thrombocytopenia
AVE-0991	CCNC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2c(C=O)c(OC)nc2-c2ccccc2)cc1	Preclinical	MRGPRX1	angiotensin receptor agonist		
AVE-3085	FC1(F)Oc2ccc(cc2O1)C(=O)NC1Cc2ccccc2C1	Preclinical		nitric oxide synthase stimulant		
AVex-73	CN(C)C[C@H]1CCOC1(c1ccccc1)c1ccccc1 |&1:4	Preclinical		sigma receptor agonist		
avibactam	NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	Launched		beta lactamase inhibitor	infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis
avitinib	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3cc[nH]c3n2)cc1F	Phase 2		EGFR inhibitor		
AVL-292	COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1	Phase 2	BTK|YES1	Bruton's tyrosine kinase (BTK) inhibitor		
AVN-492	CNc1nn2c(C)c(N(C)C)c(C)nc2c1S(=O)(=O)c1ccccc1	Preclinical		serotonin receptor antagonist		
AVN-944	CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1	Phase 2	IMPDH1|IMPDH2	inosine monophosphate dehydrogenase inhibitor		
avobenzone	COc1ccc(cc1)C(=O)C=C(O)c1ccc(cc1)C(C)(C)C	Launched		topical sunscreen agent	dermatology	cosmetic, sunscreen lotion
avoralstat	COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(N)=N)-c1ccc(nc1C(O)=O)C(=O)NCC1CC1	Phase 3		kallikrein inhibitor		
avridine	CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)CCCN(CCO)CCO	Preclinical		immunostimulant		
AX-024	COc1ccc2OCC(CN3CCCC3)=C(c3ccc(F)cc3)c2c1 |t:15|	Preclinical		cytokine production inhibitor		
axitinib	CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1	Launched	CSF1|FLT1|FLT4|KDR|PLK4	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
AY-9944	Clc1ccccc1CNC[C@H]1CC[C@H](CNCc2ccccc2Cl)CC1 |r|	Preclinical		hedgehog pathway modulator		
AZ-10417808	[O-][N+](=O)c1cc(C(=O)NCC=C)c2[nH]c(Nc3ccc(Cl)c(Cl)c3)nc(=O)c2c1	Preclinical	CASP3	caspase inhibitor		
AZ-10606120	OCCNCCNc1ccc2c(NC(=O)CC34CC5CC(CC(C5)C3)C4)cccc2n1	Preclinical	P2RX7	purinergic receptor antagonist		
AZ-12080282	Cc1ccc(cc1NC(=O)c1ccc(OCc2ccccn2)cc1)-c1ncc[nH]1	Preclinical	DHH	hedgehog pathway inhibitor		
AZ-628	Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1	Preclinical	BRAF|RAF1	RAF inhibitor		
AZ-7371	COc1ncnc(Cn2cc(C(=O)NCCO)c3ncc(C)cc23)c1C	Preclinical		antibacterial 		
azacitidine	Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	Launched	DNMT1|DNMT3A	DNA methyltransferase inhibitor	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)
azacyclonol	OC(C1CCNCC1)(c1ccccc1)c1ccccc1	Preclinical	HRH1	histamine receptor antagonist		
azaguanine-8	Nc1nc2nn[nH]c2c(=O)[nH]1	Preclinical	PNP	purine antagonist		
azalomycin-B	CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@H]1OC(=O)\C=C\C=C\[C@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1 |t:32	Preclinical		bacterial 50S ribosomal subunit inhibitor		
azaperone	Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1	Launched	DRD2|DRD3	dopamine receptor antagonist	neurology/psychiatry	sedative
azapropazone	CCC[C@H]1C(=O)N2N(C1=O)c1cc(C)ccc1N=C2N(C)C |r	Withdrawn	PTGS2	cyclooxygenase inhibitor		
azaserine	N[C@@H](COC(=O)C[N+]#N)C(O)=O	Preclinical		purine antagonist		
azasetron	CN1C(=O)COc2c1cc(Cl)cc2C(=O)N[C@H]1CN2CCC1CC2 |&1:16|	Launched	HTR3A|HTR3B	serotonin receptor antagonist	infectious disease	genitial herpes
azatadine	CN1CCC(CC1)=C1c2ccccc2CCc2cccnc12	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis
azathioprine	Cn1cnc(c1Sc1ncnc2nc[nH]c12)[N+]([O-])=O	Launched	HPRT1|IMPDH1|PPAT	dehydrogenase inhibitor	transplant, rheumatology	renal homotransplantation, rheumatoid arthritis
AZD0156	CN(C)CCCOc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCOCC4)c3c2c1	Phase 1		ATM kinase inhibitor		
AZD1080	O=C1Nc2ccc(cc2C1c1ccc(CN2CCOCC2)cn1)C#N	Phase 1	GSK3A|GSK3B	glycogen synthase kinase inhibitor		
AZD1208	N[C@@H]1CCCN(C1)c1c(\C=C2/SC(=O)NC2=O)cccc1-c1ccccc1	Phase 1	PIM1|PIM2|PIM3	Pim kinase inhibitor		
AZD1283	CCOC(=O)c1cc(C#N)c(nc1C)N1CCC(CC1)C(=O)NS(=O)(=O)Cc1ccccc1	Preclinical	P2RY12	purinergic receptor antagonist		
AZD1390	CC(C)n1c2c(cnc3cc(F)c(cc23)-c2ccc(OCCCN3CCCCC3)nc2)n(C)c1=O	Phase 1		ATM kinase inhibitor		
AZD1446	Clc1ccc(o1)C(=O)N1C[C@H]2CNC[C@@H]2C1 |&1:10	Phase 2	CHRNA4|CHRNB2	acetylcholine receptor agonist		
AZD1480	C[C@H](Nc1ncc(Cl)c(Nc2cc(C)n[nH]2)n1)c1ncc(F)cn1	Phase 1	JAK1|JAK2|JAK3	JAK inhibitor		
AZD1981	CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12	Phase 2	PTGDR2	CRTH receptor antagonist		
AZD2014	CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 2	MTOR	mTOR inhibitor		
AZD2461	COC1CCN(CC1)C(=O)c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F	Phase 1		PARP inhibitor		
AZD2858	CN1CCN(CC1)S(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1cccnc1	Preclinical	GSK3B	glycogen synthase kinase inhibitor		
AZD3264	Cc1noc(C)c1-c1ccc(-c2cc(C(N)=O)c(NC(N)=O)s2)c(O[C@H]2CCNC2)c1	Preclinical	IKBKB	IKK inhibitor		
AZD3463	COc1cc(ccc1Nc1ncc(Cl)c(n1)-c1c[nH]c2ccccc12)N1CCC(N)CC1	Preclinical	ALK|IGF1R	ALK tyrosine kinase receptor inhibitor, insulin growth factor receptor inhibitor		
AZD3514	CC(=O)N1CCN(CCOc2ccc(cc2)C2CCN(CC2)C2=Nn3c(CC2)nnc3C(F)(F)F)CC1 |t:24|	Phase 1	AR	androgen receptor modulator		
AZD3759	COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C	Phase 2/Phase 3	EGFR	EGFR inhibitor		
AZD3839	NC1=N[C@@](c2cccc(F)c12)(c1cccc(c1)-c1cncnc1)c1ccnc(c1)C(F)F |t:1|	Phase 1	BACE1	beta-secretase inhibitor		
AZD3965	CC(C)n1c2sc(Cc3c(C)[nH]nc3C(F)(F)F)c(C(=O)N3C[C@](C)(O)CO3)c2c(=O)n(C)c1=O	Phase 1	SLC16A1	monocarboxylate transporter inhibitor		
AZD3988	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(NC(=O)c2nnc(Nc3ccc(F)c(F)c3)o2)cc1 |r|	Preclinical	DGAT1	diacylglycerol kinase inhibitor		
AZD4282	NCC(O)=O	Phase 1	AGXT|AGXT2|ALAS1|ALAS2|BAAT|GARS|GATM|GCAT|GCSH|GLDC|GLRA1|GLRA2|GLRA3|GLRB|GLYAT|GLYATL1|GLYATL2|GNMT|GPR18|GPRC6A|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3B|GSS|PIPOX|SHMT1|SHMT2|SLC32A1|SLC36A1|SLC6A5|SLC6A9	glutamate receptor antagonist		
AZD4547	COc1cc(CCc2cc(NC(=O)c3ccc(cc3)N3C[C@H](C)N[C@H](C)C3)[nH]n2)cc(OC)c1	Phase 2/Phase 3	FGFR1|FGFR2|FGFR3|FGFR4|IGF1R|KDR	FGFR inhibitor		
AZD4573	CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1	Phase 1		CDK9 inhibitor		
AZD4635	Cc1cc(cc(Cl)n1)-c1nnc(N)nc1-c1ccc(F)cc1	Phase 1/Phase 2		adenosine receptor antagonist		
AZD5069	C[C@@H](Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	Phase 2	CXCR2	CC chemokine receptor antagonist		
AZD5153	[H][C@]1(C)N(CCOc2ccc(cc2)C2CCN(CC2)c2ccc3nnc(OC)n3n2)CCN(C)C1=O |r|	Phase 1		bromodomain inhibitor		
AZD5363	NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1	Phase 3	AKT1|AKT2|AKT3	AKT inhibitor		
AZD5438	CC(C)n1c(C)ncc1-c1ccnc(Nc2ccc(cc2)S(C)(=O)=O)n1	Phase 1	KCNH2	CDK inhibitor		
AZD5582	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]1[C@@H](Cc2ccccc12)OCC#CC#CCO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C)NC)C1CCCCC1	Preclinical	BIRC2|BIRC3|XIAP	XIAP inhibitor		
AZD5991	Cc1c-2c(CSCc3cc(CSc4cc(OCCCc5c(C(O)=O)n(C)c6c-2c(Cl)ccc56)c2ccccc2c4)n(C)n3)nn1C	Phase 1		MCL1 inhibitor		
AZD6482	C[C@@H](Nc1ccccc1C(O)=O)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1	Phase 1	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
AZD6738	C[C@@H]1COCCN1c1cc(nc(n1)-c1ccnc2[nH]ccc12)C1(CC1)[S@@](C)(=N)=O |a:1	Phase 2	ATR	ATR kinase inhibitor		
AZD6765	N[C@@H](Cc1ccccn1)c1ccccc1 |&1:1	Phase 2	GRIN1	glutamate receptor antagonist		
AZD7545	CN(C)C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(NC(=O)[C@@](C)(O)C(F)(F)F)c(Cl)c1	Phase 1	PDK1	pyruvate dehydrogenase kinase inhibitor		
AZD7594	C[C@H](NC(=O)C(C)(F)F)[C@H](Oc1ccc2n(ncc2c1)-c1cccc(c1)C(=O)N[C@@H]1CCOC1)c1ccc2OCCOc2c1	Phase 2		glucocorticoid receptor modulator		
AZD7687	Cc1nc(C)c(nc1C(N)=O)-c1ccc(cc1)[C@H]1CC[C@H](CC(O)=O)CC1 |r|	Phase 1	DGAT1	diacylglycerol O acyltransferase inhibitor		
AZD7762	NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)-c1cccc(F)c1	Phase 1	CHEK1|CHEK2	CHK inhibitor		
AZD7986	Cn1c2cc(ccc2oc1=O)-c1ccc(C[C@H](NC(=O)[C@@H]2CNCCCO2)C#N)cc1	Phase 1		dipeptidyl peptidase inhibitor		
AZD8055	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C	Phase 1	MTOR	mTOR inhibitor		
AZD8186	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C	Phase 1	PIK3CB|PIK3CD	PI3K inhibitor		
AZD8330	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O	Phase 1	MAP3K1	MEK inhibitor		
AZD8797	CC(C)C[C@H](CO)Nc1nc(S[C@@H](C)c2ccccc2)nc2nc(N)sc12	Preclinical		CC chemokine receptor antagonist		
AZD8835	CCn1nc(nc1-c1cnc(N)c(n1)-c1nnc(o1)C(C)(C)C)C1CCN(CC1)C(=O)CCO	Phase 1	PIK3CA|PIK3CD	PI3K inhibitor		
AZD8931	CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC	Phase 2	EGFR|ERBB2|ERBB3	EGFR inhibitor		
AZD9056	OCCCNCCCc1ccc(Cl)c(c1)C(=O)NCC12CC3CC(CC(C3)C1)C2	Phase 2		purinergic receptor antagonist		
AZD9272	Fc1ccc(nc1)-c1noc(n1)-c1cc(F)cc(c1)C#N	Preclinical	GRM5	glutamate receptor antagonist		
AZD9496	C[C@@H]1Cc2c([nH]c3ccccc23)[C@H](N1CC(C)(C)F)c1c(F)cc(\C=C\C(O)=O)cc1F	Phase 1	ESR1	estrogen receptor agonist		
AZD9668	Cc1c(cc(C(=O)NCc2ccc(cn2)S(C)(=O)=O)c(=O)n1-c1cccc(c1)C(F)(F)F)-c1ccnn1C	Phase 2	ELANE	elastase inhibitor		
azelaic-acid	OC(=O)CCCCCCCC(O)=O	Launched	AKR1D1|SRD5A2|TYR	tyrosinase inhibitor	dermatology	rosacea
azelastine	CN1CCC[C@@H](CC1)n1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O |&1:5|	Launched	HRH1	histamine receptor antagonist	ophthalmology	conjunctivitis
azeliragon	CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1	Phase 3	AGER	RAGE receptor antagonist		
azelnidipine	CC(C)OC(=O)C1=C(C)NC(N)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1 |r	Launched	CACNA1C	calcium channel blocker	cardiology	hypertension
azilsartan	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	Launched	AGTR1|AGTR2	angiotensin receptor antagonist	cardiology	hypertension
azilsartan-medoxomil	CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1	Launched	AGTR1|AGTR2	angiotensin receptor antagonist	cardiology	hypertension
azimilide	CN1CCN(CCCCN2C(=O)CN(\N=C\c3ccc(o3)-c3ccc(Cl)cc3)C2=O)CC1	Phase 3	KCNA5	potassium channel blocker		
azithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	MLNR	bacterial 50S ribosomal subunit inhibitor	infectious disease	pelvic inflammatory disease, pneumonia
azlocillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections, gram-negative bacterial infections
AZM-475271	COc1ccc(Cl)c(Nc2ncnc3cc(OCC4CCN(C)CC4)c(OC)cc23)c1	Preclinical	SRC	SRC inhibitor		
azodicarbonamide	NC(=O)\N=N\C(N)=O	Phase 2		DNA synthesis inhibitor		
azomycin-(2-nitroimidazole)	[O-][N+](=O)c1ncc[nH]1	Preclinical		protein synthesis inhibitor		
azosemide	NS(=O)(=O)c1cc(-c2nn[nH]n2)c(NCc2cccs2)cc1Cl	Launched	SLC12A1|SLC12A2	electrolyte reabsorption inhibitor	cardiology	edema
aztreonam	C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections
AZ191	COc1cc(ccc1Nc1nccc(n1)-c1cn(C)c2cnccc12)N1CCN(C)CC1	Preclinical	DYRK1B	DYRK inhibitor		
AZ20	C[C@@H]1COCCN1c1cc(nc(n1)-c1cccc2[nH]ccc12)C1(CC1)S(C)(=O)=O	Preclinical	ATR|MTOR	ATR kinase inhibitor		
AZ3146	COc1cc(OC2CCN(C)CC2)ccc1Nc1ncc2n(C)c(=O)n(C3CCCC3)c2n1	Preclinical		monopolar spindle 1 kinase inhibitor		
AZ505	Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12	Preclinical	SMYD2	histone lysine methyltransferase inhibitor		
AZ5104	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1c[nH]c2ccccc12	Preclinical	EGFR	EGFR inhibitor		
AZ7550	CNCCN(C)c1cc(OC)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C	Phase 1		insulin growth factor receptor inhibitor		
AZ960	C[C@H](Nc1nc(Nc2cc(C)n[nH]2)c(F)cc1C#N)c1ccc(F)cc1	Preclinical	JAK2	JAK inhibitor		
A0001	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O |c:21	Phase 2				
A12B4C3	CCCCCCCCCC[C@@H](O)[C@H]1C=C[C@H]2[C@@H](N1Nc1ccc(cc1)[N+]([O-])=O)C(=O)N(C2=O)c1ccccc1 |&1:10	Preclinical	PNKP	polynucleotide kinase/phosphatase inhibitor		
A205804	Cc1ccc(Sc2cncc3sc(cc23)C(N)=O)cc1	Preclinical	ICAM1|SELE	ICAM1 expression inhibitor		
A61603	CS(=O)(=O)Nc1c(O)ccc2[C@@H](CCCc12)C1=NCCN1 |r	Preclinical	ADRA1A	adrenergic receptor agonist		
A66	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C	Preclinical	PIK3CA	PI3K inhibitor		
A740003	COc1ccc(CC(=O)N[C@@H](N\C(Nc2cccc3ncccc23)=N\C#N)C(C)(C)C)cc1OC |&1:10	Preclinical	P2RX7	purinergic receptor antagonist		
A77636	NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)[C@@]12CC3CC(CC(C3)C1)C2	Preclinical	CALY	dopamine receptor agonist		
A922500	OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1	Preclinical	DGAT1	diacylglycerol O acyltransferase inhibitor		
bacampicillin	CCOC(=O)O[C@@H](C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O |a:11	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections, gram-negative bacterial infections
bacitracin	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H]1CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC1=O)[C@@H](C)CC |t:6|	Launched	IDE	bacterial cell wall synthesis inhibitor	infectious disease	first-aid antibiotic
bacitracin-zinc	CC[C@H](C)[C@H](N)C1=N[C@@H](CS1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]1CCC(=O)O[Zn]OC(=O)C[C@H]2NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)[C@@H](CCCN)NC(=O)[C@H](CCCCNC(=O)[C@H](CC(N)=O)NC2=O)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)[C@@H](C)CC |t:6|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	first-aid antibiotic
baclofen	NC[C@@H](CC(O)=O)c1ccc(Cl)cc1 |&1:2|	Launched	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8	benzodiazepine receptor agonist	neurology/psychiatry	multiple sclerosis, spasms
BADGE	CC(C)(c1ccc(OC[C@H]2CO2)cc1)c1ccc(OC[C@H]2CO2)cc1 |&1:9	Preclinical	PPARG	PPAR receptor antagonist		
bafetinib	CN(C)[C@H]1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cncnc3)c2)C1	Phase 2	ABL1|BCR|LYN	Bcr-Abl kinase inhibitor, LYN tyrosine kinase inhibitor		
bafilomycin-a1	[H][C@@]1(OC(=O)\C(OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C\C(C)=C\C=C\[C@@H]1OC)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O)[C@H](C)[C@H](O1)C(C)C |c:10	Preclinical		ATPase inhibitor		
BAG-956	Cc1nc2cnc3ccc(cc3c2n1-c1ccc(cc1)C(C)(C)C#N)C#Cc1cccnc1	Preclinical	PIK3CG	phosphoinositide dependent kinase inhibitor		
baicalein	Oc1cc2oc(cc(O)c2c(=O)c1O)-c1ccccc1	Preclinical	ALOX5|GLO1|PREP|SELL|SELP|TNF|XDH	lipoxygenase inhibitor		
baicalin	O[C@H]1[C@H](Oc2cc3oc(cc(O)c3c(=O)c2O)-c2ccccc2)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O	Launched	PREP	beta glucuronidase inhibitor	neurology/psychiatry	anxiety
bakuchiol	CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1	Phase 2	HIF1A	DNA polymerase inhibitor		
balaglitazone	Cn1c(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc2ccccc2c1=O |r|	Phase 3	PPARG	insulin sensitizer, PPAR receptor partial agonist		
balapiravir	CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)n1ccc(N)nc1=O)N=[N+]=[N-]	Phase 2		RNA polymerase inhibitor		
balicatib	CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N	Phase 2	CTSK	cathepsin inhibitor		
balofloxacin	CN[C@H]1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 |&1:2	Launched		bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections
baloxavir	[H][C@@]12COCCN1C(=O)c1c(O)c(=O)ccn1N2[C@@H]1c2ccccc2SCc2c(F)c(F)ccc12	Phase 3		endonuclease inhibitor		
baloxavir-marboxil	[H][C@@]12COCCN1C(=O)c1c(OCOC(=O)OC)c(=O)ccn1N2[C@H]1c2ccc(F)c(F)c2CSc2ccccc12	Launched		endonuclease inhibitor	infectious disease	influenza A virus infection
balsalazide	OC(=O)CCNC(=O)c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O	Launched	ALOX5|PPARG|PTGS1|PTGS2	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
bamaquimast	CCCn1c2ccccc2nc(CCCOC(=O)NC)c1=O	Preclinical		proton pump inhibitor		
bambuterol	CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C	Launched	ADRB2|BCHE	adrenergic receptor agonist	pulmonary	asthma
BAM7	CCOc1ccccc1N\N=C1/C(C)=NN(C1=O)c1nc(cs1)-c1ccccc1 |c:14|	Preclinical	BAX	BAX activator		
BAN-ORL-24	O=C(NCCCN1CCC2(CC1)OCc1ccccc21)[C@H]1CCCN1Cc1ccccc1	Preclinical	OPRL1	nociceptin/orphanin FQ receptor antagonist		
banoxantrone	C[N+](C)([O-])CCNc1ccc(NCC[N+](C)(C)[O-])c2C(=O)c3c(O)ccc(O)c3C(=O)c12	Phase 1/Phase 2	TOP2A	topoisomerase inhibitor		
barasertib	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1)CCOP(O)(O)=O	Phase 2/Phase 3	AURKA|AURKB	Aurora kinase inhibitor		
barasertib-HQPA	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)n[nH]3)ncnc2c1	Phase 2/Phase 3	AURKB	Aurora kinase inhibitor		
bardoxolone	CC1(C)CC[C@@]2(CC[C@]3(C)[C@@H]([C@@H]2C1)C(=O)C=C1[C@@]2(C)C=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]31C)C(O)=O |t:17	Phase 1	NOS2|PPARG	nuclear factor erythroid derived, like (NRF2) activator		
bardoxolone-methyl	COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:16	Phase 3	PPARG|STAT3	nuclear factor erythroid derived, like (NRF2) activator		
baricitinib	CCS(=O)(=O)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Launched	JAK1|JAK2	JAK inhibitor	rheumatology	rheumatoid arthritis
barium-6-O-phosphonato-D-glucose	O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H](O)C=O	Preclinical				
barnidipine	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@H]1CCN(Cc2ccccc2)C1 |c:4	Launched		calcium channel blocker	cardiology	hypertension
basic-fuchsin	CC1=CC(C=CC1=N)=C(c1ccc(N)cc1)c1ccc(N)cc1 |c:4	Preclinical				
basimglurant	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1	Phase 2	GRM5	glutamate receptor antagonist		
basmisanil	Cc1onc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)-c1ccc(F)cc1	Phase 2		GABA receptor inverse agonist		
batefenterol	COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2-c2ccccc2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2nc(O)ccc12	Phase 2		acetylcholine receptor antagonist, adrenergic receptor agonist		
batimastat	CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO	Phase 3	ADAM28|ADAMTS5|MMP12|MMP16|MMP2|MMP8	matrix metalloprotease inhibitor		
bavisant	O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1	Phase 2	HRH3	histamine receptor antagonist		
BAX-channel-blocker	O[C@@H](CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1|	Preclinical	BAX	cytochrome C release inhibitor		
BAY-K-8644-(+/-)	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |r	Preclinical		L-type calcium channel blocker		
BAY-K-8644-(s)-(-)	COC(=O)C1=C(C)NC(C)=C([C@H]1c1ccccc1C(F)(F)F)[N+]([O-])=O |c:4	Preclinical	CACNA1C	L-type calcium channel activator		
BAY-W-9798	COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC |c:4	Phase 2		antioxidant		
BAY-11-7082	Cc1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical	RELA	NFkB pathway inhibitor		
BAY-11-7085	CC(C)(C)c1ccc(cc1)S(=O)(=O)\C=C\C#N	Preclinical	NFKBIA	NFkB pathway inhibitor		
BAY-1251152	COc1cc(F)ccc1-c1cc(Nc2cc(C[S@](C)(=N)=O)ccn2)ncc1F |r|	Phase 1		CDK9 inhibitor		
BAY-1436032	C[C@H]1C[C@H](CC(C)(C)C1)n1c(Nc2ccc(OC(F)(F)F)cc2)nc2cc(CCC(O)=O)ccc12	Phase 1		isocitrate dehydrogenase inhibitor		
BAY-1895344	C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1	Phase 1		ATR kinase inhibitor		
BAY-2402234	CCn1c(CO)nn(-c2cc(O[C@@H](C)C(F)(F)F)c(cc2F)C(=O)Nc2c(F)cccc2Cl)c1=O	Phase 1		dihydroorotate dehydrogenase inhibitor		
BAY-41-2272	Nc1nc(ncc1C1CC1)-c1nn(Cc2ccccc2F)c2ncccc12	Preclinical	GUCY1A3|GUCY1B3	guanylyl cyclase activator		
BAY-60-6583	NC(=O)CSc1nc(N)c(C#N)c(-c2ccc(OCC3CC3)cc2)c1C#N	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor agonist		
BAY-60-7550	COc1ccc(Cc2nc(=O)c3c(C)nc([C@@H](CCCc4ccccc4)[C@@H](C)O)n3[nH]2)cc1OC	Preclinical	PDE2A	phosphodiesterase inhibitor		
BAY-61-3606	COc1ccc(cc1OC)-c1cc2nccn2c(Nc2ncccc2C(N)=O)n1	Preclinical	SYK	SYK inhibitor		
BAY-8002	OC(=O)c1ccccc1NC(=O)c1cc(ccc1Cl)S(=O)(=O)c1ccccc1	Preclinical		monocarboxylate transporter inhibitor		
BAY-85-8050	N[C@@H](C[C@@H](F)C(O)=O)C(O)=O |&1:1	Phase 1				
BAY-87-2243	Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	Phase 1	HIF1A	hypoxia inducible factor inhibitor		
BAY1125976	NC(=O)c1ccc2nc(c(-c3ccccc3)n2n1)-c1ccc(cc1)C1(N)CCC1	Phase 1		AKT inhibitor		
BAY1217389	COc1ccc(Oc2cc(NCCC(F)(F)F)c3ncc(-c4ccc(C(=O)NC5CC5)c(C)c4)n3n2)c(F)c1F	Phase 1		kinase inhibitor		
bazedoxifene	Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12	Launched	ESR1|ESR2	selective estrogen receptor modulator (SERM)	orthopedics, endocrinology	osteoporosis, menopause
BAZ2-ICR	Cn1cc(CCn2cnc(-c3cnn(C)c3)c2-c2ccc(cc2)C#N)cn1	Preclinical	ZNF215	bromodomain inhibitor		
BC-11	NC(=N)SCc1ccc(cc1)B(O)O	Preclinical	PLAU	urokinase inhibitor		
BCI-540	Cc1oc2nc3CCCCc3c(NC(=O)CN3CCCC3=O)c2c1C	Phase 2		glutamate receptor agonist		
BCTC	CC(C)(C)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2Cl)cc1	Preclinical	TRPV1	TRPV antagonist		
BCX-1470	NC(=N)c1cc2ccc(OC(=O)c3cccs3)cc2s1	Phase 1	CFD	complement inhibitor, serine protease inhibitor		
BD-1008	CN(CCN1CCCC1)CCc1ccc(Cl)c(Cl)c1	Preclinical		sigma receptor antagonist		
BD-1047	CN(C)CCN(C)CCc1ccc(Cl)c(Cl)c1	Preclinical	SIGMAR1	adrenergic receptor antagonist		
BD-1063	CN1CCN(CCc2ccc(Cl)c(Cl)c2)CC1	Preclinical	SIGMAR1	sigma receptor antagonist		
BE-2254	Oc1ccc(CCNC[C@H]2CCc3ccccc3C2=O)cc1 |r|	Phase 2	ADRA1A	adrenergic receptor antagonist		
BEBT-908	CNc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	Preclinical		PI3K inhibitor		
beclabuvir	COc1ccc2-c3c(C4CCCCC4)c4ccc(cc4n3C[C@]3(C[C@H]3c2c1)C(=O)N1[C@H]2CC[C@@H]1CN(C)C2)C(=O)NS(=O)(=O)N(C)C |THB:27:29:31.32:34.35.37|	Phase 2		antiviral		
beclamide	ClCCC(=O)NCc1ccccc1	Launched		anticonvulsant	neurology/psychiatry	sedative, seizures
beclomethasone	C[C@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]2(C)[C@@]1(O)C(=O)CO |&1:1	Launched	NR3C1|SERPINA6	glucocorticoid receptor agonist	allergy	allergic rhinitis
beclomethasone-dipropionate	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C |c:25	Launched	GPR97|NR3C1	glucocorticoid receptor agonist	allergy	allergic rhinitis
bedaquiline	COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12	Launched		ATPase inhibitor	infectious disease	tuberculosis
befuraline	O=C(N1CCN(Cc2ccccc2)CC1)c1cc2ccccc2o1	Phase 2				
begacestat	OC[C@@H](NS(=O)(=O)c1ccc(Cl)s1)C(C(F)(F)F)C(F)(F)F	Phase 1	PSEN1	gamma secretase inhibitor		
bekanamycin	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections
belinostat	ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1	Launched	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
belizatinib	CC(C)NC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccc(F)cc2)nc2ccc(CN3CCC(CC3)C(C)(C)O)cc12 |r|	Preclinical		receptor tyrosine protein kinase inhibitor		
belotecan	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CCNC(C)C)c3Cn1c2=O	Phase 3		topoisomerase inhibitor		
bemegride	CCC1(C)CC(=O)NC(=O)C1	Launched	GABRA1	chemoreceptor agonist	critical care	poison antidote
bemesetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1 |r	Phase 3	HTR3A|HTR3B	serotonin receptor antagonist		
bemotrizinol	CCCC[C@H](CC)COc1ccc(c(O)c1)-c1nc(nc(n1)-c1ccc(OC[C@H](CC)CCCC)cc1O)-c1ccc(OC)cc1 |&1:28	Launched			dermatology	sunscreen lotion
bempedoic-acid	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O	Launched	ACLY	AMPK inhibitor		
benactyzine	CCN(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	Preclinical		butyrylcholinesterase inhibitor		
benaxibine	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1				
benazepril	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(O)=O)C1=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension
bendamustine	Cn1c(CCCC(O)=O)nc2cc(ccc12)N(CCCl)CCCl	Launched		DNA inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL)
bendazac	OC(=O)COc1nn(Cc2ccccc2)c2ccccc12	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry, rheumatology	muscle pain, joint pain
bendazol	C(c1nc2ccccc2[nH]1)c1ccccc1	Launched		nitric oxide synthase stimulant		
bendroflumethiazide	NS(=O)(=O)c1cc2c(N[C@@H](Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F |&1:9	Launched	SLC12A1|SLC12A3	sodium/potassium/chloride transporter inhibitor	cardiology	hypertension
benethamine	C(Cc1ccccc1)NCc1ccccc1	Preclinical				
benfluorex	C[C@@H](Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1 |r|	Withdrawn	HMGCR	gluconeogenesis inhibitor		
benfluralin	CCCCN(CC)c1c(cc(cc1[N+]([O-])=O)C(F)(F)F)[N+]([O-])=O	Phase 3	CYP1A1|CYP1A2|CYP2B6|CYP3A4|ESR1|MMP1|SULT2A1|UGT1A1			
benfotiamine	C\C(N(Cc1cnc(C)nc1N)C=O)=C(/CCOP(O)(O)=O)SC(=O)c1ccccc1	Launched	AGER	antioxidant	rheumatology	lumbago
benidipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(Cc2ccccc2)C1	Launched	CACNA1C|CACNA1G	calcium channel blocker	cardiology	hypertension
benperidol	Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	Launched	DRD2	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
benproperine	C[C@@H](COc1ccccc1Cc1ccccc1)N1CCCCC1 |&1:1	Launched	SCN5A	antitussive	pulmonary	cough suppressant
benserazide	NC(CO)C(=O)NNCc1ccc(O)c(O)c1O	Launched	DDC	DOPA decarboxylase inhibitor	neurology/psychiatry	Parkinson's Disease
bentiromide	OC(=O)c1ccc(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)c2ccccc2)cc1	Launched	HPN		gastroenterology	pancreas diagnostic agent
benurestat	ONC(=O)CNC(=O)c1ccc(Cl)cc1	Phase 1		urease inhibitor		
benzalkonium	CCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	Launched		cationic surfactant	dermatology	abrasions, superficial cuts
benzamil	NC(NCc1ccccc1)=NC(=O)c1nc(Cl)c(N)nc1N	Phase 2	ASIC1|PKD2L1|SCNN1A|SCNN1B|SCNN1D|SCNN1G|SLC8A1	sodium channel blocker		
benzbromarone	CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1	Launched	ABCC1	chloride channel blocker	rheumatology	gout
benzenemethanol,-2,5-dimethyl-[[(1-methylethyl)amino]methyl]	CC(C)NC[C@@H](O)c1cc(C)ccc1C |&1:5	Preclinical				
benzethonium	CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1	Launched	SCN10A	sodium channel blocker	infectious disease	first-aid antiseptic
benznidazole	[O-][N+](=O)c1nccn1CC(=O)NCc1ccccc1	Launched		DNA synthesis inhibitor	infectious disease	Chagas disease
benzo[d]thiazole-2(3H)-thione	S=c1[nH]c2ccccc2s1	Phase 1				
benzocaine	CCOC(=O)c1ccc(N)cc1	Launched	SCN10A	sodium channel blocker	infectious disease	first-aid antiseptic
benzoclidine	O=C(O[C@H]1CN2CCC1CC2)c1ccccc1 |&1:3	Preclinical				
benzofenac	OC(=O)Cc1ccc(OCc2ccccc2)c(Cl)c1	Phase 1				
benzoic-acid	OC(=O)c1ccccc1	Launched	DAO|HRSP12|PRDX5|RAB9A	food preservative	infectious disease	tinea pedis
benzoin	O[C@@H](C(=O)c1ccccc1)c1ccccc1 |&1:1	Preclinical	CES1			
benzonatate	CCCCNc1ccc(cc1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	Launched	SCN5A	local anesthetic	pulmonary	cough suppressant
benzoquinonium-dibromide	CC[N+](CC)(CCCNC1=CC(=O)C(NCCC[N+](CC)(CC)Cc2ccccc2)=CC1=O)Cc1ccccc1 |c:30	Preclinical	CHRNA1	cholinergic receptor antagonist		
benzotript	OC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1	Phase 1	CCKAR|CCKBR	CCK receptor antagonist		
benzoxiquine	O=C(Oc1cccc2cccnc12)c1ccccc1	Preclinical		antiinfective drug		
benzoyl-peroxide	O=C(OOC(=O)c1ccccc1)c1ccccc1	Launched		oxidizing agent	dermatology	acne vulgaris (AV)
benzoylpas	OC(=O)c1ccc(NC(=O)c2ccccc2)cc1O	Preclinical				
benzthiazide	NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)=CSCc2ccccc2)cc1Cl	Launched	CA2	carbonic anhydrase inhibitor	cardiology	hypertension, edema
benztropine-mesylate	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccccc1)c1ccccc1	Launched	CHRM1|HRH1|SLC6A3	acetylcholine receptor antagonist	neurology/psychiatry	extrapyramidal symptoms (EPS), Parkinson's Disease
benzydamine	CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12	Launched		prostanoid receptor antagonist	dental, otolaryngology	mouth inflammation, throat inflammation
benzyl-alcohol	OCc1ccccc1	Launched		local anesthetic	infectious disease	virus herpes simplex (HSV)
benzyl-benzoate	O=C(OCc1ccccc1)c1ccccc1	Launched	LIPE	lipase inhibitor	allergy	sweet itch
benzyl-isothiocyanate	S=C=NCc1ccccc1	Preclinical		methylazoxymethanol acetate inhibitor		
benzyldimethylhexadecylammonium	CCCCCCCCCCCCCCCC[N+](C)(C)Cc1ccccc1	Preclinical		cationic surfactant		
benzyldimethyloctylammonium	CCCCCCCC[N+](C)(C)Cc1ccccc1	Preclinical				
benzylpenicillin	CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched		penicillin binding protein inhibitor	infectious disease	celluitis, meningitis, endocarditis, syphilis, pneumonia, bacterial septicemia
bephenium-hydroxynaphthoate	C[N+](C)(CCOc1ccccc1)Cc1ccccc1	Launched		anthelmintic agent	infectious disease	ascariasis
bepotastine	OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1	Launched	HRH1	histamine receptor antagonist	ophthalmology	conjunctivitis
bepridil	CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	Launched	KCNQ4	calcium channel blocker	cardiology	angina pectoris
berberine	COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC	Launched	LDLR	LDL receptor activator		
bergapten	COc1c2ccoc2cc2oc(=O)ccc12	Phase 3				
bergenin	COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O	Preclinical	IL1B|TNF	interleukin inhibitor		
besifloxacin	N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1	Launched		bacterial DNA gyrase inhibitor	ophthalmology	conjunctivitis
BET-BAY-002	Cc1nnc(C[C@@H]2C=C(c3ccc(Cl)cc3)c3ccccc3-n3c(C)nnc23)o1 |t:7|	Preclinical		bromodomain inhibitor		
beta-amyloid-synthesis-inhibitor	Oc1cccc(Nc2ccc(Nc3cccc(O)c3)nn2)c1	Preclinical	APP	beta amyloid synthesis inhibitor		
beta-carotene	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)CCCC1(C)C |c:9	Launched				
beta-CCB	CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21	Launched	GABRA1|GABRG2	benzodiazepine receptor ligand		
beta-elemene	CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@@H](C1)C(C)=C	Launched	MMP2|MMP9	apoptosis stimulant		
beta-funaltrexamine	COC(=O)\C=C\C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45	Preclinical	OPRD1|OPRK1|OPRM1	opioid receptor antagonist		
beta-glycerophosphoric-acid	OCC(CO)OP(O)(O)=O	Preclinical				
beta-hydroxy-beta-methylbutyrate	CC(C)(O)CC(O)=O.CC(C)(O)CC(O)=O	Launched	MTOR	protein synthesis stimulant		
beta-hydroxybutyrate	CC(O)CC(O)=O	Phase 1	HCAR2			
beta-lapachone	CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O |c:5|	Phase 2	TOP1	topoisomerase inhibitor		
beta-naphthol	Oc1ccc2ccccc2c1	Preclinical				
betahistine	CNCCc1ccccn1	Launched	HRH1|HRH3	histamine receptor agonist, histamine receptor antagonist	neurology/psychiatry	Meniere's disease
betaine	C[N+](C)(C)CC(O)=O	Launched		nitric oxide donor	metabolism	homocystinuria
betamethasone	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
betamethasone-acetate	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
betamethasone-butyrate-propionate	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |c:18	Launched			rheumatology	rheumatoid arthritis
betamethasone-dipropionate	CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:25	Launched	NR3C1	anti-inflammatory agent	dermatology	corticosteroid-responsive dermatoses
betamethasone-phosphate	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(O)(O)=O |c:11	Launched			rheumatology	rheumatoid arthritis
betamethasone-valerate	CCCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO |c:19	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
betamipron	OC(=O)CCNC(=O)c1ccccc1	Launched		panipenem uptake inhibitor	nephrology	renal toxicity
betaxolol	CC(C)NC[C@@H](O)COc1ccc(CCOCC2CC2)cc1 |&1:5	Launched	ADRB1|ADRB2	adrenergic receptor antagonist	ophthalmology	intraocular pressure, glaucoma, ocular hypertension
betazole	NCCc1ccn[nH]1	Launched	HRH2	histamine receptor agonist	gastroenterology	gastric hypersecretion diagnostic
bethanechol	C[C@@H](C[N+](C)(C)C)OC(N)=O |r|	Launched	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor agonist	urology	urinary retention
BETP	CC[S@](=O)c1nc(cc(n1)C(F)(F)F)-c1cccc(OCc2ccccc2)c1 |&1:2	Preclinical	GLP1R	GLP receptor positive allosteric modulator		
betrixaban	COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1	Launched	KCNH2	coagulation factor inhibitor	hematology	deep vein thrombosis (DVT)
betulinic-acid	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 1/Phase 2	GPBAR1	apoptosis stimulant, NFkB pathway inhibitor		
bevantolol	COc1ccc(CCNC[C@@H](O)COc2cccc(C)c2)cc1OC |&1:10|	Launched		adrenergic receptor antagonist	cardiology	angina pectoris, hypertension
bevenopran	COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(N)=O	Phase 1		opioid receptor antagonist		
bevirimat-dimeglumine	CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(O)=O	Phase 2		HIV capsid assembly inhibitor		
bexagliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(OCCOC3CC3)cc2)c1	Phase 3		solute carrier family member inhibitor		
bexarotene	Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C	Launched	RXRA|RXRB|RXRG	retinoid receptor agonist	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
bezafibrate	CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O	Launched	PPARA|PPARD|PPARG	PPAR receptor agonist	cardiology	cholesterol
BFH772	OCc1cc(Oc2ccc3c(cccc3c2)C(=O)Nc2cccc(c2)C(F)(F)F)ncn1	Phase 2		VEGFR inhibitor		
BGP-15	O[C@H](CONC(=N)c1cccnc1)CN1CCCCC1 |&1:1	Phase 2		PARP inhibitor		
BGT226	COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1	Phase 1/Phase 2	MTOR|PIK3CA|PIK3CB|PIK3CG	PI3K inhibitor		
BHQ	CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C	Preclinical	ATP2A1	ATPase inhibitor		
BI-D1870	CC(C)CCN1[C@@H](C)C(=O)N(C)c2cnc(Nc3cc(F)c(O)c(F)c3)nc12 |&1:6	Preclinical	RPS6KA1|RPS6KA2|RPS6KA3|RPS6KA6	ribosomal protein inhibitor		
BI-224436	Cc1nc2ccccc2c(-c2ccc3OCCc4ccnc2c34)c1[C@H](OC(C)(C)C)C(O)=O	Phase 1		HIV integrase inhibitor		
BI-2536	CC[C@H]1N(C2CCCC2)c2nc(Nc3ccc(cc3OC)C(=O)NC3CCN(C)CC3)ncc2N(C)C1=O	Phase 2	BRD4|PLK1|PLK2|PLK3	PLK inhibitor		
BI-409306	Oc1nc(Cc2ccccn2)nc2n(ncc12)C1CCOCC1	Phase 1		phosphodiesterase inhibitor		
BI-78D3	[O-][N+](=O)c1cnc(Sc2n[nH]c(=O)n2-c2ccc3OCCOc3c2)s1	Preclinical	MAPK8	JNK inhibitor		
BI-847325	CCNC(=O)C#Cc1ccc2\C(=C(/Nc3ccc(CN(C)C)cc3)c3ccccc3)C(=O)Nc2c1	Phase 1	AURKA|AURKB|AURKC|MAP2K1|MAP2K2	Aurora kinase inhibitor, MEK inhibitor		
BIA-10-2474	CN(C1CCCCC1)C(=O)n1cnc(c1)-c1ccc[n+]([O-])c1	Preclinical		Fatty acid hydrolase inhibitor		
biapenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3Cn4cnc[n+]4C3)=C(N2C1=O)C(O)=O |a:1	Launched		bacterial cell wall synthesis inhibitor	infectious disease	bacterial septicemia, pneumonia, urinary tract infections
BIBN4096	NCCCC[C@H](NC(=O)[C@@H](Cc1cc(Br)c(O)c(Br)c1)NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)C(=O)N1CCN(CC1)c1ccncc1	Phase 2	CALCA|CALCRL|RAMP1	calcitonin antagonist		
BIBR-1532	C\C(=C/C(=O)Nc1ccccc1C(O)=O)c1ccc2ccccc2c1	Preclinical	TERT	telomerase inhibitor		
BIBU-1361	CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	Preclinical	EGFR	EGFR inhibitor		
BIBX-1382	CN1CCC(CC1)Nc1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1	Phase 1	EGFR|ERBB2	EGFR inhibitor		
bicalutamide	CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F |&1:1|	Launched	AR	androgen receptor antagonist	oncology	prostate cancer
bicifadine	[H][C@@]12C[C@@]1(CNC2)c1ccc(C)cc1 |&1:1	Phase 3		dopamine reuptake inhibitor, serotonin receptor antagonist		
bictegravir	[H][C@@]12CC[C@@]([H])(C1)N1C(=O)c3c(O)c(=O)c(cn3C[C@@]1([H])O2)C(=O)NCc1c(F)cc(F)cc1F	Launched		HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
bicuculline-(+)	CN1CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	Preclinical	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|KCNN1	GABA receptor antagonist		
bicuculline-methochloride-(-)	C[N+]1(C)CCc2cc3OCOc3cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1OCOc21	Preclinical		GABA receptor antagonist		
bicyclol	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO	Launched	HSPA1A|HSPB1	NFkB pathway inhibitor	infectious disease	hepatitis B, hepatitis C
bifemelane	CNCCCCOc1ccccc1Cc1ccccc1	Launched	MAOA|MAOB	acetylcholine release enhancer	ophthalmology, neurology/psychiatry	glaucoma, senile dementia
bifendate	COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1C(=O)OC	Launched			infectious disease	hepatitis B, hepatitis C
bifonazole	c1cn(cn1)[C@@H](c1ccccc1)c1ccc(cc1)-c1ccccc1 |&1:5	Launched		sterol demethylase inhibitor	infectious disease	tinea pedis, tinea cruris
BIIB021	COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C	Phase 2	HSP90AA1	HSP inhibitor		
bilastine	CCOCCn1c(nc2ccccc12)C1CCN(CCc2ccc(cc2)C(C)(C)C(O)=O)CC1	Launched	HRH1	histamine receptor antagonist	ophthalmology	conjunctivitis
bilobalide	CC(C)(C)[C@]1(O)C[C@@H]2OC(=O)C[C@@]22C(=O)O[C@@H]3OC(=O)[C@H](O)[C@]123	Preclinical	GLRA1|GLRA2|GLRB|HTR3A|HTR3B	GABA receptor modulator		
bimatoprost	CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCc1ccccc1	Launched	AKR1C3|PTGER1|PTGER3|PTGFR	prostanoid receptor agonist	ophthalmology	intraocular pressure, glaucoma, ocular hypertension
BIMU-8	CC(C)n1c2ccccc2n(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3C)c1=O |&1:14	Preclinical	HTR4	serotonin receptor agonist		
BINA	Cc1c2C(=O)[C@H](Cc2cc(OCc2cccc(c2)-c2ccc(cc2)C(O)=O)c1C)C1CCCC1 |&1:5	Preclinical	GRM2	glutamate receptor positive allosteric modulator		
bindarit	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(O)=O	Phase 2	CCL2|CCL7|CCL8	NFkB pathway inhibitor		
binimetinib	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO	Launched	MAP2K1|MAP2K2	MEK inhibitor	oncology	melanoma
BIO-1211	CC(C)C[C@H](NC(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(O)=O	Phase 2	ITGA4|ITGB1	integrin antagonist		
BIO-5192	CC(C)C[C@H](N(C)C(=O)Cc1ccc(NC(=O)Nc2ccccc2C)cc1)C(=O)NCC[C@H](NC(=O)[C@@H]1CCCN1S(=O)(=O)c1cc(Cl)cc(Cl)c1)C(O)=O	Preclinical	ITGA4|ITGB1	integrin inhibitor		
biotin	OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	Launched	ACACA|ACACB|HLCS|MCCC1|MCCC2|PC|PCCA|PCCB|SLC5A6	vitamin B		
bipenamol	NCc1ccccc1Sc1ccccc1CO	Phase 2	CTSC	dipeptidyl peptidase inhibitor		
biperiden	O[C@@](CCN1CCCCC1)([C@@H]1C[C@@H]2C[C@H]1C=C2)c1ccccc1 |&1:12	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease
birinapant	CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c([nH]c2cc(F)ccc12)-c1[nH]c2cc(F)ccc2c1C[C@@H]1C[C@H](O)CN1C(=O)[C@H](CC)NC(=O)[C@H](C)NC	Phase 2	BIRC2|XIAP	XIAP inhibitor		
BIRT-377	CN1C(=O)N(C(=O)[C@@]1(C)Cc1ccc(Br)cc1)c1cc(Cl)cc(Cl)c1	Preclinical	ICAM1	lymphocyte function-associated antigen negative modulator		
bis(maltolato)oxovanadium(IV)	Cc1occc(=O)c1O[V](=O)Oc1c(C)occc1=O	Phase 2	PTPN1	tyrosine phosphatase inhibitor		
bisacodyl	CC(=O)Oc1ccc(cc1)C(c1ccc(OC(C)=O)cc1)c1ccccn1	Launched		laxative	gastroenterology	constipation
bisantrene	C1CN=C(N\N=C\c2c3ccccc3c(\C=N\NC3=NCCN3)c3ccccc23)N1 |t:2	Phase 2		topoisomerase inhibitor		
bisindolylmaleimide-IX	Cn1cc(C2=C(C(=O)NC2=O)c2cn(CCCSC(N)=N)c3ccccc23)c2ccccc12 |t:4|	Preclinical	AKT1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SIRT1	PKC inhibitor		
bismuth(III)-trifluoromethanesulfonate	[Bi].OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F.OS(=O)(=O)C(F)(F)F	Preclinical		direct substitution catalyst		
bismuth-oxalate	[Bi].[Bi].OC(=O)C(O)=O.OC(=O)C(O)=O.OC(=O)C(O)=O	Preclinical				
bismuth-subcitrate-potassium	OC(=O)C[C@](O)(CC(=O)O[Bi]1OC(=O)C[C@@](O)(CC(O)=O)C(=O)O1)C(O)=O |&1:4	Launched			gastroenterology	duodenal ulcer disease
bismuth-subgallate	O[Bi]1Oc2cc(cc(O)c2O1)C(O)=O	Launched	NOS1	nitric oxide synthase inhibitor	gastroenterology	internal deoderant
bismuth-subsalicylate	O[Bi]1OC(=O)c2ccccc2O1	Launched		antacid	gastroenterology	diarrhea
bisoctrizole	CC(C)(C)CC(C)(C)c1cc(Cc2cc(cc(c2O)-n2nc3ccccc3n2)C(C)(C)CC(C)(C)C)c(O)c(c1)-n1nc2ccccc2n1	Phase 2				
bisoprolol	CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1 |&1:5|	Launched	ADRB1	adrenergic receptor antagonist	cardiology	hypertension
bisphenol-A	CC(C)(c1ccc(O)cc1)c1ccc(O)cc1	Phase 1	AR|ESR1|ESR2|ESRRG|PPARG	synthetic estrogen		
bithionol	Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O	Withdrawn	ESR1|ESR2|MCL1	autotaxin inhibitor		
bitopertin	C[C@H](Oc1ccc(cc1C(=O)N1CCN(CC1)c1ncc(cc1F)C(F)(F)F)S(C)(=O)=O)C(F)(F)F	Phase 3	SLC6A5|SLC6A9	glycine transporter inhibitor		
bitoscanate	S=C=Nc1ccc(cc1)N=C=S	Preclinical		anthelmintic agent		
bivalirudin	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(O)=O	Launched	F2	thrombin inhibitor	cardiology	angina pectoris
BIX-01294	COc1cc2nc(nc(NC3CCN(Cc4ccccc4)CC3)c2cc1OC)N1CCCN(C)CC1	Preclinical	EHMT1|EHMT2	histone lysine methyltransferase inhibitor		
BIX-02188	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(N)=O)c2ccccc2)c1	Preclinical	MAP2K5	MEK inhibitor		
BIX-02189	CN(C)Cc1cccc(N\C(=C2/C(=O)Nc3cc(ccc23)C(=O)N(C)C)c2ccccc2)c1	Preclinical	MAP2K5|MAPK7	MEK inhibitor		
BL-5583	OC(=O)c1cc2ccccc2s1	Preclinical		hypercalcaemic agent		
blebbistatin-(+/-)	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |&1:10	Preclinical	MYH14|MYH2	ATPase inhibitor		
blebbistatin-(-)	Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccccc1 |t:5|	Preclinical		ATPase inhibitor		
bleomycetin	C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1)C(=O)NCCc1nc(cs1)-c1nc(cs1)C(=O)NCCCNCCCCN	Launched		EGFR expression inhibitor		
bleomycin	[H][C@]1(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]2O)[C@@H](O[C@H]([C@H](NC(=O)c2nc(nc(N)c2C)[C@H](CC(N)=O)NC[C@@H](N)C(N)=O)C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@@H](C)O)C(=O)NCCc2nc(cs2)-c2nc(cs2)C(=O)NCCC[S+](C)C)c2c[nH]cn2)O[C@H](CO)[C@H](O)[C@H]1O	Launched		DNA synthesis inhibitor	hematologic malignancy, pulmonary, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, pleural effusion, testicular carcinoma, squamous cell carcinoma
blonanserin	CCN1CCN(CC1)c1cc(-c2ccc(F)cc2)c2CCCCCCc2n1	Launched	DRD2|HTR2A	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia
BLU9931	COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(Nc3c(C)cccc3NC(=O)C=C)ncc2c1	Preclinical	FGFR4	FGFR inhibitor		
BLZ945	CNC(=O)c1cc(Oc2ccc3nc(N[C@@H]4CCCC[C@H]4O)sc3c2)ccn1	Phase 1/Phase 2		CSF1R inhibitor		
BML-190	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N3CCOCC3)c2c1	Preclinical	CNR2	cannabinoid receptor inverse agonist		
BML-284	COc1cccc(c1)-c1cc(NCc2ccc3OCOc3c2)nc(N)n1	Preclinical		WNT agonist		
BMS-CCR2-22	CSc1ccc(cc1)C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)CNC(=O)c1cc(ccc1NC(=O)NC(C)C)C(F)(F)F	Preclinical	CCR2	CC chemokine receptor antagonist		
BMS-182874	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1onc(C)c1C	Phase 2	EDNRA	endothelin receptor antagonist		
BMS-191011	Oc1ccc(Cl)cc1Cn1nc(oc1=O)-c1ccc(cc1)C(F)(F)F	Preclinical	KCNMA1	potassium channel activator		
BMS-191095	CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N(Cc1ncc[nH]1)c1ccc(Cl)cc1)C#N	Phase 1		KATP activator, potassium channel agonist		
BMS-207940	CN(Cc1cc(ccc1-c1ccccc1S(=O)(=O)Nc1noc(C)c1C)-c1ncco1)C(=O)CC(C)(C)C	Preclinical		endothelin receptor antagonist		
BMS-214662	O=S(=O)(N1Cc2cc(ccc2N(Cc2cnc[nH]2)C[C@H]1Cc1ccccc1)C#N)c1cccs1	Phase 1		farnesyltransferase inhibitor		
BMS-265246	CCCCOc1c(cnc2n[nH]cc12)C(=O)c1c(F)cc(C)cc1F	Preclinical	CDK1|CDK2	CDK inhibitor		
BMS-299897	C[C@@H](N(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1)c1ccc(F)cc1CCCC(O)=O	Phase 1		gamma secretase inhibitor		
BMS-309403	CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1	Preclinical	FABP4	fatty acid binding protein inhibitor		
BMS-345541	Cc1cnc2c(NCCN)nc3ccc(C)cc3n12	Preclinical	CHUK|IKBKB	IKK inhibitor		
BMS-387032	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1	Phase 1	CDK2|CDK7|CDK9	CDK inhibitor, cell cycle inhibitor, MCL1 inhibitor		
BMS-470539	CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)[C@@H](N)Cc1cncn1C)c1ccccc1	Preclinical	MC1R	melanocortin receptor agonist		
BMS-536924	Cc1cc(cc2[nH]c(nc12)-c1c(NC[C@@H](O)c2cccc(Cl)c2)cc[nH]c1=O)N1CCOCC1	Preclinical	AKT1|CCNE1|CDK2|CYP3A4|ERBB2|IGF1R|KDR|LCK|MAPK1|MET|PDGFRA|PDGFRB	IGF-1 inhibitor		
BMS-566419	CCN1CCN(CC1)c1ccc(cn1)C(C)(C)NC(=O)c1cc2[nH]c3ccccc3c(=O)c2cc1F	Preclinical	IMPDH1|IMPDH2	inosine monophosphate dehydrogenase inhibitor		
BMS-582949	CCCNC(=O)c1cn2ncnc(Nc3cc(ccc3C)C(=O)NC3CC3)c2c1C	Phase 2		p38 MAPK inhibitor		
BMS-587101	CN1C(=O)N(C(=O)[C@]11CN(Cc2cc(cs2)C(O)=O)C[C@H]1c1ccc(cc1)C#N)c1cc(Cl)cc(Cl)c1	Phase 2	ITGAL|ITGB2	integrin antagonist		
BMS-599626	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4n(Cc5cccc(F)c5)ncc4c3)c12	Phase 1	EGFR|ERBB2|ERBB4	EGFR inhibitor, protein tyrosine kinase inhibitor		
BMS-626529	COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	Phase 3		HIV attachment inhibitor		
BMS-626531	Cc1c(cnn1-c1ncccc1C(F)(F)F)C(=O)Nc1cc(ccc1C)C(=O)NC1CC1	Phase 1		p38 MAPK inhibitor		
BMS-649	CC1(C)CCC(C)(C)c2cc(ccc12)C1(OCCO1)c1ccc(cc1)C(O)=O	Preclinical	RXRA	retinoid receptor agonist		
BMS-688521	CN1C(=O)N(C(=O)[C@]11CN(C[C@H]1c1ccc(cc1)C#N)c1ccc(cn1)C(O)=O)c1cc(Cl)cc(Cl)c1	Preclinical	ICAM1	ICAM1 antagonist, leukocyte function-associated antigen receptor antagonist		
BMS-690514	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1	Phase 2	EGFR|ERBB2|FLT3|KDR	EGFR inhibitor, VEGFR inhibitor		
BMS-707035	Cn1c(nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)N1CCCCS1(=O)=O	Phase 2		HIV integrase inhibitor		
BMS-754807	C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1	Phase 2	AKT1|IGF1R	IGF-1 inhibitor		
BMS-770767	O[C@@]12CC[C@@](CC1)(C2)c1nnc2c(Oc3ccccc3Cl)cccn12 |r|	Phase 2		11-beta-HSD1 inhibitor		
BMS-777607	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1	Phase 1/Phase 2	AXL|MERTK|MET|MST1R|TYRO3	AXL kinase inhibitor, c-Met inhibitor, FLT3 inhibitor, hepatocyte growth factor receptor inhibitor, macrophage migration inhibiting factor inhibitor, tyrosine kinase inhibitor		
BMS-779788	CC(C)(O)c1cn(c(n1)C(C)(C)c1ccccc1Cl)-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O	Phase 1		LXR agonist		
BMS-806	COc1ccnc2[nH]cc(C(=O)C(=O)N3CCN(C[C@H]3C)C(=O)c3ccccc3)c12	Phase 1		HIV attachment inhibitor		
BMS-813160	CC(=O)N[C@@H]1C[C@@H](CC[C@@H]1N1CC[C@H](Nc2ncnc3cc(nn23)C(C)(C)C)C1=O)NC(C)(C)C	Phase 2		CC chemokine receptor antagonist		
BMS-817378	Nc1nccc(Oc2ccc(NC(=O)c3cn(COP(O)(O)=O)cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	Phase 1	KDR|MET	c-Met inhibitor, VEGFR inhibitor		
BMS-833923	CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1	Phase 2	SMO	smoothened receptor antagonist		
BMS-863233	Clc1ccc2oc3c(nc([nH]c3=O)[C@@H]3CCCN3)c2c1	Phase 1/Phase 2	CDC7|PIM1	CDC inhibitor		
BMS-906024	CN1c2ccccc2C(=N[C@H](NC(=O)[C@H](CCC(F)(F)F)[C@H](CCC(F)(F)F)C(N)=O)C1=O)c1ccccc1 |c:9|	Phase 1		gamma secretase inhibitor		
BMS-911543	CCn1c(cc2c1nc(Nc1cc(C)n(C)n1)c1ncn(C)c21)C(=O)N(C1CC1)C1CC1	Phase 1/Phase 2		JAK inhibitor		
BMS-935177	Cc1c(cccc1-n1cnc2ccccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O	Preclinical		Bruton's tyrosine kinase (BTK) inhibitor		
BMS-983970	NC(=O)[C@@H](CC1CC1)[C@@H](CCC(F)(F)F)C(=O)N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O |t:20|	Phase 1		notch signaling inhibitor		
BMS-986020	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(cc1)-c1ccc(cc1)C1(CC1)C(O)=O)c1ccccc1	Phase 2	LPAR1	lysophosphatidic acid receptor antagonist		
BMS-986142	Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1c(F)cc(C(N)=O)c2[nH]c3C[C@H](CCc3c12)C(C)(C)O	Phase 2		Bruton's tyrosine kinase (BTK) inhibitor		
BMS-986158	Cc1nnn(C)c1-c1cnc2c(c1)n([C@@H](C1CCOCC1)c1ccccc1)c1cc(ccc21)C(C)(C)O	Phase 1/Phase 2		bromodomain inhibitor		
BMS-986195	CC#CC(=O)N[C@H]1CCCN(C1)c1c(F)cc(C(N)=O)c2[nH]c(C)c(C)c12	Phase 1		Bruton's tyrosine kinase (BTK) inhibitor		
BMS-986205	[H][C@]1(CC[C@@H](CC1)c1ccnc2ccc(F)cc12)[C@@H](C)C(=O)Nc1ccc(Cl)cc1	Phase 3		indoleamine 2,3-dioxygenase inhibitor		
BMY-14802	O[C@@H](CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1 |&1:1|	Phase 2	HTR1A	sigma receptor antagonist		
BMY-45778	OC(=O)COc1cccc(c1)-c1ocnc1-c1nc(c(o1)-c1ccccc1)-c1ccccc1	Preclinical	PTGIR	IP1 prostacyclin receptor agonist		
BMY-7378	COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1	Preclinical	ADRA1A|ADRA1B|ADRA1D|HTR1A	adrenergic receptor antagonist, serotonin receptor antagonist		
BNC105	COc1ccc2c(C(=O)c3cc(OC)c(OC)c(OC)c3)c(C)oc2c1O	Phase 2		tubulin polymerization inhibitor		
BNTX		Preclinical	OPRD1|OPRK1|OPRM1	opioid receptor antagonist		
boceprevir	CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)N[C@@H](CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C |a:8	Launched	CMA1|CTSA|CTSF|CTSK|CTSL|CTSS	HCV inhibitor	infectious disease	hepatitis C
bonaphthone	Brc1ccc2C(=O)C(=O)C=Cc2c1 |c:9|	Phase 3				
bopindolol	Cc1cc2c(OC[C@@H](CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1 |&1:7|	Launched		adrenergic receptor antagonist	cardiology	hypertension, coronary artery disease (CAD)
bornyl-acetate	CC(=O)O[C@H]1C[C@H]2CC[C@@]1(C)C2(C)C |&1:4	Preclinical				
boronophenylalanine	N[C@@H](Cc1ccc(cc1)B(O)O)C(O)=O	Phase 2				
bortezomib	CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O	Launched	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9|PSMD1|PSMD2|RELA	NFkB pathway inhibitor, proteasome inhibitor	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL)
BOS-172722	CCOc1cc(ccc1Nc1ncc2cc(C)nc(NCC(C)(C)C)c2n1)-c1nncn1C	Phase 1		monopolar spindle 1 kinase inhibitor		
bosentan	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(cc2)C(C)(C)C)nc(nc1OCCO)-c1ncccn1	Launched	EDNRA|EDNRB	endothelin receptor antagonist	pulmonary	pulmonary arterial hypertension (PAH)
bosutinib	COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl	Launched	ABL1|BCR|CAMK1D|CAMK2G|CDK2|FRK|FYN|HCK|LYN|MAP2K1|MAP2K2|MAP3K2|MAP4K5|SRC|STK10|STK24|STK4|TNK2|TXK	Abl kinase inhibitor, Bcr-Abl kinase inhibitor, SRC inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
BP-554	C(COc1ccc2OCOc2c1)CN1CCN(CC1)c1ccccc1	Preclinical	HTR1A	serotonin receptor agonist		
BP-897	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1	Phase 2	ADRA1A|ADRA1D|ADRA2A|DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2B	dopamine receptor agonist		
BQ-123	[H][C@@]12CCCN1C(=O)[C@@]([H])(CC(O)=O)NC(=O)[C@@H](Cc1c[nH]c3ccccc13)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC2=O)C(C)C	Phase 2	EDNRA	endothelin receptor antagonist		
BQ-788	CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(O)=O	Phase 1	EDNRB	endothelin receptor antagonist		
BQU57	Cc1nn(C)c2OC(=N)C(C#N)[C@@H](c12)c1ccc(cc1)C(F)(F)F |&1:12	Preclinical	RALA|RALB	Ras GTPase inhibitor		
BRD4770	COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1	Preclinical	EHMT2	histone lysine methyltransferase inhibitor		
BRD7389	O=C1c2ccccc2-c2c(NCCc3ccccc3)c(=O)[nH]c3cccc1c23	Preclinical	RPS6KA1|RPS6KA2|RPS6KA3	ribosomal protein inhibitor		
BRD9876	CC(C)(C)c1ccc2cc(C#N)c(cc2c1)C#N	Preclinical	KIF11	kinesin inhibitor		
brefeldin-A	C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1 |t:5	Preclinical	ARF1|CYTH2	protein synthesis inhibitor		
bremelanotide	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(O)=O	Launched	MC1R|MC2R|MC3R|MC4R|MC5R	melanocortin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
brequinar	Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F	Phase 2	DHODH	dihydroorotate dehydrogenase inhibitor		
bretazenil	CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21	Phase 2	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6	GABA benzodiazepine site receptor partial agonist		
bretylium	CC[N+](C)(C)Cc1ccccc1Br	Launched	ATP1A1	norepinephrine inhibitor	cardiology	ventricular arrhythmias, ventricular fibrillation (VF), ventricular tachycardia (VT)
brexpiprazole	O=c1ccc2ccc(OCCCCN3CCN(CC3)c3cccc4sccc34)cc2[nH]1	Launched	DRD2	dopamine receptor partial agonist	neurology/psychiatry	depression, schizophrenia
briciclib	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(OP(O)(O)=O)c2)c(OC)c1	Phase 1	CCND1	cyclin D inhibitor		
brigatinib	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1	Launched	ALK|EGFR	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
brilliant-green	CCN(CC)c1ccc(cc1)[C+](c1ccccc1)c1ccc(cc1)N(CC)CC	Launched			infectious disease	antiseptic
brimonidine	Brc1c(NC2=NCCN2)ccc2nccnc12 |t:4|	Launched	ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	ophthalmology	intraocular pressure, glaucoma, ocular hypertension
brincidofovir	CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](CO)Cn1ccc(N)nc1=O	Phase 3		antiviral		
brinzolamide	CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched	CA1|CA12|CA14|CA2|CA4|CA5A|CA7	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure, glaucoma, ocular hypertension
brivanib	C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C	Phase 3	CYP3A4|FGFR1|FLT1|KCNH2|KDR	FGFR inhibitor, VEGFR inhibitor		
brivanib-alaninate	C[C@H](COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C)OC(=O)[C@H](C)N	Phase 3	FGFR3	FGFR inhibitor, VEGFR inhibitor		
brivudine	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(\C=C\Br)c(=O)[nH]c1=O |a:2	Launched		DNA directed DNA polymerase inhibitor	infectious disease	shingles
BRL-15572	O[C@@H](CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1 |&1:1|	Preclinical	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6	serotonin receptor antagonist		
BRL-26314	OC(=O)[C@@H](Cc1ccccc1)NCc1ccc(Cl)cc1 |&1:3	Phase 1	LPL	cholesterol inhibitor		
BRL-37344	C[C@H](Cc1ccc(OCC(O)=O)cc1)NC[C@H](O)c1cccc(Cl)c1	Phase 2	ADRB1|ADRB2|ADRB3	adrenergic receptor agonist		
BRL-44408	C[C@H]1N(CC2=NCCN2)Cc2ccccc12 |&1:1	Preclinical	ADRA2A|ADRA2B|ADRA2C	adrenergic receptor antagonist		
BRL-50481	CN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical	PDE7A|PDE7B	phosphodiesterase inhibitor		
BRL-52537	Clc1ccc(CC(=O)N2CCCC[C@@H]2CN2CCCC2)cc1Cl |&1:13|	Preclinical	OPRK1	opioid receptor agonist		
BRL-54443	CN1CCC(CC1)c1c[nH]c2ccc(O)cc12	Preclinical	HTR1E|HTR1F	serotonin receptor agonist		
brolitene	OCCNC(=O)\C=C\c1ccccc1	Launched	RYR1	muscle relaxant	rheumatology	lumbago
bromantan	Brc1ccc(NC2C3CC4CC(C3)CC2C4)cc1	Launched		dopamine reuptake inhibitor, serotonin reuptake inhibitor	neurology/psychiatry	neurasthenia
bromebric-acid	COc1ccc(cc1)C(=O)C(\Br)=C\C(O)=O	Preclinical		DNA synthesis inhibitor, purine antagonist		
bromfenac	Nc1c(CC(O)=O)cccc1C(=O)c1ccc(Br)cc1	Withdrawn	PTGS1|PTGS2	cyclooxygenase inhibitor		
bromhexine	CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1	Launched		mucolytic agent	pulmonary	chest congestion
bromindione	Brc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Phase 2		anticoagulant		
bromisoval	CC(C)[C@@H](Br)C(=O)NC(N)=O |&1:3	Preclinical		anti-inflammatory agent		
bromocriptine	CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C |c:28|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7	dopamine receptor agonist	endocrinology, neurology/psychiatry	hyperprolactinemia, Parkinson's Disease, acromegaly
bromopride	CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC	Launched	DRD2	dopamine receptor antagonist	gastroenterology	nausea, vomiting, gastroesophageal reflux disease (GERD)
bromosporine	CCOC(=O)Nc1cc(nn2c(C)nnc12)-c1ccc(C)c(NS(C)(=O)=O)c1	Preclinical		bromodomain inhibitor		
bromperidol	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Br)cc1	Launched	DRD2	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
brompheniramine	CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1 |&1:5|	Launched	HRH1	histamine receptor antagonist	allergy, otolaryngology	allergic rhinitis, common cold
bronopol	OCC(Br)(CO)[N+]([O-])=O	Launched			obstetrics/gynecology	mastitis
bropirimine	Nc1nc(=O)c(Br)c([nH]1)-c1ccccc1	Phase 3		interferon inducer		
broxaldine	Cc1ccc2c(Br)cc(Br)c(OC(=O)c3ccccc3)c2n1	Preclinical				
broxaterol	CC(C)(C)NC[C@@H](O)c1cc(Br)no1 |&1:6	Phase 3	ADRB2	adrenergic receptor agonist		
broxuridine	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(Br)c(=O)[nH]c1=O	Phase 2		antimetabolite		
broxyquinoline	Oc1c(Br)cc(Br)c2cccnc12	Phase 1		antiprotozoal agent		
bruceantin	COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1[C@@H](C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O |a:4	Phase 2		protein synthesis inhibitor		
brucine	COc1cc2N3[C@H]4[C@@H]5[C@H](CC3=O)OCC=C3CN6CC[C@]4([C@@H]6C[C@H]53)c2cc1OC |t:15|	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	glycine receptor antagonist		
BS-181	CC(C)c1cnn2c(NCc3ccccc3)cc(NCCCCCCN)nc12	Preclinical	CDK7	CDK inhibitor		
BT-11	O=C(N1CCN(CC1)C(=O)c1cccc(n1)-c1nc2ccccc2[nH]1)c1cccc(n1)-c1nc2ccccc2[nH]1	Phase 2		cAMP stimulant		
BTB06584	[O-][N+](=O)c1ccc(cc1OC(=O)c1ccc(Cl)cc1)S(=O)(=O)c1ccccc1	Preclinical	ATP5F1	ATPase inhibitor		
BTB1	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)c1ccccc1	Preclinical	KIF18A	mitotic kinesin inhibitor		
BTK-IN-1	Clc1cccc(NCC(=O)N[C@@H]2CCCN(C2)c2ncnc3[nH]ccc23)c1 |&1:11	Preclinical		Bruton's tyrosine kinase (BTK) inhibitor		
BTS	Cc1ccc(cc1)S(=O)(=O)NCc1ccccc1	Preclinical				
BTS-54505	CC(C)C[C@@H](N)C1(CCC1)c1ccc(Cl)cc1 |&1:4|	Withdrawn	SLC6A2|SLC6A3|SLC6A4	dopamine reuptake inhibitor		
BTS-71321	CC(C)(NCCCn1ccnc1)c1ccc(Cl)cc1	Phase 2				
BTS-72664	C[C@@H](Oc1ccc(Cl)cc1)c1ccnc2ncnn12 |&1:1	Phase 1	GABBR1	GABA receptor antagonist		
BTT-3033	CN(c1ccc(NC(=O)Nc2ccccc2)cc1)S(=O)(=O)c1cnn(c1)-c1ccc(F)cc1	Preclinical	ITGA2|ITGB1	integrin inhibitor		
BTZ043-racemate	C[C@H]1COC2(CCN(CC2)c2nc(=O)c3cc(cc([N+]([O-])=O)c3s2)C(F)(F)F)O1 |&1:1	Phase 1/Phase 2		DPRE1 inhibitor		
BU-224	C1CN=C(N1)c1ccc2ccccc2n1 |c:2|	Preclinical	MAOA|MAOB	imidazoline receptor ligand		
BU-239	C1CN=C(N1)c1cnc2ccccc2n1 |c:2|	Preclinical		imidazoline receptor agonist, imidazoline receptor ligand		
bucetin	CCOc1ccc(NC(=O)C[C@@H](C)O)cc1 |&1:11	Withdrawn		analgesic agent		
bucillamine	CC(C)(S)C(=O)N[C@@H](CS)C(O)=O	Launched		immunosuppressant	rheumatology	rheumatoid arthritis
bucladesine	CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2CO[P@](O)(=O)O[C@H]2[C@H]1OC(=O)CCC |a:15	Launched	PRKACA	adenosine receptor agonist, cAMP stimulant	dermatology	skin ulcer
buclizine	CC(C)(C)c1ccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)cc1 |&1:15|	Launched	HRH1	histamine receptor antagonist	neurology/psychiatry	migraine headache
budesonide	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |a:5	Launched	NR3C1	glucocorticoid receptor agonist	gastroenterology	Crohn's disease
budipine	CC(C)(C)N1CCC(CC1)(c1ccccc1)c1ccccc1	Launched	GRIN1	glutamate receptor antagonist	neurology/psychiatry	Parkinson's Disease
bufexamac	CCCCOc1ccc(CC(=O)NO)cc1	Withdrawn	HDAC10|HDAC6	cyclooxygenase inhibitor		
buflomedil	COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1	Launched	ADRA1A	adrenergic receptor antagonist, calcium channel blocker	cardiology	peripheral artery disease (PAD)
bumetanide	CCCCNc1cc(cc(c1Oc1ccccc1)S(N)(=O)=O)C(O)=O	Launched	CFTR|GPR35|SLC12A1|SLC12A2|SLC12A4|SLC12A5	solute carrier family member inhibitor	cardiology	edema, congestive heart failure
bunazosin	CCCC(=O)N1CCCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1	Launched	ADRA1A	adrenergic receptor antagonist	ophthalmology	glaucoma, intraocular pressure
buparlisib	Nc1cc(c(cn1)-c1cc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 3	PIK3CA|PIK3CG	PI3K inhibitor		
buparvaquone	CC(C)(C)C1CCC(C[C@H]2C(=O)C(=O)c3ccccc3C2=O)CC1 |&1:9	Launched		antiprotozoal agent	infectious disease	protozoan infection
buphenine	CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1	Launched	ADRB2	adrenergic receptor agonist	rheumatology	Raynaud's disease
bupicomide	CCCCc1ccc(nc1)C(N)=O	Phase 1	ADRB1	adrenergic receptor antagonist		
bupivacaine	CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C |&1:9	Launched	KCNA5|SCN10A	sodium channel blocker	neurology/psychiatry	peripheral nerve block, caudal epidural block, lumbar epidural block
bupranolol	Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1 |&1:9	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist	cardiology, ophthalmology	hypertension, glaucoma
bupropion	C[C@@H](NC(C)(C)C)C(=O)c1cccc(Cl)c1 |&1:1	Launched	SLC6A2|SLC6A3	dopamine reuptake inhibitor	neurology/psychiatry	depression
buramate	OCCOC(=O)NCc1ccccc1	Preclinical		antiepileptic		
buserelin	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	Launched		gonadotropin releasing factor hormone receptor agonist	oncology, obstetrics/gynecology	prostate cancer, endometriosis
buspirone	O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1	Launched	DRD2|HTR1A	serotonin receptor agonist	neurology/psychiatry	generalized anxiety disorder (GAD)
busulfan	CS(=O)(=O)OCCCCOS(C)(=O)=O	Launched		DNA inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
butabindide	CCCCNC(=O)[C@@H]1Cc2ccccc2N1C(=O)[C@@H](N)CC	Preclinical	TPP2	tripeptidyl peptidase inhibitor		
butacaine	CCCCN(CCCC)CCCOC(=O)c1ccc(N)cc1	Launched		local anesthetic	neurology/psychiatry	local anesthetic
butaclamol	CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc([C@@H]2C1)c34	Phase 2	DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A	dopamine receptor antagonist		
butalbital	CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O	Launched	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2	GABA receptor antagonist	neurology/psychiatry	headache, muscle relaxant
butamben	CCCCOC(=O)c1ccc(N)cc1	Withdrawn		sodium channel blocker		
butaprost	CCCC1(CCC1)[C@H](O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC	Preclinical		prostaglandin receptor agonist		
butein	Oc1ccc(C(=O)\C=C\c2ccc(O)c(O)c2)c(O)c1	Preclinical	ACE	EGFR inhibitor, SRC inhibitor		
butenafine	CN(Cc1ccc(cc1)C(C)(C)C)Cc1cccc2ccccc12	Launched	SQLE	fungal squalene epoxidase inhibitor	infectious disease	tinea pedis, tinea cruris, tinea corporis
buthionine-sulfoximine	CCCCS(=N)(=O)CC[C@H](N)C(O)=O |a:9	Phase 1	GCLM	glutathione transferase inhibitor		
butibufen	CC[C@@H](C(O)=O)c1ccc(CC(C)C)cc1 |&1:2	Withdrawn		cyclooxygenase inhibitor		
butoconazole	Clc1ccc(CC[C@@H](Cn2ccnc2)Sc2c(Cl)cccc2Cl)cc1 |&1:7	Launched		bacterial cell wall synthesis inhibitor	infectious disease	vulvovaginal candidiasis
butofilolol	CCCC(=O)c1cc(F)ccc1OC[C@@H](O)CNC(C)(C)C |&1:14	Phase 2		adrenergic receptor antagonist		
butyl-paraben	CCCCOC(=O)c1ccc(O)cc1	Preclinical		DNA synthesis inhibitor		
butylated-hydroxyanisole	COc1ccc(O)c(c1)C(C)(C)C	Preclinical		antioxidant		
butylated-hydroxytoluene	Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Phase 1	CA2	carbonic anhydrase inhibitor		
butylidenephthalide	CCC\C=C1/OC(=O)c2ccccc12	Phase 1/Phase 2		cyclooxygenase inhibitor		
butylphthalide	CCCC[C@H]1OC(=O)c2ccccc12 |&1:4	Launched	KCNK2	potassium channel antagonist	neurology/psychiatry	stroke
butylscopolamine-bromide	CCCC[N@@+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6	Launched		cholinergic receptor antagonist	gastroenterology	abdominal pain
BU226	C1CN=C(N1)c1cc2ccccc2cn1 |c:2|	Preclinical		imidazoline receptor ligand		
BVD-523	CC(C)Nc1cc(-c2c[nH]c(c2)C(=O)N[C@H](CO)c2cccc(Cl)c2)c(Cl)cn1	Phase 2		MAP kinase inhibitor		
BVT-2733	CN1CCN(CC1)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1	Preclinical	HSD17B1	11-beta hydroxysteroid dehydrogenase inhibitor		
BVT-948	CC1(C)C(=O)NC2=C1C(=O)C(=O)c1ccccc21 |c:6|	Preclinical	PTPN1|PTPN11|PTPN2	tyrosine phosphatase inhibitor		
BW-A4C	CC(=O)N(O)C\C=C\c1cccc(Oc2ccccc2)c1	Phase 1	ALOX5	lipoxygenase inhibitor		
BW-B70C	C[C@@H](\C=C\c1cccc(Oc2ccc(F)cc2)c1)N(O)C(N)=O |&1:1	Preclinical	ALOX5	lipoxygenase inhibitor		
BW-180C	CC(C)C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O	Phase 2	OPRD1|OPRM1	opioid receptor agonist		
BW-348U87	C\C(=N/NC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	Preclinical		antiviral		
BW-373U86	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(O)c1	Preclinical	OPRD1	opioid receptor agonist		
BW-616U	CNC(=O)c1ccc2C(=O)c3ccccc3S(=O)(=O)c2c1	Preclinical	MAOA	monoamine oxidase inhibitor		
BW-723C86	C[C@@H](N)Cc1c[nH]c2ccc(OCc3cccs3)cc12 |&1:1|	Preclinical	HTR2A|HTR2B|HTR2C	serotonin receptor agonist		
BX-795	Ic1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCCNC(=O)c1cccs1	Preclinical	CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1	IKK inhibitor		
BX-912	Brc1cnc(Nc2cccc(NC(=O)N3CCCC3)c2)nc1NCCc1cnc[nH]1	Preclinical	CDK2|CHEK1|GSK3B|KDR|PDK1|PDPK1	pyruvate dehydrogenase kinase inhibitor		
BYK-204165	Cn1cccc1\C=C1/C(=O)NC(=O)c2ccccc12	Preclinical	PARP1	PARP inhibitor		
C-021	COc1cc2nc(nc(NC3CCCCCC3)c2cc1OC)N1CCC(CC1)N1CCCCC1	Preclinical	CCR4	CC chemokine receptor antagonist		
C-1	O=S(=O)(N1CCNCC1)c1cccc2cnccc12	Preclinical	PRKCA	protein kinase inhibitor		
C-751	CCOC(=O)c1cnc[nH]1	Preclinical				
CA-4948	Nc1ccc(cn1)-c1cccc(n1)C(=O)Nc1cnc2nc(oc2c1)N1CCOCC1	Phase 1		kinase inhibitor		
cabagin	C[S+](C)CC[C@H](N)C(O)=O	Launched			gastroenterology	dyspepsia
cabaletta	OC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2		pharmacological chaperone		
cabazitaxel	CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C |t:51|	Launched	TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	microtubule inhibitor	oncology	prostate cancer
cabergoline	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR7	dopamine receptor agonist	endocrinology	hyperprolactinemia
cabotegravir	C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	Phase 3		HIV integrase inhibitor		
cabozantinib	COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3)c2cc1OC	Launched	KDR|MET|RET	RET tyrosine kinase inhibitor, VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
CaCCinh-A01	CC(C)(C)[C@H]1CCc2c(C1)sc(NC(=O)c1ccco1)c2C(O)=O |&1:4	Preclinical	CLCA1	calcium-activated chloride channel inhibitor		
cadazolid	OC[C@H]1CN(C(=O)O1)c1ccc(OCC2(O)CCN(CC2)c2cc3n(cc(C(O)=O)c(=O)c3cc2F)C2CC2)c(F)c1	Phase 3		antibacterial 		
cadralazine	CCOC(=O)NNc1ccc(nn1)N(CC)C[C@@H](C)O |&1:17	Launched		adrenergic receptor antagonist	cardiology	hypertension
cafestol	C[C@@]12CCc3occc3[C@H]1CC[C@@]13C[C@@H](CC[C@@H]21)[C@@](O)(CO)C3	Launched		pregnane X receptor agonist		
caffeic-acid	OC(=O)\C=C\c1ccc(O)c(O)c1	Preclinical	ALOX5|MIF	HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor		
caffeic-acid-phenethyl-ester	Oc1ccc(\C=C\C(=O)OCCc2ccccc2)cc1O	Preclinical	RELA	HIV integrase inhibitor		
caffeine	Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Launched	ADORA1|ADORA2A|ADORA2B|ADORA3|ATM|ITPR1|ITPR2|ITPR3|PDE10A|PDE11A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|PIK3CA|PIK3CB|PIK3CD|PRKDC|RYR1|RYR2|RYR3	adenosine receptor antagonist, phosphodiesterase inhibitor	neurology/psychiatry	fatigue, drowsiness
calcifediol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched	VDR	vitamin D receptor agonist	endocrinology	hyperparathyroidism
calcipotriol	C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched	VDR	vitamin D receptor agonist	dermatology	psoriasis
calcitonin	[H]N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC1=O)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O |r|	Launched		calcitonin agonist	orthopedics	osteoporosis
calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched	VDR	vitamin D receptor agonist	endocrinology, orthopedics	hypocalcemia, hypoparathyroidism, osteoporosis
calcium-gluceptate	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O	Launched				
calcium-levofolinate	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	Launched				
Calhex-231	C[C@@H](N[C@H]1CCCC[C@@H]1NC(=O)c1ccc(Cl)cc1)c1cccc2ccccc12	Preclinical	CASR	calcium sensing receptor negative allosteric modulator		
calpeptin	CCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	Preclinical		calpain inhibitor		
camicinal	C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(CC3)Nc3cccc(F)c3)cc2)CCN1	Phase 2	MLNR	motilin receptor agonist		
CaMKII-IN-1	Cc1c(Cl)cccc1S(=O)(=O)Nc1nc(NCCc2ccccc2)nc2CCN(Cc3ccccc3)Cc12	Preclinical	AKT1|CAMK2A|CAMK4|MYLK	calcium/calmodulin dependent protein kinase inhibitor		
camobucol	CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	Preclinical		anti-inflammatory agent		
camostat-mesilate	CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(N)=N)cc2)cc1	Launched	PRSS1	protease inhibitor	gastroenterology	pancreatitis
camphor-(+)	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2	Phase 2				
camphor-(1R)	CC1(C)[C@@H]2CC[C@]1(C)C(=O)C2	Phase 1	TRPV1	TRPV activator		
camptothecin	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4cc3Cn1c2=O	Phase 3	TOP1	topoisomerase inhibitor		
camylofine-chlorhydrate	CCN(CC)CCN[C@@H](C(=O)OCCC(C)C)c1ccccc1 |&1:8|	Launched			gastroenterology	abdominal pain
canagliflozin	Cc1ccc(cc1Cc1ccc(s1)-c1ccc(F)cc1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Launched	SLC5A1|SLC5A2	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
candesartan	CCOc1nc2cccc(C(O)=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Launched	AGTR1	angiotensin receptor antagonist	cardiology	hypertension, congestive heart failure
candesartan-cilexetil	CCOc1nc2cccc(C(=O)O[C@@H](C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |&1:13	Launched		angiotensin receptor antagonist	cardiology	hypertension, congestive heart failure, hypertension
candicidin	C[C@@H](C[C@@H](C)[C@H]1OC(=O)CC(=O)CCCC(=O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)C[C@@H](O)[C@@H]([C@@H](O)C[C@@H](O[C@@H]2O[C@H](C)[C@H](O)[C@@H](O)[C@@H]2N)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@@H]1C)C(O)=O)[C@@H](O)CC(=O)c1ccc(N)cc1 |a:38	Launched		fungal ergosterol inhibitor	infectious disease	vulvovaginal candidiasis
canertinib	Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl	Phase 3	AKT1|EGFR|ERBB2|ERBB4	EGFR inhibitor		
cangrelor	CSCCNc1nc(SCCC(F)(F)F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)C(Cl)(Cl)P(O)(O)=O)[C@@H](O)[C@H]1O	Launched		purinergic receptor antagonist	cardiology	myocardial infarction
canrenone	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]21CCC(=O)O1 |c:6	Withdrawn	NR3C2	mineralocorticoid receptor antagonist		
cantharidin	C[C@]12[C@@H]3CC[C@@H](O3)[C@@]1(C)C(=O)OC2=O	Launched		protein phosphatase inhibitor	dermatology	blisters
capadenoson	Nc1nc(SCc2csc(n2)-c2ccc(Cl)cc2)c(C#N)c(-c2ccc(OCCO)cc2)c1C#N	Phase 2	ADORA1	adenosine receptor agonist		
capecitabine	CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O	Launched	TYMS	DNA synthesis inhibitor, thymidylate synthase inhibitor	oncology	breast cancer, colorectal cancer
capobenic-acid	COc1cc(cc(OC)c1OC)C(=O)NCCCCCC(O)=O	Preclinical				
capreomycin	C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@@H](NC(=O)\C(NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O)=C/NC(N)=O)[C@H]1CCN=C(N)N1 |t:43|	Launched		protein synthesis inhibitor	infectious disease	tuberculosis
capromorelin	CN1N=C2CCN(C[C@@]2(Cc2ccccc2)C1=O)C(=O)[C@@H](COCc1ccccc1)NC(=O)C(C)(C)N |t:2|	Preclinical		growth hormone secretagogue receptor agonist		
caprylic-acid	CCCCCCCC(O)=O	Launched				
capsaicin	COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O	Launched	CFTR|TRPV1	TRPV agonist	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis
capsazepine	Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc1ccc(Cl)cc1	Preclinical	TRPV1|TRPV4	TRPV agonist		
captamine	CN(C)CCS	Preclinical				
captan	ClC(Cl)(Cl)SN1C(=O)[C@H]2CC=CC[C@@H]2C1=O |r	Phase 1				
captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O	Launched	ACE|LTA4H|MMP2|MMP9	angiotensin converting enzyme inhibitor	cardiology, endocrinology, nephrology	hypertension, congestive heart failure, myocardial infarction, diabetes mellitus, diabetic nephropathy
caracemide	CNC(=O)ON(C(C)=O)C(=O)NC	Phase 2	RRM1	ribonucleotide reductase inhibitor		
caramiphen	CCN(CC)CCOC(=O)C1(CCCC1)c1ccccc1	Launched	CHRM1|CHRM2	cholinergic receptor antagonist	neurology/psychiatry	Parkinson's Disease
carazolol	CC(C)NC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:5	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist	cardiology	angina pectoris, cardiac arrythmia, hypertension, myocardial infarction
carbachol	C[N+](C)(C)CCOC(N)=O	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA2	cholinergic receptor agonist	ophthalmology	intraocular pressure
carbadox	COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-]	Launched		other antibiotic	infectious disease, gastroenterology	dysentry, enteritis
carbamazepine	NC(=O)N1c2ccccc2C=Cc2ccccc12 |c:11|	Launched	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	carboxamide antiepileptic	neurology/psychiatry	seizures
carbaril	CNC(=O)Oc1cccc2ccccc12	Launched		acetylcholinesterase inhibitor		
carbarsone	NC(=O)Nc1ccc(cc1)[As](O)(O)=O	Launched		antiprotozoal agent	infectious disease	amebiasis
carbazochrome	CN1[C@@H](CC2=C\C(=N\NC(N)=O)C(=O)C=C12)S(O)(=O)=O |&1:2	Launched			hematology	hemorrhage
carbendazim	COC(=O)Nc1nc2ccccc2[nH]1	Launched	TP53|TUBB	microtubule inhibitor, tubulin polymerization inhibitor	infectious disease	fungicide
carbenicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@@H](C(O)=O)c3ccccc3)C(=O)N2[C@H]1C(O)=O |a:4	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections
carbenoxolone	CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)OC(=O)CCC(O)=O |t:18|	Launched	GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|HSD11B1|PANX1|PANX2|PANX3	11-beta hydroxysteroid dehydrogenase inhibitor	gastroenterology, dental	peptic ulcer disease (PUD), mouth inflammation
carbetapentane	CCN(CC)CCOCCOC(=O)C1(CCCC1)c1ccccc1	Launched	CHRM2	acetylcholine receptor antagonist	otolaryngology, pulmonary	common cold, nasal congestion, bronchitis
carbetocin	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Launched	OXTR	oxytocin receptor agonist	hematology	hemorrhage
carbidopa	C[C@@](Cc1ccc(O)c(O)c1)(NN)C(O)=O	Launched	DDC	aromatic L-amino acid decarboxylase inhibitor	neurology/psychiatry	Parkinson's Disease
carbimazole	CCOC(=O)n1ccn(C)c1=S	Launched	TPO	antithyroid agent	endocrinology	hyperthyroidism
carbinoxamine	CN(C)CCO[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:6|	Launched	HRH1	histamine receptor antagonist	allergy, ophthalmology, otolaryngology, dermatology	allergic rhinitis, conjunctivitis, vasomotor rhinitis, dermatographism
carboplatin	N[Pt]1(N)OC(=O)C2(CCC2)C(=O)O1	Launched		DNA alkylating agent, DNA inhibitor	oncology	ovarian cancer
carboxyamidotriazole	NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N	Phase 3	CXCL8	calcium channel blocker		
carboxylosartan	CCCCc1nc(Cl)c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Phase 1	AGTR1	angiotensin antagonist		
carboxypyridine-disulfide	OC(=O)c1ccc(SSc2ccc(cn2)C(O)=O)nc1	Phase 2				
cardiogenol-C	COc1ccc(Nc2nccc(NCCO)n2)cc1	Preclinical		cardiomyogenesis inducer		
cardionogen-1	C1CCC(CC1)c1nn2c(nnc2s1)-c1ccco1	Preclinical	CTNNB1	WNT signaling inhibitor		
carebastine	CC(C)(C(O)=O)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Phase 1	HRH1	histamine receptor antagonist		
carfilzomib	CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1	Launched	PSMA1|PSMA2|PSMA3|PSMA4|PSMA5|PSMA6|PSMA7|PSMA8|PSMB1|PSMB10|PSMB11|PSMB2|PSMB3|PSMB4|PSMB5|PSMB6|PSMB7|PSMB8|PSMB9	proteasome inhibitor	hematologic malignancy	multiple myeloma
carglumic-acid	NC(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	CPS1	carbamoyl phosphate synthase activator	metabolism	hyperammonemia
caricotamide	NC(=O)CN1C=CCC(=C1)C(N)=O |c:5	Phase 2	NQO2	NADPH quinone oxidoreductase inhibitor		
cariporide	CC(C)c1ccc(cc1S(C)(=O)=O)C(=O)N=C(N)N	Phase 3	SLC9A1	sodium/hydrogen exchanger inhibitor		
cariprazine	CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)c2cccc(Cl)c2Cl)CC1 |r|	Launched	DRD2|DRD3	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
carmofur	CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O	Launched	TYMS	thymidylate synthase inhibitor	oncology	breast cancer, colorectal cancer
carmoterol	COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1	Phase 2	ADRB2	adrenergic receptor agonist		
carmoxirole	OC(=O)c1ccc2[nH]cc(CCCCN3CCC(=CC3)c3ccccc3)c2c1 |c:17|	Phase 2	DRD2	dopamine receptor agonist		
carmustine	[O-][NH2+]N(CCCl)C(=O)NCCCl	Launched	GSR	DNA alkylating agent, DNA inhibitor	hematologic malignancy, oncology	non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma
carnitine-(D/L)	C[N+](C)(C)C[C@@H](O)CC(O)=O |&1:5|	Phase 3				
carnosine	NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O |&1:6	Phase 2		antiglycating agent		
caroverin	CCN(CC)CCn1c2ccccc2nc(Cc2ccc(OC)cc2)c1=O	Phase 3		cytochrome P450 inhibitor		
caroxazone	NC(=O)CN1Cc2ccccc2OC1=O	Withdrawn	MAOA|MAOB	monoamine oxidase inhibitor		
carprofen	C[C@@H](C(O)=O)c1ccc2c(c1)[nH]c1ccc(Cl)cc21 |&1:1	Launched	PTGS2	cyclooxygenase inhibitor	rheumatology	osteoarthritis
carsalam	O=c1[nH]c(=O)c2ccccc2o1	Preclinical		analgesic agent		
carteolol	CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist	ophthalmology	intraocular pressure, glaucoma, ocular hypertension
carumonam	NC(=O)OC[C@@H]1[C@H](NC(=O)C(=N/OCC(O)=O)\c2csc(N)n2)C(=O)N1S(O)(=O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections, gram-negative bacterial infections
carvedilol	COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12 |&1:13|	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist	cardiology	myocardial infarction, hypertension
carzenide	NS(=O)(=O)c1ccc(cc1)C(O)=O	Preclinical	CA1|CA12|CA14|CA2|CA6|CA9			
casanthranol-variant	OC[C@H]1O[C@@H](Oc2c3cccc(O)c3c(O)c3c(O)cc(CO)cc23)[C@H](O)[C@H](O)[C@H]1O	Launched			gastroenterology	constipation
casin	OCCN[C@H]1CCCc2c1[nH]c1ccc(cc21)-c1ccccc1 |&1:4	Preclinical	CDC42	GTPase inhibitor		
caspofungin	[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]1[C@@H](O)CCN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@H](O)CCN)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@@H](C)O	Launched		bacterial cell wall synthesis inhibitor, fungal 1,3-beta-D-glucan synthase inhibitor	infectious disease	candidemia, esophageal candidiasis, aspergillosis, peritonitis, fungal infection
castanospermine	O[C@H]1CCN2C[C@H](O)[C@@H](O)[C@H](O)[C@@H]12	Phase 2	GAA|GBA	glucosidase inhibitor		
catharanthine	CCC1=C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@](C2)([C@@H]13)C(=O)OC |t:2|	Preclinical		tubulin polymerization inhibitor		
cathepsin-inhibitor-1	Cn1nc(cc1C(=O)N[C@@H](Cc1cccc(Cl)c1)C(=O)NCC#N)C(C)(C)C	Preclinical	CTSB|CTSL|CTSV	cathepsin inhibitor		
CAY10505	Fc1ccc(cc1)-c1ccc(\C=C2\SC(=O)NC2=O)o1	Preclinical	PIK3CG	PI3K inhibitor		
CB-03-01	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO |t:12|	Phase 3	AR	androgen receptor antagonist		
CB-10-277	CN(C)\N=N\c1ccc(cc1)C(O)=O	Phase 1		DNA synthesis inhibitor		
CB-5083	Cc1cc2c(cccc2n1-c1nc2CCOCc2c(NCc2ccccc2)n1)C(N)=O	Phase 1	VCP	valosin-containing protein inhibitor		
CB-839	FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1	Phase 2	GLS	glutaminase inhibitor		
CBiPES	CCS(=O)(=O)N(Cc1cccnc1)c1cccc(c1)-c1ccc(cc1)C#N	Preclinical	GRM2	glutamate receptor positive allosteric modulator		
cbl0137	CC(C)NCCn1c2ccc(cc2c2cc(ccc12)C(C)=O)C(C)=O	Phase 1		histone chaperone inhibitor		
CBS-1114	NC(=NNc1ccccc1)c1ccccc1	Phase 1	ALOX5	lipoxygenase inhibitor		
CC-115	CCN1C(=O)CN=C2NC=C(N=C12)c1ccc(nc1C)-c1nnc[nH]1 |c:9	Phase 2	MTOR	DNA protein kinase inhibitor, mTOR inhibitor		
CC-223	CO[C@H]1CC[C@@H](CC1)N1C(=O)CNc2ncc(nc12)-c1ccc(nc1)C(C)(C)O |r|	Phase 2	MTOR	mTOR inhibitor		
CC-401	C(CN1CCCCC1)Oc1cccc(c1)-c1n[nH]c2ccc(cc12)-c1nnc[nH]1	Phase 1	MAPK8	JNK inhibitor		
CC-90003	COc1cc(Nc2ncc(c(Nc3ccc(C)cc3NC(=O)C=C)n2)C(F)(F)F)c(C)cn1	Phase 1		MAP kinase inhibitor		
CC-930	O[C@H]1CC[C@@H](CC1)Nc1ncc2nc(Nc3c(F)cc(F)cc3F)n([C@H]3CCOC3)c2n1	Phase 2		JNK inhibitor		
CCG-1423	C[C@@H](ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |&1:1	Preclinical	RHOC|SRF	apoptosis stimulant		
CCG-50014	Cc1ccc(cc1)-n1sc(=O)n(Cc2ccc(F)cc2)c1=O	Preclinical	RGS4|RGS8	G protein signaling inhibitor		
CCG-63802	Cc1cccc(Oc2nc3c(C)cccn3c(=O)c2\C=C(/C#N)c2nc3ccccc3s2)c1	Preclinical	RGS4	G protein signaling inhibitor		
CCG-63808	Cc1cccn2c1nc(Oc1ccc(F)cc1)c(\C=C(/C#N)c1nc3ccccc3s1)c2=O	Preclinical	RGS4	G protein signaling inhibitor		
CCMI	Cc1cc(on1)C(=CNc1ccc(Cl)cc1)C(=O)Nc1ccc(Cl)cc1	Preclinical	CHRNA7	acetylcholine receptor allosteric modulator		
CCMQ	OC(=O)Cc1cc2ccccc2nc1C(O)=O	Preclinical		homoquinolinic acid binding inhibitor		
CCT-031374	O=C(CN1C2=NCCN2c2ccccc12)c1ccc(cc1)-c1ccccc1 |t:4|	Preclinical	CTNNB1	WNT signaling inhibitor		
CCT018159	CCc1cc(-c2n[nH]c(C)c2-c2ccc3OCCOc3c2)c(O)cc1O	Preclinical	HSP90AA1|HSP90AB1	HSP inhibitor		
CCT128930	NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12	Preclinical		AKT inhibitor		
CCT129202	CN(C)c1ccc(cc1)-c1nc2ncc(Cl)c(N3CCN(CC(=O)Nc4nccs4)CC3)c2[nH]1	Preclinical	AURKA|AURKB|AURKC	Aurora kinase inhibitor		
CCT137690	CN1CCN(CC1)c1ccc(cc1)-c1nc2ncc(Br)c(N3CCN(Cc4cc(C)on4)CC3)c2[nH]1	Preclinical	AURKA|AURKB|AURKC	Aurora kinase inhibitor		
CCT196969	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc4nc(O)cnc34)cc2F)n(n1)-c1ccccc1	Preclinical		RAF inhibitor		
CCT245737	FC(F)(F)c1cnc(Nc2cnc(cn2)C#N)cc1NC[C@H]1CNCCO1	Preclinical		kinase inhibitor		
CC4	O=c1cccc2[C@@H]3C[C@@H](CN(CCN4C[C@@H]5C[C@H](C4)c4cccc(=O)n4C5)C3)Cn12	Preclinical	CHRNB2	nicotinic receptor agonist		
CD-1530	OC(=O)c1ccc(cc1)-c1ccc2cc(O)c(cc2c1)C12CC3CC(CC(C3)C1)C2	Preclinical	RARG	retinoid receptor agonist		
CD-437	OC(=O)c1ccc2cc(ccc2c1)-c1ccc(O)c(c1)C12CC3CC(CC(C3)C1)C2	Preclinical	RARG	retinoid receptor agonist		
CDBA	OC[C@H]1O[C@H]2O[C@H]3[C@@H](CO)O[C@@H](O[C@H]4[C@@H](CO)O[C@@H](O[C@H]5[C@@H](CO)O[C@@H](O[C@H]6[C@@H](CO)O[C@@H](O[C@H]7[C@@H](CO)O[C@@H](O[C@H]8[C@@H](CO)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O |&1:2	Phase 3				
CDK1-5-inhibitor	Nc1[nH]nc2nc3ccccc3nc12	Preclinical	CDK1|CDK5|GSK3B	CDK inhibitor, glycogen synthase kinase inhibitor		
CDK9-IN-6	COC[C@H](C)N[C@H]1CC[C@@H](CC1)Nc1cc(c(Cl)cn1)-c1cccc(NCC2(CCOCC2)C#N)n1	Preclinical	CDK9	CDK inhibitor		
CDPPB	O=C(Nc1cc(nn1-c1ccccc1)-c1ccccc1)c1cccc(c1)C#N	Preclinical	GRM5	glutamate receptor positive allosteric modulator		
cebranopadol	CN(C)[C@]1(CC[C@@]2(CC1)OCCc1c2[nH]c2ccc(F)cc12)c1ccccc1 |r|	Phase 3	OPRL1|OPRM1	opioid receptor agonist		
cediranib	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1	Phase 3	CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB	KIT inhibitor, VEGFR inhibitor		
cedrol	C[C@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O |&1:1	Phase 2				
cedrol-(+)	C[C@@H]1CC[C@H]2C(C)(C)[C@H]3C[C@@]12CC[C@@]3(C)O	Phase 2		sedative		
cefaclor	N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	Launched		bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology	pneumonia, skin infections, urinary tract infections, respiratory tract infections, tonsillitis, pharyngitis
cefadroxil	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:1|	Launched	SLC15A1|SLC15A2|SLC22A6|SLC22A8	bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology	urinary tract infections, skin infections, tonsillitis, pharyngitis
cefalonium	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc2cccs2)C3=O)C(O)=O)cc1 |t:8|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
cefamandole	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](O)c1ccccc1)C2=O)C(O)=O |t:9|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections, urinary tract infections, respiratory tract infections
cefamandole-nafate	Cn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](OC=O)c1ccccc1)C2=O)C(O)=O |t:9|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections, urinary tract infections, respiratory tract infections
cefathiamidine	CC(C)N\C(SCC(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)=N/C(C)C |c:19|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
cefazolin	Cc1nnc(SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cn2cnnn2)C3=O)C(O)=O)s1 |t:7|	Launched	PON1	bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections, skin infections, bacterial septicemia, endocarditis, surgical prophylaxis, bone and joint infections
cefcapene-pivoxil	CC\C=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:16|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections, pneumonia, urinary tract infections
cefdinir	Nc1nc(cs1)C(=N\O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:19|	Launched	MPO	bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology, pulmonary	pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis
cefditoren-pivoxil	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(\C=C/c3scnc3C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:20|	Launched		bacterial cell wall synthesis inhibitor	infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, tonsillitis, pharyngitis
cefepime	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |&1:7	Launched		bacterial cell wall synthesis inhibitor	infectious disease	pneumonia, urinary tract infections, skin infections, intra-abdominal infections
cefetamet	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:12|	Launched		bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology, pulmonary	ear infections, pneumonia, otitis, sinusitis, bronchitis, urinary tract infections
cefetamet-pivoxil	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C)c1csc(N)n1 |c:12|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
cefiderocol	[H][C@]12SCC(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\c1csc(N)n1)C(O)=O |c:26|	Launched		antibacterial 		
cefixime	Nc1nc(cs1)C(=N\OCC(O)=O)\C(=O)N[C@H]1[C@H]2SCC(C=C)=C(N2C1=O)C(O)=O |c:23|	Launched		bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology, pulmonary	urinary tract infections, otitis, pharyngitis, tonsillitis, gonorrhea, bronchitis
cefmenoxime	[H][C@]12SCC(CSc3nnnn3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C(O)=O |c:13|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections
cefmetazole	CO[C@]1(NC(=O)CSCC#N)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:23|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections, skin infections
cefminox	CO[C@]1(NC(=O)CSC[C@@H](N)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |c:26|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections
cefodizime	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(C)c(CC(O)=O)s3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:24|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	respiratory tract infections, skin infections, gonorrhea
cefonicid	O[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CS(O)(=O)=O)=C(N2C1=O)C(O)=O)c1ccccc1 |c:22|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
cefoperazone	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(CSc4nnnn4C)=C(N3C2=O)C(O)=O)c2ccc(O)cc2)C(=O)C1=O |c:26|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections
ceforanide	NCc1ccccc1CC(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3CC(O)=O)=C(N2C1=O)C(O)=O |c:29|	Launched		penicillin binding protein inhibitor	infectious disease	gram-negative bacterial infections
cefoselis	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(Cn3ccc(=N)n3CCO)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:22|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
cefotaxime	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(C)=O)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:16|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	respiratory tract infections, bone and joint infections, pelvic inflammatory disease, intra-abdominal infections, skin infections, meningitis, urinary tract infections, bacterial septicemia, gynecologic infections
cefotetan	CO[C@]1(NC(=O)C2SC(S2)=C(C(N)=O)C(O)=O)[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2	Launched		bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis
cefotiam	CN(C)CCn1nnnc1SCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1csc(N)n1)C2=O)C(O)=O |t:13|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	bacterial septicemia, bone and joint infections, respiratory tract infections, skin infections, urinary tract infections
cefotiam-cilexetil	C[C@@H](OC(=O)OC1CCCCC1)OC(=O)C1=C(CSc2nnnn2CCN(C)C)CS[C@H]2[C@@H](NC(=O)Cc3csc(N)n3)C(=O)N12 |&1:1	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
cefoxitin	CO[C@]1(NC(=O)Cc2cccs2)[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O |c:21|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections
cefozopran	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccn4ncccc34)=C(N2C1=O)C(O)=O)c1nsc(N)n1 |c:23|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
cefpiramide	Cc1cc(=O)c(c[nH]1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1 |c:29|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections
cefpirome	CO\N=C(\C(=O)N[C@H]1[C@H]2SCC(C[n+]3cccc4CCCc34)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections
cefpodoxime	COCC1=C(N2[C@H](SC1)[C@H](NC(=O)C(=N/OC)\c1csc(N)n1)C2=O)C(=O)O[C@@H](C)OC(=O)OC(C)C |a:6	Launched		bacterial cell wall synthesis inhibitor	otolaryngology, infectious disease, pulmonary	pharyngitis, pneumonia, bronchitis, gonorrhea, skin infections, urinary tract infections, sinusitis, tonsillitis
cefprozil	C\C=C\C1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccc(O)cc1)C2=O)C(O)=O |t:3|	Launched		bacterial cell wall synthesis inhibitor	otolaryngology, infectious disease, pulmonary	pharyngitis, tonsillitis, otitis, sinusitis, respiratory tract infections, skin infections, bronchitis
cefradine	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |c:17	Launched	CYP3A4	bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, urinary tract infections, tonsillitis, pharyngitis, pneumonia
cefsulodin	NC(=O)c1cc[n+](CC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@@H](c2ccccc2)S(O)(=O)=O)C3=O)C(O)=O)cc1 |t:8|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections
ceftaroline-fosamil	CCO\N=C(\C(=O)N[C@H]1[C@H]2SCC(Sc3nc(cs3)-c3cc[n+](C)cc3)=C(N2C1=O)C(O)=O)c1nc(=NP(O)(O)=O)s[nH]1 |c:27|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections, pneumonia
ceftazidime	CC(C)(O\N=C(/C(=O)N[C@H]1[C@H]2SCC(C[n+]3ccccc3)=C(N2C1=O)C(O)=O)c1csc(N)n1)C(O)=O |c:21|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	respiratory tract infections, skin infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections, meningitis
ceftibuten	Nc1nc(cs1)C(=C\CC(O)=O)\C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O |c:20|	Launched		bacterial cell wall synthesis inhibitor	pulmonary, otolaryngology	bronchitis, otitis, pharyngitis, tonsillitis
ceftiofur	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSC(=O)c3ccco3)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:21|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	pneumonia, respiratory tract infections
ceftizoxim	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:11|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	respiratory tract infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, intra-abdominal infections, bacterial septicemia, skin infections, bone and joint infections, meningitis
ceftobiprole	[H][C@]12SCC(\C=C3/CCN([C@@H]4CCNC4)C3=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\c1nsc(N)n1)C(O)=O |c:18|	Phase 3		antiinfective drug		
ceftriaxone	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(CSc3nc(=O)c(O)nn3C)=C(N2C1=O)C(O)=O)c1csc(N)n1 |c:23|	Launched		bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology	gonorrhea, pneumonia, otitis, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intra-abdominal infections, meningitis, surgical prophylaxis
cefuroxime	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(O)=O)c1ccco1 |c:16|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections
cefuroxime-axetil	CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(COC(N)=O)=C(N2C1=O)C(=O)O[C@@H](C)OC(C)=O)c1ccco1 |a:7	Launched		bacterial cell wall synthesis inhibitor	otolaryngology	pharyngitis, tonsillitis, otitis, sinusitis
celecoxib	Cc1ccc(cc1)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)(F)F	Launched	CA12|PDPK1|PTGS2	cyclooxygenase inhibitor	rheumatology, endocrinology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, primary dysmenorrhea (PD)
celgosivir	[H][C@]12[C@@H](O)CCN1C[C@H](OC(=O)CCC)[C@@H](O)[C@@H]2O	Phase 2		glucosidase inhibitor		
celiprolol	CCN(CC)C(=O)Nc1ccc(OC[C@@H](O)CNC(C)(C)C)c(c1)C(C)=O |&1:14|	Launched	ADRA2A|ADRB1|ADRB2	adrenergic receptor antagonist	genetics	Ehlers-Danlos syndrome (EDS)
cenerimod	CCc1cc(cc(C)c1OC[C@@H](O)CO)-c1noc(n1)-c1cc(OC)nc(c1)C1CCCC1	Phase 2		sphingosine 1-phosphate receptor modulator		
cenicriviroc	CCCCOCCOc1ccc(cc1)-c1ccc2N(CC(C)C)CCC\C(=C/c2c1)C(=O)Nc1ccc(cc1)[S@@](=O)Cc1cncn1CCC |c:27|	Phase 3		CC chemokine receptor antagonist		
cenobamate	NC(=O)O[C@@H](Cn1ncnn1)c1ccccc1Cl	Launched		GABA receptor modulator, voltage-gated sodium channel blocker		
centanafadine	C1[C@@H]2CNC[C@]12c1ccc2ccccc2c1	Phase 3		dopamine reuptake inhibitor		
centazolone	Nn1cnc2cc3ccccc3cc2c1=O	Phase 1		monoamine oxidase inhibitor		
centhaquin	Cc1cccc(c1)N1CCN(CCc2ccc3ccccc3n2)CC1	Phase 1		analgesic agent		
centpropazine	CCC(=O)c1ccc(OC[C@@H](O)CN2CCN(CC2)c2ccccc2)cc1 |&1:10	Phase 3		inositol monophosphatase inhibitor		
CEP-32496	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(on4)C(C)(C)C(F)(F)F)c3)c2cc1OC	Phase 1/Phase 2	BRAF|RAF1	RAF inhibitor		
CEP-33779	CN1CCN(CC1)c1cccc(Nc2nc3c(cccn3n2)-c2ccc(cc2)S(C)(=O)=O)c1	Preclinical	JAK2	JAK inhibitor		
CEP-37440	CNC(=O)c1ccccc1Nc1nc(Nc2ccc3C[C@H](CCCc3c2OC)N2CCN(CCO)CC2)ncc1Cl	Phase 1	ALK	ALK tyrosine kinase receptor inhibitor		
CEP-40783	COc1cc2nccc(Oc3ccc(NC(=O)c4cn(C(C)C)c(=O)n(-c5ccc(F)cc5)c4=O)cc3F)c2cc1OC	Preclinical		AXL kinase inhibitor		
cephalexin	CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O)C(O)=O |t:1|	Launched		bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology	respiratory tract infections, otitis, skin infections, bone and joint infections, genitourinary tract infections
cephalomannine	C\C=C(/C)C(=O)N[C@H]([C@@H](O)C(=O)O[C@H]1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O)c1ccccc1 |t:47|	Preclinical		DNA polymerase inhibitor		
cephalosporin-c-zn	CC(=O)OCC1=C2N3[C@H](SC1)[C@H](NC(=O)CCC[C@H](N)C(=O)O[Zn]OC2=O)C3=O |t:5|	Preclinical		bacterial cell wall synthesis inhibitor		
cephalothin	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)Cc1cccs1)C2=O)C(O)=O |t:5|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections, surgical prophylaxis
cephapirin	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CSc1ccncc1)C2=O)C(O)=O |t:5|	Launched		bacterial cell wall synthesis inhibitor	obstetrics/gynecology	mastitis
cepharanthine	COc1ccc2C[C@H]3N(C)CCc4cc(OC)c(Oc5c6OCOc6cc6CCN(C)[C@@H](Cc7ccc(Oc1c2)cc7)c56)cc34	Phase 2		NFkB pathway inhibitor		
cephradine	CC1=C(N2[C@@H](SC1)[C@H](NC(=O)[C@H](N)C1=CCC=CC1)C2=O)C(O)=O |a:7	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections, respiratory tract infections, urinary tract infections
ceramide	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O	Launched		phosphoenolpyruvate carboxylase activator, serine/threonine protein phosphatase activator	dermatology	cosmetic
ceritinib	CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1	Launched	ALK|FLT3|IGF1R|INSR|TSSK1B	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
cerulenin	C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O	Launched	FASN	fatty acid synthase inhibitor	infectious disease	fungal infection
ceruletide	[H][C@](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)([C@@H](C)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Preclinical	CCKAR	CCK receptor agonist		
cetaben	CCCCCCCCCCCCCCCCNc1ccc(cc1)C(O)=O	Phase 2	PPARA	ACAT inhibitor, cholesterol inhibitor		
cetilistat	CCCCCCCCCCCCCCCCOc1nc2ccc(C)cc2c(=O)o1	Phase 3	PNLIP	triacylglycerol lipase inhibitor		
cetirizine	OC(=O)COCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:13|	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis
cetrimonium	CCCCCCCCCCCCCCCC[N+](C)(C)C	Launched			dermatology	cosmetic
cetrorelix	CC(C)C[C@H](NC(=O)[C@@H](CCCNC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	Launched	GNRHR|LHCGR	gonadotropin releasing factor hormone receptor antagonist	endocrinology	premature luteinizing hormone surges
cetylpyridinium	CCCCCCCCCCCCCCCC[n+]1ccccc1	Launched			dental	gingivitis, mouth inflammation
cevimeline	C[C@H]1O[C@]2(CS1)CN1CCC2CC1 |&1:1	Launched	CHRM3	acetylcholine receptor agonist	rheumatology	sjogren's syndrome
cevipabulin	[H][C@@](C)(Nc1c(c(Cl)nc2ncnn12)-c1c(F)cc(OCCCNC)cc1F)C(F)(F)F	Phase 1	TUBB	microtubule stimulant, tubulin polymerization inhibitor		
CE3F4	C[C@H]1CCc2c(Br)c(F)c(Br)cc2N1C=O |&1:1	Preclinical	RAPGEF3	rap guanine nucleotide exchange factor inhibitor		
CFI-400945	COc1ccc2NC(=O)[C@@]3(C[C@H]3c3ccc4c(\C=C\c5ccc(CN6C[C@H](C)O[C@H](C)C6)cc5)[nH]nc4c3)c2c1	Phase 2		serine/threonine kinase inhibitor		
CFI-402257	Cc1cc(ccc1C(=O)NC1CC1)-c1cnn2c(NC[C@H]3C[C@@](C)(O)C3)cc(Oc3cccnc3)nc12 |r|	Phase 1/Phase 2		dual specificity protein kinase inhibitor		
CFM-1571	COc1ccc(NC(=O)c2cc(OCCCN(C)C)nn2Cc2ccccc2)cc1	Preclinical		guanylate cyclase activator		
CFM-2	COc1cc2CC(=O)NN=C(c3ccc(N)cc3)c2cc1OC |t:9|	Preclinical		glutamate receptor antagonist		
CFTRinh-172	OC(=O)c1ccc(\C=C2\SC(=S)N(C2=O)c2cccc(c2)C(F)(F)F)cc1	Preclinical	CFTR	chloride channel blocker		
CF102	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)nc(Cl)nc12	Phase 2	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor agonist		
CG-400549	Cc1c(N)cccc1Cn1ccc(OCCc2cccs2)cc1=O	Phase 2		FABI inhibitor		
CGH2466	Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1	Preclinical	ADORA1|ADORA2B|ADORA3	adenosine receptor antagonist		
CGK-733	[O-][N+](=O)c1cc(NC(=S)N[C@@H](NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F |&1:10	Preclinical	ATM|ATR	ATM kinase inhibitor, ATR kinase inhibitor		
CGM097	COc1cc2CC(=O)N([C@@H](c3ccc(Cl)cc3)c2cc1OC(C)C)c1ccc(cc1)N(C)C[C@H]1CC[C@@H](CC1)N1CCN(C)C(=O)C1	Phase 1	MDM2	MDM inhibitor		
CGP-12177	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(=O)[nH]c12 |&1:6|	Phase 1	ADRB1|ADRB2|ADRB3	adrenergic receptor agonist		
CGP-13501	CC(C)(C)c1cc(CC(C)(C)C=O)cc(c1O)C(C)(C)C	Preclinical	GABBR1	GABA receptor modulator		
CGP-20712A	CS(O)(=O)=O.Cn1cc(nc1-c1ccc(OC[C@H](O)CNCCOc2ccc(O)c(c2)C(N)=O)cc1)C(F)(F)F |&1:17	Preclinical	ADRB1|ADRB3	adrenergic receptor antagonist		
CGP-25454A	CCN(CC)CCNC(=O)c1cc(C#N)c(Cl)cc1OC	Preclinical		dopamine receptor antagonist		
CGP-37157	Clc1ccc2NC(=O)CS[C@@H](c3ccccc3Cl)c2c1 |&1:10	Preclinical	SLC8A1	mitochondrial Na+/Ca2+ exchanger antagonist, sodium/calcium exchange inhibitor		
CGP-37849	C\C(CP(O)(O)=O)=C/[C@@H](N)C(O)=O |&1:8	Phase 1	GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor antagonist		
CGP-39551	CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O |&1:5	Preclinical		NMDA receptor antagonist		
CGP-52411	O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12	Preclinical	EGFR	EGFR inhibitor		
CGP-53353	Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1	Preclinical	EGFR|PRKCB	EGFR inhibitor, PKC inhibitor		
CGP-54626	C[C@H](NC[C@H](O)CP(O)(=O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1 |a:1	Preclinical	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8	GABA receptor antagonist		
CGP-55845	C[C@H](NC[C@H](O)CP(O)(=O)Cc1ccccc1)c1ccc(Cl)c(Cl)c1	Preclinical	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8	GABA receptor antagonist		
CGP-57380	Nc1ncnc2n[nH]c(Nc3ccc(F)cc3)c12	Preclinical	AURKB|LCK|MKNK1|MKNK2|SGK1	MAP kinase inhibitor		
CGP-60474	OCCCNc1cc(ccn1)-c1ccnc(Nc2cccc(Cl)c2)n1	Preclinical	CDK1|CDK2	CDK inhibitor		
CGP-71683	Nc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3cccc4ccccc34)CC2)nc2ccccc12 |r|	Preclinical	NPY5R	neuropeptide receptor antagonist		
CGP-74514	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc12	Preclinical	CDK1	CDK inhibitor		
CGP-78608	C[C@@H](NCc1cc(Br)cc2[nH]c(=O)c(=O)[nH]c12)P(O)(O)=O	Preclinical		glutamate receptor antagonist		
CGP-7930	CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Preclinical	GABBR1	GABA receptor modulator		
CGS-15943	Nc1nc2ccc(Cl)cc2c2nc(nn12)-c1ccco1	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
CGS-20625	COc1ccc(cc1)-n1[nH]c2c3CCCCCc3ncc2c1=O	Phase 1	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6	benzodiazepine receptor agonist, GABA benzodiazepine site receptor partial agonist		
CGS-21680	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)nc(NCCc3ccc(CCC(O)=O)cc3)nc12	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor agonist		
CGS-9896	Clc1ccc(cc1)-n1[nH]c2c(cnc3ccccc23)c1=O	Preclinical	GABRA1|GABRB2|GABRG2	GABA receptor antagonist		
CH-170	Cc1nc(Cn2cnc3n(C)c(=O)n(C)c(=O)c23)no1	Phase 1				
CH-5183284	Cc1nc2ccc(cc2[nH]1)-n1ncc(C(=O)c2cc3ccccc3[nH]2)c1N	Phase 2	FGFR1|FGFR2|FGFR3	fibroblast growth factor inhibitor		
CHC	OC(=O)C(=C\c1ccc(O)cc1)\C#N	Preclinical	SLC16A1	monocarboxylate transporter inhibitor		
chenodeoxycholic-acid	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	HSD11B1|NR1H4	11-beta hydroxysteroid dehydrogenase inhibitor, FXR agonist	cardiology, gastroenterology	cerebral cholesterosis, gallstones
CHF5074	OC(=O)C1(CC1)c1ccc(c(F)c1)-c1ccc(Cl)c(Cl)c1	Phase 2	PSEN1	gamma secretase modulator		
chicago-sky-blue-6b	COc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(OC)c1 |c:12	Preclinical	MIF	glutamate inhibitor, macrophage migration inhibiting factor inhibitor		
chidamide	Nc1ccc(F)cc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	Launched	HDAC10|HDAC3	HDAC inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
chiniofon	Oc1c(I)cc(c2cccnc12)S(O)(=O)=O	Launched		antiprotozoal agent	infectious disease	amebiasis
CHIR-124	Clc1ccc2[nH]c(=O)c(-c3nc4ccccc4[nH]3)c(N[C@@H]3CN4CCC3CC4)c2c1	Preclinical	CHEK1	CHK inhibitor		
CHIR-98014	Nc1nc(NCCNc2ncc(c(n2)-c2ccc(Cl)cc2Cl)-n2ccnc2)ccc1[N+]([O-])=O	Preclinical	GSK3A|GSK3B	glycogen synthase kinase inhibitor		
CHIR-99021	Cc1c[nH]c(n1)-c1cnc(NCCNc2ccc(cn2)C#N)nc1-c1ccc(Cl)cc1Cl	Preclinical	CDK1|GSK3A|GSK3B|MAPK1	glycogen synthase kinase inhibitor		
chloralose	OC[C@@H](O)[C@H]1O[C@@H]2O[C@@H](O[C@@H]2[C@H]1O)C(Cl)(Cl)Cl	Preclinical				
chlorambucil	OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl	Launched		DNA inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma
chloramine-T	Cc1ccc(cc1)S(=O)(=O)NCl	Launched			infectious disease	bacterial gill disease
chloramphenicol	OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched	CD55	bacterial 50S ribosomal subunit inhibitor	infectious disease, endocrinology	meningitis, fever, cholera
chloramphenicol-palmitate	CCCCCCCCCCCCCCCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+]([O-])=O	Launched		protein synthesis inhibitor	infectious disease, endocrinology	meningitis, fever, cholera
chloramphenicol-sodium-succinate	O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)[N+]([O-])=O	Launched		protein synthesis inhibitor	infectious disease	gram-negative bacterial infections
chlorazanil	Nc1ncnc(Nc2ccc(Cl)cc2)n1	Preclinical				
chlorcyclizine	CN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:7|	Launched		histamine receptor antagonist	allergy	allergic rhinitis
chlorfenson	Clc1ccc(OS(=O)(=O)c2ccc(Cl)cc2)cc1	Phase 2		other antifungal		
chlorhexidine	NC(Nc1ccc(Cl)cc1)=NC(=N)NCCCCCCNC(=N)N=C(N)Nc1ccc(Cl)cc1	Launched		membrane integrity inhibitor	dermatology, infectious disease, dental	cosmetic, skin infections, gingivitis
chlorindanol	Oc1ccc(Cl)c2CCCc12	Preclinical				
chlorindione	Clc1ccc(cc1)C1C(=O)c2ccccc2C1=O	Preclinical				
chlorisondamine-diiodide	C[N+](C)(C)CC[N+]1(C)Cc2c(C1)c(Cl)c(Cl)c(Cl)c2Cl	Preclinical	CHRNA1	acetylcholine receptor antagonist		
chlormadinone-acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9	Launched	PGR	5 alpha reductase inhibitor	endocrinology	hypermenorrhea, amenorrhea, oligomenorrhea, polymenorrhea
chlormezanone	CN1[C@@H](c2ccc(Cl)cc2)S(=O)(=O)CCC1=O |&1:2	Withdrawn	GABRA1	GABA receptor modulator		
chlormidazole	Cc1nc2ccccc2n1Cc1ccc(Cl)cc1	Launched		fungal lanosterol demethylase inhibitor	infectious disease	fungal infection
chlorobutanol	CC(C)(O)C(Cl)(Cl)Cl	Launched			neurology/psychiatry	anesthetic, sedative
chlorocresol	Cc1cc(O)ccc1Cl	Launched		ryanodine receptor activator	infectious disease	first-aid antiseptic
chlorogenic-acid	O[C@@H]1C[C@](O)(C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)C(O)=O	Launched	SLC37A4	antioxidant	neurology/psychiatry, pulmonary, allergy	headache, chest congestion, allergic rhinitis
chlorophyllin	CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(O)=O)[C@@H]4C)c(CC(O)=O)c4[nH]c(cc1n2)c(C)c4C(O)=O)c(C)c3C=C	Preclinical			urology	urinary incontinence
chlorophyllin-copper	CCC1=C(C)\C2=C\c3c(C=C)c(C)c4\C=C5/N=C([C@@H](CCC(O)=O)[C@@H]5C)/C(/CC(O)=O)=c5/c(C(O)=O)c(C)\c(=C\C1=N2)n5[Cu]n34 |&1:18	Phase 1		cytochrome P450 inhibitor		
chloroprocaine	CCN(CC)CCOC(=O)c1ccc(N)cc1Cl	Launched	ATP1A1|CHRNA10|GRIN3A|HTR3A|SCN10A|SLC6A3	sodium channel blocker	neurology/psychiatry	local anesthetic
chloropyramine	CN(C)CCN(Cc1ccc(Cl)cc1)c1ccccn1	Launched	HRH1	histamine receptor antagonist	cardiology, ophthalmology, allergy, pulmonary	edema, conjunctivitis, allergic rhinitis, asthma
chloroquine	CCN(CC)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12 |&1:8|	Launched	MRGPRX1	antimalarial agent	infectious disease	malaria, amebiasis
chlorothiazide	NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O |c:12|	Launched	CA1|CA2|CA4|SLC12A3	diuretic	cardiology	hypertension
chlorothymol	CC(C)c1cc(Cl)c(C)cc1O	Launched				
chlorotrianisene	COc1ccc(cc1)C(Cl)=C(c1ccc(OC)cc1)c1ccc(OC)cc1	Launched	ESR1|ESR2	estrogenic hormone	endocrinology, oncology	menopause, prostate cancer
chloroxine	Oc1c(Cl)cc(Cl)c2cccnc12	Launched	OPRK1	opioid receptor antagonist	gastroenterology, infectious disease, dermatology	diarrhea, inflammatory bowel disease, giardiasis, dandruff
chloroxoquinoline	Clc1ccc2c(c1)[nH]ccc2=O	Launched				
chloroxylenol	Cc1cc(O)cc(C)c1Cl	Launched		ATP synthase inhibitor	infectious disease	skin infections
chlorphenamine	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1 |&1:5|	Launched		histamine receptor antagonist	allergy	allergic rhinitis, urticaria
chlorphenesin	OC[C@@H](O)COc1ccc(Cl)cc1 |&1:2	Launched		muscle relaxant	neurology/psychiatry	muscle relaxant, sedative
chlorphenoxamine	CN(C)CCO[C@@](C)(c1ccccc1)c1ccc(Cl)cc1 |r|	Preclinical		histamine receptor antagonist		
chlorphensin-carbamate	NC(=O)OC[C@@H](O)COc1ccc(Cl)cc1 |&1:5	Launched		muscle relaxant	neurology/psychiatry	spasms
chlorproguanil	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)c(Cl)c1	Launched	DHFR	dihydrofolate reductase inhibitor	infectious disease	malaria
chlorpromazine	CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALM1|CHRM1|CHRM3|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR2A|HTR2B|HTR2C|HTR6|HTR7|KCNH2|ORM1|ORM2|SMPD1|TRPC5	dopamine receptor antagonist	neurology/psychiatry, gastroenterology, hematology, infectious disease	schizophrenia, nausea, vomiting, acute intermittent porphyria (AIP), tetanus
chlorpropamide	CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1	Launched	ABCC8|KCNJ10	ATP channel blocker	endocrinology	diabetes mellitus
chlorpropham	CC(C)OC(=O)Nc1cccc(Cl)c1	Phase 1		antiviral		
chlorprothixene	CN(C)CC\C=C1\c2ccccc2Sc2ccc(Cl)cc12	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|HRH1|HTR2A|HTR2B|HTR2C	dopamine receptor antagonist	neurology/psychiatry	schizophrenia, bipolar disorder
chlorpyrifos	CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl	Launched	ACHE	acetylcholinesterase inhibitor		
chlorquinaldol	Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	Launched		other antibiotic	infectious disease	fungal infection
chlortetracycline	[H][C@@]12C[C@@]3([H])[C@H](C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:25	Launched		protein synthesis inhibitor	ophthalmology	conjunctivitis
chlorthalidone	NS(=O)(=O)c1cc(ccc1Cl)[C@@]1(O)NC(=O)c2ccccc12 |&1:11	Launched	CA1|CA12|CA14|CA2|CA4|CA7|SLC12A1	carbonic anhydrase inhibitor	cardiology, gastroenterology, rheumatology, nephrology	hypertension, edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure
chlorzoxazone	Clc1ccc2oc(=O)[nH]c2c1	Launched	KCNMA1|KCNN4	bacterial 30S ribosomal subunit inhibitor	neurology/psychiatry	muscle relaxant
cholecalciferol	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched	VDR		endocrinology	vitamin D deficiency
cholesterol	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	Preclinical	RORA			
cholic-acid	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Launched	ADH1C|CES1|COX4I1|COX5A|COX5B|COX6A2|COX6B1|COX6C|COX7A1|COX7B|COX7C|COX8A|ESRRG|FABP6|FECH|GPBAR1|MT-CO1|MT-CO2|MT-CO3|PLA2G1B	bile acid	gastroenterology, neurology/psychiatry, genetics	bile acid synthesis disorders, peroxisomal disorders, Zellweger syndrome
choline	C[N+](C)(C)CCO	Phase 3	ACHE|BCHE|CHRNA2|PCYT1A|PCYT1B|PHOSPHO1|PLD1|PLD2	acetylcholine precursor		
choline-alfoscerate	C[N+](C)(C)CCOP(O)(=O)OC[C@H](O)CO	Launched		acetylcholine precursor		
CHPG	N[C@@H](C(O)=O)c1cc(O)ccc1Cl |&1:1	Preclinical	GRM5	glutamate receptor agonist		
CHR-6494	CCCNc1ccc2ncc(-c3ccc4n[nH]cc4c3)n2n1	Preclinical	GSG2	serine/threonine kinase inhibitor		
chromanol-(+/-)	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N.CCS(=O)(=O)N(C)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Preclinical		potassium channel blocker		
chromanol-293B-(-)-[3R,4S]	CCS(=O)(=O)N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2ccc(cc12)C#N	Preclinical		potassium channel blocker		
chromium-picolinate	O=C(O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1)c1ccccn1	Launched		insulin sensitizer	endocrinology	diabetes mellitus
chromocarb	OC(=O)c1cc(=O)c2ccccc2o1	Launched		antispasmodic		
chrysin	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1	Phase 1	AKR1B1|CDK6|CYP19A1|CYP1B1	breast cancer resistance protein inhibitor		
chrysophanic-acid	Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Preclinical	EGFR|MTOR	EGFR inhibitor		
chuanxiongzine	Cc1nc(C)c(C)nc1C	Phase 2				
CH223191	Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1	Preclinical	AHR	aryl hydrocarbon receptor antagonist		
CH5132799	CS(=O)(=O)N1CCc2c1nc(nc2-c1cnc(N)nc1)N1CCOCC1	Phase 1	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
CH55	CC(C)(C)c1cc(cc(c1)C(C)(C)C)C(=O)\C=C\c1ccc(cc1)C(O)=O	Preclinical	RARA|RARB	retinoid receptor binder		
CI-844	O(c1ccccc1)c1cccnc1	Phase 2				
CI-923	CCN[C@@H](C)CN1CCc2c(C1)c(=O)oc1ccccc21 |&1:3	Phase 1		acetylcholine receptor antagonist		
CI-953	Cc1cccc(Cl)c1NC(=O)Nc1ccncc1	Phase 1		voltage-gated sodium channel blocker		
CI-966	OC(=O)C1=CCCN(CCOC(c2ccc(cc2)C(F)(F)F)c2ccc(cc2)C(F)(F)F)C1 |t:3|	Phase 1	SLC6A1	GAT inhibitor		
CI-976	CCCCCCCCCCC(C)(C)C(=O)Nc1c(OC)cc(OC)cc1OC	Phase 1	ACAT1|CES1	ACAT inhibitor		
ciaftalan-zinc	[Zn]1n2c3\N=C4/N=C(/N=c5\n1\c(=N/C1=N/C(=N\c2c2ccccc32)/c2ccccc12)c1ccccc51)c1ccccc41 |c:3	Phase 1		reactive oxygen species stimulant		
cianidanol	O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1ccc(O)c(O)c1	Withdrawn	PTGS1	fatty acid synthase inhibitor		
cibenzoline	C1[C@@H](C2=NCCN2)C1(c1ccccc1)c1ccccc1 |r	Launched		sodium channel blocker	cardiology	cardiac arrythmia
ciclesonide	CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1 |c:24	Launched	NR3C1|SERPINA6	glucocorticoid receptor agonist	allergy	allergic rhinitis
ciclopirox	Cc1cc(C2CCCCC2)n(O)c(=O)c1	Launched	ATP1A1	membrane integrity inhibitor	infectious disease	onychomycosis
cicloprofen	C[C@@H](C(O)=O)c1ccc-2c(Cc3ccccc-23)c1 |&1:1	Preclinical	PTGS1|PTGS2	cyclooxygenase inhibitor		
CID-16020046	Cc1ccc(cc1)-c1n[nH]c2C(=O)N([C@H](c12)c1cccc(O)c1)c1ccc(cc1)C(O)=O |&1:14	Preclinical	GPR55	G protein-coupled receptor antagonist		
CID-2011756	Clc1cccc(c1)-c1ccc(o1)C(=O)Nc1ccc(CN2CCOCC2)cc1	Preclinical	PKD1	protein kinase inhibitor		
CID-2745687	COC(=O)c1cnn(c1\C=N\NC(=S)NC(C)(C)C)-c1ccc(F)cc1F	Preclinical	GPR35	G protein-coupled receptor antagonist		
CID-5458317	OC1=c2ccccc2=C(NC2CCCCC2)\C1=C/c1ccccc1 |c:1	Preclinical	MAPK3	MAP kinase phosphatase inhibitor		
cidofovir	Nc1ccn(C[C@@H](CO)OCP(O)(O)=O)c(=O)n1	Launched		DNA polymerase inhibitor	infectious disease	acquired immunodeficiency syndrome (AIDS), cytomegalovirus retinitis
ciglitazone	CC1(COc2ccc(C[C@H]3SC(=O)NC3=O)cc2)CCCCC1 |r|	Phase 2	PPARG	PPAR receptor agonist		
cilastatin	CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O	Launched	DPEP1	dehydropeptidase inhibitor		
cilazapril	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCCN2CCC[C@H](N2C1=O)C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension, congestive heart failure
cilengitide	CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O	Phase 3	ITGAV|ITGB3	integrin antagonist		
cilnidipine	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |&1:14	Launched	CACNA1B	calcium channel blocker	cardiology	hypertension
cilofexor	OC(=O)c1ccnc(c1)N1CC(O)(C1)c1ccc(OCc2c(onc2-c2c(Cl)cccc2Cl)C2CC2)cc1Cl	Phase 3		FXR agonist		
cilomilast	COc1ccc(cc1OC1CCCC1)[C@]1(CC[C@@H](CC1)C(O)=O)C#N |r|	Phase 3	PDE4A|PDE4B|PDE4D	phosphodiesterase inhibitor		
cilostamide	CN(C1CCCCC1)C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1	Preclinical	PDE3A|PDE3B	phosphodiesterase inhibitor		
cilostazol	O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1	Launched	PDE3A|PDE3B	phosphodiesterase inhibitor	cardiology	claudication
ciluprevir	COc1ccc2c(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(O)=O)NC(=O)OC3CCCC3)cc(nc2c1)-c1csc(NC(C)C)n1 |c:22|	Preclinical		serine protease inhibitor		
CIM-0216	Cc1cc(NC(=O)[C@@H](N2CCCc3ccccc23)c2ccccc2)no1 |&1:7	Preclinical	TRPM3	transient receptor potential channel agonist		
cimaterol	CC(C)NC[C@@H](O)c1ccc(N)c(c1)C#N |&1:5	Preclinical	ADRB1|ADRB2|ADRB3	adrenergic receptor agonist		
cimetidine	CN\C(NCCSCc1[nH]cnc1C)=N/C#N	Launched	HRH2|SLC29A4|SLC47A1|SLC47A2	histamine receptor antagonist	gastroenterology, hematologic malignancy, endocrinology	duodenal ulcer disease, peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD), aggressive systemic mastocytosis (ASM), Zollinger-Ellison syndrome, endocrine adenoma
cimetropium	C[N@@+]1(CC2CC2)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:6	Launched	CHRM1	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
cinacalcet	C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12	Launched	CASR	calcium channel activator	endocrinology, nephrology, oncology	hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia
cinaciguat	OC(=O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(cc1)C(O)=O	Phase 2	GUCY1A3|GUCY1B3	guanylate cyclase activator		
cinalukast	CCC(CC)(CC(=O)Nc1cccc(\C=C\c2nc(cs2)C2CCC2)c1)C(O)=O	Phase 2	CYSLTR1	leukotriene receptor antagonist		
cinanserin	CN(C)CCCSc1ccccc1NC(=O)\C=C\c1ccccc1	Preclinical	HTR2A	serotonin receptor antagonist		
cinchocaine	CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1	Launched	CALM1|SCN10A|SCN5A	sodium channel blocker	neurology/psychiatry	local anesthetic
cinchonidine	O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	Phase 1		P glycoprotein inhibitor		
cinchonine	O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12	Preclinical	CYP2D6	P glycoprotein inhibitor		
cinchophen	OC(=O)c1cc(nc2ccccc12)-c1ccccc1	Launched		analgesic agent	rheumatology	gout
cinepazet	CCOC(=O)CN1CCN(CC1)C(=O)\C=C\c1cc(OC)c(OC)c(OC)c1	Launched		vasodilator		
cinepazide	COc1cc(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)cc(OC)c1OC	Withdrawn		calcium channel activator		
cinflumide	Fc1cccc(\C=C\C(=O)NC2CC2)c1	Phase 2		muscle relaxant		
cinnamaldehyde	O=C\C=C\c1ccccc1	Preclinical	TRPA1	aldose reductase inhibitor, TRPV agonist		
cinnarazine	C(\C=C\c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched		calcium channel blocker	neurology/psychiatry, gastroenterology, ophthalmology	Meniere's disease, nausea, vomiting, Cogan's syndrome
cinobufotalin	[H][C@@]12CC[C@]3(O)C[C@@H](O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H]([C@@H](OC(C)=O)[C@H]3O[C@@]213)c1ccc(=O)oc1	Phase 1		anticancer agent		
cinoctramide	COc1cc(\C=C\C(=O)N2CCCCCCC2)cc(OC)c1OC	Preclinical				
cinoxacin	CCn1nc(C(O)=O)c(=O)c2cc3OCOc3cc12	Launched		topoisomerase inhibitor	infectious disease	urinary tract infections
cinoxate	CCOCCOC(=O)\C=C\c1ccc(OC)cc1	Launched			dermatology	sunscreen lotion
CINPA-1	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(CC)CC)c2c1	Preclinical	NR1H4|NR1I3|PPARG	CAR antagonist		
cinromide	CCNC(=O)\C=C\c1cccc(Br)c1	Phase 3				
cintirorgon	CC(C)(C[C@H]1CN(c2cc(ccc2O1)-c1cc(F)cc(OC(F)F)c1)S(=O)(=O)c1cccc(c1)C(F)(F)F)C(O)=O	Phase 1/Phase 2		ROR agonist		
cintriamide	COc1cc(\C=C\C(N)=O)cc(OC)c1OC	Preclinical				
cipamfylline	Nc1nc2n(CC3CC3)c(=O)n(CC3CC3)c(=O)c2[nH]1	Phase 2		phosphodiesterase inhibitor		
cipargamin	C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc21	Phase 2		antimalarial agent		
cipemastat	CN1C(=O)N(C[C@@H]([C@@H](CC2CCCC2)C(=O)N2CCCCC2)C(=O)NO)C(=O)C1(C)C	Phase 3	ADAM17|MMP1|MMP13|MMP2|MMP3|MMP8|MMP9	metalloproteinase inhibitor		
ciprofibrate	CC(C)(Oc1ccc(cc1)[C@H]1CC1(Cl)Cl)C(O)=O |&1:10	Launched	PPARA	PPAR receptor agonist	endocrinology	hyperlipidemia
ciprofloxacin	OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O	Launched	TOP2A	bacterial DNA gyrase inhibitor	otolaryngology	otitis
ciproxifan	O=C(C1CC1)c1ccc(OCCCc2cnc[nH]2)cc1	Preclinical	ADRA2A|ADRA2C|HRH3|HRH4|HTR3A	histamine receptor antagonist		
CIQ	COc1ccc(OC[C@H]2N(CCc3cc(OC)c(OC)cc23)C(=O)c2cccc(Cl)c2)cc1 |&1:8	Preclinical	GRIN2C|GRIN2D	glutamate receptor potentiator		
cirazoline	C(Oc1ccccc1C1CC1)C1=NCCN1 |t:13|	Preclinical	ADRA1A	adrenergic receptor agonist		
cis-aconitic-acid	OC(=O)C\C(=C\C(O)=O)C(O)=O	Preclinical	ACO2			
cis-ACPD	[H][C@]1(CC[C@@](N)(C1)C(O)=O)C(O)=O |&1:1	Preclinical	GRM2|GRM3|GRM6|GRM7|GRM8	glutamate receptor agonist		
cis-exo-camphanediol-2,3	CC1(C)[C@H]2CC[C@]1(C)[C@@H](O)[C@H]2O	Phase 1	NOS3	nitric oxide stimulant		
cis-urocanic-acid	OC(=O)\C=C\c1cnc[nH]1	Phase 2	HTR2A	serotonin receptor agonist		
cis-9,trans-11-conjugated-linoleic-acid	CCCCCC\C=C\C=C/CCCCCCCC(O)=O	Launched				
cisapride	CO[C@H]1CN(CCCOc2ccc(F)cc2)CC[C@H]1NC(=O)c1cc(Cl)c(N)cc1OC	Withdrawn	HTR2A|HTR3A|HTR4|KCNH2	serotonin receptor agonist		
cisatracurium	COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC	Launched	CHRNA2	acetylcholine receptor antagonist	neurology/psychiatry, critical care	muscle relaxant, endotracheal intubation
cisplatin	N[Pt](N)(Cl)Cl	Launched	XIAP	DNA alkylating agent, DNA synthesis inhibitor	oncology	testicular carcinoma, ovarian cancer, bladder cancer
citalopram	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1 |&1:6|	Launched	ADRA1A|CHRM1|HRH1|SLC6A2|SLC6A3|SLC6A4	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression
citarinostat	ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1Cl	Phase 1		HDAC inhibitor		
CITCO	Clc1ccc(cc1)-c1nc2sccn2c1\C=N\OCc1ccc(Cl)c(Cl)c1	Preclinical	NR1I3	constitutive androstane receptor (CAR) agonist		
citicoline	C[N+](C)(C)CCOP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(N)nc1=O |a:16	Launched	ACHE|SLC1A2	glutathione transferase stimulant, membrane permeability enhancer	neurology/psychiatry, ophthalmology	stroke, Alzheimer's disease, senile dementia, Parkinson's Disease, attention-deficit/hyperactivity disorder (ADHD), glaucoma
citiolone	CC(=O)N[C@H]1CCSC1=O |&1:4	Preclinical		lipotropic, mucolytic agent		
citric-acid	OC(=O)CC(O)(CC(O)=O)C(O)=O	Preclinical	AKR1B1|ANG|APRT|BHMT|C8G|CA4|CPB1|CS|CTDSP1|GNMT|HGS|HS3ST3A1|IL4I1|ITPA|LSM6|MDH2|MIF|PDE5A|PKD2L1|PLEKHA1|RNASE1|RNASE3|SRC|TNFSF13B|UCK2	coagulation factor inhibitor		
CJ-033466	CC(C)CN1CCC(CNC(=O)c2cc(Cl)c(N)n3cc(C)nc23)CC1	Preclinical	HTR4	serotonin receptor agonist		
CJ-13610	Cc1nccn1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	Phase 2		lipoxygenase inhibitor		
CK-101	OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F	Preclinical		EGFR inhibitor		
CK-636	Cc1[nH]c2ccccc2c1CCNC(=O)c1cccs1	Preclinical	ACTR2|ACTR3|ARPC1B|ARPC2|ARPC3|ARPC4|ARPC5	actin related protein inhibitor		
CKD-712	Oc1cc2CCN[C@@H](Cc3cccc4ccccc34)c2cc1O |&1:7|	Phase 1	JAK2|STAT1	NFkB pathway inhibitor		
CKI-7	NCCNS(=O)(=O)c1ccc(Cl)c2ccncc12	Preclinical	CSNK1G2	casein kinase inhibitor		
CL-218872	Cc1nnc2ccc(nn12)-c1cccc(c1)C(F)(F)F	Phase 1	GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2	benzodiazepine receptor agonist		
CL-225385	O=C(CC#N)c1ccccc1	Phase 2				
cladribine	Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1	Launched	ADA|PNP|POLA1|POLE|POLE2|POLE3|POLE4|RRM1|RRM2|RRM2B	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
clamikalant	CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC	Preclinical		ATP-sensitive potassium channel antagonist		
clanfenur	CN(C)c1cccc(F)c1C(=O)NC(=O)Nc1ccc(Cl)cc1	Preclinical		anticancer agent		
clarithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O)OC	Launched	CYP3A4	bacterial 50S ribosomal subunit inhibitor	otolaryngology, pulmonary, infectious disease	pharyngitis, tonsillitis, sinusitis, bronchitis, pneumonia, skin infections, otitis
clavulanate	OC\C=C1/O[C@@H]2CC(=O)N2[C@H]1C(O)=O	Launched		beta lactamase inhibitor	otolaryngology	otitis
clebopride	COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1	Launched	ACHE|DRD2	dopamine receptor antagonist	gastroenterology	nausea
clemastine	CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis, urticaria
clemizole	Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1	Launched		HCV inhibitor	allergy	allergic rhinitis
clenbuterol	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1 |r|	Launched	ABCC8|ADRB2|KCNJ11	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD), asthma
cleviprex	CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:17	Launched	CACNA1C|CACNA1D|CACNA1F|CACNA1S	calcium channel blocker	cardiology	hypertension
clevudine	Cc1cn([C@H]2O[C@@H](CO)[C@H](O)[C@H]2F)c(=O)[nH]c1=O	Launched		DNA polymerase inhibitor	infectious disease	hepatitis B
clidinium	C[N+]12CCC(CC1)[C@@H](C2)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:7	Launched	CHRM1|CHRM3	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD), irritable bowel syndrome, enterocolitis
climbazole	CC(C)(C)C(=O)[C@@H](Oc1ccc(Cl)cc1)n1ccnc1 |&1:6	Launched		enzyme inducer	dermatology	dandruff, eczema
clinafloxacin	N[C@H]1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)C1CC1 |&1:1|	Phase 3		bacterial DNA gyrase inhibitor		
clindamycin	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	Launched		protein synthesis inhibitor	infectious disease	respiratory tract infections, pneumonia, skin infections, gynecologic infections, intra-abdominal infections, bacterial septicemia, bone and joint infections
clindamycin-palmitate	CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]1SC)[C@H](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)[C@H](C)Cl	Launched		bacterial 50S ribosomal subunit inhibitor	infectious disease	intra-abdominal infections, skin infections, pneumonia, peritonitis, gynecologic infections
clindamycin-phosphate	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]1O	Launched		protein synthesis inhibitor	obstetrics/gynecology	bacterial vaginosis
clinofibrate	CCC(C)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(O[C@](C)(CC)C(O)=O)cc1)C(O)=O |&1:22	Launched	LPL	lipase clearing factor inhibitor	endocrinology	hypertriglyceridemia
clioquinol	Oc1c(I)cc(Cl)c2cccnc12	Withdrawn	OPRK1	chelating agent		
clobenpropit	Clc1ccc(CNC(=N)SCCCc2cnc[nH]2)cc1	Preclinical	HRH1|HRH2|HRH3|HRH4	histamine receptor antagonist		
clobetasol-propionate	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:17	Launched	NR3C1|PLA2G1B	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
clobetasone-butyrate	CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl |c:18	Launched	NR3C1	corticosteroid agonist	dermatology	eczema, psoriasis, dermatitis
clobutinol	C[C@@H](CN(C)C)C(C)(O)Cc1ccc(Cl)cc1 |&1:1	Withdrawn		antitussive		
clocortolone-pivalate	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C |c:12	Launched	NR3C1|PLA2G1B	steroid	dermatology	corticosteroid-responsive dermatoses
clodronic-acid	OP(O)(=O)C(Cl)(Cl)P(O)(O)=O	Launched	SLC25A4|SLC25A5|SLC25A6	bone resorption inhibitor	orthopedics, endocrinology, hematologic malignancy	osteoporosis, hyperparathyroidism, hypercalcemia, multiple myeloma
clofarabine	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	Launched	POLA1|POLD1|POLE|RRM1|RRM2|RRM2B	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
clofazimine	CC(C)\N=c1/cc2n(-c3ccc(Cl)cc3)c3ccccc3nc2cc1Nc1ccc(Cl)cc1	Launched		GK0582 inhibitor	infectious disease	leprosy
clofedanol	CN(C)CC[C@@](O)(c1ccccc1)c1ccccc1Cl |&1:5	Launched	HRH1	histamine receptor antagonist	pulmonary	cough suppressant
clofibrate	CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1	Launched	LPL|PPARA	PPAR receptor agonist	endocrinology, cardiology	hyperlipidemia, cholesterol
clofibric-acid	CC(C)(Oc1ccc(Cl)cc1)C(O)=O	Launched	PPARA	PPAR receptor agonist	endocrinology	hyperlipidemia
clofilium	CCCCCCC[N+](CC)(CC)CCCCc1ccc(Cl)cc1	Phase 2	KCNA5|KCNH1	potassium channel blocker		
clofoctol	CC(C)(C)CC(C)(C)c1ccc(O)c(Cc2ccc(Cl)cc2Cl)c1	Launched		protein synthesis inhibitor	infectious disease	gram-positive bacterial infections
clomesone	CS(=O)(=O)CS(=O)(=O)OCCCl	Phase 1		DNA inhibitor		
clomethiazole	Cc1ncsc1CCCl	Launched	GABRA1	GABA receptor antagonist, GABA receptor modulator	neurology/psychiatry	Parkinson's Disease, sedative, muscle relaxant
clomifene	CCN(CC)CCOc1ccc(cc1)C(=C(/Cl)c1ccccc1)\c1ccccc1	Launched	ESR1	estrogen receptor antagonist	obstetrics/gynecology	infertility
clomipramine	CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12	Launched	GSTP1|HTR2A|HTR2B|HTR2C|SLC6A2|SLC6A3|SLC6A4	serotonin transporter (SERT) inhibitor	neurology/psychiatry	obsessive compulsive disorder (OCD)
clonidine	Clc1cccc(Cl)c1NC1=NCCN1 |t:10|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	cardiology, neurology/psychiatry	hypertension, attention-deficit/hyperactivity disorder (ADHD)
clonixin	Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	Preclinical	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology, infectious disease	rheumatoid arthritis, soft tissue infection
clonixin-lysinate	NCCCC[C@H](N)C(O)=O.Cc1c(Cl)cccc1Nc1ncccc1C(O)=O	Launched		cyclooxygenase inhibitor	neurology/psychiatry	pain relief
clopamide	C[C@H]1CCC[C@@H](C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O	Launched		sodium/chloride cotransporter inhibitor	cardiology	hypertension
cloperastine	Clc1ccc(cc1)[C@@H](OCCN1CCCCC1)c1ccccc1 |&1:7|	Launched		antitussive	pulmonary	cough suppressant
cloperastine-fendizoate		Preclinical		potassium channel antagonist		
clopidogrel	COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl	Launched	P2RY12	purinergic receptor antagonist	cardiology, neurology/psychiatry	myocardial infarction, stroke, peripheral artery disease (PAD), acute coronary syndrome (ACS)
clopidol	Cc1[nH]c(C)c(Cl)c(=O)c1Cl	Launched			infectious disease	coccidiosis
cloprostenol-(+/-)	O[C@@H](COc1cccc(Cl)c1)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	Launched	PTGDR|PTGER1|PTGER3|PTGFR|TBXA2R	prostaglandin receptor agonist	obstetrics/gynecology	endometriosis
cloranolol	CC(C)(C)NC[C@@H](O)COc1cc(Cl)ccc1Cl |&1:6|	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist	cardiology	hypertension
clorgiline	CN(CCCOc1ccc(Cl)cc1Cl)CC#C	Phase 2	MAOA	monoamine oxidase inhibitor		
clorotepine	CN1CCN(CC1)[C@H]1Cc2ccccc2Sc2ccc(Cl)cc12 |&1:7|	Launched	ADRA1A|ADRA1B|ADRA1D|DRD2|HRH1|HTR2C|HTR6	adrenergic receptor antagonist, dopamine receptor antagonist	neurology/psychiatry	psychosis
clorprenaline	CC(C)NC[C@@H](O)c1ccccc1Cl |&1:5|	Launched	ADRB1|ADRB2	adrenergic receptor agonist	pulmonary	asthma
clorsulon	Nc1cc(C(Cl)=C(Cl)Cl)c(cc1S(N)(=O)=O)S(N)(=O)=O	Launched		glycolysis inhibitor	infectious disease	gastrointestinal roundworms, lungworms, liver flukes, lice, mites
closantel	Cc1cc([C@@H](C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O |&1:4|	Launched		chitinase inhibitor, NFkB pathway inhibitor	infectious disease	liver flukes
clotiapine	CN1CCN(CC1)C1=Nc2ccccc2Sc2ccc(Cl)cc12 |t:8|	Launched			neurology/psychiatry	psychosis
clotrimazole	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1	Launched	CYP3A4|KCNN4|NR1I2|NR1I3|TRPM2|TRPM4|TRPM8	cytochrome P450 inhibitor, imidazoline receptor ligand	infectious disease	vulvovaginal candidiasis, oropharyngeal candidiasis
cloxacillin	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1Cl	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
cloxyquin	Oc1ccc(Cl)c2cccnc12	Preclinical	KCNK18	potassium channel activator		
clozapine	CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2ccccc12 |t:8|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CALY|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia
CL316243	C[C@H](Cc1ccc2OC(Oc2c1)(C(O)=O)C(O)=O)NC[C@H](O)c1cccc(Cl)c1	Phase 2	ADRB3|UCP1|UCP2|UCP3	adrenergic receptor agonist		
CM-4620	Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl	Phase 2		calcium release activated channel modulator		
CMPD-1	Oc1ccc(NC(=O)CCCc2ccc(cc2)-c2ccccc2F)cc1	Preclinical	GNRHR|MAPK14	p38 MAPK inhibitor		
CNQX	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N	Phase 1	GRIA1|GRIA2|GRIA3|GRIA4	glutamate receptor antagonist		
CNX-2006	COc1cc(NC2CN(CCF)C2)ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F	Preclinical	EGFR	EGFR inhibitor		
CNX-774	CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1	Preclinical	BTK	Bruton's tyrosine kinase (BTK) inhibitor		
CO-101244	Cc1ccc(CC2(O)CCN(CCOc3ccc(O)cc3)CC2)cc1	Preclinical	GRIN2B	glutamate receptor antagonist		
CO-102862	NC(=O)N\N=C\c1ccc(Oc2ccc(F)cc2)cc1	Phase 1	SCN4A|SCN9A	sodium channel blocker		
cobicistat	CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1	Launched	CYP3A4|CYP3A43|CYP3A5|CYP3A7	cytochrome P450 inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
cobimetinib	OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1	Launched	MAP2K1	MEK inhibitor	oncology	melanoma
coenzyme-A	CC(C)(COP(O)(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1OP(O)(O)=O)n1cnc2c(N)ncnc12)[C@@H](O)C(=O)NCCC(=O)NCCS |a:14	Launched	ACAT2|CRAT|CS|DBI|HMGCR|KAT2A|KAT2B|KAT5			
coenzyme-I	NC(=O)C1=CN(C=CC1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9	Phase 2	AASS|ACADS|ADH1A|ADH1B|ADH1C|ADH4|ADH5|ADH7|AKR1B1|AKR1C1|AKR1C2|AKR1C3|AKR1C4|ALDH1A1|ALDH1A2|ALDH1A3|ALDH1B1|ALDH2|ALDH3A1|ALDH3A2|ALDH3B1|ALDH3B2|ALDH4A1|ALDH5A1|ALDH6A1|ALDH7A1|ALDH9A1|AMT|BDH1|BLVRA|BLVRB|CDO1|CYB5R3|CYP17A1|CYP4A11|DHCR7|DHFR|DLAT|DLD|EHHADH|GAPDH|GAPDHS|GLUD1|GLUD2|GPD1|GSR|H6PD|HADH|HADHA|HIBADH|HMGCR|HMOX1|HMOX2|HPGD|HSD11B1|HSD11B2|HSD17B1|HSD17B10|HSD17B2|HSD17B3|HSD17B4|HSD17B7|HSD17B8|HSD3B1|HSD3B2|IDH3A|IDH3B|IDH3G|IMPDH1|IMPDH2|LDHA|LDHAL6A|LDHAL6B|LDHB|LDHC|MDH1|MDH2|ME1|ME2|ME3|MSMO1|MT-ND1|MT-ND2|MT-ND3|MT-ND4|MT-ND4L|MT-ND5|MT-ND6|MTHFD1|MTHFD2|NDUFA1|NDUFA10|NDUFA11|NDUFA12|NDUFA13|NDUFA2|NDUFA3|NDUFA4|NDUFA4L2|NDUFA5|NDUFA6|NDUFA7|NDUFA8|NDUFA9|NDUFAB1|NDUFB1|NDUFB10|NDUFB2|NDUFB3|NDUFB4|NDUFB5|NDUFB6|NDUFB7|NDUFB8|NDUFB9|NDUFC1|NDUFC2|NDUFS1|NDUFS2|NDUFS3|NDUFS4|NDUFS5|NDUFS6|NDUFS7|NDUFS8|NDUFV1|NDUFV2|NDUFV3|NNT|NQO2|NSDHL|OGDH|PDHA1|PDHA2|PDHB|PHGDH|PYCR1|PYCR2|QDPR|RDH5|SORD|TSTA3|TYR|UGDH			
coenzyme-Q10	COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O |c:2	Launched				
COH29	Oc1ccc(cc1O)C(=O)Nc1nc(c(s1)-c1ccccc1)-c1ccc(O)c(O)c1	Phase 1		ribonucleotide reductase inhibitor		
colchicine	COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC	Launched	GLRA1|GLRA2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	microtubule inhibitor	rheumatology, endocrinology	gout, fever
colforsin	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C |a:4	Phase 2	ADCY2|ADCY5	adenylyl cyclase activator		
colforsin-daproate	CN(C)CCC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@]2(C)O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@H]12)C=C	Launched		adenylyl cyclase activator		
colfosceril-palmitate	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC |a:19	Launched		pulmonary surfactant	pulmonary	respiratory distress syndrome (RDS)
colistimethate	[H][C@@](CCNCS(O)(=O)=O)(NC(=O)CCCC(C)C)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)N[C@@]([H])(CCNCS(O)(=O)=O)C(=O)N[C@@]1([H])CCNC(=O)[C@@]([H])(NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CC(C)C)NC(=O)[C@]([H])(CCNCS(O)(=O)=O)NC1=O)[C@@H](C)O	Launched		bacterial permeability inducer	infectious disease	gram-negative bacterial infections
colistin	CC[C@@H](C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O |a:10	Launched		bacterial permeability inducer	infectious disease	gram-negative bacterial infections, gram-negative bacterial infections
combretastatin-A-4	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1O	Phase 2		tubulin polymerization inhibitor		
compound-w	OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1	Preclinical	BACE1	beta-secretase inhibitor		
compound-401	O=c1cc(nc2c3ccccc3ccn12)N1CCOCC1	Preclinical	MTOR|PRKDC	DNA dependent protein kinase inhibitor		
compound-58112	COc1cccc(CN2C[Si](C)(C)O[Si](C)(C)C2)c1	Preclinical				
conivaptan	Cc1nc-2c(CCN(C(=O)c3ccc(NC(=O)c4ccccc4-c4ccccc4)cc3)c3ccccc-23)[nH]1	Launched	AVPR1A|AVPR2	vasopressin receptor antagonist	endocrinology	hyponatremia
convallatoxin	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C=O)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:31|	Preclinical		cardiac glycoside		
copanlisib	COc1c(OCCCN2CCOCC2)ccc2C3=NCCN3C(NC(=O)c3cnc(N)nc3)=Nc12 |c:35	Launched	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor	hematologic malignancy	follicular lymphoma
copper-histidine	N[C@H](Cc1cnc[nH]1)C(O)=O	Phase 3	SLC15A3|SLC15A4|SLC38A5			
COR-170	CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)c2cc(ccc12)-c1ccccc1	Preclinical	CNR2	cannabinoid receptor inverse agonist		
cordycepin	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@H]1O	Phase 1/Phase 2		DNA inhibitor		
corosolic-acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	Phase 2	HSD11B1|PTPN1	PKC inhibitor, protein tyrosine kinase inhibitor		
CORT-108297	CCOC[C@@]12CN(CCC1=Cc1c(C2)cnn1-c1ccc(F)cc1)S(=O)(=O)c1ccc(cc1)C(F)(F)F |c:10|	Preclinical		glucocorticoid receptor antagonist		
corticosterone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:9|	Preclinical	HSD11B1|NCOA1|NR3C2	mineralocorticoid receptor agonist		
cortisone	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	Launched	NR3C1	glucocorticoid receptor agonist	gastroenterology, rheumatology, dermatology	ulcerative colitis, rheumatoid arthritis, psoriasis, joint inflammation, eczema
cortisone-acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C |t:15|	Launched	NR3C1	glucocorticoid receptor agonist	pulmonary, rheumatology, allergy, dermatology, ophthalmology, gastroenterology, infectious disease	asthma, rheumatoid arthritis, urticaria, osteoarthritis, psoriasis, allergic rhinitis, conjunctivitis, ulcerative colitis, meningitis
cortodoxone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:8|	Phase 3	AR	androgen receptor antagonist		
costunolide	C\C1=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1	Preclinical		telomerase inhibitor		
cot-inhibitor-1	Fc1ccc(Nc2c(cnc3c(Cl)cc(NCc4cn(CCN5CCCCCC5)nn4)cc23)C#N)cc1Cl	Preclinical	MAP3K8	MAPK-interacting kinase inhibitor		
cot-inhibitor-2	CCN1CCC(CC1)n1cc(CNc2cc(Cl)c3ncc(C#N)c(Nc4ccc(F)c(Cl)c4)c3c2)nn1	Preclinical	MAP3K8	MAPK-interacting kinase inhibitor		
COTI-2	S=C(N\N=C1/CCCc2cccnc12)N1CCN(CC1)c1ccccn1	Phase 1		anticancer agent		
cotinine	CN1[C@@H](CCC1=O)c1cccnc1	Phase 2		nicotine metabolite		
coumarin	O=c1ccc2ccccc2o1	Launched	CA1|CA12|CA14|CA2|CA4|CA6|CA9|CYP2A6	vitamin K antagonist	gastroenterology, pulmonary	ulcerative colitis, asthma, celiac disease
coumophos	CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1	Preclinical		cholinesterase inhibitor		
CP-105,696	O[C@@H]1[C@@H](Cc2ccc(cc2)-c2ccccc2)COc2cc(ccc12)C1(CCCC1)C(O)=O	Preclinical		leukotriene receptor antagonist		
CP-316819	CON(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical	PYGL	glycogen phosphorylase inhibitor		
CP-339818	CCCCC\N=c1/ccn(Cc2ccccc2)c2ccccc12	Preclinical	KCNA3	potassium channel blocker		
CP-376395	CCC(CC)Nc1cc(C)nc(Oc2c(C)cc(C)cc2C)c1C	Phase 1	CRHR1	corticotropin releasing factor receptor antagonist		
CP-471474	CC(C)(NS(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1)C(=O)NO	Preclinical	MMP1|MMP13|MMP2|MMP3|MMP9	matrix metalloprotease inhibitor		
CP-532623	CC[C@@H]1C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(C)=O)c2cc(ccc2N1C(=O)OC(C)C)C(F)(F)F	Phase 1	CETP	cholesteryl ester transfer protein inhibitor		
CP-547632	NC(=O)c1c(NC(=O)NCCCCN2CCCC2)snc1OCc1c(F)cc(Br)cc1F	Phase 2		kinase inhibitor		
CP-640186	O=C([C@@H]1CCCN(C1)C1CCN(CC1)C(=O)c1c2ccccc2cc2ccccc12)N1CCOCC1	Preclinical	ACACA|ACACB	acetyl-CoA carboxylase inhibitor		
CP-673451	COCCOc1ccc2n(cnc2c1)-c1ccc2cccc(N3CCC(N)CC3)c2n1	Preclinical	KIT|PDGFRA|PDGFRB	PDGFR tyrosine kinase receptor inhibitor		
CP-724714	COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1	Phase 2	ERBB2	EGFR inhibitor, protein tyrosine kinase inhibitor		
CP-775146	CC(C)c1ccc(CC(=O)N2CCC[C@H](C2)c2cccc(OC(C)(C)C(O)=O)c2)cc1	Preclinical	PPARA	PPAR receptor agonist		
CP-91149	CN(C)C(=O)[C@H](O)[C@H](Cc1ccccc1)NC(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical	PYGL	glycogen phosphorylase inhibitor		
CP-93129	O=c1ccc2[nH]cc(C3=CCNCC3)c2[nH]1 |t:8|	Preclinical	HTR1A	serotonin receptor agonist		
CP-94253	CCCOc1ccc2[nH]cc(C3=CCNCC3)c2n1 |t:11|	Preclinical	HTR1B	serotonin receptor agonist		
CP-945,598	CCNC1(CCN(CC1)c1ncnc2n(c(nc12)-c1ccccc1Cl)-c1ccc(Cl)cc1)C(N)=O	Phase 3	CNR1	cannabinoid receptor antagonist		
CP-99994	COc1ccccc1CN[C@H]1CCCN[C@H]1c1ccccc1	Phase 2	TACR1	tachykinin antagonist		
CPA-inhibitor	ON(C[C@@H](Cc1ccccc1)C(O)=O)C(=O)Cc1ccccc1 |&1:3	Preclinical	CPA1|CPA2	carboxypeptidase inhibitor		
CPCCOEt	CCOC(=O)[C@]12C[C@H]1\C(=N/O)c1ccccc1O2 |&1:5	Preclinical	GRM1	glutamate receptor antagonist		
CPI-0610	Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 |t:10|	Phase 2	BRD4	bromodomain inhibitor		
CPI-1189	CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C	Phase 2	TNF	tumor necrosis factor release inhibitor		
CPI-1205	COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12	Phase 1/Phase 2		EZH2 inhibitor		
CPI-169	CCS(=O)(=O)N1CCC(CC1)[C@@H](C)n1c(C)c(C(=O)NCc2c(OC)cc(C)[nH]c2=O)c2ccccc12	Preclinical	EZH2	histone lysine methyltransferase inhibitor		
CPI-203	Cc1nnc2[C@H](CC(N)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:10|	Preclinical	BRD4	bromodomain inhibitor		
CPI-360	COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCOCC2)c2ccccc12	Preclinical	EZH2	histone lysine methyltransferase inhibitor		
CPI-444	Cc1ccc(o1)-c1nc(N)nc2n(Cc3cccc(CO[C@H]4CCOC4)n3)nnc12	Phase 1/Phase 2		adenosine receptor antagonist		
CPI-613	OC(=O)CCCC[C@@H](CCSCc1ccccc1)SCc1ccccc1 |&1:7	Phase 3	PDHA1	pyruvate dehydrogenase inhibitor		
CPP	OC(=O)[C@H]1CN(CCCP(O)(O)=O)CCN1	Phase 2	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor antagonist		
CPSI-1306-(+/-)	Fc1ccc(C2=NO[C@@H](CC(=O)N3CCOCC3)C2)c(F)c1 |&1:8	Preclinical	MIF	macrophage migration inhibiting factor inhibitor		
CQS	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(Cl)cccc2n1	Preclinical				
creatine	CN(CC(O)=O)C(N)=N	Launched	CKB|CKM|CKMT1A|CKMT2|GAMT|SLC6A8			
creatinine	CN1CC(=O)NC1=N	Preclinical				
creatinol-phosphate	CN(CCOP(O)(O)=O)C(N)=N	Launched				
crenigacestat	C[C@H](NC(=O)CCC(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2cccnc2N(CCO)C1=O	Preclinical		notch signaling inhibitor		
crenolanib	CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1	Phase 3	CSF1R|FLT3|KIT|PDGFRA|PDGFRB	PDGFR tyrosine kinase receptor inhibitor		
cresol	Cc1ccc(O)cc1	Launched				
cresopirine	CC(=O)Oc1c(C)cccc1C(O)=O	Preclinical				
cridanimod	OC(=O)Cn1c2ccccc2c(=O)c2ccccc12	Launched	PGR	progesterone receptor agonist	infectious disease	influenza A virus infection
crisaborole	OB1OCc2cc(Oc3ccc(cc3)C#N)ccc12	Launched	PDE4A|PDE4B|PDE4C|PDE4D	phosphodiesterase inhibitor	dermatology	dermatitis
crisdesalazine	OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O	Preclinical		free radical scavenger		
crizotinib	C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Launched	ALK|MET	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
crizotinib-(S)	C[C@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl	Preclinical	NUDT1	MTH1 inhibitor		
croconazole	Clc1cccc(COc2ccccc2C(=C)n2ccnc2)c1	Launched		bacterial cell wall synthesis inhibitor	infectious disease	fungal infection
crolibulin	COc1cc(cc(Br)c1OC)[C@H]1C(C#N)=C(N)Oc2c(N)c(N)ccc12 |t:15|	Phase 1/Phase 2		tubulin polymerization inhibitor		
cromakalim	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N.CC1(C)Oc2ccc(cc2[C@@H]([C@H]1O)N1CCCC1=O)C#N	Phase 2	KCNJ8			
cromoglicic-acid	OC(COc1cccc2oc(cc(=O)c12)C(O)=O)COc1cccc2oc(cc(=O)c12)C(O)=O	Launched	KCNMA1|S100P	immunosuppressant	pulmonary, ophthalmology, allergy, gastroenterology	asthma, conjunctivitis, urticaria, ulcerative colitis
crotamiton	CCN(C(=O)\C=C\C)c1ccccc1C	Launched		antipruritic	infectious disease	scabies
CRT0044876	OC(=O)c1cc2cccc([N+]([O-])=O)c2[nH]1	Preclinical				
cryptotanshinone	C[C@H]1COC2=C1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc21 |c:4|	Preclinical	STAT3	acetylcholinesterase inhibitor, STAT inhibitor		
crystal-violet	CN(C)c1ccc(cc1)C(=C1C=CC(C=C1)=[N+](C)C)c1ccc(cc1)N(C)C |c:12	Launched		other antibiotic		
CR8-(R)	CC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1	Preclinical	CCNA2	CDK inhibitor		
CS-110266	C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1	Preclinical	SLC6A3	dopamine receptor agonist		
CS-917	CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O	Phase 2	FBP1	fructose biphosphate inhibitor		
CT-7758	OC(=O)[C@H](Cc1ccc(Nc2nccc3ccncc23)cc1)NC1=C(Br)C(=O)C11CCCCC1 |c:26|	Phase 2	ITGA4	integrin antagonist		
CTEP	Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(OC(F)(F)F)cc1	Preclinical	GRM5	glutamate receptor antagonist		
CTS-1027	ONC(=O)C1(CS(=O)(=O)c2ccc(Oc3ccc(Cl)cc3)cc2)CCOCC1	Phase 2	MMP1|MMP13|MMP2|MMP3|MMP9	metalloproteinase inhibitor		
CTS21166	CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C(C)C)[C@@H](O)C[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O	Phase 1	BACE1	beta-secretase inhibitor		
CT7001	CC(C)c1cnn2c(NCc3ccccc3)cc(NC[C@H]3CCNC[C@@H]3O)nc12	Phase 1/Phase 2		CDK inhibitor		
CU-CPT-4a	OC(=O)[C@@H](Cc1ccccc1)NC(=O)c1sc2cc(F)ccc2c1Cl	Preclinical	TLR3	toll-like receptor inhibitor		
CU-T12-9	CNc1ccc(cc1-n1cnc(c1)-c1ccc(cc1)C(F)(F)F)[N+]([O-])=O	Preclinical	TLR1|TLR2	toll-like receptor agonist		
CUDC-101	COc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCCCCCC(=O)NO	Phase 1	EGFR|ERBB2	EGFR inhibitor		
CUDC-427	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1-c1ccccc1)-c1ncco1	Phase 1	XIAP	apoptosis inhibitor		
CUDC-907	COc1ccc(cn1)-c1nc(N2CCOCC2)c2sc(CN(C)c3ncc(cn3)C(=O)NO)cc2n1	Phase 2	HDAC2|PIK3R1	PI3K inhibitor		
CUR-61414	COc1cccc(CN([C@H]2C[C@H](N(Cc3ccc4OCOc4c3)C2)C(=O)N2CCNCC2)C(=O)CC(C)(C)C)c1	Phase 1	DHH|IHH|SMO	smoothened receptor antagonist		
curcumin	COc1cc(\C=C\C(O)=CC(=O)\C=C\c2ccc(O)c(OC)c2)ccc1O	Launched	APP|CA1|CA12|CA14|CA2|CA4|CA6|CA9|CHRM3|CYP3A4|DNMT3B|EP300|MMP13|MMP9|NOS2|PTGS1|PTGS2|XDH	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor		
curcumol	CC(C)[C@@H]1C[C@@]23O[C@]1(O)CC(=C)[C@@H]2CC[C@@H]3C	Phase 1	JAK1|JAK2|JAK3	JAK inhibitor		
cutamesine	COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC	Phase 2	SIGMAR1	sigma receptor agonist		
CV-1808	Nc1nc(Nc2ccccc2)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical	ADORA2A	adenosine receptor agonist		
CVT-10216	CS(=O)(=O)Nc1ccc(cc1)-c1coc2cc(OCc3cccc(c3)C(O)=O)ccc2c1=O	Phase 1	ALDH2	aldehyde dehydrogenase inhibitor		
CW-008	COc1ccn2ncc(-c3nc4n[nH]c(NC(=O)c5ccc(F)cc5)c4cc3F)c2c1	Preclinical	PRKACA	PKA activator		
CX-4945	OC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc21	Phase 1/Phase 2	CSNK2A1|CSNK2A2|DAPK3|HIPK3	casein kinase inhibitor		
CX-516	O=C(N1CCCCC1)c1ccc2OCOc2c1	Phase 2/Phase 3		glutamate receptor modulator		
CX-5461	CN1CCCN(CC1)c1ccc2c(n1)n1c3ccccc3sc1c(C(=O)NCc1cnc(C)cn1)c2=O	Phase 1		RNA polymerase inhibitor		
CXD101	Cc1nn(C)cc1CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N	Phase 1/Phase 2		HDAC inhibitor		
cyacetacide	NNC(=O)CC#N	Preclinical				
cyamemazine	C[C@@H](CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N |&1:1	Launched	HTR1A|HTR2A|HTR2C|HTR7	serotonin receptor antagonist	neurology/psychiatry	schizophrenia, anxiety
cyanocobalamin	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)O[P@@](O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |a:1	Launched	MUT	methylmalonyl CoA mutase stimulant, vitamin B	hematology, infectious disease, gastroenterology	anemia, fish tapeworm infestation, celiac disease
cyanopindolol	CC(C)(C)NC[C@@H](O)COc1cccc2[nH]c(cc12)C#N |&1:6|	Phase 2	ADRB1|HTR1A|HTR1D	adrenergic receptor antagonist		
cyclamic-acid	OS(=O)(=O)NC1CCCCC1	Preclinical				
cyclandelate	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)[C@@H](O)c1ccccc1 |&1:1	Launched		calcium channel blocker	cardiology, rheumatology	claudication, arteriosclerosis, Raynaud's disease
cyclic-AMP	Nc1ncnc2n(cnc12)[C@H]1O[C@H]2CO[P@](O)(=O)O[C@@H]2[C@@H]1O |&1:10	Preclinical	CNGA3|TRPM7			
cyclizine	CN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	HRH1|SULT1E1	histamine receptor modulator	gastroenterology, neurology/psychiatry	nausea, vomiting, vertigo, motion sickness
cyclobenzaprine	CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 |c:14|	Launched	HTR2A	adrenergic receptor agonist, serotonin receptor agonist	neurology/psychiatry	spasms
cyclocreatine	NC1=NCCN1CC(O)=O |t:1|	Phase 1		creatine kinase substrate		
cyclocytidine	OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O	Preclinical		DNA synthesis inhibitor, RNA synthesis inhibitor		
cycloheximide	C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1	Preclinical	RPL3	protein synthesis inhibitor		
cyclopamine	C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@]11CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC2=C1C |c:32	Preclinical		hedgehog pathway inhibitor		
cyclopenthiazide	NS(=O)(=O)c1cc2c(N[C@@H](CC3CCCC3)NS2(=O)=O)cc1Cl |&1:9	Launched		thiazide diuretic	cardiology	hypertension, congestive heart failure
cyclopentolate	CN(C)CCOC(=O)[C@@H](c1ccccc1)C1(O)CCCC1 |&1:8|	Launched		acetylcholine receptor antagonist	ophthalmology	mydriasis, cycloplegia
cyclophosphamide	ClCCN(CCCl)[P@@]1(=O)NCCCO1 |r|	Launched	CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP3A4|CYP3A5|CYP3A7	DNA alkylating agent	hematologic malignancy, oncology	Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), breast cancer, neuroblastoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), true histiocytic lymphoma (THL), retinoblastoma, ovarian cancer
cyclopiazonic-acid	CC(=O)C1=C(O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O |a:6	Preclinical	ATP2A1	ATPase inhibitor		
cycloserine-(D)	N[C@@H]1CONC1=O	Launched	GRIN1	bacterial cell wall synthesis inhibitor	infectious disease	tuberculosis, tuberculosis
cyclosporin-A	CC[C@H]1NC(=O)[C@@H]([C@@H](O)[C@@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C |&1:2	Launched	ABCB11|CAMLG|FPR1|PPIA|PPIF|PPP3CA|PPP3R2|SLC10A1|SLCO1B1|SLCO1B3	calcineurin inhibitor	rheumatology, dermatology	rheumatoid arthritis, psoriasis
cyclothiazide	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)[C@H]2C[C@H]3C[C@@H]2C=C3)cc1Cl |&1:9	Launched	CA2|GRIA1|GRIA2|GRIA3|GRIA4|SLC12A3	glutamate receptor modulator	cardiology	hypertension
cyclovalone	COc1cc(\C=C2/CCC\C(=C/c3ccc(O)c(OC)c3)C2=O)ccc1O	Launched	ABCG2	breast cancer resistance protein inhibitor	gastroenterology	bile stimulation
cyclovirobuxin-D	CN[C@@H](C)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC[C@@H]4[C@]5(C[C@@]35CC[C@]12C)CC[C@H](NC)C4(C)C	Preclinical		calcium channel modulator		
CycLuc1	OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 |c:6|	Preclinical				
CYC065	CC[C@H](Nc1nc(NCc2cnc(C)cc2C)c2ncn(C(C)C)c2n1)[C@@H](C)O	Phase 1		CDK inhibitor		
CYC116	Cc1nc(N)sc1-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	Phase 1	AURKA|AURKB|KDR	Aurora kinase inhibitor		
CYM-50260	FCc1ccc(OCCOc2ccc(Cl)cc2Cl)c(Cl)n1	Preclinical	S1PR4	sphingosine 1-phosphate receptor agonist		
CYM-50358	Cc1cc(CN)cc(C)c1NC(=O)c1ccc(o1)-c1cc(Cl)ccc1Cl	Preclinical	S1PR4	sphingosine 1-phosphate receptor antagonist		
CYM-50769	COc1ccc(Oc2c(Cl)cnn(C3c4ccccc4-c4ccccc34)c2=O)cc1	Preclinical	NPBWR1	neuropeptide receptor antagonist		
CYM-5442	CCOc1ccc(cc1OCC)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCO |&1:22|	Preclinical	S1PR1	sphingosine 1-phosphate receptor agonist		
CYM-5520	Cc1cc(C(=O)Cn2cc(ccc2=O)C#N)c(C)n1Cc1ccccc1	Preclinical	S1PR2	sphingosine 1-phosphate receptor agonist		
CYM-5541	O=C(N(C1CCCCC1)C1CCCCC1)c1cc(on1)C1CC1	Preclinical	S1PR3	sphingosine 1-phosphate receptor agonist		
cypermethrin	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)O[C@@H](C#N)c1cccc(Oc2ccccc2)c1 |&1:3	Launched			infectious disease	flea control
cyproheptadine	CN1CCC(CC1)=C1c2ccccc2C=Cc2ccccc12 |c:16|	Launched	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|HRH1|HTR2A|HTR2C|HTR6|HTR7	histamine receptor antagonist	allergy, otolaryngology, ophthalmology, dermatology	allergic rhinitis, vasomotor rhinitis, conjunctivitis, urticaria, dermatographism
cyproterone-acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9	Launched	ADORA1|AR	androgen receptor antagonist	oncology	prostate cancer
cyromazine	Nc1nc(N)nc(NC2CC2)n1	Launched				
cysteamine	NCCS	Launched	NPY2R|SST	tissue transglutaminase inhibitor	metabolism	cystinosis
CYT-997	CCC[C@H](Nc1nc(ncc1C)-c1ccc(NC(=O)NCC)c(OC)c1)c1cccnc1	Phase 2	TUBB	tubulin polymerization inhibitor		
cytarabine	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	Launched	POLA1|POLB|POLD1|POLE	ribonucleotide reductase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL)
cytidine	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1	Launched	UCK2			
cytisine	O=c1cccc2[C@H]3CNC[C@H](C3)Cn12	Launched	CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB2|CHRNB4	acetylcholine receptor agonist	neurology/psychiatry	nicotinism
cytochalasin-B	C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C |t:20	Phase 2	ACTB	microtubule inhibitor		
cytochlor	Nc1nc(=O)n(cc1Cl)[C@H]1C[C@@H](O)[C@@H](CO)O1	Phase 1				
cyt387	O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1	Phase 3	JAK1|JAK2|JAK3	JAK inhibitor		
CY208-243	CN1Cc2ccccc2[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	Phase 2	CALY	dopamine receptor agonist		
CZC-54252	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1	Preclinical	LRRK2	leucine rich repeat kinase inhibitor		
CZC24832	CC(C)(C)NS(=O)(=O)c1cncc(c1)-c1cc(F)c2nc(N)nn2c1	Preclinical	PIK3CG	PI3K inhibitor		
C106	CN1CCC[C@@H]1c1cccnc1.Cc1ccc(cc1)C(=O)O[C@@H]([C@@H](OC(=O)c1ccc(C)cc1)C(O)=O)C(O)=O |&1:5	Phase 3				
C11-Acetate	[Y+3]	Phase 3	ABAT|ACE|AKR1C3|CA2|CELA1|ESR2|FFAR2|FFAR3|HPRT1|LTA4H|MMP12|NOS1|NOS3|PLA2G1B|PTPN1|SOD1|TXN			
C188-9	COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12	Preclinical		STAT inhibitor		
C34	CC(C)O[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(C)=O	Preclinical	TLR4	toll-like receptor inhibitor		
C646	CC1=NN(C(=O)C1=Cc1ccc(o1)-c1cc(C)c(C)cc1[N+]([O-])=O)c1ccc(cc1)C(O)=O |t:1|	Preclinical	EP300	histone acetyltransferase inhibitor		
D,L-mevalonic-acid-lactone	C[C@@]1(O)CCOC(=O)C1 |&1:1	Preclinical				
D-(+)-maltose	OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical	MGAM			
D-alpha-tocopheryl-succinate	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(O)=O)c(C)c(C)c2O1	Launched				
D-delta-tocopherol	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2cc(O)cc(C)c2O1	Launched				
D-limonene	CC(=C)[C@@H]1CCC(C)=CC1 |c:7|	Phase 1				
D-phenylalanine	N[C@H](Cc1ccccc1)C(O)=O	Preclinical	CCBL1|CRH|HCAR3	enkephalinase inhibitor		
D-serine	N[C@H](CO)C(O)=O	Launched	GLRA1|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|SERPINB3	glutamate receptor agonist		
D-157495	Nc1nc(N)c2c(OCC3CCN(Cc4c(Cl)cccc4Cl)CC3)cccc2n1	Preclinical		decapping scavenger enzyme inhibitor		
D-3263	COc1ccc2n(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)c(=O)n(CCN)c2c1	Phase 1		transient receptor potential channel agonist		
D-4476	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCCOc2c1)-c1ccccn1	Preclinical	CSNK1A1|CSNK1D|TGFB1	TGF beta receptor inhibitor		
D-64131	COc1ccc2[nH]c(cc2c1)C(=O)c1ccccc1	Preclinical	TUBB	microtubule inhibitor		
D-7193	CC(=O)N[C@@H](CSSC[C@H](NC(C)=O)C(O)=O)C(O)=O	Phase 2				
DAA-1106	COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	Preclinical	TSPO	benzodiazepine receptor agonist		
dabigatran	Cn1c(CNc2ccc(cc2)C(N)=N)nc2cc(ccc12)C(=O)N(CCC(O)=O)c1ccccn1	Launched	F2	thrombin inhibitor	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)
dabigatran-etexilate	CCCCCCOC(=O)\N=C(\N)c1ccc(NCc2nc3cc(ccc3n2C)C(=O)N(CCC(=O)OCC)c2ccccn2)cc1	Launched	F2	thrombin inhibitor	neurology/psychiatry, hematology	stroke, systemic embolism, pulmonary embolism (PE), deep vein thrombosis (DVT)
dabrafenib	CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F	Launched	BRAF|LIMK1|NEK11|RAF1|SIK1	RAF inhibitor	oncology	melanoma
dacarbazine	CN(C)\N=N\c1nc[nH]c1C(N)=O	Launched	PGD|POLA2	DNA alkylating agent	oncology, hematologic malignancy	melanoma, Hodgkin's lymphoma
dacinostat	OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1	Phase 1	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	HDAC inhibitor		
daclatasvir	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched		HCV inhibitor	infectious disease	hepatitis C
dacomitinib	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1	Launched	EGFR|ERBB2|ERBB4	EGFR inhibitor		
dactinomycin	CC(C)[C@H]1NC(=O)[C@@H](NC(=O)c2ccc(C)c3oc4c(C)c(=O)c(N)c(C(=O)N[C@H]5[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]6CCCN6C(=O)[C@H](NC5=O)C(C)C)c4nc23)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C1=O	Launched	POLR2A	RNA polymerase inhibitor	oncology	testicular carcinoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, gestational trophoblastic disease (GTD)
daidzein	Oc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	Phase 2	ESRRA|ESRRB|ESRRG|TRPC5	estrogen receptor agonist		
daidzin	OC[C@H]1O[C@@H](Oc2ccc3c(c2)occ(-c2ccc(O)cc2)c3=O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1	ALDH2	antioxidant		
dalargin	CC(C)C[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=N)C(O)=O |a:23	Phase 2	OPRM1	opioid receptor agonist		
dalbavancin	CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2	Launched	PNLIP	bacterial cell wall synthesis inhibitor	infectious disease	skin infections
dalcetrapib	CCC(CC)CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C	Phase 3	CETP	cholesteryl ester transfer protein inhibitor		
dalfampridine	Nc1ccncc1	Launched	KCNA1|KCNA10|KCNA2|KCNA3|KCNA4|KCNA5|KCNA6|KCNA7|KCNB1|KCNB2|KCNC1|KCNC2|KCNC3|KCNC4|KCND1|KCND2|KCND3|KCNF1|KCNG1|KCNG2|KCNG3|KCNG4|KCNH1|KCNH2|KCNH3|KCNH4|KCNH5|KCNH6|KCNH7|KCNH8|KCNJ13|KCNJ5|KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5|KCNS1|KCNS2|KCNS3|KCNV1|KCNV2	potassium channel blocker	neurology/psychiatry	multiple sclerosis
dalfopristin	[H][C@]12[C@@H](CCN1C(=O)c1coc(CC(=O)C[C@H](O)\C=C(/C)\C=C/CNC(=O)\C=C\[C@@H](C)[C@@H](OC2=O)C(C)C)n1)S(=O)(=O)CCN(CC)CC |c:19	Preclinical		antibacterial 		
daltroban	OC(=O)Cc1ccc(CCNS(=O)(=O)c2ccc(Cl)cc2)cc1	Phase 3	TBXA2R	thromboxane receptor antagonist		
daminozide	CN(C)NC(=O)CCC(O)=O	Preclinical	KDM2A|KDM7A|PHF8	KDM2A inhibitor		
danazol	C[C@]12CC[C@H]3[C@@H](CCC4=Cc5oncc5C[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	Launched	AR|CCL2|ESR1|GNRHR|GNRHR2|PGR	estrogen receptor antagonist, progesterone receptor agonist	obstetrics/gynecology, cardiology	endometriosis, angioedema
danegaptide	NCC(=O)N1C[C@@H](C[C@H]1C(O)=O)NC(=O)c1ccccc1	Phase 2		gap junction modulator		
danirixin	Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1	Phase 2	CXCR2	CC chemokine receptor antagonist		
danofloxacin	CN1C[C@@H]2C[C@H]1CN2c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Launched		bacterial DNA gyrase inhibitor	pulmonary	bovine respiratory disease (BRD)
danoprevir	CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1Cc2cccc(F)c2C1)C(=O)NS(=O)(=O)C1CC1 |c:14|	Phase 3		HCV inhibitor		
dantrolene	[O-][N+](=O)c1ccc(cc1)-c1ccc(\C=N\N2CC(=O)NC2=O)o1	Launched	RYR1|RYR3	calcium channel blocker	neurology/psychiatry, endocrinology	spasms, malignant hyperthermia (MH)
dantron	Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12	Withdrawn		laxative		
danusertib	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1)c1ccccc1	Phase 2	AURKA|AURKB|AURKC|FGFR1|NTRK1|RET|SLK	Aurora kinase inhibitor, growth factor receptor inhibitor		
dapagliflozin	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1	Launched	SLC5A1|SLC5A2	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
dapansutrile	CS(=O)(=O)CCC#N	Phase 2		anti-inflammatory agent		
daphnetin	Oc1ccc2ccc(=O)oc2c1O	Preclinical		protein kinase inhibitor		
dapiprazole	Cc1ccccc1N1CCN(CCc2nnc3CCCCn23)CC1	Launched	ADRA1A|ADRA1B|ADRA1D	adrenergic receptor antagonist	ophthalmology	mydriasis
dapivirine	Cc1cc(C)c(Nc2ccnc(Nc3ccc(cc3)C#N)n2)c(C)c1	Phase 3	CYP3A4|CYP3A5	non-nucleoside reverse transcriptase inhibitor		
dapoxetine	CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1	Launched	HTR1A|HTR1B|HTR2C|SLC6A4	selective serotonin reuptake inhibitor (SSRI)	urology	premature ejaculation (PE)
daprodustat	OC(=O)CNC(=O)c1c(O)n(C2CCCCC2)c(=O)n(C2CCCCC2)c1=O	Phase 3	EGLN1	hypoxia inducible factor inhibitor		
dapsone	Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1	Launched	DHFR	bacterial antifolate	dermatology, infectious disease	dermatitis herpetiformis (DH), leprosy
DAPT	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H](C(=O)OC(C)(C)C)c1ccccc1	Preclinical		gamma secretase inhibitor		
daptomycin	[H][C@]1(CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CCCCCCCCC)[C@@H](C)OC(=O)[C@]([H])(CC(=O)c2ccccc2N)NC(=O)[C@@]([H])(NC1=O)[C@H](C)CC(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections, endocarditis
darapladib	CCN(CC)CCN(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c2CCCc2c(=O)nc1SCc1ccc(F)cc1	Phase 3	PLA2G7	phospholipase inhibitor		
darglitazone	Cc1oc(nc1CCC(=O)c1ccc(CC2SC(=O)NC2=O)cc1)-c1ccccc1	Phase 2	PPARG	PPAR receptor antagonist		
darifenacin	NC(=O)C([C@@H]1CCN(CCc2ccc3OCCc3c2)C1)(c1ccccc1)c1ccccc1	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	urology	urinary incontinence
darolutamide	C[C@@H](Cn1ccc(n1)-c1ccc(C#N)c(Cl)c1)NC(=O)c1cc(n[nH]1)[C@@H](C)O |a:1	Launched	AR	androgen receptor antagonist	oncology	prostate cancer
darunavir	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1	Launched	CYP3A4	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
darusentan	COc1cc(OC)nc(O[C@H](C(O)=O)C(OC)(c2ccccc2)c2ccccc2)n1	Phase 3	EDNRA	endothelin receptor antagonist		
dasabuvir	COc1c(cc(cc1C(C)(C)C)-n1ccc(=O)[nH]c1=O)-c1ccc2cc(NS(C)(=O)=O)ccc2c1	Launched		HCV inhibitor	infectious disease	hepatitis C
dasatinib	Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1	Launched	ABL1|ABL2|BLK|EPHA2|FGR|FRK|FYN|HCK|KIT|LCK|LYN|PDGFRB|SRC|SRMS|STAT5B|YES1	Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)
dasotraline	N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	Phase 3		dopamine-norepinephrine-serotonin reuptake inhibitor		
DAU-5884	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1Cc2ccccc2NC1=O	Preclinical	CHRM3	acetylcholine receptor antagonist		
daucosterol	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C(C)C |t:13|	Phase 2		apoptosis stimulant		
daunorubicin	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O	Launched	TOP2A|TOP2B	RNA synthesis inhibitor, topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL)
dazmegrel	Cc1c(Cn2ccnc2)c2ccccc2n1CCC(O)=O	Phase 2	TBXAS1	thromboxane synthase inhibitor		
dazoxiben	OC(=O)c1ccc(OCCn2ccnc2)cc1	Phase 2	TBXAS1	thromboxane synthase inhibitor		
DBeQ	C(Nc1nc(NCc2ccccc2)c2ccccc2n1)c1ccccc1	Preclinical	CASP3	ATPase inhibitor		
DBPR-211	FC(F)(F)c1ccc(cc1)C#Cc1ccc(s1)-c1c(CNS(=O)(=O)N2CCCC2)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical		cannabinoid receptor antagonist		
DBPR108	CC(C)(CC(=O)N1CCCC1)NCC(=O)N1C[C@@H](F)C[C@H]1C#N	Phase 1	DPP4	dipeptidyl peptidase inhibitor		
DC-260126	CCCCc1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1	Preclinical	FFAR1	free fatty acid receptor antagonist		
DCC-2618	Cn1cc(cn1)-c1cc(Oc2cc(F)c(NC(=O)C3(CC3)C(=O)Nc3ccccc3)cc2F)ccn1	Phase 1	KIT|PDGFRA	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor		
DCEBIO	CCn1c2cc(Cl)c(Cl)cc2[nH]c1=O	Preclinical	KCNN2|KCNN3|KCNN4	potassium channel activator		
DCP-LA	CCCCC[C@H]1C[C@H]1C[C@H]1C[C@H]1CCCCCCCC(O)=O |&1:11	Preclinical		protein kinase activator		
DCPIB	CCCC[C@]1(Cc2cc(OCCCC(O)=O)c(Cl)c(Cl)c2C1=O)C1CCCC1 |&1:4	Preclinical	SLC1A2	chloride channel blocker, gap junction modulator, glutamate inhibitor		
DDR1-IN-1	CCN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2ccc(C)c(Oc3ccc4NC(=O)Cc4c3)c2)CC1	Preclinical	DDR1|DDR2	discoidin domain receptor inhibitor		
deazaguanine	Nc1cc2[nH]cnc2c(O)n1	Preclinical		DNA synthesis inhibitor		
Debio-0932	CN(C)c1cc2OCOc2cc1Sc1nc2c(N)nccc2n1CCNCC(C)(C)C	Phase 1		HSP inhibitor		
debrisoquin	NC(=N)N1CCc2ccccc2C1	Launched	SLC6A2	adrenergic neuron blocker	cardiology	hypertension
decamethonium	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	Launched	ACHE|CHRNA2	acetylcholine receptor agonist	neurology/psychiatry	muscle relaxant
decamethoxine	CC(C)[C@H]1CC[C@H](C)C[C@@H]1OC(=O)C[N+](C)(C)CCCCCCCCCC[N+](C)(C)CC(=O)O[C@H]1C[C@H](C)CC[C@@H]1C(C)C |&1:40	Phase 2		antiseptic		
decernotinib	CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F |&1:2	Phase 2/Phase 3	JAK3	JAK inhibitor		
decitabine	Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	Launched	DNMT1|DNMT3A	DNA methyltransferase inhibitor	hematologic malignancy, hematology	myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)
declopramide	CCN(CC)CCNC(=O)c1ccc(N)c(Cl)c1	Preclinical		cell cycle inhibitor		
decloxizine	OCCOCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	Preclinical		histamine receptor antagonist		
decoquinate	CCCCCCCCCCOc1cc2c(cc1OCC)[nH]cc(C(=O)OCC)c2=O	Launched		antiprotozoal agent	infectious disease	coccidiosis
defactinib	CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1	Phase 2	PTK2	focal adhesion kinase inhibitor		
deferasirox	OC(=O)c1ccc(cc1)-n1nc(nc1-c1ccccc1O)-c1ccccc1O	Launched	CYP3A4	chelating agent	hematology	transfusional hemosiderosis, thalassemia, iron overload
deferasirox-iron-chelate	OC(=O)c1ccc(cc1)-n1nc-2nc1-c1ccccc1O[Fe]Oc1ccccc-21	Launched				
deferiprone	Cc1c(O)c(=O)ccn1C	Launched	UGT1A6	chelating agent	hematology	transfusional hemosiderosis, thalassemia, iron overload
deferoxamine-mesylate	CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN	Launched		chelating agent	hematology	acute iron intoxication, iron overload
deflazacort	CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C |c:23	Launched	NR3C1	glucocorticoid receptor agonist	rheumatology	joint inflammation
deforolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OP(C)(C)=O |c:14	Phase 3	MTOR	mTOR inhibitor		
degarelix	CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(N)=O)cc1)NC(=O)[C@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O	Launched	GNRHR	gonadotropin releasing factor hormone receptor antagonist	oncology	prostate cancer
dehydroacetic-acid	CC(=O)c1c(O)cc(C)oc1=O	Preclinical				
dehydrocholate	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@@H]1CC3=O |a:1	Preclinical				
dehydrocholate-acid	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]1(C)CCC(=O)C[C@H]1CC3=O	Preclinical				
dehydrocorydaline	COc1ccc2c(C)c3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC	Phase 3	ACHE	acetylcholinesterase inhibitor		
dehydroepiandrosterone	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O |t:7|	Launched	ESR1|ESR2|G6PD|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|HSD17B1|NR1I2|NR1I3|PPARA|SIGMAR1|SULT2A1|SULT2B1	protein synthesis stimulant	endocrinology	menopause
dehydroepiandrosterone-sulfate	C[C@]12CC[C@H]3[C@@H](CC=C4C[C@H](CC[C@]34C)OS(O)(=O)=O)[C@@H]1CCC2=O |t:7|	Launched	AR|ESR1|ESR2	androgen receptor agonist, estrogen receptor agonist	endocrinology	menopause
delafloxacin	Nc1nc(c(F)cc1F)-n1cc(C(O)=O)c(=O)c2cc(F)c(N3CC(O)C3)c(Cl)c12	Phase 3		antiinfective drug		
delamanid	C[C@]1(COc2ccc(cc2)N2CCC(CC2)Oc2ccc(OC(F)(F)F)cc2)Cn2cc(nc2O1)[N+]([O-])=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	tuberculosis
delanzomib	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(n1)-c1ccccc1)[C@@H](C)O)B(O)O	Phase 1/Phase 2	CMA1|CTSG|CYP3A4|ELANE	proteasome inhibitor		
delapril	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N(CC(O)=O)C1Cc2ccccc2C1	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension
delavirdine	CC(C)Nc1cccnc1N1CCN(CC1)C(=O)c1cc2cc(NS(C)(=O)=O)ccc2[nH]1	Launched	CYP3A4	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
delcasertib	CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(O)=O	Phase 1		PKC inhibitor		
delgocitinib	C[C@H]1CN(C(=O)CC#N)[C@]11CCN(C1)c1ncnc2[nH]ccc12	Phase 2		JAK inhibitor		
delivert	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@H](Cc1ccccc1)C(O)=O	Launched	AGTR1|AGTR2	angiotensin receptor agonist	critical care	sepsis
delpazolid	CN1CCN(C=N1)c1ccc(cc1F)N1C[C@H](CO)OC1=O |c:5|	Phase 2		antibacterial		
delphinidin	Oc1cc(O)c2cc(O)c([o+]c2c1)-c1cc(O)c(O)c(O)c1	Phase 2	GLO1	membrane permeability inhibitor		
delta-tocotrienol	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@]1(C)CCc2cc(O)cc(C)c2O1	Phase 1	HMGCR	HMGCR inhibitor		
deltarasin	C(Oc1ccc(cc1)-c1nc2ccccc2n1Cc1ccccc1)[C@H](C1CCNCC1)n1c(nc2ccccc12)-c1ccccc1	Preclinical	KRAS	phosphodiesterase inhibitor		
demecarium	CN(CCCCCCCCCCN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched	ACHE|BCHE	acetylcholinesterase inhibitor	ophthalmology	intraocular pressure, glaucoma
demeclocycline	[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(=O)[C@@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)ccc(Cl)c1[C@H]2O |&1:11	Launched		bacterial 30S ribosomal subunit inhibitor	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, cholera, syphilis, listeria, anthrax, actinomycosis, tularemia, brucellosis
denatonium-benzoate	CC[N+](CC)(CC(=O)Nc1c(C)cccc1C)Cc1ccccc1	Preclinical				
denopamine	COc1ccc(CCNC[C@H](O)c2ccc(O)cc2)cc1OC	Launched		adrenergic receptor agonist	cardiology	angina pectoris
denotivir	Cc1nsc(NC(=O)c2ccccc2)c1C(=O)Nc1ccc(Cl)cc1	Launched		antiviral	infectious disease	virus herpes simplex (HSV), skin infections
deoxyarbutin	Oc1ccc(O[C@H]2CCCCO2)cc1 |&1:6	Preclinical		tyrosinase inhibitor		
deoxycholic-acid	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Launched	FPR1|GPBAR1	biliverdin reductase A activator, G protein-coupled receptor agonist	endocrinology	submental fat
deoxycorticosterone-acetate	CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:14|	Preclinical	NR3C2	progestogen hormone		
deoxyepinephrine	CNCCc1ccc(O)c(O)c1	Preclinical	ADRA1A|DRD1|DRD2	adrenergic receptor agonist, dopamine receptor agonist		
deptropine	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC1c2ccccc2CCc2ccccc12 |r	Preclinical	HRH1	histamine receptor antagonist		
dequalinium	Cc1cc(N)c2ccccc2[n+]1CCCCCCCCCC[n+]1c(C)cc(N)c2ccccc12	Launched	KCNN1|KCNN3	PKC inhibitor	infectious disease	first-aid antiseptic
deracoxib	COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F	Launched	PTGS2	cyclooxygenase inhibitor	rheumatology	osteoarthritis
derazantinib	COCCNCCc1cccc(Nc2ncc3C[C@@H](c4ccccc4F)c4ccccc4-c3n2)c1	Phase 2		tyrosine kinase inhibitor		
deserpidine	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	Launched	ACE|SLC18A2	angiotensin converting enzyme inhibitor	cardiology	hypertension
desidustat	OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCC2CC2)c1=O	Preclinical		hypoxia inducible factor prolyl hydroxylase inhibitor		
desipramine	CNCCCN1c2ccccc2CCc2ccccc12	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A4|SMPD1	tricyclic antidepressant	neurology/psychiatry	depression
desisobutyryl-ciclesonide	[H][C@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)CO |c:13	Launched		cytochrome P450 inhibitor	allergy	allergic rhinitis
deslanoside	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@H](CC[C@@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:66|	Launched	ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2	Na/K-ATPase inhibitor	cardiology	congestive heart failure, cardiac arrythmia
desloratadine	Clc1ccc2c(CCc3cccnc3C2=C2CCNCC2)c1	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis, urticaria
deslorelin	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	Phase 2		gonadotropin releasing factor hormone receptor agonist		
desmethylclozapine	Clc1ccc2Nc3ccccc3C(=Nc2c1)N1CCNCC1 |c:13|	Phase 2	HTR2C	acetylcholine receptor agonist		
desmopressin-acetate	NC(=O)CC[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCSSC[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O |r|	Launched	AVPR1A|AVPR1B|AVPR2|OXTR	vasopressin receptor agonist	endocrinology, urology	central diabetes insipidus, nocturnal enuresis
desogestrel	CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:10|	Launched	ESR1|PGR	progesterone receptor agonist	endocrinology	contraceptive
desonide	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14	Launched	NR3C1|PLA2G1B	glucocorticoid receptor agonist	gastroenterology	Crohn's disease
desoximetasone	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO |c:11	Launched	NR3C1|PLA2G1B	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
desoxycorticosterone-pivalate	CC(C)(C)C(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:17|	Launched	NR3C2	corticosteroid agonist	endocrinology	Addison's disease
desoxycortone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2C(=O)CO |t:8|	Preclinical	NR3C1|NR3C2	mineralocorticoid receptor agonist		
desoxypeganine	C1CN2Cc3ccccc3N=C2C1 |c:11|	Phase 1	ACHE	acetylcholinesterase inhibitor, monoamine oxidase inhibitor		
desvenlafaxine	CN(C)C[C@@H](c1ccc(O)cc1)C1(O)CCCCC1 |&1:4|	Launched	SLC6A2|SLC6A3|SLC6A4	serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
detomidine	Cc1cccc(Cc2cnc[nH]2)c1C	Launched	ADRA2A	adrenergic receptor agonist	neurology/psychiatry	sedative
devazepide	CN1c2ccccc2C(=N[C@H](NC(=O)c2cc3ccccc3[nH]2)C1=O)c1ccccc1 |c:9|	Preclinical		CCK receptor antagonist		
dexamethasone	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11	Launched	ANXA1|NOS2|NR0B1|NR3C1|NR3C2	glucocorticoid receptor agonist	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis
dexamethasone-acetate	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(C)=O |c:11	Launched		glucocorticoid receptor agonist	endocrinology, rheumatology, allergy, gastroenterology, hematology, neurology/psychiatry, dermatology	hypercalcemia, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, allergic rhinitis, ulcerative colitis, anemia, multiple sclerosis, enteritis, lupus, dermatitis herpetiformis (DH), nephrotic syndrome, psoriasis
dexchlorpheniramine	CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1	Launched		histamine receptor antagonist	allergy, cardiology	allergic conjunctivitis, allergic rhinitis, urticaria, angioedema
dexfosfoserine	N[C@@H](COP(O)(O)=O)C(O)=O	Preclinical	CFTR|GRM4|GRM6|GRM7|GRM8|KCNC4|PDPK1|PIM1|PRKACA|PRKCQ|PYGL|PYGM|REG1A|RHO|SERPINB3|SMAD2|TAOK2	membrane integrity inhibitor		
dexlansoprazole	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1	Launched	ATP4A	ATPase inhibitor	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE)
dexloxiglumide	CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1	Phase 3	CCKAR	CCK receptor antagonist		
dexmedetomidine	C[C@H](c1cnc[nH]1)c1cccc(C)c1C	Launched	ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	neurology/psychiatry	sedative
dexniguldipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4	Phase 2	ADORA3	calmodulin antagonist		
dexpanthenol	CC(C)(CO)[C@@H](O)C(=O)NCCCO	Launched			gastroenterology	paralytic ileus
dexrazoxane	C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1	Launched	TOP2A|TOP2B	chelating agent, topoisomerase inhibitor	cardiology	cardiomyopathy
dextran	OC[C@H]1O[C@H](OC[C@H]2O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Launched			hematology, critical care	thrombosis, hypovolemia
dextromethorphan	COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1	Launched	CHRNA2|CHRNA3|CHRNA4|CHRNA7|CHRNB2|CHRNB4|CYBA|CYBB|GRIN3A|NCF1|NCF2|NCF4|OPRD1|OPRK1|OPRM1|PGRMC1|RAC1|RAC2|SIGMAR1|SLC6A2|SLC6A4	glutamate receptor antagonist, sigma receptor agonist	pulmonary	cough suppressant
dextrorotation-nimorazole-phosphate-ester	Cc1ncc(n1C[C@@H](CN1CCOCC1)OP(O)(O)=O)[N+]([O-])=O	Preclinical		antiinfective drug		
dextrose	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O	Launched			endocrinology	hypoglycemia
DFB	Fc1cccc(\C=N\N=C\c2cccc(F)c2)c1	Preclinical	GRM5	glutamate receptor agonist		
DG-172	CN1CCN(CC1)c1ccc(\C=C(/C#N)c2ccccc2Br)cc1	Preclinical	PPARD	PPAR receptor inverse agonist		
DG051	OC(=O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1	Preclinical		leukotriene synthesis inhibitor		
DH-97	CCCCC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	Preclinical	MTNR1B	melatonin receptor antagonist		
DHBP	CCCCCCC[n+]1ccc(cc1)-c1cc[n+](CCCCCCC)cc1	Preclinical		ryanodine receptor blocker		
diacerein	CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O	Launched	IL1B	interleukin inhibitor	rheumatology	osteoarthritis
diacetamate	CC(=O)Nc1ccc(OC(C)=O)cc1	Preclinical				
diadenosine-tetraphosphate	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:10	Phase 1	P2RY13|P2RY2	adenosine kinase inhibitor		
dianhydrogalactitol	O[C@@H]([C@@H](O)[C@H]1CO1)[C@@H]1CO1	Phase 3		DNA alkylating agent		
diarylpropionitrile	Oc1ccc(C[C@@H](C#N)c2ccc(O)cc2)cc1 |&1:6	Preclinical	ESR2	estrogen receptor agonist		
diatrizoic-acid	CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Launched			radiology	contrast agent
diaveridine	COc1ccc(Cc2cnc(N)nc2N)cc1OC	Launched		dihydrofolate reductase inhibitor	infectious disease	coccidiosis
diazoxide	CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1 |t:1|	Launched	ATP1A1|CA1|CA2|KCNJ11|KCNJ8|KCNMA1|SLC12A3	potassium channel activator	endocrinology	hypoglycemia
dibekacin	NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections
dibenzepine	CN(C)CCN1c2ccccc2N(C)c2ccccc2C1=O	Preclinical		norepinephrine reputake inhibitor		
dibenzothiophene	c1ccc2c(c1)sc1ccccc21	Preclinical				
dibutyl-phthalate	CCCCOC(=O)c1ccccc1C(=O)OCCCC	Preclinical	TRPA1			
dichlorisone-acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](Cl)C[C@]12C |c:19	Phase 2				
dichloroacetate	[Na].OC(=O)C(Cl)Cl	Phase 3		pyruvate dehydrogenase kinase inhibitor		
dichlorophen	Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O	Launched		anticestodal agent	infectious disease	hookworm, tapeworm
dichlorvos	COP(=O)(OC)OC=C(Cl)Cl	Launched		acetylcholinesterase inhibitor		
diclazuril	Clc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7	Launched		antiprotozoal agent	infectious disease	equine protozoal myeloencephalitis (EPM)
diclofenac	OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl	Launched	AKR1C3|ALOX5|ASIC1|ASIC3|KCNQ2|KCNQ3|PLA2G2A|PPARG|PTGS1|PTGS2|SCN4A	cyclooxygenase inhibitor	rheumatology, neurology/psychiatry	rheumatoid arthritis, osteoarthritis, migraine headache
diclofenamide	NS(=O)(=O)c1cc(Cl)c(Cl)c(c1)S(N)(=O)=O	Launched	CA1|CA12|CA2|CA4|CA7	carbonic anhydrase inhibitor	ophthalmology, neurology/psychiatry	glaucoma, epilepsy
diclofensine	COc1ccc2[C@@H](CN(C)Cc2c1)c1ccc(Cl)c(Cl)c1 |&1:6|	Phase 3	DRD1|MAOA|MAOB	dopamine reuptake inhibitor		
dicloralurea	O[C@@H](NC(=O)N[C@@H](O)C(Cl)(Cl)Cl)C(Cl)(Cl)Cl |&1:1	Preclinical				
dicloxacillin	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(Cl)cccc1Cl	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
dicoumarol	Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc2ccccc12	Launched	CRYZ|NQO1|VKORC1	NADPH inhibitor	hematology	deep vein thrombosis (DVT)
dicyclohexylamine	C1CCC(CC1)NC1CCCCC1	Preclinical				
dicycloverine	CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1	Launched	CHRM1|CHRM2|CHRM3	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
didanosine	OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O	Launched	PNP	nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
dideoxyadenosine	Nc1ncnc2n(cnc12)[C@H]1CC[C@@H](CO)O1	Phase 1		nucleoside reverse transcriptase inhibitor		
didox	ONC(=O)c1ccc(O)c(O)c1	Launched	RRM1	ribonucleotide reductase inhibitor	oncology	breast cancer
dienestrol	C\C=C(\C(=C\C)\c1ccc(O)cc1)/c1ccc(O)cc1	Launched	ESR1	estrogen receptor agonist	endocrinology	menopause
dienogest	C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N |c:4	Launched	PGR	progesterone receptor agonist	endocrinology, obstetrics/gynecology	contraceptive, endometriosis
diethylcarbamazine	CCN(CC)C(=O)N1CCN(C)CC1	Launched	ALOX5|PTGS1	lipoxygenase inhibitor	infectious disease	filariasis
diethylstilbestrol	CC\C(=C(\CC)c1ccc(O)cc1)c1ccc(O)cc1	Withdrawn	ESR1|ESR2|ESRRB|ESRRG	estrogen receptor agonist		
diethyltoluamide	CCN(CC)C(=O)c1cccc(C)c1	Launched		ionotropic receptor IR40a activator	dermatology	sunscreen lotion
difenpiramide	O=C(Cc1ccc(cc1)-c1ccccc1)Nc1ccccn1	Launched		cyclooxygenase inhibitor, prostaglandin inhibitor	neurology/psychiatry	pain relief
diflorasone-diacetate		Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
difloxacin	CN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1	Launched		bacterial DNA gyrase inhibitor	infectious disease	skin infections, urinary tract infections
diflunisal	OC(=O)c1cc(ccc1O)-c1ccc(F)cc1F	Launched	PTGS1|PTGS2	prostanoid receptor antagonist	rheumatology	rheumatoid arthritis, osteoarthritis
difluprednate	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:18	Launched	NR3C1	glucocorticoid receptor agonist	ophthalmology	endogenous uveitis
diftalone	O=C1N2Cc3ccccc3C(=O)N2Cc2ccccc12	Launched		cyclooxygenase inhibitor	endocrinology	thyroiditis
digitoxigenin	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:25|	Preclinical	ATP1A1	ATPase inhibitor		
digitoxin	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@H]1[C@@H](O)C[C@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3CC[C@@]4(C)[C@H](CC[C@@H]5[C@@H]4CC[C@]4(C)[C@H](CC[C@]54O)C4=CC(=O)OC4)C3)O[C@@H]2C)O[C@@H]1C |t:45|	Launched	ATP1A1|ATP1A2|ATP1A3|ATP1A4|ATP1B1|ATP1B2|ATP1B3|FXYD2	ATPase inhibitor	cardiology	congestive heart failure, cardiac arrythmia
digoxigenin	C[C@@]12[C@H](CC[C@]1(O)[C@@H]1CC[C@@H]3C[C@@H](O)CC[C@]3(C)[C@H]1C[C@H]2O)C1=CC(=O)OC1 |t:26|	Preclinical		steroid		
digoxin	[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@]([H])(CC[C@]3([H])[C@]2([H])C[C@@H](O)[C@@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |t:60|	Launched	ATP1A1	ATPase inhibitor	cardiology	congestive heart failure, atrial fibrillation (AF)
dihomo-gamma-linolenic-acid	CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O	Phase 2	PTGS1|PTGS2	prostanoid receptor agonist		
dihydrexidine	Oc1cc2CC[C@H]3NCc4ccccc4[C@@H]3c2cc1O	Phase 2	DRD1|DRD2|DRD3|DRD4|DRD5	dopamine receptor agonist		
dihydroartemisinin	C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4	Launched		antimalarial agent	infectious disease	malaria
dihydroergocristine	CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched	ADRA1A|ADRB1|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR2A|HTR3A|HTR4|HTR5A|HTR6|HTR7	adrenergic receptor antagonist, prolactin inhibitor	neurology/psychiatry	senile dementia, cerebrovascular insufficiency
dihydroergotamine	CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O	Launched	ADRA2A|DRD2|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	serotonin receptor agonist	neurology/psychiatry	migraine headache
dihydromyricetin	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1cc(O)c(O)c(O)c1	Preclinical				
dihydrostreptomycin	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]2NC(N)=N)O[C@@H](C)[C@]1(O)CO	Withdrawn		bacterial 30S ribosomal subunit inhibitor		
dihydrotachysterol	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2\C(CCC[C@@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C |&1:3	Launched	VDR	vitamin analog	orthopedics, endocrinology	rickets, hypocalcemia, osteomalacia
dihydroxyacetone	OCC(=O)CO	Launched			dermatology	skin protectant
dihydroxyphenylglycine	N[C@@H](C(O)=O)c1cc(O)cc(O)c1 |&1:1	Preclinical	GRM1|GRM5	glutamate receptor agonist		
diiodothyropropionic-acid	OC(=O)CCc1cc(I)c(Oc2ccc(O)cc2)c(I)c1	Phase 2		thyroid hormone stimulant		
dilazep	COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1	Launched	SLC29A1	adenosine reuptake inhibitor	cardiology	coronary heart disease
dilmapimod	Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2n(-c3c(F)cccc3F)c(=O)ccc12	Phase 1		p38 MAPK inhibitor		
diloxanide	CN(C(=O)C(Cl)Cl)c1ccc(OC(=O)c2ccco2)cc1	Launched		protein synthesis inhibitor	infectious disease	amebiasis
diltiazem	COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O	Launched	CACNA1C|CACNA1S|CACNA2D1|CACNG1|HTR3A|KCNA5	calcium channel blocker	cardiology	hypertension, angina pectoris
DIM-C-pPhCO2Me	COC(=O)c1ccc(cc1)C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	Preclinical		nuclear receptor antagonist		
dimaprit	CN(C)CCCSC(N)=N	Preclinical	HRH2|HRH3|HRH4	histamine receptor agonist		
dimemorfan	CN1CC[C@@]23CCCC[C@@H]2[C@@H]1Cc1ccc(C)cc31	Launched	SIGMAR1	sigma receptor agonist	pulmonary	cough suppressant
dimenhydrinate		Launched	HRH1	histamine receptor antagonist	neurology/psychiatry, gastroenterology	motion sickness, nausea, vomiting
dimercaprol	OC[C@@H](S)CS |&1:2	Launched		chelating agent	neurology/psychiatry	metal toxicity
dimercaptosuccinic-acid	OC(=O)[C@@H](S)[C@@H](S)C(O)=O	Launched	DNMT1	chelating agent	neurology/psychiatry	metal toxicity
dimesna	OS(=O)(=O)CCSSCCS(O)(=O)=O	Phase 3		tubulin polymerization inhibitor		
dimethadione	CC1(C)OC(=O)NC1=O	Preclinical		oxazolidine antiepileptic		
dimethicone	C[Si](C)(C)O[Si](C)(C)C	Launched			dermatology	cosmetic
dimethindene-(S)-(+)	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |c:2|	Preclinical	HRH1	acetylcholine receptor antagonist		
dimethisoquin	CCCCc1cc2ccccc2c(OCCN(C)C)n1	Launched		local anesthetic	neurology/psychiatry	local anesthetic
dimethyl-fumarate	COC(=O)\C=C\C(=O)OC	Launched	KEAP1	nuclear factor erythroid derived, like (NRF2) activator	neurology/psychiatry	multiple sclerosis
dimethyl-isosorbide	CO[C@@H]1CO[C@H]2[C@H](CO[C@@H]12)OC |&1:6	Preclinical		cosmetic moisturizer		
dimetindene	C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1 |&1:1	Launched	HRH1	cholinergic receptor antagonist, histamine receptor antagonist	allergy	allergic rhinitis
dimetridazole	Cc1ncc(n1C)[N+]([O-])=O	Launched		bacterial DNA inhibitor	infectious disease	protozoan infection
diminazene-aceturate	NC(=N)c1ccc(N\N=N\c2ccc(cc2)C(N)=N)cc1	Phase 3	AOC1|PRDX5|PRSS1	angiotensin converting enzyme activator		
dimpylate	CCOP(=S)(OCC)Oc1cc(C)nc(n1)C(C)C	Launched	ACHE	acetylcholinesterase inhibitor	infectious disease	flea control
dinaciclib	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO	Phase 3	CDK1|CDK2|CDK5|CDK9	CDK inhibitor		
dinitolmide	Cc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(N)=O	Launched			infectious disease	coccidiosis
dinoprost	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O	Launched	PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R	prostacyclin analog	obstetrics/gynecology	labor induction
dinoprostone	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	Withdrawn	CATSPER1|CATSPER2|CATSPER3|CATSPER4|PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|TBXA2R	prostanoid receptor agonist		
dioscin	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CO1 |t:8|	Preclinical	CXCR3	apoptosis stimulant		
diosgenin	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@@H](C)CO1 |t:8|	Preclinical		steroid		
diosmetin	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1	Launched	CYP1B1	aryl hydrocarbon receptor agonist	dermatology	cosmetic
diosmin	COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2o1	Launched	AHR	aryl hydrocarbon receptor agonist, capillary stabilizing agent	cardiology, hematology, dermatology	chronic venous insufficiency (CVI), edema, deep vein thrombosis (DVT), statis dermatitis, heavy leg syndrome
dioxybenzone	COc1ccc(C(=O)c2ccccc2O)c(O)c1	Preclinical		topical sunscreen agent		
dipeptamin	C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Launched				
diperodon	O=C(Nc1ccccc1)OC[C@@H](CN1CCCCC1)OC(=O)Nc1ccccc1 |&1:11|	Preclinical		local anesthetic		
diphemanil	C[N+]1(C)CCC(CC1)=C(c1ccccc1)c1ccccc1	Launched	CHRM3	acetylcholine receptor antagonist	neurology/psychiatry	spasms
diphencyprone	O=c1c(c1-c1ccccc1)-c1ccccc1	Phase 2		immunostimulant		
diphenhydramine	CN(C)CCOC(c1ccccc1)c1ccccc1	Launched	HRH1	histamine receptor antagonist	neurology/psychiatry	headache
diphenidol	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	Launched	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor agonist	neurology/psychiatry	vertigo
diphenyleneiodonium	[I]1c2ccccc2-c2ccccc12 |^1:0|	Preclinical	NOS2|NOS3	nitric oxide synthase inhibitor		
diphenylguanidine	N=C(Nc1ccccc1)Nc1ccccc1	Preclinical				
diphenylpyraline	CN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched	HRH1|SLC6A3	dopamine reuptake inhibitor	allergy	allergic rhinitis
dipivefrine	CNC[C@@H](O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1 |&1:3|	Launched		adrenergic receptor agonist	ophthalmology	glaucoma, intraocular pressure
dipraglurant	Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1	Phase 2	GRM5	glutamate receptor negative allosteric modulator		
DIPT	CC(C)N(CCc1c[nH]c2ccccc12)C(C)C	Launched	HTR1A|HTR2A|HTR2C	dopamine reuptake inhibitor, serotonin reuptake inhibitor		
dipyridamole	OCCN(CCO)c1nc(N2CCCCC2)c2nc(nc(N3CCCCC3)c2n1)N(CCO)CCO	Launched	ADA|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|SLC29A1	phosphodiesterase inhibitor	cardiology	coronary artery disease (CAD), peripheral artery disease (PAD), hypertension
dipyrocetyl	CC(=O)Oc1cccc(C(O)=O)c1OC(C)=O	Launched		chelating agent	endocrinology, neurology/psychiatry	fever, pain relief
diquafosol	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2ccc(=O)[nH]c2=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O	Phase 3		purinergic receptor activator		
dirithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O	Launched		bacterial 50S ribosomal subunit inhibitor	pulmonary	bronchitis
diroximel-fumarate	COC(=O)\C=C\C(=O)OCCN1C(=O)CCC1=O	Phase 3		anti-inflammatory agent		
disodium-sebacate	OC(=O)CCCCCCCCC(O)=O	Phase 1	HBB			
disopyramide	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C |&1:6|	Launched	CHRM1|CHRM2|CHRM3|KCND2|KCND3|KCNH2|SCN5A	sodium channel blocker	cardiology	ventricular tachycardia (VT), ventricular arrhythmias
disulfiram	CCN(CC)C(=S)SSC(=S)N(CC)CC	Launched	ALDH2|DBH	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	neurology/psychiatry	abstinence from alcohol
dithranol	Oc1cccc2cc3cccc(O)c3c(O)c12	Launched		DNA synthesis inhibitor	dermatology	psoriasis
ditiocarb-sodium-trihydrate	CCN(CC)C(S)=S	Phase 3	CA1|CA2|CA4	immunostimulant		
ditolylguanidine	Cc1ccccc1NC(=N)Nc1ccccc1C	Preclinical	GRIN1|GRIN2A|GRIN2B|SIGMAR1	sigma receptor agonist		
dixanthogen	CCOC(=S)SSC(=S)OCC	Preclinical				
dixyrazine	C[C@H](CN1CCN(CCOCCO)CC1)CN1c2ccccc2Sc2ccccc12 |&1:1	Preclinical		antipsychotic		
dizocilpine-(+)	C[C@]12N[C@H](Cc3ccccc13)c1ccccc21	Preclinical	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor antagonist		
dizocilpine-(-)	C[C@@]12N[C@@H](Cc3ccccc13)c1ccccc21	Phase 1		glutamate receptor antagonist		
DMAB-anabaseine	CN(C)c1ccc(\C=C2/CCCN=C2c2cccnc2)cc1 |c:12|	Preclinical	CHRNA7	adrenergic receptor agonist		
DMeOB	COc1cccc(\C=N\N=C\c2cccc(OC)c2)c1	Preclinical	GRM5	glutamate receptor modulator		
DMH1	CC(C)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	Preclinical	ACVR1	ALK tyrosine kinase receptor inhibitor		
DMH4	C(CN1CCOCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccccc1	Preclinical	KDR	VEGFR inhibitor		
DMNB	COc1cc(C=O)c(cc1OC)[N+]([O-])=O	Preclinical		DNA dependent protein kinase inhibitor		
DMP-543	Fc1cc(CC2(Cc3ccnc(F)c3)c3ccccc3C(=O)c3ccccc23)ccn1	Phase 2		acetylcholine release enhancer		
DMP-777	CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1	Phase 2	MPO	elastase inhibitor		
DMPS	OS(=O)(=O)C[C@@H](S)CS |&1:5	Phase 1		chelating agent		
DMSO	CS(C)=O.CS(C)=O	Preclinical		control vehicle		
DNQX	[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O	Preclinical	GRIA1|GRIA2|GRIK1|GRIN1|GRIN2A|GRIN2B	glutamate receptor antagonist		
dobutamine	CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1	Launched	ADRB1|ADRB2	adrenergic receptor agonist	cardiology	congestive heart failure
docebenone	CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O |c:1	Phase 2	ALOX5	lipoxygenase inhibitor		
docetaxel	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C |t:53|	Launched	BCL2|MAP2|MAP4|MAPT|NR1I2|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	tubulin polymerization inhibitor	oncology	breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC)
doconexent	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O	Launched	FFAR1|PTGS1|PTGS2	PPAR receptor agonist		
doconexent-ethyl-ester	CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	Launched		omega 3 fatty acid stimulant	endocrinology	hypertriglyceridemia
docosanol	CCCCCCCCCCCCCCCCCCCCCCO	Launched	TLR7	lipase clearing factor inhibitor	dental	cold sore
docusate	CCCC[C@@H](CC)COC(=O)C[C@@H](C(=O)OC[C@@H](CC)CCCC)S(O)(=O)=O |&1:4	Launched		laxative	gastroenterology	constipation
dodecyl-sulfate	CCCCCCCCCCCCOS(O)(=O)=O	Preclinical	LYZ			
dofequidar	OC(COc1cccc2ncccc12)CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1	Phase 3	ABCB1	MRP inhibitor, P glycoprotein inhibitor		
dofetilide	CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1	Withdrawn	KCNH1|KCNH2|KCNJ12|KCNK2	potassium channel blocker		
dolasetron	O=C(O[C@H]1C[C@H]2C[C@H]3C[C@@H](C1)N2CC3=O)c1c[nH]c2ccccc12	Launched	HTR3A	serotonin receptor antagonist	gastroenterology	nausea, vomiting
dolastatin-10	CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)c1nccs1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C	Phase 2	TUBB	tubulin polymerization inhibitor		
dolutegravir	C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12	Launched	CYP3A4|CYP3A5|CYP3A7|POU2F2|UGT1A1	HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
domiphen	CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1	Preclinical				
domperidone	Clc1ccc2n(C3CCN(CCCn4c5ccccc5[nH]c4=O)CC3)c(=O)[nH]c2c1	Launched	DRD2|DRD3	dopamine receptor antagonist	infectious disease	fescue toxicosis
donepezil	COc1cc2C[C@@H](CC3CCN(Cc4ccccc4)CC3)C(=O)c2cc1OC |r|	Launched	ACHE	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease
donitriptan	NCCc1c[nH]c2ccc(OCC(=O)N3CCN(CC3)c3ccc(cc3)C#N)cc12	Phase 2	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR5A|HTR6	serotonin receptor agonist		
dopamine	NCCc1ccc(O)c(O)c1	Launched	DBH|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR7|SLC6A2|SLC6A3|SLC6A4	dopamine receptor agonist	cardiology, neurology/psychiatry	ventricular arrhythmias, depression, headache, tremors
doramapimod	Cc1ccc(cc1)-n1nc(cc1NC(=O)Nc1ccc(OCCN2CCOCC2)c2ccccc12)C(C)(C)C	Phase 2	MAPK11|MAPK12|MAPK13|MAPK14	p38 MAPK inhibitor		
doramectin	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@@]5(O[C@H](C6CCCCC6)[C@@H](C)C=C5)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4	Launched			infectious disease	gastrointestinal roundworms
doravirine	Cn1c(Cn2ccc(c(Oc3cc(Cl)cc(c3)C#N)c2=O)C(F)(F)F)n[nH]c1=O	Launched		non-nucleoside reverse transcriptase inhibitor		
doripenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N2C1=O)C(O)=O |c:20|	Launched	DPEP1	bacterial cell wall synthesis inhibitor	infectious disease	intra-abdominal infections, urinary tract infections, pyelonephritis
dorsomorphin	C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1	Preclinical	ACVR1|BMPR1A|BMPR1B|EPHA2|FKBP1A|FLT1|FLT3|KDR|LCK|MKNK1|PRKAA1|RPS6KA1|SRC	AMPK inhibitor		
dorzolamide	CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O	Launched	CA1|CA12|CA14|CA2|CA4|CA7	carbonic anhydrase inhibitor	ophthalmology	intraocular pressure, glaucoma
dosulepin	CN(C)CC\C=C1/c2ccccc2CSc2ccccc12	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HRH1|SLC6A2|SLC6A4	norepinephrine reuptake inhibitor, serotoninâ€“norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant	neurology/psychiatry	depression
DOTMP	OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1	Preclinical				
dovitinib	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O	Phase 3	CSF1R|EGFR|FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|INSR|KDR|KIT|PDGFRA|PDGFRB	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
doxapram	CCN1C[C@@H](CCN2CCOCC2)C(C1=O)(c1ccccc1)c1ccccc1 |&1:4|	Launched		potassium channel blocker	pulmonary, neurology/psychiatry	respiratory depression, central nervous system depression, acute hypercapnia (AHC)
doxazosin	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1COc2ccccc2O1 |&1:23	Launched	ADRA1A|ADRA1B|ADRA1D	adrenergic receptor antagonist	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension
doxepin	CN(C)CC\C=C1\c2ccccc2COc2ccccc12	Launched	HRH1|SLC6A2|SLC6A4	histamine receptor antagonist	neurology/psychiatry	depression, anxiety
doxercalciferol	CC(C)[C@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)C[C@H](O)C1=C	Launched	VDR	vitamin D receptor agonist	nephrology, endocrinology	chronic kidney disease (CKD), hyperparathyroidism
doxifluridine	C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	Launched	TYMS	thymidylate synthase inhibitor	oncology	colorectal cancer
doxofylline	Cn1c2ncn(CC3OCCO3)c2c(=O)n(C)c1=O	Launched	ADORA1|PDE4A|PDE4B|PDE4C|PDE4D	adenosine receptor antagonist	pulmonary	asthma
doxorubicin		Launched	TOP2A	topoisomerase inhibitor	hematologic malignancy, oncology	acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Wilm's tumor, breast cancer, ovarian cancer, Hodgkin's lymphoma, bladder cancer, multiple myeloma
doxycycline	C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C2C(=O)c2c(O)cccc12 |a:1	Launched	MMP8	bacterial 30S ribosomal subunit inhibitor, metalloproteinase inhibitor	dental	periodontitis
doxylamine	CN(C)CCOC(C)(c1ccccc1)c1ccccn1	Launched	HRH1	histamine receptor antagonist	neurology/psychiatry	sedative
DpC	CN(C1CCCCC1)C(=S)NN=C(c1ccccn1)c1ccccn1	Phase 1				
DPC-681	CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNCc1cccc(F)c1)C(C)(C)C)S(=O)(=O)c1cccc(N)c1	Phase 1		HIV protease inhibitor		
DPCPX	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C1CCCC1	Phase 1	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
DPI-201106	O[C@@H](COc1cccc2[nH]c(cc12)C#N)CN1CCN(CC1)C(c1ccccc1)c1ccccc1 |&1:1	Phase 2	ADRB2	sodium channel activator		
DPO-1	CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1P(=O)(c1ccccc1)c1ccccc1	Preclinical	KCNA5	potassium channel blocker		
DPPE	CCN(CC)CCOc1ccc(Cc2ccccc2)cc1	Phase 3	ABCB1|HRH1	histamine receptor antagonist		
DQP-1105	Cc1ccc2[nH]c(=O)c(C3=NN([C@@H](C3)c3ccc(Br)cc3)C(=O)CCC(O)=O)c(-c3ccccc3)c2c1 |&1:12	Preclinical	GRIN2C|GRIN2D	glutamate receptor antagonist		
DR-2313	Cc1nc(=O)c2CSCCc2[nH]1	Preclinical	PARP1|PARP3	PARP inhibitor		
DR-4485	Clc1ccc(cc1)C1=CCN(CCCC[C@@]23CCCc4c2c(NC3=O)ccc4Cl)CC1 |&1:15	Preclinical	HTR7	serotonin receptor antagonist		
DRF053-(R)	CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1	Preclinical	CSNK1A1	CDK inhibitor		
drofenine	CCN(CC)CCOC(=O)[C@@H](C1CCCCC1)c1ccccc1 |&1:10|	Launched			neurology/psychiatry	spasms
droloxifene	CC\C(=C(\c1ccc(OCCN(C)C)cc1)c1cccc(O)c1)c1ccccc1	Phase 3	ESR1	selective estrogen receptor modulator (SERM)		
dromostanolone-propionate	CCC(=O)O[C@H]1CC[C@H]2[C@H]3CC[C@H]4CC(=O)[C@@H](C)C[C@@]4(C)[C@@H]3CC[C@@]12C |&1:5	Launched	AR	androgen receptor modulator	oncology	breast cancer
dronedarone	CCCCN(CCCC)CCCOc1ccc(cc1)C(=O)c1c(CCCC)oc2ccc(NS(C)(=O)=O)cc12	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|CACNA1C|CACNA1D|CACNA1F|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|KCNA5|KCNH2|KCNK2|SCN1A	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF)
droperidol	Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c2ccccc2[nH]c1=O |c:16|	Launched	ADRA1A|DRD2|DRD3|DRD4|HTR2A	dopamine receptor antagonist	gastroenterology	nausea, vomiting
dropropizine	OC[C@@H](O)CN1CCN(CC1)c1ccccc1 |&1:2	Launched		antitussive	pulmonary	cough suppressant
drospirenone	C[C@]12CC[C@H]3[C@@H]([C@H]4C[C@H]4C4=CC(=O)CC[C@]34C)[C@@H]1[C@@H]1C[C@@H]1[C@@]21CCC(=O)O1 |t:10|	Launched	AR|NR3C2|PGR	mineralocorticoid receptor antagonist	endocrinology	contraceptive
drotaverine	CCOc1ccc(CC2=NCCc3cc(OCC)c(OCC)cc23)cc1OCC |t:8|	Launched		phosphodiesterase inhibitor	obstetrics/gynecology	labor induction
droxicam	CN1c2c(oc(=O)n(-c3ccccn3)c2=O)-c2ccccc2S1(=O)=O	Launched	PTGS1	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis, osteoarthritis
droxidopa	N[C@@H]([C@H](O)c1ccc(O)c(O)c1)C(O)=O	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH	norepinephrine precursor	cardiology, neurology/psychiatry	hypertension, Parkinson's Disease
droxinostat	Cc1cc(Cl)ccc1OCCCC(=O)NO	Preclinical	HDAC6|HDAC8	HDAC inhibitor		
DSM265	Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2nc(nc2n1)C(C)(F)F	Phase 2		dihydroorotate dehydrogenase inhibitor		
DSPC	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC |&1:21	Preclinical				
DSR-6434	CCCCNc1nc(N)c2[nH]c(=O)n(Cc3ccc(OCCN(C)C)nc3)c2n1	Preclinical	TLR7	toll-like receptor agonist		
DS2-(806622)	Clc1ccc(cc1)C(=O)Nc1c(nc2ccccn12)-c1cccs1	Preclinical				
DU-728	N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O	Phase 1	ITGA2B|ITGB3	structural glycoprotein antagonist		
duloxetine	CNCC[C@H](Oc1cccc2ccccc12)c1cccs1	Launched	HTR2A|HTR2C|HTR6|SLC6A2|SLC6A3|SLC6A4	norepinephrine reuptake inhibitor, serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression, generalized anxiety disorder (GAD), muscle pain, peripheral neuropathy
DUP-697	CS(=O)(=O)c1ccc(cc1)-c1cc(Br)sc1-c1ccc(F)cc1	Phase 1	PTGS2	cyclooxygenase inhibitor		
dutasteride	C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F |c:12|	Launched	SRD5A1|SRD5A2|SRD5A3	5 alpha reductase inhibitor	urology	benign prostatic hyperplasia (BPH)
duvelisib	C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1	Launched	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
DVD-111	CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1	Phase 2				
DWK-1339	COCCCc1ccc2oc(cc2c1)-c1ccc(OC)c(OC)c1	Preclinical		beta amyloid aggregation inhibitor		
dyclonine	CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1	Launched	SCN10A|SCN5A	sodium channel blocker	neurology/psychiatry	local anesthetic
dydrogesterone	CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C |c:8	Launched	PGR	progesterone receptor agonist	obstetrics/gynecology	infertility
dynasore	Oc1ccc(\C=N\NC(=O)c2cc3ccccc3cc2O)cc1O	Preclinical	DNM1|DNM1L|DNM2	dynamin inhibitor		
dynole-34-2	CCCCCCCCNC(=O)C(=C\c1cn(CCCN(C)C)c2ccccc12)\C#N	Preclinical	DNM1	dynamin inhibitor		
dyphylline	Cn1c2ncn(C[C@@H](O)CO)c2c(=O)n(C)c1=O |&1:7	Launched	PDE4A	adenosine receptor antagonist, phosphodiesterase inhibitor	pulmonary	asthma, bronchitis, emphysema
DY131	CCN(CC)c1ccc(\C=N\NC(=O)c2ccc(O)cc2)cc1	Preclinical	ESRRB|ESRRG	estrogen-related receptor agonist		
D609	SC(=S)OC1CC2CC1C1CCCC21	Preclinical		phospholipase inhibitor		
E-2001	Fc1ccc(cc1)C(=O)C1CCN(CC(=O)c2ccc3ccccc3c2)CC1	Preclinical		antioxidant		
E-2012	COc1cc(\C=C2/CCCN([C@@H](C)c3ccc(F)cc3)C2=O)ccc1-n1cnc(C)c1	Phase 1	APH1A|APH1B|PSENEN	gamma secretase modulator		
E-4031	Cc1cccc(CCN2CCC(CC2)C(=O)c2ccc(NS(C)(=O)=O)cc2)n1	Phase 1	KCNH1|KCNH2	potassium channel blocker		
E-64	CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(O)=O)C(=O)NCCCCNC(N)=N	Preclinical	CTSS	calpain inhibitor, cysteine protease inhibitor		
eact	COCCN(C(=O)c1cc(OC)c(OC)c(OC)c1)c1nc(cs1)-c1ccccc1	Preclinical	ANO1	calcium-activated chloride channel inhibitor		
EB-47	Nc1ncnc2n(cnc12)[C@H]1O[C@H]([C@H](O)[C@@H]1O)C(=O)N1CCN(CC(=O)Nc2cccc3C(=O)NCc23)CC1	Preclinical	PARP1	PARP inhibitor		
ebastine	CC(C)(C)c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1	Launched	CYP3A4|HRH1	histamine receptor antagonist	allergy	allergic rhinitis, urticaria
EBPC	CCOC(=O)[C@@H]1CN(Cc2ccccc2)C(=O)C1=O |&1:5	Preclinical	AKR1B1	aldose reductase inhibitor		
ebrotidine	NC(=N)Nc1nc(CSCCN\C=N\S(=O)(=O)c2ccc(Br)cc2)cs1	Withdrawn	HRH2	histamine receptor antagonist		
ebselen	O=c1n([se]c2ccccc12)-c1ccccc1	Phase 2/Phase 3	ALB	cyclooxygenase inhibitor, glutathione peroxidase agonist, H+/K+-ATPase inhibitor, nitric oxide synthase inhibitor		
EC-144	COc1c(C)cnc(Cn2cc(C#CCC(C)(C)O)c3c(Cl)nc(N)nc23)c1C	Preclinical	HSP90AA1|HSP90AB1	HSP inhibitor		
EC-23	CC1(C)CCC(C)(C)c2cc(ccc12)C#Cc1ccc(cc1)C(O)=O	Preclinical	RARA|RARB|RARG	retinoid receptor agonist		
ecabapide	CNC(=O)c1cccc(NCC(=O)NCCc2ccc(OC)c(OC)c2)c1	Phase 3				
ecabet	CC(C)c1cc2CC[C@H]3[C@@](C)(CCC[C@]3(C)c2cc1S(O)(=O)=O)C(O)=O	Launched	NOXO1	gastrin inhibitor, urease inhibitor	ophthalmology	dry eye syndrome
ecamsule-triethanolamine	CC1(C)[C@H]2CC[C@]1(CS(O)(=O)=O)C(=O)C2=Cc1ccc(C=C2[C@@H]3CC[C@](CS(O)(=O)=O)(C2=O)C3(C)C)cc1 |&1:3	Launched			dermatology	skin protectant, sunscreen lotion
echinomycin	[H][C@]1(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]2([H])N(C)C(=O)[C@H](C)NC(=O)[C@@]([H])(COC(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@]([H])(CS[C@]2([H])SC)N(C)C(=O)[C@H](C)NC1=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 |&1:45	Phase 2		DNA intercalating agent		
econazole	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	Launched	NPY1R|NPY2R|TRPM2|TRPV5	lanosterol demethylase inhibitor, sterol demethylase inhibitor	infectious disease	tinea pedis, tinea cruris, tinea corporis, tinea versicolor, cutaneous candidiasis
ectoine	CC1=NCC[C@H](N1)C(O)=O |t:1|	Launched		anti-inflammatory agent		
edaglitazone	Cc1oc(nc1CCOc1ccc(C[C@@H]2SC(=O)NC2=O)c2sccc12)-c1ccccc1 |&1:14	Phase 2	PPARG	PPAR receptor agonist		
edaravone	Cc1cc(=O)n([nH]1)-c1ccccc1	Launched	BCL2	nootropic agent	neurology/psychiatry	stroke
edasalonexent	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)c1ccccc1O	Phase 3		NFkB pathway inhibitor		
edelfosine	CCCCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC |a:20	Phase 2		phospholipase inhibitor		
editol	C[C@@H](O)CN(CCN(C[C@@H](C)O)C[C@@H](C)O)C[C@@H](C)O |&1:1	Preclinical				
EDO-S101	Cn1c(CCCCCCC(=O)NO)nc2cc(ccc12)N(CCCl)CCCl	Phase 1/Phase 2		HDAC inhibitor		
edonerpic-maleate	OC1CN(CCCOCCc2ccc3sccc3c2)C1	Preclinical		beta amyloid inhibitor		
edoxaban	CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)Nc2ccc(Cl)cn2)[C@@H](C1)NC(=O)c1nc2CCN(C)Cc2s1	Launched	F10	coagulation factor inhibitor	neurology/psychiatry, hematology, cardiology	stroke, pulmonary embolism (PE), systemic embolism, deep vein thrombosis (DVT), atrial fibrillation (AF)
edoxudine	CCc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O	Launched		DNA directed DNA polymerase inhibitor	infectious disease	virus herpes simplex (HSV)
edrophonium	CC[N+](C)(C)c1cccc(O)c1	Launched	ACHE|BCHE	acetylcholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
EDTMP	OP(O)(=O)CN(CCN(CP(O)(O)=O)CP(O)(O)=O)CP(O)(O)=O	Preclinical		chelating agent		
EED226	CS(=O)(=O)c1ccc(cc1)-c1cnc(NCc2ccco2)n2cnnc12	Preclinical	EED	polycomb protein inhibitor		
efaproxiral	Cc1cc(C)cc(NC(=O)Cc2ccc(OC(C)(C)C(O)=O)cc2)c1	Phase 3	HBA1|HBB	hemoglobin oxygen release stimulant		
efaroxan	CCC1(Cc2ccccc2O1)C1=NCCN1	Phase 2	ADORA2A	adrenergic receptor antagonist		
efatutazone	Cc1cc(Oc2ccc3nc(COc4ccc(C[C@H]5SC(=O)NC5=O)cc4)n(C)c3c2)cc(C)c1N |r|	Phase 2	PPARG	PPAR receptor agonist		
efavirenz	FC(F)(F)[C@]1(OC(=O)Nc2ccc(Cl)cc12)C#CC1CC1	Launched	CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
efinaconazole	C[C@@H](N1CCC(=C)CC1)[C@@](O)(Cn1cncn1)c1ccc(F)cc1F |a:1	Launched	CYP51A1	lanosterol demethylase inhibitor	infectious disease	onychomycosis
efletirizine	OC(=O)COCCN1CCN(CC1)C(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3		antihistamine		
eflornithine	NCCCC(N)(C(F)F)C(O)=O |&1:4|	Launched	ARG2|ODC1	ornithine decarboxylase inhibitor	dermatology	facial hair reduction
efloxate	CCOC(=O)COc1ccc2c(c1)oc(cc2=O)-c1ccccc1	Preclinical		vasodilator		
efonidipine	CC1=C([C@@H](C(=C(C)N1)P1(=O)OCC(C)(C)CO1)c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(Cc1ccccc1)c1ccccc1 |&1:3	Launched		calcium channel blocker	cardiology	hypertension
EF5	[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F	Phase 2		cytochrome P450 activator		
EGF816	CN(C)C\C=C\C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(C)c2)nc2cccc(Cl)c12	Phase 2	EGFR	EGFR inhibitor		
eglumetad	N[C@]1(CC[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 2	GRM2|GRM3|GRM6|GRM8	glutamate receptor agonist		
EG00229	NC(=N)NCCC[C@H](NC(=O)c1sccc1NS(=O)(=O)c1cccc2nsnc12)C(O)=O	Preclinical	NRP1	neuropilin receptor antagonist		
EHop-016	CCn1c2ccccc2c2cc(Nc3ccnc(NCCCN4CCOCC4)n3)ccc12	Preclinical	RAC1|RAC3	Ras GTPase inhibitor		
EIPA	CCN(C(C)C)c1nc(N)c(nc1Cl)C(=O)N=C(N)N	Preclinical	ADRA2A|ASIC1|PKD2L1	sodium/hydrogen exchanger inhibitor, transient receptor potential polycystic inhibitor		
EIT-hydrobromide	CCSC(N)=N	Preclinical	NOS2|NOS3	nitric oxide synthase inhibitor		
EI1	CCC(CC)n1ccc2c(cc(cc12)C#N)C(=O)NCc1c(C)cc(C)[nH]c1=O	Preclinical	EZH2	histone lysine methyltransferase inhibitor		
elacestrant	CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1	Phase 3		estrogen receptor degrader		
elacridar	COc1cc2CCN(CCc3ccc(NC(=O)c4cccc5c4[nH]c4c(OC)cccc4c5=O)cc3)Cc2cc1OC	Phase 1	ABCB1	P glycoprotein inhibitor		
elactocin		Phase 1	XPO1	exportin antagonist		
elacytarabine	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)n1ccc(N)nc1=O	Phase 3	DCK	antineoplastic agent		
elafibranor	CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1	Phase 3	PPARA|PPARD|PPARG	PPAR receptor agonist		
elagolix	COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O	Launched	GNRHR	gonadotropin releasing factor hormone receptor antagonist		
elbasvir	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1nc(c[nH]1)-c1ccc2-c3cc4cc(ccc4n3[C@@H](Oc2c1)c1ccccc1)-c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched		HCV inhibitor	infectious disease	hepatitis C
eldecalcitol	[H][C@@]12CC[C@H]([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC\C2=C/C=C1/C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C	Phase 3	VDR	bone formation stimulant		
eleclazine	FC(F)(F)Oc1ccc(cc1)-c1ccc2OCCN(Cc3ncccn3)C(=O)c2c1	Phase 3		late sodium current inhibitor		
elemene	CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C1)C(C)=C	Phase 3		VEGFR inhibitor		
elesclomol	CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1	Phase 3	HSPA1A	oxidative stress inducer		
eletriptan	CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12	Launched	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2B|HTR7	serotonin receptor agonist	neurology/psychiatry	migraine headache
eliglustat	CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	Launched	UGCG	glycosyl transferase inhibitor	hematology	Gaucher disease
elinogrel	CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F	Phase 2	P2RY12	purinergic receptor antagonist		
eliprodil	O[C@@H](CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1 |&1:1	Phase 3	GRIN1|GRIN2B	glutamate receptor antagonist		
ellagic-acid	Oc1cc2c3c(oc(=O)c4cc(O)c(O)c(oc2=O)c34)c1O	Phase 2	CA1|CA12|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9|CSNK2A1|GSK3B|PRKACA|PRKCA|PRKCB|SQLE|SYK	glutathione transferase inhibitor, non-nucleoside reverse transcriptase inhibitor		
ELN-441958	Clc1cccc2CN(C(=O)c12)c1cccc(c1)C(=O)N1CCC2(CC1)CCN(CC2)c1ccncc1	Preclinical	BDKRB1	bradykinin receptor antagonist		
eltanexor	NC(=O)C(=C/n1cnc(n1)-c1cc(cc(c1)C(F)(F)F)C(F)(F)F)\c1cncnc1	Preclinical		exportin inhibitor		
eltanolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2	GABA receptor positive allosteric modulator		
eltoprazine	C1CN(CCN1)c1cccc2OCCOc12	Phase 2	HTR1A|HTR1B	serotonin receptor agonist		
eltrombopag	CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 |t:1|	Launched	MPL	thrombopoietin receptor agonist	hematology, infectious disease	anemia, hepatitis C, thrombocytopenia
eluxadoline	COc1ccc(CN([C@@H](C)c2nc(c[nH]2)-c2ccccc2)C(=O)[C@@H](N)Cc2c(C)cc(cc2C)C(N)=O)cc1C(O)=O	Launched	OPRD1|OPRK1|OPRM1	opioid receptor agonist, opioid receptor antagonist	gastroenterology	irritable bowel syndrome
elvitegravir	COc1cc2n(cc(C(O)=O)c(=O)c2cc1Cc1cccc(Cl)c1F)[C@H](CO)C(C)C	Launched		HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
emamectin	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@]([H])(O[C@H]4C[C@H](OC)[C@@]([H])(O[C@H]5C[C@@H](OC)[C@H](NC)[C@@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@@H]4C[C@@H](C[C@]5(O4)O[C@H](C(C)C)[C@@H](C)C=C5)OC(=O)[C@H](C=C(C)[C@H]1O)[C@@]23O |c:4	Preclinical		GABA receptor agonist		
embelin	CCCCCCCCCCCC1C(=O)C(O)=CC(=O)C1=O |c:15|	Preclinical	XIAP	HCV inhibitor, XIAP inhibitor		
EMD-1214063	CN1CCC(COc2cnc(nc2)-c2cccc(Cn3nc(ccc3=O)-c3cccc(c3)C#N)c2)CC1	Phase 2	MET	hepatocyte growth factor receptor inhibitor		
EMD-386088	Cc1[nH]c2ccc(Cl)cc2c1C1=CCNCC1 |t:13|	Preclinical	HTR6	serotonin receptor agonist		
EMD-53998	COc1ccc(cc1OC)C(=O)N1CCCc2cc(ccc12)C1=NNC(=O)S[C@@H]1C |r	Phase 1	TNNC1	phosphodiesterase inhibitor		
EMD-66684	CCCCc1nc2ccn(CC(=O)N(C)C)c(=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Preclinical	AGTR1	angiotensin receptor antagonist		
EMD534085	[H][C@@]12CC[C@H](CNC(=O)NCCN(C)C)O[C@]1([H])c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F	Preclinical		kinesin inhibitor		
emedastine	CCOCCn1c(nc2ccccc12)N1CCCN(C)CC1	Launched	HRH1	histamine receptor antagonist	ophthalmology	conjunctivitis
emeramide	SCCNC(=O)c1cccc(c1)C(=O)NCCS	Phase 2		antioxidant		
emetine	CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc12	Phase 2	RPS2	protein synthesis inhibitor		
emiglitate	CCOC(=O)c1ccc(OCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)cc1	Preclinical		alpha glucoside inhibitor		
emixustat	NCC[C@@H](O)c1cccc(OCC2CCCCC2)c1	Phase 3		retinoid isomerohydrolase inhibitor		
emodepside	[H][C@]1(C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)OC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](Cc2ccc(cc2)N2CCOCC2)OC(=O)[C@H](CC(C)C)N(C)C1=O	Phase 1		nematocide		
emodin	Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1	Preclinical	CSNK2A1	11-beta hydroxysteroid dehydrogenase inhibitor		
emorfazone	CCOc1c(cnn(C)c1=O)N1CCOCC1	Launched		anti-inflammatory agent, cyclooxygenase inhibitor	dental	mouth inflammation
emoxipin	CCc1nc(C)ccc1O	Phase 3				
empagliflozin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(Cl)c(Cc2ccc(O[C@H]3CCOC3)cc2)c1	Launched	SLC5A1|SLC5A2	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
emricasan	C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F	Phase 2	CASP1|CASP3|CASP7	caspase inhibitor		
emtricitabine	Nc1nc(=O)n(cc1F)[C@@H]1CS[C@H](CO)O1	Launched		nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
enalapril	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension, congestive heart failure, left ventricular systolic dysfunction (LVSD)
enalaprilat	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension
enasidenib	CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F	Launched	IDH1	isocitrate dehydrogenase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
enbucrilate	CCCCOC(=O)C(=C)C#N	Launched			dermatology	skin lacerations, tissue adhesive
enciprazine	COc1ccccc1N1CCN(C[C@@H](O)COc2cc(OC)c(OC)c(OC)c2)CC1 |&1:13	Phase 3	GABRA1	GABA receptor modulator		
encorafenib	COC(=O)N[C@@H](C)CNc1nccc(n1)-c1cn(nc1-c1cc(Cl)cc(NS(C)(=O)=O)c1F)C(C)C	Launched	BRAF	RAF inhibitor	oncology	melanoma
endo-IWR-1	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@@H]3C[C@@H](C=C3)[C@H]2C1=O |c:29|	Preclinical	TNKS|TNKS2	PARP inhibitor		
endoxifen	CC\C(=C(/c1ccc(O)cc1)c1ccc(OCCNC)cc1)c1ccccc1	Phase 2	ESR1	estrogen receptor antagonist		
enflurane	FC(F)OC(F)(F)[C@@H](F)Cl |&1:7	Launched	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9	membrane permeability inhibitor	neurology/psychiatry	anesthetic
enilconazole	Clc1ccc([C@@H](Cn2ccnc2)OCC=C)c(Cl)c1 |&1:5|	Launched	CYP19A1|CYP1A2|CYP2B6|CYP2C9|CYP2J2|CYP3A4|CYP3A5|NR1I2|PPARA|PTGER2	sterol demethylase inhibitor	infectious disease	skin infections
eniluracil	O=c1[nH]cc(C#C)c(=O)[nH]1	Phase 3	AOX1|DPYD|XDH	dihydropyrimidine dehydrogenase inhibitor		
eniporide	Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)-n1cccc1	Preclinical		sodium/hydrogen antiport inhibitor		
enisamium-iodide	C[n+]1ccc(cc1)C(=O)NCc1ccccc1	Launched				
ENMD-2076	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(\C=C\c2ccccc2)n1	Phase 2	AURKA|FLT3|KDR|PDGFRA|PTK2|SRC	Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor		
enocitabine	CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1	Launched	CMPK1|RRM1|TYMS	DNA synthesis inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
enoxacin	CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1	Launched	TOP2A	topoisomerase inhibitor	infectious disease	urinary tract infections, gonorrhea
enoximone	CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C	Launched	PDE3A	phosphodiesterase inhibitor	cardiology	congestive heart failure
enoxolone	CC1(C)[C@@H](O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O |t:19|	Launched	HSD11B1	gap junction modulator	gastroenterology, otolaryngology	peptic ulcer disease (PUD), common cold
enprofylline	CCCn1c2nc[nH]c2c(=O)[nH]c1=O	Phase 3	ADORA1|ADORA2A|ADORA2B|ADORA3|PDE4A|PDE4B	phosphodiesterase inhibitor		
enrofloxacin	CCN1CCN(CC1)c1cc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1	Launched		bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections
entacapone	CCN(CC)C(=O)C(=C\c1cc(O)c(O)c(c1)[N+]([O-])=O)\C#N	Launched	COMT	catechol O methyltransferase inhibitor	neurology/psychiatry	Parkinson's Disease
entasobulin	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccc4ncccc4c3)c3ccccc23)cc1	Preclinical		tubulin polymerization inhibitor		
entecavir	Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1	Launched		DNA replication inhibitor, nucleoside reverse transcriptase inhibitor	infectious disease	hepatitis B
entinostat	Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1	Phase 3	HDAC1|HDAC2|HDAC3|HDAC9	HDAC inhibitor		
entrectinib	CN1CCN(CC1)c1ccc(C(=O)Nc2[nH]nc3ccc(Cc4cc(F)cc(F)c4)cc23)c(NC2CCOCC2)c1	Launched	ALK|NTRK1|NTRK2|NTRK3|ROS1	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	oncology	non-small cell lung cancer (NSCLC)
enzalutamide	CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(C#N)c(c1)C(F)(F)F	Launched	AR	androgen receptor antagonist	oncology	prostate cancer
enzastaurin	Cn1cc(C2=C(C(=O)NC2=O)c2cn(C3CCN(Cc4ccccn4)CC3)c3ccccc23)c2ccccc12 |t:4|	Phase 3	AKT1|GSK3B|PRKCA|PRKCB|PRKCD|PRKCG	PKC inhibitor		
EN460	OC(=O)c1cc(ccc1Cl)N1N=C(\C(=C\c2ccc(o2)-c2ccccc2)C1=O)C(F)(F)F |c:12|	Preclinical	ERO1A	endoplasmic reticulum oxidation inhibitor		
EO-1428	Cc1ccccc1C(=O)c1ccc(Nc2ccc(Br)cc2N)cc1Cl	Preclinical	MAPK11|MAPK14	p38 MAPK inhibitor		
epacadostat	NS(=O)(=O)NCCNc1nonc1C(NO)=Nc1ccc(F)c(Br)c1	Phase 3	IDO1	indoleamine 2,3-dioxygenase inhibitor		
epalrestat	C\C(\C=C1/SC(=S)N(CC(O)=O)C1=O)=C/c1ccccc1	Launched	AKR1B1	aldose reductase inhibitor	nephrology	diabetic nephropathy
eperezolid	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCN(CC2)C(=O)CO)c(F)c1	Phase 1		bacterial 30S ribosomal subunit inhibitor		
eperisone	CCc1ccc(cc1)C(=O)[C@@H](C)CN1CCCCC1 |r|	Launched	CYP2J2	acetylcholine receptor antagonist	neurology/psychiatry	amyotrophic lateral sclerosis (ALS), spasms, head injury, spinal injury
epetraborole	NC[C@H]1OB(O)c2c1cccc2OCCCO	Preclinical		leucyl-tRNA synthetase inhibitor		
ephedrine	CN[C@@H](C)[C@H](O)c1ccccc1	Launched	ACHE|ADRA1A|ADRB2|SLC18A2|SLC6A2	adrenergic receptor agonist	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity
ephedrine-(racemic)	CN[C@@H](C)[C@@H](O)c1ccccc1 |&1:2	Launched	ADRA1A|ADRA2A|ADRB1|ADRB2|ATF1|ATF2|ATF3|ATF4|ATF5|ATF6|ATF7|FOS|IL2|JDP2|JUN|NFATC1|SLC6A2|SLC6A3|SLC6A4|TNF	adrenergic receptor agonist	cardiology, pulmonary, neurology/psychiatry, endocrinology	hypotension, asthma, narcolepsy, obesity
epiandrosterone	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O	Preclinical	G6PD	steroid		
epicatechin-gallate-(-)	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1ccc(O)c(O)c1	Phase 2	BACE1|FASN	bacterial DNA gyrase inhibitor		
epiestriol	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@H](O)[C@@H]2O	Preclinical				
epigallocatechin-(-)	O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1	Phase 2				
epigallocatechin-gallate-(-)	Oc1cc(O)c2C[C@@H](OC(=O)c3cc(O)c(O)c(O)c3)[C@H](Oc2c1)c1cc(O)c(O)c(O)c1	Phase 2/Phase 3	ELANE|EP300|FASN|KAT2B|MMP14|MMP2	bacterial DNA gyrase inhibitor		
epinastine	NC1=NC[C@H]2N1c1ccccc1Cc1ccccc21 |&1:4	Launched	HRH1	histamine receptor antagonist	ophthalmology	conjunctivitis
epinephrine	CNC[C@H](O)c1ccc(O)c(O)c1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|TNF	adrenergic receptor agonist, carbonic anhydrase activator, neurotransmitter	cardiology, allergy, pulmonary	cardiac arrest, anaphylactic shock, asthma
epirizole	COc1cc(C)nn1-c1nc(C)cc(OC)n1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
epirubicin	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched	CHD1|TOP2A	topoisomerase inhibitor	oncology	breast cancer
epitiostanol	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H]5S[C@@H]5C[C@]34C)[C@@H]1CC[C@@H]2O	Launched	AR	androgen receptor agonist	oncology	breast cancer
eplerenone	COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]22CCC(=O)O2)[C@H]13 |t:6|	Launched	NR3C2	cytochrome P450 inhibitor	cardiology	congestive heart failure, hypertension
epomediol	CC1(C)OC2(C)[C@@H](O)C[C@H]1C[C@@H]2O |&1:11	Launched	CYP7A1	cholesterol inhibitor	neurology/psychiatry	itching
epoprostenol	CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC(O)=O	Launched	P2RY12|PTGER1|PTGER4|PTGIR|PTGIS	prostacyclin analog	cardiology	hypertension
epothilone-A	C[C@H]1CCC[C@H]2O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Preclinical		microtubule stabilizing agent		
epothilone-B	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Phase 3	TUBB	microtubule stabilizing agent, tubulin polymerization inhibitor		
epothilone-D	C[C@H]1CCC\C(C)=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1 |c:6|	Phase 2	TUBB	microtubule stabilizing agent, tubulin polymerization inhibitor		
EPPTB	CCOc1cccc(NC(=O)c2ccc(N3CCCC3)c(c2)C(F)(F)F)c1	Preclinical	TAAR1	trace amine associated receptor antagonist		
eprazinone	CCO[C@@H](CN1CCN(C[C@@H](C)C(=O)c2ccccc2)CC1)c1ccccc1 |a:10	Launched		mucolytic agent	pulmonary	bronchospasm
eprinomectin	[H][C@@]12OC\C3=C/C=C/[C@]([H])(C)[C@]([H])(O[C@@]4([H])C[C@H](OC)[C@@H](O[C@@]5([H])C[C@H](OC)[C@@H](NC(C)=O)[C@H](C)O5)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(O4)O[C@]([H])([C@@H](C)CC)[C@@]([H])(C)C=C5)OC(=O)[C@]([H])(C=C(C)[C@@]1([H])O)[C@@]23O |c:4	Launched		benzodiazepine receptor agonist	infectious disease	gastrointestinal roundworms, lungworms
epristeride	[H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C=C(CC[C@]12C)C(O)=O |c:25	Preclinical		5 alpha reductase inhibitor		
eprobemide	Clc1ccc(cc1)C(=O)NCCCN1CCOCC1	Launched	MAOA	monoamine oxidase inhibitor	neurology/psychiatry	depression
eprodisate	OS(=O)(=O)CCCS(O)(=O)=O	Phase 3	SAA1	amyloid protein inhibitor, antiamyloidogenic agent		
eprosartan	CCCCc1ncc(\C=C(/Cc2cccs2)C(O)=O)n1Cc1ccc(cc1)C(O)=O	Launched	AGTR1	angiotensin receptor antagonist	cardiology	hypertension
eptifibatide	NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O	Launched	ITGA2B|ITGB3	platelet aggregation inhibitor	cardiology	acute coronary syndrome (ACS), percutaneous coronary intervention (PCI)
EPZ-5676	CC(C)N(C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12)[C@@H]1C[C@H](CCc2nc3ccc(cc3[nH]2)C(C)(C)C)C1	Phase 1	DOT1L	histone lysine methyltransferase inhibitor		
EPZ004777	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc2c(N)ncnc12	Preclinical	DOT1L	histone lysine methyltransferase inhibitor		
EPZ005687	Cc1cc(C)c(CNC(=O)c2cc(cc3n(ncc23)C2CCCC2)-c2ccc(CN3CCOCC3)cc2)c(=O)[nH]1	Preclinical	EZH2	histone lysine methyltransferase inhibitor		
EPZ011989	CCN([C@H]1CC[C@@H](CC1)N(C)CCOC)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C#CCN1CCOCC1 |r|	Preclinical	EZH2	histone lysine methyltransferase inhibitor		
EPZ015666	O[C@@H](CNC(=O)c1cc(NC2COC2)ncn1)CN1CCc2ccccc2C1	Preclinical	PRMT5	protein arginine N-methyltransferase inhibitor		
EPZ020411	CNCCN(C)Cc1c[nH]nc1-c1ccc(O[C@H]2C[C@@H](C2)OCCC2CCOCC2)cc1 |r|	Preclinical	PRMT6	protein arginine N-methyltransferase inhibitor		
equilin	C[C@@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CCC2=O |&1:1	Preclinical	HSD17B1	estrogen receptor agonist		
equol	Oc1ccc(cc1)[C@H]1COc2cc(O)ccc2C1	Launched	ESR1|ESR2	estrogen receptor agonist		
ER-27319	Cc1ccc2c(c1C)n(CCCN)c1ccccc1c2=O	Preclinical	SYK	mediator release inhibitor, SYK inhibitor		
ER-50891	CC(C)c1cccc2c(cc(nc12)-c1ccc([nH]1)-c1ccc(cc1)C(O)=O)-c1ccccc1	Preclinical	RARA	retinoid receptor antagonist		
erastin	CCOc1ccccc1-n1c(nc2ccccc2c1=O)[C@@H](C)N1CCN(CC1)C(=O)COc1ccc(Cl)cc1 |&1:20	Preclinical	VDAC2	ion channel antagonist		
eravacycline	[H][C@@]12Cc3c(F)cc(NC(=O)CN4CCCC4)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:29	Launched		antibacterial		
erbstatin-analog	COC(=O)\C=C\c1cc(O)ccc1O	Preclinical	EGFR	EGFR inhibitor, tyrosine kinase inhibitor		
ercalcitriol	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Phase 1	VDR	vitamin D receptor agonist		
erdafitinib	COc1cc(OC)cc(c1)N(CCNC(C)C)c1ccc2ncc(nc2c1)-c1cnn(C)c1	Launched	FGFR1|FGFR2|FGFR3|FGFR4	FGFR inhibitor		
erdosteine	OC(=O)CSCC(=O)N[C@H]1CCSC1=O |&1:9	Launched		mucolytic agent	pulmonary, infectious disease	bronchitis, cough suppressant, chronic obstructive pulmonary disease (COPD), respiratory tract infections
ergocalciferol	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched	VDR	vitamin analog	endocrinology, orthopedics	hypoparathyroidism, rickets, hypophosphatemia
ergonovine	C[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:22|	Launched	ADRA1A|HTR1E	adrenergic receptor agonist, serotonin receptor agonist	hematology	postpartum hemorrhage (PPH)
ergosterol	CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:13	Preclinical		vitamin D precursor		
ergotamine	CN1C[C@@H](C=C2[C@H]1Cc1c[nH]c3cccc2c13)C(=O)N[C@]1(C)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O |c:4|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|DRD1|DRD2|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|SLC6A2	adrenergic receptor antagonist	neurology/psychiatry	migraine headache
eribulin	[H][C@@]12CC(=C)[C@]([H])(CC[C@@]3([H])C[C@@H](C)C(=C)[C@@]([H])(C[C@]4([H])O[C@H](C[C@H](O)CN)[C@H](OC)[C@@]4([H])CC(=O)C[C@@]4([H])CC[C@]5([H])O[C@@]6([H])[C@@]7([H])O[C@@]8(C[C@@]7([H])O[C@@]6([H])[C@@]([H])(O8)[C@@]5([H])O4)CC1)O3)O2 |THB:43:44:51.53:48.49.56.58	Launched		microtubule inhibitor	oncology	breast cancer
ERK5-IN-1	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCN(C)CC1	Preclinical	MAPK7	MAP kinase inhibitor		
erlotinib	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC	Launched	EGFR|NR1I2	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC), pancreatic cancer
ertapenem	C[C@@H](O)[C@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)Nc3cccc(c3)C(O)=O)=C(N2C1=O)C(O)=O |a:1	Launched		bacterial cell wall synthesis inhibitor	infectious disease	intra-abdominal infections, skin infections, pneumonia, urinary tract infections, gynecologic infections, postpartum endomyometritis
erteberel	Oc1ccc(cc1)[C@@H]1Oc2ccc(O)cc2[C@@H]2CCC[C@H]12	Phase 2	ESR1|ESR2	estrogen receptor agonist		
ertugliflozin	CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1	Launched	SLC5A2	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
erythritol	OC[C@H](O)[C@H](O)CO	Launched				
erythromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	MLNR	NFkB pathway inhibitor	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma
erythromycin-estolate	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)CC)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1	bacterial 50S ribosomal subunit inhibitor	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma
erythromycin-ethylsuccinate	CCOC(=O)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C	Launched	ABCB1|ALB|CYP3A4|CYP51A1|KCNH2|MLNR|SLC47A1	cytochrome P450 inhibitor, protein synthesis inhibitor	infectious disease	listeria, respiratory tract infections, skin infections, syphilis, amebiasis, pelvic inflammatory disease, chlamydia, diphtheria, erythrasma
erythrosine	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3ccccc23)c1I	Preclinical		coloring agent		
esaprazole	O=C(CN1CCNCC1)NC1CCCCC1	Phase 2				
esaxerenone	Cc1c(cn(CCO)c1-c1ccccc1C(F)(F)F)C(=O)Nc1ccc(cc1)S(C)(=O)=O	Preclinical		mineralocorticoid receptor antagonist		
escin	CC=C(C)C(=O)O[C@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2CC1(C)C |c:21|	Launched		nitric oxide synthase stimulant	dermatology	varicose veins
escitalopram	CN(C)CCC[C@]1(OCc2cc(ccc12)C#N)c1ccc(F)cc1	Launched	SLC6A4	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression, generalized anxiety disorder (GAD)
esculin	OC[C@H]1O[C@@H](Oc2cc3ccc(=O)oc3cc2O)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1		antioxidant		
eseroline-(-)	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(O)cc21	Preclinical	OPRD1|OPRM1	acetylcholinesterase inhibitor		
ESI-09	CC(C)(C)c1cc(no1)C(=O)C(=N\Nc1cccc(Cl)c1)\C#N	Preclinical	RAPGEF3|RAPGEF4	EPAC inhibitor		
eslicarbazepine-acetate	CC(=O)O[C@H]1Cc2ccccc2N(C(N)=O)c2ccccc12	Launched	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	sodium channel blocker	neurology/psychiatry	seizures
esmolol	COC(=O)CCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:12	Launched	ADRB1	adrenergic receptor antagonist	cardiology	ventricular tachycardia (VT), hypertension
esomeprazole	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C	Launched	ATP4A	ATPase inhibitor	gastroenterology	gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease (PUD)
esonarimod	CC(=O)SC[C@H](CC(=O)c1ccc(C)cc1)C(O)=O |&1:5	Preclinical		antirheumatic drug		
estetrol	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1[C@@H](O)[C@@H](O)[C@@H]2O	Phase 3	ESR1	selective estrogen receptor modulator (SERM)		
estradiol	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O	Launched	ESR1|ESR2|GPER1|KCNMA1|NR1I2	estrogen receptor agonist	endocrinology	contraceptive
estradiol-acetate	CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1	Launched	ESR1	estrogen receptor agonist	endocrinology, obstetrics/gynecology	menopause, vaginal atrophy
estradiol-benzoate	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)c5ccccc5)ccc34)[C@@H]1CC[C@@H]2O	Preclinical	ESR1	contraceptive agent		
estradiol-cypionate	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1	Launched	ESR1	estrogen receptor agonist	endocrinology	hypoestrogenism, menopause
estradiol-valerate	CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C	Launched	ESR1	estrogen receptor agonist	oncology, endocrinology, obstetrics/gynecology	prostate cancer, hypoestrogenism, menopause, vaginal atrophy
estradiol-3-O-sulfamate	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(N)(=O)=O)ccc34)[C@@H]1CC[C@@H]2O	Phase 2		steryl sulfatase inhibitor		
estramustine		Launched	ESR1|ESR2|MAP1A|MAP2	DNA alkylating agent	oncology	prostate cancer
estramustine-phosphate	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)[C@@H]1CC[C@@H]2OP(O)(O)=O	Launched	ESR1|ESR2|MAP1A|MAP2	DNA synthesis inhibitor, microtubule inhibitor	oncology	prostate cancer
estriol	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1C[C@@H](O)[C@@H]2O	Launched	ESR1|ESR2	estrogen receptor agonist	endocrinology, obstetrics/gynecology, infectious disease	menopause, vaginal atrophy, urinary tract infections
estrone	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O	Launched	ESR1|ESR2	estrogen receptor agonist, estrogenic hormone	endocrinology	menopause
estropipate	C[C@]12CC[C@H]3[C@@H](CCc4cc(OS(O)(=O)=O)ccc34)[C@@H]1CCC2=O	Launched	ESR1|ESR2	estrogen receptor agonist	orthopedics, endocrinology, obstetrics/gynecology	osteoporosis, menopause, vaginal atrophy, hypoestrogenism
etacrynic-acid	CCC(=C)C(=O)c1ccc(OCC(O)=O)c(Cl)c1Cl	Launched	ATP1A1|SLC12A1	sodium/potassium/chloride transporter inhibitor	cardiology, gastroenterology, nephrology, rheumatology	hypertension, congestive heart failure, edema, hepatic cirrhosis, chronic renal failure, nephrotic syndrome
etafenone	CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1	Launched		calcium channel blocker		
etamsylate	Oc1ccc(O)c(c1)S(O)(=O)=O	Launched		hemostatic agent	hematology	hemorrhage
etanidazole	OCCNC(=O)Cn1ccnc1[N+]([O-])=O	Phase 3		bacterial cell wall synthesis inhibitor		
etazolate	CCOC(=O)c1cnc2n(CC)ncc2c1NN=C(C)C	Phase 2	GABRB3|PDE4A	phosphodiesterase inhibitor		
ETC-159	Cn1c2ncn(CC(=O)Nc3ccc(nn3)-c3ccccc3)c2c(=O)n(C)c1=O	Phase 1	PORCN	beta catenin inhibitor, porcupine inhibitor		
ETC-206	O=C(N1CCOCC1)c1ccc(cc1)-c1ccc2ncc(-c3ccc(cc3)C#N)n2c1	Phase 1		MAPK-interacting kinase inhibitor		
etebenecid	CCN(CC)S(=O)(=O)c1ccc(cc1)C(O)=O	Preclinical		uricosuric blocker		
eterobarb	CCC1(C(=O)N(COC)C(=O)N(COC)C1=O)c1ccccc1	Phase 2		anticonvulsant		
ethacizin	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN(CC)CC)c2c1	Launched		anticonvulsant	cardiology	ventricular tachycardia (VT), Wolff-Parkinson-White Syndrome (WPW)
ethacridine-lactate-monohydrate	CCOc1ccc2nc3cc(N)ccc3c(N)c2c1	Preclinical		DNA intercalating agent		
ethambutol	CC[C@@H](CO)NCCN[C@@H](CC)CO	Launched		bacterial cell wall synthesis inhibitor	infectious disease	tuberculosis
ethamivan	CCN(CC)C(=O)c1ccc(O)c(OC)c1	Preclinical		respiratory stimulant		
ethanolamine-oleate	NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O	Launched	F12|FABP4|FFAR1|FFAR4|PLD2	immunostimulant	gastroenterology	esophageal varices
ethaverine	CCOc1ccc(Cc2nccc3cc(OCC)c(OCC)cc23)cc1OCC	Launched		calcium channel blocker	neurology/psychiatry	muscle relaxant, spasms
ethenzamide	CCOc1ccccc1C(N)=O	Launched		analgesic agent	neurology/psychiatry, endocrinology, otolaryngology	headache, fever, common cold
ethimizol	CCn1cnc(C(=O)NC)c1C(=O)NC	Phase 1				
ethinyl-estradiol	C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C	Launched	ESR1|ESR2|NR1I2	estrogen receptor agonist, estrogenic hormone	endocrinology	contraceptive
ethionamide	CCc1cc(ccn1)C(N)=S	Launched		mycolic synthesis inhibitor	infectious disease	tuberculosis
ethisterone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)C#C |t:8|	Launched	TYR	progestogen hormone	endocrinology	amenorrhea
ethopabate	CCOc1cc(NC(C)=O)ccc1C(=O)OC	Launched		antiprotozoal agent	infectious disease	coccidiosis
ethosuximide	CC[C@@]1(C)CC(=O)NC1=O |&1:2	Launched	CACNA1G|CACNA1H|CACNA1I	succinimide antiepileptic	neurology/psychiatry	epilepsy
ethotoin	CCN1C(=O)N[C@@H](C1=O)c1ccccc1 |r|	Launched	SCN5A	hydantoin antiepileptic	neurology/psychiatry	seizures
ethoxyquin	CCOc1ccc2NC(C)(C)C=C(C)c2c1 |t:11|	Preclinical		antioxidant		
ethoxzolamide	CCOc1ccc2nc(sc2c1)S(N)(=O)=O	Launched	CA1|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA9	carbonic anhydrase inhibitor	ophthalmology, gastroenterology	glaucoma, duodenal ulcer disease
ethyl-paraben	CCOC(=O)c1ccc(O)cc1	Preclinical				
ethyl-pyruvate	CCOC(=O)C(O)=C	Phase 2		tumor necrosis factor production inhibitor		
ethyl-vanillin	CCOc1cc(C=O)ccc1O	Preclinical				
ethyl-2-(carbamoyloxy)benzoate	CCOC(=O)c1ccccc1OC(N)=O	Phase 1				
ethylenediaminetetraacetic-acid	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O	Launched		PKC inhibitor	neurology/psychiatry	metal toxicity
ethylnorepinephrine	CC[C@@H](N)[C@@H](O)c1ccc(O)c(O)c1 |&1:2	Preclinical		bronchodilator		
ethynodiol-diacetate	CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(OC(C)=O)C#C)[C@@H]3CCC2=C1 |c:29|	Launched	ESR1|PGR		endocrinology	contraceptive
ethynylcytidine	Nc1ccn([C@@H]2O[C@H](CO)[C@](O)(C#C)[C@H]2O)c(=O)n1	Preclinical		antimetabolite		
eticlopride	CCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC	Preclinical	DRD2|DRD3|DRD4	dopamine receptor antagonist		
etidronic-acid	CC(O)(P(O)(O)=O)P(O)(O)=O	Launched	ATP6V1A|PTPRS	bone resorption inhibitor	endocrinology, orthopedics	Paget's disease, heterotopic ossification
etifenin	CCc1cccc(CC)c1NC(=O)CN(CC(O)=O)CC(O)=O	Preclinical		renal function diagnostic agent		
etifoxine	CCNC1=Nc2ccc(Cl)cc2[C@@](C)(O1)c1ccccc1 |&1:12	Launched	GABRA1|GABRA2|GABRA3|GABRA5	GABA receptor modulator	neurology/psychiatry	anxiety
etilefrine	CCNCC(O)c1cccc(O)c1	Launched	ADRA1A|ADRB1	adrenergic receptor agonist	neurology/psychiatry, otolaryngology, endocrinology, pulmonary	headache, nasal congestion, fever, cough suppressant, common cold
etilevodopa	CCOC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	Phase 3	DRD3	dopamine receptor agonist		
etizolam	CCc1cc2c(s1)-n1c(C)nnc1CN=C2c1ccccc1Cl |c:16|	Launched	GABRA1	benzodiazepine receptor agonist	neurology/psychiatry	insomnia, anxiety
etodolac	CCc1cccc2c3CCO[C@@](CC)(CC(O)=O)c3[nH]c12 |&1:11	Launched	PTGS2	cyclooxygenase inhibitor	rheumatology	osteoarthritis, rheumatoid arthritis
etofenamate	OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry, rheumatology	muscle pain, joint pain
etofibrate	CC(C)(Oc1ccc(Cl)cc1)C(=O)OCCOC(=O)c1cccnc1	Launched	PPARA	PPAR receptor agonist	endocrinology	hypertriglyceridemia
etofylline	Cn1c2ncn(CCO)c2c(=O)n(C)c1=O	Launched	ADORA1	adenosine receptor antagonist	pulmonary	asthma, bronchitis
etofylline-clofibrate	Cn1c2ncn(CCOC(=O)C(C)(C)Oc3ccc(Cl)cc3)c2c(=O)n(C)c1=O	Launched	PPARA	platelet aggregation inhibitor	endocrinology	hyperlipidemia
etomidate	CCOC(=O)c1cncn1[C@H](C)c1ccccc1	Launched	ADRA2B|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	GABA receptor modulator	neurology/psychiatry	general anaesthetic
etomoxir	CCOC(=O)[C@@]1(CCCCCCOc2ccc(Cl)cc2)CO1	Phase 2	CPT1A	carnitine palmitoyltransferase inhibitor		
etonogestrel	[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:23|	Launched	ESR1|PGR	progesterone receptor agonist	endocrinology	contraceptive
etoposide	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	Launched	TOP2A|TOP2B	topoisomerase inhibitor	oncology	non-small cell lung cancer (NSCLC)
etoposide-phosphate	COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12	Launched	TOP2A	topoisomerase inhibitor	oncology	testicular carcinoma, small cell lung cancer
etoricoxib	Cc1ccc(cn1)-c1ncc(Cl)cc1-c1ccc(cc1)S(C)(=O)=O	Launched	PTGS2	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis, psoriatic arthritis, osteoarthritis, gout, ankylosing spondylitis
etosalamide	CCOCCOc1ccccc1C(N)=O	Preclinical		anti-inflammatory agent		
etoxybamide	OCCCC(=O)NCCO	Phase 2				
ETP-45658	Cn1ncc2c(nc(nc12)-c1cccc(O)c1)N1CCOCC1	Preclinical	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
ETP-46464	CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1	Preclinical		ATR kinase inhibitor		
etrabamine	CN[C@H]1CCc2ncsc2C1 |&1:2	Phase 2		dopamine receptor agonist		
etrasimod	OC(=O)C[C@H]1CCc2c1[nH]c1ccc(OCc3ccc(C4CCCC4)c(c3)C(F)(F)F)cc21	Phase 3		sphingosine 1-phosphate receptor antagonist		
etravirine	Cc1cc(cc(C)c1Oc1nc(Nc2ccc(cc2)C#N)nc(N)c1Br)C#N	Launched	CYP2C19|CYP2C9|CYP3A4	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
etretinate	CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\c1c(C)cc(OC)c(C)c1C	Withdrawn	RARA|RXRG	protein synthesis inhibitor		
eucalyptol	CC12CCC(CC1)C(C)(C)O2	Launched	ACHE	acetylcholinesterase inhibitor	dental	gingivitis
eucatropine	C[C@H]1C[C@@H](CC(C)(C)N1C)OC(=O)[C@@H](O)c1ccccc1 |&1:1	Preclinical		acetylcholine receptor antagonist		
eugenol	COc1cc(CC=C)ccc1O	Launched	AR	androgen receptor antagonist	dental	toothache
EUK-134	COc1cccc2C=[N+]3CC[N+]4=Cc5cccc(OC)c5O[Mn]34(Cl)Oc12 |t:7	Preclinical	APP|SOD2	catalase stimulant		
eupatilin	COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1	Launched		mucus protecting agent		
evacetrapib	Cc1cc(C)c2N(C[C@H]3CC[C@@H](CC3)C(O)=O)CCC[C@H](N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)c3nnn(C)n3)c2c1	Phase 3	CETP	cholesteryl ester transfer protein inhibitor		
evans-blue	Cc1cc(ccc1NN=C1C=Cc2c(cc(c(N)c2C1=O)S(O)(=O)=O)S(O)(=O)=O)-c1ccc(NN=C2C=Cc3c(cc(c(N)c3C2=O)S(O)(=O)=O)S(O)(=O)=O)c(C)c1 |c:11	Launched	GRIA1|PTPN1	glutamate receptor negative allosteric modulator		
evatanepag	CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1	Phase 2	PTGER2|PTGER4	prostaglandin inhibitor		
evenamide	CCCCOc1cccc(CCNCC(=O)N(C)C)c1	Phase 2		voltage-gated sodium channel blocker		
everolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO |c:14	Launched	MTOR	mTOR inhibitor	oncology, neurology/psychiatry, genetics, urology	breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma
evobrutinib	Nc1ncnc(NCC2CCN(CC2)C(=O)C=C)c1-c1ccc(Oc2ccccc2)cc1	Phase 2		Bruton's tyrosine kinase (BTK) inhibitor		
evocalcet	C[C@@H](N[C@H]1CCN(C1)c1ccc(CC(O)=O)cc1)c1cccc2ccccc12	Phase 3		calcium sensitizer		
evodiamine	CN1[C@H]2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12 |&1:2	Preclinical	TRPV1	ATPase inhibitor, TRPV agonist		
EVP-6124	Clc1cccc2cc(sc12)C(=O)N[C@H]1CN2CCC1CC2	Phase 3	CHRNA7	acetylcholine receptor agonist		
EVP4593	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1	Preclinical		NFkB pathway inhibitor		
EW-7197	Cc1cccc(n1)-c1nc(CNc2ccccc2F)[nH]c1-c1ccc2ncnn2c1	Phase 2	ACVR1B|TGFBR1	TGF beta receptor inhibitor		
EX-527	NC(=O)[C@H]1CCCc2c1[nH]c1ccc(Cl)cc21 |&1:3	Phase 2	SIRT1	SIRT inhibitor		
exalamide	CCCCCCOc1ccccc1C(N)=O	Launched		membrane permeability inhibitor		
examorelin	C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 2	GHRHR|GHSR	growth hormone releasing factor agonist		
exatecan-mesylate	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cc(F)c(C)c5CC[C@H](N)c(c3Cn1c2=O)c45	Phase 3	TOP1	topoisomerase inhibitor		
exemestane	C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O |c:13	Launched	CYP19A1	aromatase inhibitor	oncology	breast cancer
exenatide	[H]N[C@@H](Cc1c[nH]cn1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O |r|	Launched	GLP1R	GLP receptor agonist	endocrinology	diabetes mellitus
exherin	CC(C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(N)=O)NC(C)=O	Phase 2	CDH2	cadherin antagonist		
exifone	Oc1ccc(C(=O)c2cc(O)c(O)c(O)c2)c(O)c1O	Withdrawn	TYR	nootropic agent		
exisulind	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)S(C)(=O)=O |c:1|	Phase 3	PDE5A	phosphodiesterase inhibitor		
exo-IWR-1	O=C(Nc1cccc2cccnc12)c1ccc(cc1)N1C(=O)[C@H]2[C@H]3C[C@H](C=C3)[C@H]2C1=O |c:29|	Preclinical	TNKS	WNT signaling inhibitor negative control		
EXO-1	COC(=O)c1ccccc1NC(=O)c1ccc(F)cc1	Preclinical		ARF inhibitor		
ezatiostat	CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c1ccccc1	Phase 2	GSTP1	glutathione transferase inhibitor		
ezetimibe	O[C@@H](CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1	Launched	ANPEP|NPC1L1|SOAT1	cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist	endocrinology, metabolism	hyperlipidemia, hypercholesterolemia, sitosterolemia
ezutromid	CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1	Phase 2	UTRN	utrophin enhancer		
E3330	CCCCCCCCC\C(=C/C1=C(C)C(=O)C(OC)=C(OC)C1=O)C(O)=O |c:11	Preclinical		NFkB pathway inhibitor		
E7046	C[C@H](NC(=O)c1c(nn(C)c1Oc1cccc(c1)C(F)(F)F)C(F)F)c1ccc(cc1)C(O)=O	Phase 1		prostanoid receptor antagonist		
E7449	O=c1[nH][nH]c2nc(CN3Cc4ccccc4C3)nc3cccc1c23	Phase 2	PARP1|PARP2|TNKS|TNKS2	PARP inhibitor		
E7820	Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12	Phase 2		angiogenesis inhibitor		
F-11440	Cn1c(=O)cnn(CCCCN2CCN(CC2)c2ncccn2)c1=O	Phase 2	HTR1A	serotonin receptor agonist		
F-16915	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)OCc1cccnc1	Preclinical				
fadrozole	N#Cc1ccc(cc1)[C@H]1CCCc2cncn12 |&1:8|	Launched	CYP11B1|CYP19A1	aromatase inhibitor	oncology	breast cancer
fagomine	OC[C@H]1NCC[C@@H](O)[C@@H]1O	Phase 2	GLB1	glucosidase inhibitor		
falecalcitriol	C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched	VDR	vitamin D receptor agonist	endocrinology	hyperparathyroidism
famciclovir	CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(C)=O	Launched		DNA polymerase inhibitor	dental, infectious disease	cold sore, genitial herpes, shingles
famotidine	NC(=N)Nc1nc(CSCC\C(N)=N/S(N)(=O)=O)cs1	Launched	HRH2	histamine receptor antagonist	gastroenterology	heartburn
famprofazone	CC(C)c1c(CN(C)[C@@H](C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O |&1:8	Preclinical		cyclooxygenase inhibitor		
fananserin	Fc1ccc(cc1)N1CCN(CCCN2c3cccc4cccc(c34)S2(=O)=O)CC1	Phase 2	HTR2A	dopamine receptor antagonist, serotonin receptor antagonist		
fanetizole	C(Cc1ccccc1)Nc1nc(cs1)-c1ccccc1	Phase 3		neutrophil superoxide production		
fantofarone	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3ccccc23)C(C)C)cc1OC	Preclinical		calcium channel blocker		
farampator	O=C(N1CCCCC1)c1ccc2nonc2c1	Preclinical		ionotropic glutamate receptor agonist		
farnesyl-thiosalicylic-acid-amide	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(N)=O	Phase 1	HRAS	Ras GTPase inhibitor		
faropenem	C[C@@H](O)[C@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(O)=O |&1:1	Launched		lactamase inhibitor	infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, skin infections, urinary tract infections, sinusitis
faropenem-medoxomil	C[C@@H](O)[C@@H]1[C@H]2SC([C@H]3CCCO3)=C(N2C1=O)C(=O)OCc1oc(=O)oc1C |c:12|	Launched		lactamase inhibitor	otolaryngology, infectious disease, pulmonary	sinusitis, pneumonia, bronchitis, skin infections, urinary tract infections
fasoracetam	O=C([C@H]1CCC(=O)N1)N1CCCCC1	Preclinical		GABA receptor antagonist		
fasudil	O=S(=O)(N1CCCNCC1)c1cccc2cnccc12	Launched	PKIA|PRKACA|ROCK1|ROCK2	rho associated kinase inhibitor	neurology/psychiatry	cerebral vasospasm
favipiravir	NC(=O)c1nc(F)c[nH]c1=O	Phase 3		RNA polymerase inhibitor		
FCE-22250	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N=C\N4CCCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:34	Phase 1		DNA directed DNA polymerase inhibitor		
fdcyd	Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1	Phase 2		DNA methyltransferase inhibitor		
febuprol	CCCCOC[C@@H](O)COc1ccccc1 |&1:6	Launched		choleretic agent		
febuxostat	CC(C)COc1ccc(cc1C#N)-c1nc(C)c(s1)C(O)=O	Launched	XDH	xanthine oxidase inhibitor	nephrology	hyperuricemia
fedratinib	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C	Launched	BRD4|JAK1|JAK2|JAK3|TYK2	FLT3 inhibitor, JAK inhibitor	hematologic malignancy	myelofibrosis
felbamate	NC(=O)OCC(COC(N)=O)c1ccccc1	Launched	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	glutamate receptor antagonist	neurology/psychiatry	epilepsy
felbinac	OC(=O)Cc1ccc(cc1)-c1ccccc1	Launched	CTSL	cyclooxygenase inhibitor	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain
felbinac-ethyl	CCOC(=O)Cc1ccc(cc1)-c1ccccc1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor		
felodipine	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(Cl)c1Cl)C(=O)OC |&1:12	Launched	CFTR	calcium channel blocker	cardiology	hypertension
felypressin	[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)NCC(N)=O	Preclinical		vasopressin receptor agonist		
fenaclon	ClCCC(=O)NCCc1ccccc1	Preclinical				
fenbendazole	COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1	Launched	TUBB	tubulin polymerization inhibitor	infectious disease	gastrointestinal parasites, gastrointestinal roundworms
fenbufen	OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
fenclonine-(+/-)	N[C@@H](Cc1ccc(Cl)cc1)C(O)=O |&1:1|	Preclinical	PAH|TPH1|TPH2	tryptophan hydroxylase inhibitor		
fendiline	C[C@@H](NCCC(c1ccccc1)c1ccccc1)c1ccccc1 |&1:1|	Preclinical	HTR2B	calcium channel blocker		
fenebrutinib	C[C@H]1CN(CCN1c1ccc(Nc2cc(cn(C)c2=O)-c2ccnc(N3CCn4c5CC(C)(C)Cc5cc4C3=O)c2CO)nc1)C1COC1	Phase 2		Bruton's tyrosine kinase (BTK) inhibitor		
fenigam	NC[C@@H](CC(O)=O)c1ccccc1 |&1:2	Launched	GABBR1|GABBR2	benzodiazepine receptor agonist	neurology/psychiatry	posttraumatic stress disorder, anxiety, depression
fenipentol	CCCC[C@@H](O)c1ccccc1 |&1:4	Launched		choleretic agent	gastroenterology	bile stimulation
fenobam	CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1 |c:5|	Phase 2	GRM5	glutamate receptor antagonist		
fenofibrate	CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1	Launched	MMP25|PPARA	PPAR receptor agonist	endocrinology	hypercholesterolemia, hypertriglyceridemia
fenofibric-acid	CC(C)(Oc1ccc(cc1)C(=O)c1ccc(Cl)cc1)C(O)=O	Launched	CLCN1|PPARA	cytochrome P450 inhibitor	cardiology	dyslipidemia
fenoldopam	Oc1ccc(cc1)[C@H]1CNCCc2c(Cl)c(O)c(O)cc12 |&1:7|	Launched	DRD1|DRD4	dopamine receptor agonist	cardiology	hypertension
fenoprofen	C[C@@H](C(O)=O)c1cccc(Oc2ccccc2)c1 |&1:1|	Launched	PTGS1|SLC5A8	prostaglandin inhibitor	rheumatology	rheumatoid arthritis, osteoarthritis
fenoterol	C[C@@H](Cc1ccc(O)cc1)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:1	Withdrawn	ADRB2	adrenergic receptor agonist		
fenoverine	O=C(CN1CCN(Cc2ccc3OCOc3c2)CC1)N1c2ccccc2Sc2ccccc12	Launched		acetylcholine receptor antagonist	neurology/psychiatry	spasms
fenoxaprop-p-ethyl	CCOC(=O)[C@@H](C)Oc1ccc(Oc2nc3ccc(Cl)cc3o2)cc1	Preclinical	NOS3			
fenretinide	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(=O)Nc1ccc(O)cc1 |c:4|	Phase 3	RARA	apoptosis stimulant, retinoid receptor agonist		
fenspiride	O=C1NCC2(CCN(CCc3ccccc3)CC2)O1	Launched		bronchodilator	pulmonary, otolaryngology	asthma, otitis, sinusitis, rhinopharyngitis, laryngitis
fenthion	COP(=S)(OC)Oc1ccc(SC)c(C)c1	Launched		cholinesterase inhibitor		
fentiazac	OC(=O)Cc1sc(nc1-c1ccc(Cl)cc1)-c1ccccc1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry, rheumatology	muscle pain, joint pain
fenticonazole	Clc1ccc([C@@H](Cn2ccnc2)OCc2ccc(Sc3ccccc3)cc2)c(Cl)c1 |&1:5|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	vulvovaginal candidiasis
FERb-033	O\N=C\c1ccc(c(Cl)c1O)-c1ccc(O)c(F)c1	Preclinical	ERBB2	EGFR inhibitor		
ferroquine	CN(C)CC1=CC=C[C@@]1(CNc1ccnc2cc(Cl)ccc12)[Fe]C1C=CC=C1 |&1:8	Phase 2		antimalarial agent		
ferrostatin-1	CCOC(=O)c1ccc(NC2CCCCC2)c(N)c1	Preclinical		ferroptosis inhibitor		
ferulic-acid	COc1cc(\C=C\C(O)=O)ccc1O	Phase 2	CA1|CA12|CA14|CA2|CA4|CA6|CA9	antioxidant		
fesoterodine	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	urology	urinary incontinence
fevipiprant	Cc1c(CC(O)=O)c2cccnc2n1Cc1ccc(cc1C(F)(F)F)S(C)(=O)=O	Phase 2		prostaglandin inhibitor		
fexaramine	COC(=O)\C=C\c1cccc(c1)N(Cc1ccc(cc1)-c1ccc(cc1)N(C)C)C(=O)C1CCCCC1	Preclinical	NR1H4	FXR agonist		
fexinidazole	CSc1ccc(OCc2ncc(n2C)[N+]([O-])=O)cc1	Phase 3				
fexofenadine	CC(C)(C(O)=O)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:12|	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis, urticaria
fezolinetant	C[C@H]1N(CCn2c1nnc2-c1nc(C)ns1)C(=O)c1ccc(F)cc1	Phase 2		neurokinin receptor antagonist		
FG-2216	OC(=O)CNC(=O)c1nc(Cl)c2ccccc2c1O	Phase 2	EGLN1|EGLN2|HIF1A	hypoxia inducible factor prolyl hydroxylase inhibitor		
FG-4592	Cc1nc(C(=O)NCC(O)=O)c(O)c2ccc(Oc3ccccc3)cc12	Phase 3	EGLN1|EGLN2|EGLN3	hypoxia inducible factor prolyl hydroxylase inhibitor		
FG-7142	CNC(=O)c1cc2c(cn1)[nH]c1ccccc21	Preclinical		GABA benzodiazepine site receptor inverse agonist		
FGIN-1-27	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)-c1ccc(F)cc1	Preclinical	TSPO	inositol monophosphatase inhibitor		
FGIN-1-43	CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccc(Cl)cc12)-c1ccc(Cl)cc1	Preclinical	TSPO	benzodiazepine receptor agonist		
FH-535	Cc1cc(ccc1NS(=O)(=O)c1cc(Cl)ccc1Cl)[N+]([O-])=O	Preclinical	PPARD|PPARG	PPAR receptor antagonist, WNT signaling inhibitor		
FH1	CC(=O)Nc1ccc(Cc2ccc(NC(C)=O)cc2)cc1	Preclinical		hepatocyte function enhancer		
fiacitabine	Nc1nc(=O)n(cc1I)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F	Phase 2		DNA synthesis inhibitor		
fidarestat	NC(=O)[C@H]1C[C@]2(NC(=O)NC2=O)c2cc(F)ccc2O1 |&1:3	Phase 3	AKR1B1	aldose reductase inhibitor		
fidaxomicin	CC[C@H]1\C=C(C)\[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@@H](C\C=C(/C)\C=C(C)\[C@@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@@H]1O)[C@@H](C)O |c:3	Launched		RNA polymerase inhibitor	gastroenterology	diarrhea
filanesib	CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F |c:7|	Phase 3	KIF11	kinesin inhibitor, kinesin-like spindle protein inhibitor		
filgotinib	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1	Phase 3	JAK1|JAK2|JAK3|TYK2	JAK inhibitor		
fimasartan	CCCCc1nc(C)c(CC(=S)N(C)C)c(=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Launched	AGTR1	angiotensin receptor antagonist	cardiology	hypertension, congestive heart failure
finafloxacin	OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O	Launched		bacterial DNA gyrase inhibitor	infectious disease, pulmonary	intra-abdominal infections, chronic obstructive pulmonary disease (COPD), cystic fibrosis
finasteride	CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C |c:18|	Launched	AKR1D1|SRD5A1|SRD5A2	5 alpha reductase inhibitor	endocrinology	androgenetic alopecia
fingolimod	CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1	Launched	S1PR1|S1PR5	immunosuppressant, sphingosine 1-phosphate receptor agonist	neurology/psychiatry	multiple sclerosis
fipexide	Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1	Withdrawn		psychoactive drug		
FIPI	Fc1ccc2[nH]c(cc2c1)C(=O)NCCN1CCC(CC1)n1c2ccccc2[nH]c1=O	Preclinical	PLD1|PLD2	phospholipase inhibitor		
fipronil	Nc1c(c(nn1-c1c(Cl)cc(cc1Cl)C(F)(F)F)C#N)[S@@](=O)C(F)(F)F |&1:20	Launched		chloride channel blocker, GABA gated chloride channel blocker	infectious disease	flea control
firategrast	CCOCc1cc(OC)c(c(OC)c1)-c1ccc(C[C@H](NC(=O)c2c(F)cccc2F)C(O)=O)cc1	Phase 2	ITGA4	integrin antagonist		
firocoxib	CC1(C)OC(=O)C(OCC2CC2)=C1c1ccc(cc1)S(C)(=O)=O |c:12|	Launched	PTGS2	cyclooxygenase inhibitor	rheumatology	osteoarthritis
firsocostat	COc1ccccc1[C@H](Cn1c2sc(c(C)c2c(=O)n(c1=O)C(C)(C)C(O)=O)-c1ncco1)OC1CCOCC1	Phase 2		acetyl-CoA carboxylase inhibitor		
fisetin	Oc1ccc2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	Preclinical	CDK6|FASN	Aurora kinase inhibitor		
fisogatinib	COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1	Phase 1		fibroblast growth factor inhibitor		
FIT	CCC(=O)N(C1CCN(CCc2ccc(cc2)N=C=S)CC1)c1ccccc1	Preclinical	OPRD1	opioid receptor agonist		
FK-33-824	C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CC[S@@](C)=O |a:1	Phase 2	OPRM1	opioid receptor agonist		
FK-3311	CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1	Phase 2	PTGS2	cyclooxygenase inhibitor		
FK-409	CC\C(=C/C(=N/O)/C(N)=O)[C@@H](C)[N+]([O-])=O |&1:10	Phase 2		guanylyl cyclase activator		
FK-866	O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1	Phase 2	NAMPT	niacinamide phosphoribosyltransferase inhibitor		
FK-888	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)c1cn(C)c2ccccc12	Phase 2	TACR1|TACR2	tachykinin antagonist		
FK-962	CC(=O)N1CCC(CC1)NC(=O)c1ccc(F)cc1	Phase 2		somatostatin receptor agonist		
flavin-adenine-dinucleotide	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO[P@@](O)(=O)O[P@@](O)(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)c2cc1C |a:15	Preclinical	ACAD8|ACADM|ACADS|ACOX1|AIFM1|CYB5R1|CYB5R3|DAO|DLD|DPYD|ERO1LB|FDXR|GCDH|GFER|GSR|IL4I1|IVD|MAOA|MAOB|NOS1|NQO1|NQO2|POR|TXNRD1|XDH			
flavoxate	Cc1c(oc2c(cccc2c1=O)C(=O)OCCN1CCCCC1)-c1ccccc1	Launched	CHRM1|CHRM2	acetylcholine receptor antagonist	urology	urinary incontinence, interstitial cystitis (IC), urethritis, prostatitis
flecainide	FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC1CCCCN1	Launched	KCNA5|KCNA7|SCN5A	sodium channel blocker	cardiology	ventricular tachycardia (VT), atrial fibrillation (AF), ventricular arrhythmias
fleroxacin	CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O	Launched	TOP2A	topoisomerase inhibitor	infectious disease, gastroenterology	gonorrhea, enteritis, diarrhea, respiratory tract infections
FLI-06	CC1=NC2=C([C@@H](C1C(=O)OC1CCCCC1)c1ccc(cc1)[N+]([O-])=O)C(=O)CC(C)(C)C2 |&1:5	Preclinical		notch signaling inhibitor		
flibanserin	FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1	Launched	DRD4|HTR1A|HTR2A	serotonin receptor agonist	neurology/psychiatry	hypoactive sexual desire disorder
flindokalner	COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F	Phase 3	KCNMA1|KCNN4|KCNQ2|KCNQ4|KCNQ5	potassium channel agonist		
floctafenine	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2c(cccc12)C(F)(F)F |&1:2	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
flopropione	CCC(=O)c1c(O)cc(O)cc1O	Launched	HTR1A	serotonin receptor antagonist	neurology/psychiatry	spasms
florfenicol	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl	Launched		protein synthesis inhibitor	pulmonary	bovine respiratory disease (BRD)
florifenine	FC(F)(F)c1ccc2c(Nc3ccccc3C(=O)OCCN3CCCC3)ccnc2c1	Preclinical		anti-inflammatory agent		
flosequinan	Cn1cc([S@@](C)=O)c(=O)c2ccc(F)cc12 |r|	Withdrawn		phosphodiesterase inhibitor		
floxuridine	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O	Launched	TYMS	DNA synthesis inhibitor	oncology	colorectal cancer
FLT3-IN-1	CCCNc1nc(Nc2ccc(cc2)C#N)ncc1C#CCCCNC(=O)[C@H](C)N(C)C(=O)\C=C\CN(C)C	Preclinical		FLT3 inhibitor		
flubendazole	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccc(F)cc1	Launched	TUBB	tubulin polymerization inhibitor	infectious disease	gastrointestinal parasites
flucloxacillin	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1c(F)cccc1Cl	Launched		bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology, dermatology, gastroenterology	gram-positive bacterial infections, tonsillitis, sinusitis, pneumonia, eczema, endocarditis, meningitis, enteritis, bacterial septicemia
fluconazole	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Launched	CYP51A1	sterol demethylase inhibitor	infectious disease	esophageal candidiasis, meningitis
flucytosine	Nc1nc(=O)[nH]cc1F	Launched	DNMT1	other antifungal	infectious disease	bacterial septicemia, endocarditis, urinary tract infections, meningitis
fludarabine	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	ADA|DCK|POLA1|RRM1|RRM2	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludarabine-phosphate	Nc1nc(F)nc2n(cnc12)[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O	Launched	POLA1|POLD1|POLE|RRM1|RRM2|RRM2B	ribonucleotide reductase inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
fludrocortisone-acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |t:15|	Launched	NR3C2		endocrinology	Addison's disease, adrenogenital syndrome
fludroxycortide	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |t:11|	Launched	NR3C1|SERPINA6	glucocorticoid receptor agonist	infectious disease, dermatology	skin infections, psoriasis
flufenamic-acid	OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Preclinical	AKR1C3|ANO1|AR|GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1|PANX1|PANX2|PANX3|PKD2L1|PTGS1|PTGS2|TRPC5|TRPM2|TRPM5	chloride channel blocker		
flumatinib	CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Phase 3	ABL1|PDGFRB	Bcr-Abl kinase inhibitor		
flumazenil	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	Launched	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ	benzodiazepine receptor antagonist	neurology/psychiatry	sedative
flumecinol	CC[C@@](O)(c1ccccc1)c1cccc(c1)C(F)(F)F |&1:2	Launched				
flumequine	C[C@H]1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O |&1:1	Launched		topoisomerase inhibitor	infectious disease	urinary tract infections
flumethasone	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:12	Launched	NR3C1|PLA2G1B	glucocorticoid receptor agonist	otolaryngology, infectious disease, dermatology	otitis, ear infections, corticosteroid-responsive dermatoses
flumethasone-pivalate	C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C(C)(C)C |c:12	Launched	NR3C1|SERPINA6	glucocorticoid receptor agonist	allergy	allergic rhinitis
flumexadol	FC(F)(F)c1cccc(c1)[C@H]1CNCCO1 |&1:10	Preclinical				
flunarizine	Fc1ccc(cc1)C(N1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	Launched	CACNA1G|CACNA1H|CACNA1I|CALM1|HRH1	calcium channel blocker	neurology/psychiatry, cardiology	migraine headache, vertigo, peripheral artery disease (PAD)
flunisolide	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15	Launched	NR3C1	cytochrome P450 inhibitor	allergy	allergic rhinitis
flunixin-meglumin	Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F	Launched		prostanoid receptor antagonist	pulmonary	bovine respiratory disease (BRD)
fluocinolone-acetonide	CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:15	Launched	NR3C1|SERPINA6	glucocorticoid receptor agonist	dermatology	seborrheic dermatitis
fluocinonide	CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]21C |c:25	Launched	NR3C1|SERPINA6|SMO	glucocorticoid receptor agonist	dermatology	seborrheic dermatitis, eczema
fluorescein	Oc1ccc2c(Oc3cc(O)ccc3C22OC(=O)c3ccccc23)c1	Launched	SLC22A6		ophthalmology	ophthalmology diagnostic
fluorometholone		Launched	NR3C1	glucocorticoid receptor agonist	ophthalmology	eye inflammation
fluorometholone-acetate	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12 |c:26	Launched	NR3C1		ophthalmology	eye inflammation
fluoromethylcholine	C[N+](C)(CF)CCO	Launched				
fluoxetine	CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1	Launched	ANO1|HTR2B|SLC6A4	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), bulimia nervosa, panic disorders, bipolar disorder
flupentixol	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	ADRA1A|CHRM1|DRD1|DRD2|DRD3|DRD5|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia, depression
fluphenazine	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	CALM1|DRD1|DRD2|DRD5|HRH1|HTR2A|HTR6|HTR7	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
fluphenazine-decanoate	CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	DRD2|HTR1B|HTR4	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
flupirtine	CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N	Launched	ADRA2A|KCNQ1|KCNQ2	glutamate receptor antagonist	neurology/psychiatry	pain relief
fluprazine	NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F	Phase 1	HTR1A|HTR1B	serotonin receptor agonist		
fluralaner	Cc1cc(ccc1C(=O)NCC(=O)NCC(F)(F)F)C1=NO[C@](C1)(c1cc(Cl)cc(Cl)c1)C(F)(F)F |&1:22	Preclinical		GABA receptor antagonist		
flurbiprofen-(+/-)	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1	Launched		cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis, osteoarthritis
flurbiprofen-(S)-(+)	C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis, osteoarthritis
flurbiprofen-axetil	C[C@H](OC(C)=O)OC(=O)[C@H](C)c1ccc(c(F)c1)-c1ccccc1 |&1:9	Launched		analgesic agent		
flurizan	C[C@@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1	Phase 3	APH1B|BACE1|IKBKG|PSEN1|PSEN2|PTGS1|PTGS2	gamma secretase inhibitor		
flurofamide	NP(N)(=O)NC(=O)c1ccc(F)cc1	Preclinical		urease inhibitor		
flurothyl	FC(F)(F)COCC(F)(F)F	Preclinical				
fluroxene	FC(F)(F)COC=C	Preclinical		local anesthetic		
fluspirilene	Fc1ccc(cc1)C(CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1)c1ccc(F)cc1	Launched	CACNG1|DRD2|HRH1|HTR1A|HTR1D|HTR1E|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
flutamide	CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Launched	AHR|AR	androgen receptor antagonist	oncology	prostate cancer
fluticasone-propionate	CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)SCF |c:18	Launched	NR3C1|NR3C2|PGR|PLA2G4A	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
flutrimazole	Fc1ccc(cc1)C(c1ccccc1)(c1ccccc1F)n1ccnc1 |&1:7|	Launched		sterol demethylase inhibitor	infectious disease	mycosis
fluvastatin	CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)c(-c2ccc(F)cc2)c2ccccc12	Launched	HMGCR	HMGCR inhibitor	endocrinology, cardiology	hypercholesterolemia, congenital heart defects
fluvoxamine	COCCCC\C(=N/OCCN)c1ccc(cc1)C(F)(F)F	Launched	SLC6A4	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	obsessive compulsive disorder (OCD)
fmoc-L-leucine	CC(C)C[C@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	Phase 2		PPAR receptor agonist		
FN-1501	CN1CCN(Cc2ccc(NC(=O)c3[nH]ncc3Nc3ncnc4[nH]ccc34)cc2)CC1	Phase 1		tyrosine kinase inhibitor		
folic-acid	Nc1nc(=O)c2nc(CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2[nH]1	Launched	FOLR2|FOLR3|SLC19A1|SLC46A1	folate receptor ligand	hematology	megaloblastic anemia
fomepizole	Cc1cn[nH]c1	Launched	ADH1A|ADH1B|ADH1C|AKR1A1|CAT	alcohol dehydrogenase inhibitor	critical care	poison antidote
fomocaine	C(CN1CCOCC1)Cc1ccc(COc2ccccc2)cc1	Launched		voltage-gated sodium channel modulator	neurology/psychiatry	local anesthetic
fondaparinux	[H][C@@]1(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@H](O[C@@]3([H])[C@H](O)[C@@H](OS(O)(=O)=O)[C@H](O[C@@]4([H])[C@H](O)[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@@H]4COS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](NS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]([C@@H](O[C@@]2([H])O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]2NS(O)(=O)=O)[C@H](O)[C@H]1O)C(O)=O	Launched	F10|SERPINC1	coagulation factor inhibitor	hematology	deep vein thrombosis (DVT)
foretinib	COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1	Phase 2	FLT1|FLT4|KDR|MET	VEGFR inhibitor		
formestane	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C(=O)C(=O)CC[C@]34C)[C@@H]1CCC2=O |a:1	Launched	CYP19A1	aromatase inhibitor	oncology	breast cancer
formononetin	COc1ccc(cc1)-c1coc2cc(O)ccc2c1=O	Preclinical	ADH1C|SLC5A2	alcohol dehydrogenase inhibitor		
formoterol	COc1ccc(C[C@H](C)NC[C@@H](O)c2ccc(O)c(NC=O)c2)cc1	Launched	ADRB2	adrenergic receptor agonist	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm
forodesine	OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O	Launched	PNP	purinergic receptor antagonist	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
foropafant	CC(C)c1cc(C(C)C)c(-c2csc(n2)N(CCN(C)C)Cc2cccnc2)c(c1)C(C)C	Phase 3	PTAFR	platelet activating factor receptor antagonist		
forskolin	CC(=O)O[C@H]1[C@@H](O)[C@H]2C(C)(C)CC[C@H](O)[C@]2(C)[C@@]2(O)C(=O)C[C@@](C)(O[C@]12C)C=C	Launched	ADCY2|ADCY5|GNAS	adenylyl cyclase activator		
fosamprenavir	CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1	Launched		HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
fosaprepitant-dimeglumine	C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Launched	TACR1	tachykinin antagonist	gastroenterology	nausea, vomiting
fosbretabulin	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O	Phase 3	CDH5	tubulin polymerization inhibitor, VE-cadherin antagonist		
foscarnet	OC(=O)P(O)(O)=O	Launched		DNA polymerase inhibitor	infectious disease	cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)
fosfestrol	CC\C(=C(\CC)c1ccc(OP(O)(O)=O)cc1)c1ccc(OP(O)(O)=O)cc1	Launched	ESR1|ESR2	synthetic estrogen	oncology	prostate cancer
fosfluconazole	OP(O)(=O)OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F	Preclinical		other antifungal		
fosfomycin	C[C@@H]1O[C@@H]1P(O)(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections
fosfosal	OC(=O)c1ccccc1OP(O)(O)=O	Launched	PTGS1|PTGS2	phosphodiesterase inhibitor	neurology/psychiatry	pain relief
fosfructose	O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)C(=O)COP(O)(O)=O	Phase 3		fructose diphosphate stimulant		
fosinopril	CCC(=O)O[C@@H](OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C |a:5	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension, congestive heart failure
fosinoprilat	OC(=O)[C@@H]1C[C@H](CN1C(=O)C[P@](O)(=O)CCCCc1ccccc1)C1CCCCC1 |a:3	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension
fosphenytoin	OP(O)(=O)OCN1C(=O)NC(C1=O)(c1ccccc1)c1ccccc1	Launched	SCN5A	sodium channel blocker	neurology/psychiatry	epilepsy, seizures
fostamatinib	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC	Launched	SYK	SYK inhibitor	hematology	chronic immune thrombocytopenia (ITP)
fostemsavir	COc1cnc(-n2cnc(C)n2)c2n(COP(O)(O)=O)cc(C(=O)C(=O)N3CCN(CC3)C(=O)c3ccccc3)c12	Phase 3		antiviral		
fotemustine	CCOP(=O)(OCC)[C@@H](C)NC(=O)N(CCCl)[NH2+][O-] |&1:8	Launched		thioredoxin inhibitor	oncology	melanoma
foxy-5	CSCC[C@H](NC=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O	Phase 2	WNT5A	WNT5a peptide mimetic		
FPA-124		Preclinical		AKT inhibitor		
FPH1-(BRD-6125)	Cc1ccc(Cl)cc1N(CC(=O)Nc1c(F)cccc1F)S(C)(=O)=O	Preclinical		hepatocyte function enhancer		
FPL-12495	CC(N)(Cc1ccccc1)c1ccccc1 |&1:1|	Phase 1		glutamate receptor antagonist		
FPL-55712	CCCc1c(OC[C@@H](O)COc2ccc3c(oc(cc3=O)C(O)=O)c2CCC)ccc(C(C)=O)c1O |&1:7	Phase 1		leukotriene receptor antagonist		
FPL-62064	COc1ccc(Nc2ccn(n2)-c2ccccc2)cc1	Phase 2		cyclooxygenase inhibitor, lipoxygenase inhibitor		
FPL-64176	COC(=O)c1c(C)[nH]c(C)c1C(=O)c1ccccc1Cc1ccccc1	Preclinical	CACNA1C|CACNA1S	calcium channel activator		
FPS-ZM1	Clc1ccc(cc1)C(=O)N(Cc1ccccc1)C1CCCCC1	Preclinical	AGER	RAGE receptor antagonist		
FR-122047	COc1ccc(cc1)-c1nc(sc1-c1ccc(OC)cc1)C(=O)N1CCN(C)CC1	Preclinical		cyclooxygenase inhibitor		
FR-139317	CC(C)C[C@H](NC(=O)N1CCCCCC1)C(=O)N[C@H](Cc1cn(C)c2ccccc12)C(=O)N[C@H](Cc1ccccn1)C(O)=O	Phase 1	EDNRA	endothelin receptor antagonist		
FR-180204	Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1	Preclinical	MAPK1|MAPK3	MAP kinase inhibitor		
FRAX486	CCn1c2nc(Nc3ccc(N4CCNCC4)c(F)c3)ncc2cc(-c2ccc(Cl)cc2Cl)c1=O	Preclinical	PAK1|PAK2|PAK3|PAK4	serine/threonine kinase inhibitor		
frentizole	COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1	Phase 1		immunosuppressant		
freselestat	CC(C)[C@@H](NC(=O)Cn1c(ncc(N)c1=O)-c1ccccc1)[C@@H](O)c1nnc(o1)C(C)(C)C	Preclinical	CELA1|ELANE	elastase inhibitor		
frovatriptan	CN[C@@H]1CCc2[nH]c3ccc(cc3c2C1)C(N)=O	Launched	HTR1A|HTR1B|HTR1D	serotonin receptor agonist	neurology/psychiatry	migraine headache
fruquintinib	CNC(=O)c1c(C)oc2cc(Oc3ncnc4cc(OC)c(OC)cc34)ccc12	Launched	KDR	VEGFR inhibitor	oncology	colorectal cancer
ftaxilide	Cc1cccc(C)c1NC(=O)c1ccccc1C(O)=O	Preclinical				
ftorafur	Fc1cn([C@H]2CCCO2)c(=O)[nH]c1=O	Launched	TYMS	thymidylate synthase inhibitor	oncology	colorectal cancer
FT011	COc1cc(\C=C\C(=O)Nc2ccccc2C(O)=O)ccc1OCC#C	Preclinical		TGF beta receptor inhibitor		
fucoxanthin	[H]C(=[C@@]=C1C(C)(C)C[C@@H](C[C@@]1(C)O)OC(C)=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]12O[C@@]1(C)C[C@H](O)CC2(C)C	Phase 2		anticancer agent		
fudosteine	N[C@@H](CSCCCO)C(O)=O	Launched		mucolytic agent	pulmonary	chest congestion
fulvestrant	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@H](CCCCCCCCC[S@@](=O)CCCC(F)(F)C(F)(F)F)Cc1cc(O)ccc31 |a:1	Launched	ESR1|ESR2|GPER1	estrogen receptor antagonist	oncology	breast cancer
fumagillin	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O |a:2	Launched	METAP2	methionine aminopeptidase inhibitor	infectious disease	microsporidiosis
fumonisin-B1	CCCC[C@@H](C)[C@@H](OC(=O)C[C@@H](CC(O)=O)C(O)=O)[C@H](C[C@@H](C)C[C@H](O)CCCC[C@@H](O)C[C@H](O)[C@H](C)N)OC(=O)C[C@@H](CC(O)=O)C(O)=O	Preclinical	CERS1			
funapide	FC(F)(F)c1ccc(CN2C(=O)[C@@]3(COc4cc5OCOc5cc34)c3ccccc23)o1	Preclinical		sodium channel blocker		
furagin	[O-][N+](=O)c1ccc(\C=C\C=N\N2CC(=O)NC2=O)o1	Preclinical		antibacterial		
furaltadone	[O-][N+](=O)c1ccc(\C=N\N2C[C@@H](CN3CCOCC3)OC2=O)o1 |&1:11	Launched		bacterial DNA inhibitor	infectious disease	gram-negative bacterial infections
furamidine	NC(=N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=N	Preclinical	PRMT1	protein arginine N-methyltransferase inhibitor		
furazolidone	[O-][N+](=O)c1ccc(\C=N\N2CCOC2=O)o1	Launched		bacterial DNA inhibitor	gastroenterology, infectious disease	diarrhea, enteritis, cholera
furegrelate	OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1	Phase 1	TBXAS1	thromboxane synthase inhibitor		
furosemide	NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl	Launched	CA2|GPR35|SLC12A1|SLC12A2	diuretic	cardiology, rheumatology	edema, hypertension, congestive heart failure, nephrotic syndrome
fursultiamine	C\C(N(Cc1cnc(C)nc1N)C=O)=C(\CCO)SSC[C@H]1CCCO1 |&1:21|	Launched		vitamin B	metabolism	thiamine deficiency
furvina	[O-][N+](=O)C(\Br)=C/c1ccc(Br)o1	Preclinical		quorum sensing signaling inhibitor		
fusidic-acid	C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)[C@H]2[C@H](O)C[C@H]2\C([C@H](C[C@]12C)OC(C)=O)=C(/CCC=C(C)C)C(O)=O	Launched		bacterial 30S ribosomal subunit inhibitor	dermatology	acne vulgaris (AV)
futibatinib	COc1cc(OC)cc(c1)C#Cc1nn([C@H]2CCN(C2)C(=O)C=C)c2ncnc(N)c12	Phase 3		FGFR inhibitor		
F351	Cc1ccc(=O)n(c1)-c1ccc(O)cc1	Phase 2	TGFB1	TGF beta receptor inhibitor		
g-caryophyllene	C\C1=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]2CC1 |c:1|	Preclinical	ACHE	acetylcholinesterase inhibitor		
G-1	CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br |c:11|	Preclinical	GPER1	G protein-coupled receptor agonist		
G-15	Brc1cc2OCOc2cc1[C@H]1Nc2ccccc2[C@H]2C=CC[C@@H]12 |&1:10	Preclinical	GPER1	estrogen receptor antagonist		
G-749	CN1CCC(CC1)Nc1nc(Nc2ccc(Oc3ccccc3)cc2)c2c(O)ncc(Br)c2n1	Preclinical		tyrosine kinase inhibitor		
GABA-linoleamide	CCCCC\C=C/C\C=C/CCCCCCCC(=O)NCCCC(O)=O	Phase 2		benzodiazepine receptor agonist		
gabapentin	NCC1(CC(O)=O)CCCCC1	Launched	ADORA1|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1E|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNA2D4|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CACNG2|CACNG3|CACNG4|CACNG5|CACNG6|CACNG7|CACNG8|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	calcium channel blocker	infectious disease, neurology/psychiatry	virus herpes simplex (HSV), shingles, seizures, restless leg syndrome
gabapentin-enacarbil	CC(C)C(=O)O[C@@H](C)OC(=O)NCC1(CC(O)=O)CCCCC1 |&1:6	Launched	CACNA1G	adrenergic receptor agonist	neurology/psychiatry	restless leg syndrome, postherpetic neuralgia
gabazine	COc1ccc(cc1)-c1ccc(=N)n(CCCC(O)=O)n1	Preclinical	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRG2	GABA receptor antagonist		
gabexate	CCOC(=O)c1ccc(OC(=O)CCCCCNC(N)=N)cc1	Launched	PRSS1|TPSAB1	serine protease inhibitor	gastroenterology	pancreatitis
gaboxadol	O=c1[nH]oc2CNCCc12	Phase 3	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRD|GABRR1|GABRR2|GABRR3	benzodiazepine receptor agonist		
gadobutrol	[H]O[C@@H](CO)[C@H](CO)N1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C3)OC(=O)C2 |&1:2	Launched		radiopaque medium	radiology	MRI contrast agent
gadodiamide	CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	Launched		radiopaque medium	radiology	MRI contrast agent
gadopentetic-acid	OC(=O)CN1CCN2CCN(CC(O)=O)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2	Launched	PGD	contrast agent	radiology	contrast agent
gadoterate-meglumine	OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1	Launched		radiopaque medium	radiology	MRI contrast agent
gadoteridol	C[C@@H](O)CN1CCN2CCN3CCN(CC1)CC(=O)O[Gd](OC(=O)C2)OC(=O)C3 |&1:1	Launched		radiopaque medium	radiology	MRI contrast agent
GAL-021	CCCNc1nc(NCCC)nc(n1)N(C)OC	Preclinical		calcium channel blocker		
galantamine	COc1ccc2CN(C)CC[C@@]34C=C[C@H](O)C[C@@H]3Oc1c24 |c:12|	Launched	ACHE|BCHE|CHRNA1|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB1|CHRNB2|CHRNB3|CHRNB4|CHRND|CHRNE|CHRNG	acetylcholinesterase inhibitor	neurology/psychiatry	senile dementia
galeterone	[H][C@@]12CC=C(n3cnc4ccccc34)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C |t:3	Phase 3	AR|CYP17A1	androgen receptor modulator		
galidesivir	Nc1ncnc2c(c[nH]c12)[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O	Phase 1		antiviral		
gallamine-triethiodide	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	Launched	CHRM2|CHRNA1	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant
gallic-acid	OC(=O)c1cc(O)c(O)c(O)c1	Preclinical	CA1|CA12|CA14|CA2|CA4|CA6|CA9|SELP	beta amyloid protein neurotoxicity inhibitor, PPAR receptor agonist		
gallium-triquinolin-8-olate	O([Ga](Oc1cccc2cccnc12)Oc1cccc2cccnc12)c1cccc2cccnc12	Phase 1				
gallopamil	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC |&1:13|	Launched	ATP2A2	L-type calcium channel blocker	cardiology	hypertension, cardiac arrythmia
gambogic-acid	CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C |c:22	Phase 2	BCL2	caspase activator		
gamithromycin	[H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C	Preclinical		antibacterial 		
gamma-aminobutyric-acid	NCCCC(O)=O	Preclinical	GABBR1|GABBR2|GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2|GATM|KCTD12|KCTD16|KCTD8|SLC6A1	benzodiazepine receptor agonist		
gamma-linolenic-acid	CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O	Phase 2	PTGS1|PTGS2	cyclooxygenase inhibitor, prostanoid receptor agonist		
ganaxolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6	GABA receptor modulator		
ganciclovir	Nc1nc(=O)c2ncn(COC(CO)CO)c2[nH]1	Launched		DNA polymerase inhibitor	infectious disease	cytomegalovirus (CMV)
ganetespib	CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O	Phase 3	HSP90AA1	HSP inhibitor		
ganoderic-acid-a	[H][C@@]12C[C@H](O)C3=C(C(=O)C[C@]4(C)[C@H](C[C@H](O)[C@@]34C)[C@H](C)CC(=O)C[C@@H](C)C(O)=O)[C@@]1(C)CCC(=O)C2(C)C |t:5|	Preclinical		JAK inhibitor		
GANT-58	c1cc(ccn1)-c1sc(c(c1-c1ccncc1)-c1ccncc1)-c1ccncc1	Preclinical	GLI1	GLI antagonist		
GANT-61	CN(C)c1ccccc1CN1CCCN(Cc2ccccc2N(C)C)C1c1ccncc1	Preclinical	GLI1|GLI2	GLI antagonist		
garenoxacin	C[C@H]1NCc2cc(ccc12)-c1ccc2c(c1OC(F)F)n(cc(C(O)=O)c2=O)C1CC1	Launched	TOP2A	topoisomerase inhibitor	infectious disease	respiratory tract infections
gastrodin	OC[C@H]1O[C@@H](Oc2ccc(CO)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2				
gatifloxacin	COc1c(N2CCN[C@@H](C)C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1 |&1:8|	Withdrawn		bacterial DNA gyrase inhibitor		
gavestinel	OC(=O)c1[nH]c2cc(Cl)cc(Cl)c2c1\C=C\C(=O)Nc1ccccc1	Phase 3	GLRB|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B	glutamate receptor antagonist		
GBR-12783	C(CN1CCN(C\C=C\c2ccccc2)CC1)OC(c1ccccc1)c1ccccc1	Preclinical		dopamine reuptake inhibitor		
GBR-12935	C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1	Preclinical	AGTR1|SLC6A3	dopamine reuptake inhibitor		
GBR-13069	Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1	Preclinical	SLC6A3	dopamine reuptake inhibitor		
GDC-0068	CC(C)NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2[C@H](O)C[C@@H](C)c12)c1ccc(Cl)cc1	Phase 3	AKT1|AKT2|AKT3|PRKG1	AKT inhibitor		
GDC-0077	C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O	Phase 1		PI3K inhibitor		
GDC-0084	CC1(C)OCCn2c1nc1c(nc(nc21)-c1cnc(N)nc1)N1CCOCC1	Phase 2		mTOR inhibitor, PI3K inhibitor		
GDC-0152	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1C(=O)Nc1snnc1-c1ccccc1	Phase 1	BIRC2|BIRC3|BIRC7|XIAP	XIAP inhibitor		
GDC-0349	CCNC(=O)Nc1ccc(cc1)-c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1	Phase 1	PIK3CA	Pim kinase inhibitor		
GDC-0575	N[C@@H]1CCCN(C1)c1c(Br)cnc2[nH]cc(NC(=O)C3CC3)c12	Phase 1		CHK inhibitor		
GDC-0623	OCCONC(=O)c1ccc2cncn2c1Nc1ccc(I)cc1F	Phase 1		MEK inhibitor		
GDC-0810	CC\C(=C(\c1ccc(\C=C\C(O)=O)cc1)c1ccc2n[nH]cc2c1)c1ccc(F)cc1Cl	Phase 2	ESR1	selective estrogen receptor destabilizer		
GDC-0834	CN1CCN(C)C(=O)[C@@H]1c1ccc(Nc2nc(cn(C)c2=O)-c2cccc(NC(=O)c3cc4CCCCc4s3)c2C)cc1 |&1:8	Phase 1	BTK	Bruton's tyrosine kinase (BTK) inhibitor		
GDC-0879	OCCn1cc(c(n1)-c1ccncc1)-c1ccc2\C(CCc2c1)=N\O	Preclinical	BRAF	RAF inhibitor		
GDC-0927	CC1=C([C@@H](Oc2ccc(O)cc12)c1ccc(OCCN2CC(CF)C2)cc1)c1cccc(O)c1 |t:1|	Phase 1		estrogen receptor antagonist		
GDC-0941	CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)-c2cccc3n[nH]cc23)CC1	Phase 2	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
GDC-0980	C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1	Phase 2	FGR|MAP3K9|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|SYK	mTOR inhibitor, PI3K inhibitor		
GDC-0994	Cn1nccc1Nc1nccc(n1)-c1ccn([C@@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |&1:17	Phase 1	MAPK1|MAPK3	MAP kinase inhibitor		
gedunin	CC(=O)O[C@@H]1C[C@H]2C(C)(C)C(=O)C=C[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](OC(=O)[C@H]4O[C@@]34[C@]12C)c1ccoc1 |c:12|	Preclinical	HSP90AA1	HSP inhibitor		
gefapixant	COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O	Phase 3		purinergic receptor antagonist		
gefitinib	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1	Launched	EGFR	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
geldanamycin	CO[C@H]1C[C@H](C)CC2=C(OC)C(=O)C=C(NC(=O)\C(C)=C\C=C\[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7	Preclinical	HSP90AA1	HSP inhibitor		
gemcadiol	CC(C)(CO)CCCCCCC(C)(C)CO	Phase 2		antilipemic		
gemcitabine	Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Launched	CMPK1|RRM1|RRM2|TYMS	ribonucleotide reductase inhibitor	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC), pancreatic cancer
gemcitabine-elaidate	CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O	Phase 1	CMPK1|RRM1|TYMS	apoptosis inhibitor, DNA synthesis inhibitor		
gemfibrozil	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1	Launched	LPL|PPARA|SLCO1B1|SLCO1B3|SLCO2B1	lipoprotein lipase activator	endocrinology, cardiology	hyperlipidemia, coronary heart disease
gemifloxacin	CO\N=C1/CN(C[C@@H]1CN)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)C1CC1 |&1:7|	Launched		bacterial DNA gyrase inhibitor	pulmonary, infectious disease	bronchitis, pneumonia
gemigliptin	N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F	Launched		dipeptidyl peptidase inhibitor		
genipin	COC(=O)C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO |c:13	Preclinical		choleretic agent		
geniposide	COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO |c:25	Preclinical	GLP1R	GLP receptor agonist		
geniposidic-acid	OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H]3CC=C(CO)[C@@H]23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |c:8	Preclinical		cyclooxygenase inhibitor		
genistein	Oc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Phase 2/Phase 3	CFTR|ESR1|ESR2|ESRRA|ESRRB|ESRRG|NCOA1|NCOA2|PPARG|PTK2B|TOP2A|TRPC5	tyrosine kinase inhibitor		
gentamycin	CN[C@H](C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	Launched	HSPA8	bacterial 50S ribosomal subunit inhibitor	infectious disease, critical care	bone and joint infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, sepsis
gentiopicrin	OC[C@H]1O[C@@H](O[C@@H]2OC=C3C(=O)OCC=C3[C@H]2C=C)[C@H](O)[C@@H](O)[C@@H]1O |c:14	Phase 3	GRIN2B	glutamate receptor downregulator		
genz-123346	CCCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1	Preclinical	UGCG	glucosylceramidase inhibitor		
genz-644282	CNCCn1c2c3cc4OCOc4cc3ncc2c2cc(OC)c(OC)cc2c1=O	Phase 1	TOP1	topoisomerase inhibitor		
gepefrine	C[C@@H](N)Cc1cccc(O)c1 |&1:1	Launched		adrenergic receptor agonist	cardiology	hypotension
gepon	CC(C)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCCCN)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](N)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O |a:3	Phase 1				
gepotidacin	O=c1ccc2ncc(=O)n3[C@H](CN4CCC(CC4)NCc4cc5CCCOc5cn4)Cn1c23	Phase 2		topoisomerase inhibitor		
geranyl-farnesylacetate	CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C	Phase 2		mucin production enhancer		
gestodene	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1C=C[C@@]2(O)C#C |c:20	Launched		contraceptive agent	endocrinology	contraceptive
gestrinone	CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C |c:3	Launched	AR|ESR1|PGR	progesterone receptor antagonist	obstetrics/gynecology	endometriosis
GF109203X	CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc12 |t:9|	Preclinical	PDPK1|PIM1|PRKCI|PRKCZ	PKC inhibitor		
GGsTop	COP(=O)(CC[C@@H](N)C(O)=O)Oc1cccc(CC(O)=O)c1 |&1:2	Preclinical	GGT1	gamma glutamyltransferase Inhibitor		
GGTI-298	COC(=O)[C@H](CC(C)C)NC(=O)c1ccc(NC[C@@H](N)CS)cc1-c1cccc2ccccc12	Preclinical	CDKN1A	GGTase inhibitor		
gilteritinib	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(CC3)N3CCN(C)CC3)c(OC)c2)nc1NC1CCOCC1	Launched	FLT3	FLT3 inhibitor		
gimeracil	Oc1cc(=O)[nH]cc1Cl	Launched	DPYD	dihydropyrimidine dehydrogenase inhibitor	oncology	gastric adenocarcinoma
ginkgolide-A	C[C@@H]1C(=O)O[C@H]2C[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Preclinical	GLRA1|GLRB	GABA receptor antagonist		
ginkgolide-B	C[C@@H]1C(=O)O[C@H]2[C@H](O)[C@@]34[C@H]5C[C@@H](C(C)(C)C)[C@@]33[C@@H](O)C(=O)O[C@H]3O[C@@]4(C(=O)O5)[C@@]12O	Phase 3	GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B	platelet activating factor receptor antagonist		
ginsenoside-C-K	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 1	PTGS2	NFkB pathway inhibitor, nitric oxide synthase inhibitor		
ginsenoside-RD	CC(C)=CCC[C@@](C)(O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9	Phase 3		calcium channel blocker		
ginsenoside-RE	[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O)C(C)(C)[C@]3([H])[C@H](C[C@@]21C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Phase 1		anti-inflammatory agent		
ginsenoside-RE3	CC(C)=CCC[C@@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C |a:9	Launched	KCNH2	angiogenesis inhibitor, apoptosis stimulant		
givinostat	CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1	Phase 3	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	HDAC inhibitor		
GKA-50	COC[C@H](C)Oc1cc(O[C@@H](C)Cc2ccccc2)cc(c1)C(=O)Nc1ccc(cn1)C(O)=O	Preclinical	GCK	glucokinase activator		
GKT137831	CN(C)c1cccc(c1)-c1n(C)c(=O)cc2[nH]n(-c3ccccc3Cl)c(=O)c12	Phase 2	NOX1|NOX4	NADPH oxidase inhibitor		
GK921	C(CN1CCCC1)Oc1nc2cccnc2nc1C#Cc1ccccc1	Preclinical	TGM2	transglutaminase inhibitor		
glafenine	OC[C@@H](O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12 |&1:2|	Withdrawn	CFTR	DeltaF508-CFTR Correctors		
glasdegib	CN1CC[C@H](C[C@@H]1c1nc2ccccc2[nH]1)NC(=O)Nc1ccc(cc1)C#N	Launched	SMO	hedgehog pathway inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
glecaprevir	[H]\C1=C([H])/C(F)(F)c2nc3ccccc3nc2O[C@@]2([H])CN(C(=O)[C@@]([H])(NC(=O)O[C@]3([H])CCC[C@@]3([H])OC1)C(C)(C)C)[C@@]([H])(C2)C(=O)N[C@@]1(C[C@@]1([H])C(F)F)C(=O)NS(=O)(=O)C1(C)CC1 |t:1|	Launched		serine protease inhibitor	infectious disease	hepatitis C
glesatinib	COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccc(F)cc4)cc3F)c2s1	Phase 2		tyrosine kinase inhibitor		
gliclazide	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@@H]2C1 |&1:16	Launched		ATP channel blocker, insulin secretagogue	endocrinology	diabetes mellitus
glimepiride	CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]2CC[C@H](C)CC2)C1=O |r	Launched	ABCC8|KCNJ1|KCNJ11	insulin secretagogue	endocrinology	diabetes mellitus
glipizide	Cc1cnc(cn1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	ABCC8|KCNJ10|KCNJ11|PPARG	sulfonylurea	endocrinology	diabetes mellitus, hyperglycemia
gliquidone	COc1ccc2c(c1)C(=O)N(CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)C(=O)C2(C)C	Launched	ABCC8|KCNJ10|KCNJ8	sulfonylurea	endocrinology	diabetes mellitus
Gln-1062	COc1ccc2CN(C)CC[C@@]34C=C[C@@H](C[C@@H]3Oc1c24)OC(=O)c1ccccc1 |c:12|	Preclinical		cholinesterase inhibitor		
GLPG0187	COc1ccc(cc1)S(=O)(=O)N[C@@H](CNc1nc(C)nc(N2CCC(CC2)c2ccc3CCCNc3n2)c1C)C(O)=O	Phase 1		integrin antagonist		
GLPG0492	CN1C(=O)N(C(=O)[C@@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	Phase 1	AR	androgen receptor modulator		
GLPG0492-R-enantiomer	CN1C(=O)N(C(=O)[C@]1(CO)c1ccccc1)c1ccc(C#N)c(c1)C(F)(F)F	Phase 1	AR	androgen receptor modulator		
GLPG1837	CC1(C)Cc2c(sc(NC(=O)c3cc[nH]n3)c2C(N)=O)C(C)(C)O1	Phase 2		CFTR channel potentiator		
glucaric-acid	O[C@@H]([C@H](O)[C@@H](O)C(O)=O)[C@H](O)C(O)=O	Phase 1				
gluconolactone	OC[C@@H]1OC(=O)[C@@H](O)[C@H](O)[C@H]1O	Launched	LCT			
glucosamine	N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	IL1B	glycosylated protein precursor	neurology/psychiatry, rheumatology	muscle pain, rheumatoid arthritis, joint pain, backache
glutathione	N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O	Phase 3	ESD|GGT1|GLO1|GLRX|GLRX2|GPX1|GPX2|GPX3|GPX4|GPX5|GPX6|GPX7|GPX8|GSR|GSS|GSTA1|GSTA2|GSTA3|GSTA4|GSTA5|GSTK1|GSTM1|GSTM2|GSTM3|GSTM4|GSTM5|GSTO1|GSTO2|GSTP1|GSTT1|GSTZ1|HAGH|HPGDS|LTC4S|MGST1|MGST2|MGST3|TXNDC12	antioxidant		
glutathione-monoisopropyl-ester	CC(C)OC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O	Phase 2		lipid peroxidase inhibitor		
gly-gln	NCC(=O)N[C@@H](CCC(N)=O)C(O)=O	Phase 2				
glyburide	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1	Launched	ABCA1|ABCB11|ABCC8|ABCC9|CFTR|CPT1A|KCNJ1|KCNJ11|KCNJ5|KCNJ8|SLCO2B1	ATP channel blocker, insulin secretagogue, sulfonylurea	endocrinology	diabetes mellitus, hyperglycemia
glycerol-monolaurate	CCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:15	Launched		beta lactamase inhibitor		
glycerol-phenylbutyrate	O=C(CCCc1ccccc1)OCC(COC(=O)CCCc1ccccc1)OC(=O)CCCc1ccccc1	Phase 1		sigma receptor ligand		
glycitein	COc1cc2c(cc1O)occ(-c1ccc(O)cc1)c2=O	Phase 3	TNF	tumor necrosis factor release inhibitor		
glycopyrrolate	C[N+]1(C)CC[C@@H](C1)OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:5	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
GM-1485	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O	Preclinical	FKBP1A	immunophilin ligand		
GMX1778	Clc1ccc(OCCCCCCN\C(NC#N)=N\c2ccncc2)cc1	Phase 1/Phase 2	NAMPT	NAMPT inhibitor		
GNE-7915	CCNc1nc(Nc2cc(F)c(cc2OC)C(=O)N2CCOCC2)ncc1C(F)(F)F	Preclinical		leucine rich repeat kinase inhibitor		
GNF-2	NC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	Preclinical	ABL1|BCR	Bcr-Abl kinase inhibitor		
GNF-5	OCCNC(=O)c1cccc(c1)-c1cc(Nc2ccc(OC(F)(F)F)cc2)ncn1	Preclinical	ABL1|BCR	Bcr-Abl kinase inhibitor		
GNF-5837	Cc1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)cc1Nc1ccc2\C(=C\c3ccc[nH]3)C(=O)Nc2c1	Preclinical	NTRK1|NTRK2|NTRK3	growth factor receptor inhibitor		
GNF-7	CN1C(=O)N(Cc2cnc(Nc3ccc(C)nc3)nc12)c1cc(NC(=O)c2cccc(c2)C(F)(F)F)ccc1C	Preclinical	GCK|TNK2	glucokinase inhibitor, protein kinase inhibitor		
GNTI	NC(=N)Nc1ccc2[nH]c3[C@@H]4Oc5c6c(C[C@H]7N(CC8CC8)CC[C@@]46[C@@]7(O)Cc3c2c1)ccc5O	Preclinical	OPRK1|OPRM1	opioid receptor antagonist		
go-6983	COc1ccc2n(CCCN(C)C)cc(C3=C(C(=O)NC3=O)c3c[nH]c4ccccc34)c2c1 |t:15|	Preclinical	PRKCA|PRKCB|PRKCD|PRKCG|PRKCZ	protein kinase inhibitor		
golgicide-A	Fc1cc(F)c2N[C@@H]([C@@H]3CC=C[C@@H]3c2c1)c1cccnc1 |a:8	Preclinical	GBF1	ARF inhibitor		
golvatinib	CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1	Phase 2	KDR|MET	VEGFR inhibitor		
gonadorelin	CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Launched	GNRHR	gonadotropin releasing factor hormone receptor agonist	obstetrics/gynecology	cystic ovaries, reproductive synchrony
goserelin-acetate	CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O	Launched	GNRHR|LHCGR	gonadotropin releasing factor hormone receptor agonist	oncology, obstetrics/gynecology	prostate cancer, breast cancer, endometriosis
gossypol	CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O	Phase 2	BCL2	BCL inhibitor, MCL1 inhibitor		
GPBAR-A	Fc1ccccc1-c1ccnc2OCC(=O)N(Cc3cc(cc(c3)C(F)(F)F)C(F)(F)F)Cc12	Preclinical	GPBAR1	G protein-coupled receptor agonist		
GPI-1046	CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1	Preclinical	FKBP1A	FKBP inhibitor		
GPi-688	OC[C@H](O)CN1C(=O)[C@@H](Cc2ccccc12)NC(=O)c1cc2cc(Cl)sc2[nH]1 |a:2	Preclinical		glycogen phosphorylase inhibitor		
GPP-78	O=C(CCCCCCCn1cc(nn1)-c1cccnc1)Nc1ccccc1-c1ccccc1	Preclinical	NAMPT	NAMPT inhibitor		
GPR120-modulator-1	Cc1cc(OCc2nc(cs2)-c2ccccc2Cl)ccc1OCC(O)=O	Preclinical	FFAR4	G protein-coupled receptor modulator		
GP1a	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NN2CCCCC2)c1	Preclinical	CNR2	cannabinoid receptor agonist		
GP2a	Cc1ccc-2c(Cc3c(nn(c-23)-c2ccc(Cl)cc2Cl)C(=O)NC2CCCCC2)c1	Preclinical	CNR2	cannabinoid receptor agonist		
GR-103691	COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1	Preclinical	DRD3	dopamine receptor antagonist		
GR-113808	Cn1cc(C(=O)OCC2CCN(CCNS(C)(=O)=O)CC2)c2ccccc12	Preclinical	HTR4	serotonin receptor antagonist		
GR-127935	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1N1CCN(C)CC1	Preclinical	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6	serotonin receptor antagonist		
GR-135531	COC(=O)Nc1ccc2[nH]cc(CCNC(C)=O)c2c1	Preclinical		melatonin receptor agonist		
GR-144053	NC(=N)c1ccc(cc1)N1CCN(CC1)C1CCN(CC(O)=O)CC1	Preclinical	ITGA2B|ITGB3	integrin antagonist		
GR-159897	COC1(C[S@@](=O)c2ccccc2)CCN(CCc2c[nH]c3ccc(F)cc23)CC1	Preclinical	TAC1|TACR2	tachykinin antagonist		
GR-235	[H][C@@]12CC(=O)C(=CC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |t:20|	Launched	NR1H4	estrogen receptor agonist, FXR antagonist, progesterone receptor agonist		
GR-79236	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@H]3CCC[C@@H]3O)ncnc12	Phase 1	ADORA1|ADORA2A	adenosine receptor agonist		
gramicidin	CC(C)C[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCO	Launched		bacterial permeability inducer	infectious disease	first-aid antibiotic
gramine	CN(C)Cc1c[nH]c2ccccc12	Preclinical		norepinephrine reputake inhibitor		
granisetron	CN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12 |&1:2	Launched	HTR3A	serotonin receptor antagonist	gastroenterology	nausea, vomiting
grapiprant	CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCNC(=O)NS(=O)(=O)c2ccc(C)cc2)cc1	Launched	PTGER4	prostaglandin inhibitor	rheumatology	osteoarthritis
grazoprevir	COc1ccc2nc3CCCCC[C@@H]4C[C@H]4OC(=O)N[C@H](C(=O)N4C[C@@H](C[C@H]4C(=O)N[C@@]4(C[C@H]4C=C)C(=O)NS(=O)(=O)C4CC4)Oc3nc2c1)C(C)(C)C	Launched		HCV inhibitor	infectious disease	hepatitis C
griseofulvin	COC1=CC(=O)C[C@@H](C)[C@]11Oc2c(C1=O)c(OC)cc(OC)c2Cl |t:2|	Launched	KRT12	tubulin polymerization inhibitor	infectious disease	ringworm, tinea pedis
GR125487	COc1[nH]c2ccc(F)cc2c1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical	HTR4	serotonin receptor antagonist		
GR46611	COc1ccc(CNC(=O)\C=C\c2ccc3[nH]cc(CCN(C)C)c3c2)cc1	Preclinical	HTR1D	serotonin receptor agonist		
GS-143	OC(=O)c1ccc(cc1)N1N=C(Cc2ccccc2)\C(=C/c2ccc(o2)-c2ccccc2F)C1=O |t:11|	Preclinical	BTRC|NFKBIA	ubiquitin ligase inhibitor		
GS-39783	CSc1nc(NC2CCCC2)c(c(NC2CCCC2)n1)[N+]([O-])=O	Preclinical	GABBR1	GABA receptor modulator		
GS-6201	CCCn1c(=O)n(CC)c2nc([nH]c2c1=O)-c1cnn(Cc2cccc(c2)C(F)(F)F)c1	Phase 1	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
GS-9620	CCCCOc1nc(N)c2NC(=O)CN(Cc3cccc(CN4CCCC4)c3)c2n1	Phase 2	TLR7	toll-like receptor agonist		
GS-967	FC(F)(F)Oc1ccc(cc1)-c1ccc2nnc(n2c1)C(F)(F)F	Preclinical		voltage-gated sodium channel blocker		
GS-9973	C1CN(CCO1)c1ccc(Nc2nc(cn3ccnc23)-c2ccc3c[nH]nc3c2)cc1	Phase 2	SYK	SYK inhibitor		
GSK-J1	OC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	Preclinical	KDM6B	histone demethylase inhibitor		
GSK-J2	OC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	Preclinical		histone demethylase inhibitor		
GSK-J4	CCOC(=O)CCNc1cc(nc(n1)-c1ccccn1)N1CCc2ccccc2CC1	Preclinical	KDM6A|KDM6B	histone lysine demethylase inhibitor		
GSK-J5	CCOC(=O)CCNc1cc(nc(n1)-c1cccnc1)N1CCc2ccccc2CC1	Preclinical		histone demethylase control		
GSK-LSD-1	C1[C@@H](NC2CCNCC2)[C@@H]1c1ccccc1	Preclinical	KDM1A	histone lysine demethylase inhibitor		
GSK-3-inhibitor-IX	O\N=C1/C(/Nc2ccccc/12)=C1/C(=O)Nc2cc(Br)ccc12	Preclinical	GSK3A|GSK3B	glycogen synthase kinase inhibitor, lipoxygenase inhibitor		
GSK0660	COC(=O)c1sccc1S(=O)(=O)Nc1ccc(Nc2ccccc2)cc1OC	Preclinical	PPARD	PPAR receptor antagonist		
GSK1059615	O=C1NC(=O)\C(S1)=C\c1ccc2nccc(-c3ccncc3)c2c1	Phase 1	PIK3CG	PI3K inhibitor		
GSK1070916	CCn1cc(c(n1)-c1ccc(NC(=O)N(C)C)cc1)-c1ccnc2[nH]c(cc12)-c1cccc(CN(C)C)c1	Phase 1	AURKA|AURKB|AURKC|CYP2D6|CYP3A4	Aurora kinase inhibitor		
GSK1292263	CC(C)c1noc(n1)N1CCC(COc2ccc(nc2)-c2ccc(cc2)S(C)(=O)=O)CC1	Phase 2	GRPR	glucose dependent insulinotropic receptor agonist		
GSK1562590	CN([C@@H](CN1CCCC1)c1ccc(cc1)-c1cccc(c1)C(N)=O)C(=O)CN1C(=O)COc2cc(Cl)c(Cl)cc12	Preclinical	UTS2R	urotensin receptor antagonist		
GSK163090	Cc1ccc2c(cccc2n1)N1CCN(CCc2cccc(c2)N2CCNC2=O)CC1	Phase 2	HTR1A|HTR1B|HTR1D	serotonin receptor antagonist		
GSK1838705A	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3N(CCc3cc2OC)C(=O)CN(C)C)nc2[nH]ccc12	Preclinical	ALK|IGF1R|INSR|RPS6KA1	insulin growth factor receptor inhibitor		
GSK189254	CNC(=O)c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	Phase 2		histamine receptor antagonist		
GSK1904529A	CCc1cc(Nc2nccc(n2)-c2c(nc3ccccn23)-c2ccc(OC)c(c2)C(=O)Nc2c(F)cccc2F)c(OC)cc1N1CCC(CC1)N1CCN(CC1)S(C)(=O)=O	Preclinical	IGF1R|INSR	IGF-1 inhibitor, insulin growth factor receptor inhibitor, insulin receptor ligand		
GSK2110183	Cn1ncc(Cl)c1-c1cc(sc1Cl)C(=O)N[C@H](CN)Cc1cccc(F)c1	Phase 2	AKT1|AKT2|AKT3	AKT inhibitor		
GSK2126458	COc1ncc(cc1NS(=O)(=O)c1ccc(F)cc1F)-c1ccc2nccc(-c3ccnnc3)c2c1	Phase 1	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG	mTOR inhibitor, PI3K inhibitor		
GSK2190915	CCOc1ccc(cn1)-c1ccc(Cn2c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c3cc(OCc4ccc(C)cn4)ccc23)cc1	Phase 2	ALOX5AP	lipoxygenase inhibitor		
GSK2193874	FC(F)(F)c1cccc(c1)-c1nc2cc(Br)ccc2c(C(=O)NC2(CC2)c2ccccc2)c1CN1CCC(CC1)N1CCCCC1	Preclinical	TRPV4	transient receptor potential channel antagonist		
GSK2194069	O=C(C1CC1)N1CC[C@@H](Cc2n[nH]c(=O)n2-c2ccc(cc2)-c2ccc3occc3c2)C1	Preclinical	FASN	fatty acid synthase inhibitor		
GSK2239633A	COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12	Preclinical		CC chemokine receptor antagonist		
GSK2256098	CONC(=O)c1ccccc1Nc1cc(Nc2cc(C)nn2C(C)C)ncc1Cl	Phase 2		kinase inhibitor		
GSK2256294A	CNc1nc(C)nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)n1	Phase 1	EPHX2	epoxide hydolase inhibitor		
GSK2330672	CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1	Phase 2	SLC10A2	bile acid transporter inhibitor		
GSK2334470	CNc1nc(cc(n1)-c1ccc2c(N)[nH]nc2c1)N1C[C@H](CC[C@H]1C)C(=O)NC1CCCCC1	Preclinical	AURKA|AURKB|PDPK1	phosphoinositide dependent kinase inhibitor		
GSK239512	O=C1CCCN1c1ccc(Oc2ccc3CCN(CCc3c2)C2CCC2)nc1	Preclinical		histamine receptor antagonist		
GSK256066	COc1cccc(Nc2c(cnc3c(C)cc(cc23)S(=O)(=O)c2cccc(c2)C(=O)N(C)C)C(N)=O)c1	Phase 2	PDE4A	phosphodiesterase inhibitor		
GSK2578215A	Fc1cc(ccn1)-c1ccc(OCc2ccccc2)c(c1)C(=O)Nc1cccnc1	Preclinical	LRRK2	leucine rich repeat kinase inhibitor		
GSK2606414	Cn1cc(-c2ccc3N(CCc3c2)C(=O)Cc2cccc(c2)C(F)(F)F)c2c(N)ncnc12	Preclinical	EIF2AK3|MYLK2	protein kinase inhibitor		
GSK2636771	Cc1nc2c(cc(cc2n1Cc1cccc(c1C)C(F)(F)F)N1CCOCC1)C(O)=O	Phase 2	PIK3CB	PI3K inhibitor		
GSK2656157	Cc1cccc(CC(=O)N2CCc3c2ccc(-c2cn(C)c4ncnc(N)c24)c3F)n1	Preclinical		PERK inhibitor		
GSK269962	CCn1c(nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc12)-c1nonc1N	Preclinical	ROCK1|ROCK2	rho associated kinase inhibitor		
GSK2801	CCCOc1ccn2c(cc(-c3ccccc3S(C)(=O)=O)c2c1)C(C)=O	Preclinical	BAZ2A|BAZ2B	bromodomain inhibitor		
GSK2816126	CC[C@H](C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCNCC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	Phase 1	EZH2	histone lysine methyltransferase inhibitor		
GSK2830371	Cc1ncc(Cl)cc1NCc1ccc(s1)C(=O)N[C@@H](CC1CCCC1)C(=O)NC1CC1	Preclinical	PPM1D	protein phosphatase inhibitor		
GSK2837808A	COc1ncc(-c2ccc3c(Nc4cc(Oc5cc(F)cc(F)c5)cc(c4)C(O)=O)c(cnc3c2)S(=O)(=O)NC2CC2)c(OC)n1	Preclinical	LDHA	lactate dehydrogenase inhibitor		
GSK2838232	CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@]2(CC1=O)[C@@H](O)CN(CCN(C)C)Cc1ccc(Cl)cc1 |c:3|	Phase 2		HIV gag inhibitor		
GSK2879552	OC(=O)c1ccc(CN2CCC(CN[C@@H]3C[C@H]3c3ccccc3)CC2)cc1	Phase 1/Phase 2	KDM1A	histone lysine demethylase inhibitor		
GSK2881078	C[C@H](CS(C)(=O)=O)n1ccc2c(c(ccc12)C#N)C(F)(F)F	Phase 2		androgen receptor modulator		
GSK2981278	CCc1ccc(cc1)N(CC(C)C)S(=O)(=O)c1ccc(OCC2CCOCC2)c(CO)c1	Phase 1/Phase 2		ROR modulator		
GSK2982772	CN1c2ccccc2OC[C@H](NC(=O)c2nc(Cc3ccccc3)n[nH]2)C1=O	Phase 2		RIPK inhibitor		
GSK3117391	ONC(=O)CCc1ccc(CN[C@@H](C2CCCCC2)C(=O)OC2CCCC2)cn1	Phase 1/Phase 2		HDAC inhibitor		
GSK3179106	CCOc1cc(=O)[nH]cc1-c1ccc(CC(=O)Nc2cc(on2)C(C)(C)C(F)(F)F)c(F)c1	Phase 1		RET tyrosine kinase inhibitor		
GSK3326595	CC(=O)N1CCC(CC1)Nc1cc(ncn1)C(=O)NC[C@H](O)CN1CCc2ccccc2C1	Phase 1/Phase 2		protein arginine N-methyltransferase inhibitor		
GSK356278	CCn1ncc2c(NC3CCOCC3)c(cnc12)-c1nnc(Cc2sc(C)nc2C)o1	Preclinical		phosphodiesterase inhibitor		
GSK369796	CC(C)(C)NCc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1O	Phase 1		potassium channel antagonist		
GSK37647	COc1ccc(cc1)S(=O)(=O)Nc1c(C)cc(C)cc1C	Preclinical	FFAR4	free fatty acid receptor agonist		
GSK3787	FC(F)(F)c1ccc(nc1)S(=O)(=O)CCNC(=O)c1ccc(Cl)cc1	Preclinical	PPARD	PPAR receptor antagonist		
GSK429286A	CC1=C([C@@H](CC(=O)N1)c1ccc(cc1)C(F)(F)F)C(=O)Nc1cc2c[nH]nc2cc1F |&1:3	Preclinical	ROCK1	rho associated kinase inhibitor		
GSK461364	C[C@@H](Oc1cc(sc1C(N)=O)-n1cnc2ccc(CN3CCN(C)CC3)cc12)c1ccccc1C(F)(F)F	Phase 1	PLK1	PLK inhibitor		
GSK503	CC(C)n1cc(C)c2c(cc(cc12)-c1ccc(nc1)N1CCN(C)CC1)C(=O)NCc1c(C)cc(C)[nH]c1=O	Preclinical	EZH2	histone lysine methyltransferase inhibitor		
GSK650394	OC(=O)c1ccc(cc1C1CCCC1)-c1c[nH]c2ncc(cc12)-c1ccccc1	Preclinical	SGK1|SGK2	serum/glucocorticoid regulated kinase inhibitor		
GSK656	NC[C@H]1OB(O)c2c1c(Cl)ccc2OCCO	Preclinical		leucyl-tRNA synthetase inhibitor		
GSK690693	CCn1c(nc2c(ncc(OC[C@H]3CCCNC3)c12)C#CC(C)(C)O)-c1nonc1N	Phase 1	AKT1|AKT2|AKT3|PAK4|PAK6|PAK7|PRKCQ|PRKG1|PRKX	AKT inhibitor		
GSK9027	Fc1ccc(cc1)-n1ncc2cc(ccc12)-c1ccc(NS(=O)(=O)Cc2ccccc2)cc1C(F)(F)F	Preclinical	NR3C1	glucocorticoid receptor agonist		
GSK923295	CC(C)Oc1ccc(cc1Cl)C(=O)N[C@H](CNC(=O)CN(C)C)Cc1ccc(cc1)-c1cn2cccc([C@H](C)O)c2n1	Phase 1	CENPE	centromere associated protein inhibitor		
GTP-14564	c1ccc(cc1)-c1[nH]nc2c3ccccc3oc12	Preclinical	CSF1R|FLT3|KIT|PDGFRB	FLT3 inhibitor, tyrosine kinase inhibitor		
GTS21	COc1ccc(\C=C2/CCCN=C2c2cccnc2)c(OC)c1 |c:11|	Phase 1/Phase 2	CHRNA7	cholinergic receptor agonist		
guacetisal	COc1ccccc1OC(=O)c1ccccc1OC(C)=O	Launched		immunosuppressant	pulmonary	cough suppressant
guadecitabine	Nc1ncn([C@H]2C[C@H](OP(O)(=O)OC[C@H]3O[C@H](C[C@@H]3O)n3cnc4c3[nH]c(N)nc4=O)[C@@H](CO)O2)c(=O)n1	Phase 3		DNA methyltransferase inhibitor		
guaiacol	COc1ccccc1O	Launched	CA2	local anesthetic	pulmonary	cough suppressant
guaifenesin	COc1ccccc1OC[C@@H](O)CO |&1:10	Launched		expectorant	pulmonary	cough suppressant
guanaben-acetate	NC(=N)N\N=C\c1c(Cl)cccc1Cl	Launched	ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	cardiology	hypertension
guanadrel	NC(=N)NC[C@H]1COC2(CCCCC2)O1 |&1:5|	Launched		adrenergic inhibitor	cardiology	hypertension
guancydine	CCC(C)(C)NC(=N)NC#N	Preclinical		antihypertensive agent		
guanethidine	NC(=N)NCCN1CCCCCCC1	Launched	SLC6A2	adrenergic inhibitor	cardiology	hypertension
guanfacine	NC(=N)NC(=O)Cc1c(Cl)cccc1Cl	Launched	ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	cardiology	hypertension
guanidine	NC(N)=N	Launched	ALDH2|DLG4|GAMT|RNASE1	HSP inhibitor	neurology/psychiatry	Lambert-Eaton myasthenic syndrome (LEMS)
guanidinoethyldisulfide-bicarbonate	NC(=N)NCCSSCCNC(N)=N	Phase 2	NOS2	nitric oxide synthase inhibitor		
guanidinopropionic-acid	NC(=N)NCCC(O)=O	Phase 2	CKM	creatine kinase inhibitor		
guanosine	Nc1nc(=O)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	Preclinical	PNP			
Gue-1654	CSc1nc2ccc3nc(NC(=O)C(c4ccccc4)c4ccccc4)sc3c2s1	Preclinical	OXER1	oxoeicosanoid receptor modulator		
guvacine	OC(=O)C1=CCCNC1 |t:3|	Preclinical	SLC6A1|SLC6A11|SLC6A12|SLC6A13	GABA uptake inhibitor		
GW-0742	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F	Preclinical	PPARD	PPAR receptor agonist		
GW-1100	CCOC(=O)c1ccc(cc1)-n1cc(Cc2cnc(OCC)nc2)c(=O)nc1SCc1ccc(F)cc1	Preclinical	FFAR1	G protein-coupled receptor agonist		
GW-1929	CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1	Preclinical	PPARG	PPAR receptor agonist		
GW-2580	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1	Preclinical	CSF1R	cFMS kinase inhibitor		
GW-311616	CC(C)[C@H]1[C@H]2[C@@H](CCN2C(=O)\C=C\CN2CCCCC2)N(C1=O)S(C)(=O)=O	Phase 1	ELANE	elastase inhibitor, leukocyte elastase inhibitor		
GW-3965	OC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)Cc2cccc(c2Cl)C(F)(F)F)c1	Preclinical	NR1H2|NR1H3	LXR agonist		
GW-405833	COc1ccc2n(C(=O)c3cccc(Cl)c3Cl)c(C)c(CCN3CCOCC3)c2c1	Preclinical	CNR2	cannabinoid receptor agonist		
GW-4064	CC(C)c1onc(c1COc1ccc(\C=C\c2cccc(c2)C(O)=O)c(Cl)c1)-c1c(Cl)cccc1Cl	Preclinical	NR1H4	FXR agonist		
GW-438014A	O=C(Nc1nc2ccccc2n1CCc1ccccc1)c1ccccc1	Preclinical	NPY5R	neuropeptide receptor antagonist		
GW-441756	Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12	Preclinical	NTRK1	growth factor receptor inhibitor		
GW-501516	Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(cc1)C(F)(F)F	Phase 2	PPARA|PPARD	PPAR receptor agonist		
GW-5074	Oc1c(Br)cc(C=C2C(=O)Nc3ccc(I)cc23)cc1Br	Phase 1/Phase 2	NTRK1|RAF1	leucine rich repeat kinase inhibitor, RAF inhibitor		
GW-542573X	COc1ccccc1NC(=O)OCC1CCN(CC1)C(=O)OC(C)(C)C	Preclinical	KCNN1	calcium channel activator		
GW-583340	CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	Preclinical	EGFR|ERBB2	EGFR inhibitor		
GW-627368	CCOc1c2CN(C(=O)c2c(OCC)c2ccccc12)c1ccc(CC(=O)NS(=O)(=O)c2ccccc2)cc1	Preclinical	PTGER4	prostanoid receptor antagonist		
GW-6471	CCC(=O)NC[C@H](Cc1ccc(OCCc2nc(oc2C)-c2ccccc2)cc1)N\C(C)=C/C(=O)c1ccc(cc1)C(F)(F)F	Preclinical	PPARA	PPAR receptor antagonist		
GW-7647	CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)cc1)C(O)=O	Preclinical	PPARA	PPAR receptor agonist		
GW-788388	O=C(NC1CCOCC1)c1ccc(cc1)-c1cc(ccn1)-c1c[nH]nc1-c1ccccn1	Preclinical	LCK|MAPK14|TGFBR1	ALK tyrosine kinase receptor inhibitor		
GW-803430	COc1cc(ccc1OCCN1CCCC1)-n1cnc2cc(sc2c1=O)-c1ccc(Cl)cc1	Phase 1	KCNH2|MCHR1	melanin inhibitor		
GW-842166	FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1	Phase 2	CNR2	cannabinoid receptor agonist		
GW-843682X	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(s3)C(N)=O)c2cc1OC	Preclinical	PLK1|PLK3	PLK inhibitor		
GW-9508	OC(=O)CCc1ccc(NCc2cccc(Oc3ccccc3)c2)cc1	Preclinical	FFAR1|FFAR4	free fatty acid receptor agonist, G protein-coupled receptor agonist		
GW-9662	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1	Preclinical	NCOA2|PPARG|RXRA	PPAR receptor antagonist		
GW274150	CC(=N)NCCSCC[C@H](N)C(O)=O	Phase 2		nitric oxide synthase inhibitor		
GYKI-52466	CC1=NN=C(c2ccc(N)cc2)c2cc3OCOc3cc2C1 |t:1	Preclinical	GRIA1|GRIA2|GRIA3|GRIA4	glutamate receptor antagonist		
gynostemma-extract	CC(C)=CCC[C@](C)(O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 2		calcium channel modulator		
GZD824	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4n[nH]cc4c3)cc2C(F)(F)F)CC1	Preclinical	ABL1|BCR	Bcr-Abl kinase inhibitor		
G007-LK	CS(=O)(=O)c1ccc(nc1)-c1nnc(\C=C\c2nnc(o2)-c2ccc(cc2)C#N)n1-c1ccccc1Cl	Preclinical	TNKS|TNKS2	tankyrase inhibitor		
H-151	CCc1ccc(NC(=O)Nc2c[nH]c3ccccc23)cc1	Preclinical		STING antagonist		
H-89	Brc1ccc(\C=C\CNCCNS(=O)(=O)c2cccc3cnccc23)cc1	Preclinical	GSG2|PKIA|PRKACA	PKA inhibitor		
HA-1004	NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12	Phase 2		calcium channel blocker		
HA-130	OB(O)c1cccc(COc2ccc(\C=C3/SC(=O)N(Cc4ccc(F)cc4)C3=O)cc2)c1	Preclinical	ENPP2	autotaxin inhibitor		
HA-966-(R)-(+)	N[C@@H]1CCN(O)C1=O	Preclinical	GRIA1	glutamate receptor agonist		
HA-966-(S)-(-)	N[C@H]1CCN(O)C1=O	Preclinical	GRIA1	glutamate receptor antagonist		
halazone	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cl)Cl	Launched			infectious disease	disinfectant
halcinonide	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl |t:10|	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
halobetasol-propionate	CCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CCl |c:18	Launched	NR3C1|PLA2G1B	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
halofantrine	CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(ccc12)C(F)(F)F |&1:11|	Launched	KCNN4	antimalarial agent	infectious disease	malaria
halofuginone	O[C@H]1CCCN[C@@H]1CC(=O)Cn1cnc2cc(Br)c(Cl)cc2c1=O	Launched	COL1A1|MMP2	collagenase inhibitor	rheumatology	scleroderma
halopemide	Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O	Phase 2	PLD1|PLD2	phospholipase inhibitor		
haloperidol	OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Launched	DRD1|DRD2|DRD3|DRD4|DRD5|GRIN2B|HRH1|HTR1A|HTR1D|HTR2A|HTR2B|HTR7|KCNH1	dopamine receptor antagonist	neurology/psychiatry	schizophrenia, Tourette's disorder
haloperidol-decanoate	CCCCCCCCCC(=O)OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1	Launched	DRD2|DRD3|DRD4|HTR2A	psychoactive drug	neurology/psychiatry	schizophrenia
haloprogin	Clc1cc(Cl)c(OCC#CI)cc1Cl	Launched		other antifungal	infectious disease	tinea pedis
halothane	FC(F)(F)[C@@H](Cl)Br |&1:4	Launched	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK12|KCNK13|KCNK15|KCNK18|KCNK2|KCNK3|KCNK9	glutamate receptor antagonist	neurology/psychiatry	general anaesthetic
harmane	Cc1nccc2c3ccccc3[nH]c12	Preclinical	MAOA|MAOB	monoamine oxidase inhibitor		
harringtonine	[H][C@@]12[C@H](OC(=O)[C@@](O)(CCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 |c:21|	Phase 3		protein synthesis inhibitor		
HA14-1	CCOC(=O)[C@@H](C#N)[C@H]1C(C(=O)OCC)=C(N)Oc2ccc(Br)cc12 |&1:5	Preclinical	BCL2	BCL inhibitor		
HBED	OC(=O)CN(CCN(CC(O)=O)Cc1ccccc1O)Cc1ccccc1O	Phase 3		chelating agent		
HC-030031	CC(C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1	Phase 1	TRPA1	TRPA1 channel blocker		
HC-067047	Cc1c(cc(-c2ccccc2)n1CCCN1CCOCC1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical	TRPV4	transient receptor potential channel antagonist		
HC-070	Cn1c2nc(Oc3cccc(Cl)c3)n(Cc3ccc(Cl)cc3)c2c(=O)n(CCCO)c1=O	Preclinical		transient receptor potential channel antagonist		
heclin	CCc1ccc(\C=C\C(=O)Nc2ccc(cc2)C(C)=O)o1	Preclinical	NEDD4|SMURF2|WWP1	ubiquitin ligase inhibitor		
HEMADO	CCCCC#Cc1nc(NC)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor agonist		
hematoporphyrin	C[C@@H](O)c1c(C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C)c5[C@@H](C)O)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C |&1:25	Launched			neurology/psychiatry	depression, psychosis
hematoxylin	Oc1ccc2[C@H]3c4cc(O)c(O)cc4C[C@@]3(O)COc2c1O	Preclinical				
hemin	CC1=C(CCC(O)=O)\C2=C\c3c(CCC(O)=O)c(C)c4\C=C5/N=C(/C=c6/c(C=C)c(C)\c(=C\C1=N2)n6[Fe](O)n34)C(C)=C5C=C |c:1	Launched		enzyme inducer	hematology, cardiology	acute intermittent porphyria (AIP), hypertension, ventricular tachycardia (VT)
hemomex-s	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3[C@@H](O)C[C@@]21C	Launched	PPARG			
hepsulfam	NS(=O)(=O)OCCCCCCCOS(N)(=O)=O	Preclinical		DNA cross-linking		
heptaminol	C[C@@H](N)CCCC(C)(C)O |&1:1|	Launched		vasoconstrictor	cardiology	hypotension
HER2-Inhibitor-1	Cc1cc(Nc2ncnc3ccc(cc23)-c2ccc(CNCCS(C)(=O)=O)o2)ccc1Oc1ccn2ncnc2c1	Preclinical		EGFR inhibitor		
hesperadin	CCS(=O)(=O)Nc1ccc2NC(=O)\C(=C(/Nc3ccc(CN4CCCCC4)cc3)c3ccccc3)c2c1	Preclinical	AURKB	Aurora kinase inhibitor		
hesperetin	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	Launched	DGAT1|MTTP|SOAT1|SOAT2	ACAT inhibitor		
hesperidin	COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1	Launched	AURKB|CACNA1B	flavanone glycoside		
hetacillin	CC1(C)S[C@@H]2[C@H](N3C(=O)[C@H](NC3(C)C)c3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched		bacterial cell wall synthesis inhibitor	obstetrics/gynecology	mastitis
hexachlorophene	Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl	Launched	GLUD1|SDHD	potassium channel activator	infectious disease	gram-positive bacterial infections
hexamethonium	C[N+](C)(C)CCCCCC[N+](C)(C)C	Preclinical	CHRNA2|CHRNA3|CHRNA4|CHRNA6	cholinergic receptor antagonist		
hexamethylenebisacetamide	CC(=O)NCCCCCCNC(C)=O	Phase 2	AKT1	AKT inhibitor, differentiation inducer, NFKB pathway inhibitor		
hexaminolevulinate	CCCCCCOC(=O)CCC(=O)CN	Launched			radiology	diagnostic agent
hexasodium-phytate	OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O	Phase 2				
hexestrol	CC[C@@H]([C@@H](CC)c1ccc(O)cc1)c1ccc(O)cc1	Launched	AKR1C1|ESR1|ESR2	synthetic estrogen	endocrinology	hypoestrogenism
hexetidine	CCCC[C@H](CC)CN1CN(C[C@H](CC)CCCC)C[C@](C)(N)C1 |&1:12	Launched		local anesthetic	otolaryngology, infectious disease, dental, gastroenterology	pharyngitis, meningitis, laryngitis, gingivitis, ulcerative colitis
hexonic-acid	OC[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O |&1:2	Preclinical				
hexoprenaline	O[C@@H](CNCCCCCCNC[C@@H](O)c1ccc(O)c(O)c1)c1ccc(O)c(O)c1 |&1:1	Launched	ADRB2	adrenergic receptor agonist	pulmonary	asthma
hexylcaine	C[C@@H](CNC1CCCCC1)OC(=O)c1ccccc1 |&1:1|	Launched	SCN5A	sodium channel blocker	neurology/psychiatry	local anesthetic
hexylene-glycol	C[C@@H](O)CC(C)(C)O |&1:1	Preclinical	AKR1C3|CTPS1|DLG4|HSP90AA1|NOS3|PGF|PLA2G1B|PTPN1|SELP			
hexylresorcinol	CCCCCCc1ccc(O)cc1O	Launched	TYR	local anesthetic	infectious disease	skin infections, first-aid antiseptic
higenamine	Oc1ccc(C[C@H]2NCCc3cc(O)c(O)cc23)cc1 |&1:6|	Phase 1	ADRB2	adrenergic receptor agonist		
hippuric-acid	OC(=O)CNC(=O)c1ccccc1	Preclinical				
histamine	NCCc1cnc[nH]1	Launched	HRH1|HRH2|HRH3|HRH4	histamine receptor agonist	allergy	allergic rhinitis
HJC-0350	Cc1cc(C)n(c1)S(=O)(=O)c1c(C)cc(C)cc1C	Preclinical	RAPGEF4	GTPase inhibitor		
HKI-357	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 1	EGFR	EGFR inhibitor		
HLCL-61	CCn1c2ccccc2c2cc(CNCc3ccccc3OC)ccc12	Preclinical	PRMT5	protein arginine N-methyltransferase inhibitor		
HM-30181	COc1cc2CCN(CCc3ccc(cc3)-n3nnc(n3)-c3cc(OC)c(OC)cc3NC(=O)c3cc(=O)c4ccccc4o3)Cc2cc1OC	Phase 1		P glycoprotein inhibitor		
HMN-214	COc1ccc(cc1)S(=O)(=O)N(C(C)=O)c1ccccc1\C=C\c1cc[n+]([O-])cc1	Phase 1	PLK1	PLK inhibitor		
HOKU-81	CC(C)(C)NC[C@H](O)c1ccc(O)cc1Cl |r|	Preclinical		bronchodilator		
homatropine	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:2	Launched	CHRM1	acetylcholine receptor antagonist	ophthalmology	uveal tract inflammation, pupil dilation
homatropine-methylbromide	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](O)c1ccccc1 |a:3	Launched	CHRM5	acetylcholine receptor antagonist	ophthalmology	uveal tract inflammation
homidium	CC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	Preclinical				
homochlorcyclizine		Launched	HRH1	antihistamine	allergy	allergic rhinitis
homoharringtonine	COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC |c:39|	Launched	RPL3	protein synthesis inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
homoquinolinic-acid	OC(=O)Cc1cccnc1C(O)=O	Preclinical	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor agonist		
homosalate	C[C@H]1C[C@@H](CC(C)(C)C1)OC(=O)c1ccccc1O |&1:1	Preclinical		HSP inducer		
homoveratrylamine	COc1ccc(CCN)cc1OC	Preclinical		monoamine oxidase inhibitor		
honokiol	Oc1ccc(cc1CC=C)-c1cc(CC=C)ccc1O	Phase 3	ALOX5|PTGS1|PTGS2	AKT inhibitor		
hordenine	CN(C)CCc1ccc(O)cc1	Preclinical				
HP-228	CCCC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCC(N)=O	Preclinical		nitric oxide synthase inhibitor		
hPGDS-IN-1	CC(C)(O)c1nc(no1)-c1cccc(CNC(=O)c2cnc(nc2)-c2ccccn2)c1	Preclinical		prostaglandin inhibitor		
HPPH	CCCCCCO[C@H](C)c1c(C)c2cc3nc([C@@H](CCC(O)=O)[C@@H]3C)c3CC(=O)c4c(C)c(cc5nc(cc1[nH]2)c(C)c5CC)[nH]c34 |&1:7|	Phase 2		photosensitizing agent		
HQK-1001	CCC(C)(C)C(O)=O	Phase 2				
HSR6071	O=C(Nc1nnn[nH]1)c1cncc(n1)N1CCCC1	Preclinical		antiallergic agent		
HT-2157	FC(F)(F)c1cccc(c1)\N=C1/C(=O)N(c2ccccc12)c1ccccc1	Phase 1/Phase 2		galanin receptor 3 antagonist		
HTH-01-015	CN1c2cc3ccccc3cc2C(=O)N(C)c2c(C)nc(Nc3cnn(c3)C3CCNCC3)nc12	Preclinical	NUAK1	protein kinase inhibitor		
HTHQ	CCCCCCOc1cc(C)c(O)c(C)c1C	Preclinical		antioxidant		
HTMT	C[C@@H](CCCCC(=O)Nc1ccc(cc1)C(F)(F)F)NCCc1cnc[nH]1 |&1:1|	Preclinical	HRH4	histamine receptor agonist		
huperzine-A	C\C=C1/[C@@H]2Cc3[nH]c(=O)ccc3[C@@]1(N)CC(C)=C2 |c:18|	Phase 2	ACHE	acetylcholinesterase inhibitor		
hyaluronic-acid	CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1C(O)=O	Launched	C1QBP|CD44|HABP2|HAPLN1|HAPLN3|HAPLN4|HMMR|ICAM1|NCAN|VCAN		rheumatology, urology	osteoarthritis, interstitial cystitis (IC)
hycanthone	CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12	Launched		RNA synthesis inhibitor	infectious disease	schistosomiasis
hydralazine	NNc1nncc2ccccc12	Launched		vasodilator	cardiology	hypertension
hydrastine-(1R,9S)	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3cc12	Preclinical		tyrosine hydroxylase inhibitor		
hydrastinine	C[N+]1=Cc2cc3OCOc3cc2CC1 |t:1|	Preclinical		hemostatic agent		
hydrochlorothiazide	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1Cl	Launched	CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A3	thiazide diuretic	cardiology	hypertension, congestive heart failure
hydrocortisone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |t:9|	Launched	ANXA1|NOS2|NR3C1|NR3C2	glucocorticoid receptor agonist	dermatology, neurology/psychiatry	eczema, psoriasis, seborrheic dermatitis, itching
hydrocortisone-acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |t:15|	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
hydrocortisone-butyrate	CCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:13|	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses, eczema
hydrocortisone-hemisuccinate	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |t:9|	Phase 2/Phase 3				
hydrocortisone-phosphate	C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]34C)[C@@H]1CC[C@]2(O)C(=O)COP(O)(O)=O |a:3	Launched			pulmonary, gastroenterology, hematologic malignancy, ophthalmology	asthma, nausea, vomiting, multiple myeloma, contact dermatitis, enteritis, colitis
hydrocortisone-valerate	CCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)CO |t:14|	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
hydroflumethiazide	NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F	Launched	ATP1A1|CA1|CA12|CA2|CA4|CA9|KCNMA1|SLC12A1|SLC12A3	sodium/potassium/chloride transporter inhibitor	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, chronic renal failure, acute glomerulonephritis (AGN), hypertension
hydroquinidine	CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12	Launched		antiarrhythmic	cardiology	cardiac arrythmia
hydroquinone	Oc1ccc(O)cc1	Launched	TYR	melanin inhibitor	dermatology	dyschromia
hydroxocobalamin	[H]O[Co+]N1\C2=C(C)/C3=N/C(=C/C4=N/C(=C(C)\C5=N[C@@](C)([C@@]1([H])[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)/[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)/C(C)(C)[C@@H]3CCC(N)=O |r	Launched		vitamin B		
hydroxyamphetamine	C[C@@H](N)Cc1ccc(O)cc1 |&1:1|	Launched	TAAR1	trace amine associated receptor agonist	ophthalmology	mydriasis
hydroxychloroquine	CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12	Launched	TLR7|TLR9	antimalarial agent	infectious disease	malaria
hydroxyfasudil	O=c1[nH]ccc2c(cccc12)S(=O)(=O)N1CCCNCC1	Preclinical	PKIA|PRKACA|ROCK1	rho associated kinase inhibitor		
hydroxyprogesterone	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:11|	Launched	PGR	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
hydroxyprogesterone-acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:11|	Launched	PGR	progesterone receptor agonist		
hydroxypropyl-beta-cyclodextrin	C[C@@H](O)COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]4[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]5[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]6[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]7[C@@H](COC[C@@H](C)O)O[C@H](O[C@@H]8[C@@H](COC[C@@H](C)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |a:6	Phase 2/Phase 3				
hydroxysafflor-yellow-A	[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)[C@]1(O)C(=O)[C@@H]([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=O)[C@H](C(=O)\C=C\c2ccc(O)cc2)C1=O |&1:12	Preclinical		antitumor agent		
hydroxystilbamidine	NC(=N)c1ccc(\C=C\c2ccc(cc2O)C(N)=N)cc1	Launched				
hydroxytacrine-maleate-(R,S)	Nc1c2[C@@H](O)CCCc2nc2ccccc12 |&1:3|	Preclinical	ACHE	cholinesterase inhibitor		
hydroxytoluic-acid	Cc1cccc(C(O)=O)c1O	Preclinical				
hydroxyurea	NC(=O)NO	Launched	RRM1|RRM2|RRM2B	ribonucleotide reductase inhibitor	hematologic malignancy, oncology	chronic myeloid leukemia (CML), head and neck squamous cell carcinoma (HNSCC)
hydroxyzine	OCCOCCN1CCN(CC1)[C@@H](c1ccccc1)c1ccc(Cl)cc1 |&1:12|	Launched	HRH1	antihistamine	neurology/psychiatry, allergy, dermatology	anxiety, urticaria, itching, dermatosis
hygromycin-B	CN[C@H]1C[C@@H](N)[C@H](O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@@H]3O[C@@]4(O[C@H]23)O[C@H]([C@@H](N)CO)[C@H](O)[C@H](O)[C@H]4O)[C@@H]1O |a:2	Preclinical		polypeptide synthesis inhibitor		
hymecromone	Cc1cc(=O)oc2cc(O)ccc12	Phase 2	MAOA|MAOB	monoamine oxidase inhibitor		
hyodeoxycholic-acid	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 1		atherosclerosis formation inhibitor		
hyoscyamine	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c1ccccc1	Launched	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor antagonist	gastroenterology, urology, neurology/psychiatry, allergy	peptic ulcer disease (PUD), acute abdominal visceral spasm, ulcerative colitis, interstitial cystitis (IC), enterocolitis, irritable bowel syndrome, tremors, allergic rhinitis
hypericin	Cc1cc(O)c2c3c1c1c(C)cc(O)c4c1c1c3c3c(c(O)cc(O)c3c2=O)c2c(O)cc(O)c(c12)c4=O	Phase 3		tyrosine kinase inhibitor		
hyperin	OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2	Preclinical	ACE|AKR1B1	aldose reductase inhibitor		
hypoestoxide	CC(=O)O[C@@H]1C[C@]2(C)O[C@H]2CC[C@]2(C)O[C@H]2C[C@@H]2CC(=O)C(=C)[C@@H]1C2(C)C	Phase 1	IKBKB|IL1B|TNF	IKK inhibitor		
hypoxanthine	O=c1nc[nH]c2nc[nH]c12	Preclinical	PNP	PARP inhibitor		
H2L-5765834	OC(=O)c1ccc2C(=O)N(C(=O)c2c1)c1cccc(Oc2ccc(cc2)[N+]([O-])=O)c1	Preclinical	LPAR1|LPAR3	lysophosphatidic acid receptor antagonist		
I-BET-762	CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 |t:7|	Phase 2	BRD2|BRD3|BRD4	bromodomain inhibitor		
I-BET151	COc1cc2c3n([C@H](C)c4ccccn4)c(=O)[nH]c3cnc2cc1-c1c(C)noc1C	Preclinical	BRD2|BRD3|BRD4	bromodomain inhibitor		
I-BRD9	CCn1cc(-c2cccc(c2)C(F)(F)F)c2sc(cc2c1=O)C(=N)NC1CCS(=O)(=O)CC1	Preclinical	BRD9	bromodomain inhibitor		
I-BZA	CCN(CC)CCNC(=O)c1ccc(I)cc1	Phase 2				
I-BZA2	CCN(CC)CCNC(=O)c1ccccc1I	Phase 3				
I-CBP-112	CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1	Preclinical	CREBBP|EP300	bromodomain inhibitor		
IACS-10759	Cc1nc(nn1Cc1cccc(c1)N1CCC(CC1)S(C)(=O)=O)-c1nc(no1)-c1ccc(OC(F)(F)F)cc1	Preclinical		mitochondrial complex I inhibitor		
IB-MECA	CNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NCc3cccc(I)c3)ncnc12	Phase 3	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor agonist		
ibandronate	CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	FDPS	bone resorption inhibitor	orthopedics	osteoporosis
IBC-293	CC(C)n1nnc2cc(ccc12)C(O)=O	Preclinical	HCAR3	hydroxycarboxylic acid receptor agonist		
iberdomide	O=C1N(Cc2c1cccc2OCc1ccc(CN2CCOCC2)cc1)[C@H]1CCC(=O)NC1=O	Preclinical		cereblon modulator		
ibiglustat	CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1	Preclinical		glucosylceramidase inhibitor		
IBMX	CC(C)Cn1c2nc[nH]c2c(=O)n(C)c1=O	Preclinical	ADORA1|PDE2A|PDE3B|PDE4D|PDE5A|PDE6G|PDE7A|PDE8A|PDE9A	phosphodiesterase inhibitor		
ibotenic-acid	N[C@@H](C(O)=O)c1cc(=O)[nH]o1 |&1:1	Preclinical	GRIN1	glutamate receptor agonist		
ibrolipim	CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(Br)cc1C#N)OCC	Phase 2	LPL	lipoprotein lipase activator		
ibrutinib	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C	Launched	BLK|BMX|BTK	Bruton's tyrosine kinase (BTK) inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)
ibudilast	CC(C)C(=O)c1c(nn2ccccc12)C(C)C	Launched	IL1B|IL6|PDE3A|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A	leukotriene receptor antagonist, phosphodiesterase inhibitor	pulmonary, neurology/psychiatry	asthma, stroke
ibuprofen	CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |&1:10	Launched		cyclooxygenase inhibitor	neurology/psychiatry, rheumatology, otolaryngology, obstetrics/gynecology, endocrinology, dental	headache, muscle pain, rheumatoid arthritis, backache, common cold, menstrual pain, fever, toothache
ibuprofen-(S)	CC(C)Cc1ccc(cc1)[C@H](C)C(O)=O	Launched	ASIC1|PTGS1|PTGS2|SLC5A8	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ibuprofen-lysine	NCCCC[C@H](N)C(O)=O.CC(C)Cc1ccc(cc1)[C@@H](C)C(O)=O |a:5	Launched		cyclooxygenase inhibitor	cardiology	patent ductus arteriosus (PDA)
ibuprofen-piconol	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)OCc1ccccn1 |&1:10	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ibuproxam	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NO |r|	Launched	ALOX5	cyclooxygenase inhibitor, prostaglandin inhibitor	endocrinology, rheumatology, neurology/psychiatry	fever, joint inflammation, pain relief
ibutamoren	CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CN(c3ccccc23)S(C)(=O)=O)CC1	Phase 2	GHR|GHSR	growth hormone secretagogue receptor agonist		
ibutilide	CCCCCCCN(CC)CCC[C@@H](O)c1ccc(NS(C)(=O)=O)cc1 |&1:13|	Launched	CACNA1C|KCNH2	potassium channel blocker	cardiology	atrial fibrillation (AF)
ICA-069673	Fc1ccc(cc1F)C(=O)Nc1cnc(Cl)nc1	Preclinical	KCNQ2|KCNQ3	voltage-gated potassium channel activator		
ICA-110381	Clc1ccc(cc1)C(=O)Nc1ccc(Cl)nc1	Preclinical	KCNQ2	voltage-gated potassium channel activator		
ICA-121431	O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)C(c1ccccc1)c1ccccc1	Preclinical	SCN1A|SCN3A	sodium channel blocker		
icariin	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c2c(=O)c1O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Phase 3	PDE5A	phosphodiesterase inhibitor		
icaritin	COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O	Phase 3	PDE5A	PPAR receptor antagonist		
icatibant-acetate	N[C@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Launched	BDKRB2	bradykinin receptor antagonist	cardiology	angioedema
ICG-001	Oc1ccc(C[C@@H]2N3[C@H](CN(Cc4cccc5ccccc45)C2=O)N(CCC3=O)C(=O)NCc2ccccc2)cc1	Preclinical	CTNNB1	beta-catenin inhibitor		
ICI-118,551	CC(C)N[C@@H](C)[C@H](O)COc1ccc(C)c2CCCc12	Phase 2	ADRB2|ADRB3	adrenergic receptor antagonist		
ICI-162846	NC(=O)CCCCn1ccc(NC(=N)NCC(F)(F)F)n1	Phase 1	HRH2	histamine receptor antagonist		
ICI-169369	CN(C)CCSc1nc2ccccc2cc1-c1ccccc1	Phase 2		serotonin receptor antagonist		
ICI-185,282	OC(=O)CCC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F	Phase 1		thromboxane receptor antagonist		
ICI-192605	OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl	Phase 2	TBXA2R	thromboxane receptor antagonist		
ICI-199441	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical	CYP2D6|OPRD1|OPRK1|OPRM1|UTS2R	opioid receptor agonist		
ICI-215,001	O[C@@H](CNCCOc1ccc(OCC(O)=O)cc1)COc1ccccc1	Preclinical	ADRB3	adrenergic receptor agonist		
ICI-63197	CCCn1c2nc(N)nn2cc(C)c1=O	Preclinical		phosphodiesterase inhibitor		
ICI-89406	O[C@@H](CNCCNC(=O)Nc1ccccc1)COc1ccccc1C#N |&1:1	Phase 1	ADRB1|ADRB2	adrenergic receptor antagonist		
icilin	Oc1ccccc1N1CC=C(NC1=O)c1cccc(c1)[N+]([O-])=O |c:10|	Phase 1	TRPA1|TRPM8	TRPV agonist		
iclaprim	COc1cc(Cc2cnc(N)nc2N)c2C=C[C@H](Oc2c1OC)C1CC1 |&1:17	Phase 3		dihydrofolate reductase inhibitor		
icomucret	CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O	Phase 3	LTB4R2	mucin production enhancer		
icosapent	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Launched	ACSL3|ACSL4|FADS1|FFAR1|PPARD|PPARG|PTGS1|PTGS2|SLC8A1|TRPV1	platelet aggregation inhibitor	endocrinology	hypertriglyceridemia
icotinib	C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1	Launched	EGFR	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
iCRT-14	Cc1cc(\C=C2/SC(=O)N(C2=O)c2ccccc2)c(C)n1-c1cccnc1	Preclinical	CTNNB1|TCF4	beta catenin inhibitor, WNT signaling inhibitor		
IC261	COc1cc(OC)c(\C=C2\C(=O)Nc3ccccc23)c(OC)c1	Preclinical	CSNK1A1|CSNK1D|CSNK1E|CSNK1G2	casein kinase inhibitor		
ID-1101	C[C@H](O)[C@H](C)[C@H](N)C(O)=O	Phase 1	INS	insulin sensitizer		
ID-8	COc1ccc(cc1)-n1c(C)c([N+]([O-])=O)c2ccc(O)cc12	Preclinical				
idalopirdine	FC(F)C(F)(F)COc1cccc(CNCCc2c[nH]c3cc(F)ccc23)c1	Phase 3	HTR6	serotonin receptor antagonist		
idarubicin	C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(Cc2c(O)c3C(=O)c4ccccc4C(=O)c3c(O)c12)C(C)=O	Launched	TOP2A	topoisomerase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
idasanutlin	COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O	Phase 3	MDM2|TP53	MDM inhibitor		
idazoxan	C1CN=C(N1)[C@H]1COc2ccccc2O1 |r	Phase 3	ADRA2A|PTGS2	adrenergic receptor antagonist		
idebenone	COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |c:2	Launched		calcium channel modulator	neurology/psychiatry, ophthalmology	Alzheimer's disease, Friedreich's ataxia, Leber hereditary optic neuropathy (LHON)
idelalisib	CC[C@H](Nc1ncnc2nc[nH]c12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1	Launched	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
IDF-11774	CN1CCN(CC1)C(=O)COc1ccc(cc1)C12CC3CC(CC(C3)C1)C2	Preclinical		hypoxia inducible factor inhibitor		
IDH-305	C[C@H](F)[C@H]1COC(=O)N1c1ccnc(N[C@@H](C)c2cc(C)c(cn2)-c2ccnc(c2)C(F)(F)F)n1	Phase 2		isocitrate dehydrogenase inhibitor		
idoxuridine	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O	Launched		DNA directed DNA polymerase inhibitor, DNA synthesis inhibitor	infectious disease	virus herpes simplex (HSV)
IDO5L	Nc1nonc1\C(NO)=N/c1ccc(F)c(Cl)c1	Preclinical	IDO1	indoleamine 2,3-dioxygenase inhibitor		
IDRA-21	C[C@H]1Nc2ccc(Cl)cc2S(=O)(=O)N1 |&1:1	Preclinical	GRIA1|GRIA2|GRIA3|GRIA4	glutamate receptor positive allosteric modulator		
idramantone	[H][C@@]12C[C@@]3([H])C[C@@](O)(C1)C[C@@]([H])(C2)C3=O |&1:1	Preclinical				
idronoxil	Oc1ccc(cc1)C1=Cc2ccc(O)cc2OC1 |t:8|	Phase 3	ENOX2|SPHK1	XIAP inhibitor		
IEM1460	C[N+](C)(C)CCCCCNCC12CC3CC(CC(C3)C1)C2	Preclinical	GRIA2	glutamate receptor antagonist		
IEM1754	NCCCCCNCC12CC3CC(CC(C3)C1)C2	Preclinical	GRIA1	glutamate receptor antagonist		
ifenprodil	C[C@@H]([C@H](O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1 |&1:1	Launched	GRIN2B	adrenergic receptor antagonist, glutamate receptor antagonist		
ifosfamide	ClCCN[P@@]1(=O)OCCCN1CCCl |r|	Launched	CYP2A6|CYP2B6|CYP2C18|CYP2C19|CYP2C8|CYP2C9|CYP3A4|CYP3A5|CYP3A7|PTGS1	DNA alkylating agent	oncology, urology	testicular carcinoma, hemorrhagic cystitis
igmesine	CCC(C\C=C\c1ccccc1)(N(C)CC1CC1)c1ccccc1 |&1:2|	Phase 2	SIGMAR1	sigma receptor agonist		
iguratimod	CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1	Launched	PTGS2	cyclooxygenase inhibitor, NFkB pathway inhibitor	rheumatology	rheumatoid arthritis
IKK-16	O=C(N1CCC(CC1)N1CCCC1)c1ccc(Nc2nccc(n2)-c2cc3ccccc3s2)cc1	Preclinical	IKBKB	IKK inhibitor		
IKK-2-inhibitor	NC(=O)c1sc(cc1N)-c1ccsc1	Preclinical	IKBKB	IKK inhibitor, SYK inhibitor		
IKK-2-inhibitor-V	Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F	Phase 1	IKBKB	IKK inhibitor, NFkB pathway inhibitor		
ilaprazole	COc1ccnc(C[S@@](=O)c2nc3ccc(cc3[nH]2)-n2cccc2)c1C |&1:8	Launched		proton pump inhibitor	gastroenterology	gastroesophageal reflux disease (GERD)
ilepcimide	O=C(\C=C\c1ccc2OCOc2c1)N1CCCCC1	Phase 3		anticonvulsant		
ilomastat	CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)CC(=O)NO	Phase 3	ACAN|ADAM28|MMP1|MMP12|MMP13|MMP14|MMP2|MMP3|MMP8|MMP9	matrix metalloprotease inhibitor		
iloperidone	COc1cc(ccc1OCCCN1CCC(CC1)c1noc2cc(F)ccc12)C(C)=O	Launched	ADRA1A|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR2A|HTR6|HTR7	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia
iloprost	CC#CC[C@@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O |a:6	Launched	PTGDR|PTGER1|PTGER2|PTGER3|PTGER4|PTGFR|PTGIR|TBXA2R	platelet aggregation inhibitor, prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
imatinib	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1	Launched	ABL1|CSF1R|DDR1|KIT|NTRK1|PDGFRA|PDGFRB|RET	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy, oncology	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)
Imazodan	O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1 |c:4|	Phase 1		phosphodiesterase inhibitor		
imeglimin	C[C@H]1NC(=NC(N)=N1)N(C)C |c:3	Phase 2		gluconeogenesis inhibitor		
imetit	NC(=N)SCCc1cnc[nH]1	Preclinical	HRH3|HRH4	histamine receptor agonist		
imexon	NC1=NC(=O)N2C[C@@H]12 |r	Phase 2		apoptosis stimulant, ribonucleotide reductase inhibitor		
imidacloprid	[O-][N+](=O)N=C1NCCN1Cc1ccc(Cl)nc1	Launched		acetylcholine receptor antagonist		
imidafenacin	Cc1nccn1CCC(C(N)=O)(c1ccccc1)c1ccccc1	Launched	CHRM1|CHRM3	acetylcholine receptor antagonist	neurology/psychiatry	spasms
imidapril	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@@H](CN(C)C1=O)C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension, congestive heart failure
imidazoacridinone	CCN(CC)CCNc1ccc2ncn3c2c1c(=O)c1cc(O)ccc31	Preclinical		anticancer agent		
imidurea	OCN1[C@@H](NC(=O)NCNC(=O)N[C@@H]2N(CO)C(=O)NC2=O)C(=O)NC1=O |&1:3	Preclinical		other antibiotic		
imiloxan	CCn1ccnc1C[C@H]1COc2ccccc2O1 |&1:8|	Phase 1	ADRA2A|ADRA2B	adrenergic receptor antagonist		
imipenem	C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O |c:12|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	pneumonia, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial septicemia, bone and joint infections, skin infections, endocarditis
imipramine	CN(C)CCCN1c2ccccc2CCc2ccccc12	Launched	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7|KCND2|KCND3|KCNH1|KCNH2|SLC6A2|SLC6A3|SLC6A4	norepinephrine reputake inhibitor, serotonin reuptake inhibitor	neurology/psychiatry, urology	depression, nocturnal enuresis
imiquimod	CC(C)Cn1cnc2c(N)nc3ccccc3c12	Launched	TLR7|TLR8	interferon inducer, toll-like receptor agonist	dermatology, infectious disease, oncology	actinic keratosis (AK), genital warts, basal cell carcinoma (BCC)
imirestat	Fc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1	Preclinical		aldose reductase inhibitor		
imisopasem-manganese	[H][C@@]12CCCC[C@@]1([H])N1Cc3cccc(CN4[C@]5([H])CCCC[C@@]5([H])N5CCN2[Mn]145(Cl)Cl)n3	Preclinical		superoxide dismutase mimetic		
immepip	C(C1CCNCC1)c1cnc[nH]1	Preclinical	HRH3|HRH4	histamine receptor agonist		
immethridine	C(c1cnc[nH]1)c1ccncc1	Phase 1	HRH3	histamine receptor agonist		
impentamine	NCCCCCc1cnc[nH]1	Preclinical	HRH3	histamine receptor antagonist		
IMREG-1	N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(O)=O	Phase 3				
inarigivir	CO[C@@H]1[C@H](O[P@](S)(=O)OC[C@H]2O[C@H](C[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](CO)O[C@H]1n1ccc(=O)[nH]c1=O |a:2	Phase 2		antiviral		
inarigivir-soproxil	[H][C@]1(O)C[C@@]([H])(O[C@]1([H])CO[P@](=O)(O[C@]1([H])[C@@]([H])(CO)O[C@@]([H])(n2ccc(=O)[nH]c2=O)[C@]1([H])OC)SCOC(=O)OC(C)C)n1cnc2c(N)ncnc12 |&1:11	Phase 2		antiviral		
INC-280	CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1	Phase 3	MET	c-Met inhibitor		
INCA-6	O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc12 |c:2	Preclinical	NFATC1	calcineurin inhibitor		
INCB-003284	COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	Phase 2		CC chemokine receptor antagonist		
INCB-057643	CN1C(=O)C(C)(C)Oc2c1cc(cc2-c1cn(C)c(O)c2nccc12)S(C)(=O)=O	Phase 1/Phase 2		bromodomain inhibitor		
INCB-3284	COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F	Phase 2	CCR2	CC chemokine receptor antagonist		
incyclinide	[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)C[C@]1([H])C2 |&1:19	Phase 2		matrix metalloprotease inhibitor		
indacaterol	CCc1cc2CC(Cc2cc1CC)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	Launched	ADRB1|ADRB2	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)
indalpine	C(Cc1c[nH]c2ccccc12)C1CCNCC1	Withdrawn	SLC6A4	selective serotonin reuptake inhibitor (SSRI)		
indapamide	C[C@H]1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O |&1:1	Launched	CA2|HTR3A|KCNQ1	thiazide diuretic	cardiology	hypertension, congestive heart failure
indatraline	CN[C@@H]1C[C@H](c2ccccc12)c1ccc(Cl)c(Cl)c1	Preclinical	MAOA|MAOB	norepinephrine transporter inhibitor		
indeglitazar	COc1ccc(cc1)S(=O)(=O)n1cc(CCC(O)=O)c2cc(OC)ccc12	Phase 2	NCOA1|PPARA|PPARD|PPARG	PPAR receptor agonist		
indeloxazine	C(Oc1cccc2C=CCc12)[C@H]1CNCCO1 |&1:11	Withdrawn		norepinephrine reuptake inhibitor, serotonin reuptake inhibitor		
indibulin	Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1	Phase 1/Phase 2		tubulin polymerization inhibitor		
indinavir	CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](O)Cc2ccccc12	Launched	CYP3A4|CYP3A5|CYP3A7	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
indiplon	CN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C(=O)c1cccs1	Phase 3	GABRA1	benzodiazepine receptor agonist		
indirubin	O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O	Phase 2/Phase 3	CDK1|CDK5|GSK3A	CDK inhibitor, glycogen synthase kinase inhibitor		
indirubin-3-monoxime	O\N=C1\C(\Nc2ccccc\12)=C1\C(=O)Nc2ccccc12	Preclinical	CDK1|CDK2|CDK5|CDK5R1|GSK3B	CDK inhibitor, glycogen synthase kinase inhibitor		
indisulam	NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12	Phase 2	CA1|CA12|CA14|CA2|CA6|CA7|CA9	CDK inhibitor		
indium(III)-isopropoxide	[In].CC(C)O.CC(C)O.CC(C)O	Preclinical				
indium-tri(2-propanolate)	CC(C)O[In](OC(C)C)OC(C)C	Preclinical				
indobufen	CC[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:2	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor, platelet aggregation inhibitor	hematology	thrombosis
indocyanine-green	CC1(C)\C(=C/C=C/C=C/C=C/C2=[N+](CCCCS(O)(=O)=O)c3ccc4ccccc4c3C2(C)C)N(CCCCS(O)(=O)=O)c2ccc3ccccc3c12 |c:11|	Launched	SLCO1B1	contrast agent	cardiology	vascular imaging agent
indole-3-carbinol	OCc1c[nH]c2ccccc12	Phase 2/Phase 3	AHR	aryl hydrocarbon receptor agonist, indoleamine 2,3-dioxygenase inhibitor		
indole-3-pyrubate	OC(=O)C(O)=Cc1c[nH]c2ccccc12	Phase 2		melatonin receptor agonist		
indomethacin	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1	Launched	GLO1|PLA2G2A|PPARA|PPARG|PTGDR2|PTGR2|PTGS1|PTGS2|SLC46A1	cyclooxygenase inhibitor	rheumatology, orthopedics	rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, bursitis, tendinitis
indoprofen	C[C@@H](C(O)=O)c1ccc(cc1)N1Cc2ccccc2C1=O |&1:1	Withdrawn	CXCR1|CXCR2|PTGS1|PTGS2	cyclooxygenase inhibitor, prostanoid receptor antagonist		
indoramin	O=C(NC1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccccc1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2B|ADRA2C	adrenergic receptor antagonist	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension
indoximod	Cn1cc(C[C@@H](N)C(O)=O)c2ccccc12	Phase 2	IDO1	indoleamine 2,3-dioxygenase inhibitor		
ingenol	[H][C@]12C=C(CO)[C@@H](O)[C@]3(O)[C@@H](O)C(C)=C[C@]3([C@H](C)C[C@@H]3[C@H]1C3(C)C)C2=O |c:13	Launched	PRKCD|PRKCE	PKC activator	dermatology	keratosis
ingenol-mebutate	C\C=C(\C)C(=O)O[C@H]1C(C)=C[C@@]23[C@H](C)C[C@@H]4[C@H]([C@H](C=C(CO)[C@@H](O)[C@]12O)C3=O)C4(C)C |c:9	Launched	PRKCA|PRKCB|PRKCD|PRKCE|PRKCG	PKC activator	dermatology	actinic keratosis (AK)
INH1	Cc1ccc(-c2csc(NC(=O)c3ccccc3)n2)c(C)c1	Preclinical	NDC80	Hec1 inhibitor		
inimur	CSC[C@H]1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1 |&1:3	Launched		other antifungal		
iniparib	NC(=O)c1ccc(I)c(c1)[N+]([O-])=O	Phase 3	PARP1	PARP inhibitor		
inosine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c1[nH]cnc2=O	Launched	PARP1|PNP	neurotrophic agent		
inositol	O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O	Launched	CDIPT	insulin sensitizer	obstetrics/gynecology	polycystic ovary syndrom (PCOS)
inositol-hexanicotinate	O=C(O[C@H]1[C@H](OC(=O)c2cccnc2)[C@@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@@H]1OC(=O)c1cccnc1)c1cccnc1	Launched			dermatology, cardiology, rheumatology, neurology/psychiatry	statis dermatitis, claudication, Raynaud's disease, hypertension, insomnia, atherosclerosis, restless leg syndrome, schizophrenia, psoriasis, acne vulgaris (AV)
INS316	O[C@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:2	Phase 2		purinergic receptor antagonist		
INT-747	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	Phase 3		FXR agonist		
INT-767	CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@H]([C@H](C)CCOS(O)(=O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12	Phase 1	GPBAR1	FXR agonist		
integrin-antagonist-1	Cc1cc(C)n(n1)-c1cccc(c1)[C@@H](CN1CC[C@@H](CCc2ccc3CCCNc3n2)C1)CC(O)=O	Phase 1	ITGAV|ITGB6	integrin antagonist		
INX-08189	[H][C@@](C)(N[P@](=O)(OC[C@@]1([H])O[C@@]([H])(n2cnc3c(OC)nc(N)nc23)[C@](C)(O)[C@]1([H])O)Oc1cccc2ccccc12)C(=O)OCC(C)(C)C |r|	Phase 2		antiviral		
iobenguane	NC(=N)NCc1cccc(I)c1	Launched		antineoplastic agent	oncology, cardiology, endocrinology	neuroblastoma, congestive heart failure, pheochromocytoma
iocetamic-acid	C[C@@H](CN(C(C)=O)c1c(I)cc(I)c(N)c1I)C(O)=O |&1:1	Launched		radiopaque medium	radiology	contrast agent
iodipamide	OC(=O)c1c(I)cc(I)c(NC(=O)CCCCC(=O)Nc2c(I)cc(I)c(C(O)=O)c2I)c1I	Launched	ALB	radiopaque medium	radiology	contrast agent
iodixanol	CC(=O)N(CC(O)CN(C(C)=O)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:20	Launched		radiopaque medium	radiology	contrast agent
iodoantipyrine	Cc1c(I)c(=O)n(-c2ccccc2)n1C	Preclinical				
iododexetimide	Ic1ccc(CN2CCC(CC2)[C@]2(CCC(=O)NC2=O)c2ccccc2)cc1 |&1:12	Phase 2		acetylcholine receptor antagonist		
iodophenpropit	Ic1ccc(CCNC(=N)SCCCc2cnc[nH]2)cc1	Preclinical	HRH3|HRH4	histamine receptor antagonist		
iodoquinol	Oc1c(I)cc(I)c2cccnc12	Launched		antiseptic	infectious disease	amebiasis
iohexol	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5	Launched		radiopaque medium	radiology	contrast agent
iopamidol	C[C@H](O)C(=O)Nc1c(I)c(C(=O)NC(CO)CO)c(I)c(C(=O)NC(CO)CO)c1I	Launched		radiopaque medium	radiology	contrast agent
iopanic-acid	CC[C@@H](Cc1c(I)cc(I)c(N)c1I)C(O)=O |&1:2	Withdrawn		thyroid hormone inhibitor		
iopodic-acid	CN(C)\C=N\c1c(I)cc(I)c(CCC(O)=O)c1I	Launched			radiology	contrast agent
iopromide	COCC(=O)Nc1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)N(C)C[C@@H](O)CO)c1I |&1:14	Launched		radiopaque medium	radiology	contrast agent
iothalamic-acid-d3	CNC(=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Preclinical		radiopaque medium		
ioversol	OCCN(C(=O)CO)c1c(I)c(C(=O)NC[C@@H](O)CO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:16	Launched		radiopaque medium	radiology	contrast agent
IOWH032	Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1	Phase 2	CFTR	CFTR channel antagonist		
ioxaglic-acid	CNC(=O)c1c(I)c(N(C)C(C)=O)c(I)c(C(=O)NCC(=O)Nc2c(I)c(C(O)=O)c(I)c(C(=O)NCCO)c2I)c1I	Launched		radiopaque medium	radiology	contrast agent
ioxilan	CC(=O)N(C[C@@H](O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NC[C@@H](O)CO)c1I |&1:5	Launched		radiopaque medium	radiology	angiography
IOX1	OC(=O)c1ccc(O)c2ncccc12	Preclinical	EGLN1|KDM3A|KDM4C|KDM6B	histone demethylase inhibitor		
IOX2	OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O	Preclinical	EGLN1|KDM2A|KDM5C	hypoxia inducible factor inhibitor		
IPA-3	Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12	Preclinical	PAK1	p21 activated kinase inhibitor		
IPAG	Ic1ccc(NC(=N)NC2C3CC4CC(C3)CC2C4)cc1	Preclinical				
ipidacrine	Nc1c2CCCc2nc2CCCCc12	Phase 3	ACHE	acetylcholinesterase inhibitor		
IPI549	C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1	Phase 2		PI3K inhibitor		
ipragliflozin-L-proline	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1ccc(F)c(Cc2cc3ccccc3s2)c1	Launched	SLC5A2	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
ipratropium	CC(C)[N@@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |a:5	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	pulmonary	bronchospasm, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema
ipriflavone	CC(C)Oc1ccc2c(c1)occ(-c1ccccc1)c2=O	Launched		bone resorption inhibitor	orthopedics	osteoporosis
iproniazid	CC(C)NNC(=O)c1ccncc1	Withdrawn	MAOA|MAOB	monoamine oxidase inhibitor		
ipsapirone	O=C1N(CCCCN2CCN(CC2)c2ncccn2)S(=O)(=O)c2ccccc12	Phase 3	HTR1A	serotonin receptor agonist		
irbesartan	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1 |t:4|	Launched	AGTR1|JUN|SLC10A1	angiotensin receptor antagonist	cardiology, nephrology	hypertension, diabetic nephropathy
irganox-1010	CC(C)(C)c1cc(CCC(=O)OCC(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)(COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)COC(=O)CCc2cc(c(O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	Preclinical		antioxidant		
iRGD-peptide	[H][C@@]12CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@]([H])(CC(O)=O)NC(=O)CNC(=O)[C@]([H])(CCCNC(N)=N)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC2=O)C(O)=O	Preclinical		integrin signaling activator		
irinotecan	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12	Launched	TOP1|TOP1MT	topoisomerase inhibitor	oncology	colorectal cancer
IRL-2500	CN([C@H](Cc1ccc(cc1)-c1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O)C(=O)c1cc(C)cc(C)c1	Preclinical	EDNRB	endothelin receptor antagonist		
irosustat	NS(=O)(=O)Oc1ccc2c3CCCCCc3c(=O)oc2c1	Phase 2	CA2|STS	steroid sulfatase inhibitor		
irsogladine	Nc1nc(N)nc(n1)-c1cc(Cl)ccc1Cl	Launched	PDE4A	phosphodiesterase inhibitor	gastroenterology	peptic ulcer disease (PUD)
isamoltane	CC(C)NC[C@@H](O)COc1ccccc1-n1cccc1 |&1:5|	Phase 1	HTR1A|HTR1B	adrenergic receptor antagonist		
isavuconazole	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@@](O)(Cn1cncn1)c1cc(F)ccc1F |a:1	Phase 3	CYP3A4	cytochrome P450 inhibitor		
isaxonine	CC(C)Nc1ncccn1	Withdrawn		nerve growth factor agonist		
isbufylline	CC(C)Cn1cnc2n(C)c(=O)n(C)c(=O)c12	Phase 2		phosphodiesterase inhibitor		
isepamicin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O	Launched		protein synthesis inhibitor	infectious disease	pneumonia, peritonitis
ISO-1	COC(=O)C[C@H]1CC(=NO1)c1ccc(O)cc1 |&1:5	Preclinical	MIF	macrophage migration inhibiting factor inhibitor		
isobutamben	CC(C)COC(=O)c1ccc(N)cc1	Preclinical		local anesthetic		
isobutyramide	CC(C)C(N)=O	Phase 2	HBE1|HBG1	gene expression stimulant		
isocarboxazid	Cc1cc(no1)C(=O)NNCc1ccccc1	Launched	MAOA|MAOB	monoamine oxidase inhibitor	neurology/psychiatry	depression
isoconazole	Clc1ccc([C@@H](Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1 |&1:5|	Launched	CYP17A1	fungal lanosterol demethylase inhibitor	infectious disease	gram-positive bacterial infections
isodibut	OC(=O)CCCN1C(=O)c2cccc3cccc(C1=O)c23	Phase 2		aldehyde reductase inhibitor		
isoetharine	CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c(O)c1 |&1:2	Launched		adrenergic receptor agonist	pulmonary	bronchospasm, asthma
isofloxythepin	CC(C)c1ccc2Sc3cc(F)ccc3C[C@@H](N3CCN(CCO)CC3)c2c1 |&1:16	Phase 2		dopamine receptor antagonist		
isoflupredone-acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |c:19	Preclinical	NR3C1			
isoflurane	FC(F)O[C@@H](Cl)C(F)(F)F |&1:4	Launched	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9	inhaled anaesthetic	neurology/psychiatry	general anaesthetic
isoflurophate	CC(C)OP(F)(=O)OC(C)C	Launched	ACHE|BCHE	cholinesterase inhibitor	ophthalmology	glaucoma
isoguvacine	OC(=O)C1=CCNCC1 |t:3|	Preclinical	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3	benzodiazepine receptor agonist		
isoleucine	CC[C@@H](C)[C@@H](N)C(O)=O |&1:2	Launched				
isoliquiritigenin	Oc1ccc(\C=C\C(=O)c2ccc(O)cc2O)cc1	Preclinical	GABBR1	guanylate cyclase activator		
isometheptene-mucate	CN[C@@H](C)CCC=C(C)C |&1:2	Launched			neurology/psychiatry	headache
isoniazid	NNC(=O)c1ccncc1	Launched	CYP1A2|CYP2C19|CYP2C8|CYP2E1|CYP3A4	FABI inhibitor	infectious disease	tuberculosis
isopentyl-4-methoxycinnamate	COc1ccc(\C=C\C(=O)OCCC(C)C)cc1	Launched			dermatology	sunscreen lotion
isoprenaline	CC(C)NC[C@@H](O)c1ccc(O)c(O)c1 |&1:5|	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor agonist	cardiology, pulmonary	bradycardia, heart block, asthma
isopropamide-iodide	CC(C)[N+](C)(CCC(C(N)=O)(c1ccccc1)c1ccccc1)C(C)C	Launched	CHRM3|CHRM4	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD), gastrointestinal acidosis
isopropyl-myristate	CCCCCCCCCCCCCC(=O)OC(C)C	Launched			dermatology	cosmetic
isopropyl-palmitate	CCCCCCCCCCCCCCCC(=O)OC(C)C	Launched		cosmetic moisturizer	dermatology	cosmetic
isoquercitrin	OC[C@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2/Phase 3		antioxidant		
Isoquinoline,-6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro,	COc1cc2CCN[C@@H](C)c2cc1OC |&1:8|	Preclinical				
isosorbide	O[C@H]1CO[C@@H]2[C@H](O)CO[C@H]12	Launched		nitric oxide stimulant	cardiology	angina pectoris, coronary artery disease (CAD)
isosorbide-dinitrate	[O-][N+](=O)O[C@@H]1CO[C@@H]2[C@H](CO[C@H]12)O[N+]([O-])=O	Launched	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3|NPR1	nitric oxide stimulant	cardiology	angina pectoris, coronary artery disease (CAD)
isosorbide-mononitrate	O[C@H]1CO[C@@H]2[C@@H](CO[C@H]12)O[N+]([O-])=O	Launched	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3	nitric oxide stimulant	cardiology	angina pectoris, coronary artery disease (CAD)
isosteviol	C[C@]12C[C@@]3(CC1=O)CC[C@H]1[C@@](C)(CCC[C@@]1(C)C(O)=O)[C@@H]3CC2 |a:1	Phase 2				
isotiquimide	Cc1ccnc2[C@@H](CCCc12)C(N)=S |&1:6	Phase 1				
isotretinoin	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C\C(O)=O |c:4|	Launched	RARA|RARB|RARG	retinoid receptor agonist	dermatology	acne vulgaris (AV)
isovaleramide	CC(C)CC(N)=O	Phase 2		alcohol dehydrogenase inhibitor		
isoxepac	OC(=O)Cc1ccc2OCc3ccccc3C(=O)c2c1	Phase 2		anti-inflammatory agent		
isoxicam	CN1C(C(=O)Nc2cc(C)on2)=C(O)c2ccccc2S1(=O)=O |t:12|	Withdrawn	PTGS1|PTGS2	cyclooxygenase inhibitor		
isoxsuprine	C[C@@H](COc1ccccc1)N[C@H](C)[C@@H](O)c1ccc(O)cc1 |&1:13	Launched	ADRB2	adrenergic receptor agonist	rheumatology, cardiology	Raynaud's disease, arteriosclerosis, Buerger's disease
ispinesib	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1	Phase 2	KIF11	kinesin inhibitor		
isradipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc2nonc12)C(=O)OC(C)C |r	Launched	CACNA1D|CACNA1F|CACNA2D1	calcium channel blocker	cardiology	hypertension
ISRIB	Clc1ccc(OCC(=O)N[C@H]2CC[C@@H](CC2)NC(=O)COc2ccc(Cl)cc2)cc1 |r|	Preclinical	EIF2A|EIF2AK3	eukaryotic translation initiation factor inhibitor, PERK inhibitor		
istaroxime	C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O	Phase 2	ATP1A1	ATPase inhibitor		
istradefylline	CCn1c2nc(\C=C\c3ccc(OC)c(OC)c3)n(C)c2c(=O)n(CC)c1=O	Launched	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist	neurology/psychiatry	Parkinson's Disease, dyskinesia
ISX-9	O=C(NC1CC1)c1cc(on1)-c1cccs1	Preclinical	NEUROD1	neural stem cell inducer		
itacitinib	Fc1c(ccnc1C(F)(F)F)C(=O)N1CCC(CC1)N1CC(CC#N)(C1)n1cc(cn1)-c1ncnc2[nH]ccc12	Phase 3	JAK1	JAK inhibitor		
ITD-1	CCOC(=O)C1=C(C)NC2=C([C@@H]1c1ccc(cc1)-c1ccccc1)C(=O)CC(C)(C)C2 |&1:11	Preclinical	TGFBR2	TGF beta receptor inhibitor		
ITE	COC(=O)c1csc(n1)C(=O)c1c[nH]c2ccccc12	Preclinical	AHR	aryl hydrocarbon receptor agonist		
ITI214	CN1C2=N[C@@H]3CCC[C@@H]3N2c2nn(Cc3ccc(cc3)-c3cccc(F)n3)c(Nc3ccccc3)c2C1=O |t:2|	Phase 1/Phase 2	PDE1A	phosphodiesterase inhibitor		
itopride	COc1ccc(cc1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	Launched	CHRM3|DRD2	dopamine receptor antagonist	gastroenterology, neurology/psychiatry	dyspepsia, gastroparesis, heartburn, nausea, vomiting, anorexia
itraconazole	CC[C@H](C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O |&1:26	Launched		cytochrome P450 inhibitor	infectious disease	onychomycosis, histoplasmosis, blastomycosis, aspergillosis
ITX3	Cc1cc(\C=c2\sc3nc4ccccc4n3c2=O)c(C)n1-c1ccccc1	Preclinical	TRIO	GEF inhibitor		
ITX5061	COc1c(NC(=O)C(=O)c2ccc(OCCN3CCOCC3)c3ccccc23)cc(cc1NS(C)(=O)=O)C(C)(C)C	Phase 1		SR-BI inhibitor		
IT1t	CC1(C)CN2C(CS\C(NC3CCCCC3)=N\C3CCCCC3)=CSC2=N1 |c:24	Preclinical	CXCR4	CC chemokine receptor antagonist		
IU1	Cc1cc(C(=O)CN2CCCC2)c(C)n1-c1ccc(F)cc1	Preclinical	USP14	ubiquitin C-terminal hydrolase inhibitor		
ivabradine	COc1cc2C[C@H](CN(C)CCCN3CCc4cc(OC)c(OC)cc4CC3=O)c2cc1OC	Launched	HCN1|HCN3|HCN4	HCN channel blocker, potassium channel blocker, sodium channel blocker	cardiology	angina pectoris
ivacaftor	CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C	Launched	CFTR	CFTR channel potentiator	pulmonary	cystic fibrosis
ivermectin	CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2 |c:17	Launched	CHRNA7|P2RX7	benzodiazepine receptor agonist	infectious disease	gastrointestinal roundworms, lungworms, cattle grubs, mites, lice, horn flies
ivosidenib	Fc1cncc(c1)N([C@H](C(=O)NC1CC(F)(F)C1)c1ccccc1Cl)C(=O)[C@@H]1CCC(=O)N1c1cc(ccn1)C#N	Launched	IDH1	isocitrate dehydrogenase inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
IWP-L6	O=C(CSc1nc2CCSc2c(=O)n1-c1ccccc1)Nc1ccc(cn1)-c1ccccc1	Preclinical	PORCN	porcupine inhibitor		
ixabepilone	C[C@H]1CCC[C@@]2(C)O[C@H]2C[C@H](NC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)C(\C)=C\c1csc(C)n1	Launched	TUBB	microtubule stabilizing agent	oncology	breast cancer
ixazomib	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O	Launched		proteasome inhibitor	hematologic malignancy	multiple myeloma
ixazomib-citrate	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C[C@@](CC(O)=O)(O1)C(O)=O |a:4	Launched		proteasome inhibitor	hematologic malignancy	multiple myeloma
JAK3-inhibitor-V	C=CC(=O)c1ccc2ccccc2c1	Preclinical	JAK3	JAK inhibitor		
JD-5037	CC(C)[C@H](\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O |c:21|	Preclinical		cannabinoid receptor antagonist		
JDTic	CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)c1cccc(O)c1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1	Phase 1	OPRK1	opioid receptor antagonist		
JHW-007	CCCCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical	SLC6A3	dopamine reuptake inhibitor		
JI-101	COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12	Phase 1/Phase 2		kinase inhibitor		
JIB04	Clc1ccc(N\N=C(/c2ccccc2)c2ccccn2)nc1	Preclinical	KDM4E	histone lysine demethylase inhibitor		
JK-184	CCOc1ccc(Nc2nc(cs2)-c2c(C)nc3ccccn23)cc1	Preclinical		hedgehog pathway inhibitor		
JLK-6	COc1oc(=O)c2cc(N)ccc2c1Cl	Preclinical	PSEN1	gamma secretase inhibitor		
JNJ-10191584	CN1CCN(CC1)C(=O)c1nc2ccc(Cl)cc2[nH]1	Preclinical	HRH4	histamine receptor antagonist		
JNJ-10397049	CC1(C)OC[C@H](NC(=O)Nc2ccc(Br)cc2Br)[C@@H](O1)c1ccccc1	Preclinical	HCRTR1|HCRTR2	orexin receptor antagonist		
JNJ-16259685	CO[C@H]1CC[C@H](CC1)C(=O)c1ccc2nc3OCCCc3cc2c1 |r|	Preclinical	GRM1	glutamate receptor antagonist		
JNJ-1661010	O=C(Nc1ccccc1)N1CCN(CC1)c1nc(ns1)-c1ccccc1	Preclinical	FAAH	FAAH inhibitor		
JNJ-17203212	FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1	Preclinical	TRPV1	TRPV antagonist		
JNJ-26481585	Cn1cc(CNCC2CCN(CC2)c2ncc(cn2)C(=O)NO)c2ccccc12	Phase 2	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9|MDM2	HDAC inhibitor		
JNJ-26990990	NS(=O)(=O)NCc1csc2ccccc12	Phase 2		anticonvulsant		
JNJ-27141491	CC[C@@H](c1ccc(F)c(F)c1)n1c(C(=O)OC)c([nH]c1=S)-c1ccno1	Preclinical	CCR2	CC chemokine receptor antagonist		
JNJ-37822681	Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F	Phase 2	DRD2	dopamine receptor antagonist		
JNJ-38877605	Cn1cc(cn1)-c1ccc2nnc(n2n1)C(F)(F)c1ccc2ncccc2c1	Phase 1	MET	tyrosine kinase inhibitor		
JNJ-38877618	FC(F)(c1nnc2ccc(nn12)-c1ccncc1)c1ccc2ncccc2c1	Phase 1		c-Met inhibitor		
JNJ-39758979	CC(C)c1cc(nc(N)n1)N1CC[C@@H](N)C1	Phase 2		histamine receptor antagonist		
JNJ-40411813	CCCCn1ccc(N2CCC(CC2)c2ccccc2)c(Cl)c1=O	Phase 2	GRM2	glutamate receptor positive allosteric modulator		
JNJ-42041935	OC(=O)c1cnn(c1)-c1nc2cc(Cl)c(OC(F)(F)F)cc2[nH]1	Preclinical	PDK2	hypoxia inducible factor prolyl hydroxylase inhibitor		
JNJ-42165279	FC1(F)Oc2ccc(CN3CCN(CC3)C(=O)Nc3cnccc3Cl)cc2O1	Phase 2	FAAH	FAAH inhibitor		
JNJ-47965567	O=C(NCC1(CCOCC1)N1CCN(CC1)c1ccccc1)c1cccnc1Sc1ccccc1	Preclinical	P2RX7	purinergic receptor antagonist		
JNJ-54175446	C[C@H]1N(CCc2c1nnn2-c1ncc(F)cn1)C(=O)c1cccc(c1Cl)C(F)(F)F	Phase 1		purinergic receptor antagonist		
JNJ-63533054	C[C@H](NC(=O)CNC(=O)c1cccc(Cl)c1)c1ccccc1	Preclinical	GPR139	G protein-coupled receptor agonist		
JNJ-64619178	Nc1nc2cc(CC[C@H]3C[C@H]([C@H](O)[C@@H]3O)n3ccc4c(N)ncnc34)ccc2cc1Br	Phase 1		protein arginine N-methyltransferase inhibitor		
JNJ-678	CS(=O)(=O)CCCn1c(Cn2c3cnccc3n(CC(F)(F)F)c2=O)cc2cc(Cl)ccc12	Phase 1		RSV fusion inhibitor		
JNJ-7706621	Nc1nc(Nc2ccc(cc2)S(N)(=O)=O)nn1C(=O)c1c(F)cccc1F	Preclinical	AURKA|AURKB|CDK1|CDK2	CDK inhibitor		
JNJ-7777120	CN1CCN(CC1)C(=O)c1cc2cc(Cl)ccc2[nH]1	Preclinical	HRH4	histamine receptor antagonist		
josamycin	[H][C@@]1(C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1)O[C@@H]1[C@@H](C)O[C@@]([H])(O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@]([H])(OC(C)=O)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:36	Launched		bacterial 50S ribosomal subunit inhibitor	pulmonary	bronchitis
JPH203	N[C@@H](Cc1cc(Cl)c(OCc2cc(N)cc3nc(oc23)-c2ccccc2)c(Cl)c1)C(O)=O	Preclinical		solute carrier family member inhibitor		
JQ1-(+)	Cc1nnc2[C@H](CC(=O)OC(C)(C)C)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1 |c:14|	Preclinical	BRD4|BRDT	bromodomain inhibitor		
JTC-801	CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1	Phase 2	OPRL1	opioid receptor antagonist		
JTE-013	CC(C)c1cc(NNC(=O)Nc2cc(Cl)nc(Cl)c2)nc2n(C)nc(C)c12	Preclinical	P2RY10|S1PR2	lysophospholipid receptor antagonist		
JTE-607	CCOC(=O)[C@H](Cc1ccccc1)NC(=O)c1cc(Cl)c(OCCN2CCN(C)CC2)c(Cl)c1O	Phase 2	IL10|IL1B|IL6|TNF	cytokine production inhibitor		
JTE-907	CCCCCOc1c(OC)ccc2cc(C(=O)NCc3ccc4OCOc4c3)c(=O)[nH]c12	Phase 1	CNR2	cannabinoid receptor inverse agonist		
JW-55	COc1ccc(cc1)C1(CNC(=O)c2ccc(NC(=O)c3ccco3)cc2)CCOCC1	Preclinical	TNKS|TNKS2	tankyrase inhibitor		
JW-642	FC(F)(F)C(OC(=O)N1CCN(Cc2cccc(Oc3ccccc3)c2)CC1)C(F)(F)F	Preclinical	MGLL	monoacylglycerol lipase inhibitor		
JW-67	O=C1Nc2ccccc2C11OCC2(CO1)COC1(OC2)C(=O)Nc2ccccc12	Preclinical	APC|AXIN1|GSK3B	WNT pathway inhibitor		
JW-74	COc1ccc(cc1)-n1c(SCc2nc(no2)-c2ccc(C)cc2)nnc1-c1ccncc1	Preclinical	TNKS|TNKS2	tankyrase inhibitor, WNT signaling inhibitor		
JX-401	COc1cc(SC)ccc1C(=O)N1CCC(Cc2ccccc2)CC1	Preclinical	MAPK14	p38 MAPK inhibitor		
JZL-184	OC(C1CCN(CC1)C(=O)Oc1ccc(cc1)[N+]([O-])=O)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	Preclinical	MGLL	monoacylglucerol lipase inhibitor		
JZL-195	[O-][N+](=O)c1ccc(OC(=O)N2CCN(Cc3cccc(Oc4ccccc4)c3)CC2)cc1	Preclinical	FAAH|MGLL	FAAH inhibitor, monoacylglycerol lipase inhibitor		
J147	COc1cccc(\C=N\N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1	Phase 1		BDNF inducer		
K-MAP	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2	Phase 2				
K-Ras(G12C)-inhibitor-12	Oc1cc(Cl)c(I)cc1NCC(=O)N1CCN(CC1)C(=O)C=C	Preclinical	KRAS	K-Ras inhibitor		
K-Ras(G12C)-inhibitor-6	SCCCC(=O)NC1CCN(CC1)C(=O)COc1ccc(Cl)cc1Cl	Preclinical		K-Ras inhibitor		
K-strophanthidin	C[C@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1 |t:27|	Phase 2	ATP1A1	ATPase inhibitor		
K-247	OC[C@H]1O[C@@H](Nc2ccc(cc2)C(O)=O)[C@@H](O)[C@@H]1O |&1:2	Phase 1				
K-858	CC(=O)NC1=NN(C(C)=O)[C@@](C)(S1)c1ccccc1 |&1:10	Preclinical	KIF11	kinesin-like spindle protein inhibitor		
kaempferol	Oc1ccc(cc1)-c1oc2cc(O)cc(O)c2c(=O)c1O	Preclinical	AKR1B1|ALOX15B|ALOX5|AR|CYP1B1|GLO1|HSD17B1|UGT3A1	bone resorption inhibitor, estrogen-related receptor inverse agonist		
KAF-156	CC1(C)N(CCn2c(Nc3ccc(F)cc3)c(nc12)-c1ccc(F)cc1)C(=O)CN	Preclinical		antimalarial agent		
kainic-acid	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(O)=O)C(O)=O	Preclinical	GRIA1|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5	kainate receptor agonist		
kakonein	OC[C@H]1O[C@@H]([C@@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O |&1:2	Phase 2		GABA receptor antagonist, serotonin receptor antagonist		
kanamycin	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections
karenitecin	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccccc4c(CC[Si](C)(C)C)c3Cn1c2=O	Phase 3	TOP1	topoisomerase inhibitor		
kartogenin	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)-c1ccccc1	Preclinical	FLNA	chondrocyte differentiation stimulator		
kasugamycin	C[C@H]1O[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]2O)[C@@H](N)C[C@@H]1NC(=N)C(O)=O	Preclinical		bacterial 30S ribosomal subunit inhibitor		
KB-R7943	NC(=N)SCCc1ccc(OCc2ccc(cc2)[N+]([O-])=O)cc1	Preclinical	SLC8A1|TRPC3|TRPC5|TRPC6	sodium/calcium exchange inhibitor		
KB-SRC-4	Nc1ncnc2n(nc(-c3ccc(Cl)cc3)c12)-c1cccc(c1)-c1cnnn1Cc1cccc(c1)-c1ccccc1	Preclinical	SRC	SRC inhibitor		
KBG	O[C@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H](O)[C@H]1O)c1ccccc1 |a:3	Phase 2	MME	neprilysin inhibitor		
KD-023	CCCCCCCCCCCCCCOc1ccc(o1)C(O)=O	Phase 2	ACACA|ACACB	ACAT inhibitor		
KD025	CC(C)NC(=O)COc1cccc(c1)-c1nc(Nc2ccc3n[nH]cc3c2)c2ccccc2n1	Phase 2	ROCK2	rho associated kinase inhibitor		
kenpaullone	Brc1ccc2[nH]c-3c(CC(=O)Nc4ccccc-34)c2c1	Preclinical	CCNB1|CDK1|CDK5|GSK3B	CDK inhibitor, glycogen synthase kinase inhibitor		
ketanserin	Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1	Launched	ADRA1A|ADRA1B|ADRA1D|DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|SLC18A1|SLC18A2	serotonin receptor antagonist	cardiology	hypertension
ketoconazole	CC(=O)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1 |&1:15	Launched	KCNA10	sterol demethylase inhibitor	dermatology	seborrheic dermatitis
ketohexokinase-inhibitor-1	[H][C@@]12CN(C[C@]1([H])[C@H]2CC(O)=O)c1cc(nc(n1)N1CC[C@@H]1C)C(F)(F)F	Preclinical		kinase inhibitor		
ketoprofen	C[C@@H](C(O)=O)c1cccc(c1)C(=O)c1ccccc1 |&1:1	Launched	PTGS1|PTGS2|SLC5A8	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis, osteoarthritis
ketorolac	OC(=O)[C@H]1CCn2c1ccc2C(=O)c1ccccc1 |&1:3	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
ketotifen	CN1CCC(CC1)=C1c2ccsc2C(O)=Cc2ccccc12 |c:16|	Launched	HRH1	histamine receptor agonist, leukotriene receptor antagonist, phosphodiesterase inhibitor	neurology/psychiatry	itching
kevetrin	NC(=N)SCCCC#N	Phase 1		p53 activator		
KF-38789	COc1ccc([C@H]2CC(=NCCS2)c2c(O)cc(C)oc2=O)c(OC)c1 |&1:6	Preclinical	SELP	P selectin inhibitor		
KG-5	CSc1nc(N)cc(Oc2ccc(cc2)-c2nnc(Nc3cccc(c3)C(F)(F)F)[nH]2)n1	Preclinical	BRAF|FLT3|KIT|PDGFRB	RAF inhibitor		
KH-CB19	CCOC(=O)c1c(C(C=N)C#N)c2ccc(Cl)c(Cl)c2n1C	Preclinical	CLK1|CLK3|DYRK1A	CDC inhibitor		
khellin	COc1c2ccoc2c(OC)c2oc(C)cc(=O)c12	Phase 2		vasodilator		
KHK-IN-1	CSc1ccccc1Nc1nc(nc2c(NCC3CC3)ncnc12)N1CCNCC1	Preclinical	KHK	hexokinase inhibitor		
KHS-101	CC(C)CNc1ccnc(NCc2csc(n2)-c2ccccc2)n1	Preclinical	TACC3	neural stem cell inducer		
KI-16425	C[C@@H](OC(=O)Nc1c(C)noc1-c1ccc(CSCCC(O)=O)cc1)c1ccccc1Cl |&1:1	Preclinical	LPAR1|LPAR3	lysophosphatidic acid receptor antagonist		
KI-20227	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)N[C@@H](C)c1nccs1 |&1:27	Preclinical	CSF1R|KDR|KIT|PDGFRB	c-Fms inhibitor		
KI-8751	COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC	Preclinical	KDR	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
kifunensine	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H]2NC(=O)C(=O)N12	Phase 1	MAN1B1|MAN2A1	mannosidase inhibitor		
kinetin	C(Nc1ncnc2nc[nH]c12)c1ccco1	Launched		cell division inducer	dermatology	sunburn
ki16198	COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)O[C@@H](C)c1ccccc1Cl |&1:24	Preclinical	LPA	lipoprotein antagonist		
KL-001	CS(=O)(=O)N(C[C@@H](O)Cn1c2ccccc2c2ccccc12)Cc1ccco1 |&1:6	Preclinical	CRY1|CRY2	proteasome inhibitor		
KM-0118	CN(C)CCNC(=O)COc1c2Cc3cccc(Cc4cccc(Cc5cccc(Cc1ccc2)c5OCC(=O)NCCN(C)C)c4OCC(=O)NCCN(C)C)c3OCC(=O)NCCN(C)C	Phase 1		anticancer agent		
KME-4	CC(C)(C)c1cc(\C=C2/CCOC2=O)cc(c1O)C(C)(C)C	Preclinical		prostaglandin inhibitor		
KML29	OC(C1CCN(CC1)C(=O)OC(C(F)(F)F)C(F)(F)F)(c1ccc2OCOc2c1)c1ccc2OCOc2c1	Preclinical	MGLL	monoacylglucerol lipase inhibitor		
KN-62	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(CC1)c1ccccc1)S(=O)(=O)c1cccc2cnccc12 |&1:2	Preclinical	AKT1|CAMK2A|CHEK1|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|P2RX7|PRKCA|ROCK1|RPS6KB1|SGK1	calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist		
KN-93	COc1ccc(cc1)S(=O)(=O)N(CCO)c1ccccc1CN(C)C\C=C\c1ccc(Cl)cc1	Preclinical	CAMK2A	calcium/calmodulin dependent protein kinase inhibitor		
Ko143	COc1ccc2c3C[C@@H]4N([C@@H](CC(C)C)c3[nH]c2c1)C(=O)[C@H](CCC(=O)OC(C)(C)C)NC4=O	Preclinical	ABCB1|ABCC1	BCRP inhibitor		
KP-1212	NC1=NC(=O)N(CN1)[C@H]1C[C@@H](O)[C@@H](CO)O1 |t:1|	Phase 2				
KPT-185	COc1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)OC(C)C)n1	Preclinical	XPO1	exportin antagonist		
KPT-276	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)N2CC(F)(F)C2)n1	Preclinical	XPO1	exportin antagonist		
KPT-9274	Nc1ccc(\C=C\C(=O)NCc2cc3cc(cc(-c4ccc(F)cc4)c3o2)-c2ccc(cc2)C(=O)N2CCC(F)(F)CC2)cn1	Phase 1		NAMPT inhibitor		
KR-33494	OC(=O)c1nn(CCc2ccccc2)cc1NC(=O)CSc1ccc(Br)cc1	Preclinical		cell death inhibitor 		
KRCA-0008	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccc(cc2OC)N2CCN(CC2)C(C)=O)n1)N1CCN(CC1)C(C)=O	Preclinical	ALK	ALK inihibitor		
KRN-633	CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl	Preclinical	FLT1|FLT4|KDR	VEGFR inhibitor		
KS-176	OCCc1ccc(NC(=O)c2ccccc2NC(=O)c2ccc(cc2)[N+]([O-])=O)cc1	Preclinical	ABCG2	BCRP inhibitor		
KT-433	CCc1oc2ccccc2c1C(=O)c1ccc(OCC(O)=O)cc1	Phase 2		uricosuric agent		
KU-0063794	COc1ccc(cc1CO)-c1ccc2c(nc(nc2n1)N1C[C@H](C)O[C@H](C)C1)N1CCOCC1	Preclinical	MTOR	mTOR inhibitor		
KU-55933	O=c1cc(oc(c1)-c1cccc2Sc3ccccc3Sc12)N1CCOCC1	Preclinical	ATM|PRKDC	ATM kinase inhibitor		
KU-60019	C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1	Preclinical	ATM	ATM kinase inhibitor		
kuromanin	OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2ccc(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical	CD38	ribosyl cyclase inhibitor		
KU14R	CC[C@]1(Cc2ccccc2O1)c1ncc[nH]1 |&1:2	Preclinical		imidazoline receptor antagonist		
KW-2449	O=C(N1CCNCC1)c1ccc(\C=C\c2[nH]nc3ccccc23)cc1	Phase 1	ABL1|AURKA|AURKB|FLT3	Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor		
KW-2478	CCc1c(O)cc(O)c(C(=O)c2ccc(OCCN3CCOCC3)c(OC)c2)c1CC(=O)N(CCOC)CCOC	Phase 1/Phase 2		HSP inhibitor		
KW-3902	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)C12C[C@@H]3C[C@H]1C[C@H](C2)C3 |&1:23	Phase 3	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
KX2-391	O=C(Cc1ccc(cn1)-c1ccc(OCCN2CCOCC2)cc1)NCc1ccccc1	Phase 3	SRC	SRC inhibitor, tubulin polymerization inhibitor		
kynurenic-acid	OC(=O)c1cc(=O)c2ccccc2[nH]1	Phase 1	GPR35|GRIN1|GRIN2A|GRIN2B	glutamate receptor antagonist		
KY02111	COc1ccc(CCC(=O)Nc2nc3ccc(Cl)cc3s2)cc1OC	Preclinical	DKK1	WNT pathway inhibitor		
K02288	COc1cc(cc(OC)c1OC)-c1cc(cnc1N)-c1cccc(O)c1	Preclinical	BMP1	bone morphogenic protein inhibitor		
K145	CCCCOc1ccc(CC\C=C2/SC(=O)N(CCN)C2=O)cc1	Preclinical	SPHK2	sphingosine kinase inhibitor		
L-(+)-rhamnose-monohydrate	C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O	Preclinical				
L-alanine	C[C@H](N)C(O)=O	Launched	AARS|AARS2|ABAT|AGXT|AGXT2|GPRC6A|GPT|GPT2|KYNU|NFS1|PHYKPL|SLC1A4|SLC36A1|SLC7A8			
L-arginine	N[C@@H](CCCNC(N)=N)C(O)=O	Launched	ARG2|ASL|ASS1|AZIN2|GPRC6A|NOS2|NOS3|SLC7A1|SLC7A3|SLC7A4	nitric oxide precursor	cardiology, neurology/psychiatry, urology, obstetrics/gynecology, otolaryngology	congestive heart failure, hypertension, coronary artery disease (CAD), claudication, senile dementia, erectile dysfunction, infertility, common cold
L-ascorbyl-6-palmitate	CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(=O)[C@@H]1O |a:19	Preclinical				
L-asparagine	N[C@@H](CC(N)=O)C(O)=O	Phase 3	ASNS|ASRGL1|NARS|NARS2|SLC1A5|SLC38A3			
L-asparagine-N-hydroxy	N[C@@H](CC(=O)NO)C(O)=O	Preclinical				
L-aspartic-acid	N[C@@H](CC(O)=O)C(O)=O	Launched	ACY1|ACY3|ADSS|ADSSL1|ASNS|ASPA|ASPH|ASRGL1|ASS1|CAD|DARS|DARS2|GOT1|GOT2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|LYZ|PAICS|RNASE1|SLC1A1|SLC25A12|SLC25A13	metallic radical formation stimulant		
L-citrulline	N[C@@H](CCCNC(N)=O)C(O)=O |&1:1	Launched	ASS1|DDAH1|DDAH2|GPRC6A|NOS1|NOS2|NOS3|OTC|PADI1|PADI2|PADI3|PADI4|PADI6	nitric oxide stimulant	cardiology, urology	hypertension, erectile dysfunction
L-cysteine	N[C@@H](CS)C(O)=O	Launched	CARS|CARS2|CBS|CDO-1|CDO1|CSAD|CTH|GCLC|GCLM|GOT1|GSS|MGMT|NFS1|SLC19A3		rheumatology	osteoarthritis, rheumatoid arthritis
L-cysteinesulfinic-acid	N[C@@H](C[S@@](O)=O)C(O)=O |a:1	Preclinical	GRM1|GRM5|GSR|HMGCS2|PAPOLA|PRDX2	glutamate receptor agonist		
L-cystine	N[C@@H](CSSC[C@H](N)C(O)=O)C(O)=O	Launched	CTNS|SLC3A1|SLC7A11|SLC7A9			
L-ergothioneine	C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O	Phase 3		free radical scavenger		
L-glutamic-acid	N[C@@H](CCC(O)=O)C(O)=O	Launched	AADAT|AASS|ABAT|ALDH18A1|ASNS|BCAT1|BCAT2|CCBL2|DNPEP|EARS2|ENPEP|EPRS|FOLH1|FPGS|FTCD|GAD1|GAD2|GATB|GCLC|GCLM|GGCX|GLS|GLS2|GLUD1|GLUD2|GLUL|GMPS|GOT1|GOT2|GPT|GPT2|GRIA1|GRIA2|GRIA3|GRIA4|GRID1|GRID2|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D|GRIN3A|GRIN3B|GRM1|GRM2|GRM3|GRM4|GRM6|GRM7|GRM8|LGSN|NADSYN1|NAGS|OPLAH|PFAS|PGCP|PSAT1|SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7|SLC25A18|SLC25A22|SLC7A11|TAT	glutamate receptor agonist		
L-glutamine	N[C@@H](CCC(N)=O)C(O)=O	Launched	CTPS1|GLUL|GPRC6A|PPAT		gastroenterology, dental, neurology/psychiatry, rheumatology	diarrhea, mucositis, muscle pain, joint pain, peptic ulcer disease (PUD), ulcerative colitis, Crohn's disease, anxiety, insomnia
L-hydroxyproline	O[C@H]1CN[C@@H](C1)C(O)=O |&1:1	Launched				
L-kynurenine	N[C@@H](CC(=O)c1ccccc1N)C(O)=O	Phase 1		aryl hydrocarbon receptor agonist		
L-leucine	CC(C)C[C@H](N)C(O)=O	Phase 3	BCAT1|BCAT2|LARS|LARS2|LCMT1|LCMT2			
L-lysine	NCCCC[C@H](N)C(O)=O	Phase 2	GPRC6A|KARS|SLC7A1|SLC7A2|SLC7A3|SLC7A4	serotonin receptor agonist		
L-methionine	CSCC[C@H](N)C(O)=O	Launched	BHMT|BHMT2|METAP2|MTR|MTRR	voltage-gated calcium channel ligand	pulmonary, allergy, neurology/psychiatry	asthma, allergic rhinitis, depression, Parkinson's Disease, schizophrenia
L-mimosine	N[C@@H](CN1CC(=O)C(=O)C=C1)C(O)=O |c:9|	Preclinical	DBH|EIF5A	dopamine beta hydroxylase inhibitor, eukaryotic translation initiation factor inhibitor		
L-monomethylarginine	CN[C@@H](CCCNC(N)=N)C(O)=O	Phase 3	NOS1|NOS2	nitric oxide synthase inhibitor		
L-NAME	COC(=O)[C@@H](N)CCCNC(N)=N[N+]([O-])=O	Phase 2/Phase 3	NOS3	nitric oxide synthase inhibitor		
L-NIL	CC(=N)NCCCC[C@H](N)C(O)=O	Preclinical	NOS1|NOS2|NOS3	nitric oxide synthase inhibitor		
L-phenylisopropyladenosine	C[C@H](Cc1ccccc1)Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical				
L-proline	OC(=O)[C@@H]1CCCN1	Launched	EPRS|L3HYPDH|P3H1|P3H2|P3H3|P4HA1|P4HA2|PARS2|PPIA|PPIB|PPIC|PPIF|PPIG|PPIH|PRODH|PROSC|PYCR1|PYCR2|PYCRL|SLC6A14|SLC6A7	glutamate receptor agonist		
L-quisqualic-acid	N[C@@H](Cn1oc(=O)[nH]c1=O)C(O)=O	Preclinical	FOLH1|GRIA2|GRIK1|GRIK2|GRM1|GRM2|GRM3|GRM5|GRM7|GRM8	glutamate receptor agonist		
L-theanine	CCNC(=O)CC[C@H](N)C(O)=O	Launched		glutamate receptor antagonist		
L-threonine	C[C@@H](O)[C@H](N)C(O)=O	Phase 2	TARS|TARS2|THNSL1			
L-valine	CC(C)[C@@H](N)C(O)=O	Phase 2				
L-152804	CC1(C)CC(=O)C([C@@H]2C3=C(CC(C)(C)CC3=O)Oc3ccccc23)C(=O)C1 |&1:7	Preclinical	NPY5R	neuropeptide receptor antagonist		
L-161982	CCCCc1nn(-c2ccccc2C(F)(F)F)c(=O)n1Cc1ccc(cc1)-c1ccccc1S(=O)(=O)NC(=O)c1sccc1C	Preclinical	PTGER4	prostanoid receptor antagonist		
L-165041	CCCc1c(O)c(ccc1OCCCOc1ccc(OCC(O)=O)cc1)C(C)=O	Preclinical	PPARD	PPAR receptor agonist		
L-168049	CCCOc1ccc(Br)cc1-c1cc([nH]c1-c1ccncc1)-c1ccc(Cl)cc1	Preclinical	GCGR	glucagon receptor antagonist		
L-365260	CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1 |c:9|	Phase 2	CCKAR|CCKBR|KCNQ1	CCK receptor antagonist		
L-368899	Cc1ccccc1N1CCN(CC1)S(=O)(=O)C[C@]12CC[C@H](C[C@@H]1NC(=O)[C@@H](N)CCS(C)(=O)=O)C2(C)C	Phase 1	AVPR1A|AVPR2|OXTR	oxytocin receptor antagonist		
L-655,708	CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21	Preclinical	GABRA1|GABRA2|GABRA3|GABRA5|GABRG2	GABA receptor inverse agonist		
L-655240	Cc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(F)cc12	Phase 1	PTGES	thromboxane receptor antagonist		
L-670596	CS(=O)(=O)c1ccc(Cn2c3[C@@H](CC(O)=O)CCCc3c3cc(F)cc(F)c23)cc1 |&1:11	Preclinical		prostanoid receptor antagonist		
L-689560	OC(=O)[C@H]1C[C@H](NC(=O)Nc2ccccc2)c2c(Cl)cc(Cl)cc2N1	Preclinical	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor antagonist		
L-690330	CC(Oc1ccc(O)cc1)(P(O)(O)=O)P(O)(O)=O	Preclinical	IMPA1	inositol monophosphatase inhibitor		
L-693403	C(N1CCC2(CCc3ccccc23)CC1)c1ccccc1	Preclinical	DRD2|SIGMAR1	sigma receptor agonist, sigma receptor antagonist		
L-694247	CS(=O)(=O)Nc1ccc(Cc2noc(n2)-c2ccc3[nH]cc(CCN)c3c2)cc1	Preclinical	HTR1A|HTR1B|HTR1D	serotonin receptor agonist		
L-701252	Oc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12	Preclinical	GRIN1	glutamate receptor antagonist		
L-701324	Oc1c(-c2cccc(Oc3ccccc3)c2)c(=O)[nH]c2cc(Cl)ccc12	Preclinical	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor antagonist		
L-732,138	CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)OCc1cc(cc(c1)C(F)(F)F)C(F)(F)F	Preclinical	TACR1|TACR2	tachykinin antagonist		
L-733060	FC(F)(F)c1cc(CO[C@H]2CCCN[C@H]2c2ccccc2)cc(c1)C(F)(F)F	Preclinical	TACR1	tachykinin antagonist		
L-741742	Cc1c(noc1-c1ccc(Cl)cc1)C1CCN(CCc2ccccc2)CC1	Preclinical	DRD3|DRD4|SCN1A|SCN3A	dopamine receptor antagonist		
L-745870	Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1	Preclinical	DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR6|HTR7	dopamine receptor antagonist		
L-755507	CCCCCCNC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)COc2ccc(O)cc2)cc1	Preclinical	ADRB1|ADRB2|ADRB3	adrenergic receptor agonist		
L-760735	C[C@@H](O[C@H]1OCCN(Cc2n[nH]nc2CN(C)C)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Preclinical	TACR1	tachykinin antagonist		
L-778123	Clc1cccc(c1)N1CCN(Cc2cncn2Cc2ccc(cc2)C#N)CC1=O	Phase 1	FNTA|FNTB|PGGT1B	farnesyltransferase inhibitor		
L-798106	COc1ccc(Br)cc1S(=O)(=O)NC(=O)\C=C\c1ccccc1Cc1ccc2ccccc2c1	Preclinical	PTGER3	prostanoid receptor antagonist		
L-838417	Cn1ncnc1COc1nn2c(nnc2cc1C(C)(C)C)-c1cc(F)ccc1F	Preclinical	GABRA1|GABRA2|GABRA3|GABRA5	GABA receptor partial agonist		
labetalol	C[C@@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O |&1:1	Launched	ADRA1D|ADRB1|ADRB2	adrenergic receptor antagonist	cardiology	hypertension
lacidipine	CCOC(=O)C1=C(C)NC(C)=C(C1c1ccccc1\C=C\C(=O)OC(C)(C)C)C(=O)OCC |c:5	Launched	CACNA1C	calcium channel blocker	cardiology	hypertension
lacitol	OC[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO	Launched		laxative	gastroenterology	constipation
lactulose	OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O	Launched		laxative	gastroenterology	portal-systemic encephalopathy (PSE)
lafutidine	O=C(C[S@@](=O)Cc1ccco1)NC\C=C/COc1cc(CN2CCCCC2)ccn1 |&1:3|	Launched	HRH2	histamine receptor antagonist	gastroenterology	duodenal ulcer disease, peptic ulcer disease (PUD)
lamivudine	Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1	Launched		nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS), hepatitis B
lamotrigine	Nc1nnc(c(N)n1)-c1cccc(Cl)c1Cl	Launched	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	serotonin receptor antagonist, sodium channel blocker	neurology/psychiatry	epilepsy, bipolar disorder
lanabecestat	CO[C@H]1CC[C@@]2(Cc3ccc(cc3[C@@]22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1 |c:20	Phase 3		beta secretase inhibitor		
lanatoside-C	C[C@H]1O[C@H](C[C@H](O)[C@@H]1O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](OC(C)=O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@@H](C)O2)[C@@H](C)O1)O[C@H]1CC[C@@]2(C)[C@@H](CC[C@H]3[C@@H]2C[C@@H](O)[C@]2(C)[C@H](CC[C@]32O)C2=CC(=O)OC2)C1 |a:1	Preclinical		cardiac glycoside		
landiolol	CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1	Launched	ADRB1	adrenergic receptor antagonist	cardiology	cardiac arrythmia
lanifibranor	OC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1ccc2ncsc2c1	Phase 2		PPAR receptor agonist		
lanoconazole	Clc1ccccc1[C@H]1CS\C(S1)=C(\C#N)n1ccnc1 |&1:7	Launched		sterol demethylase inhibitor	infectious disease	fungal infection
lansoprazole	Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1 |&1:14	Launched	ATP4A|ATP4B	ATPase inhibitor	gastroenterology	heartburn
lapatinib	CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1	Launched	EGFR|ERBB2	EGFR inhibitor	oncology	breast cancer
lappaconite	CCN1C[C@@]2(CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@]5(O)[C@](O)(C[C@@H]6OC)[C@@H](C[C@H]23)[C@@H]14)OC(=O)c1ccccc1NC(C)=O	Phase 2		sodium channel blocker		
laquinimod	CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1	Phase 3	CXCL2	immunosuppressant		
larazotide-acetate	CC(C)C[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CN)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O	Phase 2		tight junction regulator		
laropiprant	CS(=O)(=O)c1cc(F)cc2c3CC[C@H](CC(O)=O)c3n(Cc3ccc(Cl)cc3)c12	Launched	PTGDR|PTGDR2|PTGER1|PTGER2|PTGER3|PTGFR|PTGIR|TBXA2R	prostanoid receptor antagonist	cardiology	cholesterol
larotrectinib	O[C@H]1CCN(C1)C(=O)Nc1cnn2ccc(nc12)N1CCC[C@@H]1c1cc(F)ccc1F	Launched	NTRK1|NTRK2|NTRK3	tropomyosin receptor kinase inhibitor		
lasalocid	CC[C@H]([C@H]1O[C@@](CC)(C[C@@H]1C)[C@H]1CC[C@](O)(CC)[C@H](C)O1)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O	Launched		bacterial permeability inducer	infectious disease	coccidiosis
lasmiditan	CN1CCC(CC1)C(=O)c1cccc(NC(=O)c2c(F)cc(F)cc2F)n1	Launched		serotonin receptor agonist		
lasofoxifene	O[C@@H]([C@H](O)C(O)=O)C(O)=O.Oc1ccc2[C@H]([C@H](CCc2c1)c1ccccc1)c1ccc(OCCN2CCCC2)cc1	Launched	ESR1|ESR2	selective estrogen receptor modulator (SERM)	orthopedics, oncology	osteoporosis, breast cancer
latanoprost	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1	Launched	PTGFR	prostanoid receptor agonist	ophthalmology	ocular hypertension, glaucoma
latrepirdine	CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(C)nc1	Phase 3	HRH1|HTR6	glutamate receptor antagonist		
latrunculin-B	C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]2CSC(=O)N2)OC(=O)\C=C(C)/CC\C=C/1 |c:27	Phase 1	ACTA1|MKL1|SPIRE2	actin polymerization inhibitor		
lauric-acid	CCCCCCCCCCCC(O)=O	Phase 3	GPR84|HNF4A|LTF|LY96|PLA2G2A|TLR4	bacterial permeability inducer		
lauric-diethanolamide	CCCCCCCCCCCC(=O)N(CCO)CCO	Preclinical				
laurocapram	CCCCCCCCCCCCN1CCCCCC1=O	Phase 3				
lazabemide	NCCNC(=O)c1ccc(Cl)cn1	Phase 3	MAOB	monoamine oxidase inhibitor		
lazertinib	COc1cc(N2CCOCC2)c(NC(=O)C=C)cc1Nc1nccc(n1)-n1cc(CN(C)C)c(n1)-c1ccccc1	Phase 1/Phase 2		tyrosine kinase inhibitor		
LB-100	CN1CCN(CC1)C(=O)[C@@H]1[C@H]2CC[C@H](O2)[C@@H]1C(O)=O |&1:10	Phase 2		protein phosphatase inhibitor		
LB42708	Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1	Preclinical		farnesyltransferase inhibitor		
LCL-161	CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1	Phase 2	BIRC2|XIAP	XIAP inhibitor		
LCQ908	OC(=O)C[C@H]1CC[C@@H](CC1)c1ccc(cc1)-c1ccc(Nc2ccc(nc2)C(F)(F)F)cn1 |r|	Phase 3	DGAT1	diacylglycerol O acyltransferase inhibitor		
LCZ696		Launched		angiotensin receptor antagonist	cardiology	angioedema, hypotension
LDC1267	CCOc1cn(nc1C(=O)Nc1ccc(Oc2ccnc3cc(OC)c(OC)cc23)c(F)c1)-c1ccc(F)cc1C	Preclinical	AXL|MERTK|TYRO3	protein tyrosine kinase inhibitor		
LDN-209929	COc1ccc2nc3ccc(Cl)cc3c(SCCCN)c2c1	Preclinical	GSG2	haspin kinase inhibitor		
LDN-212854	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	Preclinical	ABL1|ACVR1|RIPK2	bone morphogenic protein inhibitor		
LDN-27219	NNC(=O)CSc1nc2scc(-c3ccccc3)c2c(=O)n1-c1ccccc1	Preclinical	TGM2	tissue transglutaminase inhibitor		
LDN-57444	CC(=O)O\N=C1\C(=O)N(Cc2cc(Cl)ccc2Cl)c2ccc(Cl)cc12	Preclinical		ubiquitin C-terminal hydrolase inhibitor		
LDN193189	C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccnc2ccccc12	Preclinical	ACVR1|BMPR1A	bone morphogenic protein inhibitor		
LE-135	CN1c2cc3c(cc2N=C(c2ccc(cc2)C(O)=O)c2ccccc12)C(C)(C)CCC3(C)C |t:9|	Preclinical	RARB	retinoid receptor agonist		
ledipasvir	COC(=O)N[C@@H](C(C)C)C(=O)N1CC2(CC2)C[C@H]1c1nc(c[nH]1)-c1ccc2-c3ccc(cc3C(F)(F)c2c1)-c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2CC[C@H](C2)N1C(=O)[C@@H](NC(=O)OC)C(C)C	Launched		HCV inhibitor	infectious disease	hepatitis C
leflunomide	Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F	Launched	AHR|DHODH|PTK2B	dihydroorotate dehydrogenase inhibitor, PDGFR tyrosine kinase receptor inhibitor	rheumatology	rheumatoid arthritis
lemborexant	Cc1ncc(OC[C@]2(C[C@H]2C(=O)Nc2ccc(F)cn2)c2cccc(F)c2)c(C)n1	Launched	HCRTR1|HCRTR2	orexin receptor antagonist		
lenalidomide	Nc1cccc2C(=O)N(Cc12)[C@H]1CCC(=O)NC1=O |&1:11	Launched	TNF	anticancer agent	hematologic malignancy	multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS)
leniolisib	CCC(=O)N1CC[C@@H](C1)Nc1ncnc2CCN(Cc12)c1cnc(OC)c(c1)C(F)(F)F	Phase 2/Phase 3		PI3K inhibitor		
lenvatinib	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O	Launched	FLT4|KDR	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	oncology	thyroid cancer
leonurine	COc1cc(cc(OC)c1O)C(=O)OCCCCNC(N)=N	Preclinical		anti-inflammatory agent		
LEQ506	C[C@@H]1CN(CCN1c1cnc(cn1)C(C)(C)O)c1nnc(Cc2ccccc2)c(C)c1C	Phase 1		G protein signaling inhibitor		
lercanidipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(c1ccccc1)c1ccccc1 |r	Launched	CACNA2D1	calcium channel blocker	cardiology	hypertension
lerisetron	C(c1ccccc1)n1c(nc2ccccc12)N1CCNCC1	Phase 3	HTR3A	serotonin receptor antagonist		
lersivirine	CCc1nn(CCO)c(CC)c1Oc1cc(cc(c1)C#N)C#N	Phase 2		non-nucleoside reverse transcriptase inhibitor		
lesinurad	OC(=O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12	Launched	SLC22A12	uric acid diuretic	rheumatology	gout
lestaurtinib	C[C@]12O[C@@H](C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13 |a:1	Phase 3	FLT3|NTRK1	FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor		
leteprinim	OC(=O)c1ccc(NC(=O)CCn2cnc3c2[nH]cnc3=O)cc1	Phase 2		nerve growth factor agonist		
letermovir	COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@H](CC(O)=O)N1c1cc(ccc1OC)C(F)(F)F |t:16|	Launched		CMV terminase inhibitor	infectious disease	cytomegalovirus (CMV)
letosteine	CCOC(=O)CSCC[C@H]1N[C@@H](CS1)C(O)=O |&1:9	Launched		mucolytic agent	pulmonary, infectious disease	bronchitis, pneumonia
letrazuril	Fc1ccc(cc1)[C@@H](C#N)c1c(Cl)cc(cc1Cl)-n1ncc(=O)[nH]c1=O |&1:7	Phase 1		antiinfective drug		
letrozole	N#Cc1ccc(cc1)C(c1ccc(cc1)C#N)n1cncn1	Launched	CYP19A1	aromatase inhibitor	oncology	breast cancer
leucomethylene-blue	CN(C)c1ccc2Nc3ccc(cc3Sc2c1)N(C)C	Phase 3	MAPT	nitric oxide production inhibitor, tau aggregation inhibitor		
leucovorin	Nc1nc(=O)c2N(C=O)[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:21	Launched		folate receptor ligand	oncology	osteosarcoma
leucylleucine-methyl-ester	COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C	Phase 2				
leuprolide	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1	Launched	GNRHR	gonadotropin releasing factor hormone receptor agonist	oncology	prostate cancer
levalbuterol	CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1	Launched	ADRB2	adrenergic receptor agonist	pulmonary	bronchospasm
levallorphan	Oc1ccc2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3CC=C)c2c1	Launched	CHRNA2|OPRM1	opioid receptor antagonist	pulmonary	respiratory depression
levamisole	C1CN2C[C@@H](N=C2S1)c1ccccc1 |c:5|	Withdrawn	ALPL	acetylcholine receptor agonist		
levamlodipine	CCOC(=O)C1=C(COCCN)NC(C)=C([C@@H]1c1ccccc1Cl)C(=O)OC |c:5	Launched		calcium channel blocker	cardiology	hypertension
levcromakalim	CC1(C)Oc2ccc(cc2[C@H]([C@@H]1O)N1CCCC1=O)C#N	Phase 3	KCNJ5	potassium channel activator		
levetiracetam	CC[C@H](N1CCCC1=O)C(N)=O	Launched	CACNA1B|SCN1A|SV2A	calcium channel blocker	neurology/psychiatry	seizures
levo-phencynonate	CN1C[C@@H]2CCC[C@H](C1)[C@H]2OC(=O)[C@@](O)(C1CCCC1)c1ccccc1 |&1:7	Launched	CHRM1	acetylcholine receptor antagonist		
levobetaxolol	CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1	Launched	ADRB1|ADRB2	adrenergic receptor antagonist	ophthalmology	intraocular pressure, glaucoma
levobunolol	CC(C)(C)NC[C@H](O)COc1cccc2C(=O)CCCc12	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist	ophthalmology	glaucoma, ocular hypertension
levobunolol-(+)	CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12	Preclinical		adrenergic receptor antagonist		
levobunolol-(+/-)	CC(C)(C)NC[C@@H](O)COc1cccc2C(=O)CCCc12 |&1:6|	Preclinical		adrenergic receptor antagonist		
levocabastine	C[C@@H]1CN(CC[C@]1(C(O)=O)c1ccccc1)[C@H]1CC[C@](CC1)(C#N)c1ccc(F)cc1	Launched	HRH1|NTSR2	histamine receptor antagonist	ophthalmology	conjunctivitis
levocarnitine	C[N+](C)(C)C[C@H](O)CC(O)=O	Launched	CRAT|CROT		endocrinology	carnitine deficiency
levocarnitine-propionate	CCC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C	Launched	CRAT	carnitine palmitoyltransferase inhibitor	neurology/psychiatry, endocrinology	peripheral neuropathy, carnitine deficiency
levocetirizine	OC(=O)COCCN1CCN(CC1)[C@H](c1ccccc1)c1ccc(Cl)cc1	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis, urticaria
levodopa	N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O	Launched	DRD1|DRD2|DRD3|DRD4|DRD5|GPR143	dopamine precursor	neurology/psychiatry	Parkinson's Disease
levodropropizine	OC[C@@H](O)CN1CCN(CC1)c1ccccc1	Launched		antitussive	pulmonary	cough suppressant
levofloxacin	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O	Launched	TOP2A	bacterial DNA gyrase inhibitor	infectious disease, otolaryngology, pulmonary, urology	pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague
levomenol	CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 |c:13|	Launched			neurology/psychiatry, infectious disease	spasms, skin infections
levomenthol	CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O	Launched	OPRK1|TRPA1|TRPM8|TRPV3		neurology/psychiatry	pain relief
levomepromazine	COc1ccc2Sc3ccccc3N(C[C@H](C)CN(C)C)c2c1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR2A|HTR2C	dopamine receptor antagonist	neurology/psychiatry, gastroenterology	psychosis, schizophrenia, bipolar disorder, nausea, insomnia
levomequitazine	C([C@H]1CN2CCC1CC2)N1c2ccccc2Sc2ccccc12 |&1:1	Phase 2	HRH1	histamine receptor antagonist		
levonordefrin	C[C@H](N)[C@H](O)c1ccc(O)c(O)c1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|SLC6A2	vasodilator	hematology	hemorrhage
levonorgestrel	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:9|	Launched	PGR	estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist	endocrinology	contraceptive
levopropoxyphene	CCC(=O)OC(Cc1ccccc1)([C@@H](C)CN(C)C)c1ccccc1 |&1:5	Launched		antitussive	pulmonary	cough suppressant
levosimendan	C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1 |c:6|	Launched	KCNJ11|KCNJ8|PDE3A|TNNC1	calcium sensitizer	cardiology	congestive heart failure
levosulpiride	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O	Launched	CA1|CA12|CA7|DRD2|DRD3	dopamine receptor antagonist	neurology/psychiatry, gastroenterology, urology	schizophrenia, psychosis, anxiety, vertigo, dyspepsia, irritable bowel syndrome, premature ejaculation (PE)
levothyroxine	N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(O)=O	Launched	THRA|THRB	thyroid hormone stimulant	endocrinology	myxedema coma
LFM-A13	CC(=O)[C@@H](C#N)C(=O)Nc1cc(Br)ccc1Br |&1:3	Preclinical	BTK	Bruton's tyrosine kinase (BTK) inhibitor		
LGD-6972	Cc1cc(C)c(c(C)c1)-c1ccc(NC(=O)[C@H](Cc2ccc(cc2)C(=O)NCCS(O)(=O)=O)c2ccc(cc2)-c2ccc(cc2)C(C)(C)C)cc1	Phase 2		glucagon receptor antagonist		
LGK-974	Cc1cc(ccn1)-c1ncc(CC(=O)Nc2ccc(cn2)-c2cnccn2)cc1C	Phase 2	PORCN	porcupine inhibitor		
LH846	Cc1cc2sc(NC(=O)Cc3ccccc3)nc2cc1Cl	Preclinical	CSNK1D	casein kinase inhibitor		
liarozole	Clc1cccc(c1)[C@H](c1ccc2nc[nH]c2c1)n1ccnc1 |&1:7	Phase 2/Phase 3	CYP19A1|CYP26A1	cytochrome P450 inhibitor		
licarbazepine	NC(=O)N1c2ccccc2C[C@@H](O)c2ccccc12 |&1:11	Phase 3	SCN5A	voltage-gated sodium channel blocker		
licochalcone-A	COc1cc(O)c(cc1\C=C\C(=O)c1ccc(O)cc1)C(C)(C)C=C	Phase 3	PTPN1	topoisomerase inhibitor		
licofelone	CC1(C)Cc2c(c(c(CC(O)=O)n2C1)-c1ccc(Cl)cc1)-c1ccccc1	Phase 3	ALOX5|PLA2G2E|PTGS2	cyclooxygenase inhibitor, lipoxygenase inhibitor		
licogliflozin	CCc1ccc(cc1Cc1ccc2OCCOc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Preclinical		sodium/glucose cotransporter inhibitor		
licostinel	[O-][N+](=O)c1c(Cl)c(Cl)cc2[nH]c(=O)c(=O)[nH]c12	Phase 1		NMDA receptor antagonist 		
lidamidine	CNC(=N)NC(=O)Nc1c(C)cccc1C	Launched		adrenergic receptor agonist	gastroenterology	diarrhea
lidocaine	CCN(CC)CC(=O)Nc1c(C)cccc1C	Launched	EGFR|SCN10A|SCN5A|SCN9A	histamine receptor agonist	neurology/psychiatry, dermatology, hematology	itching, eczema, hemorrhage
lidoflazine	Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1	Launched	SCN1A|SCN3A|SLC29A1	calcium channel blocker	cardiology	coronary artery disease (CAD)
lifirafenib	FC(F)(F)c1ccc2nc([nH]c2c1)[C@@H]1[C@H]2Oc3ccc(Oc4ccnc5NC(=O)CCc45)cc3[C@@H]12	Phase 1/Phase 2		RAF inhibitor		
lifitegrast	CS(=O)(=O)c1cccc(C[C@H](NC(=O)c2c(Cl)cc3CN(CCc3c2Cl)C(=O)c2ccc3ccoc3c2)C(O)=O)c1	Launched		lymphocyte function-associated antigen negative modulator	ophthalmology	dry eye syndrome
ligustilide	CCC\C=C1/OC(=O)C2=C1CCC=C2 |c:8	Preclinical	TNF	tumor necrosis factor production inhibitor		
limaprost-alfadex	CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O	Launched	PTGER1	prostanoid receptor agonist	cardiology	claudication
LIMKi-3	CC(C)C(=O)Nc1ncc(s1)-c1cc(nn1-c1c(Cl)cccc1Cl)C(F)F	Preclinical	LIMK1	LIM kinase inhibitor		
limonin	CC1(C)O[C@H]2CC(=O)OC[C@@]22[C@H]1CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@@H](OC(=O)[C@H]3O[C@@]123)c1ccoc1	Preclinical		HIV protease inhibitor		
linaclotide	[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@]1([H])CSSC[C@H](N)C(=O)N[C@@]3([H])CSSC[C@]([H])(NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CSSC[C@]([H])(NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	Launched	GUCY2C	guanylate cyclase activator	gastroenterology	irritable bowel syndrome, constipation
linagliptin	CC#CCn1c(nc2n(C)c(=O)n(Cc3nc(C)c4ccccc4n3)c(=O)c12)N1CCC[C@@H](N)C1	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
linalool	CC(C)=CCC[C@@](C)(O)C=C |&1:6	Phase 1		anticonvulsant		
linaprazan	Cc1nc2c(NCc3c(C)cccc3C)cc(cn2c1C)C(=O)NCCO	Preclinical		ATP-sensitive potassium channel inhibitor		
lincomycin	CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O	Launched		bacterial 30S ribosomal subunit inhibitor	gastroenterology	enteritis
lindane	Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl	Launched	GABRB1|GLRA1|GLRA2|GLRA3|GLRB		infectious disease	scabies
linezolid	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCOCC2)c(F)c1	Launched	MAOA|MAOB	bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia, skin infections
linifanib	Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3n[nH]c(N)c23)c1	Phase 3	CSF1|CSF1R|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RET|TEK	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
linoleic-acid	CCCCC\C=C/C\C=C/CCCCCCCC(O)=O	Phase 3	FABP4|FFAR1|FFAR4|HNF4A|KCNB1|PPARG|TRPM8	oxidative stress inducer		
linopirdine	O=C1N(c2ccccc2C1(Cc1ccncc1)Cc1ccncc1)c1ccccc1	Phase 3	KCNQ2|KCNQ3|KCNQ4|KCNQ5	potassium channel blocker		
linsidomine	Nc1c[n+](no1)N1CCOCC1	Launched		nitric oxide donor	urology	erectile dysfunction
linsitinib	C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 |r|	Phase 3	IGF1R|INSR|INSRR	IGF-1 inhibitor		
lintopride	CCN1CCN=C1CNC(=O)c1cc(Cl)c(N)cc1OC |c:5|	Preclinical		serotonin receptor antagonist		
liothyronine	N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	Launched	THRA|THRB	thyroid hormone stimulant	endocrinology	hypothyroidism, myxedema coma
liothyronine-(isomer)	N[C@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(O)=O	Preclinical				
lipoamide	NC(=O)CCCC[C@H]1CCSS1 |&1:7	Preclinical				
liquiritin	OC[C@H]1O[C@@H](Oc2ccc(cc2)[C@@H]2CC(=O)c3ccc(O)cc3O2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical		antioxidant		
liraglutide	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O	Launched	GLP1R	GLP receptor agonist	endocrinology	weight-loss aid, diabetes mellitus
liranaftate	COc1cccc(n1)N(C)C(=S)Oc1ccc2CCCCc2c1	Launched		fungal squalene epoxidase inhibitor	infectious disease	fungal infection
lirimilast	CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl	Phase 2		phosphodiesterase inhibitor		
lisadimate	Nc1ccc(cc1)C(=O)OC[C@@H](O)CO |&1:11	Launched		topical sunscreen agent	dermatology	sunscreen lotion
lisinopril	NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O	Launched	ACE|ACE2	angiotensin converting enzyme inhibitor	cardiology, endocrinology	hypertension, congestive heart failure, diabetes mellitus
lisofylline	C[C@@H](O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |&1:1	Phase 2		interleukin receptor antagonist, STAT inhibitor		
lisuride	CCN(CC)C(=O)N[C@@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	Launched	ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR6	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
lithium-acetoacetate	CC(=O)CC(O)=O	Preclinical	FAH			
lithium-citrate	[Li].[Li].[Li].OC(=O)CC(O)(CC(O)=O)C(O)=O	Launched			neurology/psychiatry	bipolar disorder, depression
lithocholic-acid	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Preclinical	GPBAR1|NR1H4|NR1I2|VDR	FXR antagonist, vitamin D receptor agonist		
litronesib	CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 |c:19|	Phase 2	KIF11	kinesin-like spindle protein inhibitor		
lixivaptan	Cc1ccc(F)cc1C(=O)Nc1ccc(C(=O)N2Cc3cccn3Cc3ccccc23)c(Cl)c1	Phase 3	AVPR2	vasopressin receptor antagonist		
LM-22A4	OCCNC(=O)c1cc(cc(c1)C(=O)NCCO)C(=O)NCCO	Preclinical	NTRK2	tropomyosin receptor kinase inhibitor		
LMI070	CC1(C)CC(CC(C)(C)N1)Oc1ccc(nn1)-c1ccc(cc1O)-c1cn[nH]c1	Phase 1/Phase 2	SMN1	survival motor neuron protein modulator		
LMK-235	Cc1cc(C)cc(c1)C(=O)NOCCCCCC(=O)NO	Preclinical	HDAC4|HDAC5	HDAC inhibitor		
LM11A-31	CC[C@@H](C)[C@@H](N)C(=O)NCCN1CCOCC1 |&1:2	Phase 1	NGFR	neurotrophic agent		
lobeline	CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c1ccccc1	Launched	CHRNA10|CHRNA9|SLC18A2	acetylcholine receptor antagonist	neurology/psychiatry	smoking cessation
lobendazole	CCOC(=O)Nc1nc2ccccc2[nH]1	Preclinical		anthelmintic agent		
lobenzarit	OC(=O)c1ccccc1Nc1cc(Cl)ccc1C(O)=O	Launched		immunosuppressant	rheumatology	rheumatoid arthritis
lodenosine	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)C[C@@H]1F	Phase 2		antiretroviral 		
lodoxamide	OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N	Launched		histamine receptor antagonist	ophthalmology	vernal keratoconjunctivitis (VKC)
lofemizole	Cc1[nH]cnc1-c1ccc(Cl)cc1	Phase 3		cyclooxygenase inhibitor		
lofepramine	CN(CCCN1c2ccccc2CCc2ccccc12)CC(=O)c1ccc(Cl)cc1	Launched	HTR1A|SLC6A2|SLC6A4	norepinephrine reuptake inhibitor, serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression
lofexidine	C[C@@H](Oc1c(Cl)cccc1Cl)C1=NCCN1 |r	Launched		adrenergic receptor agonist	neurology/psychiatry	opioid withdrawal
lomefloxacin	CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCN[C@@H](C)C3)c(F)c12 |&1:19|	Launched		bacterial DNA gyrase inhibitor	infectious disease	respiratory tract infections, urinary tract infections
lomeguatrib	Nc1nc(OCc2cc(Br)cs2)c2[nH]cnc2n1	Phase 2	MGMT	O6-alkylguanine-DNA alkyltransferase inhibitor		
lomerizine	COc1ccc(CN2CCN(CC2)C(c2ccc(F)cc2)c2ccc(F)cc2)c(OC)c1OC	Launched	CACNA1B|SCN5A	calcium channel blocker	neurology/psychiatry	migraine headache
lometrexol	Nc1nc(=O)c2C[C@@H](CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1	Phase 2	GART	glycinamide ribonucleotide formyltransferase inhibitor		
lomitapide	FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)c2ccccc2-c2ccc(cc2)C(F)(F)F)c2ccccc2-c2ccccc12	Launched	MTTP	microsomal trigylceride transfer protein inhibitor	endocrinology	hypercholesterolemia
lomustine	[O-][NH2+]N(CCCl)C(=O)NC1CCCCC1	Launched		DNA synthesis inhibitor	hematologic malignancy, oncology	Hodgkin's lymphoma, brain tumors
lonafarnib	NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]2c3ncc(Br)cc3CCc3cc(Cl)cc(Br)c23)CC1	Phase 3	FNTA|HRAS|KRAS|NRAS	farnesyltransferase inhibitor		
lonidamine	OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12	Launched	GCK	glucokinase inhibitor		
loperamide	CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1	Launched	CACNA1A|CALM1|OPRD1|OPRK1|OPRM1|POMC	opioid receptor agonist	gastroenterology	diarrhea
lopinavir	CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1	Launched		HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
loracarbef	N[C@@H](C(=O)N[C@H]1[C@H]2CCC(Cl)=C(N2C1=O)C(O)=O)c1ccccc1 |c:10|	Launched		bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology, pulmonary	ear infections, laryngitis, bronchitis, pneumonia, urinary tract infections, skin infections
loratadine	CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12	Launched	HRH1	histamine receptor antagonist	allergy, neurology/psychiatry	allergic rhinitis, itching
loreclezole	Cl\C(=C/n1cncn1)c1ccc(Cl)cc1Cl	Phase 2	GABRB2|GABRB3	benzodiazepine receptor agonist		
lorediplon	CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1	Phase 2	GABRA1	GABA receptor modulator		
lorglumide	CCCCCN(CCCCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:13	Phase 1	CCKAR|CCKBR	CCK receptor antagonist		
lorlatinib	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N	Launched	ALK	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
lornoxicam	CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O |t:12|	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology, neurology/psychiatry	osteoarthritis, sciata
losartan	CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1	Launched	AGTR1	angiotensin receptor antagonist	cardiology, nephrology	hypertension, diabetic nephropathy, hypertension
losmapimod	Cc1c(F)cc(cc1-c1ccc(cn1)C(=O)NCC(C)(C)C)C(=O)NC1CC1	Phase 3	MAPK14	p38 MAPK inhibitor		
lotamilast	CNc1nc(-c2cccc(NC(=O)c3ccc(cc3)C(=O)OC)c2)c2cc(OC)c(OC)cc2n1	Preclinical		phosphodiesterase inhibitor		
loteprednol	CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl |c:17	Launched	NR3C1	glucocorticoid receptor agonist, phospholipase inhibitor	ophthalmology	conjunctivitis
lovastatin	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:13	Launched	HDAC2|HMGCR|ITGAL|NR1I2	HMGCR inhibitor	cardiology, endocrinology	coronary heart disease, myocardial infarction, hypercholesterolemia
loxapine	CN1CCN(CC1)C1=Nc2ccccc2Oc2ccc(Cl)cc12 |t:8|	Launched	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A2|SLC6A3|SLC6A4	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia
loxistatin-acid	CC(C)CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O	Preclinical	CTSB	cysteine peptidase inhibitor		
loxoprofen	C[C@@H](C(O)=O)c1ccc(C[C@H]2CCCC2=O)cc1 |&1:1	Launched	PTGS2	cyclooxygenase inhibitor, prostanoid receptor antagonist	neurology/psychiatry	pain relief
LP-533401	N[C@@H](Cc1ccc(cc1)-c1cc(O[C@@H](c2ccc(cc2)-c2cccc(F)c2)C(F)(F)F)nc(N)n1)C(O)=O |&1:13|	Preclinical		tryptophan hydroxylase inhibitor		
LPA2-antagonist-1	C[C@@H](CN1CCN(CC1)S(=O)(=O)c1ccc(Cl)c(Cl)c1)Nc1ncnc2c(C)csc12	Preclinical	LPAR2	lysophosphatidic acid receptor antagonist		
LRRK2-IN-1	COc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	Preclinical	LRRK2	leucine rich repeat kinase inhibitor		
LSN-2463359	CC(C)NC(=O)c1ccc(cn1)C#Cc1ccncc1	Preclinical	GRM5	glutamate receptor positive allosteric modulator		
LSZ-102	CC(F)(F)c1cc(F)ccc1-c1sc2cc(O)ccc2c1Oc1ccc(\C=C\C(O)=O)cc1	Phase 1		selective estrogen receptor modulator (SERM)		
LTA	N=C(Nc1ccccc1)c1cccs1	Phase 2				
LTB4	CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O	Phase 2	LTB4R|LTB4R2	leukocyte activator		
LTX-315	NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 2		anticancer agent		
Lu-AA-47070	CC(C)(C)CC(=O)Nc1c(F)cc(cc1F)C(=O)\N=c1/sccn1COP(O)(O)=O	Phase 2	ADORA2A	adenosine receptor antagonist		
lubiprostone	CCCCC(F)(F)C(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O	Launched	CLCN2	chloride channel activator	gastroenterology	constipation, irritable bowel syndrome
lucanthone	CCN(CC)CCNc1ccc(C)c2sc3ccccc3c(=O)c12	Phase 2	APEX1|TOP1|TOP2A	endonuclease inhibitor		
lucitanib	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12	Phase 2	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET	FGFR inhibitor, VEGFR inhibitor		
LUF-5834	Nc1nc(SCc2ncc[nH]2)c(C#N)c(-c2ccc(O)cc2)c1C#N	Preclinical	ADORA2A|ADORA2B	adenosine receptor agonist		
lufenuron	F[C@@H](C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl |&1:1	Launched		chitin inhibitor	infectious disease	flea control
luliconazole	Clc1ccc([C@@H]2CS\C(S2)=C(\C#N)n2ccnc2)c(Cl)c1	Launched		sterol demethylase inhibitor	infectious disease	tinea pedis, tinea cruris, tinea corporis
lumacaftor	Cc1ccc(NC(=O)C2(CC2)c2ccc3OC(F)(F)Oc3c2)nc1-c1cccc(c1)C(O)=O	Launched	CFTR	CFTR channel agonist	pulmonary	cystic fibrosis
lumateperone	CN1CCN2[C@H]3CCN(CCCC(=O)c4ccc(F)cc4)C[C@H]3c3cccc1c23	Launched	DRD2|HTR2A	dopamine receptor modulator, serotonin receptor antagonist		
lumefantrine	CCCCN(CCCC)C[C@@H](O)c1cc(Cl)cc2\C(=C/c3ccc(Cl)cc3)c3cc(Cl)ccc3-c12 |&1:10	Launched	ATP1A1	antimalarial agent	infectious disease	malaria
lumiracoxib	Cc1ccc(Nc2c(F)cccc2Cl)c(CC(O)=O)c1	Withdrawn	PTGS1|PTGS2	cyclooxygenase inhibitor		
lupanine	[H][C@@]12CCCCN1C[C@@H]1C[C@H]2CN2C(=O)CCC[C@]12[H]	Phase 1	INS	sodium channel blocker		
lurasidone	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)c1nsc2ccccc12	Launched	ADRA2A|ADRA2C|DRD2|HTR1A|HTR2A|HTR7	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia
lurbinectedin	[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1c3[nH]c2ccc(OC)cc12 |THB:16:15:2.3.12:20.19.17|	Phase 3		DNA binding agent		
lusaperidone	Cc1nc2ccccn2c(=O)c1CCN1CCc2oc3ccccc3c2C1	Preclinical		adrenergic receptor antagonist		
lusutrombopag	CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(\C=C(/C)C(O)=O)c(Cl)c3)n2)c1OC	Launched		thrombopoietin receptor agonist		
lutein	C\C(\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C |c:11	Launched		antioxidant	ophthalmology	macular degeneration, cataracts, retinitis pigmentosa (RP)
luteolin	Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1	Phase 2	TOP1	glucosidase inhibitor		
luzindole	CC(=O)NCCc1c(Cc2ccccc2)[nH]c2ccccc12	Preclinical	MTNR1A|MTNR1B	melatonin receptor antagonist		
LXH254	Cc1ccc(NC(=O)c2ccnc(c2)C(F)(F)F)cc1-c1cc(OCCO)nc(c1)N1CCOCC1	Phase 1		RAF inhibitor		
LXR-623	Fc1ccc(cc1)-c1n(Cc2ccc(F)cc2Cl)nc2c(cccc12)C(F)(F)F	Phase 1	AR|NR1H2|NR1H3|NR1I2|NR3C1	LXR agonist		
LXS196	CC1(N)CCN(CC1)c1cccnc1NC(=O)c1nc(cnc1N)-c1ncccc1C(F)(F)F	Phase 1		PKC inhibitor		
LX1031	COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	Phase 2	TPH1	tryptophan hydroxylase inhibitor		
LX7101	CN(C)C(=O)Oc1cccc(NC(=O)C2(CN)CCN(CC2)c2ncnc3[nH]cc(C)c23)c1	Phase 1/Phase 2	LIMK2|ROCK1|ROCK2	LIM kinase inhibitor, rho associated kinase inhibitor		
lycopene	CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C	Launched		free radical scavenger		
lylamine	CC(C)c1ccc2c(CC[C@H]3[C@](C)(CN)CCC[C@]23C)c1	Preclinical	CNR1	cannabinoid receptor agonist		
lymecycline	CN(C)[C@H]1[C@@H]2C[C@H]3[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]2(O)C(=O)[C@H](C(=O)NCNCCCC[C@H](N)C(O)=O)C1=O |&1:7	Launched		bacterial 50S ribosomal subunit inhibitor	dermatology	acne vulgaris (AV)
lynestrenol	C[C@]12CC[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	Launched		progestogen hormone	endocrinology	contraceptive
lypressin	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Launched	AVPR1A|AVPR1B|AVPR2	vasopressin receptor agonist	endocrinology	central diabetes insipidus
LY2090314	Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1 |t:11|	Phase 2	GSK3B	glycogen synthase kinase inhibitor		
LY2109761	C(CN1CCOCC1)Oc1ccc2c(ccnc2c1)-c1c2CCCn2nc1-c1ccccn1	Preclinical	TGFBR1|TGFBR2	TGF beta receptor inhibitor		
LY2140023	N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 3	GRM3	glutamate receptor agonist		
LY215490	OC(=O)[C@@H]1C[C@H]2C[C@@H](CCc3nn[nH]n3)CC[C@H]2CN1	Phase 1	GRIA1|GRIA2|GRIA3|GRIA4|GRIK1	glutamate receptor antagonist		
LY2157299	Cc1cccc(n1)-c1nn2CCCc2c1-c1ccnc2ccc(cc12)C(N)=O	Phase 2/Phase 3	TGFBR1	TGF beta receptor inhibitor		
LY2183240	CN(C)C(=O)n1nnnc1Cc1ccc(cc1)-c1ccccc1	Preclinical	FAAH	FAAH inhibitor, FAAH reuptake inhibitor		
LY2228820	CC(C)(C)Cn1c(N)nc2ccc(nc12)-c1nc([nH]c1-c1ccc(F)cc1)C(C)(C)C	Phase 2	MAPK14	p38 MAPK inhibitor		
LY223982	COc1ccc(\C=C\CCCCOc2ccc(cc2CCC(O)=O)C(=O)c2cccc(c2)C(O)=O)cc1	Phase 2	LTB4R	leukotriene receptor antagonist		
LY225910	CC(C)Oc1cccc(c1)-n1c(CCc2c[nH]c3ccc(Br)cc23)nc2ccccc2c1=O	Preclinical	CCKBR	CCK receptor antagonist		
LY231617	CCNCc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Preclinical		lipid peroxidase inhibitor		
LY2334737	CCCC(CCC)C(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1	Phase 1		antitumor agent, ribonucleotide reductase inhibitor		
LY2365109	CN(CCOc1ccc(cc1C(C)(C)C)-c1ccc2OCOc2c1)CC(O)=O	Preclinical	SLC6A9	glycine transporter inhibitor		
LY2452473	CC(C)OC(=O)N[C@@H]1Cc2c(C1)c1cc(ccc1n2Cc1ccccn1)C#N	Phase 2	AR	androgen receptor modulator		
LY2510924	[H][C@]1(CCCN=C(N)N)NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@H](Cc2ccc3ccccc3c2)NC1=O)C(=O)N[C@@H](CCCCNC(C)C)C(N)=O	Phase 2		CC chemokine receptor antagonist		
LY255283	CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c1nn[nH]n1	Preclinical	LTB4R|LTB4R2	leukotriene receptor antagonist		
LY2584702	Cn1cc(nc1C1CCN(CC1)c1ncnc2n[nH]cc12)-c1ccc(F)c(c1)C(F)(F)F	Phase 1	RPS6KB1	ribosomal protein inhibitor		
LY2603618	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1	Phase 2	CHEK1	CHK inhibitor		
LY2606368	COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)[nH]n1	Phase 2	CHEK1	CHK inhibitor		
LY2608204	O=C(Nc1ncc(SCCN2CCCC2)s1)[C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1	Phase 2	GCK	glucokinase activator		
LY266097	COc1ccc(C[C@H]2NCCc3c2[nH]c2ccc(C)cc32)c(Cl)c1OC |&1:7|	Preclinical	HTR2B	serotonin receptor antagonist		
LY2784544	Cc1cc(Nc2cc(CN3CCOCC3)c3nc(C)c(Cc4ccc(Cl)cc4F)n3n2)[nH]n1	Phase 2	JAK2|JAK3	JAK inhibitor		
LY2795050	NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1	Preclinical		opioid receptor antagonist		
LY2801653	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1	Phase 2	MET	MET inhibitor		
LY2811376	C[C@]1(CCSC(N)=N1)c1cc(c(F)cc1F)-c1cncnc1 |c:6|	Phase 1	BACE1	beta-secretase inhibitor		
LY2828360	CN1CCN(CC1)c1nc(C)nc2n(C3CCOCC3)c(nc12)-c1ccccc1Cl	Phase 2		cannabinoid receptor agonist		
LY2857785	CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1 |r|	Preclinical	CDK9	CDK inhibitor		
LY2874455	C[C@@H](Oc1ccc2n[nH]c(\C=C\c3cnn(CCO)c3)c2c1)c1c(Cl)cncc1Cl	Phase 1	FGFR1|FGFR2|FGFR3|FGFR4|KDR	FGFR antagonist		
LY288513	Brc1ccc(NC(=O)N2NC(=O)[C@H]([C@@H]2c2ccccc2)c2ccccc2)cc1	Preclinical	CCKBR	CCK receptor antagonist		
LY2886721	NC1=N[C@]2(COC[C@H]2CS1)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |t:1|	Phase 1/Phase 2	BACE1	beta-secretase inhibitor		
LY294002	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCOCC1	Preclinical	AKT1|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PIM1|PLK1|PRKCA|PRKDC|ROCK1|RPS6KB1|SGK1	DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor		
LY2979165	C[C@H](N)C(=O)N[C@]1(C[C@@H](Sc2nnc[nH]2)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O	Phase 1	GRM2	glutamate receptor agonist		
LY3000328	CNC(=O)O[C@H]1COc2ccc(cc2[C@@H]1NC(=O)c1ccc(F)cc1)N1CCN(CC1)C1COC1	Phase 1	CTSS	cathepsin inhibitor		
LY3009120	CNc1ncc2cc(c(C)nc2n1)-c1cc(NC(=O)NCCC(C)(C)C)c(F)cc1C	Phase 1	BRAF|RAF1	RAF inhibitor		
LY3023414	CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O	Phase 2	MTOR	mTOR inhibitor, PI3K inhibitor		
LY303511	O=c1cc(oc2c(cccc12)-c1ccccc1)N1CCNCC1	Preclinical	BRD2|BRD3|BRD4	casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor		
LY310762	CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12	Preclinical	HTR1D	serotonin receptor antagonist		
LY311727	CCc1c(CC(N)=O)c2cc(OCCCP(O)(O)=O)ccc2n1Cc1ccccc1	Preclinical		phospholipase inhibitor		
LY3200882	CC(C)(O)c1cc(Nc2cc(Oc3cn(nc3C3CCOCC3)C3CC3)ccn2)ccn1	Phase 1		TGF beta receptor inhibitor		
LY320135	COc1ccc(cc1)-c1oc2cc(OC)ccc2c1C(=O)c1ccc(cc1)C#N	Preclinical	CNR1	cannabinoid receptor antagonist		
LY3214996	Cn1nccc1Nc1nccc(n1)-c1cc2C(=O)N(CCN3CCOCC3)C(C)(C)c2s1	Phase 1		ERK inhibitor		
LY3295668	C[C@@H]1C[C@@](Cc2nc(Nc3cc(C)[nH]n3)ccc2F)(CCN1Cc1cccc(Cl)c1F)C(O)=O	Phase 1/Phase 2		Aurora kinase inhibitor		
LY334370	CN1CCC(CC1)c1c[nH]c2ccc(NC(=O)c3ccc(F)cc3)cc12	Preclinical		serotonin receptor agonist		
LY344864	CN(C)[C@@H]1CCc2[nH]c3ccc(NC(=O)c4ccc(F)cc4)cc3c2C1	Preclinical	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR7	serotonin receptor agonist		
LY364947	c1[nH]nc(c1-c1ccnc2ccccc12)-c1ccccn1	Preclinical	TGFBR1	p38 MAPK inhibitor, TGF beta receptor inhibitor		
LY393558	CC(C)N1Cc2cc(ccc2N(CCN2CCC(=CC2)c2c[nH]c3cc(F)ccc23)S1(=O)=O)S(C)(=O)=O |c:18|	Preclinical	HTR1B|HTR1D|HTR2A|HTR2B	serotonin receptor antagonist		
LY404187	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(cc1)C#N |&1:8	Preclinical	GRIA1|GRIA2|GRIA3|GRIA4	glutamate receptor positive allosteric modulator		
LY411575	C[C@H](NC(=O)[C@@H](O)c1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	Preclinical		gamma secretase inhibitor		
LY450108	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1	Phase 1		glutamate receptor modulator		
LY456236	COc1ccc(Nc2ncnc3ccc(OC)cc23)cc1	Preclinical	GRM1	glutamate receptor antagonist		
m-chlorophenylbiguanide	NC(N)=NC(=N)Nc1cccc(Cl)c1	Preclinical	HTR3A|HTR3B	serotonin receptor agonist		
m-THP	Oc1cccc(c1)-c1c2ccc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc1n2	Phase 1				
M-14157	CCCCCC(O)CCCC(O)=O	Phase 2	KCNQ1	ATP-sensitive potassium channel antagonist		
M-25	CCCC(CCC)C(=O)NCc1ccc2n(ncc2c1)-c1ccccc1OC	Preclinical	DHH|IHH|SMO	smoothened receptor antagonist		
m-3M3FBS	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1cccc(c1)C(F)(F)F	Preclinical	PLCB2|PLCB3|PLCD1|PLCG1|PLCG2	phospholipase activator		
M-344	CN(C)c1ccc(cc1)C(=O)NCCCCCCC(=O)NO	Preclinical	HDAC8	HDAC inhibitor		
mabuprofen	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NCCO |&1:10	Launched		cyclooxygenase inhibitor	neurology/psychiatry	pain relief
mabuterol	CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(c1)C(F)(F)F |&1:6|	Launched	ADRB2	adrenergic receptor agonist	pulmonary	asthma
macelignan	COc1cc(C[C@H](C)[C@H](C)Cc2ccc3OCOc3c2)ccc1O	Preclinical		anti-inflammatory agent, antioxidant		
macitentan	CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Launched	EDNRA|EDNRB	endothelin receptor antagonist	endocrinology	contraceptive
macitentan-n-butyl-analogue	CCCCS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1	Preclinical		endothelin receptor antagonist		
macozinone	[O-][N+](=O)c1cc(cc2c1sc(nc2=O)N1CCN(CC2CCCCC2)CC1)C(F)(F)F	Preclinical		DPRE1 inhibitor		
madecassoside	[H][C@]12CC=C3[C@]4([H])[C@@H](C)[C@H](C)CC[C@@]4(CC[C@@]3(C)[C@]1(C)C[C@@H](O)[C@@]1([H])[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]21C)C(=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |t:3|	Preclinical		anti-inflammatory agent		
madrasin	COc1ccc2c(C)nc(Nc3nc(=O)c(C)c(C)[nH]3)nc2c1	Preclinical		cell splicing inhibitor		
mafenide	NCc1ccc(cc1)S(N)(=O)=O	Launched	CA12|CA14|CA2|CA4|CA6|CA9	carbonic anhydrase inhibitor	infectious disease	first-aid antibiotic, skin infections
magnolol	Oc1ccc(CC=C)cc1-c1cc(CC=C)ccc1O	Preclinical	GABRA1|PPARG	PPAR receptor agonist		
malathion	CCOC(=O)C[C@@H](SP(=S)(OC)OC)C(=O)OCC |&1:6	Launched	ACHE	cholinesterase inhibitor	infectious disease	lice
malic-acid	O[C@@H](CC(O)=O)C(O)=O |&1:1	Launched	PKD2L1			
malotilate	CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1 |c:15|	Launched		protein synthesis stimulant	gastroenterology	hepatic cirrhosis
maltobionic-acid	OC[C@@H](O)[C@@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@@H](O)C(O)=O	Launched		matrix metalloprotease inhibitor	dermatology	cosmetic
mandelic-acid	O[C@@H](C(O)=O)c1ccccc1 |&1:1	Launched				
mangafodipir	Cc1nc(COP(O)(O)=O)cc2CN(CC(O)=O)CCN(CC(O)=O)Cc3cc(COP(O)(O)=O)nc(C)c3O[Mn]Oc12	Launched		contrast agent	radiology	contrast agent
manidipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1 |r	Launched	CACNA1C|CACNA1D	calcium channel blocker	cardiology	hypertension
manitimus	FC(F)(F)c1ccc(NC(=O)[C@H](C#N)C(=O)CCC#C)cc1 |&1:11	Preclinical		dehydrogenase inhibitor		
mannitol-D	OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched		diuretic	neurology/psychiatry, ophthalmology, gastroenterology	intracranial pressure, intraocular pressure, constipation
maprotiline	CNCCC[C@@]12CC[C@@H](c3ccccc13)c1ccccc21 |r|	Launched	SLC6A2	norepinephrine reputake inhibitor, tricyclic antidepressant	neurology/psychiatry	depression, dysthymic disorder
maraviroc	CC(C)c1nnc(C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1	Launched	CCR5	CC chemokine receptor antagonist	infectious disease	human immunodeficiency virus (HIV-1)
marbofloxacin	CN1CCN(CC1)c1c(F)cc2c3c1OCN(C)n3cc(C(O)=O)c2=O	Launched		bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections
maribavir	CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O	Phase 3	PYGM	cytomegalovirus inhibitor, protein kinase inhibitor		
marimastat	CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C	Phase 3	MMP1|MMP10|MMP11|MMP12|MMP13|MMP14|MMP15|MMP16|MMP17|MMP19|MMP2|MMP20|MMP21|MMP23A|MMP24|MMP25|MMP26|MMP27|MMP28|MMP3|MMP7|MMP8|MMP9	matrix metalloprotease inhibitor		
maropitant	COc1ccc(cc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1)C(C)(C)C	Launched	TACR1	neurokinin receptor antagonist	gastroenterology	vomiting
masitinib	CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1	Launched	FGFR3|KIT|PDGFRA|PDGFRB	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor	dermatology	mastocytoma
masoprocol	C[C@@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1 |&1:1	Launched	ALOX5	lipoxygenase inhibitor	dermatology	actinic keratosis (AK)
matrine	O=C1CCC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34	Phase 2	OPRK1	opioid receptor agonist		
mavacamten	CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O	Phase 3		myosin inhibitor 		
mavatrep	CC(C)(O)c1ccccc1-c1ccc2nc(\C=C\c3ccc(cc3)C(F)(F)F)[nH]c2c1	Preclinical		transient receptor potential channel antagonist		
mavoglurant	COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1	Phase 2	GRM5	glutamate receptor antagonist		
maxacalcitol	C[C@H](OCCC(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched	VDR	vitamin D receptor agonist	endocrinology	hyperparathyroidism
maytansinol-isobutyrate	CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)O[C@H]2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 |c:5	Preclinical				
MBX-2982	CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1	Phase 2	GPR119	glucose dependent insulinotropic receptor agonist		
MC-1	Cc1ncc(COP(O)(O)=O)c(C=O)c1O	Phase 3	AADAT|ABAT|AGXT|AGXT2|ALAS1|AZIN2|BCAT1|BCAT2|CBS|CCBL1|CCBL2|CSAD|CTH|DDC|FTCD|GAD1|GAD2|GADL1|GCAT|GLDC|GOT1|GOT2|GPT|GPT2|HDC|IGSF10|KYNU|MOCOS|NFS1|OAT|ODC1|PDXDC1|PDXP|PHYKPL|PNPO|PROSC|PSAT1|PYGB|PYGL|PYGM|SCLY|SDS|SDSL|SEPSECS|SGPL1|SHMT1|SHMT2|SPTLC1|SPTLC2|SPTLC3|SRR|TAT|THNSL1			
MCC950	CC(C)(O)c1coc(c1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12	Preclinical	NLRP3	NOD like receptor inhibitor		
McN-5652-(+/-)	CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2ccccc12	Preclinical		selective serotonin reuptake inhibitor (SSRI)		
MCOPPB	CC1(CCCCCCC1)N1CCC(CC1)n1c(nc2ccccc12)[C@@H]1CCCNC1	Preclinical	OPRL1	nociceptin/orphanin FQ receptor agonist		
mCPP	Clc1cccc(c1)N1CCNCC1	Phase 2	HTR1A|HTR1D|HTR1E|HTR2A|HTR2B|HTR2C|HTR6	serotonin receptor agonist		
MC1568	Cn1c(\C=C\C(=O)NO)ccc1\C=C\C(=O)c1cccc(F)c1	Preclinical	HDAC2	HDAC inhibitor		
MD-920	C[C@@]12[C@H]3[C@H](C(O)=O)[C@@]45CC(=C)[C@@](O)(C4)CC[C@H]5[C@]3(OC1=O)C=C[C@@H]2O |c:25|	Phase 1	AADACL2	NFkB pathway inhibitor		
mdivi-1	COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O	Preclinical	DNM1	dynamin inhibitor		
MDL-11939	O[C@@H](C1CCN(CCc2ccccc2)CC1)c1ccccc1 |&1:1	Phase 2	HTR2A|HTR2B|HTR2C	serotonin receptor antagonist		
MDL-27531	Cn1c(nnc1S(C)(=O)=O)-c1ccccc1	Preclinical		glycine receptor agonist		
MDL-29951	OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(O)=O	Preclinical	FBP1	glutamate receptor antagonist		
MDL-72832	O=C1CC2(CCCC2)CC(=O)N1CCCCNC[C@H]1COc2ccccc2O1 |&1:18|	Preclinical	HTR1A	serotonin receptor agonist		
MDL-73005EF	O=C1CC2(CCCC2)CC(=O)N1CCNC[C@H]1COc2ccccc2O1 |&1:16|	Phase 1	HTR1A	serotonin receptor antagonist		
MDMS	CS(=O)(=O)OCOS(C)(=O)=O	Phase 2		DNA inhibitor		
ME-0328	C[C@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1	Preclinical	PARP3	PPAR receptor antagonist		
mebendazole	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1ccccc1	Launched	TUBA1A|TUBB|TUBB4B	tubulin polymerization inhibitor	infectious disease	pinworm, whipworm, hookworm, ascariasis
mebeverine	CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)[C@@H](C)Cc1ccc(OC)cc1 |&1:20|	Launched	CHRM1	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
mebhydrolin	CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1	Launched		antihistamine	allergy	allergic rhinitis, urticaria
mebicar	CN1C2C(N(C)C1=O)N(C)C(=O)N2C	Launched		anxiolytic	neurology/psychiatry	anxiety
mebrofenin	Cc1cc(C)c(NC(=O)CN(CC(O)=O)CC(O)=O)c(C)c1Br	Launched			radiology	diagnostic agent
mecamylamine	CNC1(C)C2CCC(C2)C1(C)C	Launched	CHRNA1|CHRNA2|CHRNA3|CHRNA4|CHRNA6|CHRNA7|CHRNB4	acetylcholine receptor antagonist	cardiology	hypertension
mecarbinate	CCOC(=O)c1c(C)n(C)c2ccc(O)cc12	Preclinical				
meclinertant	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)NC1(C2CC3CC(C2)CC1C3)C(O)=O	Phase 2/Phase 3	NTSR1|NTSR2	neurotensin receptor antagonist		
meclizine	Cc1cccc(CN2CCN(CC2)[C@@H](c2ccccc2)c2ccc(Cl)cc2)c1 |&1:13|	Launched	NR1I3	constitutive androstane receptor (CAR) agonist	gastroenterology, neurology/psychiatry	nausea, vomiting, motion sickness
meclocycline-sulfosalicylate	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)c4c(Cl)ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O |a:3	Launched		bacterial 50S ribosomal subunit inhibitor	dermatology, infectious disease	acne vulgaris (AV), skin infections
meclofenamic-acid	Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl	Launched	ALOX5|CNR1|KCNQ2|KCNQ3|PTGS1|PTGS2	cyclooxygenase inhibitor, prostanoid receptor antagonist	rheumatology, neurology/psychiatry, endocrinology	joint pain, muscle pain, rheumatoid arthritis, primary dysmenorrhea (PD)
meclofenoxate	CN(C)CCOC(=O)COc1ccc(Cl)cc1	Launched		nootropic agent	neurology/psychiatry	senile dementia, Alzheimer's disease
mecysteine	COC(=O)[C@@H](N)CS	Launched		analgesic agent	pulmonary	chest congestion
medetomidine	C[C@@H](c1cnc[nH]1)c1cccc(C)c1C |r|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	neurology/psychiatry	sedative
medica-16	CC(C)(CCCCCCCCCCC(C)(C)CC(O)=O)CC(O)=O	Phase 2	FFAR1	ATP citrase lyase inhibitor		
medorinone	Cc1nccc2[nH]c(=O)ccc12	Phase 1				
medronic-acid	OP(O)(=O)CP(O)(O)=O	Launched		bone resorption inhibitor	radiology	skeletal imaging agent
medroxyprogesterone	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	Launched	PGR	progesterone receptor agonist	endocrinology	contraceptive
medroxyprogesterone-acetate	C[C@H]1C[C@H]2[C@@H]3CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:28|	Launched	ESR1|PGR	progesterone receptor agonist	endocrinology	contraceptive
medrysone	C[C@H]1C[C@H]2[C@@H]3CC[C@H](C(C)=O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)CCC(=O)C=C12 |t:25|	Launched	NR3C1	glucocorticoid receptor agonist	ophthalmology	conjunctivitis, episcleritis
mefenamic-acid	Cc1cccc(Nc2ccccc2C(O)=O)c1C	Launched	KCNQ1|PTGS1|PTGS2|TRPM3	cyclooxygenase inhibitor	endocrinology	primary dysmenorrhea (PD)
mefexamide	CCN(CC)CCNC(=O)COc1ccc(OC)cc1	Preclinical		psychoactive drug		
mefloquine	O[C@H]([C@H]1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F	Launched		adenosine receptor antagonist, hemoglobin antagonist	infectious disease	malaria
megestrol	CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9	Launched		progesterone receptor agonist	oncology	breast cancer
megestrol-acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:9	Launched	NR3C1|PGR	progesterone receptor agonist	neurology/psychiatry, endocrinology	anorexia, cachexia
meglitinide	COc1ccc(Cl)cc1C(=O)NCCc1ccc(cc1)C(O)=O	Phase 2	CCR2	potassium channel blocker		
meglumine	CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched		excipient		
meglutol	CC(O)(CC(O)=O)CC(O)=O	Launched	HMGCR	HMGCR inhibitor		
meisoindigo	CN1C(=O)\C(=C2\C(=O)Nc3ccccc23)c2ccccc12	Phase 3	STAT3	STAT inhibitor		
MEK1-2-inhibitor	Nc1ccc(SC(=N)C(C#N)c2ccccc2C(F)(F)F)cc1	Preclinical	MAP2K2	MEK inhibitor		
melanotan-ii	CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC1=O)C(N)=O	Launched		melanocortin receptor agonist		
melatonin	COc1ccc2[nH]cc(CCNC(C)=O)c2c1	Launched	ASMT|CALM1|CALR|EPX|ESR1|HTR2B|MPO|MTNR1A|MTNR1B|NQO2|RORB	melatonin receptor agonist, nitric oxide synthase inhibitor	neurology/psychiatry	sleep cycle support
meldonium	C[N+](C)(C)NCCC(O)=O	Launched	BBOX1	gamma butyrobetaine hydroxylase inhibitor	cardiology	coronary artery disease (CAD)
melengestrol-acetate	CC(=O)O[C@]1(C(C)=O)C(=C)C[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@]12C |a:4	Preclinical		progesterone receptor agonist		
melevodopa	COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1	Launched	DDC	dopamine precursor, dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
meloxicam	CN1C(C(=O)Nc2ncc(C)s2)=C(O)c2ccccc2S1(=O)=O |t:12|	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology	osteoarthritis, rheumatoid arthritis
melperone	CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1	Launched	DRD2|HTR2A	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	psychosis
melphalan	N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(O)=O	Launched		DNA alkylating agent, DNA inhibitor	hematologic malignancy	multiple myeloma
melphalan-n-oxide	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O	Phase 1	HIF1A	hypoxia inducible factor inhibitor		
meluadrine	CC(C)(C)NC[C@@H](O)c1ccc(O)cc1Cl |&1:6	Preclinical				
memantine	C[C@@]12C[C@H]3C[C@@](C)(C1)C[C@](N)(C3)C2	Launched		glutamate receptor antagonist	neurology/psychiatry	Alzheimer's disease, senile dementia
menadione	CC1=CC(=O)c2ccccc2C1=O |t:1|	Launched	AOX1|BGLAP|F10|F2|F7|F9|GGCX|NQO1|NQO2|PROC|PROS1|PROZ|VKORC1|VKORC1L1	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	gastroenterology, neurology/psychiatry, dermatology, rheumatology	ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis
menadione-bisulfite	C[C@]1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O |&1:1|	Phase 2	GGCX|VKORC1|VKORC1L1	vitamin K		
menatetrenone	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	Launched		bone resorption inhibitor	orthopedics	osteoporosis
menbutone	COc1ccc(C(=O)CCC(O)=O)c2ccccc12	Launched			gastroenterology	bile stimulation
mepacrine	CCN(CC)CCC[C@@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12 |&1:8|	Launched	PLA2G1B	cytokine production inhibitor, NFkB pathway inhibitor, TP53 activator	infectious disease	giardiasis
meparfylon	CCC(C)(O)C#C |&1:2|	Preclinical				
mepazine	CN1CCC[C@@H](CN2c3ccccc3Sc3ccccc23)C1 |&1:5	Phase 2	MALT1	MALT1 inhibitor (JH)		
mepenzolate	C[N+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:6|	Launched		acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
mephenesin	Cc1ccccc1OC[C@@H](O)CO |&1:9	Launched		muscle relaxant	neurology/psychiatry	muscle relaxant
mephentermine	CNC(C)(C)Cc1ccccc1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3	adrenergic receptor agonist	cardiology	hypotension
mephenytoin	CC[C@]1(NC(=O)N(C)C1=O)c1ccccc1 |&1:2	Launched	SCN5A	hydantoin antiepileptic	neurology/psychiatry	seizures
mepiroxol	OCc1ccc[n+]([O-])c1	Preclinical				
mepivacaine	CN1CCCC[C@@H]1C(=O)Nc1c(C)cccc1C |&1:6|	Launched		potassium channel blocker, sodium channel blocker	neurology/psychiatry	local anesthetic
meprednisone	C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3C(=O)C[C@]2(C)[C@@]1(O)C(=O)CO |c:11	Launched	NR3C1			
meprylcaine	CCCNC(C)(C)COC(=O)c1ccccc1	Preclinical		local anesthetic		
meptazinol	CC[C@]1(CCCCN(C)C1)c1cccc(O)c1 |&1:2|	Launched	BCHE	opioid receptor agonist	neurology/psychiatry	pain relief
mepyramine	COc1ccc(CN(CCN(C)C)c2ccccn2)cc1	Launched	HRH1	histamine receptor antagonist	otolaryngology, obstetrics/gynecology	common cold, menstrual pain
mequinol	COc1ccc(O)cc1	Launched	TYR		dermatology	skin depigmentation
merbarone	Oc1[nH]c(=S)[nH]c(=O)c1C(=O)Nc1ccccc1	Phase 2	TOP2A	topoisomerase inhibitor		
merbromin	O[Hg]c1c(O)c(Br)cc2c(-c3ccccc3C(O)=O)c3cc(Br)c(=O)cc3oc12	Launched		antiseptic	infectious disease	first-aid antiseptic
mercaptopurine	S=c1nc[nH]c2nc[nH]c12	Launched	HPRT1|IMPDH1|IMPDH2|PPAT	immunosuppressant, protein synthesis inhibitor, purine antagonist	hematologic malignancy	acute lymphoblastic leukemia (ALL)
mercaptosuccinic-acid	OC(=O)C[C@@H](S)C(O)=O |&1:4	Launched				
Merck60		Preclinical	HDAC1|HDAC2	HDAC inhibitor		
mericitabine	CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C	Phase 2		HCV inhibitor		
merimepodib	COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1	Phase 2	IMPDH1	inosine monophosphate dehydrogenase inhibitor		
meropenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)=C(N2C1=O)C(O)=O |c:19|	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections, intra-abdominal infections, meningitis
mertansine	[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\Cc1cc(OC)c(Cl)c(c1)N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCS)[C@]1(C)O[C@H]1[C@@H]2C |c:16	Phase 2		microtubule inhibitor		
mesalazine	Nc1ccc(O)c(c1)C(O)=O	Launched	ALOX5|CHUK|IKBKB|MPO|PPARG|PTGS1|PTGS2	cyclooxygenase inhibitor, lipoxygenase inhibitor, prostanoid receptor antagonist	gastroenterology	ulcerative colitis, inflammatory bowel disease
mesna	OS(=O)(=O)CCS	Launched		antioxidant	urology	hemorrhagic cystitis
mesoridazine	CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc(cc12)[S@@](C)=O |a:23	Launched	DRD2|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
mestinon	CN(C)C(=O)Oc1ccc[n+](C)c1	Launched	ACHE|BCHE	cholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
mestranol	COc1ccc2[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]4(O)C#C)[C@@H]3CCc2c1	Launched	ESR1	estrogen receptor agonist	endocrinology	contraceptive
mesulergine	CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1	Phase 2	HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|HTR7	dopamine receptor agonist		
meta-cresyl-acetate	CC(=O)Oc1cccc(C)c1	Preclinical				
metacetamol	CC(=O)Nc1cccc(O)c1	Preclinical		analgesic agent		
metacresol	Cc1cccc(O)c1	Launched	INS			
metafolin	CN1[C@@H](CNc2ccc(cc2)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]c(N)nc(=O)c12	Launched				
metamizole	CN(CS(O)(=O)=O)c1c(C)n(C)n(-c2ccccc2)c1=O	Withdrawn	PTGS1	cyclooxygenase inhibitor, opioid receptor agonist		
metaphit	S=C=Nc1cccc(c1)C1(CCCCC1)N1CCCCC1	Preclinical		phencyclidine receptor acylator		
metaproterenol	CC(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:5|	Launched	ADRB2	adrenergic receptor agonist	pulmonary	bronchospasm, asthma, bronchitis, emphysema
metaraminol	C[C@H](N)[C@H](O)c1cccc(O)c1	Launched	ADRA1A	adrenergic receptor agonist	cardiology	hypotension
metatinib	Nc1nccc(Oc2ccc(NC(=O)c3c[nH]cc(-c4ccc(F)cc4)c3=O)cc2F)c1Cl	Phase 1	ABL1|BCR	Bcr-Abl kinase inhibitor		
metaxalone	Cc1cc(C)cc(OC[C@H]2CNC(=O)O2)c1 |&1:9	Launched		muscle relaxant	neurology/psychiatry	muscle pain
metazosin	CO[C@@H](C)C(=O)N1CCN(CC1)c1nc(N)c2cc(OC)c(OC)cc2n1 |&1:2	Phase 2	ADRA1A	adrenergic receptor antagonist		
metenkephalin	CSCC[C@@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(O)=O |&1:4	Phase 2	OPRD1	immunostimulant		
metergoline	CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]2[C@H]1Cc1cn(C)c3cccc2c13	Launched	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	dopamine receptor agonist, serotonin receptor antagonist	neurology/psychiatry, endocrinology	seasonal affective disorder, anxiety, hyperprolactinemia
metformin	CN(C)C(=N)N=C(N)N	Launched	ACACB|PRKAB1	insulin sensitizer	endocrinology	diabetes mellitus
methacholine	C[C@@H](C[N+](C)(C)C)OC(C)=O |&1:1|	Launched	CHRM2|CHRM4	acetylcholine receptor agonist	pulmonary	bronchial hyperresponsiveness diagnostic
methacycline	[H][C@]12[C@H](O)[C@@]3([H])[C@H](N(C)C)C(=O)[C@H](C(N)=O)C(=O)[C@@]3(O)C(=O)[C@H]1C(=O)c1c(O)cccc1C2=C |&1:22	Preclinical		protein synthesis inhibitor	pulmonary	bronchitis
methanesulfonyl-fluoride	CS(F)(=O)=O	Phase 2	ACHE	acetylcholinesterase inhibitor		
methantheline	CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc2ccccc12	Launched	CHRM1|HRH2	acetylcholine receptor antagonist	gastroenterology, neurology/psychiatry, urology	peptic ulcer disease (PUD), irritable bowel syndrome, pancreatitis, dyskinesia, neurogenic bladder
methapyrilene	CN(C)CCN(Cc1cccs1)c1ccccn1	Withdrawn	HRH1	histamine receptor antagonist		
metharbital	CCC1(CC)C(=O)NC(=O)N(C)C1=O	Launched	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2	GABA receptor modulator	neurology/psychiatry	epilepsy
methazolamide	CC(=O)N=c1sc(nn1C)S(N)(=O)=O	Launched	CA1|CA12|CA14|CA2|CA4|CA7	carbonic anhydrase inhibitor	ophthalmology	glaucoma, intraocular pressure
methenamine	C1N2CN3CN1CN(C2)C3	Launched		bacterial DNA inhibitor	infectious disease	urinary tract infections
methiazole	COC(=O)Nc1nc2ccc(SC(C)C)cc2[nH]1	Preclinical		anthelmintic agent		
methicillin	COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
methimazole	Cn1cc[nH]c1=S	Launched	TPO	antithyroid agent	endocrinology	hyperthyroidism
methionine	CSCC[C@@H](N)C(O)=O |&1:4	Launched	METAP2			
methiopril	C[C@@H]1CCC[C@@H](N1C(=O)CCSC(C)=O)C(O)=O |&1:1	Phase 2	ACE	angiotensin converting enzyme inhibitor		
methocarbamol	COc1ccccc1OC[C@@H](O)COC(N)=O |&1:10	Launched	CA1	muscle relaxant	neurology/psychiatry	muscle relaxant
methoprene-(s)	COC(C)(C)CCC[C@H](C)C\C=C\C(\C)=C\C(=O)OC(C)C	Preclinical				
methotrexate	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	DHFR	dihydrofolate reductase inhibitor	oncology, hematologic malignancy, dermatology, rheumatology	gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis
methoxamine	COc1ccc(OC)c(c1)C(O)C(C)N	Launched	ADRA1A|ADRA1B|ADRA1D	adrenergic receptor agonist	cardiology	hypotension
methoxsalen	COc1c2occc2cc2ccc(=O)oc12	Launched	CYP1A1|CYP1A2|CYP2A13|CYP2A6|CYP3A4	DNA synthesis inhibitor	dermatology	psoriasis
methoxyamine	CON	Phase 2	APEX1	DNA repair enzyme inhibitor		
methoxyflurane	COC(F)(F)C(Cl)Cl	Launched	ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|MT-ND1	membrane permeability inhibitor	neurology/psychiatry	general anaesthetic
methoxyphenamine	CN[C@@H](C)Cc1ccccc1OC |&1:2	Launched		adrenergic receptor agonist	pulmonary	asthma
methscopolamine	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched	CHRM1|CHRM2|CHRM3	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
methsuximide	CN1C(=O)C[C@@](C)(C1=O)c1ccccc1 |&1:5	Launched	CACNA1G|CACNA1H|CACNA1I	T-type calcium channel blocker	neurology/psychiatry	seizures
methyclothiazide	CN1[C@@H](CCl)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2	Launched	SLC12A1|SLC12A3	chloride reabsorption inhibitor	cardiology	hypertension, edema
methyl-aminolevulinate	COC(=O)CCC(=O)CN	Launched	FCGR1A|FECH	oxidizing agent	dermatology	actinic keratosis (AK)
methyl-nicotinate	COC(=O)c1cccnc1	Phase 2				
methyl-salicylate	COC(=O)c1ccccc1O	Launched			endocrinology, neurology/psychiatry	fever, pain relief
methyl-5-hydroxytryptamine	C[C@@H](N)Cc1c[nH]c2ccc(O)cc12 |&1:1|	Preclinical				
methylatropine-nitrate	C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c1ccccc1 |&1:3	Preclinical	CHRM1	acetylcholine receptor antagonist		
methylbenactyzium-bromide	CC[N+](C)(CC)CCOC(=O)C(O)(c1ccccc1)c1ccccc1	Preclinical		cholinergic receptor antagonist		
methylbenzethonium-chloride	Cc1cc(ccc1OCCOCC[N+](C)(C)Cc1ccccc1)C(C)(C)CC(C)(C)C	Preclinical		other antibiotic		
methylcobalamin	[H][C@]1(CO)O[C@]([H])(n2cnc3cc(C)c(C)cc23)[C@]([H])(O)[C@]1([H])OP(O)(=O)O[C@H](C)CNC(=O)CC[C@@]1(C)\C2=C(C)\C3=N\C(=C\C4=N\C(=C(C)/C5=N[C@@](C)([C@@]([H])(N2[Co+]C)[C@]1([H])CC(N)=O)[C@@](C)(CC(N)=O)[C@]5([H])CCC(N)=O)\[C@@](C)(CC(N)=O)[C@]4([H])CCC(N)=O)\C(C)(C)[C@]3([H])CCC(N)=O |c:41	Phase 3		vitamin B		
methyldopa	C[C@](N)(Cc1ccc(O)c(O)c1)C(O)=O	Launched	ADRA2A|ADRA2B|ADRA2C|DDC	adrenergic receptor agonist	cardiology	hypertension
methyldopate	CCOC(=O)[C@@](C)(N)Cc1ccc(O)c(O)c1	Launched			cardiology	hypertension
methylene-blue	CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C	Launched	ACHE	guanylyl cyclase inhibitor, nitric oxide production inhibitor	hematology	methemoglobinemia
methylergometrine	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34 |c:23|	Launched	DRD1|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C	dopamine receptor antagonist, serotonin receptor antagonist	hematology, neurology/psychiatry	postpartum hemorrhage (PPH), migraine headache
methyllycaconitine	CCN1C[C@]2(COC(=O)c3ccccc3N3C(=O)C[C@H](C)C3=O)CC[C@H](OC)[C@@]34[C@@H]5C[C@H]6[C@H](OC)[C@@H]5[C@](O)(C[C@@H]6OC)[C@@](O)([C@@H](OC)[C@H]23)[C@@H]14	Preclinical	CHRNA7	acetylcholine receptor antagonist		
methylnaltrexone	[H][C@]12Oc3c4c(C[C@]5([H])[C@](O)(CCC1=O)[C@]24CC[N@+]5(C)CC1CC1)ccc3O	Launched	OPRD1|OPRK1|OPRM1	opioid receptor antagonist	gastroenterology	constipation
methylparaben	COC(=O)c1ccc(O)cc1	Launched		other antifungal	dermatology	cosmetic
methylprednisolone	C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 |c:23	Launched	NR3C1	glucocorticoid receptor agonist	endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology	hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis
methylprednisolone-aceponate	CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)COC(C)=O |c:17	Launched	NR3C1	anti-inflammatory agent, glucocorticoid receptor agonist	endocrinology, rheumatology, infectious disease, allergy, pulmonary, gastroenterology, dermatology, neurology/psychiatry, hematology	congenital adrenal hyperplasia, thyroiditis, hypercalcemia, rheumatoid arthritis, bursitis, epicondylitis, allergic rhinitis, asthma, ulcerative colitis, enteritis, osteoarthritis, psoriasis, multiple sclerosis, anemia
methylprednisolone-sodium-succinate	[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)C=C[C@]12C |c:35	Launched		glucocorticoid receptor agonist	endocrinology, rheumatology, dermatology, pulmonary, allergy, infectious disease, ophthalmology, gastroenterology, hematology, neurology/psychiatry	hypercalcemia, thyroiditis, osteoarthritis, rheumatoid arthritis, seborrheic dermatitis, asthma, allergic rhinitis, shingles, conjunctivitis, ulcerative colitis, enteritis, anemia, multiple sclerosis, mycosis
methylthiouracil	Cc1cc(=O)[nH]c(=S)[nH]1	Launched			endocrinology	hyperthyroidism
methysergide	CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34 |c:24|	Launched	HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	serotonin receptor antagonist	neurology/psychiatry	headache
meticrane	Cc1cc2CCCS(=O)(=O)c2cc1S(N)(=O)=O	Launched		diuretic	cardiology	edema
metipranolol	CC(C)NC[C@@H](O)COc1cc(C)c(OC(C)=O)c(C)c1C |&1:5	Withdrawn		adrenergic receptor antagonist		
metirosine	C[C@](N)(Cc1ccc(O)cc1)C(O)=O	Launched	TH	tyrosine hydroxylase inhibitor	cardiology	hypertension
metitepine	CSc1ccc2Sc3ccccc3C[C@@H](N3CCN(C)CC3)c2c1 |&1:14	Preclinical	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	anti-HCVE2		
metixene	CN1CCC[C@@H](CC2c3ccccc3Sc3ccccc23)C1 |&1:5|	Launched	CHRM5	acetylcholine receptor antagonist	neurology/psychiatry	Parkinson's Disease
metoclopramide	CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC	Launched	CHRM1|DRD2|HTR3A|HTR3B|HTR4	dopamine receptor antagonist, serotonin receptor antagonist	gastroenterology	gastroparesis, nausea, vomiting
metocurine	COc1ccc2C[C@@H]3c4c(CC[N+]3(C)C)cc(OC)c(OC)c4Oc3ccc(C[C@H]4c5cc(Oc1c2)c(OC)cc5CC[N+]4(C)C)cc3	Launched	CHRM2|CHRNA2	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant
metolazone	C[C@H]1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(N)(=O)=O |&1:1	Launched	SLC12A3	carbonic anhydrase inhibitor	cardiology	edema, hypertension
metoprolol	COCCc1ccc(OC[C@@H](O)CNC(C)C)cc1 |&1:10|	Launched	ADRB1|ADRB2	adrenergic receptor antagonist	cardiology	hypertension, angina pectoris, myocardial infarction
metoxibutropate	COc1ccccc1OC(=O)[C@@H](C)c1ccc(CC(C)C)cc1 |&1:11	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor		
metrifonate	COP(=O)(OC)[C@@H](O)C(Cl)(Cl)Cl |&1:6	Phase 3	ACHE	acetylcholinesterase inhibitor		
metrizamide	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I |a:19	Launched		radiopaque medium	radiology	contrast agent
metrizoic-acid	CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(O)=O)c1I	Launched		radiopaque medium	radiology	contrast agent
metronidazole	Cc1ncc(n1CCO)[N+]([O-])=O	Launched	CYP2C9|CYP3A4	DNA inhibitor	dermatology	rosacea
metyrapone	CC(C)(C(=O)c1cccnc1)c1cccnc1	Launched	CYP11B1	cytochrome P450 inhibitor	nephrology	adrenal diagnostic agent
mevastatin	CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:12	Preclinical	HMGCR	HMGCR inhibitor		
mexeneone	COc1ccc(C(=O)c2ccc(C)cc2)c(O)c1	Preclinical				
mexiletine	C[C@@H](N)COc1c(C)cccc1C |&1:1|	Launched	PLAU|SCN4A|SCN5A	sodium channel blocker	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)
mezlocillin	CC1(C)S[C@H]2[C@@H](NC(=O)[C@@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)c3ccccc3)C(=O)N2[C@@H]1C(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
ME0328	C[C@@H](NC(=O)CCc1nc(=O)c2ccccc2[nH]1)c1ccccc1 |&1:1	Preclinical	PARP3	PARP inhibitor		
MF-101	Oc1ccc(cc1)[C@@H]1CC(=O)c2ccc(O)cc2O1	Phase 3	CYP19A1|XDH	estrogen receptor agonist		
MG-132	CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C=O	Preclinical	PSMB1	proteasome inhibitor		
MG-624	CC[N+](CC)(CC)CCOc1ccc(\C=C\c2ccccc2)cc1	Preclinical	CHRNA7	acetylcholine receptor antagonist		
MGCD-265	Cn1cnc(c1)-c1cc2nccc(Oc3ccc(NC(=S)NC(=O)Cc4ccccc4)cc3F)c2s1	Preclinical	AXL|MET	VEGFR inhibitor		
MI-14	CN(C)S(=O)(=O)c1cccc(c1)-c1c(C)nc2c(NCCNC(C)=O)cc(Cl)nn12	Preclinical	PI4KB	PI4K inhibitor		
mianserin	CN1CCN2C(C1)c1ccccc1Cc1ccccc21	Launched	ADRA1A|ADRA1B|ADRA1D|HRH1|HRH2|HTR2A|HTR2B|HTR2C|HTR6|HTR7	serotonin receptor antagonist	neurology/psychiatry	depression
mibampator	CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1	Phase 2	GRIA1	glutamate receptor modulator		
mibefradil	COCC(=O)O[C@]1(CCN(C)CCCc2nc3ccccc3[nH]2)CCc2cc(F)ccc2[C@@H]1C(C)C	Withdrawn	ANO1|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CATSPER1|CATSPER2|CATSPER3|CATSPER4	T-type calcium channel blocker		
micafungin	CCCCCOc1ccc(cc1)-c1cc(no1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)c(OS(O)(=O)=O)c1)[C@H](O)CC(N)=O	Launched		fungal 1,3-beta-D-glucan synthase inhibitor	infectious disease	candidemia, peritonitis, esophageal candidiasis
miconazole	Clc1ccc(CO[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1 |&1:7	Launched	TRPM2|TRPV5	bacterial cell wall synthesis inhibitor	infectious disease, neurology/psychiatry	yeast infection, itching
micronomicin	CNC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1	Launched		protein synthesis inhibitor	infectious disease	gram-negative bacterial infections
midafotel	OC(=O)[C@H]1CN(C\C=C\P(O)(O)=O)CCN1	Phase 3	GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor antagonist		
midecamycin	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:32	Launched		protein synthesis inhibitor	infectious disease	respiratory tract infections, ear infections, skin infections
midodrine	COc1ccc(OC)c(c1)[C@@H](O)CNC(=O)CN |&1:10|	Launched		adrenergic receptor agonist	cardiology	hypotension
midostaurin	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c4CNC(=O)c4c4c5ccccc5n2c4c13)N(C)C(=O)c1ccccc1	Launched	FLT3|PRKCG	FLT3 inhibitor, KIT inhibitor, PKC inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
mifepristone	CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c1ccc(cc1)N(C)C |c:18	Launched	AR|NR1I2|NR3C1|PGR	glucocorticoid receptor antagonist, progesterone receptor antagonist	endocrinology	hyperglycemia, diabetes mellitus
mifobate	COP(=O)(OC)O[C@@H](c1ccc(Cl)cc1)P(=O)(OC)OC |&1:7	Phase 2	PPARG	PPAR receptor antagonist		
miglitol	OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Launched	GAA|GANAB|GANC|MGAM	glucosidase inhibitor	endocrinology	diabetes mellitus
miglustat	CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Launched	UGCG	glycosyl transferase inhibitor	hematology	Gaucher disease
milacemide	CCCCCNCC(N)=O	Phase 3	MAOB	monoamine oxidase inhibitor		
milademetan	CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O	Phase 1		MDM inhibitor		
milnacipran	CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1 |r|	Launched	SLC6A2|SLC6A4	serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	rheumatology	fibromyalgia
milrinone	Cc1[nH]c(=O)c(cc1-c1ccncc1)C#N	Launched	PDE2A|PDE3A|PDE3B|PDE5A	phosphodiesterase inhibitor	cardiology	congestive heart failure
miltefosine	CCCCCCCCCCCCCCCCOP(O)(=O)OCC[N+](C)(C)C |&1:17|	Launched	PLA2G1B	membrane integrity inhibitor	infectious disease	leishmaniasis
mimosine	N[C@@H](Cn1ccc(=O)c(O)c1)C(O)=O	Preclinical	CCL2|SHMT1|SHMT2|TYR	DNA replication inhibitor		
minaprine	Cc1cc(nnc1NCCN1CCOCC1)-c1ccccc1	Withdrawn	ACHE|CHRM1|DRD1|DRD2|HTR2A|HTR2B|HTR2C|MAOA|SLC6A4	serotonin reuptake inhibitor		
minerval	CCCCCCCC\C=C/CCCCCC[C@@H](O)C(O)=O |&1:16	Phase 1/Phase 2		FAAH inhibitor		
minocycline	[H][C@@]12Cc3c(ccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:19	Launched		bacterial 30S ribosomal subunit inhibitor	endocrinology, infectious disease, ophthalmology, urology	fever, respiratory tract infections, psittacosis, trachoma, conjunctivitis, urethritis, chancroid, tularemia, cholera, brucellosis
minodronic-acid	OC(Cc1cnc2ccccn12)(P(O)(O)=O)P(O)(O)=O	Launched	FDPS|GGPS1	bone resorption inhibitor	orthopedics	osteoporosis
minoxidil	Nc1cc(nc(N)[n+]1[O-])N1CCCCC1	Launched	ABCC9|KCNJ1|KCNJ10|KCNJ11|KCNJ8|PTGS1	KATP activator, Kir6 channel (KATP) activator, vasodilator	endocrinology	androgenetic alopecia
miocamycin	CCC(=O)O[C@H]1[C@H](C)O[C@H](C[C@@]1(C)OC(C)=O)O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@@H](CC=O)C[C@@H](C)[C@@H](OC(C)=O)\C=C\C=C\C[C@@H](C)OC(=O)C[C@@H](OC(=O)CC)[C@@H]2OC)[C@H](O)[C@H]1N(C)C |t:38	Launched		other antibiotic	infectious disease	urinary tract infections, chlamydia
MIRA-1	CCC(=O)OCN1C(=O)C=CC1=O |c:9|	Preclinical		apoptosis stimulant		
mirabegron	Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor agonist	urology	urinary incontinence
miridesap	OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(O)=O	Preclinical		amyloid protein inhibitor		
mirin	NC1=NC(=O)\C(S1)=C\c1ccc(O)cc1 |t:1|	Preclinical	MRE11A	MRE11A exonuclease inhibitor		
miriplatin	[Pt++].N[C@H]1CCCC[C@@H]1N.CCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCC(O)=O |&1:2	Launched		DNA synthesis inhibitor	oncology	hepatocellular carcinoma (HCC)
mirodenafil	CCCOc1ccc(cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1)S(=O)(=O)N1CCN(CCO)CC1	Launched	PDE5A	phosphodiesterase inhibitor	urology	erectile dysfunction
mirogabalin-besylate	[H][C@@]12C[C@](CN)(CC(O)=O)[C@]1([H])C=C(CC)C2 |t:13|	Preclinical		calcium channel antagonist		
mirtazapine	CN1CCN2[C@@H](C1)c1ccccc1Cc1cccnc21 |&1:5	Launched	ADRA2A|ADRA2B|ADRA2C|HTR2A|HTR2C	adrenergic receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	depression
misonidazole	COC[C@@H](O)Cn1ccnc1[N+]([O-])=O |&1:3	Phase 3				
misoprostol	CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC |a:10	Launched	PTGER2|PTGER3|PTGER4|PTGIR	prostanoid receptor agonist	gastroenterology	duodenal ulcer disease
mitapivat	O=C(N1CCN(CC2CC2)CC1)c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1	Preclinical		pyruvate kinase isozyme activator		
mitiglinide	OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1	Launched	ABCC8|KCNJ10|PPARG	insulin secretagogue	endocrinology	diabetes mellitus
mitoflaxone	OC(=O)Cc1cccc2c1oc(cc2=O)-c1ccccc1	Phase 2	VWF	antitumor agent		
mitomycin-C	CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O |c:10	Launched		DNA alkylating agent, DNA synthesis inhibitor	oncology	pancreatic cancer, gastric adenocarcinoma
mitoquinone	COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O |c:2	Launched		antioxidant		
mitotane	ClC(Cl)[C@@H](c1ccc(Cl)cc1)c1ccccc1Cl |&1:3	Launched	CYP11A1|CYP11B1|ESR1	antineoplastic agent	oncology	adrenal cortical carcinoma
mitoxantrone	OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12	Launched	TOP2A	topoisomerase inhibitor	neurology/psychiatry, oncology, hematologic malignancy	multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)
mivacurium	COc1cc2CC[N@@+](C)(CCCOC(=O)CC\C=C\CCC(=O)OCCC[N@@+]3(C)CCc4cc(OC)c(OC)cc4[C@H]3Cc3cc(OC)c(OC)c(OC)c3)[C@H](Cc3cc(OC)c(OC)c(OC)c3)c2cc1OC |a:41	Launched	CHRNA2	acetylcholine receptor antagonist	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant
mivebresib	CCS(=O)(=O)Nc1ccc(Oc2ccc(F)cc2F)c(c1)-c1cn(C)c(=O)c2[nH]ccc12	Phase 1		bromodomain inhibitor		
mivobulin	CCOC(=O)Nc1cc2N=C(C)C(Nc2c(N)n1)c1ccccc1 |t:9|	Phase 2		microtubule inhibitor		
MIW-815	[H][C@]12CO[P@](S)(=O)O[C@@]3([H])[C@@H](O)[C@@H](O[C@]3([H])CO[P@](S)(=O)O[C@@]([H])([C@@H](O1)n1cnc3c(N)ncnc13)[C@]2([H])O)n1cnc2c(N)ncnc12	Preclinical		interferon inducer		
mizolastine	CN(C1CCN(CC1)c1nc2ccccc2n1Cc1ccc(F)cc1)c1nc(=O)cc[nH]1	Launched	HRH1	histamine receptor antagonist	allergy	urticaria, allergic rhinitis
mizoribine	NC(=O)C1N=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C1=O |c:4|	Launched	IMPDH1	immunosuppressant, inosine monophosphate dehydrogenase inhibitor	transplant, rheumatology	organ rejection, nephrotic syndrome
MJ-15	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NCc1cccnc1	Preclinical	CNR1	cannabinoid receptor antagonist		
MK-0354	C1Cc2[nH]nc(-c3nn[nH]n3)c2C1	Phase 2	HCAR2|HCAR3	niacin receptor agonist		
MK-0557	Fc1ccccc1-n1ccc(NC(=O)[C@H]2CC[C@]3(CC2)OC(=O)c2ccncc32)n1 |r|	Phase 3		neuropeptide receptor antagonist		
MK-0608	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc2c(N)ncnc12	Phase 1		antiviral		
MK-0752	OC(=O)CC[C@H]1CC[C@@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(Cl)cc1 |r|	Phase 1/Phase 2		gamma secretase inhibitor		
MK-0773	CN1[C@@H]2CC[C@H]3[C@@H]4CC[C@H](C(=O)NCc5nc6ncccc6[nH]5)[C@@]4(C)CC[C@@H]3[C@@]2(C)C=C(F)C1=O |t:35|	Phase 2	AR	androgen receptor modulator		
MK-0812	CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2ncc(cc2C1)C(F)(F)F	Phase 2	CCR2	CC chemokine receptor antagonist		
MK-0893	COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1	Phase 2	GCGR	glucagon receptor antagonist		
MK-1064	COc1ccc(CNC(=O)c2cc(cnc2-c2ccccn2)-c2cncc(Cl)c2)nc1OC	Phase 1		orexin receptor antagonist		
MK-1775	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1	Phase 2	WEE1	WEE1 kinase inhibitor		
MK-1903	OC(=O)c1n[nH]c2[C@@H]3C[C@@H]3Cc12	Phase 2		niacin receptor agonist		
MK-2048	CCN1C[C@H](C)n2c(c(O)c3c2c(nn(Cc2ccc(F)c(Cl)c2)c3=O)C(=O)NC)C1=O	Preclinical		HIV integrase inhibitor		
MK-2206	NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1	Phase 2	AKT1|AKT2|AKT3	AKT inhibitor		
MK-2295	FC(F)(F)c1ccc(Nc2ncnc3cc(ccc23)-c2ncccc2C(F)(F)F)cc1	Phase 2	TRPV1	TRPV antagonist		
MK-2461	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(cc3c(=O)c2c1)-c1cnn(C)c1	Phase 1/Phase 2	FGFR1|FGFR2|FGFR3|FLT1|FLT3|FLT4|KDR|MERTK|MET|MST1R|NTRK1|NTRK2|PDGFRB	FGFR inhibitor, VEGFR inhibitor		
MK-2894	Cc1sc(C)c(C(=O)NC2(CC2)c2ccc(cc2)C(O)=O)c1Cc1ccc(cc1)C(F)(F)F	Preclinical	PTGER4	prostaglandin inhibitor		
MK-3207	Fc1cc(F)cc(c1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)Nc1ccc2C[C@]3(Cc2c1)C(=O)Nc1ncccc31	Phase 2	CALCA	calcitonin antagonist		
MK-3697	COc1ccc(CNC(=O)c2cc(ncc2-c2nccs2)-c2cncc(C)c2)nc1OC	Phase 2	HCRTR2	orexin receptor antagonist		
MK-4074	COc1cc(cc2n(cc(C)c12)C1CC1)C(=O)N1CCC2(CC1)CC(=O)c1cc(ccc1O2)-c1cncc(c1)C(O)=O	Phase 1		acetyl-CoA carboxylase inhibitor		
MK-5046	O[C@@](Cc1ncc(CC2(CC2)C(F)(F)F)[nH]1)(c1ccc(cc1)-n1cccn1)C(F)(F)F	Preclinical	BRS3|GRPR|NMBR	bombesin receptor agonist		
MK-5108	OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F |r|	Phase 1	AURKA|AURKB|AURKC	Aurora kinase inhibitor		
MK-571	CN(C)C(=O)CCS[C@@H](SCCC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 |&1:8|	Phase 2	ABCC2|CYSLTR1	leukotriene receptor antagonist		
MK-6096	C[C@@H]1CC[C@@H](COc2ccc(F)cn2)CN1C(=O)c1cc(C)ccc1-c1ncccn1	Phase 2	HCRTR1|HCRTR2	orexin receptor antagonist		
MK-7246	CN([C@@H]1CCc2c(CC(O)=O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1	Preclinical		CRTH receptor antagonist		
MK-7622	Cc1ccc(Cc2cc3c(ncn([C@H]4CCCC[C@@H]4O)c3=O)c3ccccc23)cn1	Phase 2		cholinergic receptor agonist		
MK-8033	Cn1cc(cn1)-c1cnc2ccc3ccc(CS(=O)(=O)NCc4ccccn4)cc3c(=O)c2c1	Phase 1	MET	c-Met inhibitor		
MK-8245	OC(=O)Cn1nnc(n1)-c1cc(no1)N1CCC(CC1)Oc1cc(F)ccc1Br	Phase 2	SCD	stearoyl-CoA desaturase inhibitor		
MK-8617	COc1ccc(cc1)C(NC(=O)c1cnc(nc1O)-c1cccnn1)c1ccc(OC)cc1	Preclinical		hypoxia inducible factor prolyl hydroxylase inhibitor		
MK-8745	Fc1c(Cl)cccc1C(=O)N1CCN(Cc2cccc(Nc3nccs3)n2)CC1	Preclinical	AURKA	Aurora kinase inhibitor		
MK-886	CC(C)c1ccc2n(Cc3ccc(Cl)cc3)c(CC(C)(C)C(O)=O)c(SC(C)(C)C)c2c1	Preclinical		lipoxygenase inhibitor		
MK-8998	CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1	Phase 2		T-type calcium channel blocker		
MKT-077	CCn1\c(=C/c2cccc[n+]2CC)s\c(=C2\Sc3ccccc3N2C)c1=O	Phase 1		HSP inhibitor		
MK2-IN-1	Clc1ccc(cc1)-c1ccc(o1)C(=O)N(Cc1ccccn1)c1ccc(cc1)N1CCNCC1	Preclinical	MAPKAPK2	MAP kinase inhibitor		
MLN0128	CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12	Phase 2	MTOR|PIK3CA|PIK3CD|PIK3CG	mTOR inhibitor		
MLN1117	Nc1nc2cc(ccc2o1)-c1ccc2ncc(C(=O)N3CCOCC3)n2c1	Phase 2	PIK3CA	PI3K inhibitor		
MLN2480	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(s1)C(=O)Nc1cc(c(Cl)cn1)C(F)(F)F	Phase 1/Phase 2		RAF inhibitor		
MLN8054	OC(=O)c1ccc(Nc2ncc3CN=C(c4cc(Cl)ccc4-c3n2)c2c(F)cccc2F)cc1 |c:13|	Phase 1	AURKA	Aurora kinase inhibitor		
MLN9708	CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(O)=O)(CC(O)=O)O1	Phase 3		proteasome inhibitor		
ML10302	COc1cc(N)c(Cl)cc1C(=O)OCCN1CCCCC1	Preclinical	HTR3A|HTR3B|HTR4	serotonin receptor partial agonist		
ML130	Cc1ccc(cc1)S(=O)(=O)n1c(N)nc2ccccc12	Preclinical		NOD1 inhibitor		
ML133	COc1ccc(CNCc2cccc3ccccc23)cc1	Preclinical		potassium channel blocker		
ML141	COc1ccc(cc1)[C@H]1CC(=NN1c1ccc(cc1)S(N)(=O)=O)c1ccccc1 |&1:8	Preclinical	CDC42	GTPase inhibitor		
ML161	CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1	Preclinical		protease-activated receptor inhibitor		
ML167	Cc1ccc(CNc2ncnc3ccc(cc23)-c2ccc(CO)o2)o1	Preclinical	CLK4|DYRK1B	CLK inhibitor, DYRK inhibitor		
ML179	FC(F)(F)c1cccc(c1)N1CCN(CC1)c1cc(=O)n(C2CCCCC2)c(=O)[nH]1	Preclinical	NR5A2	liver receptor homolog inverse agonist		
ML193	Cc1noc(NS(=O)(=O)c2ccc(NC(=O)c3cc(nc4c(C)cc(C)cc34)-c3ccccn3)cc2)c1C	Preclinical	GPR55	G protein-coupled receptor antagonist		
ML204	Cc1cc(nc2ccccc12)N1CCCCC1	Preclinical	TRPC4|TRPC5	transient receptor potential channel antagonist		
ML213	Cc1cc(C)c(NC(=O)[C@@H]2C[C@H]3CC[C@@H]2C3)c(C)c1 |&1:11	Preclinical	KCNQ4	potassium channel activator		
ML218	CC(C)(C)CCN1C[C@H]2[C@H](CNC(=O)c3cc(Cl)cc(Cl)c3)[C@H]2C1	Preclinical	CACNA1G|CACNA1H|CACNA1I	T-type calcium channel blocker		
ML228	C(Nc1nc(nnc1-c1ccccc1)-c1ccccn1)c1ccc(cc1)-c1ccccc1	Preclinical	HIF1A	hypoxia inducible factor activator		
ML277	COc1ccc(cc1)-c1csc(NC(=O)[C@H]2CCCCN2S(=O)(=O)c2ccc(C)cc2)n1	Preclinical	KCNQ1	potassium channel activator		
ML281	CC(C)c1ccc(NC(=O)c2cccs2)c(c1)-c1nc2ccccc2[nH]c1=O	Preclinical	STK33	serine/threonine kinase inhibitor		
ML297	Cc1cc(NC(=O)Nc2ccc(F)c(F)c2)n(n1)-c1ccccc1	Preclinical	KCNJ3	inward rectifier potassium channel activator		
ML298	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc(F)c(F)c2)CC1	Preclinical	PLD2	phospholipase inhibitor		
ML314	COc1ccccc1N1CCN(CC1)c1nc(nc2cc(OC)c(OC)cc12)C1CC1	Preclinical	NTSR1	neurotensin agonist		
ML323	CC(C)c1ccccc1-c1ncc(C)c(NCc2ccc(cc2)-n2ccnn2)n1	Preclinical	USP1	ubiquitin specific protease inhibitor		
ML324	CN(C)CCCNC(=O)c1ccc(cc1)-c1cc(O)c2ncccc2c1	Preclinical	KDM4A	histone lysine demethylase inhibitor		
ML3403	CSc1nc(c([nH]1)-c1ccc(F)cc1)-c1ccnc(N[C@@H](C)c2ccccc2)c1 |&1:20	Preclinical	CYP3A4|MAPK11|MAPK12|MAPK14	MAP kinase inhibitor		
ML347	COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12	Preclinical	ACVR1|ACVRL1|BMPR1A	ALK tyrosine kinase receptor inhibitor		
ML348	FC(F)(F)c1ccc(Cl)c(NC(=O)CN2CCN(CC2)C(=O)c2ccco2)c1	Preclinical	LYPLA1	lysophospholipase inhibitor		
ML365	COc1ccccc1C(=O)Nc1cccc(NC(=O)c2cccc(C)c2)c1	Preclinical	KCNK3|KCNK9	potassium channel blocker		
ML786	CC(C)(N)c1cc(cc(c1)C(F)(F)F)C(=O)N[C@@H]1CCc2ccc(Oc3ccnc4NC(=O)CCc34)cc2C1	Preclinical	BRAF|RAF1	RAF inhibitor		
ML9	Clc1cccc2c(cccc12)S(=O)(=O)N1CCCNCC1	Preclinical	TRPC6	myosin light chain kinase inhibitor		
MM-102	CCC(CC)(NC(=O)C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC1(CCCC1)C(=O)NC(c1ccc(F)cc1)c1ccc(F)cc1	Preclinical		WDR5/MLL interaction inhibitor		
MM-11253	CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O	Preclinical	RARG	retinoid receptor antagonist		
MM-206	Oc1c(Sc2ccccc2)cc(NS(=O)(=O)c2c(F)c(F)c(F)c(F)c2F)c2ccccc12	Preclinical		STAT inhibitor		
MMPX	COCc1nc2n(CC(C)C)c(=O)n(C)c(=O)c2[nH]1	Preclinical		phosphodiesterase inhibitor		
MMV-390048	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(c1)-c1ccc(nc1)C(F)(F)F	Preclinical		PI4K inhibitor		
MM77	COc1ccccc1N1CCN(CCCCN2C(=O)CCC2=O)CC1	Preclinical	HTR1A	serotonin receptor antagonist		
MN-64	CC(C)c1ccc(cc1)-c1cc(=O)c2ccccc2o1	Preclinical	TNKS	tankyrase inhibitor		
MNITMT	Cn1cnnc1Sc1c(ncn1C)[N+]([O-])=O	Preclinical		lymphocyte inhibitor		
mocetinostat	Nc1ccccc1NC(=O)c1ccc(CNc2nccc(n2)-c2cccnc2)cc1	Phase 2	HDAC1|HDAC11|HDAC2|HDAC3	HDAC inhibitor		
moclobemide	Clc1ccc(cc1)C(=O)NCCN1CCOCC1	Launched	MAOA|MAOB	monoamine oxidase inhibitor	neurology/psychiatry	depression, anxiety
modaline	Cc1nccnc1N1CCCCC1	Preclinical				
moexipril	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(O)=O	Launched	ACE|ACE2	angiotensin converting enzyme inhibitor	cardiology	hypertension
mofegiline	NC\C(CCc1ccc(F)cc1)=C\F	Phase 1	MAOA|MAOB	monoamine oxidase inhibitor		
mofezolac	COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1	Launched	PTGS1	cyclooxygenase inhibitor	rheumatology, orthopedics	rheumatoid arthritis, osteoporosis
moguisteine	CCOC(=O)CC(=O)N1CCS[C@@H]1COc1ccccc1OC |&1:12	Phase 2		ATP-sensitive potassium channel inhibitor		
molidustat	O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1	Phase 3	EGLN2	hypoxia inducible factor inhibitor		
molindone	CCc1c(C)[nH]c2CC[C@@H](CN3CCOCC3)C(=O)c12 |r|	Launched	DRD2|HRH1|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
molsidomine	CCOC(=O)Nc1c[n+](no1)N1CCOCC1	Launched	GUCY1A3	guanylate cyclase stimulant	cardiology	coronary artery disease (CAD)
mometasone	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl |c:11	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
mometasone-furoate	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |c:11	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
monastrol	CCOC(=O)C1=C(C)NC(=S)N[C@@H]1c1cccc(O)c1 |r	Preclinical	KIF11	kinesin inhibitor		
monensin	CC[C@]1(CC[C@@H](O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@H](O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@H]1O[C@H](C[C@@H]1C)[C@H]1O[C@@](O)(CO)[C@H](C)C[C@@H]1C	Launched		bacterial permeability inducer	infectious disease	gastrointestinal parasites
monepantel	C[C@](COc1cc(ccc1C(F)(F)F)C#N)(NC(=O)c1ccc(SC(F)(F)F)cc1)C#N	Preclinical		mTOR inhibitor		
monobenzone	Oc1ccc(OCc2ccccc2)cc1	Launched	TYR	melanin inhibitor	dermatology	skin depigmentation
monocrotaline	C[C@H]1C(=O)O[C@@H]2CCN3CC=C(COC(=O)[C@](C)(O)[C@]1(C)O)[C@H]23 |t:10|	Preclinical		antitumor agent		
monoctanoin	CCCCCCCC(=O)OC[C@@H](O)CO |&1:11	Launched			gastroenterology	gallstones
monomethyl-fumarate	COC(=O)\C=C\C(O)=O	Launched			neurology/psychiatry	multiple sclerosis
monosodium-alpha-luminol	Nc1cccc2c1c(=O)[nH][nH]c2=O	Launched				
monostearin	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)CO |&1:21	Preclinical				
montelukast	CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(O)=O)CC1)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1	Launched	ALOX5|CYSLTR1	leukotriene receptor antagonist	pulmonary, allergy	asthma, allergic rhinitis, exercise-induced bronchoconstriction (EIB)
moprolol	COc1ccccc1OC[C@@H](O)CNC(C)C |&1:10|	Launched		adrenergic receptor antagonist	cardiology, ophthalmology, neurology/psychiatry	hypertension, glaucoma, anxiety
moracizine	CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN3CCOCC3)c2c1	Withdrawn	SCN5A	sodium channel blocker	cardiology	ventricular arrhythmias
morantel	CN1CCCN=C1\C=C\c1sccc1C |c:5|	Launched		acetylcholine receptor agonist	infectious disease	tapeworm
morin	Oc1ccc(c(O)c1)-c1oc2cc(O)cc(O)c2c(=O)c1O	Preclinical	ADORA2A|ESR2|FASN|MCL1|SLC22A12	cytochrome P450 inhibitor		
morinidazole	Cc1ncc(n1C[C@@H](O)CN1CCOCC1)[N+]([O-])=O |&1:7	Launched	CYP51A1	other antibiotic		
morniflumate	FC(F)(F)c1cccc(Nc2ncccc2C(=O)OCCN2CCOCC2)c1	Launched		anti-inflammatory agent	neurology/psychiatry	pain relief
moroxydine	NC(=N)\N=C(/N)N1CCOCC1	Launched		antiviral	infectious disease	influenza A virus infection
morphothiadin	CCOC(=O)C1=C(CN2CCOCC2)NC(=N[C@@H]1c1ccc(F)cc1Br)c1nccs1 |&1:17	Preclinical		antiinfective drug		
mosapride	CCOc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CN(Cc2ccc(F)cc2)CCO1 |&1:15|	Launched	HTR4	serotonin receptor agonist	gastroenterology	hypertrophic gastritis (GHG), gastroesophageal reflux disease (GERD), dyspepsia, irritable bowel syndrome
motapizone	CC1=C(NNC(=O)C1)c1cc(cs1)-n1ccnc1 |t:1|	Preclinical		phosphodiesterase inhibitor		
motesanib	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12	Phase 3	FLT1|FLT4|KDR|KIT	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
motolimod	CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1 |t:9	Phase 2	TLR8	toll-like receptor agonist		
moxalactam	CO[C@]1(NC(=O)[C@@H](C(O)=O)c2ccc(O)cc2)[C@H]2OCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O |a:2	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections, gram-negative bacterial infections, skin infections, bone and joint infections, pneumonia, urinary tract infections, meningitis
moxaverine	CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1	Launched		phosphodiesterase inhibitor	neurology/psychiatry	spasms
moxidectin	[H][C@@]12OC\C3=C/C=C/[C@H](C)C\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(C\C(=N/OC)[C@H](C)[C@H](O5)C(\C)=C\C(C)C)O4)OC(=O)[C@]([H])(C=C(C)[C@H]1O)[C@@]23O |c:4	Launched		chloride channel antagonist	infectious disease	gastrointestinal parasites
moxifloxacin	COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c1n(cc(C(O)=O)c2=O)C1CC1	Launched	TOP2A	bacterial DNA gyrase inhibitor	otolaryngology, pulmonary, infectious disease	sinusitis, bronchitis, pneumonia, skin infections, intra-abdominal infections
moxisylyte	CC(C)c1cc(OC(C)=O)c(C)cc1OCCN(C)C	Withdrawn		adrenergic receptor antagonist		
moxonidine	COc1nc(C)nc(Cl)c1NC1=NCCN1 |t:12|	Launched	ADRA2A|ADRA2B|ADRA2C	imidazoline receptor agonist	cardiology	hypertension
mozavaptan	CN(C)[C@H]1CCCN(C(=O)c2ccc(NC(=O)c3ccccc3C)cc2)c2ccccc12 |&1:3	Launched	AVPR1A|AVPR1B|AVPR2	vasopressin receptor antagonist	endocrinology	hyponatremia
MPEP	Cc1cccc(n1)C#Cc1ccccc1	Preclinical	GRM1|GRM4|GRM5	glutamate receptor antagonist		
MPI-0479605	Cc1cc(ccc1Nc1nc(NC2CCCCC2)c2[nH]cnc2n1)N1CCOCC1	Preclinical	TTK	mitotic kinase inhibitor		
Mps-BAY-2a	CC(C)CNc1nc(cn2c(cnc12)-c1ccc(cc1)C(=O)NC1CC1)-c1cccc2ncccc12	Preclinical	TTK	monopolar spindle 1 kinase inhibitor		
Mps1-IN-1	COc1cc(ccc1Nc1cc(Nc2ccccc2S(=O)(=O)C(C)C)c2cc[nH]c2n1)N1CCC(O)CC1	Preclinical	TTK	monopolar spindle 1 kinase inhibitor		
Mps1-IN-5	COc1cc(ccc1Nc1nc2ccc(cn2n1)-c1ccc(NC(=O)[C@H](C)c2ccc(F)cc2)cc1)S(C)(=O)=O	Phase 1		protein kinase inhibitor		
MR-16728	O=C(NCCCN1CCCCCC1)[C@@H](C1CCCCC1)c1ccccc1 |&1:13|	Preclinical		acetylcholine release enhancer		
MR-948	OCCc1ccc(OCCn2ccnc2)cc1	Phase 1	TBXAS1	thromboxane synthase inhibitor		
MRK-016	Cc1cc(no1)-c1nncc2c(c(OCc3ncnn3C)nn12)C(C)(C)C	Phase 1	GABRA1|GABRA2|GABRA3|GABRA5	GABA receptor inverse agonist		
MRK-409	Cn1ncnc1COc1nn2c(nnc2cc1C1CCC1)-c1c(F)cccc1F	Phase 1		benzodiazepine receptor agonist		
MRK-560	Fc1ccc(F)c(c1)[C@]1(CC[C@@H](CC1)NS(=O)(=O)C(F)(F)F)S(=O)(=O)c1ccc(Cl)cc1 |r|	Preclinical	APP	gamma secretase inhibitor		
MRS-1220	Clc1ccc2nc(NC(=O)Cc3ccccc3)n3nc(nc3c2c1)-c1ccco1	Preclinical	ADORA2B|ADORA3	adenosine receptor antagonist		
MRS-1334	CCOC(=O)C1=C(C)NC(=C([C@@H]1C#Cc1ccccc1)C(=O)OCc1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:11	Preclinical	ADORA3	adenosine receptor antagonist		
MRS-1845	CCOC(=O)C1=C(C)N(CC#C)C(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |&1:15	Preclinical		calcium channel blocker		
MRS-2578	S=C=Nc1cccc(NC(=S)NCCCCNC(=S)Nc2cccc(c2)N=C=S)c1	Preclinical	P2RY6	purinergic receptor antagonist		
MRS-3777	C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12.C1CCC(CC1)Nc1nc(Oc2ccccc2)nc2nc[nH]c12	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
MRX-2843	CN1CCN(Cc2ccc(cc2)-c2cn([C@H]3CC[C@H](O)CC3)c3nc(NCCC4CC4)ncc23)CC1 |r|	Phase 1		MER tyrosine kinase inhibitor		
MS-424	C[C@@H]1C=CNN1C(=O)c1cccnc1 |c:2|	Phase 2		glutamate transporter modulator		
MSDC-0160	CCc1ccc(nc1)C(=O)COc1ccc(C[C@@H]2SC(=O)NC2=O)cc1 |&1:17	Phase 2		insulin sensitizer		
MSDC-0602K	COc1cccc(c1)C(=O)COc1ccc(Cc2sc(O)nc2O)cc1	Phase 2		mitochondrial pyruvate carrier modulator		
MSX-122	C(Nc1ncccn1)c1ccc(CNc2ncccn2)cc1	Phase 2	CXCR4	CC chemokine receptor antagonist		
MTPG	C[C@@](N)(C(O)=O)c1ccc(cc1)-c1nn[nH]n1 |&1:1|	Preclinical	GRM2|GRM3	glutamate receptor antagonist		
mubritinib	FC(F)(F)c1ccc(\C=C\c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1	Phase 1	EGFR|ERBB2	protein tyrosine kinase inhibitor		
mupirocin	C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]1CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O	Launched		isoleucyl-tRNA synthetase inhibitor	infectious disease	impetigo
muscimol	NCc1cc(=O)[nH]o1	Phase 1	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRR1|GABRR2|GABRR3	benzodiazepine receptor agonist		
MUT056399	CCc1cc(O)c(Oc2ccc(cc2F)C(N)=O)cc1F	Phase 1		FABI inhibitor		
MY-5445	Clc1cccc(Nc2nnc(-c3ccccc3)c3ccccc23)c1	Preclinical	PDE5A	phosphodiesterase inhibitor, platelet aggregation inhibitor		
mycophenolate-mofetil	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1	Launched	IMPDH1|IMPDH2	dehydrogenase inhibitor, inositol monophosphatase inhibitor	transplant	organ rejection
mycophenolic-acid	COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O	Launched	IMPDH1|IMPDH2	dehydrogenase inhibitor, inositol monophosphatase inhibitor	transplant	organ rejection
myricetin	Oc1cc(O)c2c(c1)oc(-c1cc(O)c(O)c(O)c1)c(O)c2=O	Preclinical	PIK3CG	androgen receptor agonist, cytochrome P450 inhibitor		
myricitrin	C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Preclinical	NOS1|PRKCA	PKC inhibitor		
myristyl-nicotinate	CCCCCCCCCCCCCCOC(=O)c1cccnc1	Phase 1		topical sunscreen agent		
M8-B	COc1cc(CN(CCN)C(=O)c2cccs2)ccc1OCc1ccccc1	Preclinical	TRPM8	transient receptor potential channel antagonist		
N-(p-amylcinnamoyl)-anthranilic-acid	CCCCCc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1	Preclinical		phospholipase inhibitor		
N-(2-chlorophenyl)-2-({(2E)-2-[1-(2-pyridinyl)ethylidene]hydrazino}carbothioyl)hydrazinecarbothioamide	CC(=NNC(=S)NNC(=S)Nc1ccccc1Cl)c1ccccn1	Preclinical				
N-[2-(piperidinylamino)ethyl]-4-iodobenzamide	Ic1ccc(cc1)C(=O)NCCN1CCCCC1	Preclinical		sigma receptor ligand		
N-acetyl-D-glucosamine	CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO	Phase 2/Phase 3	B4GALT1|B4GALT2|B4GALT3|B4GALT4|NAGK|NAGLU|NAGPA|RENBP			
N-acetyl-tyrosine	CC(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:4	Launched				
N-acetylcarnosine	CC(=O)NCCC(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O	Launched				
N-acetylglycyl-D-glutamic-acid	CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O	Preclinical		glutamate receptor agonist		
N-acetylmannosamine	CC(=O)N[C@H]1[C@@H](O)O[C@@H](CO)[C@@H](O)[C@H]1O |a:5	Phase 2				
N-acetyltryptamine	CC(=O)NCCc1c[nH]c2ccccc12	Preclinical		melatonin receptor agonist		
N-alpha-methylhistamine-dihydrochloride	CNCCc1cnc[nH]1	Phase 3	HRH4	histamine receptor agonist		
N-benzylnaltrindole	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1c(C[C@@]35O)c2ccccc2n1Cc1ccccc1 |TLB:21:22:7.12.13:4.5.18	Preclinical		opioid receptor antagonist		
N-cyclohexyl-2-benzothiazolesulfenamide	C1CCC(CC1)NSc1nc2ccccc2s1	Preclinical				
N-hydroxynicotinamide	ONC(=O)c1cccnc1	Preclinical				
N-methyl-(-)ephedrine-[1R,2S]	C[C@@H]([C@H](O)c1ccccc1)N(C)C	Preclinical				
N-methylformamide	CNC=O	Phase 2				
N-methyllidocaine-iodide	CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C	Preclinical		antiarrhythmic medication		
N-methylpyrrolidone	CN1CCCC1=O	Phase 1				
N-methylquipazine	CN1CCN(CC1)c1ccc2ccccc2n1	Preclinical		serotonin receptor agonist		
N-MPPP	CN([C@H](CN1CCCC1)c1ccccc1)C(=O)Cc1ccccc1	Preclinical		opioid receptor agonist		
N-oxydiethylenebenzothiazole-2-sulfenamide	C1CN(CCO1)Sc1nc2ccccc2s1	Preclinical				
N-salicoylaminophenol	Oc1ccc(NC(=O)c2ccccc2O)cc1	Phase 1/Phase 2		ribonucleotide reductase inhibitor		
NAB-2	Cc1ccc(C)c(c1)-n1cnc2cc(ccc12)C(=O)NCc1ccccc1Cl	Preclinical	NEDD4	ubiquitin ligase transport promoter		
nabumetone	COc1ccc2cc(CCC(C)=O)ccc2c1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis, osteoarthritis
nadide	NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O |a:9	Launched	AHCY|AKR1A1|ALDH2|BLVRA|DHPS|DLD|GALE|HMGCR|HSD17B1|HSD17B4|IMPDH2|MGAM|P2RY11|SORD|TRPM2	free radical scavenger		
nadifloxacin	C[C@H]1CCc2c(N3CCC(O)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1	Launched		bacterial DNA gyrase inhibitor	dermatology, infectious disease	acne vulgaris (AV), skin infections
nadolol	CC(C)(C)NC[C@@H](O)COc1cccc2C[C@@H](O)[C@@H](O)Cc12 |a:16	Launched	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist	cardiology	angina pectoris, hypertension
NADPH		Preclinical	DRD2|DRD3|DRD4|GHSR|HTR2A|HTR2C			
nafadotride	CCCCN1CCC[C@@H]1CNC(=O)c1cc(C#N)c2ccccc2c1OC |&1:8	Preclinical	DRD2|DRD3|HTR1A	dopamine receptor antagonist		
nafamostat	NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2cc(ccc2c1)C(N)=N	Launched	ASIC1|ASIC2|ASIC3|C1R|PRSS1|TPSAB1|TRPM7	serine protease inhibitor	cardiology	anticoagulent
nafcillin	CCOc1ccc2ccccc2c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O	Launched	CYP1A2|CYP3A4|SLC22A6	bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
naftidrofuryl	CCN(CC)CCOC(=O)[C@@H](C[C@H]1CCCO1)Cc1cccc2ccccc12 |&1:10	Launched		adrenergic receptor antagonist	cardiology	claudication
naftifine	CN(C\C=C\c1ccccc1)Cc1cccc2ccccc12	Launched		fungal squalene epoxidase inhibitor	infectious disease	tinea pedis, tinea cruris, tinea corporis
naftopidil	COc1ccccc1N1CCN(C[C@@H](O)COc2cccc3ccccc23)CC1 |&1:13|	Launched	ADRA1A	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
nalbuphine	O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45	Launched	OPRD1|OPRK1|OPRM1	opioid receptor agonist, opioid receptor antagonist	neurology/psychiatry	pain relief
nalfurafine	CN([C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CC1)c45)C(=O)\C=C\c1ccoc1	Launched	OPRK1|OPRM1	opioid receptor agonist	nephrology	uremic pruritus
nalidixic-acid	CCn1cc(C(O)=O)c(=O)c2ccc(C)nc12	Launched		bacterial DNA gyrase inhibitor	infectious disease	urinary tract infections
nalmefene	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=C)CC[C@@]35O	Launched	OPRD1|OPRK1|OPRM1	opioid receptor antagonist	pulmonary	respiratory depression
naloxegol	COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC=C)c45	Launched	OPRM1	opioid receptor antagonist	gastroenterology	constipation
naloxone	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched	CREB1|ESR1|OPRD1|OPRK1|OPRM1|TLR4	opioid receptor antagonist	pulmonary	respiratory depression
naloxone-benzoylhydrazone	Oc1ccc2C[C@H]3N(CC=C)CC[C@@]45[C@@H](Oc1c24)\C(CC[C@@]35O)=N\NC(=O)c1ccccc1	Preclinical	OPRK1|OPRM1	opioid receptor antagonist		
naltrexone	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O	Launched	OPRD1|OPRK1|OPRM1|SIGMAR1	opioid receptor antagonist	neurology/psychiatry	abstinence from alcohol
naltriben	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1oc2ccccc2c1C[C@@]35O	Preclinical	OPRD1|OPRK1|OPRM1	opioid receptor antagonist		
naltrindole	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2ccccc2c1C[C@@]35O	Preclinical	OPRD1|OPRK1|OPRM1	opioid receptor antagonist		
Nampt-IN-1	CC(C)(O)CS(=O)(=O)Nc1ccc2CN(CCc2c1)C(=O)COc1cccnc1	Preclinical				
NAN-190	COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1	Preclinical	ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1F	serotonin receptor agonist		
nanchangmycin	CO[C@H]1CC[C@@H](O[C@H]2C[C@@H](O[C@]3(O[C@H](C[C@@H]3C)[C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)[C@@H]2C)[C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@H](O3)[C@@H](C)\C=C(/C)C(=O)[C@H](C)C[C@H](C)C(O)=O)O2)O[C@@H]1C |a:2	Preclinical		other antibiotic		
napabucasin	CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O	Phase 3	STAT3	STAT inhibitor		
napamezole	C(C1=NCCN1)C1=Cc2ccccc2CC1 |t:1	Preclinical		adrenergic receptor antagonist, monoamine reuptake inhibitor		
naphazoline	C(C1=NCCN1)c1cccc2ccccc12 |t:1|	Launched	ADRA1A|ADRA2A	adrenergic receptor agonist	ophthalmology	eye irritation
naphthoquine-phosphate	CC(C)(C)NCc1cc(Nc2ccnc3cc(Cl)ccc23)c2CCCCc2c1O	Launched		antimalarial agent	infectious disease	malaria
napirimus	Cn1cc(cc1C(O)=O)C(=O)c1cccc2ccccc12	Phase 1		immunosuppressant		
naproxen	COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry, rheumatology, dental, otolaryngology, endocrinology	pain relief, rheumatoid arthritis, headache, toothache, backache, muscle pain, common cold, fever
naquotinib	CCc1nc(C(N)=O)c(Nc2ccc(cc2)N2CCC(CC2)N2CCN(C)CC2)nc1O[C@@H]1CCN(C1)C(=O)C=C	Phase 3		EGFR inhibitor		
narasin	CC[C@H]([C@@H]1O[C@@H]([C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]2O[C@@]3(O[C@@]4(CC[C@](C)(O4)[C@H]4CC[C@](O)(CC)[C@H](C)O4)[C@H](O)C=C3)[C@H](C)C[C@@H]2C)[C@@H](C)C[C@H]1C)C(O)=O |a:2	Launched		antiprotozoal agent	infectious disease	coccidiosis
naratriptan	CNS(=O)(=O)CCc1ccc2[nH]cc(C3CCN(C)CC3)c2c1	Launched	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	serotonin receptor agonist	neurology/psychiatry	migraine headache
naringenin	Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O)cc(O)cc2O1	Phase 1	CYP19A1|CYP1B1|ESR2|GLO1|HSD17B1	aromatase inhibitor, TRPV antagonist		
naringeninic-acid	OC(=O)\C=C\c1ccc(O)cc1	Phase 1	HCAR2|PTGR1			
naringin	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(O)cc2)[C@H](O)[C@H](O)[C@H]1O	Preclinical	SLCO1A2	cytochrome P450 inhibitor		
naringin-dihydrochalcone	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c(C(=O)CCc3ccc(O)cc3)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Preclinical		cytochrome P450 inhibitor		
narlaprevir	CCCC[C@H](NC(=O)[C@@H]1[C@@H]2[C@H](CN1C(=O)[C@@H](NC(=O)NC1(CS(=O)(=O)C(C)(C)C)CCCCC1)C(C)(C)C)C2(C)C)C(=O)C(=O)NC1CC1	Phase 3		HCV inhibitor		
NAS-181	C(Oc1cccc2C=C(CN3CCOCC3)COc12)[C@H]1CNCCO1 |t:7|	Preclinical	HTR1B	serotonin receptor antagonist		
nastorazepide	CC(C)(C)C(=O)CN1c2ccccc2N(C[C@@H](NC(=O)Nc2cccc(c2)C(O)=O)C1=O)C1CCCCC1	Phase 2	CCKBR	CCK receptor antagonist		
natamycin	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:27	Launched		fungal ergosterol inhibitor	ophthalmology, infectious disease	conjunctivitis, fungal keratosis, blepharitis
nateglinide	CC(C)[C@H]1CC[C@@H](CC1)C(=O)N[C@H](Cc1ccccc1)C(O)=O	Launched	ABCC8|KCNJ10|KCNJ11|PPARG	insulin secretagogue	endocrinology	diabetes mellitus
NAV-26	FC(F)(F)Oc1ccc(CNC(=O)[C@H]2N(C3CCOCC3)C(=O)c3ccccc23)cc1 |&1:13	Preclinical	SCN9A	voltage-gated sodium channel blocker		
navarixin	CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1	Phase 2	CXCR1|CXCR2	CC chemokine receptor antagonist		
navitoclax	CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 |t:5|	Phase 2	BCL2|BCL2L1|BCL2L2	BCL inhibitor		
naxagolide	CCCN1CCO[C@H]2[C@H]1CCc1ccc(O)cc21	Phase 3		dopamine receptor agonist		
NB-001	Nc1ncnc2n(CCNCCCCCO)cnc12	Preclinical		antiviral		
NBI-27914	CCCN(CC1CC1)c1nc(C)nc(Nc2c(Cl)cc(Cl)cc2Cl)c1Cl	Preclinical	CRHR1	corticotropin releasing factor receptor antagonist		
NBI-74330-(+/-)	CCOc1ccc(cc1)-n1c(nc2ncccc2c1=O)[C@@H](C)N(Cc1cccnc1)C(=O)Cc1ccc(F)c(c1)C(F)(F)F |&1:20	Preclinical	CXCR3	CC chemokine receptor antagonist		
NBI-98782	COc1cc2CCN3C[C@@H](CC(C)C)[C@H](O)C[C@@H]3c2cc1OC	Preclinical		vesicular monoamine transporter inhibitor		
NBQX	NS(=O)(=O)c1cccc2c1c(cc1[nH]c(=O)c(=O)[nH]c21)[N+]([O-])=O	Preclinical	GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIN1|GRIN2A|GRIN2B	glutamate receptor antagonist		
NCS-382	O[C@@H]1c2ccccc2CCC\C1=C/C(O)=O |&1:1|	Preclinical	GABBR1|GABBR2|SLC52A2	GABA receptor antagonist		
NCX-1015	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)c1ccc(CO[N+]([O-])=O)cc1 |c:13	Preclinical		interleukin sythesis stimulator		
NDD-094	Cc1nccn1Cc1ccccn1	Preclinical				
NDT-9513727	CCCCn1c(CN(Cc2ccc3OCOc3c2)Cc2ccc3OCOc3c2)c(nc1-c1ccccc1)-c1ccccc1	Preclinical	C5AR1	complement antagonist		
NE-100	CCCN(CCC)CCc1ccc(OC)c(OCCc2ccccc2)c1	Phase 2	SIGMAR1	sigma receptor antagonist		
nebivolol	O[C@H](CNC[C@@H](O)[C@@H]1CCc2cc(F)ccc2O1)[C@H]1CCc2cc(F)ccc2O1 |&1:1	Launched	ADRB1	adrenergic receptor antagonist	cardiology	hypertension
nebracetam	NC[C@H]1CN(Cc2ccccc2)C(=O)C1 |&1:2|	Phase 3	CHRM1	acetylcholine receptor agonist		
NECA	CCNC(=O)[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Launched	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor agonist		
necrostatin-1	CN1C(=S)N[C@@H](Cc2c[nH]c3ccccc23)C1=O |r|	Preclinical	RIPK1	RIPK inhibitor		
necrostatin-2	CN1C(=O)N[C@H](Cc2c[nH]c3c(Cl)cccc23)C1=O	Preclinical	RIPK2	necroptosis inhibitor, RIPK inhibitor		
nedaplatin	N[Pt]1(N)OC=C(O)O1 |t:4|	Launched		DNA inhibitor	oncology	non-small cell lung cancer (NSCLC), small cell lung cancer, esophageal cancer
nedocromil	CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(O)=O)C(O)=O	Launched	CYSLTR1|CYSLTR2|FPR1|HSP90AA1|PTGDR	histamine receptor antagonist	neurology/psychiatry, ophthalmology	itching, conjunctivitis
nefazodone	CCc1nn(CCCN2CCN(CC2)c2cccc(Cl)c2)c(=O)n1CCOc1ccccc1	Withdrawn	ADRA1A|ADRA1B|ADRA2A|CYP3A4|HTR1A|HTR2A|HTR2C|SLC6A2|SLC6A3|SLC6A4	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor		
nefiracetam	Cc1cccc(C)c1NC(=O)CN1CCCC1=O	Phase 3	CHRM1	acetylcholine receptor agonist, benzodiazepine receptor agonist		
nefopam	CN1CCO[C@@H](c2ccccc2)c2ccccc2C1 |&1:5|	Launched		cyclooxygenase inhibitor	neurology/psychiatry	pain relief
nelarabine	COc1nc(N)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	POLA1	DNA synthesis inhibitor, T cell inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
nelfinavir	Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C	Launched	CYP1A2|CYP2B6|CYP2C19|CYP2C9|CYP2D6|CYP3A4|CYP3A7	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nelociguat	COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	Preclinical		guanylate cyclase stimulant		
nelotanserin	COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1-c1c(Br)cnn1C	Phase 2		serotonin receptor inverse agonist		
nemazoline	Nc1c(Cl)cc(C=C2NCCN2)cc1Cl	Phase 2		adrenergic receptor agonist, adrenergic receptor antagonist		
nemiralisib	CC(C)N1CCN(Cc2cnc(o2)-c2cc(cc3[nH]ncc23)-c2cccc3[nH]ccc23)CC1	Phase 2				
nemonapride	CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C |&1:14	Launched	DRD2|DRD3|DRD4	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
nemorexant	COc1ccc(c(c1)C(=O)N1CCC[C@@]1(C)c1nc2ccc(Cl)c(C)c2[nH]1)-n1nccn1	Preclinical		orexin receptor antagonist		
nemorubicin	CO[C@@H]1CN(CCO1)[C@H]1C[C@H](O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5cccc(OC)c5C(=O)c4c(O)c23)C(=O)CO)O[C@@H](C)[C@H]1O	Phase 2	TOP1|TOP2A	topoisomerase inhibitor		
neo-gilurytmal	CCC[N@@+]12[C@H]3C[C@]45[C@@H](O)[C@@H]3[C@@H](C[C@@H]1[C@@H]4N(C)c1ccccc51)[C@H](CC)[C@H]2O |a:4	Launched			cardiology	cardiac arrythmia
neohesperidin	[H][C@@]1(O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2cc(O)c3C(=O)C[C@H](Oc3c2)c2ccc(OC)c(O)c2)O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O	Preclinical				
neohesperidin-dihydrochalcone	COc1ccc(CCC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)cc2O)cc1O	Preclinical				
neomycin	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	CXCR4	bacterial 30S ribosomal subunit inhibitor	infectious disease, gastroenterology	first-aid antibiotic, hepatic encephalopathy (HE), intra-abdominal infections
neostigmine	CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C	Launched	ACHE	acetylcholinesterase inhibitor	neurology/psychiatry	myasthenia gravis
nepafenac	NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	ophthalmology	eye inflammation
nepicastat	NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1	Phase 2	DBH	dopamine beta hydroxylase inhibitor		
neratinib	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Launched	EGFR|ERBB2|KDR	EGFR inhibitor	oncology	breast cancer
nerbacadol	Cc1oncc1C(=O)N1CCCCC1	Phase 3		cyclooxygenase inhibitor		
neridronic-acid	NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	FDPS	bone resorption inhibitor	endocrinology	brittle bone disease, Paget's disease
nesbuvir	CNC(=O)c1c(oc2cc(N(CCO)S(C)(=O)=O)c(cc12)C1CC1)-c1ccc(F)cc1	Phase 2		RNA polymerase inhibitor		
netilmicin	[H][C@]1(O[C@@H]2[C@@H](N)C[C@@H](NCC)[C@H](O[C@@]3([H])OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)OC(CN)=CC[C@H]1N |c:32|	Launched		protein synthesis inhibitor	infectious disease	gram-negative bacterial infections
netupitant	CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1	Launched	TACR1	tachykinin antagonist	gastroenterology	nausea, vomiting
neurodazine	COc1ccc(cc1)-c1nc([nH]c1-c1ccc(OC)cc1)-c1ccc(o1)-c1cccc(Cl)c1	Preclinical		neurogenesis of non-pluripotent C2C12 myoblast inducer		
neuropathiazol	CCOC(=O)c1ccc(cc1)N(C)c1csc(n1)-c1ccccc1	Preclinical	BMP2|LIF	neural stem cell inducer		
Neu2000	OC(=O)c1cc(NCc2c(F)c(F)c(c(F)c2F)C(F)(F)F)ccc1O	Phase 2		ionotropic glutamate receptor antagonist		
nevirapine	Cc1ccnc2N(C3CC3)c3ncccc3C(=O)Nc12	Launched	CYP1A2|CYP2A6|CYP2B6|CYP2C9|CYP2D6|CYP3A4|CYP3A5	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
nexturastat-A	CCCCN(Cc1ccc(cc1)C(=O)NO)C(=O)Nc1ccccc1	Preclinical	HDAC1|HDAC6	HDAC inhibitor		
NFKB-activation-inhibitor-II	Cc1ccc(NCCCc2ccccc2)c(N)c1	Preclinical	RELA	NFkB pathway inhibitor		
NG-nitro-arginine	N[C@@H](CCCNC(N)=N[N+]([O-])=O)C(O)=O	Phase 1	NOS1|NOS2|NOS3	nitric oxide synthase inhibitor		
NGB-2904	Clc1cccc(N2CCN(CCCCNC(=O)c3ccc-4c(Cc5ccccc-45)c3)CC2)c1Cl	Preclinical	DRD3	dopamine receptor antagonist		
NGD-94-1	C(N1CCN(CC1)c1ncccn1)c1cnc([nH]1)-c1ccccc1	Phase 1	DRD4	dopamine receptor antagonist		
NGD-98-2	CCC(CC)Nc1nc(C)c(nc1OC)-c1ccc(OC(F)(F)F)cc1OC	Preclinical	CRHR1	corticotropin releasing factor receptor antagonist		
NGP555	CCc1cc(Nc2nc(cs2)-c2ccc(c(F)c2)-n2cnc(C)c2)c(C)cc1C	Phase 1		gamma secretase modulator		
NHI-2	COC(=O)c1cc2c(cc(cc2n1O)-c1ccccc1)C(F)(F)F	Preclinical	LDHA	lactate dehydrogenase inhibitor		
NH125	CCCCCCCCCCCCCCCC[n+]1ccn(Cc2ccccc2)c1C	Preclinical		eukaryotic translation elongation factor 2 inhibitor		
NI-57	COc1cc(ccc1S(=O)(=O)Nc1ccc2n(C)c(=O)c(C)cc2c1)C#N	Preclinical	BRD1|BRPF1|BRPF3	bromodomain inhibitor		
niacin	OC(=O)c1cccnc1	Launched	DGAT2|HCAR1|HCAR2|HCAR3|NNMT|QPRT	NAD precursor, vitamin B	endocrinology	hypertriglyceridemia
nialamide	O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1	Withdrawn	COMT|MAOA|MAOB	monoamine oxidase inhibitor		
nibentan	CCN(CC)CCCC[C@@H](NC(=O)c1ccc(cc1)[N+]([O-])=O)c1ccccc1 |&1:9	Phase 2		potassium channel blocker		
nicainoprol	CC(C)NC[C@H](O)COc1cccc2CCCN(C(=O)c3cccnc3)c12 |&1:5	Preclinical		angiotensin converting enzyme inhibitor		
nicaraven	C[C@@H](CNC(=O)c1cccnc1)NC(=O)c1cccnc1 |&1:1	Phase 3		free radical scavenger		
nicardipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN(C)Cc1ccccc1 |r	Launched	ADORA3	calcium channel blocker	cardiology	chronic stable angina, hypertension
nicergoline	CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13	Launched	ADRA1A	adrenergic receptor antagonist	rheumatology, neurology/psychiatry, cardiology, hematology	Raynaud's disease, migraine headache, atherosclerosis, thrombosis
niceritrol	O=C(OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1)c1cccnc1	Launched		NAD precursor	endocrinology	hyperlipidemia
niclosamide	Oc1ccc(Cl)cc1C(=O)Nc1ccc(cc1Cl)[N+]([O-])=O	Launched	STAT3	DNA replication inhibitor, STAT inhibitor	infectious disease	tapeworm
nicodicosapent	CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCNC(=O)c1cccnc1	Preclinical		sterol regulatory element binding protein (SREBP) inhibitor		
nicorandil	[O-][N+](=O)OCCNC(=O)c1cccnc1	Launched	KCNJ11	nitric oxide donor, potassium channel activator	cardiology	angina pectoris
nicotinamide	NC(=O)c1cccnc1	Launched	BST1|LDHA|PARP1|SIRT5	protein synthesis stimulant	dermatology	acne vulgaris (AV)
nicotine	CN1CCC[C@H]1c1cccnc1	Launched	CHAT|CHRNA10|CHRNA2|CHRNA3|CHRNA4|CHRNA5|CHRNA6|CHRNA7|CHRNA9|CHRNB2|CHRNB3|CHRNB4|CYP19A1|TBXAS1|TRPA1	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
nicotinyl-alcohol-tartrate	OCc1cccnc1	Launched			cardiology, neurology/psychiatry	vascular spasm, vertigo
NIDA-41020	COc1ccc(cc1)-c1c(C)c(nn1-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Preclinical	CNR1	cannabinoid receptor antagonist		
nifedipine	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1[N+]([O-])=O)C(=O)OC |c:4	Launched	CACNA1C|CACNA1D|CACNA1F|CACNA1H|CACNA1S|CACNA2D1|CACNB2|CALM1|GLRA1|GLRA3|GLRB|KCNA1|KCNA5|NR1I2|TRPM3	calcium channel blocker	cardiology	vasospastic angina, chronic stable angina
nifekalant	Cn1c(NCCN(CCO)CCCc2ccc(cc2)[N+]([O-])=O)cc(=O)n(C)c1=O	Launched		potassium channel blocker	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)
nifenalol	CC(C)NC[C@@H](O)c1ccc(cc1)[N+]([O-])=O |&1:5	Launched	ADRB1|ADRB2	adrenergic receptor antagonist		
nifenazone	Cc1c(NC(=O)c2cccnc2)c(=O)n(-c2ccccc2)n1C	Launched		analgesic agent	neurology/psychiatry	pain relief
niflumic-acid	OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F	Launched	ANO1|CLCN1|CLCNKA|CLCNKB|KCNQ1|PLA2G1B|PLA2G4A|PTGS1|PTGS2|UGT1A9	cyclooxygenase inhibitor	rheumatology, neurology/psychiatry	joint pain, muscle pain
nifuroxazide	Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched		bacterial DNA inhibitor	gastroenterology	colitis, diarrhea
nifursol	Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched		bacterial DNA inhibitor		
nifurtimox	C[C@H]1CS(=O)(=O)CCN1\N=C\c1ccc(o1)[N+]([O-])=O |&1:1	Launched		DNA inhibitor	infectious disease	Chagas disease, African trypanosomiasis
niguldipine-(R)-(-)	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |r	Preclinical				
niguldipine-(S)-(+)	COC(=O)C1=C(C)NC(C)=C([C@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |c:4	Preclinical	ADRA1A	adrenergic receptor antagonist		
nikethamide	CCN(CC)C(=O)c1cccnc1	Withdrawn		immunostimulant		
nilotinib	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F	Launched	ABL1|KIT	Abl kinase inhibitor, Bcr-Abl kinase inhibitor	hematologic malignancy	chronic myeloid leukemia (CML)
nilutamide	CC1(C)NC(=O)N(C1=O)c1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Launched	AR	androgen receptor antagonist	oncology	prostate cancer
nilvadipine	COC(=O)C1=C(NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C)C#N |&1:10	Launched	CACNA1C|CACNA1D	calcium channel blocker	cardiology	hypertension, cerebral artery occlusion
nimesulide	CS(=O)(=O)Nc1ccc(cc1Oc1ccccc1)[N+]([O-])=O	Launched	LTF|PLA2G2E|PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology, obstetrics/gynecology	osteoarthritis, menstrual pain
nimodipine	COCCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC(C)C |r	Launched	CFTR|NR3C2	calcium channel blocker	hematology	hemorrhage
nimorazole	[O-][N+](=O)c1cncn1CCN1CCOCC1	Launched		bacterial DNA inhibitor	oncology	head and neck squamous cell carcinoma (HNSCC)
nimustine	Cc1ncc(CNC(=O)N(CCCl)[NH2+][O-])c(N)n1	Launched		DNA alkylating agent		
NIM811	[H][C@]1(NC(=O)[C@]([H])([C@@H](C)CC)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@]([H])(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	Phase 2		mitochondrial permeability transition inhibitor		
ningetinib-tosylate	Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C	Preclinical		protein tyrosine kinase inhibitor		
nintedanib	COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN3CCN(C)CC3)c3ccccc3)C(=O)Nc2c1	Launched	FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
niraparib	NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1	Launched	PARP1	PARP inhibitor	oncology	primary peritoneal cancer (PPC)
niridazole	[O-][N+](=O)c1cnc(s1)N1CCNC1=O	Launched		phosphofructokinase inhibitor	infectious disease	schistosomiasis
nisin		Phase 1		bacterial cell wall synthesis inhibitor		
nisoldipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccccc1[N+]([O-])=O)C(=O)OCC(C)C |r	Launched	CACNA1C|CACNA1D|CACNA1F|CACNA1S	calcium channel blocker	cardiology	hypertension
nisoxetine	CNCC[C@@H](Oc1ccccc1OC)c1ccccc1 |&1:4	Phase 1	SLC6A2|SLC6A3|SLC6A4	norepinephrine reuptake inhibitor		
nitarsone	O[As](O)(=O)c1ccc(cc1)[N+]([O-])=O	Launched			dermatology	blackhead disease
nitazoxanide	CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+]([O-])=O	Launched		pyruvate ferredoxin oxidoreductase inhibitor	gastroenterology	diarrhea
nitecapone	CC(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C(C)=O	Phase 2	COMT	catechol O methyltransferase inhibitor		
nitenpyram	CCN(Cc1ccc(Cl)nc1)C(\NC)=C\[N+]([O-])=O	Launched			infectious disease	flea control
nithiamide	CC(=O)Nc1ncc(s1)[N+]([O-])=O	Preclinical		bacterial DNA inhibitor		
nitisinone	OC(=C1C(=O)CCCC1=O)c1ccc(cc1[N+]([O-])=O)C(F)(F)F	Launched		hydroxyphenylpyruvate dioxygenase inhibitor	metabolism	tyrosinemia
nitrendipine	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC |r	Launched	CACNA1D|CACNA2D1|KCNN4	calcium channel blocker	cardiology	hypertension
nitrocaramiphen	CCN(CC)CCOC(=O)C1(CCCC1)c1ccc(cc1)[N+]([O-])=O	Preclinical	CHRM1	cholinergic receptor antagonist		
nitroflurbiprofen	C[C@@H](C(=O)OCCCCO[N+]([O-])=O)c1ccc(c(F)c1)-c1ccccc1 |&1:1	Preclinical		cyclooxygenase inhibitor		
nitrofurantoin	[O-][N+](=O)c1ccc(\C=N\N2CC(=O)NC2=O)o1	Launched		DNA inhibitor	infectious disease	urinary tract infections, pyelonephritis
nitrofurazone	NC(=O)N\N=C\c1ccc(o1)[N+]([O-])=O	Launched		bacterial DNA inhibitor	infectious disease	first-aid antibiotic
nitromide	NC(=O)c1cc(cc(c1)[N+]([O-])=O)[N+]([O-])=O	Launched			infectious disease	coccidiosis
nitrosodimethylurea	CNC(=O)N(C)[NH2+][O-]	Preclinical		DNA synthesis inhibitor		
nitroxoline	Oc1ccc([N+]([O-])=O)c2cccnc12	Launched	METAP2	cathepsin inhibitor	infectious disease	urinary tract infections
nizatidine	CN\C(NCCSCc1csc(CN(C)C)n1)=C/[N+]([O-])=O	Launched	HRH2	histamine receptor antagonist	gastroenterology	duodenal ulcer disease, erosive esophagitis (EE), ulcerative esophagitis (UE), gastroesophageal reflux disease (GERD)
nizofenone	CCN(CC)Cc1nccn1-c1ccc(cc1C(=O)c1ccccc1Cl)[N+]([O-])=O	Launched		ion channel antagonist	neurology/psychiatry	stroke
NK-252	O=C(NCc1ccccn1)Nc1nnc(o1)-c1ccco1	Preclinical	NFE2L2	nuclear factor erythroid derived, like (NRF2) activator		
NKP-1339	Cl[Ru+3](Cl)(Cl)(Cl)([n+]1cc2ccccc2[nH]1)[n+]1cc2ccccc2[nH]1	Phase 1		HSP inhibitor		
NKY-80	Nc1ncc2C(=O)C[C@@H](Cc2n1)c1ccco1 |&1:8	Preclinical	ADCY5	adenylyl cyclase inhibitor		
NLG919	O[C@@H](C[C@H]1c2ccccc2-c2cncn12)C1CCCCC1 |&1:1	Phase 1	IDO1	indoleamine 2,3-dioxygenase inhibitor		
NMDA	CN[C@H](CC(O)=O)C(O)=O	Preclinical	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor agonist		
NMS-E973	CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O	Preclinical		HSP inhibitor		
NMS-P715	CCc1cccc(CC)c1NC(=O)c1nn(C)c-2c1CCc1cnc(Nc3ccc(cc3OC(F)(F)F)C(=O)NC3CCN(C)CC3)nc-21	Preclinical		protein kinase inhibitor		
NMS-1286937	CN1CCN(CC1)c1ccc(OC(F)(F)F)c(Nc2ncc3CCc4c(nn(CCO)c4-c3n2)C(N)=O)c1	Phase 2	FLT3|PLK1|PLK2|PLK3	PLK inhibitor		
NMS-873	Cc1cc(OCc2nnc(SC3CCCC3)n2-c2cccnc2)ccc1-c1ccc(cc1)S(C)(=O)=O	Preclinical	VCP	ATPase inhibitor		
NM107	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	Phase 2		RNA polymerase inhibitor		
NN-DNJ	CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO	Preclinical	GBA	glucosidase inhibitor		
NNC-05-2090	COc1ccccc1C1(O)CCN(CCCn2c3ccccc3c3ccccc23)CC1	Preclinical	SLC6A12	GABA uptake inhibitor, GAT inhibitor		
NNC-55-0396	CC(C)[C@H]1c2ccc(F)cc2CC[C@@]1(CCN(C)CCCc1nc2ccccc2[nH]1)OC(=O)C1CC1	Preclinical	CATSPER1|CATSPER2|CATSPER3|CATSPER4	T-type calcium channel blocker		
NNC-63-0532	COC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cccc4ccccc34)CC2)C1=O	Preclinical	OPRL1	opioid receptor agonist		
NNC-711	OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1 |t:3|	Preclinical	SIGMAR1|SLC6A1	GABA uptake inhibitor		
NO-ASA	CC(=O)Oc1ccccc1C(=O)Oc1cccc(CO[N+]([O-])=O)c1	Phase 2	PTGS2	cyclooxygenase inhibitor		
nobiletin	COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical	MAP2K1	MEK inhibitor		
nocodazole	COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c1cccs1	Preclinical	HPGDS	tubulin polymerization inhibitor		
nolatrexed	Cc1ccc2[nH]c(N)nc(=O)c2c1Sc1ccncc1	Phase 3	TYMS	thymidylate synthase inhibitor		
nomegestrol-acetate	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C(C)=O |t:9	Launched	PGR	progesterone receptor agonist	endocrinology	contraceptive
nomifensine	CN1C[C@@H](c2ccccc2)c2cccc(N)c2C1 |&1:3|	Withdrawn	DRD2|SLC6A2|SLC6A3	dopamine reuptake inhibitor, noradrenaline uptake inhibitor		
nonivamide	CCCCCCCCC(=O)NCc1ccc(O)c(OC)c1	Launched	TRPV1	TRPV agonist	rheumatology, neurology/psychiatry	rheumatoid arthritis, muscle pain
nonoxynol-9	CCCCCCCCCc1ccc(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)cc1	Launched		membrane integrity inhibitor	endocrinology	contraceptive
nor-binaltorphimine	Oc1ccc2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](Oc1c24)c1[nH]c2[C@@H]4Oc6c7c(C[C@H]8N(CC9CC9)CC[C@@]47[C@@]8(O)Cc2c1C[C@@]35O)ccc6O	Preclinical	OPRD1|OPRK1|OPRM1	opioid receptor antagonist		
norcyclobenzaprine	CNCCC=C1c2ccccc2C=Cc2ccccc12 |c:13|	Preclinical		adrenergic receptor agonist, serotonin receptor antagonist		
norelgestromin	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(O)C#C |t:9|	Launched	PGR		endocrinology	contraceptive
norepinephrine	NC[C@H](O)c1ccc(O)c(O)c1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|PAH|SLC18A1|SLC18A2	adrenergic receptor agonist	cardiology, allergy, neurology/psychiatry	hypertension, urticaria, headache, seasonal affective disorder
norethindrone	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |t:8|	Launched	PGR	progesterone receptor agonist	obstetrics/gynecology	endometriosis
norethindrone-acetate	CC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:11|	Launched	PGR	progesterone receptor agonist	endocrinology, orthopedics, obstetrics/gynecology	menopause, osteoporosis, vaginal atrophy
norethisterone-enanthate	CCCCCCC(=O)O[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C)C#C |t:16|	Launched		contraceptive agent	endocrinology	contraceptive
noretynodrel	C[C@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]1CC[C@@]2(O)C#C |a:1	Launched	PGR	progestogen hormone	endocrinology	contraceptive
norfloxacin	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1	Launched	TOP2A	bacterial DNA gyrase inhibitor	infectious disease, urology	urinary tract infections, gonorrhea, prostatitis
norfluoxetine	NCC[C@@H](Oc1ccc(cc1)C(F)(F)F)c1ccccc1 |&1:3	Phase 1	HTR2B	selective serotonin reuptake inhibitor (SSRI)		
norgestimate	CC[C@]12CC[C@H]3[C@@H](CCC4=C\C(CC[C@H]34)=N\O)[C@@H]1CC[C@@]2(OC(C)=O)C#C |t:9|	Launched	ESR1|PGR	progesterone receptor agonist	endocrinology	contraceptive
norgestrel	CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C |a:2	Launched	AR|ESR1|PGR|SRD5A1	progesterone receptor agonist	endocrinology	contraceptive
nornicotine	C1CN[C@H](C1)c1cccnc1 |r|	Preclinical		acetylcholine receptor agonist		
nortriptyline	CNCCC=C1c2ccccc2CCc2ccccc12	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD2|HRH1|HTR1A|HTR2A|HTR2C|HTR6|KCNJ10|PGRMC1|SIGMAR1|SLC6A2|SLC6A4	tricyclic antidepressant	neurology/psychiatry	depression
norvancomycin	[H][C@@]1(C[C@](C)(N)[C@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@H](N)CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	Preclinical				
noscapine	COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]1N(C)CCc2cc3OCOc3c(OC)c12	Launched	SIGMAR1	bradykinin receptor antagonist, tubulin polymerization inhibitor	pulmonary	cough suppressant
NOV-002	N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@@H](N)C(O)=O)C(=O)NCC(O)=O)C(=O)NCC(O)=O)C(O)=O	Phase 3	GSR			
novobiocin	CO[C@@H]1[C@@H](OC(N)=O)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C	Launched		bacterial DNA gyrase inhibitor	obstetrics/gynecology	mastitis
NPC-01	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CCC2=O |t:9|	Phase 3		steroid		
NPC-15199	CC(C)C[C@@H](NC(=O)OCC1c2ccccc2-c2ccccc12)C(O)=O	Phase 2	PPARG	ICAM1 antagonist		
NPPB	OC(=O)c1cc(ccc1NCCCc1ccccc1)[N+]([O-])=O	Preclinical	ANO1|CLCN2|CLCN7|TRPA1	chloride channel blocker		
NPS-2143	CC(C)(Cc1ccc2ccccc2c1)NC[C@@H](O)COc1cccc(Cl)c1C#N	Preclinical	CASR	calcium receptor antagonist		
NPS-2407	CC(C)(Cc1ccccc1)NC(=O)c1cnc2ccccc2n1	Preclinical		glutamate receptor antagonist		
NPY-5RA972	CC(C)n1c2ccccc2c2c(C)c(NC(=O)N3CCOCC3)ccc12	Preclinical	NPY5R	neuropeptide receptor antagonist		
NQDI-1	CCOC(=O)c1c2-c3ccccc3C(=O)c3cccc([nH]c1=O)c23	Preclinical	CASP3	caspase inhibitor		
NS-018	C[C@H](Nc1cc(cc(Nc2cnccn2)n1)-c1cnn(C)c1)c1ccc(F)cc1	Phase 1/Phase 2	JAK1|JAK2|JAK3|TYK2	JAK inhibitor		
NS-11021	FC(F)(F)c1cc(NC(=S)Nc2ccc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	Preclinical	KCNMA1	calcium-activated potassium channel activator		
NS-11394	CC(C)(O)c1ccc2n(cnc2c1)-c1cccc(c1)-c1ccccc1C#N	Preclinical		GABA receptor agonist		
NS-1643	Oc1ccc(cc1NC(=O)Nc1cc(ccc1O)C(F)(F)F)C(F)(F)F	Preclinical	KCNH2|KCNH6|KCNMA1	voltage-gated potassium channel activator		
NS-19504	Nc1ncc(Cc2ccc(Br)cc2)s1	Preclinical	KCNMA1	calcium-activated potassium channel activator		
NS-309	O\N=C1/C(=O)Nc2c1ccc(Cl)c2Cl	Preclinical	KCNN1|KCNN2|KCNN3|KCNN4	calcium-activated potassium channel activator		
NS-3623	FC(F)(F)c1cccc(NC(=O)Nc2ccc(Br)cc2-c2nn[nH]n2)c1	Preclinical	KCNH2	voltage-gated potassium channel activator		
NS-3861	CN1[C@@H]2CC[C@H]1C=C(C2)c1sccc1Br |&1:2	Preclinical	CHRNA3|CHRNB4	acetylcholine receptor agonist		
NS-5806	FC(F)(F)c1cc(NC(=O)Nc2c(Br)cc(Br)cc2-c2nn[nH]n2)cc(c1)C(F)(F)F	Preclinical	KCND3	voltage-gated potassium channel activator		
NS-8	Cc1c([nH]c(N)c1C#N)-c1ccccc1F	Phase 2	KCNMA1	potassium channel agonist		
NS-8593	C1C[C@@H](Nc2nc3ccccc3[nH]2)c2ccccc2C1	Preclinical	KCNN1|KCNN2|KCNN3	calcium-activated potassium channel modulator		
NS-9283	N#Cc1cccc(c1)-c1nc(no1)-c1cccnc1	Preclinical	CHRNA4	acetylcholine receptor allosteric modulator		
NSC-23766	CCN(CC)CCC[C@@H](C)Nc1nc(C)cc(Nc2ccc3nc(C)cc(N)c3c2)n1 |&1:8|	Preclinical		Ras GTPase inhibitor		
NSC-319726	C\C(=N/NC(=S)N1CCC1)c1ccccn1	Preclinical		p53 activator		
NSC-3852	Oc1ccc(N=O)c2cccnc12	Preclinical	HDAC1	HDAC inhibitor		
NSC-405020	CCC[C@@H](C)NC(=O)c1ccc(Cl)c(Cl)c1 |&1:3	Preclinical	MMP1	matrix metalloprotease inhibitor		
NSC-4644	CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12	Phase 2	PYGM	ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor		
NSC-5844	Clc1ccc2c(NCCNc3ccnc4cc(Cl)ccc34)ccnc2c1	Preclinical	CCR1	CC chemokine receptor agonist		
NSC-625987	COc1ccc(OC)c2c1[nH]c1ccccc1c2=S	Preclinical	CDK2|CDK4	CDK inhibitor		
NSC-632839	Cc1ccc(\C=C2/CNC\C(=C/c3ccc(C)cc3)C2=O)cc1	Preclinical	SENP2|USP1|USP2|USP7	ubiquitin specific protease inhibitor		
NSC-636819	[O-][N+](=O)c1cc(c(\C=C\c2ccc(Cl)c(Cl)c2)cc1\C=C\c1ccc(Cl)c(Cl)c1)[N+]([O-])=O	Preclinical	KDM4A|KDM4B	histone demethylase inhibitor		
NSC-663284	ClC1=C(NCCN2CCOCC2)C(=O)c2ncccc2C1=O |c:1|	Preclinical	CDC25A|CDC25B|CDC25C	CDC inhibitor		
NSC-697923	Cc1ccc(cc1)S(=O)(=O)c1ccc(o1)[N+]([O-])=O	Preclinical	UBE2N	ubiquitin-conjugating enzyme inhibitor		
NSC-95397	OCCSC1=C(SCCO)C(=O)c2ccccc2C1=O |c:4|	Preclinical	CDC25A|CDC25B	CDC inhibitor		
NSC-9965	CO[C@H]1CC=C2CCN3CCC4=C(CC(=O)OC4)[C@]23C1 |t:4	Preclinical	CHRNA4|CHRNB2	acetylcholine receptor antagonist		
NSI-189	CC(C)CCNc1ncccc1C(=O)N1CCN(Cc2ccccc2)CC1	Phase 2		neurotrophic agent		
NSP-805	CC1=C(CCC1=O)Nc1ccc(cc1)C1=C(C)CC(=O)NN1 |c:16	Preclinical		phosphodiesterase inhibitor		
NTNCB	[O-][N+](=O)c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNC[C@H]2CCc3ccccc3C2)CC1 |a:14	Preclinical	NPY5R	neuropeptide receptor antagonist		
NTRC-824	CC(C)C[C@H](NC(=O)Cn1cc(C(=O)C(F)(F)F)c2cc(NS(=O)(=O)c3ccc(C)cc3)ccc12)C(O)=O	Preclinical	NTSR2	neurotensin receptor antagonist		
nTZDpa	OC(=O)c1c(Sc2ccccc2)c2cc(Cl)ccc2n1Cc1ccc(Cl)cc1	Preclinical	PPARG	PPAR receptor agonist		
NT157	Oc1cc(CNC(=S)\C=C\c2cc(O)c(O)c(Br)c2)cc(O)c1O	Preclinical	IGF1R	IGF-1 inhibitor		
NU-1025	Cc1nc(=O)c2cccc(O)c2[nH]1	Preclinical	PARP1	PARP inhibitor		
NU-2058	Nc1nc(OCC2CCCCC2)c2[nH]cnc2n1	Preclinical	CCNA2|CDK2	cyclin D inhibitor		
NU-6027	Nc1nc(N)c(N=O)c(OCC2CCCCC2)n1	Preclinical	CCNA2|CDK2	CDK inhibitor		
NU-7026	O=c1cc(oc2c3ccccc3ccc12)N1CCOCC1	Preclinical	PRKDC	DNA dependent protein kinase inhibitor, mTOR inhibitor, PI3K inhibitor		
NU-7441	O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1	Preclinical	PRKDC	DNA dependent protein kinase inhibitor		
nuclomedone	Clc1ccc(C[C@H]2C(=O)N=C3SCCN3C2=O)cc1 |r	Phase 3		immunosuppressant		
nutlin-3	COc1ccc(C2=N[C@H]([C@H](N2C(=O)N2CCNC(=O)C2)c2ccc(Cl)cc2)c2ccc(Cl)cc2)c(OC(C)C)c1 |&1:8	Preclinical	MDM2|TP53	MDM inhibitor		
nuvenzepine	CN1CCC(CC1)C(=O)N1c2ccccc2NC(=O)c2cccnc12	Preclinical		acetylcholine receptor antagonist		
NVP-ADW742	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@H]1C[C@H](CN2CCCC2)C1 |r|	Preclinical	IGF1R	insulin growth factor receptor inhibitor		
NVP-AEW541	Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1 |r|	Preclinical	IGF1R|INSR	IGF-1 inhibitor		
NVP-AUY922	CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O	Phase 2	HSP90AA1|HSP90AB1	HSP inhibitor		
NVP-BEZ235	Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1	Phase 3	ATR|MTOR|PIK3CA|PIK3CD|PIK3CG	mTOR inhibitor, PI3K inhibitor		
NVP-BGJ398	CCN1CCN(CC1)c1ccc(Nc2cc(ncn2)N(C)C(=O)Nc2c(Cl)c(OC)cc(OC)c2Cl)cc1	Phase 3	FGFR1|FGFR2|FGFR3|FGFR4|KDR	FGFR inhibitor		
NVP-BHG712	Cc1ccc(cc1Nc1nc(nc2n(C)ncc12)-c1cccnc1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical	EPHB4	ephrin inhibitor		
NVP-BSK805	Fc1cc(cc(F)c1CN1CCOCC1)-c1cccc2ncc(nc12)-c1cnn(c1)C1CCNCC1	Preclinical	JAK2	JAK inhibitor		
NVP-BVU972	Cn1cc(cn1)-c1ccc2ncc(Cc3ccc4ncccc4c3)n2n1	Preclinical	MET	MET inhibitor		
NVP-DPP728	O=C(CNCCNc1ccc(cn1)C#N)N1CCC[C@H]1C#N	Phase 2	DPP4	dipeptidyl peptidase inhibitor		
NVP-HSP990	COc1cccc(n1)-c1cc(F)ccc1[C@H]1Cc2nc(N)nc(C)c2C(=O)N1	Phase 1	HSP90AA1|HSP90AB1	HSP inhibitor		
NVP-TAE226	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCOCC2)ncc1Cl	Preclinical	PTK2	protein tyrosine kinase inhibitor		
NVP-TAE684	COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1)N1CCC(CC1)N1CCN(C)CC1	Preclinical	ALK|INSR	ALK tyrosine kinase receptor inhibitor		
NVP-TNKS656	COc1ccc(cc1)C(=O)C1CCN(CC(=O)N(CC2CC2)Cc2nc(=O)c3COCCc3[nH]2)CC1	Preclinical	TNKS2	tankyrase inhibitor		
NVP-231	O=C(Nc1nc2ccc(NC(=O)C34CC5CC(CC(C5)C3)C4)cc2s1)c1ccccc1	Preclinical	CERK	ceramidase inhibitor		
NVS-PAK1-1	CC(C)NC(=O)N1CC[C@@H](C1)NC1=Nc2cc(F)ccc2N(CC(F)F)c2ccc(Cl)cc12 |t:13|	Preclinical	PAK1	p21 activated kinase inhibitor		
NXY-059	CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O	Phase 3		free radical scavenger		
nystatin	C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)C[C@@H](O)CC(=O)O[C@@H](C)[C@H](C)[C@H](O)[C@@H](C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O |t:46	Launched		fungal ergosterol inhibitor	infectious disease	esophageal candidiasis, skin infections, yeast infection
N20C	NC(=O)CNCCC(c1ccccc1)c1ccccc1	Preclinical		glutamate receptor antagonist		
N6-cyclopentyladenosine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3|SLC29A1	adenosine receptor agonist		
N6-methyladenosine	CNc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical				
N6022	Cc1cc(ccc1-n1c(CCC(O)=O)ccc1-c1ccc(cc1)-n1ccnc1)C(N)=O	Phase 1/Phase 2	ADH5	alcohol dehydrogenase inhibitor		
O-acetyl-L-serine	CC(=O)OC[C@H](N)C(O)=O	Preclinical	PTGS1			
o-mercapto-benzoic-acid	OC(=O)c1ccccc1S	Preclinical				
O-1918	COc1cc(C)cc(OC)c1[C@@H]1C=C(C)CC[C@H]1C(C)=C |t:13|	Preclinical		cannabinoid receptor antagonist		
o-3M3FBS	Cc1cc(C)c(c(C)c1)S(=O)(=O)Nc1ccccc1C(F)(F)F	Preclinical		phospholipase activator		
O-304	Clc1ccc(Cn2sc(NC(=O)c3ccc(Cl)cc3)nc2=O)cc1	Preclinical		AMPK activator		
OAC1	O=C(Nc1cc2cc[nH]c2cn1)c1ccccc1	Preclinical		Oct activator		
OAC2	O=C(Nc1ccc2[nH]ccc2c1)c1ccccc1	Preclinical	POU5F1	Oct activator		
obatoclax	COC1=CC(=N\C1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 |c:4	Phase 3	BCL2	BCL inhibitor		
obeticholic-acid	CC[C@H]1[C@@H](O)[C@H]2[C@H]3CC[C@@H]([C@@H](C)CCC(O)=O)[C@@]3(C)CC[C@@H]2[C@@]2(C)CC[C@@H](O)C[C@@H]12 |&1:2	Launched	NR1H4	FXR agonist	gastroenterology	primary biliary cholangitis
obidoxime	O\N=C\c1cc[n+](COC[n+]2ccc(\C=N\O)cc2)cc1	Launched	ACHE	cholinesterase reactivator	critical care, neurology/psychiatry	poison antidote, nerve gas poisoning
ocaperidone	Cc1cccn2c1nc(C)c(CCN1CCC(CC1)c1noc3cc(F)ccc13)c2=O	Preclinical		serotonin receptor antagonist		
ochromycinone	C[C@@H]1CC(=O)c2c(C1)ccc1C(=O)c3c(O)cccc3C(=O)c21	Phase 1	STAT3	STAT inhibitor		
ocinaplon	O=C(c1cnn2c(ccnc12)-c1ccncc1)c1ccccn1	Phase 3	GABRA1|GABRA2|GABRA3|GABRA5	GABA receptor modulator		
OCO-1112	CC(C)c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(O)=O	Phase 2		cholesterol inhibitor		
octadecan-1-ol	CCCCCCCCCCCCCCCCCCO	Preclinical				
octamethyltrisiloxane	C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C	Preclinical				
octenidine	CCCCCCCCN=c1ccn(CCCCCCCCCCn2ccc(cc2)=NCCCCCCCC)cc1	Launched		membrane integrity inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
octinoxate	CCCC[C@@H](CC)COC(=O)\C=C\c1ccc(OC)cc1 |&1:4|	Launched			dermatology	sunscreen lotion
octisalate	CCCC[C@@H](CC)COC(=O)c1ccccc1O |&1:4|	Launched			dermatology	sunscreen lotion
octocrylene	CCCC[C@@H](CC)COC(=O)C(C#N)=C(c1ccccc1)c1ccccc1 |&1:4|	Launched			dermatology	sunscreen lotion
octodrine	CC(C)CCC[C@@H](C)N |&1:6	Preclinical		antitumor agent		
octopamine	NCC(O)c1ccc(O)cc1	Preclinical	F10|TAAR1	trace amine associated receptor agonist		
octreotide	C[C@@H](O)[C@@H](CO)NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 |&1:1	Launched	SSTR2|SSTR3|SSTR5	somatostatin receptor agonist	gastroenterology, endocrinology, oncology	diarrhea, acromegaly, carcinoid tumors
OC000459	Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(O)=O	Phase 2	PTGDR2	CRTH receptor antagonist		
odanacatib	CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N	Phase 3	CTSK	cathepsin inhibitor		
ODQ	O=c1onc2cnc3ccccc3n12	Preclinical	GUCY1A2|GUCY1A3|GUCY1B3	guanylyl cyclase inhibitor		
OF-1	COc1cc2n(C)c(=O)n(C)c2cc1NS(=O)(=O)c1ccc(Br)cc1C	Preclinical	BRD1	bromodomain inhibitor		
ofloxacin	C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O |&1:1|	Launched		bacterial DNA gyrase inhibitor	infectious disease, otolaryngology, gastroenterology, endocrinology	respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections
OG-L002	N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1	Preclinical	KDM1A	histone lysine demethylase inhibitor		
ogerin	Nc1nc(NCc2ccccc2)nc(n1)-c1ccccc1CO	Preclinical		G protein-coupled receptor modulator		
oglemilast	CS(=O)(=O)Nc1ccc2oc3c(OC(F)F)ccc(C(=O)Nc4c(Cl)cncc4Cl)c3c2c1	Phase 2		phosphodiesterase inhibitor		
oglufanide	N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	Phase 2		VEGF antagonist		
OICR-9429	CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)-c1cccc(CN2CCOCC2)c1	Preclinical	WDR5	WDR5/MLL interaction inhibitor		
olanzapine	CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 |t:8|	Launched	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|ADRB1|ADRB2|ADRB3|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|HRH1|HRH2|HRH4|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR5A|HTR6|HTR7	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia, bipolar disorder
olaparib	Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1	Launched	PARP1|PARP2	PARP inhibitor	oncology	ovarian cancer
OLDA	CCCCCCCC\C=C/CCCCCCCC(=O)NCCc1ccc(O)c(O)c1	Preclinical	GPR119	TRPV agonist		
oleamide	CCCCCCCC\C=C/CCCCCCCC(N)=O	Preclinical	HTR7|PLA2G2A	cannabinoid receptor agonist		
oleandrin	CO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O |t:32|	Phase 1		Na/K-ATPase inhibitor		
oleanolic-acid	CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2C1)C(O)=O |c:10|	Preclinical	GPBAR1	G protein-coupled receptor agonist		
oleoylethanolamide	CCCCCCCC\C=C/CCCCCCCC(=O)NCCO	Preclinical	CNR1|GPR119|GPR55|PPARA	cannabinoid receptor agonist, glucose dependent insulinotropic receptor agonist, potassium channel blocker, PPAR receptor agonist		
olesoxime	CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C\C(CC[C@]4(C)[C@H]3CC[C@]12C)=N\O |t:15|	Phase 2/Phase 3		apoptosis stimulant		
oleuropein	COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]2O)\C(=C/C)[C@@H]1CC(=O)OCCc1ccc(O)c(O)c1 |&1:7	Phase 2	GPER1	estrogen receptor agonist		
oligomycin-A	[H][C@]12CC[C@@H](CC)\C=C\C=C\C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)\C=C\C(=O)O[C@]([H])([C@@H]1C)[C@H](C)[C@@]1(CC[C@H](C)[C@H](C[C@@H](C)O)O1)O2 |t:7	Preclinical	ATP5A1	ATP synthase inhibitor, ATPase inhibitor		
olmesartan	CCCc1nc(c(C(O)=O)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	Launched	AGTR1	angiotensin receptor antagonist	cardiology	hypertension
olmesartan-medoxomil	CCCc1nc(c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)C(C)(C)O	Launched	AGTR1	angiotensin receptor antagonist	cardiology	hypertension
olmutinib	CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1	Launched	BTK|EGFR	Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
olodanrigan	COc1ccc2CN([C@@H](Cc2c1OCc1ccccc1)C(O)=O)C(=O)C(c1ccccc1)c1ccccc1	Phase 2		angiotensin antagonist		
olomoucine	Cn1cnc2c(NCc3ccccc3)nc(NCCO)nc12	Preclinical	CDK1|CDK2|CDK5|MAPK1	CDK inhibitor		
olopatadine	CN(C)CC\C=C1\c2ccccc2COc2ccc(CC(O)=O)cc12	Launched	HRH1|S100A1|S100A12|S100A13|S100A2|S100B	histamine receptor antagonist	ophthalmology	conjunctivitis
olprinone	Cc1[nH]c(=O)c(cc1-c1ccc2nccn2c1)C#N	Launched	PDE3A	phosphodiesterase inhibitor	cardiology	congestive heart failure
olsalazine	OC(=O)c1cc(ccc1O)\N=N\c1ccc(O)c(c1)C(O)=O	Launched	IFNG|TPMT	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
oltipraz	Cc1c(ssc1=S)-c1cnccn1	Phase 3	ANG	nuclear factor erythroid derived, like (NRF2) activator		
olumacostat-glasaretil	CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(C)CC(=O)OCC	Phase 3		acetyl-CoA carboxylase inhibitor		
olvanil	CCCCCCCC\C=C/CCCCCCCC(=O)NCc1ccc(O)c(OC)c1	Preclinical	CNR1|GPR119|TRPV1	TRPV agonist		
omadacycline	[H][C@@]12Cc3c(cc(CNCC(C)(C)C)c(O)c3C(=O)[C@H]1C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:26	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	pneumonia
omapatrilat	[H][C@]12CCC[C@H](N1C(=O)[C@H](CCS2)NC(=O)[C@@H](S)Cc1ccccc1)C(O)=O	Preclinical	ACE|MME	metalloproteinase inhibitor		
omarigliptin	CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]1CO[C@@H]([C@@H](N)C1)c1cc(F)ccc1F	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
ombitasvir	COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)cc1	Launched		HCV inhibitor	infectious disease	hepatitis C
ombrabulin	COc1ccc(\C=C/c2cc(OC)c(OC)c(OC)c2)cc1NC(=O)[C@@H](N)CO	Phase 3		tubulin polymerization inhibitor		
OMDM-2	CCCCCCCC\C=C/CCCCCCCC(=O)N[C@@H](CO)Cc1ccc(O)cc1	Preclinical	GPR119	FAAH inhibitor		
omecamtiv-mecarbil	COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1	Phase 3	MYBPC3	cardiac myosin activator		
omega-(4-iodophenyl)pentadecanoic-acid	OC(=O)CCCCCCCCCCCCCCc1ccc(I)cc1	Preclinical				
omega-3-acid-esters	CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC	Launched		cholesterol inhibitor		
omeprazole	COc1ccc2nc([nH]c2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	Launched	ATP4A|CLCN2	ATPase inhibitor	gastroenterology	heartburn
omeprazole-magnesium	COc1ccc2n([Mg]n3c(nc4cc(OC)ccc34)[S@@](=O)Cc3ncc(C)c(OC)c3C)c(nc2c1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	Launched	ATP4A|ATP4B	proton pump inhibitor	gastroenterology	gastroesophageal reflux disease (GERD), heartburn
omeprazole-sulfide	COc1ccc2nc(SCc3ncc(C)c(OC)c3C)[nH]c2c1	Phase 1		ATPase inhibitor		
omtriptolide	[H][C@@]12C[C@@H]3O[C@@]33[C@H](OC(=O)CCC(O)=O)[C@]4(O[C@H]4[C@@H]4O[C@]34[C@@]1(C)CCC1=C2COC1=O)C(C)C |c:30|	Preclinical		ERK1 and ERK2 phosphorylation inhibitor		
ON-01500	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(N)c2)c(OC)c1	Preclinical		apoptosis stimulant		
oncrasin-1	Clc1ccc(Cn2cc(C=O)c3ccccc23)cc1	Preclinical		apoptosis stimulant		
ONC201	Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O |t:10	Phase 2	TNFSF10	AKT inhibitor, MAP kinase inhibitor		
ondansetron	Cc1nccn1C[C@H]1CCc2c(C1=O)c1ccccc1n2C |r|	Launched	HTR3A|HTR3B	serotonin receptor antagonist	gastroenterology	nausea, vomiting
ONO-AE3-208	C[C@@H](C(=O)Nc1cc(ccc1CCCC(O)=O)C#N)c1ccc(F)c2ccccc12 |&1:1	Preclinical	PTGER4	prostanoid receptor antagonist		
ONO-4059	CC#CC(=O)N1CC[C@H](C1)n1c2ncnc(N)c2n(-c2ccc(Oc3ccccc3)cc2)c1=O	Phase 1	BTK	Bruton's tyrosine kinase (BTK) inhibitor		
ONO-4817	CCOCOC[C@H](C[C@H](C)C(=O)NO)NC(=O)c1ccc(Oc2ccccc2)cc1	Phase 1	MMP8	matrix metalloprotease inhibitor		
ONO-8130	CC(C)CN(c1cc2CCCc2cc1OCc1ccc(cc1)C(O)=O)S(=O)(=O)c1nc(C)cs1	Preclinical	PTGER1	prostanoid receptor antagonist		
ONX-0914	COc1ccc(C[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]2(C)CO2)cc1	Preclinical		proteasome inhibitor		
ON123300	CN1CCN(CC1)c1ccc(Nc2ncc3cc(C#N)c(=O)n(C4CCCC4)c3n2)cc1	Preclinical	CDK4|NUAK1|PDGFRB	CDK inhibitor		
OP-0595	NCCONC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O	Preclinical		beta lactamase inhibitor		
OPC-21268	CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2ccccc12	Phase 1	AVPR1A|AVPR2|OXTR	vasopressin receptor antagonist		
opicapone	Cc1c(Cl)c(C)[n+]([O-])c(Cl)c1-c1noc(n1)-c1cc(O)c(O)c(c1)[N+]([O-])=O	Phase 3	COMT	catechol O methyltransferase inhibitor		
opipramol	OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc23)CC1 |c:18|	Launched		sigma receptor agonist	neurology/psychiatry	generalized anxiety disorder (GAD)
oprozomib	COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1	Phase 1/Phase 2		proteasome inhibitor		
OR-486	Oc1cc(cc(c1O)[N+]([O-])=O)[N+]([O-])=O	Preclinical	COMT	catechol O methyltransferase inhibitor		
orantinib	Cc1[nH]c(\C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O	Phase 3	AURKA|AURKB|EGFR|FGFR1|FGFR2|KDR|PDGFRA|PDGFRB	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
orbifloxacin	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(F)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Launched		bacterial DNA gyrase inhibitor	infectious disease	urinary tract infections
ORE1001	CC(C)C[C@H](N[C@@H](Cc1cncn1Cc1cc(Cl)cc(Cl)c1)C(O)=O)C(O)=O	Phase 1/Phase 2	ACE2	angiotensin converting enzyme inhibitor		
ORG-12962	FC(F)(F)c1ccc(nc1Cl)N1CCNCC1	Phase 2	HTR2A|HTR2B|HTR2C	serotonin receptor agonist		
ORG-25543	COc1cc(cc(OC)c1OCc1ccccc1)C(=O)NCC1(CCCC1)N(C)C	Preclinical	GLRB|SLC6A5	glycine transporter inhibitor		
ORG-26576	O=C1N2CCC[C@H]2COc2ncccc12	Phase 2		glutamate receptor modulator		
ORG-27569	CCc1c([nH]c2ccc(Cl)cc12)C(=O)NCCc1ccc(cc1)N1CCCCC1	Preclinical	CNR1	cannabinoid receptor modulator		
ORG-9768	CC1(CN)Cc2ccccc2C1	Phase 1	ADRA2A	adrenergic receptor antagonist		
oridonin	[H][C@@]1(O)[C@@]2([H])CC[C@]3([H])[C@@]1(C(=O)C2=C)[C@]1(O)OC[C@]32[C@@H](O)CCC(C)(C)[C@@]2([H])[C@@H]1O	Preclinical	BCL2	BCL inhibitor		
oritavancin	[H][C@@]1(C[C@](C)(NCc2ccc(cc2)-c2ccc(Cl)cc2)[C@@H](O)[C@H](C)O1)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@]3([H])c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@]1([H])C[C@](C)(N)[C@@H](O)[C@H](C)O1)[C@]1([H])NC(=O)[C@]([H])(NC3=O)c2ccc(O)c(c2)-c2c(O)cc(O)cc2[C@]([H])(NC1=O)C(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	skin infections
orlistat	CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	Launched	CNR1|DAGLA|DAGLB|FASN|LIPF|PNLIP	lipase inhibitor	endocrinology	weight-loss aid
ormeloxifene	COc1ccc2[C@H]([C@H](c3ccccc3)C(C)(C)Oc2c1)c1ccc(OCCN2CCCC2)cc1	Launched		selective estrogen receptor modulator (SERM)	endocrinology	contraceptive
ornidazole	Cc1ncc(n1C[C@@H](O)CCl)[N+]([O-])=O |&1:7	Launched		antiprotozoal agent	infectious disease	protozoan infection
ornipressin	[H][C@@]1(Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O	Preclinical		vasoconstrictor		
ornithine	Cl.NCCC[C@@H](N)C(O)=O |&1:5	Launched	GPRC6A	NFkB pathway modulator		
orotic-acid	OC(=O)c1cc(=O)[nH]c(=O)[nH]1	Phase 2	DHODH			
orphanin-fq	CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O	Phase 1	OPRL1|OPRM1	opioid receptor agonist		
orphenadrine	CN(C)CCO[C@@H](c1ccccc1)c1ccccc1C |&1:6|	Launched		acetylcholine receptor antagonist	neurology/psychiatry	muscle pain
orteronel	CNC(=O)c1ccc2cc(ccc2c1)[C@]1(O)CCn2cncc12	Phase 3	CYP17A1	androgen biosynthesis inhibitor, androgen receptor antagonist, cytochrome P450 inhibitor		
ORY-1001	NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1	Phase 1/Phase 2	KDM1A	histone lysine demethylase inhibitor		
oseltamivir-carboxylate	CCC(CC)O[C@@H]1C=C(C[C@H](N)[C@H]1NC(C)=O)C(O)=O |c:7|	Launched		neuraminidase inhibitor	infectious disease	influenza A virus infection
oseltamivir-phosphate	CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 |t:5|	Launched	CES1|NEU1|NEU2	neuraminidase inhibitor	infectious disease	influenza A virus infection
osemozotan	C(CNC[C@H]1COc2ccccc2O1)COc1ccc2OCOc2c1	Phase 2/Phase 3	HTR1A	serotonin receptor agonist		
OSI-027	COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12 |r|	Phase 1	MTOR	mTOR inhibitor		
OSI-420	COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCO	Preclinical	EGFR	EGFR inhibitor		
OSI-930	FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1	Phase 1	FLT1|KDR|KIT	KIT inhibitor, VEGFR inhibitor		
osilodrostat	Fc1cc(ccc1[C@H]1CCc2cncn12)C#N	Launched		cytochrome P450 inhibitor		
osimertinib	COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12	Launched	EGFR	EGFR inhibitor	oncology	non-small cell lung cancer (NSCLC)
ospemifene	OCCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	Launched	ESR1|ESR2	selective estrogen receptor modulator (SERM)	obstetrics/gynecology, endocrinology	vaginal atrophy, dyspareunia, menopause
ostarine	C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F	Phase 3	AR	androgen receptor modulator		
osthol	COc1ccc2ccc(=O)oc2c1CC=C(C)C	Preclinical		calcium channel blocker		
OT-R-antagonist-1	CO\N=C1\C[C@H](N(C1)C(=O)c1ccc(cc1)-c1ccccc1C)C(=O)NC[C@@H](O)c1ccccc1	Preclinical	AVPR1A|OXTR	oxytocin receptor antagonist		
otamixaban	COC(=O)[C@H](Cc1cccc(c1)C(N)=N)[C@@H](C)NC(=O)c1ccc(cc1)-c1cc[n+]([O-])cc1	Phase 3	F10	coagulation factor inhibitor		
otenzepad	CCN(CC)C[C@H]1CCCCN1CC(=O)N1c2ccccc2C(=O)Nc2cccnc12 |&1:6	Phase 3	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist		
otilonium	CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](C)(CC)CC	Launched	CACNA1C	acetylcholine receptor antagonist	gastroenterology	irritable bowel syndrome
OTS167	CN(C)C[C@H]1CC[C@@H](CC1)Nc1c(cnc2ccc(nc12)-c1cc(Cl)c(O)c(Cl)c1)C(C)=O |r|	Phase 1/Phase 2	MELK	maternal embryonic leucine zipper kinase inhibitor		
OTS514	C[C@@H](CN)c1ccc(cc1)-c1c(O)cc(C)c2[nH]c(=O)c3sccc3c12	Preclinical		TOPK inhibitor		
OTX015	Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1 |c:8|	Phase 1/Phase 2	BRD2|BRD3|BRD4	bromodomain inhibitor		
ouabain	C[C@@H]1O[C@@H](O[C@@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C2=CC(=O)OC2)[C@H](O)[C@H](O)[C@H]1O |t:33|	Launched	ATP1A1	ATPase inhibitor	cardiology	hypertension, cardiac arrythmia
OXA-06	Fc1ccccc1CNCc1ccc(cc1)-c1ccnc2[nH]ccc12	Preclinical	ROCK1|ROCK2	rho associated kinase inhibitor		
oxaceprol	CC(=O)N1C[C@H](O)C[C@H]1C(O)=O	Preclinical		anti-inflammatory agent		
oxacillin	Cc1onc(c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O)-c1ccccc1	Launched		bacterial cell wall synthesis inhibitor	infectious disease	staphylococcal infections
oxacyclohexadecan-2-one	O=C1CCCCCCCCCCCCCCO1	Preclinical		protein kinase inhibitor		
oxaliplatin	O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O	Launched		DNA inhibitor	oncology	colorectal cancer
oxaloacetate	OC(=O)C=C(O)C(O)=O	Phase 2/Phase 3		glutamate release inhibitor		
oxantel	CN1CCCN=C1\C=C\c1cccc(O)c1 |c:5|	Launched		anthelmintic agent	infectious disease	gastrointestinal parasites
oxaprozin	OC(=O)CCc1nc(c(o1)-c1ccccc1)-c1ccccc1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology	osteoarthritis, rheumatoid arthritis
oxatomide	O=c1[nH]c2ccccc2n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis
oxcarbazepine	NC(=O)N1c2ccccc2CC(=O)c2ccccc12	Launched	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	sodium channel blocker	neurology/psychiatry	seizures
oxelaidin	CCN(CC)CCOCCOC(=O)C(CC)(CC)c1ccccc1	Launched		antitussive	pulmonary	cough suppressant
oxethazaine	CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1	Launched		local anesthetic	neurology/psychiatry	local anesthetic
OXF-BD-02	Cc1noc(C)c1-c1cc(O)cc(c1)[C@@H](O)c1ccccc1 |&1:14	Preclinical	BRD4	bromodomain inhibitor		
oxfendazole	COC(=O)Nc1nc2ccc(cc2[nH]1)[S@@](=O)c1ccccc1 |r|	Launched		anthelmintic agent	infectious disease	lungworms, tapeworm, gastrointestinal roundworms
oxfenicine	N[C@@H](C(O)=O)c1ccc(O)cc1	Phase 1	CPT1A|CPT1B	carnitine palmitoyltransferase inhibitor		
oxibendazole	CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1	Launched	TUBB|TUBB4B	tubulin polymerization inhibitor	infectious disease	strongyles
oxiconazole	Clc1ccc(CO\N=C(/Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1	Launched		bacterial cell wall synthesis inhibitor	infectious disease	tinea pedis, tinea cruris, tinea corporis
oxidopamine	NCCc1cc(O)c(O)cc1O	Preclinical		neurotoxin		
oxiniacic-acid	OC(=O)c1ccc[n+]([O-])c1	Preclinical				
oxiperomide	O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1	Phase 2		dopamine receptor antagonist		
oxiracetam	NC(=O)CN1C[C@H](O)CC1=O	Launched		acetylcholine receptor agonist	neurology/psychiatry	senile dementia
oxolamine	CCN(CC)CCc1nc(no1)-c1ccccc1	Launched		antitussive	pulmonary	cough suppressant
oxolinic-acid	CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12	Preclinical		bacterial DNA gyrase inhibitor		
oxonic-acid	OC(=O)c1nc(=O)[nH]c(=O)[nH]1	Preclinical		uricase inhibitor		
oxotremorine-M	C[N+](C)(C)CC#CCN1CCCC1=O	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor agonist		
oxotremorine-sesquifumarate	O=C1CCCN1CC#CCN1CCCC1	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4	cholinergic receptor agonist		
oxprenolol	CC(C)NC[C@@H](O)COc1ccccc1OCC=C |&1:5|	Launched	ADRB1	adrenergic receptor antagonist	cardiology	angina pectoris, hypertension, cardiac arrythmia
oxybenzone	COc1ccc(C(=O)c2ccccc2)c(O)c1	Launched	LIPE	lipase inhibitor	dermatology	sunscreen lotion
oxybuprocaine	CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC	Launched	SCN10A	local anesthetic	neurology/psychiatry	local anesthetic
oxybutynin	CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:12	Launched	CHRM1|CHRM2|CHRM3	acetylcholine receptor antagonist	urology	urinary incontinence
oxyclozanide	Oc1c(Cl)cc(Cl)cc1NC(=O)c1c(O)c(Cl)cc(Cl)c1Cl	Launched			infectious disease	fascioliasis
oxyfedrine	COc1cccc(c1)C(=O)CCN[C@@H](C)[C@H](O)c1ccccc1	Launched		adrenergic receptor agonist	cardiology	angina pectoris
oxymatrine	[H][C@]12CCC[N@@+]3([O-])CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]	Launched				
oxymetazoline	Cc1cc(c(O)c(C)c1CC1=NCCN1)C(C)(C)C |t:11|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR2C	adrenergic receptor agonist	otolaryngology	nasal congestion
oxyphenbutazone	CCCC[C@H]1C(=O)N(N(C1=O)c1ccc(O)cc1)c1ccccc1 |r|	Withdrawn		cyclooxygenase inhibitor		
oxyphencyclimine	CN1CCCN=C1COC(=O)[C@@](O)(C1CCCCC1)c1ccccc1 |&1:11	Launched		cholinergic receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
oxyphenonium	CC[N+](C)(CC)CCOC(=O)C(O)(C1CCCCC1)c1ccccc1	Launched	CHRM1|CHRM3	cholinergic receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
oxypurinol	O=c1nc2[nH][nH]cc2c(=O)[nH]1	Phase 2/Phase 3	XDH	xanthine oxidase inhibitor		
oxyquinoline	Oc1cccc2cccnc12	Launched	METAP2	chelating agent	dermatology	cosmetic
oxytetracycline	CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(N)=O)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease, urology	chlamydia, urinary tract infections, skin infections, ear infections, gonorrhea, urethritis, Lyme disease
oxytocin	CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O	Launched	AVPR1A|AVPR1B|AVPR2|OXTR	oxytocin receptor agonist	obstetrics/gynecology	labor induction
ozagrel	OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1	Launched	TBXAS1	thromboxane synthase inhibitor	neurology/psychiatry	stroke
ozanimod	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@H](CCc12)NCCO	Phase 3	S1PR1	sphingosine 1-phosphate receptor agonist		
ozenoxacin	CNc1ncc(cc1C)-c1ccc2c(c1C)n(cc(C(O)=O)c2=O)C1CC1	Phase 3		antiinfective drug		
ozolinone	CN1C(=O)[C@@H](S\C1=C/C(O)=O)N1CCCCC1 |&1:4	Phase 3		diuretic		
O4I1	COc1ccc(COc2ccc(CC#N)cc2)cc1	Preclinical	POU5F1	Oct inducer		
O6-benzylguanine	Nc1nc(OCc2ccccc2)c2[nH]cnc2n1	Phase 3	MGMT	O6-alkylguanine-DNA alkyltransferase inhibitor		
p-dimethylinamyl-benzoate	CCCCCOC(=O)c1ccc(cc1)N(C)C	Preclinical				
PA-452	CCCCCCOc1cc2c(cc1N(C)c1ncc(cn1)C(O)=O)C(C)(C)CCC2(C)C	Preclinical	RXRA	retinoid receptor antagonist		
PAC-1	Oc1c(CC=C)cccc1\C=N\NC(=O)CN1CCN(Cc2ccccc2)CC1	Phase 1	CASP3	caspase activator		
paclitaxel	CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 |c:5|	Launched	BCL2|MAP2|MAP4|MAPT|NR1I2|TLR4|TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	tubulin polymerization inhibitor	oncology	ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)
PACOCF3	CCCCCCCCCCCCCCCC(=O)C(F)(F)F	Preclinical	PLA2G4A	phospholipase inhibitor		
pacritinib	C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3 |t:29|	Phase 3	FLT3|JAK1|JAK2|JAK3	FLT3 inhibitor, JAK inhibitor		
padsevonil	COCc1nn2c(CN3C[C@@H](CC(F)(F)Cl)CC3=O)c(nc2s1)C(F)(F)F	Phase 3		antiepileptic		
paeoniflorin	C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@H]3C[C@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O	Preclinical		anticonvulsant		
paeonol	COc1ccc(C(C)=O)c(O)c1	Preclinical		anti-inflammatory agent		
pafuramidine	CON=C(N)c1ccc(cc1)-c1ccc(o1)-c1ccc(cc1)C(N)=NOC	Phase 3		DNA synthesis inhibitor		
pagoclone	CC(C)CCC(=O)C[C@@H]1N(C(=O)c2ccccc12)c1ccc2ccc(Cl)nc2n1 |&1:8	Phase 2/Phase 3		GABA receptor agonist		
palbociclib	CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O	Launched	CDK4|CDK6	CDK inhibitor	oncology	breast cancer
palifosfamide	OP(=O)(NCCCl)NCCCl	Phase 3		DNA alkylating agent		
paliperidone	Cc1nc2[C@@H](O)CCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12 |&1:4	Launched	DRD2|HTR2A	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia
palmatine-chloride	COc1cc2CC[n+]3cc4c(OC)c(OC)ccc4cc3-c2cc1OC	Preclinical	CYP3A4	dopamine synthesis inhibitor		
palmitoleic-acid	CCCCCC\C=C/CCCCCCCC(O)=O	Preclinical				
palmitoylcarnitine	CCCCCCCCCCCCCCCC(=O)O[C@@H](CC(O)=O)C[N+](C)(C)C |&1:18|	Preclinical		protein kinase inhibitor		
palmitoylethanolamide	CCCCCCCCCCCCCCCC(=O)NCCO	Launched	CNR2|GPR119|GPR55	cannabinoid receptor agonist		
palomid-529	COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)[C@@H](C)O)cc1 |&1:25	Phase 1	MTOR	AKT inhibitor, mTOR inhibitor		
palonosetron	O=C1N(C[C@H]2CCCc3cccc1c23)[C@@H]1CN2CCC1CC2	Launched	HTR3A	serotonin receptor antagonist	gastroenterology	nausea, vomiting
palosuran	Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1	Phase 2	UTS2R	urotensin receptor antagonist		
palovarotene	CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12	Phase 3	RARG	retinoid receptor agonist		
pamabrom	CC(C)(N)CO.Cn1c2nc(Br)[nH]c2c(=O)n(C)c1=O	Launched		diuretic	gastroenterology	bloating
pamidronate	NCCC(O)(P(O)(O)=O)P(O)(O)=O	Launched	FDPS	bone resorption inhibitor	endocrinology, oncology, hematologic malignancy	hypercalcemia, Paget's disease, breast cancer, multiple myeloma
pamiparib	C[C@]12CCCN1Cc1n[nH]c(=O)c3cc(F)cc4[nH]c2c1c34	Phase 3		PARP inhibitor		
pancuronium	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)[N+]1(C)CCCCC1)[N+]1(C)CCCCC1	Launched	CHRM2|CHRM3|CHRNA1|CHRNA2	acetylcholine receptor antagonist	critical care, neurology/psychiatry	endotracheal intubation, muscle relaxant
panipenem	C[C@@H](O)[C@@H]1[C@H]2CC(S[C@H]3CCN(C3)C(N)=C)=C(N2C1=O)C(O)=O |c:16|	Preclinical		antibacterial 		
panobinostat	Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1	Launched	HDAC1|HDAC2|HDAC3|HDAC4|HDAC6|HDAC7|HDAC8|HDAC9	HDAC inhibitor	hematologic malignancy	multiple myeloma
pantethine	CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO	Launched		coenzyme A precursor		
pantoprazole	COc1ccnc(C[S@@](=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC |&1:8|	Launched	ATP4A	ATPase inhibitor	gastroenterology	gastroesophageal reflux disease (GERD), erosive esophagitis (EE), Zollinger-Ellison syndrome
pantothenic-acid	CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O	Launched		coenzyme A precursor		
PAOPA	NC(=O)CN1CC[C@@H](NC(=O)[C@@H]2CCCN2)C1=O	Preclinical	DRD2	dopamine receptor modulator		
papaverine	COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC	Launched	PDE10A|PDE4B|PDE5A	phosphodiesterase inhibitor	cardiology, hematology, gastroenterology	myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm
paquinimod	CCN(C(=O)c1c(O)c2c(CC)cccc2n(C)c1=O)c1ccccc1	Phase 2		S100A9 inhibitor		
para-toluenesulfonamide	Cc1ccc(cc1)S(N)(=O)=O	Phase 3	CA12|CA2|CA6|CA9			
paracetamol	CC(=O)Nc1ccc(O)cc1	Launched	FAAH|PTGS1|PTGS2|TRPV1	cyclooxygenase inhibitor	neurology/psychiatry, endocrinology	pain relief, fever
parachlorophenol	Oc1ccc(Cl)cc1	Launched		antiinfective drug	infectious disease	first-aid antiseptic
paramethadione	CC[C@@]1(C)OC(=O)N(C)C1=O |&1:2	Launched	CACNA1G	anticonvulsant	neurology/psychiatry	seizures
paraxanthine	Cn1cnc2[nH]c(=O)n(C)c(=O)c12	Phase 1		adenosine receptor antagonist		
parbendazole	CCCCc1ccc2nc(NC(=O)OC)[nH]c2c1	Preclinical	TUBB	tubulin polymerization inhibitor		
parcetasal	CC(=O)Nc1ccc(O[C@]2(C)OC(=O)c3ccccc3O2)cc1 |&1:9	Preclinical		anti-inflammatory agent		
pardoprunox	CN1CCN(CC1)c1cccc2[nH]c(=O)oc12	Phase 3	DRD2|DRD3|DRD4|HTR1A|HTR7	dopamine receptor agonist, serotonin receptor agonist		
parecoxib	CCC(=O)NS(=O)(=O)c1ccc(cc1)-c1c(C)onc1-c1ccccc1	Launched	LTF	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
parethoxycaine	CCOc1ccc(cc1)C(=O)OCCN(CC)CC	Preclinical		local anesthetic		
pargyline	CN(CC#C)Cc1ccccc1	Launched	MAOA|MAOB	monoamine oxidase inhibitor	cardiology	hypertension
paricalcitol	C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1	Launched	VDR	vitamin D receptor agonist	nephrology, endocrinology	chronic kidney disease (CKD), hyperthyroidism
paritaprevir	Cc1cnc(cn1)C(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)Oc1nc2ccccc2c2ccccc12)C(=O)NS(=O)(=O)C1CC1 |c:17|	Launched		HCV inhibitor	infectious disease	hepatitis C
paromomycin	NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	amebiasis
paroxetine	Fc1ccc(cc1)[C@@H]1CCNC[C@H]1COc1ccc2OCOc2c1	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR2A|SLC6A2|SLC6A4	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry	depression, obsessive compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorders, posttraumatic stress disorder, social anxiety disorder
paroxypropione	CCC(=O)c1ccc(O)cc1	Launched		gonadotropin inhibitor		
parsaclisib	CCOc1c(cc(Cl)c(F)c1[C@@H]1CNC(=O)C1)[C@H](C)n1nc(C)c2c(N)ncnc12	Phase 2		PI3K inhibitor		
parthenolide	C\C1=C/CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	Phase 1		NFkB pathway inhibitor		
parthenolide-(-)	C\C1=C\CC[C@@]2(C)O[C@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |t:1|	Preclinical	HDAC1	NFkB pathway inhibitor		
parthenolide-(alternate-stereo)	C\C1=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]2CC1 |c:1|	Preclinical	IKBKB|RELA	NFkB pathway inhibitor		
pasireotide	NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1	Launched	SSTR1|SSTR2|SSTR3|SSTR5	somatostatin receptor agonist	endocrinology	Cushing's syndrome, acromegaly
PAT-1251	NCc1cc(Oc2cccc(c2)C(=O)N2C[C@@H](O)[C@H](F)C2)nc(c1)C(F)(F)F	Phase 1		lysyl oxidase inhibitor		
pavinetant	CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Phase 2		neurokinin receptor antagonist		
pazopanib	CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1	Launched	CSF1R|FGF1|FGFR1|FGFR3|FLT1|FLT4|ITK|KDR|KIT|PDGFRA|PDGFRB|SH2B3	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	oncology	renal cell carcinoma (RCC), soft tissue sarcoma (STS)
pazufloxacin	C[C@H]1COc2c(c(F)cc3c2n1cc(C(O)=O)c3=O)C1(N)CC1	Launched		topoisomerase inhibitor	infectious disease	pneumonia, peritonitis, bacterial septicemia
PBI-4050	CCCCCc1cccc(CC(O)=O)c1	Phase 2/Phase 3		free fatty acid receptor agonist		
PBT-1033	CN(C)Cc1ccc2c(Cl)cc(Cl)c(O)c2n1	Preclinical		chelating agent		
PCA-4248	COC(=O)C1=C(C)NC(C)=C([C@@H]1C)C(=O)OCCSc1ccccc1 |&1:11	Phase 1	PTAFR	platelet activating factor receptor antagonist		
PCI-24781	CN(C)Cc1c(oc2ccccc12)C(=O)NCCOc1ccc(cc1)C(=O)NO	Phase 3	HDAC1|HDAC2|HDAC3|HDAC6	HDAC inhibitor		
PCI-27483	NC(=N)c1ccc2nc([nH]c2c1)-c1cc(CC(=O)N[C@@H](CC(O)=O)C(O)=O)cc(c1O)-c1cc(ccc1O)S(N)(=O)=O	Phase 2		ERK1 and ERK2 phosphorylation inhibitor		
PCI-29732	Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)C1CCCC1	Preclinical	BTK	Bruton's tyrosine kinase (BTK) inhibitor		
PCI-34051	COc1ccc(Cn2ccc3ccc(cc23)C(=O)NO)cc1	Preclinical	HDAC1|HDAC10|HDAC6|HDAC8	HDAC inhibitor		
PCO-400	CC1(C)Oc2ccc(cc2[C@@H](OC2=CC(=O)CC2)[C@@H]1O)C#N |t:13|	Phase 1	KCNJ8	potassium channel activator		
PD-0325901	OC[C@@H](O)CONC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F	Phase 2	MAP2K1	MEK inhibitor		
PD-102807	CCOC(=O)c1c(C)[nH]c2ccc3O[C@H]4N(CCc5cc(OC)ccc45)Cc3c12 |&1:14	Preclinical	CHRM4	acetylcholine receptor antagonist		
PD-118057	OC(=O)c1ccccc1Nc1ccc(CCc2ccc(Cl)c(Cl)c2)cc1	Preclinical	KCNH2	potassium channel activator		
PD-123319	CN(C)c1ccc(Cn2cnc3CN([C@@H](Cc23)C(O)=O)C(=O)C(c2ccccc2)c2ccccc2)cc1C	Phase 1	AGTR2	angiotensin antagonist		
PD-128907	CCCN1CCO[C@H]2[C@H]1COc1ccc(O)cc21	Preclinical	DRD2|DRD3	dopamine receptor agonist		
PD-153035	COc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OC	Phase 1	EGFR|KDR	EGFR inhibitor		
PD-156707	COc1ccc(cc1)C(=O)C(\Cc1cc(OC)c(OC)c(OC)c1)=C(/C(O)=O)c1ccc2OCOc2c1	Preclinical	EDNRA|EDNRB	endothelin receptor antagonist		
PD-158780	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1	Preclinical	EGFR	EGFR inhibitor		
PD-160170	CC(C)c1ccccc1S(=O)(=O)c1cc(N)c2ncccc2c1[N+]([O-])=O	Preclinical	NPY1R	neuropeptide receptor antagonist		
PD-161570	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1c(Cl)cccc1Cl	Preclinical	FGFR1	FGFR inhibitor		
PD-166285	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1	Preclinical	EGFR|FGFR1|PDGFRB|PKMYT1|SRC|WEE1	SRC inhibitor		
PD-166793	CC(C)[C@H](NS(=O)(=O)c1ccc(cc1)-c1ccc(Br)cc1)C(O)=O	Preclinical	MMP13|MMP2|MMP3	collagenase inhibitor, metalloproteinase inhibitor		
PD-168077	Cc1cccc(c1)C(=O)NCN1CCN(CC1)c1ccccc1C#N	Preclinical	DRD2	dopamine receptor agonist		
PD-168393	Brc1cccc(Nc2ncnc3ccc(NC(=O)C=C)cc23)c1	Preclinical	EGFR|ERBB2|SRC	EGFR inhibitor		
PD-168568	Cc1ccc(cc1C)N1CCN(CC[C@H]2NC(=O)c3ccccc23)CC1 |&1:14|	Preclinical	DRD2|DRD4	dopamine receptor antagonist		
PD-173074	CCN(CC)CCCCNc1ncc2cc(c(NC(=O)NC(C)(C)C)nc2n1)-c1cc(OC)cc(OC)c1	Preclinical	FGFR1|FGFR2|FGFR3|FGFR4|FLT1|FLT4|KDR|PDGFRA|PDGFRB	FGFR inhibitor, VEGFR inhibitor		
PD-173212	CC(C)C[C@H](N(C)Cc1ccc(cc1)C(C)(C)C)C(=O)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)NC(C)(C)C	Preclinical	CACNA1B	calcium channel blocker		
PD-184352	Fc1ccc(C(=O)NOCC2CC2)c(Nc2ccc(I)cc2Cl)c1F	Phase 2	MAP2K1|MAP3K1|MAP3K2	MEK inhibitor		
PD-198306	Cc1cc(I)ccc1Nc1c(F)c(F)c(F)cc1C(=O)NOCC1CC1	Preclinical	MAP2K1|MAP2K2	MAP kinase inhibitor, MEK inhibitor		
PD-318088	OC[C@@H](O)CONC(=O)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1F |&1:2	Preclinical		MEK inhibitor		
PD-407824	Oc1ccc2[nH]c3cc(c4C(=O)NC(=O)c4c3c2c1)-c1ccccc1	Preclinical	WEE1	PKC inhibitor		
PD-81723	Cc1sc(N)c(C(=O)c2cccc(c2)C(F)(F)F)c1C	Preclinical	ADORA1	adenosine receptor agonist		
PD-98059	COc1cccc(c1N)-c1cc(=O)c2ccccc2o1	Preclinical	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1	MEK inhibitor		
PDD-00017273	Cc1cc(Cn2c3ccc(cc3c(=O)n(Cc3cnc(C)s3)c2=O)S(=O)(=O)NC2(C)CC2)n(C)n1	Preclinical		PARG inhibitor		
PDE10-IN-1	Cc1c(nc2c3cccnc3ccn12)[C@@H]1C[C@H]1c1nc2c(C)ncc(C)n2n1	Preclinical	PDE10A	phosphodiesterase inhibitor		
PDP-EA	CCCCCCCCCCCCCCCc1cccc(OCC(=O)NCCO)c1	Preclinical	FAAH	FAAH activator		
PD1-PDL-inhibitor-1	COc1cc(OCc2cccc(c2C)-c2ccccc2)cc(OC)c1CN1CCCC[C@H]1C(O)=O	Preclinical	CD274	programmed death ligand inhibitor		
peficitinib	NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2 |&1:13	Launched	JAK1|JAK2|JAK3	JAK inhibitor	rheumatology	rheumatoid arthritis
pefloxacin	CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCN(C)CC1	Launched	TOP2A	bacterial DNA gyrase inhibitor	infectious disease, urology	gastrointestinal infections, urethritis, gonorrhea, urinary tract infections
pelanserin	O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1	Phase 2	HTR2A	serotonin receptor antagonist		
pelitinib	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C	Phase 2	EGFR	EGFR inhibitor		
pelrinone	Cc1nc(=O)c(C#N)c(NCc2cccnc2)[nH]1	Phase 2		phosphodiesterase inhibitor		
pemafibrate	CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(O)=O	Phase 3		PPAR receptor agonist		
pemetrexed	Nc1nc(=O)c2c(CCc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)c[nH]c2[nH]1	Launched	ATIC|DHFR|GART|TYMS	dihydrofolate reductase inhibitor, thymidylate synthase inhibitor	oncology	non-small cell lung cancer (NSCLC), mesothelioma
pemirolast	Cc1cccn2c1ncc(-c1nn[nH]n1)c2=O	Launched	HRH1	mediator release inhibitor	pulmonary	asthma
pempidine	CN1C(C)(C)CCCC1(C)C	Launched		ganglionic blocker	cardiology	hypertension
penbutolol	CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1	Launched	ADRB1|ADRB2|HTR1A|HTR1B	adrenergic receptor antagonist	cardiology	hypertension
penciclovir	Nc1nc(=O)c2ncn(CCC(CO)CO)c2[nH]1	Launched		DNA directed DNA polymerase inhibitor	dental	cold sore
penfluridol	OC1(CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1ccc(Cl)c(c1)C(F)(F)F	Launched	CACNA1G	T-type calcium channel blocker	neurology/psychiatry	schizophrenia
penicillamine-(D)	CC(C)(S)[C@@H](N)C(O)=O	Launched		chelating agent	metabolism, rheumatology, nephrology	Wilson's disease, rheumatoid arthritis, cystinuria
penicillamine-(racemic)	CC(C)(S)[C@@H](N)C(O)=O |&1:4|	Launched				
penicillin-v-potassium	CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	pneumonia, ear infections, skin infections, throat infections, cholera, scarlet fever
pentacosanoic-acid	CCCCCCCCCCCCCCCCCCCCCCCCC(O)=O	Preclinical				
pentagastrin	CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Launched	CCKBR	CCK receptor agonist	gastroenterology	anacidity diagnostic, gastric hypersecretion diagnostic
pentamidine	NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1	Launched	TRDMT1	anti-pneumocystis agent	infectious disease	pneumonia
pentetic-acid	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	Phase 2		chelating agent		
pentolinium	C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1	Launched	CHRNA10|CHRNA3|CHRNA4|CHRNB4	cholinergic receptor antagonist	cardiology	hypertension
pentostatin	OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2[C@H](O)CN=CNc12 |c:16|	Launched	ADA	adenosine deaminase inhibitor, ribonucleotide reductase inhibitor	hematologic malignancy	hairy cell leukemia
pentoxifylline	CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O	Launched	ADORA1|ADORA2A|ADORA2B|ADRA2B|NT5E|PDE10A|PDE1A|PDE1B|PDE1C|PDE2A|PDE3A|PDE3B|PDE4A|PDE4B|PDE4C|PDE4D|PDE5A|PDE6A|PDE6B|PDE6C|PDE6D|PDE6G|PDE6H|PDE7A|PDE7B|PDE8A|PDE8B|PDE9A|TNF	phosphodiesterase inhibitor	cardiology	claudication
pentylenetetrazol	C1CCc2nnnn2CC1	Withdrawn		GABA receptor antagonist		
peposertib	COc1ccc(nn1)[C@@H](O)c1cc(c(F)cc1Cl)-c1ncnc2cc(ccc12)N1CCOCC1	Phase 1/Phase 2		DNA dependent protein kinase inhibitor		
pepstatin	CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC(C)C)C(C)C)C(C)C)[C@@H](O)CC(O)=O	Preclinical	CTSB|CTSD|CTSL|REN	aspartic protease inhibitor		
peramivir	CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O	Launched		neuraminidase inhibitor	infectious disease	influenza A virus infection
perchlozone	NC(=S)N\N=C\c1ccncc1	Launched			infectious disease	tuberculosis
peretinoin	CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O	Phase 3	RXRA	retinoid receptor agonist		
perfluamine	FC(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)F	Launched				
perflubron	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br	Launched		contrast agent	radiology	contrast agent
perfluorodecalin	FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F	Launched			dermatology	cosmetic
perfluorohexyloctane	CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	Launched				
pergolide	CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3cccc2c13	Withdrawn	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	dopamine receptor agonist		
perhexiline	C(C(C1CCCCC1)C1CCCCC1)[C@H]1CCCCN1 |&1:14|	Launched	CPT1A	carnitine palmitoyltransferase inhibitor	cardiology	angina pectoris
perifosine	CCCCCCCCCCCCCCCCCCOP(O)(=O)OC1CC[N+](C)(C)CC1 |&1:19|	Phase 3	AKT1	AKT inhibitor		
perillyl-alcohol	CC(=C)[C@H]1CCC(CO)=CC1 |&1:3	Phase 2	FNTA	apoptosis stimulant, farnesyltransferase inhibitor		
perindopril	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension, myocardial infarction, coronary artery disease (CAD)
perindoprilat	CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(O)=O	Phase 2	ACE	angiotensin converting enzyme inhibitor		
permethrin	CC1(C)[C@@H](C=C(Cl)Cl)[C@@H]1C(=O)OCc1cccc(Oc2ccccc2)c1 |&1:3	Launched			infectious disease	lice
perospirone	O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(CC1)c1nsc2ccccc12	Launched	DRD2|DRD3|DRD4	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia, bipolar disorder
perphenazine	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	CALM1|DRD1|DRD2|HRH1|HTR2A|HTR2C|HTR6|HTR7	dopamine receptor antagonist	neurology/psychiatry, gastroenterology	schizophrenia, nausea, vomiting
peruvoside	CO[C@H]1[C@@H](O)[C@@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)[C@@H]1O |a:2	Phase 1		cardiac glycoside		
perzinfotel	OP(O)(=O)CCN1CCCNc2c1c(=O)c2=O	Phase 2	GRIN1|GRIN2A|GRIN2B	glutamate receptor antagonist		
PETCM	O[C@@H](Cc1ccncc1)C(Cl)(Cl)Cl |&1:1	Preclinical	CASP3	caspase activator		
pevonedistat	NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12	Phase 3	NAE1|UBA3	nedd activating enzyme inhibitor		
pexidartinib	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1	Launched	CSF1R|FLT3|KIT	tyrosine kinase inhibitor		
pexmetinib	Cc1ccc(cc1)-n1nc(cc1NC(=O)NCc1cc(F)ccc1Oc1ccc2n(CCO)ncc2c1)C(C)(C)C	Phase 1	MAPK14|TEK	MAP kinase inhibitor, TIE tyrosine kinase inhibitor		
PF-02413873	Cc1c(Oc2cc(C)c(C#N)c(C)c2)c(nn1CS(C)(=O)=O)C1CC1	Phase 1		progesterone receptor antagonist		
PF-02545920	Cn1cc(c(n1)-c1ccc(OCc2ccc3ccccc3n2)cc1)-c1ccncc1	Phase 2	PDE10A	phosphodiesterase inhibitor		
PF-03049423	CCCOCCn1c2cc(ncc2nc(N2CCN(CCO)CC2)c1=O)-c1ccc(OC)nc1	Phase 2	PDE5A	phosphodiesterase inhibitor		
PF-03084014	CCC[C@H](N[C@H]1CCc2cc(F)cc(F)c2C1)C(=O)Nc1cn(cn1)C(C)(C)CNCC(C)(C)C	Phase 3		gamma secretase inhibitor		
PF-03758309	CN(C)C[C@@H](NC(=O)N1Cc2c(Nc3nc(C)nc4ccsc34)[nH]nc2C1(C)C)c1ccccc1	Phase 1	PAK4	p21 activated kinase inhibitor		
PF-03814735	CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1cc(Nc3ncc(c(NC4CCC4)n3)C(F)(F)F)ccc21	Phase 1	AURKA|AURKB	Aurora kinase inhibitor		
PF-03882845	OC(=O)c1ccc2C3=NN([C@@H](C4CCCC4)C3CCc2c1)c1ccc(C#N)c(Cl)c1 |t:7|	Phase 1		mineralocorticoid receptor antagonist		
PF-04136309	O[C@]1(CC[C@@H](CC1)N[C@H]1CCN(C1)C(=O)CNC(=O)c1cccc(c1)C(F)(F)F)c1ccc(cn1)-c1ncccn1	Phase 2		CC chemokine receptor antagonist		
PF-04217903	OCCn1cc(cn1)-c1cnc2nnn(Cc3ccc4ncccc4c3)c2n1	Phase 1	MET	c-Met inhibitor		
PF-04418948	COc1ccc2cc(OCC3(CN(C3)C(=O)c3ccc(F)cc3)C(O)=O)ccc2c1	Phase 1	PTGER2	prostaglandin inhibitor		
PF-04447943	C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1nc(=O)c2cnn(C3CCOCC3)c2[nH]1	Phase 2	PDE9A	phosphodiesterase inhibitor		
PF-04457845	FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1	Phase 2	FAAH	FAAH inhibitor		
PF-04620110	Nc1ncnc2OCCN(c3ccc(cc3)[C@H]3CC[C@H](CC(O)=O)CC3)C(=O)c12 |r|	Phase 1	DGAT1	diacylglycerol O acyltransferase inhibitor		
PF-04691502	COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@H]2CC[C@@H](CC2)OCCO)c1=O |r|	Phase 2	MTOR|PIK3CA	mTOR inhibitor, PI3K inhibitor		
PF-04885614	CC(C)(N)c1nc(c[nH]1)-c1ccc(OC(F)(F)F)cc1	Preclinical	SCN10A	voltage-gated sodium channel blocker		
PF-04937319	CN(C)C(=O)c1ncc(Oc2cc(cc3oc(C)cc23)C(=O)Nc2cnc(C)cn2)cn1	Phase 2	GCK	glucokinase activator		
PF-04995274	OC1(CN2CCC(COc3noc4cccc(O[C@@H]5CCOC5)c34)CC2)CCOCC1	Phase 1		serotonin receptor agonist		
PF-05089771	Nc1[nH]ncc1-c1cc(Cl)ccc1Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1	Preclinical		sodium channel blocker		
PF-05175157	[H]n1c(C)nc2ccc(cc12)C(=O)N1CCC2(CC1)Cc1cnn(C(C)C)c1C(=O)C2	Phase 2		acetyl-CoA carboxylase inhibitor		
PF-05180999	Cc1nc(-c2cnn(C)c2-c2ccc(cn2)C(F)(F)F)c2c(ncnn12)N1CCC1	Phase 1		phosphodiesterase inhibitor		
PF-05190457	Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1	Phase 2	GHSR	growth hormone secretagogue receptor inverse agonist		
PF-05212384	CN(C)C1CCN(CC1)C(=O)c1ccc(NC(=O)Nc2ccc(cc2)-c2nc(nc(n2)N2CCOCC2)N2CCOCC2)cc1	Phase 2	MTOR|PIK3CA	mTOR inhibitor, PI3K inhibitor		
PF-06260414	C[C@@H]1CNS(=O)(=O)N(C1)c1ccc2c(nccc2c1)C#N	Phase 1		androgen receptor modulator		
PF-06273340	CC(C)(CO)n1cc(C(=O)c2cncc(NC(=O)Cc3ccc(Cl)cn3)c2)c2cnc(N)nc12	Phase 1		tyrosine kinase receptor inhibitor		
PF-06282999	COc1ccc(Cl)cc1-c1cc(=O)[nH]c(=S)n1CC(N)=O	Phase 1		myeloperoxidase inhibitor		
PF-06305591	C[C@H]([C@H](N)c1nc2cc(ccc2[nH]1)C(C)(C)C)C(N)=O	Phase 1		sodium channel blocker		
PF-06409577	OC(=O)c1c[nH]c2cc(Cl)c(cc12)-c1ccc(cc1)C1(O)CCC1	Phase 1		protein kinase activator		
PF-06412562	Cc1cc(Oc2nccc3[nH]ncc23)ccc1-c1c(C)ncnc1C	Phase 1		dopamine receptor partial agonist		
PF-06447475	N#Cc1cccc(c1)-c1c[nH]c2ncnc(N3CCOCC3)c12	Preclinical	LRRK2	serine/threonine kinase inhibitor		
PF-06459988	CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(C)c2)nc2[nH]cc(Cl)c12)C(=O)C=C	Phase 2		receptor tyrosine protein kinase inhibitor		
PF-06463922	C[C@H]1Oc2cc(cnc2N)-c2c(CN(C)C(=O)c3ccc(F)cc13)nn(C)c2C#N |&1:1	Launched	ALK|FES|ROS1	ALK tyrosine kinase receptor inhibitor	oncology	non-small cell lung cancer (NSCLC)
PF-06650833	CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F	Phase 1		kinase inhibitor		
PF-06651600	C[C@H]1CC[C@H](CN1C(=O)C=C)Nc1ncnc2[nH]ccc12	Phase 2/Phase 3		JAK inhibitor		
PF-06747775	COc1nn(C)cc1Nc1nc(nc2n(C)cnc12)N1C[C@@H](F)[C@@H](C1)NC(=O)C=C	Phase 2		EGFR inhibitor		
PF-06751979	C[C@H]1C[C@H]2CSC(N)=N[C@]2(CO1)c1nc(NC(=O)c2ccc(OC(F)F)cn2)cs1 |c:7|	Phase 1		beta secretase inhibitor		
PF-06840003	Fc1ccc2[nH]cc([C@H]3CC(=O)NC3=O)c2c1 |&1:8	Phase 1		indoleamine 2,3-dioxygenase inhibitor		
PF-06873600	C[C@@]1(O)CCC[C@H]1n1c2nc(NC3CCN(CC3)S(C)(=O)=O)ncc2cc(C(F)F)c1=O	Phase 2		CDK inhibitor		
PF-06928215	OC(=O)[C@@H]1CCCC[C@@H]1NC(=O)c1cnn2c(O)cc(nc12)-c1ccccc1	Preclinical		cyclic GMP-AMP synthase inhibitor		
PF-3274167	COCc1nnc(N2CC(C2)Oc2ccc(F)cc2Cl)n1-c1ccc(OC)nc1	Phase 2	AVPR1A|OXTR	oxytocin receptor antagonist		
PF-3845	FC(F)(F)c1ccc(Oc2cccc(CC3CCN(CC3)C(=O)Nc3cccnc3)c2)nc1	Preclinical	FAAH	FAAH inhibitor		
PF-4191834	Cn1nccc1-c1ccc(Sc2cccc(c2)C2(CCOCC2)C(N)=O)cc1	Preclinical		lipoxygenase inhibitor		
PF-429242	CCN(CC)Cc1ccc(cc1)C(=O)N(CCc1ccccc1OC)[C@@H]1CCNC1	Preclinical	MBTPS1	SREBP inhibitor		
PF-431396	CN(c1ccccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	Preclinical	PTK2|PTK2B	focal adhesion kinase inhibitor		
PF-4708671	CCc1cncnc1N1CCN(Cc2nc3ccc(cc3[nH]2)C(F)(F)F)CC1	Preclinical	RPS6KB1	ribosomal protein inhibitor		
PF-477736	Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O	Phase 1	CHEK1|CHEK2	CHK inhibitor		
PF-4800567	Nc1ncnc2n(nc(COc3cccc(Cl)c3)c12)C1CCOCC1	Preclinical	CSNK1D|CSNK1E	casein kinase inhibitor		
PF-4981517	Cc1ccc(cc1)-c1c(cnn1C)-c1nn(C)c2ncnc(N3CC[C@@H](C3)N3CCCCC3)c12	Preclinical	CYP3A4	cytochrome P450 inhibitor		
PF-514273	CC(F)(F)CN1CCOc2c(nn(c2-c2ccc(Cl)cc2)-c2ccccc2Cl)C1=O	Preclinical		cannabinoid receptor antagonist		
PF-5274857	Cc1cnc(c(C)c1)-c1cc(ncc1Cl)N1CCN(CC1)C(=O)CCS(C)(=O)=O	Preclinical	SMO	smoothened receptor antagonist		
PF-562271	CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O	Phase 1	PTK2|PTK2B	focal adhesion kinase inhibitor		
PF-573228	CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1	Preclinical	CDK1|CDK2|CDK7|GSK3B|IKBKB	focal adhesion kinase inhibitor		
PF-670462	Nc1nccc(n1)-c1c(ncn1C1CCCCC1)-c1ccc(F)cc1	Preclinical	CSNK1D|CSNK1E	casein kinase inhibitor		
PF-750	O=C(Nc1ccccc1)N1CCC(Cc2cnc3ccccc3c2)CC1	Preclinical	FAAH	FAAH inhibitor		
PF-8380	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3ccc4[nH]c(=O)oc4c3)CC2)c1	Preclinical	ENPP2	autotaxin inhibitor		
PF-915275	Nc1cccc(NS(=O)(=O)c2ccc(cc2)-c2ccc(cc2)C#N)n1	Phase 1	HSD11B1	11-beta hydroxysteroid dehydrogenase inhibitor		
PFI-1	COc1ccccc1S(=O)(=O)Nc1ccc2NC(=O)N(C)Cc2c1	Preclinical	BRD4	bromodomain inhibitor		
PFI-3	Oc1ccccc1C(=O)\C=C\N1C[C@H]2C[C@@H]1CN2c1ccccn1	Preclinical	PBRM1|SMARCA4	bromodomain inhibitor		
PFI-4	COc1ccccc1C(=O)Nc1cc2n(C)c(=O)n(C)c2cc1N1CCCC1	Preclinical	BRPF1	bromodomain inhibitor		
PFK-015	O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1	Phase 1	PFKFB3	phosphofructokinase inhibitor		
PFK-158	FC(F)(F)c1ccc2ccc(\C=C\C(=O)c3ccncc3)nc2c1	Phase 1	PFKFB3	phosphofructokinase inhibitor		
PG-9	C[C@@H](C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)c1ccc(Br)cc1 |&1:5	Preclinical		acetylcholine receptor agonist		
PGL5001	N#C[C@@H](c1nc2ccccc2s1)c1ccnc(OCc2ccc(CN3CCOCC3)cc2)n1 |&1:2	Phase 2	MAPK10|MAPK8|MAPK9	JNK inhibitor		
PH-797804	CNC(=O)c1ccc(C)c(c1)-n1c(C)cc(OCc2ccc(F)cc2F)c(Br)c1=O	Phase 2	MAPK11|MAPK14	p38 MAPK inhibitor		
PHA-543613	O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1	Preclinical		nicotinic receptor agonist		
PHA-568487	O=C(N[C@H]1CN2CCC1CC2)c1ccc2OCCOc2c1	Preclinical	CHRNA7	nicotinic receptor agonist		
PHA-665752	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1	Preclinical	MET	c-Met inhibitor		
PHA-680632	CCc1cccc(CC)c1NC(=O)N1Cc2n[nH]c(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1	Preclinical	AURKA|AURKB|AURKC	Aurora kinase inhibitor		
PHA-767491	O=C1NCCc2[nH]c(cc12)-c1ccncc1	Preclinical	CDK1|RPS6KB1	CDC inhibitor		
PHA-793887	CC(C)CC(=O)Nc1[nH]nc2c1CN(C(=O)C1CCN(C)CC1)C2(C)C	Phase 1	CDK1|CDK2|CDK4|CDK5|CDK7|CDK9	CDK inhibitor		
PHA-848125	CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21	Phase 2	CDK2|CDK4|CDK7|NTRK1	CDK inhibitor, growth factor receptor inhibitor		
PHCCC	O\N=C1/[C@@H]2C[C@@]2(Oc2ccccc12)C(=O)Nc1ccccc1 |&1:3	Preclinical	GRM1|GRM4	glutamate receptor agonist		
phenacaine	CCOc1ccc(NC(C)=Nc2ccc(OCC)cc2)cc1	Launched		local anesthetic	neurology/psychiatry	local anesthetic
phenacemide	NC(=O)NC(=O)Cc1ccccc1	Launched	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	sodium channel blocker	neurology/psychiatry	epilepsy, seizures
phenacetin	CCOc1ccc(NC(C)=O)cc1	Withdrawn	PTGS1	cyclooxygenase inhibitor		
phenazone	Cc1cc(=O)n(-c2ccccc2)n1C	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
phenazopyridine	Nc1ccc(\N=N\c2ccccc2)c(N)n1	Launched	SCN1A	local anesthetic	infectious disease	urinary tract infections
phenelzine	NNCCc1ccccc1	Launched	ABAT|AOC3|GAD2|GPT|GPT2|MAOA|MAOB|SLC6A2|SLC6A3|SLC6A4	monoamine oxidase inhibitor	neurology/psychiatry	depression
phenethicillin	C[C@@H](Oc1ccccc1)C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O |a:12	Launched		bacterial cell wall synthesis inhibitor		
phenethyl-isothiocyanate	S=C=NCCc1ccccc1	Phase 2	CYP2E1	anticancer agent		
phenformin	NC(N)=NC(=N)NCCc1ccccc1	Withdrawn	KCNJ8|PRKAA1	AMPK activator		
phenindamine	CN1CCC2=C(C1)[C@@H](c1ccccc21)c1ccccc1 |&1:7	Launched	HRH1	histamine receptor antagonist	allergy, otolaryngology	allergic rhinitis, common cold
phenindione	O=C1C(C(=O)c2ccccc12)c1ccccc1	Launched	VKORC1	vitamin K antagonist	hematology	deep vein thrombosis (DVT)
pheniramine	CN(C)CC[C@@H](c1ccccc1)c1ccccn1 |&1:5|	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis, urticaria
phenol	Oc1ccccc1	Preclinical	CA1|CA12|CA14|CA2|CA4|CA9		otolaryngology	pharyngitis
phenolphthalein	Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1	Withdrawn	UGT1A9	indicator dye		
phenolsulfonphthalein	Oc1ccc(cc1)C1(OS(=O)(=O)c2ccccc12)c1ccc(O)cc1	Launched				
phenothiazine	N1c2ccccc2Sc2ccccc12	Preclinical		dopamine receptor antagonist		
phenothrin	CC(C)=C[C@H]1[C@@H](C(=O)OCc2cccc(Oc3ccccc3)c2)C1(C)C |&1:4	Launched			infectious disease	lice
phenoxybenzamine	CC(COc1ccccc1)N(CCCl)Cc1ccccc1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	adrenergic receptor antagonist	cardiology, endocrinology	hypertension, pheochromocytoma
phenprobamate	NC(=O)OCCCc1ccccc1	Launched		muscle relaxant	neurology/psychiatry	anxiety, muscle relaxant
phenprocoumon	CC[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:2	Launched	VKORC1	vitamin K antagonist	hematology	thrombosis, pulmonary embolism (PE)
phenserine	CN1CC[C@]2(C)[C@H]1N(C)c1ccc(OC(=O)Nc3ccccc3)cc21	Phase 3	ACHE|BCHE	acetylcholinesterase inhibitor, beta amyloid synthesis inhibitor		
phensuximide	CN1C(=O)C[C@@H](C1=O)c1ccccc1 |&1:5	Launched		succinimide antiepileptic	neurology/psychiatry	seizures
phentolamine	Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1 |t:10|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	adrenergic receptor antagonist	endocrinology, cardiology	pheochromocytoma, hypertension
phenyl-aminosalicylate	Nc1ccc(C(=O)Oc2ccccc2)c(O)c1	Launched			infectious disease	tuberculosis
phenyl-salicylate	Oc1ccccc1C(=O)Oc1ccccc1	Launched		antiseptic	urology	interstitial cystitis (IC)
phenylacetylglutamine	NC(=O)CC[C@H](NC(=O)Cc1ccccc1)C(O)=O	Phase 2		DNA methylase inhibitor, protein synthesis inhibitor		
phenylbenzimidazole-sulfonic-acid	OS(=O)(=O)c1ccc2nc([nH]c2c1)-c1ccccc1	Launched			dermatology	sunscreen lotion
phenylbutazone	CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Withdrawn	PTGIS|PTGS1|PTGS2	cyclooxygenase inhibitor, prostanoid receptor antagonist		
phenylbutyrate	OC(=O)CCCc1ccccc1	Launched	HDAC1	HDAC inhibitor	metabolism	urea cycle disorders
phenylephrine	CNC[C@H](O)c1cccc(O)c1	Launched	ADRA1A|ADRA1B|ADRA1D	adrenergic receptor agonist	otolaryngology, gastroenterology, cardiology	nasal congestion, hemorrhoids, hypotension
phenylethyl-alcohol	OCCc1ccccc1	Preclinical				
phenylmercuric-acetate	CC(=O)O[Hg]c1ccccc1	Preclinical		other antifungal		
phenylmethylsulfonyl-fluoride	FS(=O)(=O)Cc1ccccc1	Preclinical		serine protease inhibitor		
phenylpiracetam	NC(=O)CN1C[C@@H](CC1=O)c1ccccc1 |&1:6	Launched		noradrenaline uptake inhibitor	neurology/psychiatry	anxiety, fatigue, depression
phenytoin	O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1	Launched	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	hydantoin antiepileptic	neurology/psychiatry	seizures
PhiKan-083	CCn1c2ccccc2c2cc(CNC)ccc12	Preclinical	TP53	p53 stabilizing agent		
phloretin	Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1	Launched	AQP9|CLCN3|SLC23A1	sodium/glucose cotransporter inhibitor		
phlorizin	OC[C@H]1O[C@@H](Oc2cc(O)cc(O)c2C(=O)CCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical	SLC5A1|SLC5A11|SLC5A2|SLC5A3	sodium/glucose cotransporter inhibitor		
phloroglucin	Oc1cc(O)cc(O)c1	Launched			neurology/psychiatry	spasms
phortress	Cc1cc(ccc1NC(=O)[C@@H](N)CCCCN)-c1nc2cc(F)ccc2s1	Phase 1	AHR	aryl hydrocarbon receptor ligand		
phosphatidylcholine	CCCCCCCCCCCCCCCC(=O)OC[C@H](CO[P@](O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC |a:19	Launched			infectious disease, dermatology, gastroenterology, cardiology, obstetrics/gynecology	hepatitis B, hepatitis C, eczema, gallbladder disease, cholesterol, premenstrual syndrome
PHP-501	On1ncc(C2CCNCC2)c1-c1cccc(c1)-c1ccccc1	Preclinical	GABRA1|GABRB2|GABRG2	GABA receptor antagonist		
PHT-427	CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1	Preclinical	AKT2|PDPK1	AKT inhibitor, pyruvate dehydrogenase inhibitor		
phthalylsulfacetamide	CC(=O)NS(=O)(=O)c1ccc(NC(=O)c2ccccc2C(O)=O)cc1	Preclinical				
phthalylsulfathiazole	OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Launched		dihydropteroate synthetase inhibitor	infectious disease, gastroenterology	dysentry, colitis
PHTPP	Oc1ccc(cc1)-c1c(nn2c(cc(nc12)C(F)(F)F)C(F)(F)F)-c1ccccc1	Preclinical	ESR2	estrogen receptor antagonist		
physostigmine	CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1	Launched	ACHE|BCHE	acetylcholinesterase inhibitor, cholinesterase inhibitor	cardiology, neurology/psychiatry, ophthalmology, gastroenterology	hypotension, Alzheimer's disease, glaucoma, gastroparesis
phytonadione	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CC1=C(C)C(=O)c2ccccc2C1=O |c:20|	Launched	BGLAP|GGCX		hematology	vitamin K deficiency, anticoagulation reversal
phytosphingosine	CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO	Phase 1				
PI-103	Oc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC	mTOR inhibitor, PI3K inhibitor		
PI-828	Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1	Preclinical		PI3K inhibitor		
pibenzimol	CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1ccc2nc([nH]c2c1)-c1ccc(O)cc1	Phase 2		DNA inhibitor		
piboserod	CCCCN1CCC(CNC(=O)c2c3OCCCn3c3ccccc23)CC1	Phase 2	HTR2B|HTR4	serotonin receptor antagonist		
picartamide	CNC(=S)[C@]1(CCCS1)c1ccccn1 |&1:4	Phase 2	ATP4A	H+/K+-ATPase inhibitor		
piceatannol	Oc1cc(O)cc(\C=C\c2ccc(O)c(O)c2)c1	Preclinical	ATP5A1|ATP5B|ATP5C1|IRF3	SYK inhibitor		
piclamilast	COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl	Phase 2	PDE4A|PDE4B|PDE4C|PDE4D	phosphodiesterase inhibitor		
picolamine	NCc1cccnc1	Preclinical				
picolinic-acid	OC(=O)c1ccccn1	Phase 2		chelating agent		
piconol	OCc1ccccn1	Preclinical				
picotamide	COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1	Launched	TBXA2R	thromboxane receptor antagonist, thromboxane synthase inhibitor	hematology	thrombosis
picrotin	CC(C)(O)[C@H]1[C@H]2OC(=O)[C@@H]1[C@@]1(O)C[C@H]3O[C@]33C(=O)O[C@@H]2[C@@]13C |&1:4	Phase 2	GLRA1|GLRA2|GLRA3|GLRB	GABA receptor antagonist		
picrotoxinin	CC(=C)[C@@H]1[C@H]2OC(=O)[C@H]1[C@]1(O)C[C@H]3O[C@]33C(=O)O[C@H]2[C@]13C	Preclinical	GLRA1|GLRA2|GLRA3|GLRB|HTR3A|HTR3B	GABA receptor antagonist		
pidolic-acid	OC(=O)[C@@H]1CCC(=O)N1	Launched	ADAM28|AMY1A|AMY2A|AMY2B|ANG|CCL8|HCRT|IGLC1|KRTAP5-2|TFF2|VEGFA		dermatology	xerosis cutis
pidotimod	OC(=O)[C@@H]1CSCN1C(=O)[C@@H]1CCC(=O)N1	Launched		interferon receptor agonist, interleukin receptor agonist	infectious disease	immune adjuvant
pifithrin-alpha	Cc1ccc(cc1)C(=O)Cn1c2CCCCc2sc1=N	Preclinical	TP53	TP53 inhibitor		
pifithrin-cyclic	Cc1ccc(cc1)-c1cn2c3CCCCc3sc2n1	Preclinical	TP53	TP53 inhibitor		
pifithrin-mu	NS(=O)(=O)C#Cc1ccccc1	Preclinical	HSPA1A|TP53	HSP inhibitor		
PIK-293	Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O	Preclinical	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
PIK-294	Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc23)nc2cccc(C)c2c1=O	Preclinical	PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
PIK-75	CN(\N=C\c1cnc2ccc(Br)cn12)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O	Preclinical	PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC	DNA protein kinase inhibitor, PI3K inhibitor		
PIK-93	CC(=O)Nc1nc(C)c(s1)-c1ccc(Cl)c(c1)S(=O)(=O)NCCO	Preclinical	PI4KB|PIK3C3|PIK3CG	PI3K inhibitor		
pikamilone	OC(=O)CCCNC(=O)c1cccnc1	Phase 1				
piketoprofen	C[C@@H](C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1 |&1:1	Launched		cyclooxygenase inhibitor	neurology/psychiatry	pain relief
pilaralisib	COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1	Phase 2		PI3K inhibitor		
pilocarpine	CC[C@H]1[C@@H](Cc2cncn2C)COC1=O	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor agonist	ophthalmology, cardiology	glaucoma, hypertension
pilsicainide	Cc1cccc(C)c1NC(=O)CC12CCCN1CCC2	Launched	SCN5A	sodium channel blocker	cardiology	cardiac arrythmia
PIM-1-Inhibitor-2	Nc1nccc(n1)-c1ccc2noc(-c3ccc(Cl)cc3)c2c1	Preclinical	PIM1	Pim kinase inhibitor		
PIM-447	C[C@@H]1C[C@H](N)C[C@@H](C1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F	Phase 1		Pim kinase inhibitor		
pimavanserin	CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1	Launched	DRD2|HTR2A	serotonin receptor inverse agonist	neurology/psychiatry	Parkinson's Disease
pimecrolimus	CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC |c:3|	Launched		calcineurin inhibitor	dermatology	eczema
pimethixene	CN1CCC(CC1)=C1c2ccccc2Sc2ccccc12	Launched		antihistamine	neurology/psychiatry, allergy	attention-deficit/hyperactivity disorder (ADHD), anxiety, sleep cycle support, allergic rhinitis
pimobendan	COc1ccc(cc1)-c1nc2ccc(cc2[nH]1)C1=NNC(=O)C[C@H]1C |&1:23	Launched	PDE3A	calcium sensitizer, phosphodiesterase inhibitor	cardiology	congestive heart failure
pimodivir	OC(=O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(ncc1F)-c1c[nH]c2ncc(F)cc12	Phase 3		antiviral		
pimonidazole	O[C@@H](CN1CCCCC1)Cn1ccnc1[N+]([O-])=O |&1:1	Phase 3				
pimozide	Fc1ccc(cc1)C(CCCN1CCC(CC1)n1c2ccccc2[nH]c1=O)c1ccc(F)cc1	Launched	CACNA1I|CALM1|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|KCNA10|KCNH2	dopamine receptor antagonist	neurology/psychiatry	Tourette's disorder
pinacidil	C[C@@H](NC(Nc1ccncc1)=NC#N)C(C)(C)C |&1:1	Launched	ABCC8|ABCC9	ATP channel activator, potassium channel activator	cardiology	hypertension
pinanediol	CC1(C)[C@H]2C[C@@H]1[C@](C)(O)[C@H](O)C2	Preclinical				
pinaverium	COc1cc(Br)c(C[N+]2(CCOCC[C@H]3CC[C@@H]4C[C@H]3C4(C)C)CCOCC2)cc1OC |&1:17	Launched	CACNA1C	T-type calcium channel blocker	gastroenterology	irritable bowel syndrome
pincainide	Cc1cccc(C)c1NC(=O)CN1CCCCCC1	Phase 1		antiarrhythmic		
pindolol	CC(C)NC[C@@H](O)COc1cccc2[nH]ccc12 |&1:5	Launched	ADRB1|ADRB2|HTR1A|HTR2A|HTR2B	adrenergic receptor antagonist	cardiology	hypertension
pindolol-(-)	CC(C)NC[C@H](O)COc1cccc2[nH]ccc12	Phase 2	HTR1A	adrenergic receptor antagonist, serotonin receptor antagonist		
pinitol		Phase 2		gamma secretase inhibitor		
pinocembrin	Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c1ccccc1	Phase 2	CYP1B1	cytochrome P450 inhibitor		
pioglitazone	CCc1ccc(CCOc2ccc(C[C@H]3SC(=O)NC3=O)cc2)nc1 |&1:14|	Launched	PPARG|TRPM3	insulin sensitizer, PPAR receptor agonist	endocrinology	diabetes mellitus
pipamperone	NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1	Launched	DRD2|HRH1|HTR1A|HTR1B|HTR1D|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipecuronium		Launched	CHRM2|CHRM3|CHRNA2	neuromuscular blocker	neurology/psychiatry	anesthetic
pipemidic-acid	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCNCC1	Launched		topoisomerase inhibitor	infectious disease	gram-negative bacterial infections
pipenzolate	CC[N@@+]1(C)CCC[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1 |&1:2	Launched	CHRM1	cholinergic receptor antagonist	neurology/psychiatry	spasms
piperacetazine	CC(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	Launched		dopamine receptor antagonist	neurology/psychiatry	schizophrenia
piperacillin	CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(O)=O)c2ccccc2)C(=O)C1=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	intra-abdominal infections, skin infections, pelvic inflammatory disease, pneumonia
piperaquine-phosphate	Clc1ccc2c(ccnc2c1)N1CCN(CCCN2CCN(CC2)c2ccnc3cc(Cl)ccc23)CC1	Launched		antimalarial agent	infectious disease	malaria
piperazine	C1CNCCN1	Launched	GABRB3	benzodiazepine receptor agonist	infectious disease	gastrointestinal roundworms
piperazinedione	O=C1CNC(=O)CN1	Phase 2		DNA synthesis inhibitor		
piperidolate	CCN1CCC[C@@H](C1)OC(=O)C(c1ccccc1)c1ccccc1 |&1:6|	Launched	CHRM1	acetylcholine receptor antagonist	neurology/psychiatry	spasms
piperine	O=C(\C=C\C=C\c1ccc2OCOc2c1)N1CCCCC1	Phase 1	MAOA|MAOB|TRPV1	monoamine oxidase inhibitor		
piperonyl-butoxide	CCCCOCCOCCOCc1cc2OCOc2cc1CCC	Launched		cytochrome P450 inhibitor	infectious disease	lice
pipobroman	BrCCC(=O)N1CCN(CC1)C(=O)CCBr	Launched		DNA alkylating agent	hematology	polycythemia vera, thrombocythemia
pipofezine	CN1CCN(CC1)c1cc2N(C)c3ccccc3Oc2nn1	Preclinical		selective serotonin reuptake inhibitor (SSRI)		
pipotiazine	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCC(CCO)CC3)c2c1	Launched	DRD1|DRD2|HTR1A|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
pipotiazine-palmitate	CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)S(=O)(=O)N(C)C)CC1	Launched	DRD1|DRD2|HTR1A|HTR2A	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia
piracetam	NC(=O)CN1CCCC1=O	Launched	GRIA1|GRIA2|GRIA3|GRIA4	acetylcholine receptor agonist	neurology/psychiatry	senile dementia
pirarubicin	COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O[C@@H]6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO	Launched	TOP2A	topoisomerase inhibitor	oncology	breast cancer
pirenoxine	OC(=O)c1cc(=O)c2c3nc4ccccc4oc3cc(=O)c2[nH]1	Launched		AGE inhibitor	ophthalmology	cataracts
pirenperone	Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1	Preclinical	HTR2A|HTR7	serotonin receptor antagonist		
pirenzepine	CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc3cccnc23)CC1	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
piretanide	NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc1ccccc1)C(O)=O	Launched	SLC12A1|SLC12A2	glucocorticoid receptor agonist	cardiology	hypertension, edema
pirfenidone	Cc1ccc(=O)n(c1)-c1ccccc1	Launched	FURIN|TNF	TGF beta receptor inhibitor	pulmonary	idiopathic pulmonary fibrosis (IPF)
piribedil	C(N1CCN(CC1)c1ncccn1)c1ccc2OCOc2c1	Launched	ADRA1A|ADRA2A|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR2B	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease, dizziness
piricapiron	CC1(C)[C@@H]2CC[C@@]1(C)C(=O)N(CCCCN1CCN(CC1)c1ccccn1)C2=O |&1:3	Phase 2	HTR2A	dopamine receptor antagonist, serotonin receptor antagonist		
pirinixic-acid	Cc1cccc(Nc2cc(Cl)nc(SCC(O)=O)n2)c1C	Preclinical	PPARA	PPAR receptor agonist		
pirlindole	Cc1ccc2n3CCN[C@H]4CCCc(c34)c2c1 |&1:9|	Launched	MAOA	monoamine oxidase inhibitor	neurology/psychiatry	depression
pirmenol	C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(c1ccccc1)c1ccccn1 |a:1	Preclinical		acetylcholine receptor inhibitor		
piroctone-olamine	C[C@@H](Cc1cc(C)cc(=O)n1O)CC(C)(C)C |&1:1|	Launched			infectious disease	fungal infection
pirodavir	CCOC(=O)c1ccc(OCCC2CCN(CC2)c2ccc(C)nn2)cc1	Phase 2				
piromidic-acid	CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1	Phase 2		bacterial DNA gyrase inhibitor		
piroxicam	CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O |t:12|	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology	osteoarthritis, rheumatoid arthritis
piroximone	CCc1[nH]c(=O)[nH]c1C(=O)c1ccncc1	Phase 2	PDE3A	phosphodiesterase inhibitor		
pirozadil	COc1cc(cc(OC)c1OC)C(=O)OCc1cccc(COC(=O)c2cc(OC)c(OC)c(OC)c2)n1	Preclinical		hypolipidemic		
pirquinozol	OCc1cc2c3ccccc3[nH]c(=O)n2n1	Phase 1		histamine release inhibitor		
PIT	[O-][N+]1=C(C(=O)c2ccccc12)c1ccccn1 |t:1|	Preclinical	P2RY1	purinergic receptor antagonist		
pitavastatin	O[C@H](C[C@H](O)\C=C\c1c(nc2ccccc2c1-c1ccc(F)cc1)C1CC1)CC(O)=O	Launched	HMGCR	HMGCR inhibitor	endocrinology	hyperlipidemia
pitolisant	Clc1ccc(CCCOCCCN2CCCCC2)cc1	Launched	HRH3	histamine receptor antagonist		
pivagabine	CC(C)(C)C(=O)NCCCC(O)=O	Launched	CRHR1|CRHR2	corticotropin releasing factor receptor antagonist	neurology/psychiatry	depression
pivampicillin	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c1ccccc1)C2=O	Launched		bacterial cell wall synthesis inhibitor	pulmonary, infectious disease	bronchitis, pneumonia, gynecologic infections
pivanex	CCCC(=O)OCOC(=O)C(C)(C)C	Phase 2	HDAC1|HDAC2|HDAC3|HDAC8	HDAC inhibitor		
pivmecillinam	CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](\N=C\N1CCCCCC1)C2=O	Launched		bacterial cell wall synthesis inhibitor	infectious disease	urinary tract infections, gram-negative bacterial infections
pixantrone	NCCNc1ccc(NCCN)c2C(=O)c3cnccc3C(=O)c12	Launched	TOP2A	topoisomerase inhibitor	hematologic malignancy	non-Hodgkin lymphoma (NHL)
pizotifen	CN1CCC(CC1)=C1c2ccsc2CCc2ccccc12	Launched	HTR1A|HTR2A|HTR2C	serotonin receptor antagonist	neurology/psychiatry	migraine headache
PI3K-IN-2	Nc1cc(c(cn1)-c1nc(nc(n1)N1CCOCC1)N1CCOCC1)C(F)(F)F	Phase 2		PI3K inhibitor		
PI3Kd-IN-2	COc1ncc(cc1NS(C)(=O)=O)-c1nc(nc2c(CN3CCC(CC3)C(C)(C)O)cc(F)cc12)N1CCOCC1	Preclinical		PI3K inhibitor		
PI4KIII-beta-inhibitor-1	COc1ccc(cc1S(=O)(=O)Nc1ccc(O)cc1)-c1sc(NC(=O)C(C)(C)C)nc1C	Preclinical	PI4K2B	PI4K inhibitor		
PJ-34	CN(C)CC(=O)Nc1ccc2[nH]c(=O)c3ccccc3c2c1	Preclinical	EEF2|PARP1|PARP15|PARP3	PARP inhibitor		
PK-THPP	CCCC(=O)C1CCN(CC1)c1ncnc2CCN(Cc12)C(=O)c1ccc(cc1)-c1ccccc1	Preclinical	KCNK9	potassium channel blocker		
PK-11195	CC[C@@H](C)N(C)C(=O)c1cc2ccccc2c(n1)-c1ccccc1Cl |&1:2	Phase 1	TSPO	benzodiazepine receptor antagonist		
PK-44	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1[nH]nc2c(F)c(F)ccc12	Preclinical	DPP4	dipeptidyl peptidase inhibitor		
PKI-166	C[C@@H](Nc1ncnc2[nH]c(cc12)-c1ccc(O)cc1)c1ccccc1	Phase 1	EGFR	EGFR inhibitor		
PKI-179	O=C(Nc1ccncc1)Nc1ccc(cc1)-c1nc(nc(n1)N1CCOCC1)N1[C@H]2CC[C@@H]1COC2 |&1:29	Phase 1	MTOR	mTOR inhibitor, PI3K inhibitor		
pleconaril	Cc1cc(CCCOc2c(C)cc(cc2C)-c2noc(n2)C(F)(F)F)on1	Phase 3				
plerixafor	C(N1CCCNCCNCCCNCC1)c1ccc(CN2CCCNCCNCCCNCC2)cc1	Launched	ACKR3|CCR4|CXCR4	CC chemokine receptor antagonist	hematologic malignancy	non-Hodgkin lymphoma (NHL), multiple myeloma
plicamycin	CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@H](O)[C@@H](C)O5)[C@@H](O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@H](O)[C@@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O	Launched		alcohol dehydrogenase inhibitor	oncology, endocrinology	testicular carcinoma, Paget's disease, hypercalcemia
plinabulin	CC(C)(C)c1nc[nH]c1\C=c1/[nH]c(=O)\c(=C\c2ccccc2)[nH]c1=O	Phase 3		tubulin polymerization inhibitor		
plovamer-acetate	N[C@@H](Cc1ccc(O)cc1)C(O)=O |&1:1	Phase 2	TAT|TH|YARS|YARS2			
plumbagin	CC1=CC(=O)c2c(O)cccc2C1=O |t:1|	Preclinical		anticancer agent		
plurisin-1	O=C(NNc1ccccc1)c1ccncc1	Preclinical	SCD	stearoyl-CoA desaturase inhibitor		
PLX4720	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F	Preclinical	BRAF|KDR	RAF inhibitor		
PLX51107	C[C@@H](c1ccccn1)n1cc(-c2ccc(cc2)C(O)=O)c2ncc(cc12)-c1c(C)noc1C	Phase 1		bromodomain inhibitor		
PLX647	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncccc34)cn2)cc1	Preclinical	CSF1R|KIT	receptor tyrosine protein kinase inhibitor		
PLX8394	F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2cnc(nc2)C2CC2)c1F	Phase 1/Phase 2	BRAF	serine/threonine kinase inhibitor		
PMPA	OC(=O)CC[C@@H](CP(O)(O)=O)C(O)=O |&1:5	Preclinical	FOLH1	glutamate receptor antagonist		
PNU-120596	COc1cc(OC)c(NC(=O)Nc2cc(C)on2)cc1Cl	Preclinical	CHRNA7	acetylcholine receptor agonist		
PNU-142633	CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1	Phase 2	HTR1D	serotonin receptor agonist		
PNU-177864	CCCNCCc1ccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)cc1	Preclinical	DRD3	dopamine receptor antagonist		
PNU-22394	Cn1c2CCNCCc2c2ccccc12	Phase 2	HTR2A|HTR2B|HTR2C|MAOA|MAOB	serotonin receptor agonist		
PNU-282987	Clc1ccc(cc1)C(=O)N[C@H]1CN2CCC1CC2	Preclinical	CHRNA7	cholinergic receptor agonist		
PNU-37883	C1CCC(CC1)N=C(NC12CC3CC(CC(C3)C1)C2)N1CCOCC1	Preclinical		ATP-sensitive potassium channel antagonist		
PNU-74654	Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1	Preclinical	CTNNB1|TCF4	beta-catenin inhibitor		
PNU-89843	Cc1cc2c(nc(nc2n1C)N1CCCC1)N1CCCC1	Preclinical	GABBR1	benzodiazepine receptor agonist		
pocapavir	COc1ccc(OCc2ccc(COc3c(Cl)cccc3Cl)cc2)c(Cl)c1	Preclinical		Enterovirus capsid inhibitor		
podophyllotoxin	COc1cc(cc(OC)c1OC)[C@H]1[C@@H]2[C@H](COC2=O)[C@@H](O)c2cc3OCOc3cc12	Launched	IGF1R|TOP2A|TUBA4A|TUBB	microtubule inhibitor, tubulin polymerization inhibitor	infectious disease	genital warts
polaprezinc	O=C1CCN[Zn]OC(=O)[C@H](Cc2cnc[nH]2)N1	Preclinical		chelating agent		
polidocanol	CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO	Launched		local anesthetic	dermatology	varicose veins
polydatin	OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O	Phase 2	ICAM1	ICAM1 expression inhibitor		
polyinosine	O[C@H]1[C@@H](COP(O)(O)=O)O[C@@H]([C@@H]1O)n1cnc2c1[nH]cnc2=O |&1:1	Preclinical	HPRT1|IMPDH2|PYGM	immunostimulant		
polymyxin-B-sulfate	CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O |&1:2	Launched		bacterial permeability inducer	ophthalmology	eye infection
polythiazide	CN1[C@@H](CSCC(F)(F)F)Nc2cc(Cl)c(cc2S1(=O)=O)S(N)(=O)=O |&1:2	Launched	SLC12A3	sodium/chloride cotransporter inhibitor	cardiology, gastroenterology, rheumatology, nephrology	edema, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis (AGN), chronic renal failure, hypertension
pomalidomide	Nc1cccc2C(=O)N([C@H]3CCC(=O)NC3=O)C(=O)c12 |&1:9	Launched		angiogenesis inhibitor, tumor necrosis factor production inhibitor	hematologic malignancy	multiple myeloma
ponatinib	CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1	Launched	ABL1|BCR|FGFR1|FGFR2|FGFR3|FGFR4|FLT3|KDR|KIT|LCK|LYN|PDGFRA|RET|SRC|TEK	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	hematologic malignancy	chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)
ponesimod	CCC\N=C1/S\C(=C/c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C	Phase 3	S1PR1	sphingosine 1-phosphate receptor agonist		
posaconazole	CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@@H]3CO[C@](Cn4cncn4)(C3)c3ccc(F)cc3F)cc2)c1=O	Launched	CYP3A4	sterol demethylase inhibitor	infectious disease	oropharyngeal candidiasis
potassium-canrenoate	C[C@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@@]2(O)CCC(O)=O |c:6	Launched	NR3C2	mineralocorticoid receptor antagonist	cardiology	edema
potassium-iodide	[K].I	Launched			pulmonary	asthma, bronchitis, emphysema
potassium-p-aminobenzoate	Nc1ccc(cc1)C(O)=O	Launched			rheumatology, urology	scleroderma, dermatomyositis, Peyronie's disease
pozanicline	Cc1ncccc1OC[C@@H]1CCCN1	Phase 2	CHRNA4|CHRNB2	acetylcholine receptor antagonist		
poziotinib	COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C	Phase 2	EGFR|ERBB2|ERBB4	EGFR inhibitor		
PP-1	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)C	Preclinical	HCK|RET	SRC inhibitor		
PP-121	Nc1ncnc2n(nc(-c3cnc4[nH]ccc4c3)c12)C1CCCC1	Preclinical	ABL1|EGFR|HCK|KDR|MTOR|PDGFRA|PIK3CA|PIK3CB|PIK3CD|PIK3CG|PRKDC|SRC	protein tyrosine kinase inhibitor		
PP-2	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc12	Preclinical	ABL1|LCK|RIPK2|SRC	SRC inhibitor		
PPT	CCCc1c(nn(c1-c1ccc(O)cc1)-c1ccc(O)cc1)-c1ccc(O)cc1	Preclinical	ESR1	estrogen receptor agonist		
PPY-A	COc1ccccc1-c1c[nH]c2ncc(cc12)-c1cncc(c1)C(=O)N(C)C	Preclinical	ABL1|BCR	Abl kinase inhibitor		
PP242	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc12	Preclinical	MTOR|PASK	mTOR inhibitor		
PQ-401	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12	Preclinical	IGF1R	IGF-1 inhibitor		
PR-619	Nc1nc(N)c(SC#N)cc1SC#N	Preclinical		DUB inhibitor		
practolol	CC(C)NC[C@@H](O)COc1ccc(NC(C)=O)cc1 |&1:5	Withdrawn	ADRB1	adrenergic receptor antagonist		
pradefovir	Nc1ncnc2n(CCOC[P@@]3(=O)OCC[C@H](O3)c3cccc(Cl)c3)cnc12	Phase 2		cytochrome P450 activator		
pralatrexate	Nc1nc(N)c2nc(C[C@@H](CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 |a:22	Launched	DHFR	dihydrofolate reductase inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
pralidoxime	C[n+]1ccccc1\C=N\O	Launched	ACHE|BCHE	acetylcholinesterase inhibitor	critical care	organophosphate poisoning
pralidoxime-chloride	C[n+]1ccccc1CN=O	Launched	ACHE|BCHE	acetylcholinesterase inhibitor	pulmonary	respiratory depression
pralmorelin	C[C@@H](N)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Launched		growth hormone releasing peptide ligand agonist		
pramipexole	CCCN[C@H]1CCc2nc(N)sc2C1	Launched	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease
pramiracetam	CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C	Launched		acetylcholine receptor agonist	neurology/psychiatry	senile dementia
pramoxine	CCCCOc1ccc(OCCCN2CCOCC2)cc1	Launched		topical anesthetic	dermatology	corticosteroid-responsive dermatoses
pranidipine	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OC\C=C\c1ccccc1 |r	Phase 2	CACNA1C	calcium channel blocker		
pranlukast	O=C(Nc1cccc2c1oc(cc2=O)-c1nn[nH]n1)c1ccc(OCCCCc2ccccc2)cc1	Launched	CYSLTR1|CYSLTR2|IL5|MUC2|NFKB1|RNASE3|TNF	leukotriene receptor antagonist	pulmonary	bronchospasm, asthma
pranoprofen	C[C@@H](C(O)=O)c1ccc2Oc3ncccc3Cc2c1 |&1:1	Launched		cyclooxygenase inhibitor	neurology/psychiatry	pain relief
prasterone-acetate	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:23|	Preclinical				
prasugrel	CC(=O)Oc1cc2CN(CCc2s1)[C@@H](C(=O)C1CC1)c1ccccc1F |&1:13	Launched	P2RY12	purinergic receptor antagonist	cardiology	myocardial infarction, acute coronary syndrome (ACS)
pravadoline	COc1ccc(cc1)C(=O)c1c(C)n(CCN2CCOCC2)c2ccccc12	Preclinical	CNR1|CNR2	cyclooxygenase inhibitor		
pravastatin	CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H]12 |c:13	Launched	HMGCR|SLCO1B1	HMGCR inhibitor	endocrinology, cardiology	hypercholesterolemia, myocardial infarction, hyperlipidemia
praziquantel	O=C(C1CCCCC1)N1C[C@H]2N(CCc3ccccc23)C(=O)C1 |&1:10	Launched		anthelmintic agent	infectious disease	gastrointestinal parasites, cystic hydatid disease, schistosomiasis
prazosin	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)c1ccco1	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|KCNH2|KCNH6|KCNH7	adrenergic receptor antagonist	cardiology	hypertension
PRE-084	O=C(OCCN1CCOCC1)C1(CCCCC1)c1ccccc1	Preclinical	SIGMAR1	sigma receptor agonist		
preclamol	CCCN1CCC[C@@H](C1)c1cccc(O)c1	Phase 2	DRD2	dopamine receptor agonist		
prednicarbate	CCOC(=O)O[C@@]1(CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C)C(=O)COC(=O)CC |a:6	Launched	PLA2G1B	phospholipase activator	dermatology, ophthalmology, neurology/psychiatry	eczema, contact dermatitis, itching
prednisolone	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |a:1	Launched	NR3C1|NR3C2|SERPINA6	glucocorticoid receptor agonist	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis
prednisolone-acetate	CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:19	Launched	NR3C1	glucocorticoid receptor agonist	ophthalmology, dermatology, infectious disease	conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis
prednisolone-hemisuccinate	C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC(O)=O |a:1	Preclinical	NR3C1	glucocorticoid receptor agonist		
prednisolone-sodium-phosphate	[H][C@@]12CC[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C |c:31	Launched	NR3C1	glucocorticoid receptor agonist	allergy, pulmonary, ophthalmology, infectious disease, rheumatology, endocrinology, neurology/psychiatry, gastroenterology, hematology	allergic rhinitis, asthma, contact dermatitis, mycosis, lupus, hypercalcemia, thyroiditis, congenital adrenal hyperplasia, multiple sclerosis, ulcerative colitis, enteritis, thrombocythemia, pneumonia, meningitis, psoriatic arthritis, rheumatoid arthritis
prednisolone-tebutate	CC(C)(C)CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@H]3[C@@H](O)C[C@]12C |a:11	Launched		anti-inflammatory agent		
prednisone	C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO |c:13	Launched	HSD11B1|NR3C1	glucocorticoid receptor agonist	endocrinology, rheumatology, infectious disease, dermatology, ophthalmology, hematology, gastroenterology, neurology/psychiatry	congenital adrenal hyperplasia, hypercalcemia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, bursitis, osteoarthritis, epicondylitis, dermatomyositis, psoriasis, mycosis, conjunctivitis, anemia, ulcerative colitis, enteritis, multiple sclerosis, meningitis
pregnenolone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C |t:9|	Launched	SULT2B1	glutamate receptor modulator	rheumatology	rheumatoid arthritis
pregnenolone-succinate	CC(=O)[C@H]1CC[C@H]2[C@H]3CC=C4C[C@H](CC[C@]4(C)[C@@H]3CC[C@]12C)OC(=O)CCC(O)=O |a:3	Preclinical	CYP17A1	GABA receptor negative allosteric modulator		
preladenant	COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1	Phase 3	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
prenylamine	C[C@@H](Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1 |&2:1|	Withdrawn		calcium channel blocker		
presatovir	Cc1cn2nc(cc2nc1N1CC[C@H](N)C1)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(C)(=O)=O	Phase 2		RSV fusion inhibitor		
pretomanid	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1	Launched	FASN	nitric oxide donor		
pridinol	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	Launched		muscle relaxant	neurology/psychiatry	muscle relaxant
pridopidine	CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O	Phase 2		dopamine receptor antagonist		
prilocaine	CCCN[C@@H](C)C(=O)Nc1ccccc1C |&1:4	Launched	SCN5A	local anesthetic	neurology/psychiatry	anesthetic
primaquine	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |r|	Launched		antimalarial agent, DNA inhibitor	infectious disease	malaria
PRIMA1	OCC1(CO)N2CCC(CC2)C1=O	Preclinical	ACHE	TP53 inhibitor		
primidone	CCC1(C(=O)NCNC1=O)c1ccccc1	Launched	CHRNA4|CHRNA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA2|GRIK2|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	GABA receptor antagonist	neurology/psychiatry	seizures
prinaberel	Oc1cc(C=C)c2oc(nc2c1)-c1ccc(O)c(F)c1	Phase 2	ESR2|NCOA1	estrogen receptor agonist		
prinomastat	CC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)c1ccc(Oc2ccncc2)cc1	Phase 3		matrix metalloprotease inhibitor		
priralfinamide	C[C@H](NCc1ccc(OCc2ccccc2F)cc1)C(N)=O	Phase 3	CACNA1B	sodium channel blocker		
prisotinol	CC(C)N[C@H](C)Cc1ccc(O)cn1 |&1:4	Phase 2				
pritelivir	CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O	Phase 2		helicase primase inhibitor		
PRLX-93936	CCOc1ccccc1-n1c(CN2CCNCC2)nc2ccccc2c1=O	Phase 1/Phase 2		voltage-dependent anion selective channel protein inhibitor		
PRN1008	CC(C)(\C=C(/C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1	Preclinical		Bruton's tyrosine kinase (BTK) inhibitor		
PRN1371	CNc1ncc2cc(-c3c(Cl)c(OC)cc(OC)c3Cl)c(=O)n(CCCN3CCN(CC3)C(=O)C=C)c2n1	Phase 1		protein tyrosine kinase inhibitor		
proacipimox	COCc1c[n+]([O-])c(C)cn1	Phase 1		cholesterol inhibitor		
proadifen	CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1	Preclinical	NOS1	nitric oxide synthase inhibitor		
probenecid	CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O	Launched	PANX1|SLC22A11|SLC22A6|SLC22A8|SLCO1C1	uricosuric blocker	nephrology, rheumatology	hyperuricemia, gout
probucol	CC(C)(Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)Sc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C	Launched	ABCA1|ABCB11|CES1	atherogenesis inhibitor	cardiology	coronary artery disease (CAD)
procainamide	CCN(CC)CCNC(=O)c1ccc(N)cc1	Launched	DNMT1|SCN5A	sodium channel blocker	cardiology	ventricular arrhythmias, ventricular tachycardia (VT)
procaine	CCN(CC)CCOC(=O)c1ccc(N)cc1	Launched	CHRNA2|GRIN3A|HTR3A|KCNMA1|KCNMB1|KCNMB2|KCNMB3|KCNMB4|KCNN1|KCNN2|KCNN3|KCNN4|MAOA|MAOB|RYR1|RYR2|SCN10A|SLC6A3	HMGCR inhibitor	neurology/psychiatry	anesthetic
procarbazine	CNNCc1ccc(cc1)C(=O)NC(C)C	Launched		monoamine oxidase inhibitor	hematologic malignancy	Hodgkin's lymphoma
procaterol	CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12	Launched	ADRB2	adrenergic receptor agonist	pulmonary	asthma
prochlorperazine	CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	DRD1|DRD2|DRD3|DRD4	dopamine receptor antagonist	gastroenterology	nausea, vomiting
procodazole	OC(=O)CCc1nc2ccccc2[nH]1	Preclinical		immunostimulant		
procyanidin-B-2	O[C@H]1Cc2c(O)cc(O)c([C@@H]3[C@@H](O)[C@H](Oc4cc(O)cc(O)c34)c3ccc(O)c(O)c3)c2O[C@@H]1c1ccc(O)c(O)c1	Phase 2				
procyclidine	COc1cc(N[C@@H](C)CCCN)c2ncccc2c1 |&1:6|	Launched		acetylcholine receptor antagonist	neurology/psychiatry	parkinsonism, Parkinson's Disease, akathisia, dystonia
procysteine	OC(=O)[C@@H]1CSC(=O)N1	Phase 3		glutathione synthase stimulant		
profenamine	CCN(CC)[C@@H](C)CN1c2ccccc2Sc2ccccc12 |&1:5|	Launched	CHRM1	butyrylcholinesterase inhibitor, cholinergic receptor antagonist	neurology/psychiatry	Parkinson's Disease
proflavine-hemisulfate	Nc1ccc2cc3ccc(N)cc3nc2c1	Phase 2	F2	topical anesthetic		
progesterone	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |t:10|	Launched	CATSPER1|CATSPER2|CATSPER3|CATSPER4|CYP17A1|ESR1|NR3C2|OPRK1|PGR|TRPC5	progesterone receptor agonist	obstetrics/gynecology, endocrinology	infertility, amenorrhea
proglumetacin	CCCN(CCC)C(=O)[C@@H](CCC(=O)OCCCN1CCN(CCOC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)CC1)NC(=O)c1ccccc1 |&1:9	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
proglumide	CCCN(CCC)C(=O)[C@@H](CCC(O)=O)NC(=O)c1ccccc1 |&1:9|	Withdrawn	CCKAR|CCKBR	CCK receptor antagonist		
proguanil	CC(C)NC(=N)N=C(N)Nc1ccc(Cl)cc1	Launched	DHFR	dihydrofolate reductase inhibitor	infectious disease	malaria
prolylleucylglycinamide	CC(C)C[C@@H](NC(=O)[C@H]1CCCN1)C(=O)NCC(N)=O |&1:4	Phase 2		melanocyte-stimulating hormone release inhibitor		
promazine	CN(C)CCCN1c2ccccc2Sc2ccccc12	Launched	ADRA1A|ADRA1B|ADRA1D|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|HRH1|HTR2A|HTR2C	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
promestriene	CCCOc1ccc2[C@H]3CC[C@]4(C)[C@H](CC[C@H]4[C@@H]3CCc2c1)OC	Launched	ESR1	estrogen receptor agonist	endocrinology	androgenetic alopecia
promethazine	CC(CN1c2ccccc2Sc2ccccc12)N(C)C	Launched	HRH1	histamine receptor antagonist	neurology/psychiatry, allergy	sedative, allergic rhinitis
pronethalol	CC(C)NC[C@@H](O)c1ccc2ccccc2c1 |&1:5	Withdrawn		adrenergic receptor antagonist		
propacetamol	CCN(CC)CC(=O)Oc1ccc(NC(C)=O)cc1	Launched	PTGS2	cyclooxygenase inhibitor	endocrinology, neurology/psychiatry	fever, pain relief
propafenone	CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1 |&1:5	Launched	ADRB1|ADRB2|KCNA5|KCNH2	antiarrhythmic	cardiology	atrial fibrillation (AF), ventricular tachycardia (VT), ventricular arrhythmias
propagermanium	OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O	Launched	CCR2	CCR agonist, interferon receptor agonist	infectious disease	hepatitis B
propantheline	CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc12)C(C)C	Launched	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor antagonist	gastroenterology	peptic ulcer disease (PUD)
propatylnitrate	CCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O	Launched			cardiology	angina pectoris
propentofylline	CCCn1cnc2n(C)c(=O)n(CCCCC(C)=O)c(=O)c12	Launched	PDE1A	adenosine reuptake inhibitor, phosphodiesterase inhibitor	neurology/psychiatry	stroke
propidium-iodide	CC[N+](C)(CC)CCC[n+]1c(-c2ccccc2)c2cc(N)ccc2c2ccc(N)cc12	Preclinical	ACHE			
propiolactone	O=C1CCO1	Launched			infectious disease	antiseptic
propiverine	CCCOC(C(=O)OC1CCN(C)CC1)(c1ccccc1)c1ccccc1	Launched	CHRM1	acetylcholine receptor antagonist	urology	urinary incontinence
propofol	CC(C)c1cccc(C(C)C)c1O	Launched	FAAH|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|SCN2A|SCN4A	benzodiazepine receptor agonist	neurology/psychiatry	anesthetic
propoxur	CNC(=O)Oc1ccccc1OC(C)C	Launched			infectious disease	flea control
propoxycaine	CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC	Launched		local anesthetic	neurology/psychiatry	anesthetic
propranolol	CC(C)NCC(O)COc1cccc2ccccc12	Launched	ADRB1|ADRB2	adrenergic receptor antagonist	cardiology, neurology/psychiatry	hypertension, angina pectoris, migraine headache
propranolol-(R)	CC(C)NC[C@@H](O)COc1cccc2ccccc12	Preclinical	ADRB2|ADRB3	adrenergic receptor antagonist		
propranolol-(S)	CC(C)NC[C@H](O)COc1cccc2ccccc12	Preclinical	ADRB1|HTR1A|HTR5A|SLC10A1	adrenergic receptor antagonist		
propyl-benzoate	CCCOC(=O)c1ccccc1	Launched				
propylene-glycol	C[C@@H](O)CO |&1:1	Launched				
propylhexedrine	CN[C@@H](C)CC1CCCCC1 |&1:2	Launched		adrenergic receptor agonist	otolaryngology, endocrinology, allergy	nasal congestion, fever, allergic rhinitis
propylparaben	CCCOC(=O)c1ccc(O)cc1	Launched				
propylthiouracil	CCCc1cc(=O)[nH]c(=S)[nH]1	Launched	DIO1|TPO	thyroid peroxidase inhibitor	endocrinology	hyperthyroidism, Grave's disease, goiter
propyphenazone	CC(C)c1c(C)n(C)n(-c2ccccc2)c1=O	Preclinical		anti-inflammatory agent		
proquazone	CC(C)n1c2cc(C)ccc2c(nc1=O)-c1ccccc1	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
proscillaridin-A	C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)c2ccc(=O)oc2)[C@H](O)[C@H](O)[C@H]1O |c:26|	Launched			cardiology	congestive heart failure, cardiac arrythmia
protionamide	CCCc1cc(ccn1)C(N)=S	Launched			infectious disease	tuberculosis
protirelin	NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1	Launched	TRHR	thyrotropin releasing hormone receptor agonist	radiology	thyroid function diagnostic
protoporphyrin-IX	Cc1c(C=C)c2cc3[nH]c(cc4[nH]c(cc5nc(cc1n2)c(C=C)c5C)c(C)c4CCC(O)=O)c(CCC(O)=O)c3C	Preclinical	HMOX1	heme oxygenase inhibitor		
protriptyline	CNCCCC1c2ccccc2C=Cc2ccccc12 |c:13|	Launched	SLC6A2|SLC6A4	tricyclic antidepressant	neurology/psychiatry	depression
proxodolol	Cc1noc(COc2ccccc2OC[C@@H](O)CNC(C)(C)C)n1 |&1:15|	Launched		adrenergic receptor antagonist		
proxyfan	C(COCc1ccccc1)Cc1cnc[nH]1	Preclinical	HRH3	histamine receptor modulator		
proxymetacaine	CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC	Launched	SCN10A|SCN5A	sodium channel blocker	neurology/psychiatry	anesthetic
Proxyphylline	C[C@@H](O)Cn1cnc2n(C)c(=O)n(C)c(=O)c12 |&1:1	Launched			pulmonary	asthma
PRT062070	CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1	Phase 2/Phase 3	SYK	JAK inhibitor, SYK inhibitor		
PRT062607	N[C@H]1CCCC[C@H]1Nc1ncc(C(N)=O)c(Nc2cccc(c2)-n2nccn2)n1	Phase 2	FGR|MAP3K9|SYK	SYK inhibitor		
PRT4165	O=C1C(=Cc2cccnc2)C(=O)c2ccccc12	Preclinical	PRC1	polycomb repressive complex inhibitor		
prucalopride	COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(N)c2CCOc12	Launched	HTR4	serotonin receptor agonist	gastroenterology	constipation
prulifloxacin	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCN(Cc2oc(=O)oc2C)CC1 |&1:1	Launched		bacterial DNA gyrase inhibitor	infectious disease, pulmonary, gastroenterology	urinary tract infections, bronchitis, diarrhea
pruvanserin	Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1	Phase 2	HTR2A|HTR2C	serotonin receptor antagonist		
PRX-07034	COc1cc(Cl)cc([C@H](C)Nc2cc(ccc2S(C)(=O)=O)N2CCNCC2)c1OC |&1:8	Phase 1		serotonin receptor antagonist		
PRX-08066	Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N	Phase 2	HTR2B	serotonin receptor antagonist		
PSB-06126	Nc1c2C(=O)c3ccccc3C(=O)c2c(Nc2cccc3ccccc23)cc1S(O)(=O)=O	Preclinical	ENTPD3	NTPDase inhibitor		
PSB-11	CC[C@@H]1CN2C(=N1)c1nc([nH]c1N(C)C2=O)-c1ccccc1 |c:5|	Preclinical	ADORA1|ADORA2A|ADORA3	adenosine receptor antagonist		
PSB-1115	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(O)(=O)=O	Preclinical	ADORA1|ADORA2B|ADORA3	adenosine receptor antagonist		
PSB-36	[H][C@]12C[C@H]3C[C@]([H])(C[C@]3(C1)c1nc3n(CCCO)c(=O)n(CCCC)c(=O)c3[nH]1)C2 |r	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
PSB-603	CCCn1c(=O)[nH]c2nc([nH]c2c1=O)-c1ccc(cc1)S(=O)(=O)N1CCN(CC1)c1ccc(Cl)cc1	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
PSI-6130	C[C@@]1(F)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O	Phase 1		RNA polymerase inhibitor		
PSI-697	OC(=O)c1c(O)c(Cc2ccc(Cl)cc2)nc2c3CCCCc3ccc12	Phase 1		P selectin inhibitor		
PSI-7976	CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Preclinical		HCV inhibitor		
PSN-375963	CCCCC1CCC(CC1)c1nc(no1)-c1ccncc1	Preclinical	GPR119	glucose dependent insulinotropic receptor agonist		
PSNCBAM-1	Clc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1	Preclinical	CNR1	cannabinoid receptor modulator		
psoralen	O=c1ccc2cc3ccoc3cc2o1	Launched	MAOA|MAOB		dermatology	psoriasis, eczema, vitiligo
PS178990	Cc1c(Cl)c(ccc1N1C(=O)[C@@H]2[C@H](O)CCN2C1=O)C#N	Phase 1	AR	androgen receptor modulator		
PT-2385	CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2CC(F)(F)[C@@H](O)c12	Phase 1	EPAS1	hypoxia inducible factor inhibitor		
PTC-028	Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(cc2)C(F)(F)F)n1	Preclinical		BMI-1 inhibitor		
PTC-209	COc1cc(Br)c(Nc2nc(cs2)-c2c(C)nc3ncccn23)c(Br)c1	Preclinical		BMI-1 inhibitor		
pterostilbene	COc1cc(OC)cc(\C=C\c2ccc(O)cc2)c1	Phase 2/Phase 3	PTGS2	cyclooxygenase inhibitor, PPAR receptor agonist		
PU-H71	CC(C)NCCCn1c(Sc2cc3OCOc3cc2I)nc2c(N)ncnc12	Phase 1	HSP90AA1	HSP inhibitor		
puerarin	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O	Phase 2		serotonin receptor antagonist		
pumosetrag	O=C(N[C@H]1CN2CCC1CC2)c1c[nH]c2ccsc2c1=O	Phase 2	HTR3A|HTR4	serotonin receptor agonist		
purmorphamine	C1CCC(CC1)n1cnc2c(Nc3ccc(cc3)N3CCOCC3)nc(Oc3cccc4ccccc34)nc12	Preclinical	SMO	smoothened receptor agonist		
puromycin	COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)n2cnc3c(ncnc23)N(C)C)cc1	Preclinical	NHP2L1|RPL10L|RPL11|RPL13A|RPL15|RPL19|RPL23|RPL23A|RPL26L1|RPL3|RPL37|RPL8|RSL24D1	protein synthesis inhibitor		
purvalanol-A	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical	CDK1|CDK2|CDK4|CDK5|CSNK1G3|RPS6KA1|SRC	CDK inhibitor		
purvalanol-B	CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1	Preclinical	CDK2|CDK4|CDK5|MAPK1|MAPK3|SRPK2	tyrosine kinase inhibitor		
putrescine	NCCCCN	Phase 2	AMD1|KCNJ4|ODC1	tissue transglutaminase inhibitor		
PX-12	CC[C@@H](C)SSc1ncc[nH]1 |&1:2	Phase 2	CNR1|TXN	thioredoxin inhibitor		
PX-478	N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O |&1:1|	Phase 1		hypoxia inducible factor inhibitor		
PYM50028	C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC[C@@H]5C[C@@H](O)CC[C@]5(C)[C@H]4CC[C@]23C)O[C@]11CC[C@H](C)CO1	Phase 2		neurotrophic agent		
PYR-41	CCOC(=O)c1ccc(cc1)N1NC(=O)\C(=C\c2ccc(o2)[N+]([O-])=O)C1=O	Preclinical		ubiquitin activating enzyme inhibitor		
pyrantel	OC(=O)c1cc2ccccc2c(Cc2c(O)c(cc3ccccc23)C(O)=O)c1O	Launched		acetylcholine receptor agonist, nicotinic receptor agonist	infectious disease	gastrointestinal roundworms
pyrantel-pamoate	CN1CCCN=C1\C=C\c1cccs1 |c:5|	Launched		neuromuscular blocker	infectious disease	hookworm, tapeworm
pyrazinamide	NC(=O)c1cnccn1	Launched	FASN	fatty acid synthase inhibitor	infectious disease	tuberculosis
pyrazinoylguanidine	NC(=N)NC(=O)c1cnccn1	Phase 1		diuretic		
pyrazolanthrone	O=C1c2ccccc2-c2[nH]nc3cccc1c23	Preclinical	MAPK10|MAPK8|MAPK8IP1|MAPK9|TTK	JNK inhibitor		
pyrazoloacridine	COc1ccc2nc3c(ccc4n(CCCN(C)C)[nH]c(c34)c2c1)[N+]([O-])=O	Phase 2	TOP1|TOP2A	topoisomerase inhibitor		
pyrethrins	CC(C)=C[C@@H]1[C@@H](C(=O)O[C@H]2CC(=O)C(C\C=C/C=C)=C2C)C1(C)C |c:18|	Launched			infectious disease	flea control
pyridoxal	Cc1ncc(CO)c(C=O)c1O	Launched	PDXK		neurology/psychiatry	epilepsy
pyridoxal-isonicotinoyl-hydrazone	Cc1ncc(CO)c(\C=N\NC(=O)c2ccncc2)c1O	Phase 2		apoptosis stimulant		
pyridoxamine	Cc1ncc(CO)c(CN)c1O	Phase 3		AGE inhibitor		
pyridoxine	Cc1ncc(CO)c(CO)c1O	Launched	DDC|PDXK	vitamin B	metabolism	vitamin B6 deficiency
pyrimethamine	CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1	Launched	DHFR|SLC47A1	dihydrofolate reductase inhibitor	infectious disease	malaria
pyrintegrin	Oc1ccc2N(CCCc2c1)c1ccnc(Nc2ccc(cc2)S(=O)(=O)NCC2CC2)n1	Preclinical		integrin signaling activator		
pyrithione-zinc	O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1	Launched	KCNQ1|KCNQ2|KCNQ4|KCNQ5	ATP synthase inhibitor	dermatology	dandruff, cosmetic
pyrithyldione	CCC1(CC)C(=O)NC=CC1=O |c:8|	Withdrawn		psychoactive drug		
pyritinol	Cc1ncc(CSSCc2cnc(C)c(O)c2CO)c(CO)c1O	Launched			rheumatology, neurology/psychiatry	rheumatoid arthritis, senile dementia
pyronaridine	COc1ccc2nc3cc(Cl)ccc3c(Nc3cc(CN4CCCC4)c(O)c(CN4CCCC4)c3)c2n1	Phase 3		antimalarial agent		
pyrotinib	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\[C@H]1CCCN1C	Phase 3		kinase inhibitor		
pyroxamide	ONC(=O)CCCCCCC(=O)Nc1cccnc1	Phase 1	HDAC1	HDAC inhibitor		
pyrrolidine-dithiocarbamate	SC(=S)N1CCCC1	Preclinical	HSD11B1|RELA	NFkB pathway inhibitor		
pyrvinium-pamoate	CN(C)c1ccc2[n+](C)c(\C=C\c3cc(C)n(c3C)-c3ccccc3)ccc2c1	Launched	AR	androgen receptor antagonist	infectious disease	pinworm
PZ-2891	CC(C)c1ccc(CC(=O)N2CCN(CC2)c2ccc(nn2)C#N)cc1	Preclinical		pantothenate kinase activator		
P22077	CC(=O)c1cc(c(Sc2ccc(F)cc2F)s1)[N+]([O-])=O	Preclinical	USP7	ubiquitin specific protease inhibitor		
P276-00	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl	Phase 2	CDK1|CDK4|CDK9	CDK inhibitor		
P5091	CC(=O)c1cc(c(Sc2cccc(Cl)c2Cl)s1)[N+]([O-])=O	Preclinical	USP7	ubiquitin specific protease inhibitor		
P7C3	O[C@@H](CNc1ccccc1)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:1	Preclinical	NAMPT	NAMPT inhibitor		
Q-203	CCc1nc2ccc(Cl)cn2c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(OC(F)(F)F)cc1	Phase 2		ATP synthase inhibitor		
quazinone	CC1N2Cc3c(Cl)cccc3NC2=NC1=O |c:14|	Phase 2	PDE3A|PDE3B	phosphodiesterase inhibitor		
quercetin	Oc1cc(O)c2c(c1)oc(-c1ccc(O)c(O)c1)c(O)c2=O	Launched	ATP5A1|ATP5B|ATP5C1|HCK|HIBCH|PIK3CG|PIM1|STK17B|UGT3A1	polar auxin transport inhibitor	neurology/psychiatry, allergy	fatigue, allergic rhinitis, drowsiness
quetiapine	OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2ccccc12 |t:13|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A2	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia, bipolar disorder
quiflapon	CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12	Phase 2	ALOX5|ALOX5AP	leukotriene synthesis inhibitor		
quinagolide	CCCN1C[C@H](C[C@@H]2Cc3c(O)cccc3C[C@@H]12)NS(=O)(=O)N(CC)CC	Launched	DRD2	dopamine receptor agonist	endocrinology	hyperprolactinemia
quinapril	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension, congestive heart failure, angioedema
quinaprilat	C[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1Cc2ccccc2C[C@H]1C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension, angioedema
quinelorane	CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@@H]12	Phase 3	DRD2|DRD3	dopamine receptor agonist		
quinestrol	C[C@]12CC[C@H]3[C@@H](CCc4cc(OC5CCCC5)ccc34)[C@@H]1CC[C@@]2(O)C#C	Launched	ESR1|ESR2	estrogen receptor agonist	endocrinology	menopause
quinethazone	CC[C@H]1NC(=O)c2cc(c(Cl)cc2N1)S(N)(=O)=O |&1:2	Launched		thiazide diuretic	cardiology	hypertension
quinidine	COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	Launched	KCNA5|KCNA7|KCNH1|KCNH2|KCNH5|KCNK1|KCNK6|SCN5A|SLC29A4	sodium channel blocker	infectious disease, cardiology	malaria, atrial fibrillation (AF), ventricular arrhythmias
quinine	COc1ccc2nccc([C@@H](O)[C@@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1	Launched	GP9|KCNB2|KCNN4|SLC29A4	hemozoin biocrystallization inhibitor	infectious disease	malaria
quinine-ethyl-carbonate	CCOC(=O)O[C@H]([C@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccc(OC)cc12	Launched			infectious disease	malaria
quinolinic-acid	OC(=O)c1cccnc1C(O)=O	Preclinical		glutamate receptor agonist		
quinpirol-(-)	CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@@H]12	Phase 2	DRD1|DRD2|DRD3|DRD4|HTR1A|HTR2A|HTR2B|HTR2C	dopamine receptor agonist		
quipazine	C1CN(CCN1)c1ccc2ccccc2n1	Preclinical	HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR6|SLC6A4	serotonin receptor agonist		
quizartinib	CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1	Phase 3	CSF1R|FLT3|KIT|PDGFRA|PDGFRB|RET	FLT3 inhibitor		
QX-222	Cc1cccc(C)c1NC(=O)C[N+](C)(C)C	Preclinical		sodium channel blocker		
QX-314	CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C	Preclinical	MAPK14|TGFBR1	sodium channel blocker		
R-121919	CCCN(CCC)c1cc(C)nc2c(c(C)nn12)-c1cnc(cc1C)N(C)C	Preclinical		CRF receptor antagonist		
R-1479	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]2O)c(=O)n1	Phase 1		HCV inhibitor		
R-1485	Fc1ccccc1S(=O)(=O)N1CCOc2c(cccc12)N1CCNCC1	Phase 1	HTR6	serotonin receptor antagonist		
R-1487	Cn1c2nc(NC3CCOCC3)ncc2cc(Oc2ccc(F)cc2F)c1=O	Phase 1		p38 MAPK inhibitor		
R-268712	Cc1cccc(n1)-c1n[nH]cc1-c1ccc(F)c(c1)-c1cnn(CCO)c1	Preclinical	TGFBR1	serine/threonine kinase inhibitor		
R-428	Nc1nc(Nc2ccc3CC[C@@H](CCc3c2)N2CCCC2)nn1-c1cc2CCCc3ccccc3-c2nn1	Phase 2	AXL	AXL kinase inhibitor		
R-59022	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccccc1)c1ccc(F)cc1	Preclinical	DGKA	diacylglycerol kinase inhibitor, protein kinase inhibitor		
R-96544	COc1cccc(CCc2ccccc2OCC[C@@H]2C[C@@H](O)CN2C)c1	Preclinical	HTR2A	serotonin receptor antagonist		
rabeprazole	COCCCOc1ccnc(C[S@@](=O)c2nc3ccccc3[nH]2)c1C |r|	Launched	ATP4A	ATPase inhibitor, gastrin inhibitor	gastroenterology	gastroesophageal reflux disease (GERD), duodenal ulcer disease, Zollinger-Ellison syndrome
rac-BHFF	CC(C)(C)c1cc2c(OC(=O)[C@@]2(O)C(F)(F)F)c(c1)C(C)(C)C |&1:11	Preclinical	GABBR1	GABA receptor positive allosteric modulator		
racecadotril	CC(=O)SC[C@@H](Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1 |&1:5	Launched	MME	enkephalinase inhibitor	gastroenterology	diarrhea
raclopride	CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC	Launched	DRD2|DRD3|HTR1A	dopamine receptor antagonist		
ractopamine	C[C@@H](CCc1ccc(O)cc1)NC[C@@H](O)c1ccc(O)cc1 |&1:1	Launched		adrenergic receptor agonist	endocrinology	weight-gain aid
radafaxine	C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1	Phase 2	SLC6A3	dopamine-norepinephrine reuptake inhibitor		
radezolid	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(F)c1)-c1ccc(CNCc2cn[nH]n2)cc1	Phase 2		bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor		
radiprodil	Fc1ccc(CC2CCN(CC2)C(=O)C(=O)Nc2ccc3[nH]c(=O)oc3c2)cc1	Phase 2		acetylcholine receptor antagonist		
radotinib	Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cnccn3)c2)cc(c1)C(F)(F)F	Phase 3		Bcr-Abl kinase inhibitor		
RAD140	[H][C@@](C)(O)[C@@]([H])(Nc1ccc(C#N)c(Cl)c1C)c1nnc(o1)-c1ccc(cc1)C#N	Phase 1		androgen receptor modulator		
RAF265	Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2cc(Oc3ccnc(c3)-c3ncc([nH]3)C(F)(F)F)ccc12	Phase 2	BRAF	RAF inhibitor, VEGFR inhibitor		
RAF709	Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc(OC2CCOCC2)c(c1)N1CCOCC1	Preclinical		RAF inhibitor		
ralinepag	OC(=O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1 |r|	Phase 3		IP1 prostacyclin receptor agonist		
raloxifene	Oc1ccc(cc1)-c1sc2cc(O)ccc2c1C(=O)c1ccc(OCCN2CCCCC2)cc1	Launched	ESR1|ESR2	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	orthopedics, oncology	osteoporosis, breast cancer
raltegravir	Cc1nnc(o1)C(=O)NC(C)(C)c1nc(C(=O)NCc2ccc(F)cc2)c(O)c(=O)n1C	Launched		HIV integrase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
raltitrexed	CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	FPGS|TYMS	thymidylate synthase inhibitor	oncology	mesothelioma
ramatroban	OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1	Launched	PTGDR2|TBXA2R	prostanoid receptor antagonist	cardiology, pulmonary	coronary artery disease (CAD), asthma
ramelteon	CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12	Launched	MTNR1A|MTNR1B	melatonin receptor agonist	neurology/psychiatry	insomnia
ramifenazone	CC(C)Nc1c(C)n(C)n(-c2ccccc2)c1=O	Launched		cyclooxygenase inhibitor	neurology/psychiatry, endocrinology	pain relief, fever
ramipril	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension
ramosetron	Cn1cc(C(=O)[C@@H]2CCc3nc[nH]c3C2)c2ccccc12	Launched	HTR3A	serotonin receptor antagonist	gastroenterology	nausea, vomiting, irritable bowel syndrome
ranirestat	Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O	Phase 3	AKR1B1	aldose reductase inhibitor		
ranitidine	CN=C(C[N+]([O-])=O)NCCSCc1ccc(CN(C)C)o1	Launched	HRH2	histamine receptor antagonist	gastroenterology	heartburn
ranolazine	COc1ccccc1OC[C@@H](O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1 |&1:10|	Launched	SCN10A|SCN9A	sodium channel blocker	cardiology	chronic stable angina
rapastinel	C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O	Phase 2		glutamate receptor agonist		
rasagiline	C#CCN[C@@H]1CCc2ccccc12	Launched	BCL2|MAOB	monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease
rauwolscine	COC(=O)[C@@H]1[C@@H](O)CC[C@@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	Preclinical	ADRA2A|ADRA2B|ADRA2C|HTR1B|HTR1D|HTR1E|HTR2B	adrenergic receptor antagonist		
ravoxertinib	Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1	Phase 1	MAPK1|MAPK3	ERK1 and ERK2 phosphorylation inhibitor		
ravuconazole	C[C@@H](c1nc(cs1)-c1ccc(cc1)C#N)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Phase 2		sterol demethylase inhibitor		
RBC8	COc1ccc(OC)c(c1)[C@@H]1C(C#N)C(=N)Oc2[nH]nc(c12)-c1ccc2ccccc2c1 |&1:10	Preclinical	RALA|RALB	Ral GTPase inhibitor		
rebamipide	OC(=O)[C@@H](Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1 |&1:3	Launched	FPR1	free radical scavenger	gastroenterology	peptic ulcer disease (PUD), gastritis
rebastinib	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(nn3-c3ccc4ncccc4c3)C(C)(C)C)c(F)c2)ccn1	Phase 1/Phase 2	ABL1|BCR|FGR|FLT3|HCK|LYN|SRC	Bcr-Abl kinase inhibitor, TIE tyrosine kinase inhibitor, VEGFR inhibitor		
reboxetine	CCOc1ccccc1O[C@@H]([C@H]1CNCCO1)c1ccccc1 |&1:10	Launched	SLC6A2	adrenergic receptor antagonist	neurology/psychiatry	depression
Rec-15/2615	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C	Phase 2	ADRA1A	adrenergic receptor antagonist		
refametinib	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1	Phase 2	MAP2K1|MAP2K2	MEK inhibitor		
regadenoson	CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1	Launched	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor agonist	radiology	myocardial perfusion imaging (MPI)
regorafenib	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1	Launched	ABL1|BRAF|DDR2|EPHA2|FGFR1|FGFR2|FLT1|FLT4|FRK|KDR|KIT|MAPK11|NTRK1|PDGFRA|PDGFRB|RAF1|RET|TEK	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	oncology	colorectal cancer, gastrointestinal stromal tumors (GIST)
relcovaptan	COc1ccc(cc1OC)S(=O)(=O)N1[C@@H](C(=O)N2CCC[C@H]2C(N)=O)[C@](O)(c2cc(Cl)ccc12)c1ccccc1Cl	Phase 2	AVPR1A|AVPR1B|AVPR2|OXTR	vasopressin receptor antagonist		
relebactam	OS(=O)(=O)ON1[C@H]2CN([C@@H](CC2)C(=O)NC2CCNCC2)C1=O	Launched		beta lactamase inhibitor		
relugolix	CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccc(OC)nn3)c(=O)c2c1CN(C)C	Phase 3		gonadotropin releasing factor hormone receptor antagonist		
remacemide	C[C@@](Cc1ccccc1)(NC(=O)CN)c1ccccc1 |&1:1|	Phase 3	GRIN1	glutamate receptor antagonist		
remetinostat	COC(=O)c1ccc(OC(=O)CCCCCCC(=O)NO)cc1	Phase 2		HDAC inhibitor		
remimazolam	COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc12 |t:7|	Phase 3	GABBR1	benzodiazepine receptor agonist		
remodelin	N#Cc1ccc(cc1)-c1csc(NN=C2CCCC2)n1	Preclinical	NAT10	transferase inhibitor		
remoxipride	CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC	Withdrawn	DRD2|DRD3|DRD4|HTR2A|SIGMAR1	dopamine receptor antagonist		
repaglinide	CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(O)=O	Launched	ABCC8|KCNJ11|PPARG	insulin secretagogue	endocrinology	diabetes mellitus
reparixin	CC(C)Cc1ccc(cc1)[C@@H](C)C(=O)NS(C)(=O)=O	Phase 3	CXCR1|CXCR2	CC chemokine receptor antagonist		
repotrectinib	C[C@H]1CNC(=O)c2cnn3ccc(N[C@H](C)c4cc(F)ccc4O1)nc23	Phase 1/Phase 2		receptor tyrosine protein kinase inhibitor		
repsox	Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1	Preclinical	TGFBR1	TGF beta receptor inhibitor		
resatorvid	CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl |t:5|	Phase 3	TLR4	toll-like receptor inhibitor		
reserpine	CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1	Launched	SLC18A1|SLC18A2	vesicular monoamine transporter inhibitor	cardiology	hypertension
resibufogenin	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1	Phase 2		Na/K-ATPase inhibitor		
resiquimod	CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O	Phase 3	TLR7|TLR8	toll-like receptor agonist		
resmetirom	CC(C)c1cc(Oc2c(Cl)cc(cc2Cl)-n2nc(C#N)c(=O)[nH]c2=O)nnc1O	Phase 3		thyroid hormone receptor agonist		
resminostat	CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)NO)c1	Phase 2	HDAC1|HDAC3|HDAC6|HDAC8	HDAC inhibitor		
resorcinol	Oc1cccc(O)c1	Launched	CA12|CA14|CA2|PTGS1	phosphodiesterase inhibitor	dermatology	acne vulgaris (AV), eczema, psoriasis, seborrheic dermatitis
resorcinol-monoacetate	CC(=O)Oc1cccc(O)c1	Launched		antiseptic		
resveratrol	Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1	Launched	CSNK2A1|NQO2|PTGS1|PTGS2	cytochrome P450 inhibitor, SIRT activator		
retagliptin	COC(=O)c1nc(n2CCN(Cc12)C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F)C(F)(F)F	Phase 1		dipeptidyl peptidase inhibitor		
retapamulin	C[C@@H]1CC[C@@]23CCC(=O)[C@H]2[C@]1(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CS[C@H]1C[C@@H]2CC[C@H](C1)N2C	Launched		protein synthesis inhibitor	infectious disease	impetigo
retaspimycin	CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)cc(O)c2NCC=C |c:17	Phase 3	HSP90AA1	HSP inhibitor		
retinaldehyde	C\C(\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C)=C/C=O |c:9|	Launched			dermatology	cosmetic
retinol	C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:12|	Launched	ALDH1A1|ALDH1A2|ALDH1A3|DHRS3|DHRS4|LRAT|NR2C2|RBP1|RBP3|RDH11|RDH12|RDH13|RDH14|RDH5|RDH8|RETSAT|RHO|RLBP1|RXRA|RXRB|RXRG	retinoid receptor ligand	dermatology	cosmetic, acne vulgaris (AV), keratosis
retinyl-acetate	CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:15|	Launched				
retinyl-palmitate	CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C |c:29|	Launched				
REV-5901	CCCCC[C@@H](O)c1cccc(OCc2ccc3ccccc3n2)c1 |&1:5	Phase 2	ALOX5	leukotriene receptor antagonist, lipoxygenase inhibitor		
revaprazan	C[C@H]1N(CCc2ccccc12)c1nc(Nc2ccc(F)cc2)nc(C)c1C |&1:1	Launched	ATP4A	potassium-competitive acid antagonist	gastroenterology	gastritis
revefenacin	CN(CCN1CCC(CC1)OC(=O)Nc1ccccc1-c1ccccc1)C(=O)c1ccc(CN2CCC(CC2)C(N)=O)cc1	Launched		cholinergic receptor antagonist		
reversan	O=C(NCCCN1CCOCC1)c1cnn2c(cc(nc12)-c1ccccc1)-c1ccccc1	Preclinical	ABCC1	MRP inhibitor		
reversine	C1CCC(CC1)Nc1nc(Nc2ccc(cc2)N2CCOCC2)nc2nc[nH]c12	Preclinical	AURKB|INCENP|MAP2K1	Aurora kinase inhibitor		
reynoutrin	O[C@@H]1CO[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2ccc(O)c(O)c2)[C@H](O)[C@H]1O	Preclinical		antioxidant		
RGB-286638	COCCN1CCN(Cc2ccc(cc2)-c2n[nH]c3-c4cccc(NC(=O)NN5CCOCC5)c4C(=O)c23)CC1	Phase 1	CDK1|CDK2|CDK3|CDK4|CDK5|CDK6|CDK7|CDK9|FLT3|GSK3B|JAK2|MAP3K7|MAPK9	CDK inhibitor		
RGFP966	Nc1cc(F)ccc1NC(=O)\C=C\c1cnn(C\C=C\c2ccccc2)c1	Preclinical	HDAC3	HDAC inhibitor		
RGX-104	C[C@H](CCOc1cccc(CC(O)=O)c1)N(CC(c1ccccc1)c1ccccc1)Cc1cccc(c1Cl)C(F)(F)F	Phase 1		LXR agonist		
RG108	OC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)c2ccccc2C1=O	Preclinical	DNMT1|DNMT3B	DNA methyltransferase inhibitor		
RG1530	COc1cc2N=C3NN=C(C)C3N=C(c3ccccc3Cl)c2cc1F |t:5	Phase 1	FGFR1|FGFR2	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
RG2833	Cc1ccc(cc1)C(=O)NCCCCCC(=O)Nc1ccccc1N	Phase 1	HDAC1|HDAC3	HDAC inhibitor		
RG4733	CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O	Phase 2	PSEN1	gamma secretase inhibitor		
RG7112	CCOc1cc(ccc1C1=N[C@@](C)(c2ccc(Cl)cc2)[C@](C)(N1C(=O)N1CCN(CCCS(C)(=O)=O)CC1)c1ccc(Cl)cc1)C(C)(C)C |t:10|	Phase 1	MDM2	MDM inhibitor		
RG7800	CCc1nc(C)cn2nc(cc12)-c1cc(=O)n2cc(cc(C)c2n1)C1CCN(C)CC1	Preclinical		RNA splicing modifier		
RG7834	COCCCOc1cc2C[C@@H](C(C)C)n3cc(C(O)=O)c(=O)cc3-c2cc1OC	Preclinical		antiviral		
RHC-80267	O=C(NCCCCCCNC(=O)ON=C1CCCCC1)ON=C1CCCCC1	Preclinical	DAGLA|DAGLB	triacylglycerol lipase inhibitor		
rhein	OC(=O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	Phase 1	HSP90AA1			
rheochrysidin	COc1cc(O)c2C(=O)c3c(O)cc(C)cc3C(=O)c2c1	Preclinical	PTPN1	protein tyrosine kinase inhibitor		
rhodamine-123	COC(=O)c1ccccc1-c1c2ccc(N)cc2[o+]c2cc(N)ccc12	Phase 1				
RI-1	ClC1=C(N2CCOCC2)C(=O)N(C1=O)c1ccc(Cl)c(Cl)c1 |c:1|	Preclinical	RAD51			
ribavirin	NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Launched	ADK|ENPP1|IMPDH1|IMPDH2|NT5C2	antiviral	infectious disease	hepatitis C
ribitol	OC[C@H](O)[C@H](O)[C@H](O)CO	Preclinical				
ribociclib	CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1	Launched	CDK4|CDK6	CDK inhibitor	oncology	breast cancer
riboflavin	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C	Launched	BLVRB|RFK	vitamin B	gastroenterology	jaundice
riboflavin-tetrabutyrate	CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](Cn1c2cc(C)c(C)cc2nc2c1nc(=O)[nH]c2=O)OC(=O)CCC	Preclinical		antioxidant		
riboflavin-5-phosphate-sodium	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)c2cc1C	Launched	BLVRB|DHODH|DPYD|HAO1|HAO2|MT-ND1|NOS1|PNPO|POR|PPCDC|RFK|RPS6KA4|SGK1			
ribostamycin	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O	Launched	P4HB	bacterial 30S ribosomal subunit inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
ribostamycin-sulfate	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@@H]2O[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O |a:2	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections
ricinoleic-acid	CCCCCC[C@@H](O)C\C=C/CCCCCCCC(O)=O	Launched	PTGER3	prostanoid receptor agonist		
ridinilazole	c1cc(ccn1)-c1nc2ccc(cc2[nH]1)-c1ccc2nc([nH]c2c1)-c1ccncc1	Phase 3		antibacterial		
rifabutin	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2C4=NC5(CCN(CC(C)C)CC5)NC4=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(=O)c2c(O)c3C |c:36	Launched		protein synthesis inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
rifampin	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:33	Launched	NR1I2|SLCO1A2|SLCO1B1|SLCO1B3	RNA polymerase inhibitor	infectious disease	tuberculosis, meningitis
rifamycin	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23	Launched	SLCO1A2|SLCO1B1|SLCO1B3|SLCO2B1	DNA directed RNA polymerase inhibitor	infectious disease	tuberculosis, leprosy
rifamycin-sv	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:23	Phase 3		RNA synthesis inhibitor		
rifapentine	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:38	Launched	CYP2C8|CYP2C9|CYP3A4	RNA polymerase inhibitor	infectious disease	tuberculosis
rifaximin	CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4nc5cc(C)ccn5c4c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C |c:32	Launched		RNA synthesis inhibitor	gastroenterology	diarrhea, irritable bowel syndrome, hepatic encephalopathy (HE)
rigosertib	COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1	Phase 3	PLK1	cell cycle inhibitor, PLK inhibitor		
rilapladib	COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12	Phase 2		phospholipase inhibitor		
rilmenidine	C1CC1C(NC1=NCCO1)C1CC1 |t:6|	Launched	ADRA2A	adrenergic receptor agonist, imidazoline receptor agonist	cardiology	hypertension
rilpivirine	Cc1cc(\C=C\C#N)cc(C)c1Nc1ccnc(Nc2ccc(cc2)C#N)n1	Launched	NR1I2|SCN10A	non-nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
riluzole	Nc1nc2ccc(OC(F)(F)F)cc2s1	Launched	KCNK10|KCNK2|KCNK4|KCNN4|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A|SLC7A11	glutamate inhibitor	neurology/psychiatry	amyotrophic lateral sclerosis (ALS)
rimantadine	C[C@@H](N)C12CC3CC(CC(C3)C1)C2 |&1:1	Launched		antiviral, RNA synthesis inhibitor	infectious disease	influenza A virus infection
rimcazole	C[C@H]1CN(CCCn2c3ccccc3c3ccccc23)C[C@@H](C)N1	Phase 1	SIGMAR1	sigma receptor antagonist		
rimegepant	N[C@H]1[C@@H](CC[C@@H](OC(=O)N2CCC(CC2)n2c3cccnc3[nH]c2=O)c2ncccc12)c1cccc(F)c1F	Launched	CALCA	calcitonin antagonist		
rimeporide	Cc1cc(c(cc1C(=O)NC(N)=N)S(C)(=O)=O)S(C)(=O)=O	Phase 1		sodium/hydrogen exchanger inhibitor		
rimexolone	CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C |c:17	Launched	NR3C1|SERPINA6	glucocorticoid receptor agonist	ophthalmology	anterior uveitis
rimonabant	Cc1c(nn(c1-c1ccc(Cl)cc1)-c1ccc(Cl)cc1Cl)C(=O)NN1CCCCC1	Withdrawn	CNR1|GPR55	cannabinoid receptor antagonist		
riociguat	COC(=O)N(C)c1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncccc12	Launched	GUCY1A2|GUCY1A3|GUCY1B2|GUCY1B3	guanylate cyclase stimulant	cardiology	hypertension
riodipine	COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC |c:4	Phase 2		calcium channel blocker		
riodoxol	Oc1c(I)cc(I)c(O)c1I	Launched		other antibiotic		
ripasudil	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12	Launched	ROCK1|ROCK2	rho associated kinase inhibitor	ophthalmology	glaucoma, ocular hypertension
ripazepam	CCn1nc(C)c2NC(=O)CN=C(c12)c1ccccc1 |c:11|	Phase 2	GABRA1	benzodiazepine receptor agonist		
ripretinib	CCn1c2cc(NC)ncc2cc(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)c1=O	Phase 3		receptor tyrosine protein kinase inhibitor		
risdiplam	Cc1cn2nc(cc(C)c2n1)-c1cc(=O)n2cc(ccc2n1)N1CCNC2(CC2)C1	Phase 2/Phase 3		RNA splicing inhibitor		
risedronate	OC(Cc1cccnc1)(P(O)(O)=O)P(O)(O)=O	Launched	FDPS	osteoclast inhibitor	orthopedics, endocrinology	osteoporosis, Paget's disease
rislenemdaz	Cc1ccc(COC(=O)N2CC[C@H](CNc3ncccn3)[C@H](F)C2)cc1	Preclinical		ionotropic glutamate receptor antagonist		
risperidone	Cc1nc2CCCCn2c(=O)c1CCN1CCC(CC1)c1noc2cc(F)ccc12	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|HTR7	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia, bipolar disorder, irritability
RITA	OCc1ccc(s1)-c1ccc(o1)-c1ccc(CO)s1	Preclinical	MDM2	MDM inhibitor		
ritanserin	Cc1nc2sccn2c(=O)c1CCN1CCC(CC1)=C(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3	ADRA1A|ADRA1B|ADRA1D|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	serotonin receptor antagonist		
ritodrine	C[C@@H](NCCc1ccc(O)cc1)[C@@H](O)c1ccc(O)cc1 |&1:1	Withdrawn		adrenergic receptor agonist	obstetrics/gynecology	premature labor
ritonavir	CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1	Launched	CYP1A2|CYP2B6|CYP2C19|CYP2C8|CYP2C9|CYP2D6|CYP2E1|CYP3A4|CYP3A5|CYP3A7	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
rivanicline	CNCC\C=C\c1cccnc1	Phase 2	CHRNA4|CHRNB2|CXCL8	acetylcholine receptor agonist		
rivaroxaban	Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O	Launched	F10	coagulation factor inhibitor	neurology/psychiatry, hematology, cardiology	stroke, systemic embolism, atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE)
rivastigmine	CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C	Launched	ACHE|BCHE	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease, Parkinson's Disease, senile dementia
rizatriptan	CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12	Launched	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	serotonin receptor agonist	neurology/psychiatry	migraine headache
RKI-1447	Oc1cccc(CNC(=O)Nc2nc(cs2)-c2ccncc2)c1	Preclinical	CDC42BPA|DMPK|LIMK1|MYLK|PAK1|PKN1|ROCK1|ROCK2	rho associated kinase inhibitor		
RLX	O=c1n2CCCCCc2nc2ccccc12	Preclinical				
RMC-4550	C[C@@H]1OCC2(CCN(CC2)c2nc(C)c(nc2CO)-c2cccc(Cl)c2Cl)[C@@H]1N	Preclinical		SHIP2 phosphatase inhibitor		
RN-1	CN1CCN(CC1)C(=O)CN[C@@H]1C[C@H]1c1ccc(OCc2ccccc2)cc1	Preclinical	KDM1A	histone demethylase inhibitor		
RN-1734	CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl	Preclinical	TRPV4	TRPV antagonist		
RN-1747	[O-][N+](=O)c1cc(Cl)ccc1S(=O)(=O)N1CCN(Cc2ccccc2)CC1	Preclinical	TRPV4	TRPV agonist		
Ro-04-5595	COc1cc2CCN(C)[C@@H](CCc3ccc(Cl)cc3)c2cc1O |&1:9|	Preclinical	GRIN2B	glutamate receptor antagonist		
Ro-08-2750	Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O	Preclinical	NGF|NGFR	NGF binding inhibitor		
Ro-10-5824	Cc1ncc(CN2CCC(=CC2)c2ccccc2)c(N)n1 |c:9|	Preclinical	DRD4	dopamine receptor agonist		
Ro-106-9920	O=[S@@](c1ccccc1)c1ccc2nnnn2n1 |&1:1	Preclinical		NFkB pathway inhibitor		
Ro-1138452	CC(C)Oc1ccc(Cc2ccc(NC3=NCCN3)cc2)cc1 |t:14|	Preclinical	PTGIR	prostanoid receptor antagonist		
Ro-15-4513	CCOC(=O)c1ncn-2c1CN(C)C(=O)c1cc(ccc-21)N=[N+]=[N-]	Preclinical	GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB2|GABRG2	GABA benzodiazepine site receptor inverse agonist		
Ro-19-4605	CN1Cc2c(ncn2-c2ccsc2C1=O)C(=O)OC(C)(C)C	Preclinical	GABRA1|GABRA2|GABRA3|GABRA5	GABA benzodiazepine site receptor inverse agonist		
Ro-20-1724	CCCCOc1cc(C[C@H]2CNC(=O)N2)ccc1OC |&1:9	Preclinical	PDE3A|PDE4A|PDE4B|PDE4C|PDE4D	phosphodiesterase inhibitor		
Ro-25-6981	C[C@@H](CN1CCC(Cc2ccccc2)CC1)[C@@H](O)c1ccc(O)cc1	Preclinical	GRIN2B	glutamate receptor antagonist, monamine transporter modulator		
Ro-28-1675	CS(=O)(=O)c1ccc(cc1)[C@@H](CC1CCCC1)C(=O)Nc1nccs1	Preclinical	GCK	glucokinase activator		
Ro-3	COc1cc(Cc2cnc(N)nc2N)c(cc1OC)C(C)C	Preclinical	P2RX3	purinergic receptor antagonist		
Ro-3306	O=C1N=C(NCc2cccs2)S\C1=C/c1ccc2ncccc2c1 |t:2|	Preclinical	CDK1	CDK inhibitor		
Ro-48-6791	CCCN(CCC)Cc1nc(no1)-c1ncn-2c1CN(C)C(=O)c1cc(F)ccc-21	Preclinical		GABA receptor modulator		
Ro-48-8071	CN(CCCCCCOc1ccc(C(=O)c2ccc(Br)cc2)c(F)c1)CC=C	Preclinical	LSS	oxidosqualene cyclase inhibitor		
Ro-4987655	OCCONC(=O)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F	Phase 1	MAP2K1	MEK inhibitor		
Ro-5028442	CN(C)CCn1cc(C(=O)N2CCC3(CC2)OCc2ccccc32)c2ccc(Cl)cc12	Phase 1		vasopressin receptor antagonist		
Ro-5126766	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F	Phase 1	BRAF|MAP2K1|MAP2K2|RAF1	MEK inhibitor, RAF inhibitor		
Ro-5263397	Cc1c(F)cccc1[C@H]1COC(N)=N1 |c:13|	Preclinical		trace amine associated receptor agonist		
Ro-60-0175	C[C@H](N)Cn1ccc2cc(F)c(Cl)cc12	Preclinical	HTR2A|HTR2B|HTR2C	serotonin receptor agonist		
Ro-61-8048	COc1ccc(cc1OC)S(=O)(=O)Nc1nc(cs1)-c1cccc(c1)[N+]([O-])=O	Preclinical	KMO	kynurenine 3-monooxygenase inhibitor		
Ro-67-7476	Cc1ccc(cc1)S(=O)(=O)N1CCC[C@H]1c1ccc(F)cc1	Preclinical	GRM1	glutamate receptor positive allosteric modulator		
Ro-90-7501	Nc1ccc(cc1)-c1nc2ccc(cc2[nH]1)-c1nc2ccc(N)cc2[nH]1	Preclinical	APP	beta amyloid protein neurotoxicity inhibitor		
Ro-9187	Nc1ccn([C@@H]2O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]2O)c(=O)n1	Preclinical		HCV inhibitor		
robalzotan	NC(=O)c1ccc(F)c2OC[C@@H](Cc12)N(C1CCC1)C1CCC1	Phase 2	HTR1A	serotonin receptor antagonist		
roblitinib	COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N	Preclinical		FGFR inhibitor		
rociletinib	COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O	Phase 3	EGFR	EGFR inhibitor		
rocuronium	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCOCC1)[N+]1(CC=C)CCCC1	Launched	CHRM2|CHRNA2|HTR3A	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
rofecoxib	CS(=O)(=O)c1ccc(cc1)C1=C(C(=O)OC1)c1ccccc1 |t:11|	Withdrawn	ELN|PTGS2	cyclooxygenase inhibitor		
roflumilast	FC(F)Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl	Launched	PDE4A|PDE4B|PDE4C|PDE4D	phosphodiesterase inhibitor	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis
rogaratinib	COCc1c(CN2CCNC(=O)C2)n2ncnc(N)c2c1-c1cc2cc(C)cc(OC)c2s1	Phase 2/Phase 3		FGFR inhibitor		
rolapitant	[H][C@](C)(OC[C@]1(CC[C@]2(CCC(=O)N2)CN1)c1ccccc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F	Phase 3		neurokinin receptor antagonist		
rolipram	COc1ccc(cc1OC1CCCC1)[C@H]1CNC(=O)C1 |&1:14	Phase 3		phosphodiesterase inhibitor		
rolitetracycline	CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(O)=C(C(=O)NCN2CCCC2)C1=O)C(=O)c1c(O)cccc1[C@@]3(C)O |a:3	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
roluperidone	Fc1ccc(cc1)C(=O)CN1CCC(CN2Cc3ccccc3C2=O)CC1	Phase 2				
rolziracetam	O=C1CCC2CCC(=O)N12	Phase 2				
romidepsin	C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C |t:12|	Launched	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
ronidazole	Cn1c(COC(N)=O)ncc1[N+]([O-])=O	Launched		antiprotozoal agent	infectious disease	histomoniasis, dysentry
ropinirole	CCCN(CCC)CCc1cccc2NC(=O)Cc12	Launched	ADRA2A|ADRA2B|ADRA2C|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease, restless leg syndrome
ropivacaine	CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C	Launched	SCN10A	sodium channel blocker	neurology/psychiatry	anesthetic
roquinimex	CN(C(=O)c1c(O)c2ccccc2n(C)c1=O)c1ccccc1	Phase 3		angiogenesis inhibitor, tumor necrosis factor production inhibitor		
rosamicin	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\[C@]2(C)O[C@H]2[C@@H]1C |t:34|	Phase 2		protein synthesis inhibitor		
roscovitine	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	Phase 2	CDK2|CDK9	CDK inhibitor		
rose-bengal	OC(=O)c1c(Cl)c(Cl)c(Cl)c(Cl)c1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12	Launched		contrast agent, immunostimulant	radiology	diagnostic agent
rose-bengal-lactone	Oc1c(I)cc2c(Oc3c(I)c(O)c(I)cc3C22OC(=O)c3c2c(Cl)c(Cl)c(Cl)c3Cl)c1I	Launched		coloring agent	ophthalmology	staining agent
rosiglitazone	CN(CCOc1ccc(C[C@H]2SC(=O)NC2=O)cc1)c1ccccn1 |&1:10|	Withdrawn	FFAR1|PPARG|TRPC5|TRPM3	insulin sensitizer, PPAR receptor agonist		
rosiptor	[H][C@@]12CCC(=C)[C@@]1(C)CC[C@@]([H])([C@H]2CN)[C@@]1(C)CC[C@H](O)C[C@@H]1CO	Phase 2		SHIP1 phosphatase activator		
rosmarinic-acid	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1	Launched	MCL1|TYR	GABA transaminase inhibitor		
rosoxacin	CCn1cc(C(O)=O)c(=O)c2ccc(cc12)-c1ccncc1	Launched		topoisomerase inhibitor	infectious disease	urinary tract infections
rostafuroxine	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)c1ccoc1	Phase 2	ATP1A1	ATPase inhibitor		
rosuvastatin	CC(C)c1nc(nc(-c2ccc(F)cc2)c1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)N(C)S(C)(=O)=O	Launched	HMGCR	HMGCR inhibitor	endocrinology, cardiology	hyperlipidemia, dyslipidemia, hypertriglyceridemia, hypercholesterolemia, atherosclerosis
rotigotine	CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1	Launched	ADRA2B|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A	dopamine receptor agonist	neurology/psychiatry	Parkinson's Disease, restless leg syndrome
rotundine	COc1cc2CCN3Cc4c(C[C@H]3c2cc1OC)ccc(OC)c4OC	Launched	DRD1|DRD2|DRD3|HTR1A	serotonin receptor agonist	neurology/psychiatry	anxiety, sedative
rovazolac	CCOC(=O)Cn1nc(cc1-c1ccc(cc1)-c1cccc(c1)S(C)(=O)=O)C(F)(F)F	Preclinical		LXR agonist		
roxarsone	Oc1ccc(cc1[N+]([O-])=O)[As](O)(O)=O	Launched		antiprotozoal agent	endocrinology	weight-gain aid
roxatidine-acetate	CC(=O)OCC(=O)NCCCOc1cccc(CN2CCCCC2)c1	Launched	HRH2	histamine receptor antagonist	gastroenterology	Zollinger-Ellison syndrome, erosive esophagitis (EE), gastroesophageal reflux disease (GERD), gastritis
roxithromycin	CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)\C(=N/OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O	Launched	MLNR	bacterial 50S ribosomal subunit inhibitor	infectious disease	respiratory tract infections, urinary tract infections, skin infections
RP-001	CC(C)Oc1ccc(cc1C#N)-c1nc(no1)-c1cccc2[C@@H](CCc12)NCCC(O)=O |&1:22|	Preclinical	S1PR1	sphingosine 1-phosphate receptor agonist		
RP67580	COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1	Preclinical				
RQ-00203078	OC(=O)c1ccc(cc1)S(=O)(=O)N(Cc1ccc(OC(F)(F)F)cc1)c1ncc(cc1Cl)C(F)(F)F	Preclinical	TRPM8	transient receptor potential channel antagonist		
RRx-001	[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O	Phase 3	G6PD	glucose 6-phosphate dehydrogenase inhibitor		
RS-0481		Phase 2		immunostimulant		
RS-100329	Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O	Preclinical	ADRA1A|ADRA1D	adrenergic receptor antagonist		
RS-102221	COc1cc(OC)c(cc1NS(=O)(=O)c1ccc(cc1)C(F)(F)F)C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O	Preclinical	HTR2A|HTR2B|HTR2C	serotonin receptor antagonist		
RS-102895	FC(F)(F)c1ccc(CCN2CCC3(CC2)OC(=O)Nc2ccccc32)cc1	Preclinical	CCR2	CCR antagonist		
RS-127445	CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12	Phase 1	HTR2A|HTR2B|HTR2C	serotonin receptor antagonist		
RS-16566	CC(C)n1cnc2c(cc(Cl)cc12)C(=O)N[C@H]1C[N@@]2CC[C@H]1CC2	Preclinical		serotonin receptor antagonist		
RS-17053	CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1	Preclinical	ADRA1A|ADRA1D	adrenergic receptor antagonist		
RS-23597-190	COc1cc(N)c(Cl)cc1C(=O)OCCCN1CCCCC1	Preclinical	HTR4	serotonin receptor antagonist		
RS-39604	COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC2CCN(CCNS(C)(=O)=O)CC2)cc(OC)c1	Preclinical	HTR4	serotonin receptor antagonist		
RS-45041-190	Clc1cccc2CN(Cc12)C1=NCCN1 |t:12|	Preclinical		imidazoline receptor agonist		
RS-504393	Cc1oc(nc1CCN1CCC2(CC1)OC(=O)Nc1ccc(C)cc21)-c1ccccc1	Preclinical	CCL2|CCR2	CC chemokine receptor antagonist		
RS-56812	Cn1cc(C(=O)C(=O)N[C@H]2C[N@@]3CC[C@H]2CC3)c2ccccc12	Preclinical	HTR3A	serotonin receptor partial agonist		
RS-67333	CCCCN1CCC(CCC(=O)c2cc(Cl)c(N)cc2OC)CC1	Preclinical	HTR4	serotonin receptor partial agonist		
RS-67506	COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1	Preclinical	HTR4	serotonin receptor partial agonist		
RS-79948	CCS(=O)(=O)N1CCC[C@@H]2CN3CCc4cc(OC)ccc4[C@@H]3C[C@H]12	Preclinical	ADRA2A	adrenergic receptor antagonist		
RSV604	Fc1ccccc1NC(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2NC1=O |t:13|	Phase 2		RSV replication inhibitor		
RTA-408	CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 |t:19	Phase 2	NFE2L2	nitric oxide production inhibitor		
RU-SKI-43	CC[C@@H](C)CNCC(=O)N1CCc2sccc2[C@@H]1COc1cccc(C)c1 |&1:2	Preclinical	HHAT	hedgehog pathway inhibitor		
RU-24969	COc1ccc2[nH]cc(C3=CCNCC3)c2c1 |t:9|	Phase 1	HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C|HTR5A|HTR6	serotonin receptor agonist		
RU-28318	CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12 |t:5|	Phase 2	NR3C2	cytochrome P450 inhibitor		
RU-42173	CC(C)N[C@@H]1CCn2c3c(cccc3[nH]c2=O)[C@H]1O	Phase 2	ADRB2	adrenergic receptor agonist		
RU-58841	CC1(C)N(CCCCO)C(=O)N(C1=O)c1ccc(C#N)c(c1)C(F)(F)F	Phase 2	AR	androgen receptor antagonist		
rubitecan	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O	Phase 3	TOP1	topoisomerase inhibitor		
ruboxistaurin	CN(C)C[C@@H]1CCn2cc(C3=C(C(=O)NC3=O)c3cn(CCO1)c1ccccc31)c1ccccc21 |t:10|	Phase 3		PKC inhibitor		
rucaparib	CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23	Phase 3	PARP1|PARP2	PARP inhibitor		
rucinol	CCCCc1ccc(O)cc1O	Phase 1	TYR	tyrosinase inhibitor		
rufinamide	NC(=O)c1cn(Cc2c(F)cccc2F)nn1	Launched	GRM5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	voltage-gated sodium channel blocker	neurology/psychiatry	seizures
rufloxacin	CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(C(O)=O)c2=O	Launched		bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections
rupatadine	Cc1cncc(CN2CCC(CC2)=C2c3ccc(Cl)cc3CCc3cccnc23)c1	Launched	HRH1|PTAFR	histamine receptor antagonist, platelet activating factor receptor antagonist	allergy	allergic rhinitis, urticaria
rutaecarpine	O=c1n2CCc3c([nH]c4ccccc34)-c2nc2ccccc12	Preclinical	PTGS2	cyclooxygenase inhibitor		
rutin	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(O)cc(O)c4c3=O)-c3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched	AKR1C3	antioxidant, capillary stabilizing agent, nitric oxide scavenger	rheumatology, otolaryngology, gastroenterology, neurology/psychiatry, allergy	joint pain, nasal congestion, constipation, irritability, allergic rhinitis
ruxolitinib	N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Launched	JAK1|JAK2|JAK3|TYK2	JAK inhibitor	hematologic malignancy, hematology	myelofibrosis, polycythemia vera
ruxolitinib-(S)	N#CC[C@@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12	Preclinical	JAK1|JAK2	JAK inhibitor		
RV1729	COCCN(CCOC)C(=O)CCCC#Cc1cccc2nc(Cn3nc(-c4cccc(O)c4)c4c(N)ncnc34)n(Cc3ccccc3Cl)c(=O)c12	Phase 1		PI3K inhibitor		
RWJ-21757	Nc1nc(=O)c2n(CC=C)c(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	Phase 2	TLR7	toll-like receptor agonist		
RWJ-50271	Cc1c(cnn1-c1nc(cs1)-c1cccc(c1)C(F)(F)F)C(=O)NCCCO	Preclinical	ICAM1	integrin inhibitor		
RWJ-67657	OCCC#Cc1nc(c(-c2ccncc2)n1CCCc1ccccc1)-c1ccc(F)cc1	Phase 1	MAPK14|PTGS2	MAP kinase inhibitor		
RX-3117	Nc1ccn([C@H]2[C@H](O)[C@H](O)C(CO)=C2F)c(=O)n1 |c:12|	Phase 1/Phase 2	CDK2|DNMT1	CDK inhibitor, DNA synthesis inhibitor		
RX-821002	CO[C@]1(COc2ccccc2O1)C1=NCCN1 |&1:2	Preclinical	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	adrenergic receptor antagonist		
ryuvidine	Cc1nc2c(s1)C(=O)C=C(Nc1ccc(C)cc1)C2=O |t:9|	Preclinical	CDK2|CDK4	histone lysine methyltransferase inhibitor		
R112	Oc1cccc(Nc2ncc(F)c(Nc3cccc(O)c3)n2)c1	Phase 1	SYK	SYK inhibitor		
R306465	ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1	Phase 1		HDAC inhibitor		
R406	COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)Nc4n3)n2)cc(OC)c1OC	Phase 1	RET|SYK	SYK inhibitor		
R547	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(CC2)S(C)(=O)=O)nc1N	Phase 1	CDK1|CDK2|CDK4|CDK7	CDK inhibitor		
S-isopropylisothiourea	CC(C)SC(N)=N	Preclinical	NOS3	nitric oxide synthase inhibitor		
S-methylcysteine	CSC[C@H](N)C(O)=O	Phase 1	CTSD|MGMT			
S-nitrosoglutathione		Phase 1	PTPN1	nitric oxide stimulant		
S-sulfo-L-cysteine	N[C@@H](CSS(O)(=O)=O)C(O)=O	Preclinical		glutamate receptor agonist		
S-trityl-L-cysteine	N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(O)=O	Preclinical		mitotic kinesin inhibitor		
S-07662	Cc1oc2ccccc2c1CNC(=O)NCc1cccs1	Preclinical	NR1I3	CAR antagonist		
S-111	CC(C)=CCC[C@](C)(O)[C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@@]21C	Phase 2	PARP1	PARP inhibitor		
S-14506	COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1	Preclinical	HTR1A	serotonin receptor agonist		
S-17092	O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CCSC1	Preclinical		prolyl endopeptidase inhibitor		
S-3304	Cc1ccc(cc1)C#Cc1ccc(s1)S(=O)(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O	Phase 1/Phase 2		matrix metalloprotease inhibitor		
S-38093	NC(=O)c1ccc(OCCCN2C[C@@H]3CCC[C@@H]3C2)cc1 |r|	Preclinical		histamine receptor antagonist		
SA-47	CNC(=O)COC(=O)NCCC1CCN(CC1)c1cccc(C)n1	Preclinical	FAAH	FAAH inhibitor		
saccharin	O=C1NS(=O)(=O)c2ccccc12	Launched	CA1|CA12|CA2|CA9	DNA polymerase inhibitor		
saclofen	NC[C@@H](CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2	Preclinical	GABBR1|GABBR2|KCTD12|KCTD16|KCTD8	GABA receptor antagonist		
sacubitril	CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O	Launched	MME	neprilysin inhibitor	cardiology	congestive heart failure
sacubitrilat	[H]N([C@@H](C[C@@H](C)C(O)=O)Cc1ccc(cc1)-c1ccccc1)C(=O)CCC(O)=O	Preclinical		neprilysin inhibitor		
safflower-yellow	OC[C@H]1O[C@@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]1(O)C(=O)[C@@H](\C=C2/C(=O)C(=C(O)\C=C\c3ccc(O)cc3)C(=O)[C@@](O)([C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C2=O)C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C1=O |a:2	Preclinical		anti-inflammatory agent		
safinamide	C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O	Launched	MAOB	dopamine reuptake inhibitor, glutamate inhibitor, monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease
safingol	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO	Phase 1	TRPM3	PKC inhibitor		
safranal	CC1=C(C=O)C(C)(C)CC=C1 |c:1	Phase 2	GABBR1	benzodiazepine receptor agonist		
SAG	CN[C@H]1CC[C@@H](CC1)N(Cc1cccc(c1)-c1ccncc1)C(=O)c1sc2ccccc2c1Cl |r|	Preclinical	SMO|TRPC6	smoothened receptor agonist		
salazodine	COc1ccc(NS(=O)(=O)c2ccc(cc2)N=Nc2ccc(O)c(c2)C(O)=O)nn1	Phase 2				
salicin	OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@H](O)[C@@H](O)[C@@H]1O	Phase 1		anti-inflammatory agent		
salicyl-alcohol	OCc1ccccc1O	Preclinical				
salicylamide	NC(=O)c1ccccc1O	Launched		analgesic agent	neurology/psychiatry, endocrinology	pain relief, fever
salicylanilide	Oc1ccccc1C(=O)Nc1ccccc1	Preclinical		other antibiotic		
salicylic-acid	OC(=O)c1ccccc1O	Launched	AKR1C1|ASIC3|PTGS1|PTGS2	cyclooxygenase inhibitor, prostanoid receptor antagonist	dermatology, endocrinology, neurology/psychiatry	acne vulgaris (AV), fever, pain relief
salidroside	OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical	APP	beta amyloid protein neurotoxicity inhibitor		
salinomycin	CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)[C@H]3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O |c:46|	Launched			infectious disease	coccidiosis
salirasib	CC(C)=CCC\C(C)=C\CC\C(C)=C\CSc1ccccc1C(O)=O	Phase 2	TRPA1	mTOR inhibitor		
salmeterol	OCc1cc(ccc1O)[C@@H](O)CNCCCCCCOCCCCc1ccccc1 |&1:9|	Launched	ADRB2	adrenergic receptor agonist	pulmonary	asthma, chronic obstructive pulmonary disease (COPD), bronchospasm
salsolinol-1-carboxylic-acid	C[C@]1(NCCc2cc(O)c(O)cc12)C(O)=O |&1:1	Preclinical				
salubrinal	ClC(Cl)(Cl)[C@H](NC(=S)Nc1cccc2cccnc12)NC(=O)\C=C\c1ccccc1 |&1:4	Preclinical	EIF2S1	eukaryotic translation initiation factor inhibitor		
salvianolic-acid-A	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1	Phase 1		matrix metalloprotease inhibitor		
salvianolic-acid-B	OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c2O[C@H]([C@H](C(=O)O[C@H](Cc3ccc(O)c(O)c3)C(O)=O)c12)c1ccc(O)c(O)c1	Phase 2	MMP9	EGFR inhibitor, metalloproteinase inhibitor		
salvinorin-A	COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](C[C@]21C)c1ccoc1	Phase 1	OPRD1|OPRK1|OPRM1	opioid receptor agonist		
sal003	Clc1ccc(NC(=S)N[C@H](NC(=O)\C=C\c2ccccc2)C(Cl)(Cl)Cl)cc1 |&1:9	Preclinical	EIF2A	eukaryotic translation initiation factor inhibitor		
SAM-315	O=S(=O)(c1n[nH]c2ccc(cc12)N1CCNCC1)c1cccc2ccccc12	Preclinical		serotonin receptor antagonist		
sameridine	CCCCCCN1CCC(CC1)(C(=O)N(C)CC)c1ccccc1	Preclinical		opioid receptor modulator		
sanazole	COCCNC(=O)Cn1cnc(n1)[N+]([O-])=O	Phase 1				
sancycline	[H][C@@]12Cc3cccc(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2 |&1:19	Preclinical		antitumor agent		
sangivamycin	NC(=O)c1cn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c2ncnc(N)c12	Phase 1		DNA inhibitor		
sanguinarium-chloride	C[n+]1cc2c3OCOc3ccc2c2ccc3cc4OCOc4cc3c12	Phase 1	CASP3	apoptosis stimulant		
SANT-1	Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1	Preclinical	SHH|SMO	smoothened receptor antagonist		
SANT-2	CCOc1cc(cc(OCC)c1OCC)C(=O)Nc1ccc(Cl)c(c1)-c1nc2ccccc2[nH]1	Preclinical	SHH|SMO	smoothened receptor antagonist		
sapacitabine	CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1	Phase 3		DNA synthesis inhibitor		
sapropterin	C[C@H](O)[C@H](O)[C@H]1CNc2[nH]c(N)nc(=O)c2N1	Launched	NOS3|PAH|TH|TPH1	phenylalanine 4-hydroxylase stimulant	metabolism	hyperphenylalaninemia (HPA)
saquinavir	CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1	Launched	CYP3A4	HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
SAR-245409	COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1	Phase 1/Phase 2	MTOR|PIK3CG	PI3K inhibitor		
saracatinib	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1	Phase 2/Phase 3	ABL1|LCK|SRC|YES1	SRC inhibitor		
sarafloxacin	OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O	Launched		bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
sarcosine	CNCC(O)=O	Phase 2	SLC6A9	glycine transporter inhibitor		
sardomozide	NC(=N)N\N=C1/CCc2c1cccc2C(N)=N	Preclinical		S-adenosylmethionine decarboxylase inhibitor		
sari-59-801	CCc1noc(C)c1-c1[nH]c2ccccc2c1[C@@H](O)CN(C)C |&1:17	Phase 1				
saroglitazar	CCO[C@@H](Cc1ccc(OCCn2c(C)ccc2-c2ccc(SC)cc2)cc1)C(O)=O	Launched	PPARA|PPARG	PPAR receptor agonist	endocrinology, cardiology, gastroenterology	diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis (NASH)
sarpogrelate	COc1cccc(CCc2ccccc2OC[C@@H](CN(C)C)OC(=O)CCC(O)=O)c1 |&1:17|	Launched	HTR2A|HTR2B|HTR2C	serotonin receptor antagonist	endocrinology, cardiology, rheumatology	diabetes mellitus, angina pectoris, Raynaud's disease, atherosclerosis, Buerger's disease
SAR131675	CCn1c(N)c(C(=O)NC)c(=O)c2ccc(nc12)C#C[C@@](C)(O)COC	Preclinical	FLT4	VEGFR inhibitor		
SAR405	C[C@@H]1COCCN1c1cc(=O)n2CC[C@H](N(Cc3cncc(Cl)c3)c2n1)C(F)(F)F	Preclinical	PIK3C3	PI3K inhibitor		
SAR405838	CC(C)(C)C[C@@H]1N[C@H]([C@H](c2cccc(Cl)c2F)[C@]11C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@H]1CC[C@H](O)CC1	Phase 1	MDM2	MDM inhibitor		
SAR407899	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12	Phase 2	ROCK1	rho associated kinase inhibitor		
sasapyrine	OC(=O)c1ccccc1OC(=O)c1ccccc1O	Launched	PTGS1|PTGS2	NFkB pathway inhibitor	rheumatology	osteoarthritis, rheumatoid arthritis
satraplatin	CC(=O)O[Pt](N)(Cl)(Cl)(NC1CCCCC1)OC(C)=O	Phase 3		DNA alkylating agent		
savolitinib	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(nc12)-c1cnn(C)c1	Phase 3	MET	c-Met inhibitor		
saxagliptin	N[C@H](C(=O)N1[C@H]2C[C@H]2C[C@H]1C#N)[C@]12C[C@H]3C[C@H](C[C@](O)(C3)C1)C2	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
SB-200646	Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12	Preclinical	HTR2B|HTR2C	serotonin receptor antagonist		
SB-202190	Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1	Preclinical	AKT1|ALOX5|CHEK1|GSK3B|LCK|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1	p38 MAPK inhibitor		
SB-203186	O=C(OCCN1CCCCC1)c1c[nH]c2ccccc12	Preclinical	HTR4	serotonin receptor antagonist		
SB-203580	C[S@@](=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1 |&1:1|	Preclinical	AKT1|ALOX5|CHEK1|CYP2D6|CYP3A4|GAK|GSK3B|LCK|MAPK1|MAPK10|MAPK11|MAPK12|MAPK14|MAPK8|MAPK9|PRKCA|RAF1|RIPK2|ROCK1|RPS6KB1|SGK1|SRC|TNF	p38 MAPK inhibitor		
SB-205384	CC#CCOC(=O)c1c(C)nc2sc3C[C@@H](O)CCc3c2c1N |&1:15	Preclinical	GABRA3|GABRA5|GABRA6	GABA receptor modulator		
SB-206553	Cn1ccc2cc3N(CCc3cc12)C(=O)Nc1cccnc1	Preclinical	HTR2A|HTR2B|HTR2C	serotonin receptor antagonist		
SB-216641	COc1ccc(NC(=O)c2ccc(cc2)-c2ccc(cc2C)-c2noc(C)n2)cc1OCCN(C)C	Preclinical	HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	serotonin receptor antagonist		
SB-216763	Cn1cc(C2=C(C(=O)NC2=O)c2ccc(Cl)cc2Cl)c2ccccc12 |t:4|	Preclinical	CCNA2|CDK2|GSK3A|GSK3B	glycogen synthase kinase inhibitor		
SB-218078		Preclinical	CHEK1	CHK inhibitor		
SB-218795	COC(=O)[C@H](NC(=O)c1cc(nc2ccccc12)-c1ccccc1)c1ccccc1	Preclinical	TACR3	tachykinin antagonist		
SB-221284	CSc1cc2CCN(C(=O)Nc3cccnc3)c2cc1C(F)(F)F	Preclinical	HTR2A|HTR2B|HTR2C	serotonin receptor antagonist		
SB-222200	CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Preclinical	TACR3	tachykinin antagonist		
SB-225002	Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O	Preclinical	CXCR2	CC chemokine receptor antagonist		
SB-228357	COc1cc2CCN(C(=O)Nc3cc(F)cc(c3)-c3cccnc3)c2cc1C(F)(F)F	Preclinical	HTR2A|HTR2B|HTR2C	serotonin receptor antagonist		
SB-2343	CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1	Phase 1	MTOR|PIK3CA|PIK3CB|PIK3CD|PIK3CG	mTOR inhibitor, PI3K inhibitor		
SB-239063	COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1 |r|	Preclinical	MAPK11|MAPK14|PTGS2	p38 MAPK inhibitor		
SB-242235	COc1nccc(n1)-c1c(ncn1C1CCNCC1)-c1ccc(F)cc1	Phase 1	HSPB1|MAPK14	p38 MAPK inhibitor		
SB-243213	Cc1cc2CCN(C(=O)Nc3ccc(Oc4cccnc4C)nc3)c2cc1C(F)(F)F	Phase 1	HTR2A|HTR2B|HTR2C|HTR6	serotonin receptor inverse agonist		
SB-258585	COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1	Preclinical	HTR6	serotonin receptor antagonist		
SB-268262	CN(C(=O)c1ccc(c(c1)[N+]([O-])=O)[S@@](=O)c1nccs1)c1ccccc1C |&1:13	Preclinical	CALCA	calcitonin antagonist		
SB-269970	CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1	Preclinical	HTR7	serotonin receptor antagonist		
SB-271046	COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1	Phase 1	HTR6	serotonin receptor antagonist		
SB-297006	CCOC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1ccccc1	Preclinical	CCR3	CC chemokine receptor antagonist		
SB-328437	COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12	Preclinical		CCR antagonist		
SB-334867	Cc1nc2ccc(NC(=O)Nc3ccnc4cccnc34)cc2o1	Preclinical	HCRTR1|HCRTR2	orexin receptor antagonist		
SB-366791	COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1	Preclinical	TRPV1	TRPV antagonist		
SB-399885	COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(Cl)c1OC	Preclinical	HTR6	serotonin receptor antagonist		
SB-408124	CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1	Preclinical	HCRTR1|HCRTR2	orexin receptor antagonist		
SB-415286	Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl |t:6|	Preclinical	GSK3A|GSK3B|RPS6KB1	glycogen synthase kinase inhibitor		
SB-431542	NC(=O)c1ccc(cc1)-c1nc(c([nH]1)-c1ccc2OCOc2c1)-c1ccccn1	Preclinical	ACVR1C|TGFBR1	TGF beta receptor inhibitor		
SB-452533	CCN(CCNC(=O)Nc1ccccc1Br)c1cccc(C)c1	Preclinical	TRPV1	TRPV antagonist		
SB-505124	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2OCOc2c1)C(C)(C)C	Preclinical	TGFBR1	ALK tyrosine kinase receptor inhibitor		
SB-525334	Cc1cccc(n1)-c1nc([nH]c1-c1ccc2nccnc2c1)C(C)(C)C	Preclinical	TGFBR1	TGF beta receptor inhibitor		
SB-590885	CN(C)CCOc1ccc(cc1)-c1nc(c([nH]1)-c1ccc2\C(CCc2c1)=N\O)-c1ccncc1	Preclinical	BRAF	RAF inhibitor		
SB-612111	Cc1cccc2[C@@H](O)C[C@@H](CN3CCC(CC3)c3c(Cl)cccc3Cl)CCc12	Preclinical	OPRL1	nociceptin/orphanin FQ receptor antagonist		
SB-649868	Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(s1)-c1ccc(F)cc1	Phase 2		orexin receptor antagonist		
SB-657510	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(Cl)c(O[C@@H]2CCN(C)C2)c1	Preclinical	UTS2R	urotensin receptor antagonist		
SB-683698	COc1cccc(OC)c1-c1ccc(C[C@H](NC(=O)c2c(Cl)cccc2Cl)C(O)=O)cc1	Phase 1	ITGA4|ITGAV|ITGB1|ITGB7	integrin antagonist		
SB-705498	FC(F)(F)c1ccc(nc1)N1CC[C@H](C1)NC(=O)Nc1ccccc1Br	Phase 2	TRPV1	TRPV antagonist		
SB-706375	COc1cc(Br)c(cc1OC)S(=O)(=O)Nc1ccc(c(O[C@@H]2CCN(C)C2)c1)C(F)(F)F	Preclinical	UTS2R	urotensin receptor antagonist		
SB-742457	O=S(=O)(c1ccccc1)c1cnc2c(cccc2c1)N1CCNCC1	Phase 3	HTR6	serotonin receptor antagonist		
SB-743921	CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1	Phase 1/Phase 2	KIF11	kinesin-like spindle protein inhibitor		
SB-747651A	CCn1c(nc2cncc(CNC3CCNCC3)c12)-c1nonc1N	Preclinical	AKT1|AKT3|ROCK1|RPS6KA5|RPS6KB1	kinase inhibitor		
SB-756050	COc1ccc(cc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(OC)c(OC)c1	Phase 1	GPBAR1	G protein-coupled receptor agonist		
SB-772077B	CCn1c(nc2cncc(C(=O)N3CC[C@H](N)C3)c12)-c1nonc1N	Preclinical	ROCK1|ROCK2	rho associated kinase inhibitor		
SB-939	CCCCc1nc2cc(\C=C\C(=O)NO)ccc2n1CCN(CC)CC	Phase 3	HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC9	HDAC inhibitor		
SBE-13	COc1ccc(CCNCc2ccc(OCc3ccc(Cl)nc3)c(OC)c2)cc1OC	Preclinical	PLK1	PLK inhibitor		
SBHA	ONC(=O)CCCCCCC(=O)NO	Preclinical	HDAC1|HDAC3	HDAC inhibitor		
SBI-115	CCS(=O)(=O)c1ncc(Cl)c(n1)C(=O)Oc1cccc(C)c1	Preclinical		G protein-coupled receptor antagonist		
SC-10	CCCCCCCNS(=O)(=O)c1cccc2c(Cl)cccc12	Preclinical	PRKCA	protein kinase activator		
SC-12267	COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1 |t:16|	Phase 2	IL17A	dihydroorotate dehydrogenase inhibitor		
SC-144	Fc1ccc2c(c1)nc(NNC(=O)c1cnccn1)c1cccn21	Preclinical		P glycoprotein inhibitor		
SC-19220	CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12	Preclinical	PTGER1	prostanoid receptor antagonist		
SC-236	NS(=O)(=O)c1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	Preclinical	PTGS2	cyclooxygenase inhibitor		
SC-51089	Clc1ccc2Oc3ccccc3CN(C(=O)NNC(=O)CCc3ccncc3)c2c1	Preclinical	PTGER1	prostanoid receptor antagonist		
SC-560	COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F	Preclinical	PTGS1	cyclooxygenase inhibitor		
SC-9	Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1	Preclinical	PRKCA	protein tyrosine kinase activator		
scabertopin	[H][C@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(\C)=C/C |c:4	Preclinical		anticancer agent		
SCH-202676	CN=c1nc(-c2ccccc2)n(s1)-c1ccccc1	Preclinical	CHRM1|CHRM2|DRD1|DRD2	G protein-coupled receptor modulator		
SCH-221510	Cc1ccccc1C(N1[C@H]2CC[C@@H]1C[C@](O)(C2)c1ccccc1)c1ccccc1C |&1:9	Preclinical	OPRL1	nociceptin/orphanin FQ receptor agonist		
SCH-23390	CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c1ccccc1	Preclinical	DRD1|DRD5|HTR2C|KCNJ4|KCNJ6	dopamine receptor antagonist		
SCH-28080	Cc1nc2c(OCc3ccccc3)cccn2c1CC#N	Phase 1	ATP4A	ATPase inhibitor		
SCH-51344	COc1ccc2nc3n[nH]c(C)c3c(NCCOCCO)c2c1	Preclinical	NUDT1	MTH1 inhibitor		
SCH-58261	Nc1nc2n(CCc3ccccc3)ncc2c2nc(nn12)-c1ccco1	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
SCH-900776	Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1	Phase 2	CDK2|CHEK1	CHK inhibitor		
schisandrin-B	COc1cc2C[C@H](C)[C@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC |r|	Preclinical	ATR	antioxidant		
schisandrol-B	COc1cc2C[C@](C)(O)[C@@H](C)Cc3cc4OCOc4c(OC)c3-c2c(OC)c1OC	Phase 3		lipid peroxidase inhibitor		
sclareol	CC(O)(CC[C@H]1[C@](C)(O)CC[C@H]2C(C)(C)CCC[C@]12C)C=C |a:5	Preclinical				
sclareolide	C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2	Launched		other antifungal		
SCMC-Lys	N[C@@H](CSCC(O)=O)C(O)=O	Launched	GSTP1	mucolytic agent	pulmonary	chronic obstructive pulmonary disease (COPD)
scopine	CN1[C@H]2C[C@H](O)C[C@@H]1[C@H]1O[C@@H]21	Launched				
scopolamine	CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|SI	acetylcholine receptor antagonist	neurology/psychiatry, gastroenterology	motion sickness, vomiting, nausea
scopolamine-N-oxide	C[N@@+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1 |a:3	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor antagonist		
SCP-1	Oc1ccc(NC(=O)CN2C(=O)c3ccccc3S2(=O)=O)cc1	Phase 1		analgesic agent		
scriptaid	ONC(=O)CCCCCN1C(=O)c2cccc3cccc(C1=O)c23	Preclinical	HDAC1|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	HDAC inhibitor		
SCS	Oc1ccccc1\C=N\NC(=O)c1ccccc1O	Preclinical				
SD-0006	OCC(=O)N1CCC(CC1)c1[nH]nc(c1-c1ccncn1)-c1ccc(Cl)cc1	Phase 2		p38 MAPK inhibitor		
SD-169	NC(=O)c1ccc2[nH]ccc2c1	Preclinical	MAPK14	p38 MAPK inhibitor		
SD-208	Fc1ccc(Cl)cc1-c1nc(Nc2ccncc2)c2nccnc2n1	Preclinical	TGFBR1	TGF beta receptor inhibitor		
SD-2590	COCCN1CCC(CC1)(C(=O)NO)S(=O)(=O)c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1	Preclinical	MMP1|MMP13|MMP2	matrix metalloprotease inhibitor		
SDM25N	CC(=C)CN1CC[C@@]23[C@H]4Oc5c2c(C[C@@H]1[C@]3(O)Cc1c4[nH]c2ccccc12)ccc5O |a:7	Preclinical	OPRD1	opioid receptor antagonist		
SDZ-NKT-343	CN(Cc1ccccc1)C(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+]([O-])=O	Phase 1	TACR1	tachykinin antagonist		
SDZ-SER-082	CN1CC[C@@H]2CN3CCc4cccc([C@@H]2C1)c34	Preclinical	HTR2A|HTR2B|HTR2C	serotonin receptor antagonist		
SDZ-WAG-994	CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCCC3)ncnc12	Phase 2	ADORA1	adenosine receptor agonist		
SDZ-205-557	CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC	Preclinical	HTR3A|HTR3B	serotonin receptor antagonist		
SDZ-21009	CC(C)OC(=O)c1cc2c(OC[C@@H](O)CNC(C)(C)C)cccc2[nH]1 |&1:12	Preclinical	HTR1A|HTR1B	adrenergic receptor antagonist, serotonin receptor antagonist		
SDZ-220-040	N[C@@H](Cc1cc(cc(CP(O)(O)=O)c1O)-c1ccc(Cl)cc1Cl)C(O)=O	Preclinical	GRIN1	glutamate receptor antagonist		
SDZ-220-581	N[C@@H](Cc1cc(CP(O)(O)=O)cc(c1)-c1ccccc1Cl)C(O)=O	Preclinical	GRIN1	glutamate receptor antagonist		
Se-methylselenocysteine	C[Se]C[C@H](N)C(O)=O	Phase 2				
secalciferol	C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C	Launched	VDR	vitamin D receptor agonist	critical care	bone fracture
seclazone	Clc1ccc2O[C@H]3CCON3C(=O)c2c1 |&1:6	Phase 1		anti-inflammatory agent		
seclidemstat	CN1CCN(CC1)S(=O)(=O)c1cccc(c1)C(=O)N\N=C(/C)c1cc(Cl)ccc1O	Phase 1		histone demethylase inhibitor		
secnidazole	C[C@@H](O)Cn1c(C)ncc1[N+]([O-])=O |&1:1	Launched		acetylcholinesterase inhibitor, microtubule inhibitor	infectious disease	protozoan infection
secoisolariciresinol-(-)	COc1cc(C[C@@H](CO)[C@H](CO)Cc2ccc(O)c(OC)c2)ccc1O	Phase 2				
secoisolariciresinol-diglucoside	COc1cc(C[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc2ccc(O)c(OC)c2)ccc1O	Phase 2		antioxidant		
securinine	O=C1O[C@@]23C[C@@H](C=CC2=C1)N1CCCC[C@H]31 |c:6	Preclinical	GABRA1	GABA receptor antagonist, TP53 activator		
segesterone-acetate	[H][C@@]12CC(=C)[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H] |c:26|	Launched	PGR	progesterone receptor agonist		
seladelpar	CCO[C@H](COc1ccc(cc1)C(F)(F)F)CSc1ccc(OCC(O)=O)c(C)c1	Phase 3		PPAR receptor agonist		
selamectin	[H][C@@]12OC\C3=C/C=C/[C@H](C)[C@H](O[C@@]4([H])C[C@H](OC)[C@@H](O)[C@H](C)O4)\C(C)=C\C[C@]4([H])C[C@@]([H])(C[C@]5(CC[C@H](C)[C@H](O5)C5CCCCC5)O4)OC(=O)[C@]([H])(C=C(C)\C1=N\O)[C@@]23O |c:4	Launched		nematocide	infectious disease	flea control
selegiline	C[C@H](Cc1ccccc1)N(C)CC#C	Launched	MAOA|MAOB	monoamine oxidase inhibitor	neurology/psychiatry	Parkinson's Disease
selenomethionine	C[Se]CC[C@H](N)C(O)=O	Launched				
seletalisib	[O-][n+]1cccc(c1)-c1nc2c(Cl)cccc2cc1[C@@H](Nc1ncnc2cccnc12)C(F)(F)F	Preclinical		PI3K inhibitor		
selexipag	CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)c1cnc(-c2ccccc2)c(n1)-c1ccccc1	Launched	PTGIR	IP1 prostacyclin receptor agonist, platelet aggregation inhibitor	pulmonary	pulmonary arterial hypertension (PAH)
selfotel	OC(=O)[C@H]1C[C@@H](CP(O)(O)=O)CCN1	Phase 3	GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor antagonist		
selinexor	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2cnccn2)n1	Launched	XPO1	exportin antagonist	hematologic malignancy	multiple myeloma
selitrectinib	[H][C@]12CCCN1c1ccn3ncc(C(=O)N[C@H](C)CCc4ncc(F)cc24)c3n1	Phase 1/Phase 2		protein tyrosine kinase inhibitor		
selonsertib	CC(C)n1cnnc1-c1cccc(NC(=O)c2cc(c(C)cc2F)-n2cnc(c2)C2CC2)n1	Phase 2		MAP kinase activator		
selumetinib	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO	Phase 3	MAP2K1	MEK inhibitor		
semagacestat	CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@H]1c2ccccc2CCN(C)C1=O	Phase 3	PSEN1	gamma secretase inhibitor		
semapimod	CC(=NNC(N)=N)c1cc(NC(=O)CCCCCCCCC(=O)Nc2cc(cc(c2)C(C)=NNC(N)=N)C(C)=NNC(N)=N)cc(c1)C(C)=NNC(N)=N	Phase 2	MAPK14	cytokine production inhibitor, p38 MAPK inhibitor		
semaxanib	Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1	Phase 3	FGFR1|FLT1|KDR|KIT|PDGFRA|PDGFRB|RET	VEGFR inhibitor		
semustine	CC1CCC(CC1)NC(=O)N(CCCl)[NH2+][O-]	Phase 3		DNA alkylating agent		
SEN-1269	CN(C)c1cccc(Oc2cnc(Nc3cccc(O)c3)nc2)c1	Preclinical	APP	beta amyloid inhibitor		
senicapoc	NC(=O)C(c1ccccc1)(c1ccc(F)cc1)c1ccc(F)cc1	Phase 3	KCNN4	intermediate conductance potassium channel blocker		
sennoside-A	OC[C@H]1O[C@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O |a:2	Launched		glycoside agonist	gastroenterology	constipation
sennoside-protonated	OC[C@H]1O[C@@H](Oc2cccc3c(-c4c5cccc(O[C@H]6O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]6O)c5c(O)c5c(O)cc(cc45)C(O)=O)c4cc(cc(O)c4c(O)c23)C(O)=O)[C@@H](O)[C@@H](O)[C@@H]1O |&1:2	Preclinical				
seocalcitol	CCC(O)(CC)\C=C\C=C\[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Phase 3	VDR	vitamin D receptor agonist		
SEP-227900	OC(=O)c1cc2occc2[nH]1	Phase 1	DAO	D-amino acid oxidase Inhibitor		
seratrodast	CC1=C(C)C(=O)C([C@@H](CCCCCC(O)=O)c2ccccc2)=C(C)C1=O |r	Launched	TBXA2R	prostanoid receptor antagonist	pulmonary	asthma
serdemetan	C(Cc1c[nH]c2ccccc12)Nc1ccc(Nc2ccncc2)cc1	Phase 1	MDM2	MDM inhibitor		
serotonin	NCCc1c[nH]c2ccc(O)cc12	Launched	DRD1|DRD5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR3A|HTR3B|HTR4|HTR5A|HTR6|HTR7|SLC36A1	growth factor receptor activator	neurology/psychiatry	anxiety, depression, sleeplessness
sertaconazole	Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1 |&1:5	Launched		sterol demethylase inhibitor	infectious disease	tinea pedis
sertindole	Fc1ccc(cc1)-n1cc(C2CCN(CCN3CCNC3=O)CC2)c2cc(Cl)ccc12	Withdrawn	ADRA1A|ADRA1B|ADRA1D|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2C|HTR6|KCNH2	dopamine receptor antagonist, serotonin receptor antagonist		
sertraline	CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc12	Launched	SLC6A3|SLC6A4	selective serotonin reuptake inhibitor (SSRI)	neurology/psychiatry, obstetrics/gynecology	depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder
sesamin	C1Oc2ccc(cc2O1)[C@H]1OC[C@H]2[C@@H]1CO[C@@H]2c1ccc2OCOc2c1	Preclinical		NFkB pathway inhibitor		
setipiprant	OC(=O)Cn1c2CCN(Cc2c2cc(F)ccc12)C(=O)c1cccc2ccccc12	Phase 3	PTGDR2	prostaglandin inhibitor		
setiptiline	CN1CCC2=C(C1)c1ccccc1Cc1ccccc21 |c:4|	Launched	HRH1|HTR2A|HTR2C	adrenergic receptor antagonist	neurology/psychiatry	depression
setmelanotide	[H][C@]1(Cc2ccccc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](C)NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O	Phase 3		melanocortin receptor agonist		
sevoflurane	FCOC(C(F)(F)F)C(F)(F)F	Launched	ATP2C1|ATP5D|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GLRA1|GLRB|GRIA1|KCNA1|KCNK10|KCNK18|KCNK2|KCNK3|KCNK9|MT-ND1	membrane integrity inhibitor	neurology/psychiatry	anesthetic
SEW-2871	FC(F)(F)c1sc(cc1-c1ccccc1)-c1nc(no1)-c1cccc(c1)C(F)(F)F	Preclinical	S1PR1	lysophospholipid receptor agonist		
SF-11	CCOc1ccc(NC(=S)N2CCC(CC2)C(O)(c2ccccc2)c2ccccc2)cc1	Preclinical	MCOLN3|NPY2R	neuropeptide receptor antagonist		
SGC-CBP30	COc1ccc(CCc2nc3cc(ccc3n2C[C@H](C)N2CCOCC2)-c2c(C)noc2C)cc1Cl	Preclinical	CREBBP|EP300	bromodomain inhibitor		
SGC-0946	CC(C)N(CCCNC(=O)Nc1ccc(cc1)C(C)(C)C)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc(Br)c2c(N)ncnc12	Preclinical		histone lysine methyltransferase inhibitor		
SGC-707	O=C(NCC(=O)N1CCCC1)Nc1ccc2cnccc2c1	Preclinical	PRMT3	protein arginine N-methyltransferase inhibitor		
SGI-1027	Cc1cc(Nc2ccc(NC(=O)c3ccc(Nc4ccnc5ccccc45)cc3)cc2)nc(N)n1	Preclinical	DNMT1|DNMT3A|DNMT3B	DNA methyltransferase inhibitor		
SGI-1776	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1	Phase 1	FLT3|PIM1|PIM2|PIM3	Pim kinase inhibitor		
SGS-742	CCCCP(O)(=O)CCCN	Preclinical	GABBR1|GABBR2	GABA receptor antagonist		
SGX523	Cn1cc(cn1)-c1ccc2nnc(Sc3ccc4ncccc4c3)n2n1	Phase 1	MET	hepatocyte growth factor receptor inhibitor		
SHA-68	Fc1ccc(CNC(=O)N2CCN3[C@@H](C2)C(OC3=O)(c2ccccc2)c2ccccc2)cc1 |&1:13	Preclinical	NPSR1	neuropeptide receptor antagonist		
shikimic-acid	O[C@@H]1CC(=C[C@@H](O)[C@@H]1O)C(O)=O |a:1	Preclinical				
SHP099	CC1(N)CCN(CC1)c1cnc(c(N)n1)-c1cccc(Cl)c1Cl	Preclinical	PTPN11	protein tyrosine kinase inhibitor		
SIB-1553A	CN1CCC[C@@H]1CCSc1ccc(O)cc1 |&1:5|	Phase 2	CHRNB4	acetylcholine receptor agonist		
SIB-1757	C=C1NC(=NNc2ccccc2)C(=O)C=C1 |c:15|	Preclinical	GRM5	glutamate receptor antagonist		
SIB-1893	Cc1cccc(\C=C\c2ccccc2)n1	Preclinical	GRM4|GRM5	glutamate receptor antagonist		
SID-7969543	CCOC(=O)[C@@H](C)Oc1cccc2c1ccn(CC(=O)Nc1ccc3OCCOc3c1)c2=O |&1:5	Preclinical	NR5A1	steroidogenic factor antagonist		
siguazodan	CN\C(NC#N)=N/c1ccc(cc1)C1=NNC(=O)C[C@@H]1C |r	Phase 1	PDE3A	phosphodiesterase inhibitor		
sildenafil	CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1	Launched	PDE5A|PDE6G|PDE6H|SLCO1B1|SLCO1B3	phosphodiesterase inhibitor	urology	erectile dysfunction
silibinin	COc1cc(ccc1O)[C@H]1Oc2cc(ccc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O	Launched	ALOX5	cytochrome P450 inhibitor	gastroenterology	hepatic cirrhosis
silodosin	C[C@H](Cc1cc2CCN(CCCO)c2c(c1)C(N)=O)NCCOc1ccccc1OCC(F)(F)F	Launched	ADRA1A|ADRA1B|ADRA1D	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
silver-sulfadiazine	Nc1ccc(cc1)S(=O)(=O)N([Ag])c1ncccn1	Launched		PABA antagonist	critical care	sepsis
silymarin	COc1cc(ccc1O)[C@H]1Oc2ccc(cc2O[C@@H]1CO)[C@H]1Oc2cc(O)cc(O)c2C(=O)[C@@H]1O |&1:9	Launched				
simeprevir	COc1ccc2c(O[C@@H]3C[C@@H]4[C@@H](C3)C(=O)N(C)CCCC\C=C/[C@@H]3C[C@]3(NC4=O)C(=O)NS(=O)(=O)C3CC3)cc(nc2c1C)-c1nc(cs1)C(C)C |c:22|	Launched	CYP1A2|CYP3A4	HCV inhibitor	infectious disease	hepatitis C
simurosertib	Cc1n[nH]cc1-c1cc2[nH]c(nc(=O)c2s1)[C@H]1CC2CCN1CC2 |&1:16	Preclinical		kinase inhibitor		
simvastatin	CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12 |c:14	Launched	HMGCR|ITGB2	HMGCR inhibitor	endocrinology, cardiology, neurology/psychiatry	hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia
sincalide	CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(O)(=O)=O)cc1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O	Preclinical		cholecystokinin agonist		
sinefungin	N[C@@H](CC[C@H](N)C(O)=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12	Preclinical	CARM1	DNA methyltransferase inhibitor, RNA synthesis inhibitor		
sinomenine	COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O |t:2|	Preclinical		angiogenesis inhibitor		
sipatrigine	CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl	Phase 2	CACNA1D|SCN10A|SCN1A|SCN3A|SCN4A|SCN5A|SCN9A	voltage-gated sodium channel blocker		
siponimod	CCc1cc(ccc1CN1CC(C1)C(O)=O)C(\C)=N\OCc1ccc(C2CCCCC2)c(c1)C(F)(F)F	Launched	S1PR1	sphingosine 1-phosphate receptor modulator	neurology/psychiatry	multiple sclerosis
siramesine	Fc1ccc(cc1)-n1cc(CCCCN2CCC3(CC2)OCc2ccccc32)c2ccccc12	Phase 2	ADRA1A|ADRA1B|ADRA1D	sigma receptor antagonist		
siremadlin	COc1ncc(-c2nc3C(=O)N([C@H](c3n2C(C)C)c2ccc(Cl)cc2)c2cc(Cl)cn(C)c2=O)c(OC)n1	Preclinical		MDM inhibitor		
sirolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1O |c:14	Launched	FKBP1A|MTOR	mTOR inhibitor	transplant, pulmonary	organ rejection, lymphangioleiomyomatosis
SirReal-2	Cc1cc(C)nc(SCC(=O)Nc2ncc(Cc3cccc4ccccc34)s2)n1	Preclinical	SIRT2	SIRT inhibitor		
sirtinol	C[C@@H](NC(=O)c1ccccc1\N=C\c1c(O)ccc2ccccc12)c1ccccc1 |&1:1	Preclinical	SIRT1|SIRT2	SIRT inhibitor		
sisomicin	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |c:19|	Launched		protein synthesis inhibitor	ophthalmology	conjunctivitis, punctate keratitis
sisomicin-sulfate	CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](N)C[C@H](N)[C@@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H]2O)OC[C@]1(C)O |a:2	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	gram-negative bacterial infections
SIS3	COc1cc2CCN(Cc2cc1OC)C(=O)\C=C\c1c(-c2ccccc2)n(C)c2ncccc12	Preclinical	SMAD3|TGFBR1	serine/threonine kinase inhibitor		
sitafloxacin	N[C@@H]1CN(CC11CC1)c1c(F)cc2c(c1Cl)n(cc(C(O)=O)c2=O)[C@@H]1C[C@@H]1F	Launched		bacterial DNA gyrase inhibitor	infectious disease	buruli ulcer
sitagliptin	N[C@@H](CC(=O)N1CCn2c(C1)nnc2C(F)(F)F)Cc1cc(F)c(F)cc1F	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
sitaxentan	Cc1noc(NS(=O)(=O)c2ccsc2C(=O)Cc2cc3OCOc3cc2C)c1Cl	Withdrawn	EDNRA|EDNRB	endothelin receptor antagonist		
sitosterol	CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	Preclinical				
sitravatinib	COCCNCc1ccc(nc1)-c1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)c2s1	Phase 3		receptor tyrosine protein kinase inhibitor		
sivelestat	CC(C)(C)C(=O)Oc1ccc(cc1)S(=O)(=O)Nc1ccccc1C(=O)NCC(O)=O	Launched	CELA1|ELANE	elastase inhibitor	pulmonary	acute lung injury
SJ-172550	CCOc1cc(\C=C2/C(C)=NN(C2=O)c2ccccc2)cc(Cl)c1OCC(=O)OC |c:9|	Preclinical	MDM4	MDM inhibitor		
SJ-733	Fc1ccc(NC(=O)[C@@H]2[C@H](N(CC(F)(F)F)C(=O)c3ccccc23)c2cccnc2)cc1C#N	Phase 1		ATPase inhibitor		
SJG-136	COc1cc2c(cc1OCCCOc1cc3N=C[C@@H]4CC(=C)CN4C(=O)c3cc1OC)N=C[C@@H]1CC(=C)CN1C2=O |c:17	Phase 2		DNA intercalating agent		
SK&F-10047-(+)	C[C@@H]1[C@@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC=C	Phase 1	SIGMAR1	sigma receptor agonist		
SKA-31	Nc1nc2c(ccc3ccccc23)s1	Preclinical	KCNN4	potassium channel activator		
skepinone-L	OC[C@@H](O)COc1ccc2CCc3cc(Nc4ccc(F)cc4F)ccc3C(=O)c2c1	Preclinical	MAPK14	p38 MAPK inhibitor		
SKF-38393	Oc1cc2CCNC[C@@H](c3ccccc3)c2cc1O |&1:8|	Preclinical	CALY|DRD1|DRD5	dopamine receptor agonist		
SKF-77434	Oc1cc2CCN(CC=C)C[C@@H](c3ccccc3)c2cc1O |&1:11|	Preclinical	DRD1	dopamine receptor agonist		
SKF-81297	Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1	Preclinical	DRD1|DRD5	dopamine receptor agonist		
SKF-83566	CN1CCc2cc(Br)c(O)cc2[C@@H](C1)c1ccccc1 |&1:12|	Preclinical	DRD1|DRD5	dopamine receptor antagonist		
SKF-86002	Fc1ccc(cc1)-c1nc2SCCn2c1-c1ccncc1	Preclinical	ALOX5|MAPK14	p38 MAPK inhibitor		
SKF-89976A	OC(=O)[C@H]1CCCN(CCC=C(c2ccccc2)c2ccccc2)C1 |&1:3|	Preclinical	SLC6A1	GABA uptake inhibitor		
SKF-91488	CN(C)CCCCSC(N)=N	Preclinical	HNMT	histamine N-methyltransferase inhibitor		
SKF-96365	COc1ccc(CCCO[C@@H](Cn2ccnc2)c2ccc(OC)cc2)cc1 |&1:10|	Preclinical	CYP3A4|PKD2|TRPC1|TRPC3|TRPC4|TRPC5|TRPV2	calcium channel blocker		
SKI-II	Oc1ccc(Nc2nc(cs2)-c2ccc(Cl)cc2)cc1	Preclinical	SPHK1	sphingosine kinase inhibitor		
SKLB-1028	CC(C)n1c(Nc2cccnc2)nc2cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc12	Preclinical		Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor		
SKLB1002	COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC	Preclinical	KDR	VEGFR inhibitor		
SLV-319-(+/-)	C\N=C(\NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1 |&1:16	Phase 2	CNR1|DRD2|HTR1A	cannabinoid receptor antagonist		
SLV-320	O[C@H]1CC[C@@H](CC1)Nc1nc(nc2[nH]ccc12)-c1ccccc1 |r|	Phase 2	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
SM-108	NC(=O)C1N=CNC1=O |c:4|	Phase 2				
SM-164	CN[C@@H](C)C(=O)N[C@H]1CCCC[C@H]2CC[C@H](N2C1=O)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@@H]4CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1	Preclinical	BIRC2|BIRC3|XIAP	XIAP inhibitor		
SM-21	CC[C@H](Oc1ccc(Cl)cc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C |&1:14	Preclinical	PGRMC1	sigma receptor antagonist		
SMER-28	Brc1ccc2ncnc(NCC=C)c2c1	Preclinical	SNCA	autophagy inducer		
SMI-4a	FC(F)(F)c1cccc(\C=C2/SC(=O)NC2=O)c1	Preclinical	PIM1	Pim kinase inhibitor		
SN-2	Cc1cc(C)c(C2=NO[C@@H]3[C@H]4CC[C@H](C4)[C@H]23)c(C)c1 |&1:9	Preclinical	MCOLN3	transient receptor potential channel agonist		
SN-38	CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(O)cc12	Launched	TOP1	topoisomerase inhibitor	oncology	colorectal cancer
SN-6	CCOC(=O)[C@H]1CS[C@H](Cc2ccc(OCc3ccc(cc3)[N+]([O-])=O)cc2)N1 |&1:5	Preclinical		sodium/calcium exchange inhibitor		
SNAP	CC(=O)N[C@@H](C(O)=O)C(C)(C)S[NH2+][O-] |&1:4	Phase 2	PTPN1	nitric oxide donor		
SNAP-5089	COC(=O)C1=C(C)NC(C)=C([C@@H]1c1ccc(cc1)[N+]([O-])=O)C(=O)NCCCN1CCC(CC1)(c1ccccc1)c1ccccc1 |&1:11	Preclinical	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|CACNA1C|CACNA1D	adrenergic receptor antagonist		
SNAP-94847	CC(C)C(=O)Nc1ccc(C)c(c1)C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1	Preclinical	ADRA1A|DRD2			
SNC-80	CCN(CC)C(=O)c1ccc(cc1)[C@@H](N1C[C@@H](C)N(CC=C)C[C@@H]1C)c1cccc(OC)c1	Preclinical	OPRD1			
SNG-1153	CC(C)=CCc1c(O)cc(O)c2c1oc(c(O)c2=O)-c1ccc(cc1)C(F)(F)F	Preclinical	ESR1	selective estrogen receptor modulator (SERM)		
SNS-314	Clc1cccc(NC(=O)Nc2ncc(CCNc3ncnc4ccsc34)s2)c1	Phase 1	AURKA|AURKB|AURKC	Aurora kinase inhibitor		
SNX-2112	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@H](O)CC3)c2)C(F)(F)F)C(=O)C1 |r|	Phase 1		HSP inhibitor		
SNX-5422	CC1(C)Cc2c(c(nn2-c2ccc(C(N)=O)c(N[C@H]3CC[C@@H](CC3)OC(=O)CN)c2)C(F)(F)F)C(=O)C1 |r|	Phase 1/Phase 2	HSP90AA1|HSP90AB1	HSP inhibitor		
sobetirome	CC(C)c1cc(Cc2c(C)cc(OCC(O)=O)cc2C)ccc1O	Phase 1/Phase 2	THRA|THRB	thyroid hormone receptor agonist		
soblidotin	[H][C@]1(CCCN1C(=O)C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)[C@H](OC)[C@@H](C)C(=O)NCCc1ccccc1	Phase 2		microtubule inhibitor		
sobrepin	CC1=CC[C@H](C[C@@H]1O)C(C)(C)O |t:1|	Launched		mucolytic agent	pulmonary	chest congestion
sobuzoxane	CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	Launched		topoisomerase inhibitor	hematologic malignancy	peripheral T-cell lymphoma (PTCL)
sodium-ascorbate	OC[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@@H]1O |a:2	Launched				
sodium-butyrate	CCCC(O)=O	Phase 2	BCHE|FFAR2|FFAR3|HDAC1|HDAC2|HDAC3|HDAC8	HDAC inhibitor		
sodium-danshensu	O[C@@H](Cc1ccc(O)c(O)c1)C(O)=O |&1:1|	Preclinical				
sodium-dodecyl-sulfate	[Na].CCCCCCCCCCCCOS(O)(=O)=O	Launched	ALB			
sodium-gluconate	OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O	Launched				
sodium-gualenate	CC(C)c1ccc(C)c2c(cc(C)c2c1)S(O)(=O)=O	Launched		antacid	gastroenterology, otolaryngology	peptic ulcer disease (PUD), pharyngitis
sodium-monofluorophosphate	OP(O)(F)=O	Launched	PYGM		dental	cavities
sodium-nitrite	[O-][NH2+][O-]	Launched		nitric oxide donor	critical care	poison antidote, cyanide poisoning
sodium-nitroprusside	[O-][N+][Fe--](C#N)(C#N)(C#N)(C#N)C#N	Launched		nitric oxide donor	cardiology	hypertension, congestive heart failure
sodium-orthovanadate	O[V](O)(O)=O	Preclinical				
sodium-picosulfate	OS(=O)(=O)Oc1ccc(cc1)C(c1ccc(OS(O)(=O)=O)cc1)c1ccccn1	Launched			gastroenterology	constipation
sodium-stibogluconate	[H][C@@]1(O[Sb]2(O)(O[Sb]34(O)O[C@H]([C@@H](O3)[C@]([H])(O4)[C@H](O)CO)C(O)=O)O[C@H]([C@H]1O2)C(O)=O)[C@H](O)CO	Launched	PTPN6	tyrosine phosphatase inhibitor	infectious disease	leishmaniasis
sodium-tanshinone-II-A-sulfonate	Cc1c2c(oc1S(O)(=O)=O)-c1ccc3c(CCCC3(C)C)c1C(=O)C2=O	Phase 2		potassium channel activator		
sodium-tetradecyl-sulfate	CCCC[C@@H](CC)CC[C@@H](CC(C)C)OS(O)(=O)=O |&1:4	Launched	PROC		dermatology	varicose veins
sofalcone	CC(C)=CCOc1ccc(\C=C\C(=O)c2ccc(OCC=C(C)C)cc2OCC(O)=O)cc1	Launched	CBR1	mucus protecting agent	gastroenterology	peptic ulcer disease (PUD)
sofosbuvir	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1	Launched		HCV inhibitor	infectious disease	hepatitis C, hepatitis C
sofosbuvir-impurity-m	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@](C)(O)[C@@H]1O)Oc1ccccc1	Preclinical		antiviral		
sograzepide	CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1 |t:12|	Phase 2		gastrin inhibitor		
solamargine	C[C@H]1[C@H]2[C@@H](C[C@H]3[C@H]4CC=C5C[C@@H](CC[C@@]5(C)[C@@H]4CC[C@@]23C)O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@@H](O)[C@@H]2O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)O[C@]11CC[C@@H](C)CN1 |&1:1	Phase 3		apoptosis inhibitor		
solcitinib	CC1(C)CN(C1)C(=O)c1ccc(cc1)-c1cccc2nc(NC(=O)C3CC3)nn12	Phase 1	JAK1	JAK inhibitor		
solifenacin-succinate	[H][C@@]1(C[N@@]2CC[C@H]1CC2)OC(=O)N1CCc2ccccc2[C@@H]1c1ccccc1	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	urology	urinary incontinence, urinary frequency
solithromycin	CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC	Phase 3		protein synthesis inhibitor		
solriamfetol	N[C@@H](COC(N)=O)Cc1ccccc1	Launched		dopamine reuptake inhibitor	neurology/psychiatry	narcolepsy
somantadine	CC(C)(N)CC12CC3CC(CC(C3)C1)C2	Phase 1		antiviral		
somatostatin	C[C@@H](O)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O	Launched	OPRD1|OPRM1|SSTR1|SSTR2|SSTR3|SSTR4|SSTR5	somatostatin receptor agonist	hematology	hemorrhage
sonepiprazole	NS(=O)(=O)c1ccc(cc1)N1CCN(CC[C@@H]2OCCc3ccccc23)CC1	Phase 2		dopamine receptor antagonist		
sonidegib	C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(c2C)-c2ccc(OC(F)(F)F)cc2)cn1	Launched	SMO	smoothened receptor antagonist	oncology	basal cell carcinoma (BCC)
sophocarpine	O=C1C=CC[C@@H]2[C@H]3CCCN4CCC[C@@H](CN12)[C@@H]34 |c:2|	Phase 3				
sorafenib	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1	Launched	BRAF|DDR2|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRB|RAF1|RET	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	oncology	renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)
soraprazan	COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c(C)c(C)nc21)c1ccccc1	Preclinical		proton pump inhibitor		
sorbic-acid	C\C=C\C=C\C(O)=O	Launched				
sorbinil	Fc1ccc2OCC[C@]3(NC(=O)NC3=O)c2c1 |&1:8	Phase 3	AKR1B1	aldose reductase inhibitor		
sorbitan-monostearate	CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O |a:23	Preclinical				
sorbitol	OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	Launched		mucolytic agent	gastroenterology	constipation
sotagliflozin	CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1	Phase 3	SLC5A1|SLC5A2	sodium/glucose cotransporter inhibitor		
sotalol	CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1	Launched	ADRB1|ADRB2|KCNH2	adrenergic receptor antagonist	cardiology	atrial fibrillation (AF), ventricular arrhythmias
sotrastaurin	CN1CCN(CC1)c1nc(C2=C(C(=O)NC2=O)c2c[nH]c3ccccc23)c2ccccc2n1 |t:11|	Phase 2	PRKCA|PRKCB|PRKCD|PRKCE|PRKCH|PRKCQ	PKC inhibitor		
SP-100030	FC(F)(F)c1cc(NC(=O)c2cnc(Cl)nc2C(F)(F)F)cc(c1)C(F)(F)F	Preclinical	JUN|NFKB1	NFkB pathway inhibitor		
SP-141	COc1ccc2[nH]c3c(nccc3c2c1)-c1cccc2ccccc12	Preclinical	MDM2	ubiquitin ligase inhibitor		
SP-420	COCCOCCOc1ccc(C2=N[C@](C)(CS2)C(O)=O)c(O)c1 |t:12|	Phase 1				
spaglumic-acid	CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O	Launched	GRM3	glutamate receptor antagonist	allergy	allergic conjunctivitis, allergic rhinitis
sparfloxacin	C[C@H]1CN(C[C@@H](C)N1)c1c(F)c(N)c2c(c1F)n(cc(C(O)=O)c2=O)C1CC1	Withdrawn	TOP2A	bacterial DNA gyrase inhibitor		
sparfosate	OC(=O)C[C@@H](NC(=O)CP(O)(O)=O)C(O)=O |&1:4|	Phase 3	CA2|CA4	aspartate carbamoyltransferase inhibitor		
sparsentan	CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(c(COCC)c1)-c1ccccc1S(=O)(=O)Nc1noc(C)c1C |t:4|	Phase 3		angiotensin receptor antagonist		
sparteine-(+)	C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1	Launched				
sparteine-(-)	C1CCN2C[C@@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	Launched				
sparteine-sulfate	C1CCN2C[C@H]3C[C@@H](CN4CCCC[C@H]34)[C@@H]2C1	Launched				
spautin-1	Fc1ccc(CNc2ncnc3ccc(F)cc23)cc1	Preclinical	USP10|USP13	deubiquitinase inhibitor		
spectinomycin	CN[C@@H]1[C@H](O)[C@H](NC)[C@H]2O[C@]3(O)[C@@H](O[C@H](C)CC3=O)O[C@@H]2[C@H]1O	Launched		bacterial 30S ribosomal subunit inhibitor	pulmonary	airsacculitis, chronic respiratory disease
spermidine	NCCCCNCCCN	Preclinical	KCNJ4|TXNRD1	glutamate receptor modulator		
spermine	NCCCNCCCCNCCCN	Preclinical	CA14|CA4|CA6|CA9|CASR|GRIN1|GRIN2A|KCNJ4|ODC1|SMOX|SMS|TRPM4|TRPM5			
sphingosylphosphorylcholine	CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(=O)OCC[N+](C)(C)C |a:15	Preclinical	GPR12	gene expression stimulant		
spiperone	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1	Launched	ADRA1A|ADRA1B|ADRA1D|DRD1|DRD2|DRD3|DRD4|DRD5|HTR1A|HTR1D|HTR2A|HTR2B|HTR2C|HTR6|HTR7	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
spiradoline	CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Phase 2	OPRK1	opioid receptor agonist		
spiramycin	CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O[C@H]2CC[C@@H]([C@@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@H]2C[C@@](C)(O)[C@@H](O)[C@H](C)O2)[C@@H]([C@H]1O)N(C)C |t:12	Launched		bacterial 50S ribosomal subunit inhibitor	infectious disease	toxoplasmosis, soft tissue infection
spirobromin	BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CCN(CC1)C(=O)CCBr)CC2	Phase 1				
spironolactone	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]33CCC(=O)O3)[C@H]12 |t:6|	Launched	AR|CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1H|CACNA1I|CACNA1S|CACNA2D1|CACNA2D2|CACNA2D3|CACNB1|CACNB2|CACNB3|CACNB4|CACNG1|CYP11B2|NR3C1|NR3C2|PGR|SHBG	mineralocorticoid receptor antagonist	endocrinology, cardiology, gastroenterology, rheumatology	hyperaldosteronism, congestive heart failure, hepatic cirrhosis, nephrotic syndrome, hypertension, hypokalemia
spiroxatrine	O=C1NCN(c2ccccc2)C11CCN(C[C@H]2COc3ccccc3O2)CC1 |&1:16	Preclinical	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A|HTR2B	serotonin receptor antagonist		
spizofurone	CC(=O)c1ccc2OC3(CC3)C(=O)c2c1	Withdrawn				
splitomycin	O=C1CCc2c(O1)ccc1ccccc21	Preclinical	SIRT1	SIRT inhibitor		
SPP301	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(nc1OC)-c1ccncc1	Phase 3	EDNRA	endothelin receptor antagonist		
SPP86	CC(C)n1nc(C#Cc2ccccc2)c2c(N)ncnc12	Preclinical	RET	receptor tyrosine protein kinase inhibitor		
SQ-109	CC(C)=CCC\C(C)=C\CNCCNC1[C@H]2C[C@@H]3C[C@@H](C[C@H]1C3)C2 |r|	Phase 3	FDFT1	bacterial cell wall synthesis inhibitor		
SQ-22536	Nc1ncnc2n(cnc12)[C@H]1CCCO1 |&1:10	Preclinical	ADCY1	adenylyl cyclase inhibitor		
squalamine	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	Phase 3		antiviral		
squaric-acid-dibutyl-ester	CCCCOc1c(OCCCC)c(=O)c1=O	Preclinical		oxidative stress inducer		
SR-1078	OC(c1ccc(NC(=O)c2ccc(cc2)C(F)(F)F)cc1)(C(F)(F)F)C(F)(F)F	Preclinical	RORA|RORC	retinoid receptor agonist		
SR-11302	C\C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/c1ccc(C)cc1)=C/C(O)=O |c:8|	Preclinical				
SR-140333	CC(C)Oc1cccc(CC(=O)N2CCC[C@@](CC[N+]34CCC(CC3)(CC4)c3ccccc3)(C2)c2ccc(Cl)c(Cl)c2)c1	Phase 2	TACR1	neurokinin receptor antagonist		
SR-1664	C[C@H](NC(=O)c1ccc2n(Cc3ccc(cc3)-c3ccccc3C(O)=O)c(C)c(C)c2c1)c1ccc(cc1)[N+]([O-])=O	Preclinical	PPARG	PPAR receptor ligand		
SR-2211	OC(c1ccc(c(F)c1)-c1ccc(CN2CCN(Cc3ccncc3)CC2)cc1)(C(F)(F)F)C(F)(F)F	Preclinical	RORC	retinoid receptor inverse agonist		
SR-2640	OC(=O)c1ccccc1Nc1cccc(OCc2ccc3ccccc3n2)c1	Phase 2	CYSLTR1	leukotriene receptor antagonist		
SR-27897	OC(=O)Cn1c(cc2ccccc12)C(=O)Nc1nc(cs1)-c1ccccc1Cl	Phase 2	CCKAR	CCK receptor antagonist		
SR-3306	Cc1ccc(cn1)-c1ncn(n1)-c1ccc(Nc2nccc(n2)-c2cccc(c2)N2CCOCC2)cc1	Preclinical	MAPK10|MAPK8|MAPK9	JNK inhibitor		
SR-33805	COc1ccc(CCN(C)CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3ccccc3n2C)cc1OC	Phase 1		calcium channel blocker		
SR-3576	COc1cc(NC(=O)c2cccc(c2)-n2cc(NC(=O)Nc3cccc(C)c3)cn2)cc(OC)c1OC	Preclinical	MAPK10	JNK inhibitor		
SR-3677	CN(C)CCOc1cc(ccc1NC(=O)[C@H]1COc2ccccc2O1)-c1cn[nH]c1 |&1:15|	Preclinical	ROCK2	rho associated kinase inhibitor		
SR-57227A	NC1CCN(CC1)c1cccc(Cl)n1	Phase 2	HTR3A	serotonin receptor agonist		
SR-59230A	CCc1ccccc1OC[C@@H](O)CN[C@H]1CCCc2ccccc12	Preclinical	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist		
SR-95639A	C(CN1CCOCC1)Nc1cc2CCCc3ccccc3-c2nn1	Preclinical	CHRM1	acetylcholine receptor agonist		
SRC-kinase-inhibitor-I	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC	Preclinical	CSK|LCK|RIPK2	SRC inhibitor		
SRPIN340	FC(F)(F)c1ccc(N2CCCCC2)c(NC(=O)c2ccncc2)c1	Preclinical	SRPK1|SRPK2	serine arginine protein kinase inhibitor		
SRT1720	O=C(Nc1ccccc1-c1cn2c(CN3CCNCC3)csc2n1)c1cnc2ccccc2n1	Preclinical	SIRT1	SIRT activator		
SRT2104	Cc1nc(sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1)-c1cccnc1	Phase 2	SIRT1	SIRT activator		
SRT3190	C[C@H](Nc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)[C@@H](O)CO	Preclinical		CC chemokine receptor antagonist		
SSR128129E	COc1c(C)c(C(=O)c2ccc(N)c(c2)C(O)=O)n2ccccc12	Preclinical				
SSR180711	Brc1ccc(OC(=O)N2CC[N@@]3CC[C@H]2CC3)cc1 |r|	Phase 2	CHRNA7	acetylcholine receptor agonist		
SSR240612	COc1ccc2cc(ccc2c1)S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc1ccc(CN2[C@@H](C)CCC[C@H]2C)cc1)C(=O)N(C)C(C)C)c1ccc2OCOc2c1	Preclinical		bradykinin receptor antagonist		
ST-1535	CCCCc1nc(N)c2nc(-n3nccn3)n(C)c2n1	Preclinical		adenosine receptor antagonist		
ST-1859	Oc1ccc2ccccc2c1Cc1c(O)ccc2ccccc12	Phase 1		antiamyloidogenic agent		
ST-2825	NC(=O)[C@H]1CCS[C@@H]2C[C@]3(CCCN3C(=O)Cc3ccc(NC(=O)COc4ccc(Cl)cc4Cl)cc3)C(=O)N12	Preclinical	MYD88	myeloid differentiation primary response inhibitor		
ST-91	CCc1cccc(CC)c1NC1=NCCN1 |t:12|	Preclinical		adrenergic receptor agonist		
STA-5326	Cc1cccc(\C=N\Nc2cc(nc(OCCc3ccccn3)n2)N2CCOCC2)c1	Phase 2	IL12A	interleukin synthesis inhibitor		
statil	OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c2ccccc12	Preclinical		aldose reductase inhibitor		
stattic	[O-][N+](=O)c1ccc2C=CS(=O)(=O)c2c1 |c:7|	Preclinical				
STAT3-inhibitor-VI	Cc1ccc(cc1)S(=O)(=O)OCC(=O)Nc1ccc(C(O)=O)c(O)c1	Preclinical	STAT3	STAT inhibitor		
stavudine	Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O |c:9|	Launched		DNA directed DNA polymerase inhibitor, nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
stemregenin-1	CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12	Preclinical	AHR	aryl hydrocarbon receptor antagonist		
stepronin	C[C@@H](SC(=O)c1cccs1)C(=O)NCC(O)=O |&1:1	Launched		mucolytic agent		
stetaderm	CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@H](O)C[C@]12C |t:10|	Launched				
STF-083010	Oc1ccc2ccccc2c1\C=N\S(=O)(=O)c1cccs1	Preclinical	ERN1	serine/threonine kinase inhibitor		
STF-118804	Cc1oc(nc1CS(=O)(=O)c1ccc(C)cc1)-c1ccc(cc1)C(=O)NCc1cccnc1	Preclinical	NAMPT	NAMPT inhibitor		
STF-31	CC(C)(C)c1ccc(cc1)S(=O)(=O)NCc1ccc(cc1)C(=O)Nc1cccnc1	Preclinical	NAMPT|SLC2A1	NAMPT inhibitor		
STF-62247	Cc1cccc(Nc2nc(cs2)-c2ccncc2)c1	Preclinical		autophagy inducer		
stigmasterol	CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C |t:13|	Preclinical				
stiripentol	CC(C)(C)[C@@H](O)\C=C\c1ccc2OCOc2c1 |&1:4	Launched	GABRA3	GABA uptake inhibitor	neurology/psychiatry	epilepsy
stobadine	CN1CC[C@H]2Nc3ccc(C)cc3[C@H]2C1	Phase 2	ADRA1A	adrenergic receptor antagonist		
streptomycin	CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	tuberculosis
streptozotocin	CN([NH2+][O-])C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O	Launched		DNA alkylating agent	oncology	pancreatic cancer
strontium-ranelate	OC1=CN(C=C(O)O[Sr]O1)c1sc2c(CC(=O)O[Sr]OC2=O)c1C#N	Launched	CASR	bone formation stimulant, bone resorption inhibitor	orthopedics, rheumatology	osteoporosis, osteoarthritis
strychnine	O=C1C[C@@H]2OCC=C3CN4CC[C@@]56[C@@H]4C[C@@H]3[C@@H]2[C@@H]5N1c1ccccc61 |t:6|	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|CHRNA10|CHRNA9|GLRA1|GLRA2|GLRA3|GLRB	acetylcholine receptor antagonist		
substance-P	CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCNC(N)=N)C(N)=O	Phase 1	TACR1|TACR2|TACR3	neurokinin receptor antagonist		
succinic-acid	OC(=O)CCC(O)=O	Launched	ALDH5A1|ASPH|BBOX1|HSD17B6|OXCT1|OXCT2|P3H1|P3H2|P3H3|P4HA1|P4HA2|PLOD1|PLOD3|SDHA|SDHB|SDHC|SDHD|SLC13A1|SLC13A2|SLC13A3|SLC25A10|SUCLA2|SUCLG1|SUCLG2|SUCNR1|TMLHE			
succinobucol	CC(C)(C)c1cc(SC(C)(C)Sc2cc(c(OC(=O)CCC(O)=O)c(c2)C(C)(C)C)C(C)(C)C)cc(c1O)C(C)(C)C	Phase 2/Phase 3	VCAM1	antioxidant		
succinylcholine-chloride	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	Launched	CHRFAM7A|CHRM1|CHRM2|CHRM3|CHRNA1|CHRNA10		neurology/psychiatry	muscle relaxant
succinylsulfathiazole	OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Phase 2	DHFR	dihydrofolate reductase inhibitor		
sucralfate	O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@](COS(=O)(=O)O[Al](O)O)(O[C@H]2O[C@H](COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@H]2OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O	Launched		antacid	gastroenterology	duodenal ulcer disease
sucralose	OC[C@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@H]1Cl	Launched				
sucrose	OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O	Launched	ACTA1|ATOX1|C22orf28|LYZ			
sucrose-octaacetate	CC(=O)OC[C@H]1O[C@@](COC(C)=O)(O[C@H]2O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O	Preclinical				
sudan-IV	Cc1ccccc1\N=N\c1ccc(\N=N\c2c(O)ccc3ccccc23)c(C)c1	Preclinical				
sufugolix	CONC(=O)Nc1ccc(cc1)-c1sc2n(Cc3c(F)cccc3F)c(=O)n(-c3ccccc3)c(=O)c2c1CN(C)Cc1ccccc1	Preclinical		gonadotropin releasing factor hormone receptor antagonist		
sugammadex	O[C@H]1[C@H](O)[C@H]2O[C@@H]3O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]4O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]5O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]6O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]7O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]8O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]9O[C@@H](CSCCC(O)=O)[C@H](O[C@@H]1O[C@H]2CSCCC(O)=O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H](O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O	Launched		neuromuscular blockade reversal agent		
sulbactam	CC1(C)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	Launched		beta lactamase inhibitor	infectious disease	skin infections, intra-abdominal infections, gynecologic infections
sulbactam-pivoxil	CC(C)(C)C(=O)OCOC(=O)[C@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C |&1:11	Launched		beta lactamase inhibitor	infectious disease	skin infections
sulbentine	S=C1SCN(Cc2ccccc2)CN1Cc1ccccc1	Preclinical		other antifungal		
sulbutiamine	CC(C)C(=O)OCC\C(SS\C(CCOC(=O)C(C)C)=C(/C)N(Cc1cnc(C)nc1N)C=O)=C(\C)N(Cc1cnc(C)nc1N)C=O	Launched		acetylcholine receptor antagonist	neurology/psychiatry	asthenia
sulconazole	Clc1ccc(CS[C@@H](Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1 |&1:7|	Launched		sterol demethylase inhibitor	infectious disease	tinea pedis, tinea cruris, tinea corporis
sulfabenzamide	Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1	Launched		bacterial antifolate	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
sulfacarbamide	NC(=O)NS(=O)(=O)c1ccc(N)cc1	Withdrawn				
sulfacetamide	CC(=O)NS(=O)(=O)c1ccc(N)cc1	Launched		PABA antagonist	ophthalmology	conjunctivitis
sulfachlorpyridazine	Nc1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)nn1	Launched		bacterial antifolate	infectious disease	urinary tract infections
sulfadiazine	Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1	Launched		bacterial antifolate	infectious disease, ophthalmology	malaria, meningitis, urinary tract infections, conjunctivitis, trachoma, chancroid
sulfadoxine	COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC	Launched		dihydropteroate synthase inhibitor	infectious disease	malaria
sulfafurazole	Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C	Launched		bacterial antifolate	infectious disease	urinary tract infections
sulfaguanidine	NC(=N)NS(=O)(=O)c1ccc(N)cc1	Launched		bacterial antifolate	infectious disease	urinary tract infections
sulfamerazine	Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1	Launched		bacterial antifolate	infectious disease	coccidiosis, cholera
sulfameter	COc1cnc(NS(=O)(=O)c2ccc(N)cc2)nc1	Launched	DHFR	dihydrofolate reductase inhibitor	infectious disease	urinary tract infections
sulfamethazine	Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1	Launched		PABA antagonist	gastroenterology	enteritis
sulfamethizole	Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1	Launched		bacterial antifolate	infectious disease	urinary tract infections
sulfamethoxazole	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1	Launched		PABA antagonist	infectious disease, gastroenterology	pneumonia, enteritis, urinary tract infections
sulfamethoxypyridazine	COc1ccc(NS(=O)(=O)c2ccc(N)cc2)nn1	Withdrawn		bacterial antifolate		
sulfametopyrazine	COc1nccnc1NS(=O)(=O)c1ccc(N)cc1	Launched		PABA antagonist	infectious disease	malaria, urinary tract infections, respiratory tract infections
sulfamonomethoxine	COc1cc(NS(=O)(=O)c2ccc(N)cc2)ncn1	Launched		bacterial antifolate	infectious disease	urinary tract infections
sulfamoxole	Cc1nc(NS(=O)(=O)c2ccc(N)cc2)oc1C	Launched		PABA antagonist	infectious disease	urinary tract infections
sulfanilamide	Nc1ccc(cc1)S(N)(=O)=O	Launched	CYP2C19|CYP2C9|CYP2D6|CYP2E1|CYP3A4	carbonic anhydrase inhibitor	infectious disease	vulvovaginal candidiasis
sulfanilate-zinc	Nc1ccc(cc1)S(=O)(=O)O[Zn]OS(=O)(=O)c1ccc(N)cc1	Preclinical				
sulfanitran	CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+]([O-])=O	Launched			infectious disease	coccidiosis
sulfaphenazole	Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1	Launched	DHPS	dihydropteroate synthetase inhibitor	infectious disease	urinary tract infections
sulfapyridine	Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1	Launched		PABA antagonist	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
sulfaquinoxaline	Nc1ccc(cc1)S(=O)(=O)Nc1cnc2ccccc2n1	Launched		vitamin K antagonist	infectious disease	coccidiosis
sulfasalazine	OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1	Launched	ACAT1|ALOX5|CHUK|IKBKB|PLA2G1B|PPARG|PTGS1|PTGS2|SLC46A1|SLC7A11|TBXAS1	cyclooxygenase inhibitor	gastroenterology	ulcerative colitis
sulfathiazole	Nc1ccc(cc1)S(=O)(=O)Nc1nccs1	Launched		dihydropteroate synthase inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
sulfatinib	CN(C)CCNS(=O)(=O)Cc1cccc(Nc2nccc(Oc3ccc4[nH]c(C)cc4c3)n2)c1	Phase 1		tyrosine kinase inhibitor		
sulfinpyrazone	O=C1C(CC[S@](=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1 |&1:5	Launched	ABCC1|FPR1|SLC22A12	uricosuric blocker	rheumatology	gout
sulfisomidin	Cc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(C)n1	Preclinical		antibacterial		
sulfisoxazole-acetyl	CC(=O)N(c1onc(C)c1C)S(=O)(=O)c1ccc(N)cc1	Launched		folic acid antagonist	infectious disease, otolaryngology	meningitis, urinary tract infections, otitis, trachoma
sulforaphane	C[S@@](=O)CCCCN=C=S |r|	Phase 2	NFE2L2	anticancer agent, aryl hydrocarbon receptor antagonist		
sulindac	CC1=C(CC(O)=O)c2cc(F)ccc2\C1=C/c1ccc(cc1)[S@@](C)=O |r	Launched	AKR1B1	cyclooxygenase inhibitor	rheumatology	osteoarthritis, rheumatoid arthritis, ankylosing spondylitis
sulisobenzone	COc1cc(O)c(cc1S(O)(=O)=O)C(=O)c1ccccc1	Launched			dermatology	sunscreen lotion
sulmazole	COc1cc(ccc1-c1nc2ncccc2[nH]1)[S@@](C)=O |r|	Phase 1		adenosine receptor antagonist		
sulmetozine	COc1cc(cc(OC)c1OC)C(=S)N1CCOCC1	Launched	GAST	gastrin inhibitor	gastroenterology	peptic ulcer disease (PUD)
suloctidil	CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1 |&1:9	Withdrawn		adrenergic receptor antagonist		
sulopenem	C[C@@H](O)[C@@H]1[C@H]2SC(S[C@H]3CC[S@@](=O)C3)=C(N2C1=O)C(O)=O |&1:11	Phase 3		antibacterial		
sulphadimethoxine	COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1	Launched		dihydropteroate synthetase inhibitor	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
sulpiride	CCN1CCC[C@@H]1CNC(=O)c1cc(ccc1OC)S(N)(=O)=O |&1:6	Launched		dopamine receptor antagonist	neurology/psychiatry	schizophrenia
sultamicillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)OCOC(=O)[C@@H]1N2[C@@H](CC2=O)S(=O)(=O)C1(C)C	Launched		antibacterial 	infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
sultiame	NS(=O)(=O)c1ccc(cc1)N1CCCCS1(=O)=O	Phase 3	CA2	carbonic anhydrase inhibitor		
sultopride	CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC |&1:6	Preclinical		dopamine receptor antagonist		
sumanirole	CN[C@@H]1Cc2cccc3[nH]c(=O)n(C1)c23	Phase 3	DRD2	dopamine receptor agonist		
sumatriptan	CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1	Launched	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR5A|HTR6|HTR7	serotonin receptor agonist	neurology/psychiatry	migraine headache
SUN-B-8155	C\C(=N/c1ccccc1N)c1c(C)cc(=O)n(O)c1O	Preclinical	CALCR	calcitonin agonist		
SUN-11602	CN(C1CCN(Cc2ccc(cc2)C(N)=O)CC1)C(=O)CNc1c(C)c(C)c(N)c(C)c1C	Preclinical	FGFR1	fibroblast growth factor mimetic		
sunitinib	CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C	Launched	CSF1R|FGFR1|FLT1|FLT3|FLT4|KDR|KIT|PDGFRA|PDGFRB|RET	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	oncology	gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)
suplatast	CCOC[C@@H](O)COc1ccc(NC(=O)CC[S+](C)C)cc1 |&1:4|	Launched		histamine release inhibitor, immunoglobulin inhibitor	rheumatology	Kimura's disease
suprofen	C[C@@H](C(O)=O)c1ccc(cc1)C(=O)c1cccs1 |&1:1	Withdrawn	PTGS1|PTGS2	cyclooxygenase inhibitor		
suramin	Cc1ccc(cc1NC(=O)c1cccc(NC(=O)Nc2cccc(c2)C(=O)Nc2cc(ccc2C)C(=O)Nc2ccc(c3cc(cc(c23)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)c1)C(=O)Nc1ccc(c2cc(cc(c12)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O	Launched	F2|FSHR|P2RY1|P2RY11|P2RY13|P2RY2|PLA2G2A|RYR1|RYR2|SIRT5	DNA synthesis inhibitor	infectious disease	African trypanosomiasis, onchocerciasis
suritozole	Cn1nc(-c2cccc(F)c2)n(C)c1=S	Phase 2	GABBR1	GABA receptor inverse agonist		
sutezolid	CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(N2CCSCC2)c(F)c1	Phase 2		protein synthesis inhibitor		
suxibuzone	CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1	Launched		cyclooxygenase inhibitor	rheumatology, neurology/psychiatry	joint pain, muscle pain
SU014813	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1	Phase 2	KDR	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
SU11274	CN(c1cccc(Cl)c1)S(=O)(=O)c1ccc2NC(=O)\C(=C/c3[nH]c(C)c(C(=O)N4CCN(C)CC4)c3C)c2c1	Preclinical	MET	hepatocyte growth factor receptor inhibitor, tyrosine kinase inhibitor		
SU16f	Cc1[nH]c(\C=C2/C(=O)Nc3cc(ccc23)-c2ccccc2)c(C)c1CCC(O)=O	Preclinical	PDGFRB	PDGFR tyrosine kinase receptor inhibitor		
SU3327	Nc1nnc(Sc2ncc(s2)[N+]([O-])=O)s1	Preclinical	MAPK8	JNK inhibitor		
SU4312	CN(C)c1ccc(\C=C2/C(=O)Nc3ccccc23)cc1	Preclinical	KDR|PDGFRB	PDGFR tyrosine kinase receptor inhibitor, tyrosine kinase inhibitor, VEGFR inhibitor		
SU9516	COc1ccc2NC(=O)\C(=C/c3cnc[nH]3)c2c1	Preclinical	CDK1|CDK2|CDK4|CDK5	CDK inhibitor		
swainsonine	O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O	Phase 2	MAN2A1	alpha mannosidase inhibitor		
SX-011	CN(C)C(=O)C(=O)c1cn(C)c2cc(Cl)c(cc12)C(=O)N1CCC(Cc2ccc(F)cc2)CC1	Preclinical	MAPK14	MAP kinase inhibitor		
SY-640	CN(Cc1ccc2OCOc2c1)C(C)=O	Phase 2				
SYM-2081	C[C@H](C[C@H](N)C(O)=O)C(O)=O	Preclinical	GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SLC1A2	kainate receptor antagonist		
SYM-2206	CCCNC(=O)N1N=C(c2ccc(N)cc2)c2cc3OCOc3cc2[C@@H]1C |r	Preclinical	GRIA1|GRIA2|GRIA3|GRIA4	glutamate receptor antagonist		
symclosene	Cln1c(=O)n(Cl)c(=O)n(Cl)c1=O	Preclinical				
synephrine	CNC[C@@H](O)c1ccc(O)cc1 |&1:3|	Launched	ADRA1A	adrenergic receptor agonist	otolaryngology	sinusitis
S1P1-agonist-III	COc1ccncc1C(=O)NC(=O)Nc1ccc(-c2ccccc2)c(c1)C(F)(F)F	Preclinical	S1PR1	sphingosine kinase inhibitor		
S15535	C1C(Cc2ccccc12)N1CCN(CC1)c1cccc2OCCOc12	Preclinical		serotonin receptor agonist		
S18986	O=S1(=O)N[C@H]2CCCN2c2ccccc12	Phase 2	GRIA1|GRIA2|GRIA3|GRIA4	glutamate receptor modulator		
S26948	COC(=O)C(Cc1ccc(OCCn2c3ccc(cc3sc2=O)C(=O)c2ccccc2)cc1)C(=O)OC	Preclinical	PPARG	PPAR receptor agonist		
S4	Cc1cc(C)cc(NC(=O)Nc2ccc(OS(N)(=O)=O)cc2)c1	Preclinical	CA12|CA9	carbonic anhydrase inhibitor		
S49076	O=C1CSC(=O)N1Cc1ccc2NC(=O)\C(=C/c3cc(CN4CCOCC4)c[nH]3)c2c1	Preclinical		tyrosine kinase inhibitor		
S63845	CN1CCN(CCOc2ccc(-c3c(sc4ncnc(O[C@H](Cc5ccccc5OCc5ccnn5CC(F)(F)F)C(O)=O)c34)-c3ccc(F)o3)c(C)c2Cl)CC1	Preclinical		MCL1 inhibitor		
T-0070907	[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccncc1	Preclinical	PPARG	PPAR receptor antagonist		
T-0156	COC(=O)c1c(-c2cc(OC)c(OC)c(OC)c2)c2ccnc(OCc3ncccn3)c2c(=O)n1Cc1ccnc(C)c1	Preclinical	PDE5A	phosphodiesterase inhibitor		
T-025		Preclinical		CLK inhibitor		
T-0901317	OC(c1ccc(cc1)N(CC(F)(F)F)S(=O)(=O)c1ccccc1)(C(F)(F)F)C(F)(F)F	Preclinical	NCOA1|NCOA2|NR1H2|NR1H3|NR1I2|RXRB	LXR agonist		
T-1095	COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(O)c2C(=O)CCc2ccc3occc3c2)[C@H](O)[C@@H](O)[C@@H]1O	Preclinical		sodium/glucose cotransporter inhibitor		
T-5224	OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)o[nH]c2=O)C(=O)c1ccc(OC2CCCC2)cc1O	Phase 2	JUN	AP inhibitor		
T-5601640	Cc1cc(on1)C(=O)Nc1cccc(c1)C(=O)Nc1cccc(c1)C(F)(F)F	Preclinical	LIMK2	LIM kinase inhibitor		
T-62	Nc1sc2CCCCc2c1C(=O)c1ccc(Cl)cc1	Phase 2	ADORA2A	adenosine receptor modulator		
T-807	Fc1ccc(cn1)-c1ccc2c(c1)[nH]c1ccncc21	Phase 2		PET radiotracer		
TA-01	Fc1ccc(cc1)-c1[nH]c(nc1-c1ccncc1)-c1c(F)cccc1F	Preclinical	CSNK1D|CSNK1E|MAPK14	casein kinase inhibitor, MAP kinase inhibitor		
tabimorelin	CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1ccc2ccccc2c1)N(C)C(=O)\C=C\CC(C)(C)N	Phase 2	GHSR	growth hormone secretagogue receptor agonist		
tacalcitol	CC(C)[C@H](O)CC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C	Launched	VDR	vitamin D receptor agonist	dermatology	psoriasis, chapped lips
tacedinaline	CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N	Phase 3	HDAC1	HDAC inhibitor		
tacrine	Nc1c2CCCCc2nc2ccccc12	Launched	ACHE|BCHE	acetylcholinesterase inhibitor	neurology/psychiatry	Alzheimer's disease
tacrolimus	CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC |t:45|	Launched	FKBP1A	calcineurin inhibitor	transplant	organ rejection
tadalafil	CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3OCOc3c2)C1=O	Launched	PDE11A|PDE5A	phosphodiesterase inhibitor	urology	erectile dysfunction
tafamidis-meglumine	OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1	Launched	TTR	transthyretin amyloid inhibitor	neurology/psychiatry	familial amyloid polyneuropathy (FAP)
tafenoquine	COc1cc(C)c2c(Oc3cccc(c3)C(F)(F)F)c(OC)cc(N[C@@H](C)CCCN)c2n1 |&1:25|	Launched		antimalarial agent	infectious disease	malaria
tafluprost	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1	Launched	PTGFR	prostaglandin inhibitor	ophthalmology	glaucoma, ocular hypertension
tagatose	OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO	Launched	PYGL	phosphorylase inhibitor		
TAK-063	COc1cn(nc(-c2ccnn2-c2ccccc2)c1=O)-c1ccc(cc1F)-n1cccn1	Phase 2	PDE10A	phosphodiesterase inhibitor		
TAK-220	CC(=O)N1CCC(CC1)C(=O)N(CCCN1CCC(Cc2ccc(cc2)C(N)=O)CC1)c1ccc(C)c(Cl)c1	Phase 1	CCR5	CC chemokine receptor antagonist		
TAK-243	NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O	Phase 1		ubiquitin activating enzyme inhibitor		
TAK-285	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(c4)C(F)(F)F)c(Cl)c3)c12	Phase 1	ERBB2	EGFR inhibitor		
TAK-593	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1	Phase 1	PDGFRA	VEGFR inhibitor		
TAK-632	Fc1ccc(Oc2ccc3nc(NC(=O)C4CC4)sc3c2C#N)cc1NC(=O)Cc1cccc(c1)C(F)(F)F	Preclinical	BRAF	RAF inhibitor		
TAK-659	Cn1cc(cn1)-c1nc(N[C@@H]2CCCC[C@@H]2N)c(F)c2CNC(=O)c12	Phase 2		spleen associated tyrosine kinase inhibitor		
TAK-715	CCc1nc(c(s1)-c1ccnc(NC(=O)c2ccccc2)c1)-c1cccc(C)c1	Phase 2	MAPK14	p38 MAPK inhibitor		
TAK-733	Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O	Phase 1	MAP2K1	MEK inhibitor		
TAK-779	Cc1ccc(cc1)-c1ccc2CCCC(=Cc2c1)C(=O)Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1 |c:15|	Preclinical		CC chemokine receptor antagonist		
TAK-875	Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3[C@H](CC(O)=O)COc3c2)c1	Phase 3	FFAR1	insulin secretagogue		
TAK-901	CCS(=O)(=O)c1cccc(c1)-c1cc(C(=O)NC2CCN(C)CC2)c(C)c2[nH]c3ncc(C)cc3c12	Phase 1	AURKB	Aurora kinase inhibitor		
TAK-960	COc1cc(C(=O)NC2CCN(C)CC2)c(F)cc1Nc1ncc2N(C)C(=O)C(F)(F)CN(C3CCCC3)c2n1	Phase 1	PLK1	PLK inhibitor		
talabostat	CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O	Phase 3	DPP4	dipeptidyl peptidase inhibitor, fibroblast activation protein inhibitor		
taladegib	CN(C1CCN(CC1)c1nnc(-c2ccnn2C)c2ccccc12)C(=O)c1ccc(F)cc1C(F)(F)F	Phase 2	DHH|IHH|SMO	smoothened receptor antagonist		
talampanel	C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1 |c:14|	Phase 2	GRIA1|GRIA2|GRIA3|GRIA4	glutamate receptor antagonist		
talaporfin	CCc1c(C)c2cc3[nH]c(cc4nc([C@@H](CCC(O)=O)[C@@H]4C)c(CC(=O)N[C@@H](CC(O)=O)C(O)=O)c4nc(cc1[nH]2)c(C)c4C(O)=O)c(C)c3C=C	Phase 3		photosensitizing agent		
talarozole	CCC(CC)[C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1 |&1:5	Phase 2	CYP26A1	cytochrome P450 inhibitor		
talazoparib	Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1	Launched	PARP2	PARP inhibitor	oncology	breast cancer
talinolol	CC(C)(C)NC[C@@H](O)COc1ccc(NC(=O)NC2CCCCC2)cc1 |&1:6	Launched	ADRB1	adrenergic receptor antagonist	cardiology	hypertension
talipexole	Nc1nc2CCN(CC=C)CCc2s1	Launched	ADRA2A|DRD2|HTR3A	adrenergic receptor agonist, dopamine receptor agonist	infectious disease	genitial herpes
talmapimod	C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C	Phase 2	IL1B|MAPK11|MAPK14|MT-CO2|TNF	p38 MAPK inhibitor		
talnetant	CC[C@H](NC(=O)c1c(O)c(nc2ccccc12)-c1ccccc1)c1ccccc1	Phase 2	TACR2|TACR3	tachykinin antagonist		
talniflumate	FC(F)(F)c1cccc(Nc2ncccc2C(=O)O[C@H]2OC(=O)c3ccccc23)c1 |&1:19	Launched	CLCA1	cyclooxygenase inhibitor	neurology/psychiatry	pain relief
talopram	CNCCC[C@]1(OC(C)(C)c2ccccc12)c1ccccc1 |&1:5|	Phase 2	SLC6A2	adrenergic inhibitor		
talsaclidine	C#CCO[C@H]1CN2CCC1CC2	Phase 2/Phase 3		acetylcholine receptor agonist		
taltirelin	CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(N)=O	Launched	TRHR	thyrotropin releasing hormone receptor agonist	neurology/psychiatry	spinocerebellar ataxia
taltobulin	CN[C@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)C(C)(C)c1ccccc1	Phase 1		tubulin polymerization inhibitor		
TAME	COC(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1ccc(C)cc1	Preclinical				
tamibarotene	CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12	Launched	RARA|RARB	retinoid receptor agonist	hematologic malignancy	acute promyelocytic leukemia (APL)
taminadenant	Nc1nc(nc(c1Br)-n1cccn1)-n1cccn1	Phase 1/Phase 2		adenosine receptor antagonist		
tamoxifen	CC\C(=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1	Launched	EBP|ESR1|ESR2|GPER1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG|PRKCI|PRKCQ|PRKCZ	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	oncology	breast cancer
tamsulosin	CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(c1)S(N)(=O)=O	Launched	ADRA1A|ADRA1B|ADRA1D	adrenergic receptor antagonist	urology	benign prostatic hyperplasia (BPH)
tanaproget	Cn1c(ccc1-c1ccc2NC(=S)OC(C)(C)c2c1)C#N	Phase 2	PGR	progesterone receptor agonist		
tandospirone	O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(CC1)c1ncccn1	Launched	HTR1A	serotonin receptor agonist	neurology/psychiatry	generalized anxiety disorder (GAD), dysthymic disorder
tandutinib	COc1cc2c(ncnc2cc1OCCCN1CCCCC1)N1CCN(CC1)C(=O)Nc1ccc(OC(C)C)cc1	Phase 2	CSF1R|FLT3|KIT|PDGFD|PDGFRB	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor		
tanespimycin	CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |c:7	Phase 3	HSP90AA1	HSP inhibitor		
tangeritin	COc1ccc(cc1)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1	Preclinical		cell cycle inhibitor		
tannic-acid	Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1	Launched	ANO1	PARG inhibitor	gastroenterology	constipation
tanshinone-I	Cc1coc-2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12	Phase 2	IFNG	AP inhibitor		
tanshinone-IIA	Cc1coc-2c1C(=O)C(=O)c1c3CCCC(C)(C)c3ccc-21	Phase 2/Phase 3	IL1B|NR1I2|TNF	anti-inflammatory agent, interleukin inhibitor		
tapinarof	CC(C)c1c(O)cc(\C=C\c2ccccc2)cc1O	Phase 3		aryl hydrocarbon receptor agonist		
taprenepag	OC(=O)COc1cccc(CN(Cc2ccc(cc2)-n2cccn2)S(=O)(=O)c2cccnc2)c1	Phase 2	PTGER2	prostaglandin receptor agonist		
tarafenacin	Fc1cccc(c1)N(Cc1cc(F)c(F)c(F)c1)C(=O)O[C@H]1C[N@@]2CC[C@H]1CC2	Phase 2	CHRM3	acetylcholine receptor antagonist		
taranabant	C[C@H](NC(=O)C(C)(C)Oc1ccc(cn1)C(F)(F)F)[C@@H](Cc1ccc(Cl)cc1)c1cccc(c1)C#N	Phase 3	CNR1	cannabinoid receptor inverse agonist		
targinine	CNC(=N)NCCC[C@H](N)C(O)=O	Phase 3	NOS3	nitric oxide synthase inhibitor		
tariquidar	COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC	Phase 3	ABCB1	P glycoprotein inhibitor		
tartaric-acid	O[C@H]([C@@H](O)C(O)=O)C(O)=O	Launched		antioxidant		
TAS-103	CN(C)CCNc1nc2cc(O)ccc2c2-c3ccccc3C(=O)c12	Phase 1	TOP1	topoisomerase inhibitor		
taselisib	CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O	Phase 3	PIK3CA	PI3K inhibitor		
tasimelteon	CCC(=O)NC[C@@H]1C[C@H]1c1cccc2OCCc12	Launched	MTNR1A|MTNR1B	melatonin receptor agonist	neurology/psychiatry	Non-24-Hour Sleep-Wake Disorder
tasisulam	Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1	Phase 3		apoptosis stimulant		
tasquinimod	COc1cccc2n(C)c(=O)c(C(=O)N(C)c3ccc(cc3)C(F)(F)F)c(O)c12	Phase 3	HDAC4	angiogenesis inhibitor, S100A9 inhibitor		
tasuldine	C(Sc1ncccn1)c1cccnc1	Phase 3		mucolytic agent		
taurine	NCCS(O)(=O)=O	Launched		antioxidant	neurology/psychiatry	anxiety, irritability, sleeplessness
taurocholate	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C	Phase 1	CEL|FABP6|SLCO1C1	G protein-coupled receptor agonist		
tauroglycocholate	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O	Preclinical		membrane permeability enhancer		
taurolidine	O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1	Launched		apoptosis stimulant	infectious disease	catheter-related bloodstream infection
tavaborole	OB1OCc2cc(F)ccc12	Launched		leucyl-tRNA synthetase inhibitor	infectious disease	onychomycosis
tavilermide	NCCCC[C@@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(O)=O)[N+]([O-])=O	Phase 3		tyrosine kinase partial agonist		
taxifolin	O[C@@H]1[C@H](Oc2cc(O)cc(O)c2C1=O)c1ccc(O)c(O)c1	Phase 2	ADIPOR2	opioid receptor antagonist		
tazarotene	CCOC(=O)c1ccc(nc1)C#Cc1ccc2SCCC(C)(C)c2c1	Launched	RARA|RARB|RARG|RXRB	retinoid receptor agonist	dermatology	cosmetic, sunscreen lotion
tazemetostat	CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1	Launched	EZH2	histone lysine methyltransferase inhibitor		
tazobactam	C[C@]1(Cn2ccnn2)[C@@H](N2[C@@H](CC2=O)S1(=O)=O)C(O)=O	Launched		beta lactamase inhibitor	infectious disease	pneumonia
TBA-354	[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(nc1)-c1ccc(OC(F)(F)F)cc1	Phase 1				
TBOA-(DL)	N[C@@H]([C@H](OCc1ccccc1)C(O)=O)C(O)=O.N[C@H]([C@@H](OCc1ccccc1)C(O)=O)C(O)=O	Preclinical	SLC1A1|SLC1A2|SLC1A3|SLC1A6|SLC1A7	excitatory amino acid transporter inhibitor		
TC-A-2317	C[C@@H](CCCC(C)(C)O)Nc1nc(Nc2cc(C)n[nH]2)cc(C)c1C#N |&1:1|	Preclinical	AURKA	Aurora kinase inhibitor		
TC-ASK-10	CC(C)(C)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-n1ccnc1	Preclinical	MAP3K5|MAP3K6	MAP kinase inhibitor		
TC-E-5002	ON(CCC(O)=O)C(=O)CCCCCCCCC1CC1	Preclinical	KDM2A|KDM4A|KDM4C|KDM5A|KDM6A|KDM7A|PHF8	histone demethylase inhibitor		
TC-E-5006	C[C@@H](C(O)=O)c1ccc([C@@H](N2CCC(C)CC2)c2ccc(F)cc2)c(c1)-c1ccc(cc1)C(F)(F)F |&1:1	Preclinical	APP	gamma secretase modulator		
TC-F-2	CCn1c2ccccc2n([C@H]2CCCN(C2)c2nccc(n2)-c2cc3ccccc3o2)c1=O	Preclinical	FAAH	FAAH inhibitor		
TC-FPR-43	CC(C)c1c(NC(=O)Nc2ccc(Cl)cc2)c(=O)n(-c2ccccc2)n1C	Preclinical	FPR2	formyl peptide receptor agonist		
TC-G-1000	Cc1sc(C)c2c1CCC=C2c1cnc[nH]1 |c:10|	Preclinical	ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist		
TC-G-1004	COC1CCN(CC1)c1cccc(n1)-c1cc(NC(C)=O)nc(n1)-n1nc(C)cc1C	Preclinical	ADORA2A	adenosine receptor antagonist		
TC-G-1005	Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc23)c1	Preclinical	GPBAR1	G protein-coupled receptor agonist		
TC-G-1008	CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(n1)-c1ccccn1	Preclinical	GPR39	G protein-coupled receptor agonist		
TC-H-106	Cc1ccc(NC(=O)CCCCCC(=O)Nc2ccccc2N)cc1	Preclinical	HDAC1|HDAC2|HDAC3|HDAC8	HDAC inhibitor		
TC-I-15	CC1(C)SCN([C@@H]1C(=O)N[C@@H](CNC(=O)NCc1ccccc1)C(O)=O)S(=O)(=O)c1ccccc1	Preclinical	ITGA2|ITGB1	integrin inhibitor		
TC-I-2000	Fc1ccc(NC(=O)N2CCc3ccccc3[C@@H]2c2ccc(cc2)C(F)(F)F)cc1 |&1:17	Preclinical	TRPM8	transient receptor potential channel antagonist		
TC-I-2014	FC(F)(F)c1ccccc1-c1cc(c2[nH]c(nc2c1)C1=NOC2(C1)CCCCC2)C(F)(F)F |t:22|	Preclinical	TRPM8	transient receptor potential channel antagonist		
TC-LPA5-4	COc1cccc(c1)-n1nc(cc1-c1ccc(C2CCCCC2)c(Cl)c1)C(O)=O	Preclinical	LPAR5	lysophosphatidic acid receptor antagonist		
TC-Mps1-12	CC(C)(C)Nc1nc(Nc2ccc(cc2)C(N)=O)cc(N)c1C#N	Preclinical	TTK	monopolar spindle 1 kinase inhibitor		
TC-N-1752	CC(=O)Nc1cccc(Nc2ncnc(n2)N2CCC(CC2)OCc2ccc(OC(F)(F)F)cc2)c1C	Preclinical	SCN9A	sodium channel blocker		
TC-NTR1-17	COc1cccc(OC)c1-c1cc(nn1-c1ccnc2cc(Cl)ccc12)C(=O)N[C@@H](CC(C)C)C(O)=O	Preclinical	NTSR1	neurotensin agonist		
TC-O-9311	COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1cccc2ccccc12	Preclinical	GPR139	G protein-coupled receptor agonist		
TC-OT-39	CN1CCCN(CC1)C(=S)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1Cc2cnn(C)c2Nc2ccccc12	Preclinical	AVPR1A|OXT	oxytocin receptor agonist, vasopressin receptor agonist		
TC-S-7003	CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n2c(nc4ccccc24)n(-c2c(C)cccc2C)c3=O)cc1	Preclinical	LCK	SRC inhibitor		
TC-S-7004	COc1ncc2cc(C(=O)Nc3cc(ccc3Cl)C(=O)NCc3cccc(Cl)c3)c(=O)[nH]c2n1	Preclinical	DYRK1A|DYRK1B	DYRK inhibitor		
TC-S-7005	C[C@H](Nc1cc2c(noc2cn1)-c1ccc2OCOc2c1)c1ccccc1	Preclinical	PLK2	PLK inhibitor		
TC-S-7006	Fc1ccc(Nc2c(cnc3cnc(NCc4cccnc4)cc23)C#N)cc1Cl	Preclinical	MAP3K8	MAP kinase inhibitor		
TC-S-7009	[O-][N+](=O)c1c(Nc2cc(F)cc(Cl)c2)ccc2nonc12	Preclinical	EPAS1	hypoxia inducible factor inhibitor		
TC-SP-14	OC(=O)C1CN(Cc2ccc(-c3nc4cc(Cc5ccccc5F)ccc4s3)c(F)c2)C1	Preclinical	S1PR1	sphingosine 1-phosphate receptor agonist		
TCID	Clc1c2C(=O)CC(=O)c2c(Cl)c(Cl)c1Cl	Preclinical				
TCN201	Fc1ccc(cc1Cl)S(=O)(=O)NCc1ccc(cc1)C(=O)NNC(=O)c1ccccc1	Preclinical	GRIN2A	glutamate receptor antagonist		
TCN238	Nc1nccc(\C=C\c2ccccc2)n1	Preclinical	GRM4	glutamate receptor positive allosteric modulator		
TCS-HDAC6-20b	CC(C)C(=O)SCCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)NC12CC3CC(CC(C3)C1)C2	Preclinical	HDAC6	HDAC inhibitor		
TCS-OX2-29	COc1cc2CCN(Cc2cc1OC)C(=O)[C@@H](NCc1ccncc1)C(C)(C)C	Preclinical	HCRTR2	orexin receptor antagonist		
TCS-PIM-1-1	Oc1ccc(Br)cc1-c1cc(-c2ccccc2)c(C#N)c(=O)[nH]1	Preclinical	PIM1	Pim kinase inhibitor		
TCS-2002	Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)[S@](C)=O)c2c1 |&1:19	Preclinical	GSK3B	glycogen synthase kinase inhibitor		
TCS-21311	CC(C)(O)C(=O)N1CCN(CC1)c1ccc(c(c1)C1=C(C(=O)NC1=O)c1c[nH]c2ccccc12)C(F)(F)F |t:20|	Preclinical	JAK3	JAK inhibitor		
TCS-2210	ONC(=O)c1ccc2[nH]c(=O)c(CCCc3ccccc3)nc2c1	Preclinical		neural stem cell inducer		
TCS-2314	Cc1ccccc1NC(=O)Nc1ccc(CC(=O)N2CCOC[C@H]2C(=O)N2CCC(CC(O)=O)CC2)cc1	Preclinical	ITGA4|ITGB1	integrin inhibitor		
TCS-3035	OC(=O)COc1ccc(\C=C2/SC(=O)NC2=O)cc1	Preclinical	GPR35	G protein-coupled receptor agonist		
TCS-359	COc1ccc(cc1OC)C(=O)Nc1sc2CCCCc2c1C(N)=O	Preclinical	FLT3	FLT3 inhibitor		
TCS-5861528	CC[C@@H](C)c1ccc(NC(=O)Cn2cnc3n(C)c(=O)n(C)c(=O)c23)cc1 |&1:2	Preclinical	TRPA1	transient receptor potential channel antagonist		
TCV-309	CCC[n+]1cc(Br)cc(c1)C(=O)N(CCC(=O)NCCOC(=O)N1CCc2ccccc2C1)c1ccccc1	Preclinical		platelet activating factor receptor antagonist		
TC1	O[C@@]12[C@H]3[C@H]4[C@H]5[C@@H]3[C@@H]([C@H]3[C@@H]5C[C@@H]4[C@@H]13)N2CCc1cccc(F)c1 |&1:1	Preclinical	BACE1	beta-secretase inhibitor		
TC2559	CCOc1cncc(\C=C\CCNC)c1	Preclinical	CHRNA4	acetylcholine receptor agonist		
TD139	OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)n2cc(nn2)-c2cccc(F)c2)[C@H](O)[C@H]([C@H]1O)n1cc(nn1)-c1cccc(F)c1	Phase 2		anti-inflammatory agent		
tebipenem	C[C@@H](O)[C@@H]1[C@H]2[C@@H](C)C(SC3CN(C3)C3=NCCS3)=C(N2C1=O)C(=O)OCOC(=O)C(C)(C)C |c:19	Launched	CNR1	bacterial cell wall synthesis inhibitor	infectious disease, otolaryngology	pneumonia, otitis
tecadenoson	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N[C@@H]3CCOC3)ncnc12	Phase 2	ADORA1	adenosine receptor agonist		
tecalcet	COc1cccc(c1)[C@@H](C)NCCCc1ccccc1Cl	Phase 2	CASR	calcium-sensing receptor agonist		
tecastemizole	Fc1ccc(Cn2c(NC3CCNCC3)nc3ccccc23)cc1	Phase 3	KCNH2	histamine receptor antagonist		
tecovirimat	FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O |c:20|	Launched		orthopoxvirus egress inhibitor	infectious disease	smallpox
tedizolid	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](CO)OC1=O	Launched		bacterial 50S ribosomal subunit inhibitor	infectious disease	skin infections
tedizolid-phosphate	Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O	Launched		protein synthesis inhibitor	infectious disease	skin infections
tegaserod	CCCCCNC(=N)N\N=C\c1c[nH]c2ccc(OC)cc12	Withdrawn	HTR2A|HTR2B|HTR2C|HTR4	serotonin receptor partial agonist		
tegobuvir	Fc1ccccc1-c1nc2ccn(Cc3ccc(nn3)-c3ccc(cc3C(F)(F)F)C(F)(F)F)cc2n1	Phase 3		HCV inhibitor, protease inhibitor		
teicoplanin	CCCCCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
teicoplanin-A2-1	CCCCC\C=C\CCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O)[C@@H]1NC(=O)[C@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@H](NC1=O)C(O)=O)c5)cc3Cl |a:12	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
teicoplanin-A2-3	CC(C)CCCCCCCC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(C[C@H]4NC(=O)[C@H](N)c5ccc(O)c(Oc6cc(O)cc(c6)[C@H](NC4=O)C(=O)N[C@H]4c(c2)cc1Oc1ccc(cc1Cl)[C@@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1NC(C)=O)[C@@H]1NC(=O)[C@@H](NC4=O)c2ccc(O)c(c2)-c2c(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]4O)cc(O)cc2[C@@H](NC1=O)C(O)=O)c5)cc3Cl	Launched		bacterial cell wall synthesis inhibitor	infectious disease	gram-positive bacterial infections
teijin-compound-1	FC(F)(F)c1cccc(c1)C(=O)NCC(=O)N[C@@H]1CCN(Cc2ccc(Cl)cc2)C1	Preclinical	CCR2	CC chemokine receptor antagonist		
telaprevir	CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1	Launched	CTSA|PGR	HCV inhibitor	infectious disease	hepatitis C
telatinib	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1	Phase 2	KDR	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
telbivudine	Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O	Launched		DNA polymerase inhibitor	infectious disease	hepatitis B
telcagepant	Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F	Phase 3	CALCRL|RAMP1	calcitonin antagonist		
telenzepine	CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc3ccccc23)CC1	Phase 3	CHRM1	acetylcholine receptor antagonist		
telithromycin	CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(c3)-c3cccnc3)C(=O)O[C@]12C)OC	Launched	CYP1A2|CYP2D6|CYP3A4|CYP3A5|CYP3A7	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor	infectious disease	pneumonia
telmesteine	CCOC(=O)N1CSC[C@@H]1C(O)=O |&1:9	Launched		mucolytic agent	pulmonary	cough suppressant
telmisartan	CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C	Launched	AGTR1|PPARG	angiotensin receptor antagonist	cardiology	hypertension
telotristat	Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F	Launched	TPH1	tryptophan hydroxylase inhibitor	gastroenterology	diarrhea
telotristat-ethyl	CCOC(=O)[C@@H](N)Cc1ccc(cc1)-c1cc(O[C@H](c2ccc(Cl)cc2-n2ccc(C)n2)C(F)(F)F)nc(N)n1	Launched	TPH1	tryptophan hydroxylase inhibitor	gastroenterology	diarrhea
telratolimod	CCCCCCCCCCCCCCCCCC(=O)NCCCCOn1c(CCCC)nc2c(N)nc3ccccc3c12	Preclinical		toll-like receptor agonist		
temanogrel	COc1cccc(c1)C(=O)Nc1ccc(OCCN2CCOCC2)c(c1)-c1ccnn1C	Preclinical		serotonin receptor antagonist		
temefos	COP(=S)(OC)Oc1ccc(Sc2ccc(OP(=S)(OC)OC)cc2)cc1	Launched		cholinesterase inhibitor		
temocapril	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CS[C@@H](CN(CC(O)=O)C1=O)c1cccs1	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology, nephrology	hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)
temoporfin	Oc1cccc(c1)-c1c2CCc([nH]2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1n2	Launched		radical formation stimulant	oncology	head and neck squamous cell carcinoma (HNSCC)
temozolomide	Cn1nnc2c(ncn2c1=O)C(N)=O	Launched	MGMT	DNA alkylating agent	oncology	glioblastoma, astrocytoma
tempol	CC1(C)CC(O)CC(C)(C)N1O	Phase 2		free radical scavenger		
temsirolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO |c:14	Launched	MTOR	mTOR inhibitor	oncology	renal cell carcinoma (RCC)
TEN-010	CN1CCN(CCCNC(=O)C[C@@H]2N=C(c3c(C)c(C)sc3-n3c(C)nnc23)c2ccc(Cl)cc2)CC1 |c:13|	Preclinical		bromodomain inhibitor		
tenalisib	CC[C@H](Nc1ncnc2nc[nH]c12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1	Phase 2		PI3K inhibitor		
tenapanor	CN1C[C@@H](c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c2cccc(c2)[C@@H]2CN(C)Cc3c(Cl)cc(Cl)cc23)c2cc(Cl)cc(Cl)c2C1	Launched		sodium/hydrogen exchanger inhibitor		
tenatoprazole	COc1ccc2[nH]c(nc2n1)[S@@](=O)Cc1ncc(C)c(OC)c1C |r|	Phase 2	IDO1	ATPase inhibitor		
teneligliptin	Cc1cc(N2CCN(CC2)[C@@H]2CN[C@@H](C2)C(=O)N2CCSC2)n(n1)-c1ccccc1	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
tenidap	NC(=O)N1C(=O)[C@@H](C(=O)c2cccs2)c2cc(Cl)ccc12 |&1:6	Phase 3	KCNJ4|PTGS1	cyclooxygenase inhibitor		
tenilsetam	O=C1NCCN[C@@H]1c1cccs1 |&1:6	Phase 3		AGE inhibitor		
teniposide	COc1cc(cc(OC)c1O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@H](O[C@H]3[C@H](O)[C@H]2O)c2cccs2)c2cc3OCOc3cc12	Launched	TOP2A|TOP2B	topoisomerase inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
tenofovir	C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O	Launched		HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1), hepatitis B
tenofovir-alafenamide	CC(C)OC(=O)[C@@H](C)NP(=O)(CO[C@@H](C)Cn1cnc2c(N)ncnc12)Oc1ccccc1 |&1:6	Launched		nucleoside reverse transcriptase inhibitor	infectious disease	hepatitis B
tenofovir-disoproxil	CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)OCOC(=O)OC(C)C	Launched	CYP1A2	nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1), hepatitis B
tenovin-1	CC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	Preclinical	SIRT1	SIRT inhibitor, TP53 activator		
tenovin-6	CN(C)CCCCC(=O)Nc1ccc(NC(=S)NC(=O)c2ccc(cc2)C(C)(C)C)cc1	Preclinical	SIRT1|SIRT2|SIRT3	SIRT inhibitor		
tenoxicam	CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O |t:12|	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology, orthopedics	rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis
tenylidone	O=C1\C(CCC\C1=C/c1cccs1)=C\c1cccs1	Preclinical				
tepoxalin	COc1ccc(cc1)-n1nc(CCC(=O)N(C)O)cc1-c1ccc(Cl)cc1	Launched	ALOX5	cyclooxygenase inhibitor, lipoxygenase inhibitor	rheumatology, orthopedics	rheumatoid arthritis, hip dysplasia
TEPP-46	Cn1c2cc(sc2c2cnn(Cc3cccc(N)c3)c(=O)c12)[S@@](C)=O |r|	Preclinical	PKM	pyruvate kinase isozyme activator		
teprenone	CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O	Launched		mucus protecting agent	dermatology	cosmetic
terameprocol	COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC	Phase 1/Phase 2	BIRC5|CDK1	lipoxygenase inhibitor		
terazosin	COc1cc2nc(nc(N)c2cc1OC)N1CCN(CC1)C(=O)[C@H]1CCCO1 |&1:23	Launched	ADRA1A|ADRA1B|ADRA1D	adrenergic receptor antagonist	urology, cardiology	benign prostatic hyperplasia (BPH), hypertension
terbinafine	CN(C\C=C\C#CC(C)(C)C)Cc1cccc2ccccc12	Launched	SQLE	fungal squalene epoxidase inhibitor	infectious disease	tinea pedis, tinea cruris, tinea corporis
terbutaline	CC(C)(C)NC[C@@H](O)c1cc(O)cc(O)c1 |&1:6|	Launched	ADRB2	adrenergic receptor agonist	pulmonary	bronchospasm, bronchitis, emphysema
terciprazine	O[C@@H](COC1(CCCCC1)C#C)CN1CCN(CC1)c1cccc(c1)C(F)(F)F |&1:1	Phase 1				
terconazole	CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1	Launched		sterol demethylase inhibitor	infectious disease	vulvovaginal candidiasis
terfenadine	CC(C)(C)c1ccc(cc1)[C@@H](O)CCCN1CCC(CC1)C(O)(c1ccccc1)c1ccccc1 |&1:10	Withdrawn	HRH1|KCNH1|KCNH2	histamine receptor antagonist		
terguride	CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1 |a:8	Launched	ADRA1A|ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|DRD4|HTR1A|HTR1B|HTR1D|HTR2A|HTR2B|HTR2C	dopamine receptor agonist, serotonin receptor antagonist	neurology/psychiatry	Parkinson's Disease
teriflunomide	CC(=O)[C@@H](C#N)C(=O)Nc1ccc(cc1)C(F)(F)F |&1:3	Launched	DHODH	dihydroorotate dehydrogenase inhibitor	neurology/psychiatry	multiple sclerosis
terlipressin	NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O	Launched	AVPR1A	vasopressin receptor agonist	cardiology	hypotension
terodiline	C[C@@H](CC(c1ccccc1)c1ccccc1)NC(C)(C)C |&1:1|	Withdrawn		cholinergic receptor antagonist		
teroxirone	O=c1n(C[C@H]2CO2)c(=O)n(C[C@H]2CO2)c(=O)n1C[C@H]1CO1 |&1:4	Phase 1		DNA inhibitor		
terpene	CC(C)(O)[C@H]1CC[C@](C)(O)CC1 |&1:7	Preclinical				
terreic-acid-(-)		Preclinical	BTK	Bruton's tyrosine kinase (BTK) inhibitor		
terutroban	Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1	Phase 3	TBXA2R	prostanoid receptor antagonist		
tesaglitazar	CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(O)=O	Phase 3	PPARA|PPARG	insulin sensitizer, PPAR receptor agonist		
tetomilast	CCOc1ccc(cc1OCC)-c1nc(cs1)-c1cccc(n1)C(O)=O	Phase 2	PDE4D	phosphodiesterase inhibitor		
tetrabenazine	COc1cc2CCN3C[C@H](CC(C)C)C(=O)C[C@H]3c2cc1OC	Launched	SLC18A1|SLC18A2	vesicular monoamine transporter inhibitor	infectious disease, neurology/psychiatry	cholera, Huntington's disease
tetracaine	CCCCNc1ccc(cc1)C(=O)OCCN(C)C	Launched	SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	membrane integrity inhibitor	neurology/psychiatry	anesthetic
tetracycline	[H][C@@]12C[C@@]3([H])[C@@H](C(=O)c4c(O)cccc4[C@@]3(C)O)C(=O)[C@]1(O)C(=O)[C@@H](C(N)=O)C(=O)[C@H]2N(C)C |&1:24	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease, dermatology	respiratory tract infections, pneumonia, skin infections, urinary tract infections, acne vulgaris (AV), plague, psittacosis
tetradecylthioacetic-acid	CCCCCCCCCCCCCCSCC(O)=O	Phase 2		lipid peroxidase inhibitor		
tetraethylenepentamine	NCCNCCNCCNCCN	Phase 2/Phase 3	SOD1|SOD2	superoxide dismutase inhibitor		
tetrahydrofolic-acid	Nc1nc(=O)c2N[C@@H](CNc3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)CNc2[nH]1 |a:19	Launched	FOLR2			
tetrahydropapaverine	COc1ccc(C[C@H]2NCCc3cc(OC)c(OC)cc23)cc1OC |&1:7|	Preclinical				
tetrahydrouridine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1CC[C@@H](O)NC1=O |a:2	Phase 2	CDA	cytidine deaminase inhibitor		
tetrahydrozoline	C1CN=C(N1)[C@H]1CCCc2ccccc12 |&1:5	Launched		adrenergic receptor agonist	ophthalmology	eye irritation
tetramethylthiuram-monosulfide	CN(C)C(=S)SC(=S)N(C)C	Preclinical				
tetramisole	C1CN2C[C@@H](N=C2S1)c1ccccc1 |&1:4	Launched	ALPPL2|CHRNA3	immunostimulant	infectious disease	gastrointestinal parasites
tetrandrine	COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34	Preclinical	SLC6A3	calcium channel blocker		
tetrazol-5-yl-glycine-(RS)	N[C@@H](C(O)=O)c1nn[nH]n1 |&1:1	Preclinical	GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor agonist		
tetrindole	C1CCC(CC1)c1ccc2n3CCNC4CCCc(c34)c2c1	Phase 3	MAOA	monoamine oxidase inhibitor		
tetroquinone	OC1C(=O)C(=O)C(O)C(=O)C1=O	Preclinical				
tezacaftor	CC(C)(CO)c1cc2cc(NC(=O)C3(CC3)c3ccc4OC(F)(F)Oc4c3)c(F)cc2n1C[C@@H](O)CO	Launched		CFTR channel agonist	pulmonary	cystic fibrosis
TFC-007	O=C(Nc1ccc(cc1)N1CCC(CC1)C(=O)N1CCOCC1)c1cnc(Oc2ccccc2)nc1	Preclinical	HPGDS	prostaglandin inhibitor		
TG-003	CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O	Preclinical	CLK1|CLK4|DYRK1A|DYRK1B	CLK inhibitor		
TG-02	CN1C\C=C\CCOc2cccc(c2)-c2ccnc(Nc3cccc(C1)c3)n2 |t:3|	Phase 1/Phase 2	CDK1|CDK2|CDK7|CDK9|FLT3|JAK2	CDK inhibitor, FLT3 inhibitor, JAK inhibitor		
TG-100572	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(O)ccc1Cl	Preclinical	KDR|SRC	SRC inhibitor, VEGFR inhibitor		
TG-100713	Nc1nc(N)c2nc(cnc2n1)-c1cccc(O)c1	Preclinical		PI3K inhibitor		
TG-100801	Cc1cc(cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12)-c1cc(OC(=O)c2ccccc2)ccc1Cl	Phase 2	CSK|FGFR1|FLT1|FLT4|KDR|SRC	SRC inhibitor, VEGFR inhibitor		
TG-101209	CN1CCN(CC1)c1ccc(Nc2ncc(C)c(Nc3cccc(c3)S(=O)(=O)NC(C)(C)C)n2)cc1	Preclinical	JAK2|JAK3	JAK inhibitor		
TGR-1202	CC(C)Oc1ccc(cc1F)-c1nn([C@@H](C)c2oc3ccc(F)cc3c(=O)c2-c2cccc(F)c2)c2ncnc(N)c12	Phase 3		PI3K inhibitor		
TGX-221	C[C@@H](Nc1ccccc1)c1cc(C)cn2c1nc(cc2=O)N1CCOCC1 |&1:1	Preclinical	PIK3CB|PIK3CD	PI3K inhibitor		
TG100-115	Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1	Phase 1/Phase 2	PIK3CA|PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
TH-302	Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O	Phase 3		DNA alkylating agent		
TH-588	Nc1nc(NC2CC2)cc(n1)-c1cccc(Cl)c1Cl	Preclinical	NUDT1	MTH1 inhibitor		
thaliblastine	COc1cc(C[C@@H]2N(C)CCc3cc(OC)c(OC)cc23)c(Oc2cc3C[C@@H]4N(C)CCc5cc(OC)c(OC)c(-c3cc2OC)c45)cc1OC	Phase 2		DNA inhibitor		
thalidomide	O=C1N([C@H]2CCC(=O)NC2=O)C(=O)c2ccccc12 |&1:3	Launched	TNF	tumor necrosis factor production inhibitor	oncology	myeloma
theaflavin	O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(=O)c2c(O)c(O)cc(cc12)[C@H]1Oc2cc(O)cc(O)c2C[C@H]1O	Preclinical		antiviral		
theobromine	Cn1cnc2n(C)c(=O)[nH]c(=O)c12	Launched	ADORA1|ADORA2A|PDE4B	phosphodiesterase inhibitor		
thiamet-g	CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1 |t:3|	Preclinical	MGEA5	GLCNAC phosphotransferase inhibitor		
thiamine	Cc1c(CCO)sc[n+]1Cc1cnc(C)nc1N	Launched	SLC19A2|SLC19A3|TPK1	vitamin B	metabolism	thiamine deficiency
thiamine-pyrophosphate	Cc1c(CCOP(O)(=O)OP(O)(O)=O)sc[n+]1Cc1cnc(C)nc1N |&1:6|	Launched			hematology	anemia
thiamphenicol	CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl	Launched		bacterial 50S ribosomal subunit inhibitor	infectious disease	pelvic inflammatory disease
thiamylal	CCC[C@@H](C)C1(CC=C)C(=O)NC(=S)NC1=O |&1:3	Launched	GABRA1	glutamate receptor antagonist	neurology/psychiatry	sedative
thiazovivin	O=C(NCc1ccccc1)c1csc(Nc2ccncn2)n1	Preclinical		rho associated kinase inhibitor		
thiethylperazine	CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched	DRD1|DRD2|DRD4	dopamine receptor antagonist	gastroenterology	nausea
thiocolchicoside	COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2CC[C@H](NC(C)=O)c3cc(=O)c(SC)ccc3-c2c1OC	Launched	GABRA1|GABRB2|GABRG2|GLRA1|GLRB	GABA receptor antagonist	neurology/psychiatry	muscle relaxant
thioctic-acid	OC(=O)CCCC[C@H]1CCSS1 |&1:7	Launched	ACHE|PTGS2	reducing agent	nephrology	diabetic nephropathy
thiodiglycol	OCCSCCO	Preclinical				
thioguanine	Nc1nc2nc[nH]c2c(=S)[nH]1	Launched	IMPDH1|IMPDH2	purine antagonist	hematologic malignancy	acute myeloid leukemia (AML)
thiomersal	CC[Hg]Sc1ccccc1C(O)=O	Launched	OXCT1	other antibiotic	infectious disease	preservative
thiopental	CCC[C@@H](C)C1(CC)C(=O)NC(=S)NC1=O |&1:3	Launched	FAAH	GABA receptor antagonist	neurology/psychiatry	anesthetic
thioperamide	S=C(NC1CCCCC1)N1CCC(CC1)[C@H]1C=NC=N1 |r	Preclinical	HRH3|HRH4	histamine receptor antagonist		
thiophanate	COC(=O)NC(=S)Nc1ccccc1NC(=S)NC(=O)OC	Preclinical				
thioproperazine	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1	Launched	ADRA1A|ADRA1B|DRD1|DRD2|HTR1A|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thioridazine	CSc1ccc2Sc3ccccc3N(CCC3CCCCN3C)c2c1	Withdrawn	DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR2A|HTR2C|HTR6|HTR7	dopamine receptor antagonist		
thiorphan	OC(=O)CNC(=O)[C@@H](CS)Cc1ccccc1 |&1:7	Phase 1	MME	membrane metalloendopeptidase inhibitor		
thiostrepton	CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]2NC(=O)c3csc(n3)[C@@H](NC(=O)[C@H]3CSC(=N3)\C(NC(=O)[C@@H](NC(=O)c3csc(n3)[C@]3(CCC(=N[C@@H]3c3csc2n3)c2nc(cs2)C(=O)NC(=C)C(=O)NC(=C)C(N)=O)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)=C\C)[C@](C)(O)[C@@H](C)O)[C@H](C)O |c:7	Launched	FOXM1	FOXM1 inhibitor, protein synthesis inhibitor	obstetrics/gynecology	mastitis
thiotepa	S=P(N1CC1)(N1CC1)N1CC1	Launched	CYP2B6|CYP3A4	cytochrome P450 inhibitor	oncology	breast cancer, ovarian cancer, bladder cancer
thiothixene	CN(C)S(=O)(=O)c1ccc2Sc3ccccc3\C(=C\CCN3CCN(C)CC3)c2c1	Launched	DRD1|DRD2|HRH1|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
thiram	CN(C)C(=S)SSC(=S)N(C)C	Launched	JAK2		ophthalmology	contact dermatitis
THK5351	CNc1ccc(cn1)-c1ccc2cc(OC[C@H](O)CF)ccc2n1	Phase 2		PET radiotracer 		
thonzonium	CCCCCCCCCCCCCCCC[N+](C)(C)CCN(Cc1ccc(OC)cc1)c1ncccn1	Launched		ATPase inhibitor	infectious disease	ear infections
thonzylamine	COc1ccc(CN(CCN(C)C)c2ncccn2)cc1	Launched		antihistamine	neurology/psychiatry	itching
threo-2-methylisocitrate-(DL)	[NaH].[NaH].[NaH].[NaH].[NaH].[NaH].CC(O)([C@@H](CC(O)=O)C(O)=O)C(O)=O.CC(O)([C@H](CC(O)=O)C(O)=O)C(O)=O |a:9	Preclinical		isocitrate lyase substrate		
thymalfasin	CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O	Launched		immune response modulator	infectious disease	hepatitis B, hepatitis C
thymol	CC(C)c1ccc(C)cc1O	Launched	TRPA1	GABA receptor positive allosteric modulator	infectious disease	ringworm, antiseptic
thymol-iodide	CC(C)c1cc(c(C)cc1OI)-c1cc(C(C)C)c(OI)cc1C	Preclinical				
thymopentin	CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	Launched		immune response stimulator		
THZ1	CN(C)C\C=C\C(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical	CDK7	CDK inhibitor		
THZ1-R	CN(C)CCCC(=O)Nc1ccc(cc1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical	CDK7	CDK inhibitor		
THZ2	CN(C)C\C=C\C(=O)Nc1cccc(c1)C(=O)Nc1cccc(Nc2ncc(Cl)c(n2)-c2c[nH]c3ccccc23)c1	Preclinical	CDK7	CDK inhibitor		
tiabendazole	c1nc(cs1)-c1nc2ccccc2[nH]1	Launched		angiogenesis inhibitor	infectious disease	gastrointestinal roundworms, hookworm
tiagabine	Cc1ccsc1C(=CCCN1CCC[C@H](C1)C(O)=O)c1sccc1C	Launched	SLC6A1	GABA uptake inhibitor	neurology/psychiatry	seizures
tianeptine	CN1c2ccccc2[C@@H](NCCCCCCC(O)=O)c2ccc(Cl)cc2S1(=O)=O |&1:8	Launched	OPRD1|OPRK1|OPRM1	selective serotonin reuptake enhancer (SSRE)	neurology/psychiatry, pulmonary, gastroenterology	depression, asthma, irritable bowel syndrome
tiapride	CCN(CC)CCNC(=O)c1cc(ccc1OC)S(C)(=O)=O	Launched	DRD2|DRD3	dopamine receptor antagonist	neurology/psychiatry	dyskinesia, abstinence from alcohol, psychosis
tiaprofenic-acid	C[C@@H](C(O)=O)c1ccc(s1)C(=O)c1ccccc1 |&1:1	Launched	PTGS2	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis
tiaramide	OCCN1CCN(CC1)C(=O)Cn1c2cc(Cl)ccc2sc1=O	Launched		anti-inflammatory agent	pulmonary	asthma
tibolone	C[C@@H]1CC2=C(CCC(=O)C2)[C@H]2CC[C@@]3(C)[C@H](CC[C@@]3(O)C#C)[C@@H]12 |a:1	Launched	ESR1	androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist	obstetrics/gynecology	endometriosis
ticagrelor	CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1	Launched	P2RY12	purinergic receptor antagonist	cardiology	acute coronary syndrome (ACS), myocardial infarction
ticarcillin	CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(O)=O)c3ccsc3)C(=O)N2[C@H]1C(O)=O	Launched		lactamase inhibitor	infectious disease	gram-negative bacterial infections
ticlopidine	Clc1ccccc1CN1CCc2sccc2C1	Launched	P2RY12	purinergic receptor antagonist	hematology, neurology/psychiatry	thrombosis, stroke
TIC10	Cc1ccccc1CN1C2=NCCN2C(=O)C2=C1CCN(Cc1ccccc1)C2 |c:18	Phase 2	AKT1|MAPK1	AKT inhibitor, TRAIL modulator		
tideglusib	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1	Phase 2	GSK3B	glycogen synthase kinase inhibitor		
tienilic-acid	OC(=O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl	Withdrawn	CYP2C9|SLC12A1	cytochrome P450 inhibitor, sodium/potassium/chloride transporter inhibitor		
tie2-kinase-inhibitor	COc1ccc2cc(ccc2c1)-c1[nH]c(nc1-c1ccncc1)-c1ccc(cc1)[S@@](C)=O |r|	Preclinical	KDR|MAPK14	TIE tyrosine kinase inhibitor		
tifenazoxide	CC1(CC1)NC1=NS(=O)(=O)c2sc(Cl)cc2N1 |t:6|	Phase 1	ABCC8|KCNJ11	ATP-sensitive potassium channel agonist		
tigecycline	[H][C@@]12Cc3c(cc(NC(=O)CNC(C)(C)C)c(O)c3C(=O)[C@@H]1C(=O)[C@]1(O)C(=O)[C@H](C(N)=O)C(=O)[C@@H](N(C)C)[C@]1([H])C2)N(C)C |&1:28	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	skin infections, pneumonia, intra-abdominal infections
tilmicosin	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H]([C@H]2O)N(C)C)[C@@H](CCN2C[C@@H](C)C[C@@H](C)C2)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:43	Launched		bacterial 50S ribosomal subunit inhibitor	pulmonary	bovine respiratory disease (BRD)
tilorone	CCN(CC)CCOc1ccc2-c3ccc(OCCN(CC)CC)cc3C(=O)c2c1	Launched		interferon inducer	infectious disease, gastroenterology, neurology/psychiatry	influenza A virus infection, diarrhea, hepatitis B, multiple sclerosis, urinary tract infections, virus herpes simplex (HSV), hepatitis C
tiludronate	OP(O)(=O)C(Sc1ccc(Cl)cc1)P(O)(O)=O	Launched	ATP6V1A|MMP2|PTPN1	bone resorption inhibitor, osteoclast inhibitor	orthopedics	navicular syndrome
timofibrate	CC(C)(Oc1ccc(Cl)cc1)C(=O)N1CSC[C@@H]1C(O)=O |&1:17	Phase 2	LPL	cholesterol inhibitor, lipase clearing factor inhibitor		
timolol	CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1	Launched	ADRB1|ADRB2	adrenergic receptor antagonist	ophthalmology	ocular hypertension, glaucoma
timonacic	OC(=O)[C@H]1CSCN1 |&1:3|	Launched		antioxidant		
tinazoline	C1CN=C(N1)Sc1c[nH]c2ccccc12 |c:2|	Launched		adrenergic receptor agonist		
tinidazole	CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O	Launched		antiprotozoal agent	infectious disease, obstetrics/gynecology	giardiasis, amebiasis, bacterial vaginosis, trichomoniasis
tinoridine	CCOC(=O)c1c(N)sc2CN(Cc3ccccc3)CCc12	Launched		anti-inflammatory agent	neurology/psychiatry	pain relief
tioconazole	Clc1sccc1CO[C@@H](Cn1ccnc1)c1ccc(Cl)cc1Cl |&1:8|	Launched		sterol demethylase inhibitor	infectious disease	yeast infection
tioguanine	Nc1nc(=S)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	Launched		purine antagonist	hematologic malignancy	acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML)
tiopronin	C[C@@H](S)C(=O)NCC(O)=O |&1:1	Launched		chelating agent, reducing agent	urology	kidney stones
tiotidine	CN=C(NCCSCc1csc(NC(N)=N)n1)NC#N	Phase 2	HRH2	histamine receptor antagonist		
tiotropium	C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1	Launched	CHRM1|CHRM2|CHRM3	acetylcholine receptor antagonist	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema
tioxolone	Oc1ccc2sc(=O)oc2c1	Preclinical	CA2	carbonic anhydrase inhibitor		
tipelukast	CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O	Phase 2		leukotriene receptor antagonist		
tipifarnib	Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2n(C)c(=O)cc(-c3cccc(Cl)c3)c2c1	Phase 3	FNTA|FNTB	farnesyltransferase inhibitor		
tipiracil	Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O	Launched		thymidine phosphorylase inhibitor	oncology	colorectal cancer
tiplaxtinin	OC(=O)C(=O)c1cn(Cc2ccccc2)c2ccc(cc12)-c1ccc(OC(F)(F)F)cc1	Phase 1	SERPINE1	plasminogen activator inhibitor		
tipranavir	CCC[C@@]1(CCc2ccccc2)CC(=O)[C@@H]([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 |a:3	Launched		HIV protease inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
tiprenolol	CSc1ccccc1OC[C@@H](O)CNC(C)C |&1:10	Phase 2	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist		
tiquizium	C[N@+]12CCCC[C@@H]1CCC(C2)=C(c1cccs1)c1cccs1	Launched		acetylcholine receptor antagonist	neurology/psychiatry	spasms
tiracizine	CCOC(=O)Nc1ccc2CCc3ccccc3N(C(=O)CN(C)C)c2c1	Withdrawn	SCN5A	sodium channel blocker		
tirapazamine	Nc1n[n+]([O-])c2ccccc2[n+]1[O-]	Phase 3		DNA inhibitor		
tirasemtiv	CCC(CC)n1c2nc(cnc2[nH]c1=O)C#C	Phase 2		troponin activator		
tiratricol	OC(=O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1	Launched	THRA|THRB	thyroid hormone stimulant	endocrinology	Refetoff syndrome
tirofiban	CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O	Launched	ITGA2B|ITGB3	platelet aggregation inhibitor, structural glycoprotein antagonist	cardiology	myocardial infarction, refactory angina
titanocene-dichloride	Cl[Ti](Cl)(C1C=CC=C1)C1C=CC=C1 |c:4	Phase 2		apoptosis stimulant		
tivantinib	O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23	Phase 3	MET	tyrosine kinase inhibitor		
tivozanib	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC	Launched	FLT1|FLT4|KDR|KIT|PDGFRA|PDGFRB	VEGFR inhibitor	oncology	renal cell carcinoma (RCC)
tizanidine	Clc1ccc2nsnc2c1NC1=NCCN1 |t:13|	Launched	ADRA2A|ADRA2B|ADRA2C|NISCH	adrenergic receptor agonist	neurology/psychiatry	spasms
TMC-353121	Cc1ccc(CCCO)c(NCc2ccc3nc(NCCCN4CCOCC4)n(Cc4nc(C)ccc4O)c3c2)c1	Phase 2		RSV fusion inhibitor		
TMC647055	COc1ccc2-c3c(C4CCCCC4)c4ccc5cc4n3CC(=Cc2c1)C(=O)N(C)CCOCCN(C)S(=O)(=O)NC5=O |c:25|	Phase 2		RNA polymerase inhibitor		
TMN-355	Fc1cccc(Cl)c1C(=O)NC(=O)NC1c2ccccc2-c2ccccc12	Preclinical	PPIA	cyclophilin inhibitor		
TMPH	CCCCCCC(=O)OC1CC(C)(C)NC(C)(C)C1	Preclinical				
TMS	COc1ccc(\C=C\c2cc(OC)cc(OC)c2)c(OC)c1	Preclinical				
TNP-470	CO[C@@H]1[C@@H](CC[C@]2(CO2)[C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)OC(=O)NC(=O)CCl	Phase 2	METAP2	methionine aminopeptidase inhibitor		
tobramycin	NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O	Launched		bacterial 30S ribosomal subunit inhibitor	infectious disease	bacterial septicemia, respiratory tract infections, meningitis, skin infections, urinary tract infections
tocainide	C[C@@H](N)C(=O)Nc1c(C)cccc1C |&1:1	Launched	SCN5A	sodium channel blocker	cardiology	cardiac arrythmia
toceranib	Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1	Launched	FLT1|FLT3|KDR|PDGFRA|PDGFRB	protein tyrosine kinase inhibitor	oncology	cutaneous mast cell tumors
tocofersolan	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(OC(=O)CCC(=O)OCCO)c(C)c(C)c2O1	Launched		antioxidant	cardiology	cerebral cholesterosis
todralazine	CCOC(=O)NNc1nncc2ccccc12	Launched		antihypertensive agent	cardiology	hypertension
tofacitinib	C[C@@H]1CCN(C[C@@H]1N(C)c1ncnc2[nH]ccc12)C(=O)CC#N	Launched	JAK1|JAK2|JAK3	JAK inhibitor	rheumatology	rheumatoid arthritis
tofisopam	CCC1=C(C)NN=C(c2ccc(OC)c(OC)c2)c2cc(OC)c(OC)cc12 |c:2	Launched	CYP3A4	cytochrome P450 inhibitor, phosphodiesterase inhibitor	neurology/psychiatry	anxiety, abstinence from alcohol
tofogliflozin	CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1	Launched	GCK	sodium/glucose cotransporter inhibitor	endocrinology	diabetes mellitus
tolamolol	Cc1ccccc1OC[C@@H](O)CNCCOc1ccc(cc1)C(N)=O |&1:9	Phase 3	ADRB1|ADRB2|ADRB3	adrenergic receptor antagonist		
tolazamide	Cc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1	Launched	ABCC8|KCNJ1|KCNJ10|KCNJ11	ATP channel blocker	endocrinology	diabetes mellitus
tolazoline	C(C1=NCCN1)c1ccccc1 |t:1|	Launched	ADRA1A|ADRA2A|ADRA2B|ADRA2C|HRH1|HRH2	adrenergic receptor antagonist	neurology/psychiatry	reverse sedative
tolbutamide	CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1	Launched	ABCC8|KCNJ1|KCNJ11|KCNJ8	ATP channel blocker	endocrinology	diabetes mellitus
tolcapone	Cc1ccc(cc1)C(=O)c1cc(O)c(O)c(c1)[N+]([O-])=O	Withdrawn	COMT	catechol O methyltransferase inhibitor		
tolfenamic-acid	Cc1c(Cl)cccc1Nc1ccccc1C(O)=O	Launched		cyclooxygenase inhibitor, prostanoid receptor antagonist	neurology/psychiatry	migraine headache
tolimidone	Cc1cccc(Oc2cnc(=O)[nH]c2)c1	Phase 2	LYN|SRC	SRC activator		
tolmetin	Cc1ccc(cc1)C(=O)c1ccc(CC(O)=O)n1C	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	rheumatology	rheumatoid arthritis, osteoarthritis
tolnaftate	CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1	Launched		fungal squalene epoxidase inhibitor	infectious disease	tinea pedis, tinea corporis
tolonidine	Cc1ccc(NC2=NCCN2)c(Cl)c1 |t:6|	Launched	ADRA2A	adrenergic receptor antagonist		
tolonium	Cc1cc2nc3ccc(cc3sc2cc1N)=[N+](C)C	Launched			hematology	methemoglobinemia
toloxatone	Cc1cccc(c1)N1C[C@@H](CO)OC1=O |&1:9	Launched	MAOA|MAOB	monoamine oxidase inhibitor	neurology/psychiatry	depression
tolperisone	C[C@@H](CN1CCCCC1)C(=O)c1ccc(C)cc1 |r|	Launched	CYP2C19|CYP2D6	voltage-gated sodium channel blocker	neurology/psychiatry, infectious disease, rheumatology, cardiology	muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease
tolrestat	COc1ccc2c(cccc2c1C(F)(F)F)C(=S)N(C)CC(O)=O	Withdrawn	AKR1A1|AKR1B1|AKR1B10	aldose reductase inhibitor		
tolterodine	CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C	Launched	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	acetylcholine receptor antagonist	urology	urinary incontinence, urinary frequency
toltrazuril	Cc1cc(ccc1Oc1ccc(SC(F)(F)F)cc1)-n1c(=O)[nH]c(=O)n(C)c1=O	Launched		antiprotozoal agent	infectious disease	coccidiosis
tolvaptan	Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc23)c(C)c1 |&1:20	Launched	AVPR1A|AVPR2	vasopressin receptor antagonist	endocrinology, cardiology, gastroenterology	hyponatremia, congestive heart failure, hepatic cirrhosis
tomeglovir	CN(C)c1cccc2c(cccc12)S(=O)(=O)Nc1ccc(NC(=O)C(C)(C)CO)cc1	Preclinical		antiviral		
tomelukast	CCCc1c(OCCCCc2nn[nH]n2)ccc(C(C)=O)c1O	Phase 3	CYSLTR1	leukotriene receptor antagonist		
tomivosertib	Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1	Phase 2		MAPK-interacting kinase inhibitor		
tonabersat	CC(=O)c1ccc2OC(C)(C)[C@@H](O)[C@@H](NC(=O)c3ccc(F)c(Cl)c3)c2c1	Phase 2		gap junction modulator, nitric oxide production inhibitor		
topilutamide	C[C@](O)(CNC(=O)C(F)(F)F)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O |&1:1	Preclinical		androgen receptor antagonist		
topiramate	CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1	Launched	CA1|CA12|CA2|CA4|CA7|GABRA1|GABRA2|GABRA3|GABRA4|GABRA5|GABRA6|GABRB1|GABRB2|GABRB3|GABRD|GABRE|GABRG1|GABRG2|GABRG3|GABRP|GABRQ|GRIA1|GRIA2|GRIA3|GRIA4|GRIK1|GRIK2|GRIK3|GRIK4|GRIK5|SCN10A|SCN11A|SCN1A|SCN2A|SCN3A|SCN4A|SCN5A|SCN7A|SCN8A|SCN9A	carbonic anhydrase inhibitor, glutamate receptor antagonist, kainate receptor antagonist	neurology/psychiatry	epilepsy, migraine headache
topiroxostat	N#Cc1cc(ccn1)-c1nnc([nH]1)-c1ccncc1	Launched	XDH	xanthine oxidase inhibitor	rheumatology, nephrology	gout, hyperuricemia
topotecan	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O	Launched	TOP1|TOP1MT	topoisomerase inhibitor	oncology	small cell lung cancer, cervical cancer
torasemide	CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(C)c1	Launched	SLC12A1	electrolyte reabsorption inhibitor, thromboxane receptor antagonist	cardiology	edema, congestive heart failure, hypertension
torcetrapib	CCOC(=O)N1[C@H](CC)C[C@H](N(Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)C(=O)OC)c2cc(ccc12)C(F)(F)F	Phase 3	CETP	cholesteryl ester transfer protein inhibitor		
torcitabine	Nc1ccn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1	Phase 2	DCK|TK2	DNA polymerase inhibitor		
toremifene	CN(C)CCOc1ccc(cc1)C(=C(\CCCl)c1ccccc1)\c1ccccc1	Launched	ESR1	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	oncology	breast cancer
torin-1	CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1	Preclinical	MTOR	mTOR inhibitor		
torin-2	Nc1ccc(cn1)-c1ccc2ncc3ccc(=O)n(-c4cccc(c4)C(F)(F)F)c3c2c1	Preclinical	MTOR	mTOR inhibitor		
tosedostat	CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c1ccccc1	Phase 2	ANPEP|LAP3|NPEPPS	peptidase inhibitor		
tosufloxacin	N[C@H]1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F |&1:1|	Launched		bacterial DNA gyrase inhibitor	infectious disease	gram-negative bacterial infections
toyocamycin	Nc1ncnc2n(cc(C#N)c12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Phase 1	ERN1	serine/threonine kinase inhibitor		
tozadenant	COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12	Phase 3	ADORA2A	adenosine receptor antagonist		
tozasertib	CN1CCN(CC1)c1cc(Nc2cc(C)n[nH]2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1	Phase 2	AURKA|AURKB|AURKC|LCK	Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor		
TP-003	CC(C)(O)c1ccn2c(cnc2c1F)-c1ccc(F)c(c1)-c1ccc(F)cc1C#N	Preclinical	GABRA1|GABRA2|GABRA3|GABRA5	GABA receptor inverse agonist		
TP-0903	CN(C)S(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)ncc1Cl	Phase 1/Phase 2	AXL	AXL kinase inhibitor		
TP-3654	CC(C)(O)[C@H]1CC[C@@H](CC1)Nc1ccc2ncc(-c3cccc(c3)C(F)(F)F)n2n1 |r|	Phase 1		1,4,5-trisphosphate inhibitor		
TPCA-1	NC(=O)Nc1sc(cc1C(N)=O)-c1ccc(F)cc1	Preclinical	IKBKB	IKK inhibitor		
TPPS4	OS(=O)(=O)c1ccc(cc1)-c1c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc([nH]2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc(n2)c(-c2ccc(cc2)S(O)(=O)=O)c2ccc1[nH]2	Phase 1				
trabectedin	[H][C@@]12Cc3cc(C)c(OC)c(O)c3[C@@]([H])(N1C)[C@@]1([H])N([C@H]2O)[C@@]2([H])COC(=O)[C@]3(CS[C@]1([H])c1c(OC(C)=O)c(C)c4OCOc4c21)NCCc1cc(O)c(OC)cc31 |THB:16:15:2.3.12:17.19.20|	Phase 3		antitumor agent		
trabodenoson	O[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@H]([C@@H]1O)n1cnc2c(NC3CCCC3)ncnc12	Phase 3		adenosine receptor agonist		
tracazolate	CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12	Phase 2	GABRA1	GABA receptor modulator		
tradipitant	FC(F)(F)c1cc(Cn2nnc(c2-c2ccncc2)-c2ncccc2C(=O)c2ccccc2Cl)cc(c1)C(F)(F)F	Phase 3		neurokinin receptor antagonist		
TRAM-34	Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1cccn1	Preclinical	KCNN4	potassium channel antagonist		
TRAM-39	Clc1ccccc1C(C#N)(c1ccccc1)c1ccccc1	Preclinical	KCNN4	calcium-activated potassium channel activator		
trametinib	CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O	Launched	MAP2K1|MAP2K2	MEK inhibitor	oncology	melanoma
tramiprosate	NCCCS(O)(=O)=O	Phase 3	APP	beta amyloid protein neurotoxicity inhibitor		
trandolapril	CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension, myocardial infarction
tranexamic-acid	NC[C@H]1CC[C@@H](CC1)C(O)=O |r|	Launched	PLG	antifibrinolytic, plasminogen activator inhibitor	hematology	hemophilia
tranilast	COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC	Launched	HPGDS|HRH1	angiogenesis inhibitor	pulmonary	asthma
trans-10,cis-12-conjugated-linoleic-acid	CCCCC\C=C/C=C/CCCCCCCCC(O)=O	Launched				
trans-2-undecenoic-acid	CCCCCCCC\C=C\C(O)=O	Preclinical				
trans-4-[8-(3-fluorophenyl)-1,7-naphthyridin-6-yl]cyclohexanecarboxylic-acid	OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)-c1cccc(F)c1	Preclinical				
trans-4-hydroxycrotonic-acid	OC\C=C\C(O)=O	Preclinical		gamma hydroxybutyric acid ligand		
trans-4-methoxycinnamic-acid	COc1ccc(\C=C\C(O)=O)cc1	Preclinical				
transcrocetinate	C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O	Preclinical		glutamate receptor antagonist		
tranylcypromine	N[C@H]1C[C@@H]1c1ccccc1 |&1:1	Launched	KDM1A|MAOA|MAOB	monoamine oxidase inhibitor	neurology/psychiatry	depression
trap-101	CCn1c2ccccc2n(C2=C(CO)CN(CC3CCCCCCC3)CC2)c1=O |c:11|	Preclinical	OPRL1	nociceptin/orphanin FQ receptor antagonist, opioid receptor antagonist		
trapidil	CCN(CC)c1cc(C)nc2ncnn12	Launched	PDGFRA	PDGFR tyrosine kinase receptor inhibitor	cardiology	coronary artery disease (CAD)
travoprost	CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COc1cccc(c1)C(F)(F)F	Launched	PTGFR	prostanoid receptor agonist	ophthalmology	ocular hypertension, glaucoma
traxoprodil	C[C@@H]([C@@H](O)c1ccc(O)cc1)N1CCC(O)(CC1)c1ccccc1	Phase 2	GRIN2B	glutamate receptor antagonist		
trazodone	Clc1cccc(c1)N1CCN(CCCn2nc3ccccn3c2=O)CC1	Launched	ADRA1A|ADRA2A|HRH1|HTR1A|HTR2A|HTR2B|HTR2C|SLC6A4	adrenergic receptor antagonist, serotonin receptor antagonist, serotonin reuptake inhibitor	neurology/psychiatry	depression
trebenzomine	C[C@H]1Oc2ccccc2C[C@@H]1N(C)C |&1:1	Phase 2				
trelagliptin	Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2cc(F)ccc2C#N)c1=O	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
tremorine	C(C#CCN1CCCC1)N1CCCC1	Preclinical		acetylcholine receptor agonist		
treosulfan	CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O	Launched		DNA synthesis inhibitor	oncology	ovarian cancer
trepibutone	CCOc1cc(OCC)c(cc1OCC)C(=O)CCC(O)=O	Launched	CHRM1|CHRM2|CHRM3|CHRM4	cholinergic receptor antagonist	gastroenterology	irritable bowel syndrome
treprostinil	CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O	Launched	P2RY12|PPARD|PTGIR	prostanoid receptor agonist	pulmonary	pulmonary arterial hypertension (PAH)
trequinsin	COc1cc2CCn3c(c\c(=N/c4c(C)cc(C)cc4C)n(C)c3=O)-c2cc1OC	Phase 1	PDE5A	phosphodiesterase inhibitor		
tretazicar	NC(=O)c1cc(N2CC2)c(cc1[N+]([O-])=O)[N+]([O-])=O	Phase 2	NQO2	DNA replication inhibitor		
tretinoin	C\C(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(/C)=C/C(O)=O |c:4|	Launched	ALDH1A1|ALDH1A2|GPRC5A|NR0B1|NR2C2|PPARD|RARA|RARB|RARG|RARRES1|RORB|RORC|RXRB|RXRG	retinoid receptor agonist, retinoid receptor ligand	hematologic malignancy	acute promyelocytic leukemia (APL)
triacetin	CC(=O)OCC(COC(C)=O)OC(C)=O	Launched				
triamcinolone	C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |c:14	Launched	NR3C1	glucocorticoid receptor agonist	dermatology	corticosteroid-responsive dermatoses
triamcinolone-acetonide	CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO |c:14	Launched	NR3C1|SERPINA6	glucocorticoid receptor agonist, immunosuppressant	dermatology	corticosteroid-responsive dermatoses
triamcinolone-hexacetonide	[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(=O)CC(C)(C)C |c:13	Launched		anti-inflammatory agent		
triamterene	Nc1nc(N)c2nc(c(N)nc2n1)-c1ccccc1	Launched	SCNN1A|SCNN1B|SCNN1D|SCNN1G	sodium channel blocker	endocrinology, cardiology	hypokalemia, hypertension, edema
triapine	NC(=S)N\N=C\c1ncccc1N	Phase 2	RRM1|RRM2	ribonucleotide reductase inhibitor		
tribenoside	CCO[C@H]1O[C@H]([C@@H](COCc2ccccc2)OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1O |a:5	Launched		anti-inflammatory agent, capillary stabilizing agent		
tribomsalan	Oc1c(Br)cc(Br)cc1C(=O)Nc1ccc(Br)cc1	Preclinical				
tribromoethanol	OCC(Br)(Br)Br	Preclinical		analgesic agent		
tributyrin	CCCC(=O)OCC(COC(=O)CCC)OC(=O)CCC	Phase 1		HDAC inhibitor		
tricaprylin	CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC	Launched			dermatology	cosmetic
trichlormethiazide	NS(=O)(=O)c1cc2c(N[C@@H](NS2(=O)=O)C(Cl)Cl)cc1Cl |&1:9	Launched	PTGS1|PTGS2|SLC12A1	chloride channel blocker	cardiology	hypertension, edema
trichloroacetic-acid	OC(=O)C(Cl)(Cl)Cl	Launched			dermatology	warts
trichloroethylene	ClC=C(Cl)Cl	Preclinical				
trichostatin-a	C[C@H](\C=C(/C)\C=C\C(=O)NO)C(=O)c1ccc(cc1)N(C)C	Phase 1	HDAC1|HDAC10|HDAC2|HDAC3|HDAC4|HDAC5|HDAC6|HDAC7|HDAC8|HDAC9	HDAC inhibitor		
triciribine	Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23	Phase 1/Phase 2	AKT1|AKT2|AKT3	AKT inhibitor		
triciribine-phosphate	Cn1nc(N)c2cn([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)c3ncnc1c23	Phase 1/Phase 2		AKT inhibitor		
triclabendazole	CSc1nc2cc(Cl)c(Oc3cccc(Cl)c3Cl)cc2[nH]1	Launched	DNMT1	microtubule inhibitor	infectious disease	tapeworm
triclocarban	Clc1ccc(NC(=O)Nc2ccc(Cl)c(Cl)c2)cc1	Launched		other antibiotic	infectious disease	first-aid antiseptic
triclosan	Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl	Launched	DNMT1	antibacterial agent	infectious disease	first-aid antiseptic
tridihexethyl	CC[N+](CC)(CC)CC[C@@](O)(C1CCCCC1)c1ccccc1 |&1:9|	Launched		acetylcholine receptor antagonist	gastroenterology, ophthalmology	peptic ulcer disease (PUD), nystagmus
trientine	NCCNCCNCCN	Launched	CA14	chelating agent	metabolism	Wilson's disease
trifloxystrobin	CO\N=C(\C(=O)OC)c1ccccc1CO\N=C(/C)c1cccc(c1)C(F)(F)F	Preclinical		mitochondrial electron transport inhibitor		
trifluoperazine	CN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1	Launched	ADRA1A|CALM1|CALY|DRD2|DRD4|HRH1|HTR2A|HTR2C|S100A4|TNNC1	dopamine receptor antagonist	neurology/psychiatry	schizophrenia
triflupromazine	CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F	Launched	CHRM1|CHRM2|DRD1|DRD2|HTR2B	dopamine receptor antagonist	neurology/psychiatry, gastroenterology	psychosis, nausea, vomiting
trifluridine	OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F	Launched	TYMS	DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor	infectious disease	virus herpes simplex (HSV)
triflusal	CC(=O)Oc1cc(ccc1C(O)=O)C(F)(F)F	Launched	NFKB1|NOS2|PDE10A|PTGS1	cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor	neurology/psychiatry, cardiology	stroke, myocardial infarction, atrial fibrillation (AF)
trigonelline	C[n+]1cccc(c1)C(O)=O	Phase 1				
trihexyphenidyl	O[C@@](CCN1CCCCC1)(C1CCCCC1)c1ccccc1 |&1:1|	Launched	CHRM1	acetylcholine receptor antagonist	neurology/psychiatry	parkinsonism
trilaciclib	CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1	Phase 2		CDK inhibitor		
trilostane	C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(=O)[C@@H](C[C@]35C)C#N)[C@@H]1CC[C@@H]2O |a:1	Launched		3beta-hydroxy-delta5-steroid dehydrogenase inhibitor	endocrinology	Cushing's syndrome
TRIM	FC(F)(F)c1ccccc1-n1ccnc1	Preclinical				
trimebutine	CC[C@](COC(=O)c1cc(OC)c(OC)c(OC)c1)(N(C)C)c1ccccc1 |&1:2|	Launched	OPRD1|OPRK1|OPRM1	opioid receptor agonist	gastroenterology	irritable bowel syndrome
trimetazidine	COc1ccc(CN2CCNCC2)c(OC)c1OC	Launched	ACAA2	3-ketoacyl CoA thiolase inhibitor	cardiology	angina pectoris
trimethadione	CN1C(=O)OC(C)(C)C1=O	Launched	CACNA1G|CACNA1H|CACNA1I	oxazolidine antiepileptic	neurology/psychiatry	seizures
trimethobenzamide	COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1	Launched	DRD2	histamine receptor antagonist	gastroenterology	vomiting, nausea, gastroenteritis
trimethoprim	COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC	Launched	DHFR|TYMS	dihydrofolate reductase inhibitor	infectious disease, gastroenterology	urinary tract infections, ear infections, diarrhea
trimethoquinol	COc1cc(C[C@H]2NCCc3cc(O)c(O)cc23)cc(OC)c1OC |&1:6|	Launched	ADRB2|ADRB3	adrenergic receptor antagonist	pulmonary	asthma
trimethylolpropane-triacrylate	CCC(COC(=O)C=C)(COC(=O)C=C)COC(=O)C=C	Preclinical				
trimetozine	COc1cc(cc(OC)c1OC)C(=O)N1CCOCC1	Launched		sedative	neurology/psychiatry	sedative
trimetrexate	COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC	Phase 3	DHFR	dihydrofolate reductase inhibitor		
trimipramine	C[C@@H](CN(C)C)CN1c2ccccc2CCc2ccccc12 |&1:1|	Launched	SLC6A2|SLC6A3|SLC6A4	norepinephrine reputake inhibitor, tricyclic antidepressant	neurology/psychiatry	depression
trioxsalen	Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1	Launched		DNA synthesis inhibitor	dermatology	vitiligo, eczema
tripelennamine	CN(C)CCN(Cc1ccccc1)c1ccccn1	Launched	HRH1	histamine receptor antagonist	pulmonary, allergy	asthma, allergic rhinitis, urticaria
triprolidine	Cc1ccc(cc1)C(=C/CN1CCCC1)\c1ccccn1	Launched	HRH1	histamine receptor antagonist	allergy	allergic rhinitis
triptan	CC(C)C(C)(C)C	Phase 1	HTR1B|HTR1D	serotonin receptor agonist		
triptolide	CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O |c:17|	Phase 3	RELA	RNA polymerase inhibitor		
triptorelin	CC(C)C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O	Launched	GNRHR	gonadotropin releasing factor hormone receptor agonist	oncology, endocrinology, obstetrics/gynecology	prostate cancer, breast cancer, precocious puberty, endometriosis, myoma, gender dysphoria
troclosene	Cln1c(=O)[nH]c(=O)n(Cl)c1=O	Launched				
trodusquemine	[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@@]4([H])C[C@H](CC[C@]4(C)[C@@]3([H])CC[C@]12C)NCCCNCCCCNCCCN)[C@H](C)CC[C@@H](OS(O)(=O)=O)C(C)C	Phase 1		tyrosine phosphatase inhibitor		
trofinetide	NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O	Phase 2	IFNG|IL6|TNF	cytokine production inhibitor		
trofosfamide	ClCCN(CCCl)[P@@]1(=O)OCCCN1CCCl |&1:7	Launched		DNA alkylating agent	oncology	medulloblastoma
troglitazone	Cc1c(C)c2O[C@@](C)(COc3ccc(C[C@H]4SC(=O)NC4=O)cc3)CCc2c(C)c1O |&1:6	Withdrawn	CYP2C8|PPARG|TRPM3	insulin sensitizer, PPAR receptor agonist		
troleandomycin	CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3OC(C)=O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](OC(C)=O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1OC(C)=O	Launched		protein synthesis inhibitor	infectious disease, pulmonary, otolaryngology	pneumonia, bronchitis, tonsillitis, sinusitis
trolox	Cc1c(C)c2O[C@@](C)(CCc2c(C)c1O)C(O)=O |&1:6	Launched		antioxidant		
tromaril	OC(=O)c1ccccc1NCCc1ccccc1	Launched		prostanoid receptor antagonist	ophthalmology	eye inflammation
trometamol	NC(CO)(CO)CO	Launched	AMD1|CANT1|DCN|NEIL1|VEGFA			
tropanyl-3,5-dimethylbenzoate	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(C)cc(C)c1 |&1:2	Preclinical	HTR3A|HTR3B	serotonin receptor antagonist		
tropesin	COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)OC[C@@H](C(O)=O)c3ccccc3)c2c1 |&1:24	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor		
tropicamide	CCN(Cc1ccncc1)C(=O)[C@@H](CO)c1ccccc1 |&1:12	Launched	CHRM3|CHRM4	acetylcholine receptor antagonist	ophthalmology	mydriasis diagnostic, cycloplegia diagnostic
tropifexor	OC(=O)c1cc(F)c2nc(sc2c1)N1[C@H]2CC[C@@H]1C[C@@H](C2)OCc1c(onc1-c1ccccc1OC(F)(F)F)C1CC1 |TLB:9:13:16.15:19.20.18|	Phase 2		FXR agonist		
tropisetron	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1c[nH]c2ccccc12	Launched	GLRA1|GLRA2|GLRB|HTR3A|HTR4	serotonin receptor antagonist	gastroenterology	nausea, vomiting
trospium	[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(c1ccccc1)c1ccccc1)[N+]21CCCC1 |&1:1	Launched	CHRM1	acetylcholine receptor antagonist	urology	urinary incontinence, urinary frequency
trovafloxacin	N[C@H]1[C@@H]2CN(C[C@H]12)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F	Withdrawn	TOP2A	bacterial DNA gyrase inhibitor		
troventol	CCC(CO)(C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)C)c1ccccc1 |&1:2	Phase 1				
trovirdine	Brc1ccc(NC(=S)NCCc2ccccn2)nc1	Phase 1		non-nucleoside reverse transcriptase inhibitor		
troxerutin	C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(oc4cc(OCCO)cc(O)c4c3=O)-c3ccc(OCCO)c(OCCO)c3)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O	Launched		antioxidant		
troxipide	COc1cc(cc(OC)c1OC)C(=O)N[C@H]1CCCNC1 |&1:15	Launched		glucosamine synthetase stimulant	gastroenterology	gastroesophageal reflux disease (GERD)
TRV130	COc1ccsc1CNCC[C@]1(CCOC2(CCCC2)C1)c1ccccn1	Phase 3	OPRM1	opioid receptor agonist		
tryptanthrin	O=C1c2ccccc2-n2c1nc1ccccc1c2=O	Preclinical	IDO1	cyclooxygenase inhibitor		
tryptophan	N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O	Launched	CASR|IDO1|SLC36A1|WARS|WARS2	serotonin receptor partial agonist	neurology/psychiatry, gastroenterology	anxiety, bloating, constipation, fatigue, sleeplessness
TS-011	[O-][N+]CNc1ccc(N2CCOCC2)c(Cl)c1	Preclinical		delayed vasospasm antagonist		
TTNPB	C\C(=C/c1ccc(cc1)C(O)=O)c1ccc2c(c1)C(C)(C)CCC2(C)C	Phase 1	RARA|RARB|RARG	retinoid receptor agonist		
TTP-22	Cc1ccc(cc1)-c1csc2ncnc(SCCC(O)=O)c12	Preclinical	CSNK2A1	casein kinase inhibitor		
TU-2100	CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC	Phase 2				
tuaminoheptane	CCCCC[C@@H](C)N |&1:5|	Launched			otolaryngology	nasal congestion
tubastatin-A	CN1CCc2c(C1)c1ccccc1n2Cc1ccc(cc1)C(=O)NO	Preclinical	HDAC6	HDAC inhibitor		
tubocurarine	COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7ccc(Oc(c1O)c23)cc7)N(C)CCc6cc5OC)c4	Launched	ACHE|CHRNA2|HTR3A|HTR3B|KCNN1|KCNN2|KCNN3|ZACN	acetylcholine receptor antagonist	neurology/psychiatry	anesthetic
tucatinib	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 |t:14|	Phase 3	ERBB2	EGFR inhibitor		
tucidinostat	Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1	Phase 3		HDAC inhibitor		
tuftsin	C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O	Preclinical		macrophage activator		
TUG-770	OC(=O)CCc1ccc(cc1F)C#Cc1ccccc1CC#N	Preclinical	FFAR1	free fatty acid receptor agonist		
TUG-891	Cc1ccc(cc1)-c1ccc(F)cc1COc1ccc(CCC(O)=O)cc1	Preclinical	FFAR4	free fatty acid receptor agonist		
tulobuterol	CC(C)(C)NC[C@H](O)c1ccccc1Cl |&1:6|	Launched	ADRB2	adrenergic receptor agonist	pulmonary	asthma
tulrampator	Fc1cccc(CCn2nnc3cc4C(=O)N(COc4cc3c2=O)C2CC2)c1	Phase 2		antidepressant 		
TW-37	CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(cc2)S(=O)(=O)c2ccccc2C(C)(C)C)c(O)c(O)c1O	Preclinical	BCL2|BCL2L1|MCL1	BCL inhibitor		
TWS-119	Nc1cccc(c1)-c1cc2c(Oc3cccc(O)c3)ncnc2[nH]1	Preclinical	GSK3B|JUN|MYC	glycogen synthase kinase inhibitor		
TXA127	CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(O)=O	Phase 2		angiotensin receptor agonist		
TY-52156	CC(C)(C)C(=O)C(Nc1ccc(Cl)cc1)=NNc1ccc(Cl)cc1	Preclinical	S1PR3	sphingosine 1-phosphate receptor antagonist		
tylosin	CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(\C)=C\[C@@H]1CO[C@@H]1O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]1OC |t:46	Launched		protein synthesis inhibitor	infectious disease, gastroenterology	gram-positive bacterial infections, colitis
tymazoline	CC(C)c1ccc(C)cc1OCC1=NCCN1 |t:13|	Launched			allergy	allergic rhinitis
tyrphostin-AG-1296	COc1cc2ncc(nc2cc1OC)-c1ccccc1	Preclinical	FLT3	FLT3 inhibitor		
tyrphostin-AG-1478	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC	Preclinical	EGFR|MAPK14	EGFR inhibitor		
tyrphostin-AG-18	Oc1ccc(C=C(C#N)C#N)cc1O	Preclinical	EGFR	EGFR inhibitor, tyrosine kinase inhibitor		
tyrphostin-AG-494	Oc1ccc(\C=C(/C#N)C(=O)Nc2ccccc2)cc1O	Preclinical	EGFR	EGFR inhibitor		
tyrphostin-AG-825	COc1cc(\C=C(/C#N)C(N)=O)cc(CSc2nc3ccccc3s2)c1O	Preclinical	ERBB2	protein tyrosine kinase inhibitor		
tyrphostin-AG-835	C[C@H](NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N)c1ccccc1	Preclinical	EGFR	protein tyrosine kinase inhibitor		
tyrphostin-AG-879	CC(C)(C)c1cc(\C=C(/C#N)C(N)=S)cc(c1O)C(C)(C)C	Preclinical	ERBB2|KDR|NTRK1	tyrosine kinase inhibitor		
tyrphostin-AG-99	NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N	Preclinical	EGFR	tyrosine kinase inhibitor		
tyrphostin-A9	CC(C)(C)c1cc(C=C(C#N)C#N)cc(c1O)C(C)(C)C	Preclinical		protein tyrosine kinase inhibitor, tyrosine kinase inhibitor		
U-0124	CSC(=N)C(C#N)C(C#N)C(=N)SC	Preclinical		MEK inhibitor		
U-0126	Nc1ccccc1SC(=N)C(C#N)C(C#N)C(=N)Sc1ccccc1N	Preclinical	AKT1|CHEK1|GSK3B|LCK|MAP2K1|MAP2K2|MAP2K7|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|RAF1|ROCK1|RPS6KB1|SGK1	MEK inhibitor		
U-0521	CC(C)C(=O)c1ccc(O)c(O)c1	Preclinical	COMT	catechol O methyltransferase inhibitor		
U-104	NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	Phase 1/Phase 2	CA1|CA12|CA2|CA9	carbonic anhydrase inhibitor		
U-18666A	CCN(CC)CCO[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3CC=C2C1 |c:27|	Preclinical		oxidosqualene cyclase inhibitor		
U-50488-(-)	CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1	Preclinical	OPRK1	opioid receptor agonist		
U-54494A	CN([C@@H]1CCCC[C@@H]1N1CCCC1)C(=O)c1ccc(Cl)c(Cl)c1	Preclinical	OPRK1	opioid receptor agonist		
U-75799E	C[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O	Phase 1	GHSR	growth hormone releasing factor agonist		
U-99194	CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1	Preclinical	DRD3	dopamine receptor antagonist		
UAMC-00039	N[C@@H](CCNCc1ccc(Cl)cc1)C(=O)N1CCCCC1	Preclinical	DPP4|DPP7	dipeptidyl peptidase inhibitor		
UB-165	Clc1ccc(cn1)C1=CCC[C@H]2CC[C@@H]1N2 |&1:11	Preclinical	CHRNA3|CHRNA4|CHRNB2	acetylcholine receptor agonist		
ubenimex	CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(O)=O	Launched	LTA4H|RNPEP	leukotriene synthesis inhibitor	hematologic malignancy	acute myeloid leukemia (AML)
UBP-296	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O |&1:1	Preclinical	GRIK1	glutamate receptor antagonist		
UBP-302	N[C@@H](Cn1ccc(=O)n(Cc2ccccc2C(O)=O)c1=O)C(O)=O	Preclinical	GRIK1	glutamate receptor antagonist		
UBP-310	Cc1cn(C[C@H](N)C(O)=O)c(=O)n(Cc2ccsc2C(O)=O)c1=O	Preclinical	GRIK1|GRIK5	glutamate receptor antagonist		
UC-112	Oc1c(CN2CCCC2)cc(COCc2ccccc2)c2cccnc12	Preclinical	XIAP	XIAP inhibitor		
UCL-2077	C(NC(c1ccccc1)(c1ccccc1)c1ccccc1)c1cccnc1	Preclinical		slow afterhyperpolarization channel blocker		
udenafil	CCCOc1ccc(cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1)S(=O)(=O)NCC[C@@H]1CCCN1C |&1:30	Launched		phosphodiesterase inhibitor	urology	erectile dysfunction
UF-010	CCCCNNC(=O)c1ccc(Br)cc1	Preclinical	HDAC1|HDAC2|HDAC3|HDAC8	HDAC inhibitor		
ufenamate	CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F	Launched	PTGS1|PTGS2	cyclooxygenase inhibitor	dermatology	eczema, dermatitis
UH-232-(+)	CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C	Preclinical	DRD2|DRD3|DRD4|HTR1A	dopamine receptor antagonist		
UK-356618	C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c1ccccc1)CC(=O)NO)C(C)(C)C)c1ccccc1	Preclinical	MMP13|MMP14|MMP2|MMP3|MMP9	metalloproteinase inhibitor		
UK-383367	NC(=O)c1noc(n1)[C@H](CCCC1CCCCC1)CC(=O)NO	Phase 1	BMP1	procollagen C-endopeptidase inhibitor		
UK-5099	OC(=O)C(=C\c1cn(-c2ccccc2)c2ccccc12)\C#N	Preclinical	SLC16A1	monocarboxylate transporter inhibitor		
uki-1	CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(N)=N)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	Preclinical		urokinase inhibitor		
ulifloxacin	C[C@H]1Sc2c(C(O)=O)c(=O)c3cc(F)c(cc3n12)N1CCNCC1 |&1:1	Launched			infectious disease	gram-negative bacterial infections, gram-positive bacterial infections
ulipristal	CN(C)c1ccc(cc1)[C@H]1C[C@@]2(C)[C@@H](CC[C@]2(OC(C)=O)C(C)=O)[C@@H]2CCC3=CC(=O)CCC3=C12 |t:29	Launched	PGR	progesterone receptor antagonist	endocrinology	contraceptive
umeclidinium	OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2	Launched	CHRM1|CHRM2|CHRM3	acetylcholine receptor antagonist	pulmonary	chronic obstructive pulmonary disease (COPD), bronchitis, emphysema
unbs-5162	CN(C)CCN1C(=O)c2cccc3cc(NC(N)=O)cc(C1=O)c23	Phase 1		CC chemokine receptor antagonist		
UNC0224	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCCN(C)C)N1CCCN(C)CC1	Preclinical	EHMT1|EHMT2	histone lysine methyltransferase inhibitor		
UNC0321	COc1cc2c(NC3CCN(C)CC3)nc(nc2cc1OCCOCCN(C)C)N1CCCN(C)CC1	Preclinical	EHMT2	histone lysine methyltransferase inhibitor		
UNC0631	COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	Preclinical	EHMT2	histone lysine methyltransferase inhibitor		
UNC0638	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)C1CCCCC1	Preclinical	EHMT1|EHMT2	histone lysine methyltransferase inhibitor		
UNC0642	COc1cc2c(NC3CCN(CC3)C(C)C)nc(nc2cc1OCCCN1CCCC1)N1CCC(F)(F)CC1	Preclinical	EHMT1|EHMT2	histone lysine methyltransferase inhibitor		
UNC0646	COc1cc2c(NC3CCN(CC3)C3CCCCC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C	Preclinical	EHMT2	histone lysine methyltransferase inhibitor		
UNC0737	COc1cc2c(nc(nc2cc1OCCCN1CCCC1)C1CCCCC1)N(C)C1CCN(CC1)C(C)C	Preclinical	EHMT1|EHMT2	histone lysine methyltransferase inhibitor		
UNC1215	O=C(N1CCC(CC1)N1CCCC1)c1ccc(C(=O)N2CCC(CC2)N2CCCC2)c(Nc2ccccc2)c1	Preclinical	L3MBTL3	L3MBTL antagonist		
UNC1999	CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(cc2n(ncc12)C(C)C)-c1ccc(nc1)N1CCN(CC1)C(C)C	Preclinical	EZH2	histone lysine methyltransferase inhibitor		
UNC2025	CCCCNc1ncc2c(cn([C@H]3CC[C@H](O)CC3)c2n1)-c1ccc(CN2CCN(C)CC2)cc1 |r|	Preclinical	FLT3|MERTK	FLT3 inhibitor, MER tyrosine kinase inhibitor		
UNC2250	CCCCNc1ncc(c(N[C@H]2CC[C@H](O)CC2)n1)-c1ccc(CN2CCOCC2)cn1 |r|	Preclinical	MERTK	MER tyrosine kinase inhibitor		
UNC2327	O=C(NCC(=O)N1CCCCC1)Nc1ccc2nnsc2c1	Preclinical	PRMT3	protein arginine N-methyltransferase inhibitor		
UNC3230	NC(=O)c1nc(Nc2ccccc2)sc1NC(=O)C1CCCCC1	Preclinical	PIP5K1C	phosphatidyl-inositol activator		
UNC669	Brc1cncc(c1)C(=O)N1CCC(CC1)N1CCCC1	Preclinical	L3MBTL1	L3MBTL antagonist		
UNC926	Brc1cccc(c1)C(=O)N1CCC(CC1)N1CCCC1	Preclinical	L3MBTL1	MBT inhibitor		
undecylenic-acid	OC(=O)CCCCCCCCC=C	Launched		other antifungal	infectious disease	tinea pedis, tinea corporis
upadacitinib	CC[C@@H]1CN(C[C@@H]1c1cnc2cnc3[nH]ccc3n12)C(=O)NCC(F)(F)F	Launched		JAK inhibitor		
upamostat	CCOC(=O)N1CCN(CC1)C(=O)[C@H](Cc1cccc(c1)C(=N)NO)NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C	Phase 2		serine protease inhibitor		
UPF-1069	O=C(COc1cccc2c1cc[nH]c2=O)c1ccccc1	Preclinical	PARP2	PARP inhibitor		
uprifosbuvir	CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(Cl)[C@@H]1O)Oc1ccccc1	Preclinical		antiviral		
uprosertib	Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1	Phase 2	AKT1|AKT2|AKT3	AKT inhibitor		
uracil	O=c1cc[nH]c(=O)[nH]1	Launched	DPYD|UCKL1			
uracil-mustard	ClCCN(CCCl)c1c[nH]c(=O)[nH]c1=O	Launched		DNA synthesis inhibitor	hematologic malignancy	non-Hodgkin lymphoma (NHL)
urapidil	COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1	Launched	HTR1A	adrenergic receptor antagonist	cardiology	hypertension
URB597	NC(=O)c1cccc(c1)-c1cccc(OC(=O)NC2CCCCC2)c1	Phase 1	FAAH|FAAH2|TRPA1	FAAH inhibitor		
urea	NC(N)=O	Launched	ARG1|CA2|CTNNB1	hydroxy radical formation stimulant	dermatology	psoriasis, xerosis cutis, ichthyosis vulgaris, eczema, keratosis, dermatitis
urethane	CCOC(N)=O	Preclinical		local anesthetic		
uric-acid	O=c1[nH]c2[nH]c(=O)[nH]c(=O)c2[nH]1	Phase 3	PYGL			
uridine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O	Phase 2	LSM6|TYMP	dopamine receptor agonist		
uridine-triacetate	CC(=O)OC[C@H]1O[C@H]([C@H](OC(C)=O)[C@@H]1OC(C)=O)n1ccc(=O)[nH]c1=O	Launched			nephrology	orotic aciduria
uridine-5'-triphosphate	O[C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)n1ccc(=O)[nH]c1=O |a:1	Launched	P2RY11|P2RY2|P2RY4|P2RY6|UCK2	purinergic receptor activator		
URMC-099	CN1CCN(Cc2ccc(cc2)-c2cnc3[nH]cc(-c4ccc5[nH]ccc5c4)c3c2)CC1	Preclinical	CDKL2|DAPK3|FLT3|LRRK2|MAP3K10|MAP3K11|MAP3K2|MAP3K9|SRPK2	mixed lineage kinase inhibitor		
urolithin-A	Oc1ccc2c(c1)oc(=O)c1cc(O)ccc21	Phase 3		antioxidant		
ursodeoxycholyltaurine	C[C@H](CCC(=O)NCCS(O)(=O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Phase 3		cholesterol inhibitor		
ursodiol	C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C	Launched	AKR1C2|NR1H4	nuclear factor erythroid derived, like (NRF2) activator	gastroenterology	gallstones
ursolic-acid	C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O |c:9|	Phase 2/Phase 3	HSD11B1|PLA2G1B|PTPN1|PYGM	ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor		
usniacin-(+)	CC(O)=C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@]2(C)C1=O |a:21	Preclinical	PTPN1	MAP kinase activator		
V-51	COc1cc(CN2CCN(CC2)c2ccc(F)cc2)cc(OC)c1OC	Phase 1		adrenergic receptor antagonist		
vaborbactam	OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)Cc1cccs1	Launched		beta lactamase inhibitor		
vadadustat	OC(=O)CNC(=O)c1ncc(cc1O)-c1cccc(Cl)c1	Phase 3		hypoxia inducible factor prolyl hydroxylase inhibitor		
val-tyr	CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O	Preclinical		angiotensin converting enzyme inhibitor		
valaciclovir	CC(C)[C@H](N)C(=O)OCCOCn1cnc2c1[nH]c(N)nc2=O	Launched		DNA polymerase inhibitor	infectious disease	shingles, virus herpes simplex (HSV)
valbenazine	[H][C@]12C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN1CCc1cc(OC)c(OC)cc21	Launched		vesicular monoamine transporter inhibitor	neurology/psychiatry	dyskinesia
valdecoxib	Cc1onc(c1-c1ccc(cc1)S(N)(=O)=O)-c1ccccc1	Withdrawn	CA12|PTGS2	cyclooxygenase inhibitor		
valethamate	CC[C@@H](C)[C@@H](C(=O)OCC[N+](C)(CC)CC)c1ccccc1 |&1:2	Launched	CHRM1|CHRM4|CHRM5	acetylcholine receptor antagonist	obstetrics/gynecology	labor induction
valganciclovir	CC(C)[C@H](N)C(=O)OC[C@@H](CO)OCn1cnc2c1[nH]c(N)nc2=O |a:3	Launched		DNA synthesis inhibitor	infectious disease	cytomegalovirus (CMV)
valnemulin	CC(C)[C@@H](N)C(=O)NCC(C)(C)SCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@]23CCC(=O)[C@H]2[C@@]1(C)[C@H](C)CC3	Launched		bacterial 50S ribosomal subunit inhibitor	infectious disease, gastroenterology	dysentry, colitis, pneumonia
valnoctamide	CC[C@@H](C)[C@@H](CC)C(N)=O |&1:2	Launched		arachidonic acid acylation inhibitor, benzodiazepine receptor agonist	neurology/psychiatry	sleeplessness
valproic-acid	CCCC(CCC)C(O)=O	Launched	ABAT|ACADSB|ALDH5A1|HDAC1|HDAC2|HDAC9|OGDH|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	benzodiazepine receptor agonist, HDAC inhibitor	neurology/psychiatry	epilepsy, seizures, seizures
valpromide	CCCC(CCC)C(N)=O	Launched		epoxide hydolase inhibitor	neurology/psychiatry	epilepsy
valrocemide	CCCC(CCC)C(=O)NCC(N)=O	Phase 2				
valrubicin	CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	Launched	TOP2A	DNA inhibitor, topoisomerase inhibitor	oncology	bladder cancer
valsartan	CCCCC(=O)N(Cc1ccc(cc1)-c1ccccc1-c1nn[nH]n1)[C@@H](C(C)C)C(O)=O	Launched	AGTR1	angiotensin receptor antagonist	cardiology	hypertension, congestive heart failure, congestive heart failure
valspodar	C\C=C\C[C@@H](C)C(=O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@@H](NC1=O)C(C)C)C(C)C	Phase 3	ABCB1	P glycoprotein inhibitor		
vancomycin	CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2	Launched		bacterial cell wall synthesis inhibitor	infectious disease	endocarditis
vandetanib	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1	Launched	EGFR|EPHA1|EPHA10|EPHA2|EPHA3|EPHA4|EPHA5|EPHA6|EPHA7|EPHA8|EPHB1|EPHB2|EPHB3|EPHB4|EPHB6|ERBB2|ERBB3|ERBB4|FLT1|FLT4|KDR|PTK6|RET|SRC|TEK|VEGFA	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	oncology	medullary thyroid cancer (MTC)
vanillin	COc1cc(C=O)ccc1O	Preclinical	ABAT|ALDH5A1			
vanillylacetone	COc1cc(CCC(C)=O)ccc1O	Preclinical				
vaniprevir	CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1cccc3CN(Cc13)C(=O)O2)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1	Phase 3		serine protease inhibitor		
vanitiolide	COc1cc(ccc1O)C(=S)N1CCOCC1	Preclinical				
vanoxerine	Fc1ccc(cc1)C(OCCN1CCN(CCCc2ccccc2)CC1)c1ccc(F)cc1	Phase 3	SLC6A3	dopamine reuptake inhibitor		
vapendavir	CCOc1noc2cc(OCCC3CCN(CC3)c3ccc(C)nn3)ccc12	Phase 2		antiviral		
vardenafil	CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1	Launched	PDE5A|PDE6G|PDE6H	phosphodiesterase inhibitor	urology	erectile dysfunction
varenicline	C1[C@H]2CNC[C@@H]1c1cc3nccnc3cc21 |&1:1	Launched	CHRNA3|CHRNA4|CHRNA6|CHRNA7	acetylcholine receptor agonist	neurology/psychiatry	smoking cessation
varespladib	CCc1c(C(=O)C(N)=O)c2c(OCC(O)=O)cccc2n1Cc1ccccc1	Phase 3	PLA2G2A	secretory phospholipase inhibitor		
vasopressin	N[C@H]1CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O	Launched	AVPR1A|AVPR1B|AVPR2|OXTR	vasopressin receptor agonist	gastroenterology	abdominal distension
vatalanib	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1	Phase 3	EGFR|FLT1|FLT4|KDR|PDGFRB	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor		
vatinoxan	[H][C@@]12C[C@@]3(CNC(=O)N3CCNS(C)(=O)=O)CCN1CCc1c2oc2ccccc12	Preclinical		adrenergic receptor antagonist		
VBY-825	CC[C@H](NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@@H](c1ccc(F)cc1)C(F)(F)F)C(=O)C(=O)NC1CC1	Preclinical	CTSB|CTSL|CTSS	cathepsin inhibitor		
VCH-916	CO[C@H]1CC[C@@H](CC1)N(C(=O)[C@H]1CC[C@H](C)CC1)c1cc(sc1C(O)=O)C1=CCCCC1 |r	Phase 1		HCV inhibitor		
VE-821	CS(=O)(=O)c1ccc(cc1)-c1cnc(N)c(n1)C(=O)Nc1ccccc1	Preclinical	ATR	ATR kinase inhibitor		
VE-822	CNCc1ccc(cc1)-c1cc(on1)-c1nc(cnc1N)-c1ccc(cc1)S(=O)(=O)C(C)C	Phase 2	ATM|ATR|MTOR|PIK3CG	ATR kinase inhibitor		
vecabrutinib	NC(=O)[C@H]1CCN(C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(c2)C(F)(F)F)C1=O)c1ncnc(N)c1F	Phase 1/Phase 2		Bruton's tyrosine kinase (BTK) inhibitor		
vecuronium	CC(=O)O[C@H]1[C@H](C[C@H]2[C@@H]3CC[C@H]4C[C@H](OC(C)=O)[C@H](C[C@]4(C)[C@H]3CC[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1	Launched	CHRNA2	acetylcholine receptor antagonist	neurology/psychiatry	muscle relaxant
vedaprofen	C[C@H](C(O)=O)c1ccc(C2CCCCC2)c2ccccc12 |&1:1	Launched	PTGS2	anti-inflammatory agent	neurology/psychiatry, endocrinology	pain relief, fever
velaresol	OC(=O)CCCCOc1cccc(O)c1C=O	Preclinical				
veledimex	CCC[C@@H](N(NC(=O)c1cccc(OC)c1CC)C(=O)c1cc(C)cc(C)c1)C(C)(C)C	Phase 2		cytochrome P450 inhibitor		
veliflapon	OC(=O)[C@H](C1CCCC1)c1ccc(OCc2ccc3ccccc3n2)cc1	Phase 3	ALOX5AP	leukotriene synthesis inhibitor		
veliparib	C[C@@]1(CCCN1)c1nc2cccc(C(N)=O)c2[nH]1	Phase 3	PARP1|PARP2	PARP inhibitor		
velneperit	CC(C)(C)S(=O)(=O)N[C@H]1CC[C@@H](CC1)C(=O)Nc1ccc(cn1)C(F)(F)F |r|	Phase 2	NPY5R	neuropeptide receptor antagonist		
velpatasvir	COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)c1ccccc1)c1nc(c[nH]1)-c1ccc-2c(COc3cc4c5nc([nH]c5ccc4cc-23)[C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(=O)OC)C(C)C)c1	Launched		antiviral	infectious disease	hepatitis C
vemurafenib	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F	Launched	BRAF|RAF1	RAF inhibitor	oncology	melanoma
venetoclax	CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 |c:57|	Launched	BCL2	BCL inhibitor	hematologic malignancy	chronic lymphocytic leukemia (CLL)
venlafaxine	COc1ccc(cc1)[C@@H](CN(C)C)C1(O)CCCCC1 |&1:8|	Launched	SLC6A2|SLC6A4	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotoninâ€“norepinephrine reuptake inhibitor (SNRI)	neurology/psychiatry	depression, generalized anxiety disorder (GAD), panic disorders, social anxiety disorder
VER-155008	Nc1ncnc2n([C@@H]3O[C@H](COCc4ccc(cc4)C#N)[C@@H](O)[C@H]3O)c(NCc3ccc(Cl)c(Cl)c3)nc12	Preclinical	HSPA1A	HSP inhibitor		
VER-49009	CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O	Preclinical	HSP90AA1	HSP inhibitor		
veralipride	COc1cc(cc(C(=O)NC[C@@H]2CCCN2CC=C)c1OC)S(N)(=O)=O |&1:11	Preclinical		dopamine receptor antagonist		
verapamil	COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC |&1:13|	Launched	CACNA1A|CACNA1B|CACNA1C|CACNA1D|CACNA1F|CACNA1G|CACNA1I|CACNA1S|CACNB1|CACNB2|CACNB3|CACNB4|CYP3A4|KCNA10|KCNA7|KCNH2|KCNJ11|NALCN|SCN5A|SLC29A4|SLC6A4	calcium channel blocker	cardiology	hypertension
verbascoside	C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)\C=C\c2ccc(O)c(O)c2)[C@H](O)[C@H](O)[C@H]1O	Phase 2/Phase 3		NFkB pathway inhibitor, PKC inhibitor		
vercirnon	CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1ccc(Cl)cc1C(=O)c1cc[n+]([O-])cc1	Phase 3	CCR9	CC chemokine receptor antagonist		
verdinexor	FC(F)(F)c1cc(cc(c1)C(F)(F)F)-c1ncn(\C=C/C(=O)NNc2ccccn2)n1	Preclinical		exportin antagonist		
verdiperstat	CC(C)OCCn1c2cc[nH]c2c(=O)[nH]c1=S	Phase 3		myeloperoxidase inhibitor		
vericiguat	COC(=O)Nc1c(N)nc(nc1N)-c1nn(Cc2ccccc2F)c2ncc(F)cc12	Phase 3		guanylate cyclase stimulant		
verinurad	CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(O)=O	Phase 2	SLC22A12	urate transporter inhibitor		
vernakalant	COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC	Launched	KCNA5	potassium channel blocker	cardiology	atrial fibrillation (AF)
verteporfin	COC(=O)CCc1c(C)c2cc3[nH]c(cc4nc(cc5nc(cc1[nH]2)c(CCC(O)=O)c5C)c(C=C)c4C)C1=CC=C([C@@H](C(=O)OC)[C@@]31C)C(=O)OC |c:44	Launched		photosensitizing agent	ophthalmology	macular degeneration
verubecestat	CN1C(N)=N[C@@](C)(CS1(=O)=O)c1cc(NC(=O)c2ccc(F)cn2)ccc1F |c:3|	Phase 3		beta secretase inhibitor		
verubulin	COc1ccc(cc1)N(C)c1nc(C)nc2ccccc12	Phase 2	TUBB	tubulin polymerization inhibitor		
verucerfont	CC[C@H](Nc1cc(C)nc2c(c(C)nn12)-c1ccc(OC)cc1C)c1nc(C)no1	Phase 2		corticotropin releasing factor receptor antagonist		
vesamicol	O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1	Preclinical	SLC18A3	acetylcholinesterase inhibitor		
vesnarinone	COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2NC(=O)CCc2c1	Launched	KCNH2|PDE3A	phosphodiesterase inhibitor	cardiology	congestive heart failure
VGX-1027	OC(=O)C[C@H]1CC(=NO1)c1ccccc1 |&1:4	Phase 1	TLR4	tumor necrosis factor receptor antagonist		
vicriviroc	COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F	Phase 3	CCR5	CC chemokine receptor antagonist		
vidarabine	Nc1ncnc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O	Launched	ADA	antiviral	infectious disease	virus herpes simplex (HSV), varicella-zoster virus (VZV)
vigabatrin	N[C@@H](CCC(O)=O)C=C |&1:1|	Launched	ABAT|SLC32A1	GABA aminotransferase inhibitor	neurology/psychiatry	seizures, spasms
vilanterol		Launched	ADRB2	adrenergic receptor agonist	pulmonary	chronic obstructive pulmonary disease (COPD)
vilazodone	NC(=O)c1cc2cc(ccc2o1)N1CCN(CCCCc2c[nH]c3ccc(cc23)C#N)CC1	Launched	DRD2|DRD3|HRH1|HTR1A|HTR4|SLC6A4	serotonin reuptake inhibitor	neurology/psychiatry	depression
vildagliptin	O[C@]12C[C@@H]3C[C@H](C1)C[C@@](C3)(C2)NCC(=O)N1CCC[C@H]1C#N	Launched	DPP4	dipeptidyl peptidase inhibitor	endocrinology	diabetes mellitus
viloxazine	CCOc1ccccc1OC[C@H]1CNCCO1 |&1:11|	Launched	SLC6A2	norepinephrine reuptake inhibitor	neurology/psychiatry	depression
vinblastine	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:48|	Launched	JUN|TUBA1A|TUBB|TUBD1|TUBE1|TUBG1	microtubule inhibitor, tubulin polymerization inhibitor	hematologic malignancy, infectious disease, oncology	Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma
vinburnine	CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41	Launched	CHRM1|CHRM2|CHRM3|CHRM4	adrenergic receptor antagonist	neurology/psychiatry	stroke
vincamine	CC[C@@]12CCCN3CCc4c([C@H]13)n(c1ccccc41)[C@](O)(C2)C(=O)OC	Withdrawn	CHRM1|CHRM2|CHRM3|CHRM4	adrenergic receptor antagonist		
vincristine	CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:49|	Launched	TUBA4A|TUBB	tubulin polymerization inhibitor	hematologic malignancy	acute lymphoblastic leukemia (ALL)
vindesine	CC[C@]1(O)C[C@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(N)=O |c:48|	Launched	TUBB|TUBB1	tubulin polymerization inhibitor	oncology	breast cancer, non-small cell lung cancer (NSCLC), melanoma
vinflunine	CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)c1cc(OC)c(cc41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CCc3c1[nH]c1ccccc31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC |c:3|	Launched		microtubule inhibitor	oncology	bladder cancer
vinorelbine	CCC1=C[C@@H]2C[N@](C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC |c:46	Launched	TUBA1A|TUBA1B|TUBA1C|TUBA3C|TUBA3D|TUBA3E|TUBA4A|TUBB|TUBB1|TUBB2A|TUBB2B|TUBB3|TUBB4A|TUBB4B|TUBB6|TUBB8	tubulin polymerization inhibitor	oncology	non-small cell lung cancer (NSCLC)
vinpocetine	CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@H]23)n1c1ccccc41 |t:5|	Launched	PDE1A|PDE1C	phosphodiesterase inhibitor, sodium channel blocker	neurology/psychiatry	stroke, senile dementia
viomycin	NCCC[C@H](N)CC(=O)N[C@H]1CNC(=O)[C@@H](NC(=O)C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC1=O)C=NC(N)=O)[C@H]1C[C@H](O)N=C(N)N1 |a:4	Launched		protein synthesis inhibitor	infectious disease	tuberculosis
vipadenant	Cc1cc(Cn2nnc3c(nc(N)nc23)-c2ccco2)ccc1N	Phase 1	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
vismodegib	CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(c2)-c2ccccn2)c(Cl)c1	Launched	SMO	hedgehog pathway inhibitor, smoothened receptor antagonist	oncology	basal cell carcinoma (BCC)
visomitin	CC1=C(C)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=CC1=O |c:1	Preclinical		antioxidant		
vitamin-B12	C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2N=C1\C(C)=C1/N=C(/C=C3\N=C(\C(\C)=C4\[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@@]2(C)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]1CCC(N)=O)OP(O)(=O)O[C@@H]1[C@@H](CO)O[C@@H]([C@@H]1O)n1cnc2cc(C)c(C)cc12 |c:16	Launched			hematology	megaloblastic anemia
vitamin-E	CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1	Launched	ALOX5|DGKA|NR1I2|PPP2CA|PPP2CB|PRKCA|PRKCB|SEC14L2|SEC14L3|SEC14L4	LDL oxidation inhibitor, PKC inhibitor		
vixotrigine	NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(OCc2ccccc2F)cc1	Phase 2		sodium channel blocker		
VLX1570	[O-][N+](=O)c1cc(\C=C2/CCN(C\C(=C/c3ccc(F)c(c3)[N+]([O-])=O)C2=O)C(=O)C=C)ccc1F	Phase 1/Phase 2		deubiquitinase inhibitor		
VLX600	CC(=NNc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1	Phase 1	TP53|USP14	antitumor agent, ubiquitin C-terminal hydrolase inhibitor		
VL285	CC(C)[C@H](N1Cc2ccccc2C1=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)NCc1ccc(cc1)-c1scnc1C	Preclinical		PROTAC		
voclosporin	[H][C@@]1(CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@]([H])(NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@]([H])([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@]([H])(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C1=O)C(C)C	Phase 3		calcineurin inhibitor		
voglibose	OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O	Launched	MGAM	glucosidase inhibitor	endocrinology	diabetes mellitus, hyperglycemia
volasertib	CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O	Phase 3	PLK1	PLK inhibitor		
volinanserin	COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC	Phase 3	HTR2A|HTR2B|HTR2C|KCNH2	serotonin receptor antagonist		
vonoprazan	CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1	Launched	ATP4A	potassium-competitive acid antagonist	gastroenterology	peptic ulcer disease (PUD)
vorapaxar	CCOC(=O)N[C@@H]1CC[C@@H]2[C@H](C[C@@H]3[C@@H]([C@@H](C)OC3=O)[C@H]2\C=C\c2ccc(cn2)-c2cccc(F)c2)C1	Launched	F2R	thrombin inhibitor	cardiology	myocardial infarction, peripheral artery disease (PAD)
vorasidenib	C[C@@H](Nc1nc(N[C@H](C)C(F)(F)F)nc(n1)-c1cccc(Cl)n1)C(F)(F)F	Preclinical		isocitrate dehydrogenase inhibitor		
voreloxin	CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(C(O)=O)c2=O)-c1nccs1	Phase 3	TOP2A	topoisomerase inhibitor		
voriconazole	C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F	Launched	CYP2C19|CYP2C9|CYP3A4|CYP3A5|PTGS1	cytochrome P450 inhibitor	infectious disease	esophageal candidiasis, aspergillosis, skin infections
vorinostat	ONC(=O)CCCCCCC(=O)Nc1ccccc1	Launched	HDAC1|HDAC10|HDAC11|HDAC2|HDAC3|HDAC5|HDAC6|HDAC8|HDAC9	HDAC inhibitor	hematologic malignancy	cutaneous T-cell lymphoma (CTCL)
vortioxetine	Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1	Launched	HTR1A|HTR1B|HTR2A|HTR2C|HTR3A|HTR5A|HTR6|HTR7|SLC6A4	serotonin receptor agonist, serotonin receptor antagonist	neurology/psychiatry	depression
voruciclib	CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccc(cc1Cl)C(F)(F)F	Phase 1		CDK9 inhibitor		
voxelotor	CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O	Launched		hemoglobin modulator		
voxtalisib	CCn1c2nc(N)nc(C)c2cc(-c2cc[nH]n2)c1=O	Phase 2	MTOR|PIK3CA	mTOR inhibitor, PI3K inhibitor		
VP-20629	OC(=O)CCc1c[nH]c2ccccc12	Phase 1	PLA2G2E|SLC36A1	beta amyloid antagonist		
VS-4718	CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F	Phase 1		focal adhesion kinase inhibitor		
VT-464	CC(C)[C@@](O)(c1cn[nH]n1)c1ccc2cc(OC(F)F)c(OC(F)F)cc2c1	Phase 2	CYP17A1	cytochrome P450 inhibitor		
VTP-27999	CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1	Phase 1	REN	renin inhibitor		
VUF10166	CN1CCN(CC1)c1nc2ccccc2nc1Cl	Preclinical	HTR3A|HTR3B	serotonin receptor antagonist		
VUF10460	CN1CCN(CC1)c1cc(nc(N)n1)-c1ccccc1	Preclinical	HRH4	histamine receptor agonist		
VUF11207	COc1cc(cc(OC)c1OC)C(=O)N(CC[C@H]1CCCN1C)C\C(C)=C\c1ccccc1F |&1:17|	Preclinical	ACKR3	CC chemokine receptor agonist		
VU0155069	C[C@@H](CN1CCC(CC1)n1c2ccc(Cl)cc2[nH]c1=O)NC(=O)c1ccc2ccccc2c1	Preclinical	PLD1	phospholipase inhibitor		
VU0238429	COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1	Preclinical	CHRM5	acetylcholine receptor allosteric modulator		
VU0240551	Cc1csc(NC(=O)CSc2ccc(nn2)-c2ccccc2)n1	Preclinical	SLC12A5	potassium/chloride cotransporter inhibitor		
VU0357121	CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F	Preclinical	GRM5	glutamate receptor positive allosteric modulator		
VU0360172	Fc1cccc(c1)C#Cc1ccc(cn1)C(=O)NC1CCC1	Preclinical	GRM5	glutamate receptor positive allosteric modulator		
VU0361737	COc1cc(NC(=O)c2ccccn2)ccc1Cl	Preclinical	GRM4	glutamate receptor positive allosteric modulator		
VU0364439	Clc1ccccc1NS(=O)(=O)c1ccc(NC(=O)c2ccccn2)cc1Cl	Preclinical	GRM4	glutamate receptor positive allosteric modulator		
VU0364739	Fc1cccc(c1)N1CNC(=O)C11CCN(CCNC(=O)c2ccc3ccccc3c2)CC1	Preclinical	PLD2	phospholipase inhibitor		
VU0364770	Clc1cccc(NC(=O)c2ccccn2)c1	Preclinical	GRM4	glutamate receptor positive allosteric modulator		
VU0422288	Clc1ccc(Oc2ccc(NC(=O)c3ccccn3)cc2Cl)nc1	Preclinical	GRM3	glutamate receptor positive allosteric modulator		
VU10010	Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc1ccc(Cl)cc1	Preclinical	CHRM4	acetylcholine receptor allosteric modulator		
VU152100	COc1ccc(CNC(=O)c2sc3nc(C)cc(C)c3c2N)cc1	Preclinical	CHRM4	acetylcholine receptor allosteric modulator		
VU1545	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1F)-c1ccccc1	Preclinical	GRM5	glutamate receptor positive allosteric modulator		
VU29	[O-][N+](=O)c1ccc(cc1)C(=O)Nc1cc(nn1-c1ccccc1)-c1ccccc1	Preclinical	GRM5	glutamate receptor potentiator		
VU591	[O-][N+](=O)c1ccc2nc(COCc3nc4ccc(cc4[nH]3)[N+]([O-])=O)[nH]c2c1	Preclinical	KCNJ1	potassium channel blocker		
VX-11e	Cc1cnc(Nc2ccc(F)cc2Cl)nc1-c1c[nH]c(c1)C(=O)N[C@H](CO)c1cccc(Cl)c1	Preclinical	MAPK1	MAP kinase inhibitor		
VX-222	C[C@H]1CC[C@@H](CC1)C(=O)N([C@@H]1CC[C@H](O)CC1)c1cc(sc1C(O)=O)C#CC(C)(C)C |r|	Phase 2		HCV inhibitor		
VX-702	NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F	Phase 2	IL1B|IL6|MAPK11|MAPK12|MAPK14|TNF	p38 MAPK inhibitor		
VX-745	Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1	Phase 2	MAPK11|MAPK12|MAPK14	p38 MAPK inhibitor		
VX-765	CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C	Phase 2	CASP1	caspase inhibitor		
W-54011	COc1ccc2CCC[C@@H](C(=O)N(Cc3ccc(cc3)N(C)C)c3ccc(cc3)C(C)C)c2c1 |&1:9|	Preclinical	C5AR1	anaphylatoxin chemotactic receptor antagonist		
walrycin-B	Cn1nc(nc2c1nc(=O)n(C)c2=O)-c1ccc(cc1)C(F)(F)F	Preclinical		transcriptional regulatory protein WalR		
warfarin	CC(=O)C[C@@H](c1ccccc1)c1c(O)c2ccccc2oc1=O |&1:4|	Launched	VKORC1	vitamin K antagonist	hematology, cardiology	deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation (AF), myocardial infarction
WAY-100635	COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1	Phase 1	HTR1A	serotonin receptor antagonist		
WAY-161503	Clc1cc2NC(=O)[C@H]3CNCCN3c2cc1Cl |&1:7|	Preclinical	HTR2C	serotonin receptor agonist		
WAY-170523	Cc1cc(C)c(N(Cc2ccccc2)S(=O)(=O)c2ccc(OCCNC(=O)c3cc4ccccc4o3)cc2)c(c1)C(=O)NO	Preclinical	MMP13	metalloproteinase inhibitor		
WAY-200070	Oc1ccc(cc1)-c1nc2cc(O)cc(Br)c2o1	Preclinical	ERBB2|ERBB3|ERBB4|ESR2	estrogen receptor agonist		
WAY-207024	CC(C)(C)c1ccc(cc1)-c1nc2c(cccc2[nH]1)N1CCN(Cc2ccc3nccnc3c2)CC1	Preclinical	GNRHR|HRH2|TACR2	gonadotropin releasing factor hormone receptor antagonist		
WAY-208466	CN(C)CCn1cc(c2cccnc12)S(=O)(=O)c1cccc(F)c1	Preclinical	DRD2|HTR2A|HTR2C|HTR6|HTR7	serotonin receptor agonist		
WAY-213613	N[C@@H](CC(=O)Nc1ccc(Oc2cc(F)c(F)cc2Br)cc1)C(O)=O	Preclinical	SLC1A2	glutamate inhibitor		
WAY-255348	Cn1c(ccc1-c1cc2c(NC(=O)C2(C)C)c(F)c1)C#N	Preclinical		progesterone receptor antagonist		
WAY-316606	FC(F)(F)c1ccc(cc1S(=O)(=O)NC1CCNCC1)S(=O)(=O)c1ccccc1	Preclinical	SFRP1	secreted frizzled related protein inhibitor		
WAY-362450	CC(C)OC(=O)C1=CN(CC(C)(C)c2c1[nH]c1ccccc21)C(=O)c1ccc(F)c(F)c1 |t:6|	Phase 1	NR1H4	FXR agonist		
WAY-600	C(N1CCC(CC1)n1ncc2c(nc(nc12)-c1ccc2[nH]ccc2c1)N1CCOCC1)c1cccnc1	Preclinical	MTOR	mTOR inhibitor		
WAY-629	C1CCc2c(C1)n1CCNCc3cccc2c13	Preclinical	HTR2C	serotonin receptor agonist		
WB-4101	COc1cccc(OC)c1OCCNC[C@H]1COc2ccccc2O1 |&1:15|	Preclinical	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C|HTR1A	adrenergic receptor antagonist		
WDR5-0103	COC(=O)c1ccc(N2CCN(C)CC2)c(NC(=O)c2cccc(OC)c2)c1	Preclinical	WDR5	histone lysine methyltransferase inhibitor		
WEHI-345-analog	Cc1ccc(cc1)-c1nn(c2ncnc(N)c12)C(C)(C)CNC(=O)c1ncccc1C	Preclinical		SRC inhibitor		
WH-4-023	COc1ccc(N(C(=O)Oc2c(C)cccc2C)c2ccnc(Nc3ccc(cc3)N3CCN(C)CC3)n2)c(OC)c1	Preclinical	LCK|SRC	SRC inhibitor		
WHI-P154	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC	Preclinical	EGFR|JAK1|JAK2|JAK3	JAK inhibitor		
WIKI4	COc1ccc(cc1)-n1c(SCCCN2C(=O)c3cccc4cccc(C2=O)c34)nnc1-c1ccncc1	Preclinical	TNKS2	tankyrase inhibitor, WNT pathway inhibitor		
WIN-18446	ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl	Preclinical	ALDH1A2	aldehyde dehydrogenase inhibitor		
WIN-64338	CCCC[P+](CCCC)(CCCC)Cc1ccc(NC(=O)[C@H](Cc2ccc3ccccc3c2)N\C(NC2CCCCC2)=N\C2CCCCC2)cc1	Preclinical	BDKRB2	bradykinin receptor antagonist		
wiskostatin	CN(C)C[C@@H](O)Cn1c2ccc(Br)cc2c2cc(Br)ccc12 |&1:4	Preclinical	WASL	actin related protein inhibitor, neural Wiskott-Aldrich syndrome protein inhibitor		
wnt-c59	Cc1cc(ccn1)-c1ccc(CC(=O)Nc2ccc(cc2)-c2cccnc2)cc1	Preclinical	PORCN	porcupine inhibitor		
wortmannin	COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C([C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O)C3=O |t:16|	Preclinical	PI4KA|PI4KB|PIK3CA|PIK3CD|PIK3CG|PIK3R1|PLK1|PRKDC	PI3K inhibitor		
WP1066	C[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	Phase 1	STAT3	STAT inhibitor		
WP1130	CCC[C@H](NC(=O)C(=C\c1cccc(Br)n1)\C#N)c1ccccc1	Preclinical	JAK2|UCHL5|USP14|USP9X	deubiquitinase inhibitor		
WP921	OC(=O)Cn1nnnc1-c1ccsc1	Preclinical				
WR99210	CC1(C)N=C(N)N=C(N)N1OCCCOc1cc(Cl)c(Cl)cc1Cl |t:3	Preclinical	TYMS	dihydrofolate reductase inhibitor	infectious disease	malaria
WWL-113	CCOC(=O)c1ccc(cc1)-c1ccc(OC(=O)N(C)Cc2cccc(c2)-c2ccncc2)cc1	Preclinical	CES3	carboxylesterase inhibitor		
WWL-123	CN(Cc1cccc(c1)-c1ccccc1)C(=O)Oc1ccc(cc1)-c1ccc(cc1)C(N)=O	Preclinical	ABHD6	monoacylglycerol lipase inhibitor		
WY-16922	CCOC(=O)C(=O)Nc1cccc(OC)c1C(N)=O	Phase 1		histamine release inhibitor		
WYE-125132	CNC(=O)Nc1ccc(cc1)-c1nc(N2C[C@@H]3CC[C@H](C2)O3)c2cnn(C3CCC4(CC3)OCCO4)c2n1 |&1:16	Preclinical	MTOR	mTOR inhibitor		
WYE-354	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(CC3)C(=O)OC)c2n1	Preclinical	MTOR	mTOR inhibitor		
WYE-687	COC(=O)Nc1ccc(cc1)-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4cccnc4)CC3)c2n1	Preclinical	MTOR	mTOR inhibitor		
WZ-3146	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Oc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical	EGFR	EGFR inhibitor		
WZ-4002	COc1cc(ccc1Nc1ncc(Cl)c(Oc2cccc(NC(=O)C=C)c2)n1)N1CCN(C)CC1	Preclinical	EGFR|ERBB2	EGFR inhibitor		
WZ4003	CCC(=O)Nc1cccc(Oc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)ncc2Cl)c1	Preclinical	NUAK1|NUAK2	AMPK inhibitor		
WZ8040	CN1CCN(CC1)c1ccc(Nc2ncc(Cl)c(Sc3cccc(NC(=O)C=C)c3)n2)cc1	Preclinical	EGFR	EGFR inhibitor		
WZ811	C(Nc1ccccn1)c1ccc(CNc2ccccn2)cc1	Preclinical	CXCR4	CC chemokine receptor antagonist		
xaliproden	FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1 |t:11|	Phase 3	HTR1A	serotonin receptor agonist		
xamoterol	OC(CNCCNC(=O)N1CCOCC1)COc1ccc(O)cc1	Phase 3	ADRB1	adrenergic receptor agonist		
xanomeline	CCCCCCOc1nsnc1C1=CCCN(C)C1 |t:13|	Phase 3	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR6|HTR7	acetylcholine receptor agonist		
xanthone	O=c1c2ccccc2oc2ccccc12	Preclinical		antimalarial agent		
XAV-939	FC(F)(F)c1ccc(cc1)-c1nc(=O)c2CSCCc2[nH]1	Preclinical	TNKS|TNKS2	tankyrase inhibitor		
XBD173	CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1	Phase 2	TSPO	benzodiazepine receptor ligand		
XD-14	CCN(CC)S(=O)(=O)c1ccc(O)c(NC(=O)c2[nH]c(C)c(C(C)=O)c2CC)c1	Preclinical	BRD2|BRD3|BRD4|BRDT	bromodomain inhibitor		
XE-991	O=C1c2ccccc2C(Cc2ccncc2)(Cc2ccncc2)c2ccccc12	Preclinical	KCNQ1|KCNQ2|KCNQ3|KCNQ4|KCNQ5	potassium channel blocker		
xenalipin	OC(=O)c1ccccc1-c1ccc(cc1)C(F)(F)F	Phase 2				
xibenolol	Cc1cccc(OC[C@@H](O)CNC(C)(C)C)c1C |&1:8	Phase 3		adrenergic receptor antagonist		
xilobam	CN1CCC\C1=N\C(=O)Nc1c(C)cccc1C	Phase 1				
xipamide	Cc1cccc(C)c1NC(=O)c1cc(c(Cl)cc1O)S(N)(=O)=O	Launched	SLC12A3	carbonic anhydrase inhibitor	cardiology	edema, hypertension
XL019	O=C(Nc1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1)[C@@H]1CCCN1	Phase 1	JAK1|JAK2|JAK3	JAK inhibitor		
XL041	CC(C)(O)c1cn(c(n1)C(C)(C)c1c(Cl)cccc1Cl)-c1ccc(cc1F)-c1cc(F)c(CO)c(c1)S(C)(=O)=O	Preclinical		LXR agonist		
XL147	Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc2nsnc2c1	Phase 2	PIK3CA|PIK3CD|PIK3CG	PI3K inhibitor		
XL228	CC(C)c1cc(CNc2nc(Nc3cc(n[nH]3)C3CC3)cc(n2)N2CCN(C)CC2)on1	Phase 1	IGF1R|SRC	Abl kinase inhibitor, insulin growth factor receptor inhibitor, SRC inhibitor		
XL388	Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O	Preclinical	MTOR	mTOR inhibitor		
XL647	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1	Phase 3	EGFR|EPHB4|ERBB2|FLT4|KDR	EGFR inhibitor, VEGFR inhibitor		
XL888	[H][C@]1(C[C@@H]2CC[C@H](C1)N2c1ccc(cn1)C(=O)C1CC1)NC(=O)c1cc(N[C@H](C)CC)c(cc1C)C(N)=O |TLB:9:8:4.5:1.2.7|	Phase 1		HSP inhibitor		
XMD17-109	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C3CCCC3)c2n1)C(=O)N1CCC(CC1)N1CCN(C)CC1	Preclinical	MAPK7	MAP kinase inhibitor		
XMD8-92	CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(C)c2n1)N1CCC(O)CC1	Preclinical	DCLK2|MAPK7|PLK4|TNK1	MAP kinase inhibitor		
xylazine	Cc1cccc(C)c1NC1=NCCCS1 |t:10|	Launched	ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	neurology/psychiatry	anesthetic
xylometazoline	Cc1cc(cc(C)c1CC1=NCCN1)C(C)(C)C |t:10|	Launched	ADRA1A|ADRA1B|ADRA1D|ADRA2A|ADRA2B|ADRA2C	adrenergic receptor agonist	otolaryngology, allergy	nasal congestion, allergic rhinitis
xylose	OC[C@@H](O)[C@H](O)[C@@H](O)C=O	Launched				
Y-11	OCC[N+]12CN3CN(CN(C3)C1)C2	Preclinical	PTK2	focal adhesion kinase inhibitor		
Y-134	CC(C)N1CCN(CC1)c1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1	Preclinical	ESR1|ESR2	estrogen receptor antagonist		
Y-26763	CC(=O)N(O)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Phase 1	KCNJ8	potassium channel activator		
Y-27152	CC(=O)N(OCc1ccccc1)[C@H]1[C@H](O)C(C)(C)Oc2ccc(cc12)C#N	Phase 1	KCNJ8	potassium channel activator		
Y-27632	C[C@@H](N)[C@H]1CC[C@@H](CC1)C(=O)Nc1ccncc1	Preclinical	PKIA|PKN2|PRKACA|PRKCE|ROCK1|ROCK2	rho associated kinase inhibitor		
Y-29794	CC(C)c1ccc(C(=O)c2cccs2)c(SCCCCCCCCN(C)C)n1	Preclinical	PREP	prolyl endopeptidase inhibitor		
Y-320	Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N	Preclinical	IL17A	interleukin inhibitor		
Y-39983	C[C@@H](N)c1ccc(cc1)C(=O)Nc1ccnc2[nH]ccc12	Phase 2	ROCK1|ROCK2	rho associated kinase inhibitor		
YC-1	OCc1ccc(o1)-c1nn(Cc2ccccc2)c2ccccc12	Preclinical	GUCY1A2|GUCY1A3|GUCY1B3|HIF1A	guanylyl cyclase activator		
YIL-781	CC(C)N1CCC[C@H](Cn2c(C)nc3ccc(Oc4ccc(F)cc4)cc3c2=O)C1	Preclinical	GHSR	ghrelin receptor antagonist		
YK-4-279	COc1ccc(cc1)C(=O)C[C@@]1(O)C(=O)Nc2c1c(Cl)ccc2Cl |&1:11	Preclinical	EWSR1|FLI1	apoptosis inhibitor		
YL0919	OC1(Cn2ccccc2=O)CCN(Cc2ccccc2)CC1	Preclinical		selective serotonin reuptake inhibitor (SSRI)		
YM-022	Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1 |t:11|	Phase 2	CCKBR	CCK receptor antagonist		
YM-155	COCCn1c(C)[n+](Cc2cnccn2)c2c1C(=O)c1ccccc1C2=O	Phase 2	BIRC5	survivin inhibitor		
YM-201636	Nc1ccc(cn1)C(=O)Nc1cccc(c1)-c1nc(N2CCOCC2)c2oc3ncccc3c2n1	Preclinical		PI3K inhibitor		
YM-244769	Nc1cccc(CNC(=O)c2ccc(Oc3ccc(OCc4cccc(F)c4)cc3)nc2)c1	Preclinical		sodium/calcium exchange inhibitor		
YM-298198	CN(C1CCCCC1)C(=O)c1sc2nc3ccc(N)cc3n2c1C	Preclinical	GRM1	glutamate receptor antagonist		
YM-298198-desmethyl	Cc1c(sc2nc3ccc(N)cc3n12)C(=O)NC1CCCCC1	Preclinical	GRM1	glutamate receptor antagonist		
YM-511	Brc1ccc(CN(c2ccc(cc2)C#N)n2cnnc2)cc1	Phase 2	CYP19A1	aromatase inhibitor		
YM-58483	Cc1nnsc1C(=O)Nc1ccc(cc1)-n1nc(cc1C(F)(F)F)C(F)(F)F	Preclinical	TRPC3|TRPC5|TRPM4	calcium channel blocker		
YM-750	Cc1cc(C)c(NC(=O)N(Cc2ccc-3c(Cc4ccccc-34)c2)C2CCCCCC2)c(C)c1	Phase 1	SOAT1	ACAT inhibitor		
YM-90709	COc1cc2CC(C)(C)n3c(cc4nc5ccccc5nc34)-c2cc1OC	Preclinical	CSF2RB|IL5RA	IL5 inhibitor		
YM-976	CCc1ccc2c(nc(=O)n(CC)c2n1)-c1cccc(Cl)c1	Phase 1	PDE4A	phosphodiesterase inhibitor		
YO-01027	C[C@H](NC(=O)Cc1cc(F)cc(F)c1)C(=O)N[C@H]1c2ccccc2-c2ccccc2N(C)C1=O	Preclinical		gamma secretase inhibitor		
yoda-1	Clc1cccc(Cl)c1CSc1nnc(s1)-c1cnccn1	Preclinical	PIEZO1	piezo channel activator		
yohimbine	COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12	Launched	ADRA2A|ADRA2B|ADRA2C|DRD2|DRD3|HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR7|KCNJ1|KCNJ10|KCNJ11|KCNJ12|KCNJ14|KCNJ15|KCNJ8	adrenergic receptor antagonist	cardiology	cardiac arrythmia, bradycardia
YS-035	COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC	Preclinical		calcium channel blocker		
YS-201	CCOC(=O)C1=C(C)NC(C)=C([C@@H]1c1cccc(c1)[N+]([O-])=O)C(=O)OCCN1CCCCC1 |&1:12	Preclinical		calcium receptor antagonist		
YZ9	CCOC(=O)c1cc2ccc(O)cc2oc1=O	Preclinical	MIF|PFKFB3	phosphofructokinase inhibitor		
Y16	Cc1cccc(COc2cccc(\C=C3/C(=O)NN(C3=O)c3ccccc3)c2)c1	Preclinical	RHOA	rho associated kinase inhibitor		
zacopride	COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CN2CCC1CC2 |&1:13	Phase 2	HTR3A|HTR3B|HTR4|HTR5A	serotonin receptor antagonist		
zafirlukast	COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C	Launched	CYSLTR1|CYSLTR2	leukotriene receptor antagonist	pulmonary	asthma
zalcitabine	Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1	Launched		nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1)
zaldaride	C[C@@]1(CN2CCC(CC2)n2c3ccccc3[nH]c2=O)OCc2ccccc2-n2cccc12 |&1:1|	Phase 3	CALM1	calmodulin antagonist		
zaltidine	Cc1nc(c[nH]1)-c1csc(NC(N)=N)n1	Phase 3	HRH2	histamine receptor antagonist		
zaltoprofen	C[C@@H](C(O)=O)c1ccc2Sc3ccccc3C(=O)Cc2c1 |&1:1	Launched		cyclooxygenase inhibitor	endocrinology, neurology/psychiatry	fever, pain relief
ZAMI-633	CCC(=O)NO	Phase 3		urease inhibitor		
zamifenacin	C(Cc1ccc2OCOc2c1)N1CCC[C@H](C1)OC(c1ccccc1)c1ccccc1	Phase 3	CHRM3	acetylcholine receptor antagonist		
zanamivir	CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O |c:10|	Launched	NEU2	neuraminidase inhibitor	infectious disease	influenza A virus infection
zanubrutinib	NC(=O)c1c2NCC[C@@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1	Launched		Bruton's tyrosine kinase (BTK) inhibitor		
ZAPA	NC(=N)S\C=C/C(O)=O	Preclinical				
zaprinast	CCCOc1ccccc1-c1nc(=O)c2n[nH]nc2[nH]1	Phase 2	GPR35|PDE1A|PDE4D|PDE5A|PDE9A	phosphodiesterase inhibitor		
zardaverine	COc1cc(ccc1OC(F)F)-c1ccc(=O)[nH]n1	Phase 2	PDE4D	phosphodiesterase inhibitor		
zatebradine	COc1ccc(CCN(C)CCCN2CCc3cc(OC)c(OC)cc3CC2=O)cc1OC	Phase 3	HCN1|HCN2|HCN3|HCN4	HCN channel blocker		
ZCL-278	Cc1cc(C)nc(NS(=O)(=O)c2ccc(NC(=S)NC(=O)COc3ccc(Br)cc3Cl)cc2)n1	Preclinical	CDC42	CDC inhibitor		
ZD-0947	FC(F)(F)C1=C[C@H](C2=C(CCCC2=O)N1)c1cccc(c1)C#N |t:4	Preclinical		potassium channel activator		
ZD-2079	O[C@@H](CNCCOc1ccc(CC(O)=O)cc1)c1ccccc1	Phase 2	ADRB3	adrenergic receptor agonist		
ZD-7114	COCCNC(=O)COc1ccc(OCCNC[C@H](O)COc2ccccc2)cc1	Phase 1	ADRB3	adrenergic receptor agonist		
ZD-7155	CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nn[nH]n3)C(=O)CCc2c(CC)n1	Preclinical	AGTR1	angiotensin receptor antagonist		
ZD-7288	CCN(c1ccccc1)c1cc(=NC)n(C)c(C)n1	Phase 2	HCN1|HCN2|HCN3|HCN4	HCN channel blocker		
zeatin	C\C(CO)=C/CNc1ncnc2nc[nH]c12	Phase 1				
zebularine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cccnc1=O	Preclinical	CDA|DNMT1	DNA methyltransferase inhibitor		
zibotentan	COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(cc1)-c1nnco1	Phase 3	EDNRA	endothelin receptor antagonist		
zidovudine	Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O	Launched	TERT	nucleoside reverse transcriptase inhibitor	infectious disease	human immunodeficiency virus (HIV-1), acquired immunodeficiency syndrome (AIDS)
zileuton	C[C@@H](N(O)C(N)=O)c1cc2ccccc2s1 |&1:1	Launched	ALOX5	leukotriene synthesis inhibitor, lipoxygenase inhibitor	pulmonary	asthma
zilpaterol	CC(C)N[C@H]1CCn2c3c(cccc3[nH]c2=O)[C@@H]1O	Launched	ADRB2	adrenergic receptor agonist	endocrinology	weight-gain aid
zimelidine	CN(C)C\C=C(\c1ccc(Br)cc1)c1cccnc1	Withdrawn	MAOA|MAOB|SLC6A4	selective serotonin reuptake inhibitor (SSRI)		
zinc-undecylenate	C=CCCCCCCCCC(=O)O[Zn]OC(=O)CCCCCCCCC=C	Launched		other antifungal	infectious disease	tinea pedis
zindotrine	Cc1cc(nn2cnnc12)N1CCCCC1	Phase 2		phosphodiesterase inhibitor		
ziprasidone	Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12	Launched	ADRA1A|ADRA1B|ADRA2A|ADRA2B|ADRA2C|CHRM1|CHRM2|CHRM3|CHRM4|CHRM5|DRD1|DRD2|DRD3|DRD4|DRD5|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR3A|HTR6|HTR7|SLC6A4	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia, bipolar disorder
ziritaxestat	CCc1nc2c(C)cc(cn2c1N(C)c1nc(c(s1)C#N)-c1ccc(F)cc1)N1CCN(CC(=O)N2CC(O)C2)CC1	Phase 3		autotaxin inhibitor		
ZK-164015	CCCCCS(=O)(=O)CCCCCCCCCCn1c(c(C)c2cc(O)ccc12)-c1ccc(O)cc1	Preclinical	ESR1|ESR2	estrogen receptor antagonist		
ZK-200775	OP(O)(=O)Cn1c2cc(N3CCOCC3)c(cc2[nH]c(=O)c1=O)C(F)(F)F	Phase 2		kainate receptor antagonist		
ZK-811752	C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O	Phase 2	CCR1	CC chemokine receptor antagonist		
ZK-93423	CCOC(=O)c1ncc2[nH]c3ccc(OCc4ccccc4)cc3c2c1COC	Phase 3	GABRA1|GABRA2|GABRA3|GABRA5|GABRB2|GABRG2	benzodiazepine receptor agonist		
ZK-93426	CCOC(=O)c1ncc2[nH]c3cccc(OC(C)C)c3c2c1C	Phase 1	GABRA1|GABRA2|GABRA3|GABRA5	benzodiazepine receptor antagonist		
ZLN005	CC(C)(C)c1ccc(cc1)-c1nc2ccccc2[nH]1	Preclinical				
ZLN024	Cc1ccc(OCCSc2ncccn2)c(Br)c1	Preclinical	PRKAA1|PRKAB1|PRKAG1	AMPK activator		
ZM-226600	C[C@@](O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F |&1:1|	Preclinical		Kir6 channel (KATP) activator		
ZM-241385	Nc1nc(NCCc2ccc(O)cc2)nc2nc(nn12)-c1ccco1	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor antagonist		
ZM-306416	COc1cc2ncnc(Nc3ccc(Cl)cc3F)c2cc1OC	Preclinical	EGFR|FLT1|FLT4|KDR	Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor		
ZM-323881	Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O	Preclinical	KDR	VEGFR inhibitor		
ZM-336372	CN(C)c1cccc(c1)C(=O)Nc1ccc(C)c(NC(=O)c2ccc(O)cc2)c1	Preclinical	BRAF|LCK|MAPK14|RAF1	RAF inhibitor		
ZM-39923	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1	Preclinical	JAK1|JAK3	JAK inhibitor		
ZM-447439	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1	Preclinical	AURKA|AURKB	Aurora kinase inhibitor		
zofenopril-calcium	C[C@H](CSC(=O)c1ccccc1)C(=O)N1C[C@H](C[C@H]1C(O)=O)Sc1ccccc1	Launched	ACE	angiotensin converting enzyme inhibitor	cardiology	hypertension
zolantidine	C(CNc1nc2ccccc2s1)COc1cccc(CN2CCCCC2)c1	Preclinical		histamine receptor antagonist		
zoledronic-acid	OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O	Launched	FDPS|GGPS1	bone resorption inhibitor	endocrinology	Paget's disease
zoliflodacin	[H][C@]12[C@H](C)O[C@H](C)CN1c1c(CC22C(=O)NC(=O)NC2=O)cc2c(noc2c1F)N1[C@@H](C)COC1=O	Phase 3		antibacterial 		
zolimidine	CS(=O)(=O)c1ccc(cc1)-c1cn2ccccc2n1	Launched		mucus protecting agent	gastroenterology	peptic ulcer disease (PUD), gastroesophageal reflux disease (GERD)
zolmitriptan	CN(C)CCc1c[nH]c2ccc(C[C@H]3COC(=O)N3)cc12	Launched	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F	serotonin receptor agonist	neurology/psychiatry	migraine headache
zomepirac	Cc1cc(CC(O)=O)n(C)c1C(=O)c1ccc(Cl)cc1	Withdrawn	PTGDR2	prostaglandin synthesis inhibitor		
zometapine	Cc1nn(C)c2NCCN=C(c12)c1cccc(Cl)c1 |c:9|	Phase 2				
zoniporide	NC(N)=NC(=O)c1cnn(c1C1CC1)-c1cccc2ncccc12	Phase 3	SLC9A1	sodium/hydrogen exchanger inhibitor		
zonisamide	NS(=O)(=O)Cc1noc2ccccc12	Launched	CA1|CA10|CA11|CA12|CA13|CA14|CA2|CA3|CA4|CA5A|CA5B|CA6|CA7|CA8|CA9|CACNA1G|CACNA1H|CACNA1I|MAOA|MAOB|SCN10A|SCN11A|SCN1A|SCN1B|SCN2A|SCN2B|SCN3A|SCN3B|SCN4A|SCN4B|SCN5A|SCN7A|SCN8A|SCN9A	sodium channel blocker, T-type calcium channel blocker	neurology/psychiatry	seizures, epilepsy
zopolrestat	OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12	Phase 2	AKR1B1|AKR1B10			
zosuquidar	O[C@@H](COc1cccc2ncccc12)CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3ccccc13)C2(F)F	Phase 3	ABCB1|ABCB4	P glycoprotein inhibitor		
zotarolimus	CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1n1cnnn1 |c:14	Launched	FKBP1A	mTOR inhibitor	cardiology	coronary artery restenosis
zotepine	CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12 |t:6|	Launched	ADRA2B|DRD2|DRD3|DRD4|HRH1|HTR1A|HTR1B|HTR1D|HTR1E|HTR2A|HTR2C|HTR6|HTR7|SLC6A2|SLC6A4	dopamine receptor antagonist, serotonin receptor antagonist	neurology/psychiatry	schizophrenia
zoxazolamine	Nc1nc2cc(Cl)ccc2o1	Phase 2		myorelaxant		
ZSET1446	O=C1N=C2C=CC=CN2C11Cc2ccccc2C1 |c:4	Preclinical		nicotinic receptor agonist		
ZSTK-474	FC(F)c1nc2ccccc2n1-c1nc(nc(n1)N1CCOCC1)N1CCOCC1	Phase 1/Phase 2	PIK3CB|PIK3CD|PIK3CG	PI3K inhibitor		
zuclopenthixol	OCCN1CCN(CC\C=C2\c3ccccc3Sc3ccc(Cl)cc23)CC1	Launched	ADRA1A|ADRA2A|DRD1|DRD2|DRD5|HRH1|HTR2A	dopamine receptor antagonist	neurology/psychiatry	schizophrenia, bipolar disorder
zuranolone	[H][C@@]12CC[C@H](C(=O)Cn3cc(cn3)C#N)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@]2([H])C[C@](C)(O)CC[C@]12[H]	Phase 3		GABA receptor agonist		
Z160	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1	Phase 2	CACNA2D1	N-type calcium channel blocker		
1,12-Besm	CCNCCCNCCCCNCCCNCC	Phase 2		polyamine biosynthesis inhibitor		
1,2,3,4,5,6-hexabromocyclohexane	BrC1C(Br)C(Br)C(Br)C(Br)C1Br	Preclinical	JAK2	JAK inhibitor		
1,3-dipropyl-8-phenylxanthine	CCCn1c2nc([nH]c2c(=O)n(CCC)c1=O)-c1ccccc1	Preclinical		adenosine receptor antagonist		
1,4-butanediol	OCCCCO	Phase 1	MAN1B1|PLA2G2A|PLA2G2E	benzodiazepine receptor agonist, gamma hydroxybutyric acid agonist		
1,5-dicaffeoylquinic-acid	O[C@@H]1C[C@@](C[C@@H](OC(=O)\C=C\c2ccc(O)c(O)c2)[C@@H]1O)(OC(=O)\C=C\c1ccc(O)c(O)c1)C(O)=O	Phase 1				
1-((Z)-3-chloroallyl)-1,3,5,7-tetraazaadamantan-1-ium	Cl\C=C/C[N+]12CN3CN(CN(C3)C1)C2	Preclinical				
1-(1,2-diphenylethyl)piperidine-(+/-)	C([C@@H](N1CCCCC1)c1ccccc1)c1ccccc1 |&1:1|	Preclinical		glutamate receptor antagonist		
1-(2-chloro-5-methylphenoxy)-3-(isopropylamino)-2-propanol	CC(C)NC[C@@H](O)COc1cc(C)ccc1Cl |&1:5	Preclinical				
1-acetyl-4-methylpiperazine	CN1CCN(CC1)C(C)=O	Preclinical		acetylcholine receptor agonist		
1-azakenpaullone	Brc1ccc2[nH]c-3c(CC(=O)Nc4cccnc-34)c2c1	Preclinical	CCNB1|CDK1|CDK5|GSK3B	glycogen synthase kinase inhibitor		
1-deoxymannojirimycin	OC[C@H]1NC[C@@H](O)[C@@H](O)[C@@H]1O	Preclinical	MAN2A1	alpha mannosidase inhibitor		
1-EBIO	CCn1c2ccccc2[nH]c1=O	Preclinical	KCNN1|KCNN2|KCNN3|KCNN4	potassium channel activator		
1-ethyl-2-pyrrolidone	CCN1CCCC1=O	Preclinical		transdermal absorption-enhancing compound		
1-hexadecanal	CCCCCCCCCCCCCCCC=O	Preclinical	DBI|RHO	sphingosine 1-phosphate receptor substrate		
1-hexadecanol	CCCCCCCCCCCCCCCCO	Launched			dermatology	cosmetic
1-naphthyl-PP1	CC(C)(C)n1nc(-c2cccc3ccccc23)c2c(N)ncnc12	Preclinical	SRC	SRC inhibitor		
1-octacosanol	CCCCCCCCCCCCCCCCCCCCCCCCCCCCO	Phase 2				
1-octanol	CCCCCCCCO	Phase 2	GJA1|GJA10|GJA3|GJA4|GJA5|GJA8|GJA9|GJB1|GJB2|GJB3|GJB4|GJB5|GJB6|GJB7|GJC1|GJC2|GJC3|GJD2|GJD3|GJD4|GJE1			
1-phenylbiguanide	NC(N)=NC(=N)Nc1ccccc1	Preclinical	HTR3A|HTR3B	serotonin receptor agonist		
1E-1-(2-hydroxy-5-methylphenyl)-1-dodecanone-oxime	CCCCCCCCCCC[C@@H](N=O)c1cc(C)ccc1O |r|	Preclinical				
1S,2R-phenylpropanolamine	C[C@@H](N)[C@@H](O)c1ccccc1	Withdrawn		adrenergic receptor agonist		
10-deacetylbaccatin	CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C |t:33|	Preclinical		antitumor agent		
10-DEBC	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12	Preclinical	PIM1	AKT inhibitor		
10-hydroxycamptothecin	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)cc4cc3Cn1c2=O	Preclinical	TOP1	topoisomerase inhibitor		
10058-F4	CCc1ccc(\C=C2\SC(=S)NC2=O)cc1	Preclinical		c-Myc inhibitor		
12-O-tetradecanoylphorbol-13-acetate	CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@]2(O)[C@@H]3C=C(C)C(=O)[C@@]3(O)CC(CO)=C[C@H]2[C@@H]2C(C)(C)[C@]12OC(C)=O |c:33	Phase 2	KCNT2|TRPV4	PKC activator		
1400W	CC(=N)NCc1cccc(CN)c1	Preclinical	NOS1|NOS2|NOS3	nitric oxide synthase inhibitor		
16,16-dimethylprostaglandin-e2	CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O	Phase 2	HPGD	prostanoid receptor agonist		
17-hydroxyprogesterone-caproate	CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |t:15|	Launched	AR|ESR1|ESR2|NR1H4|NR1I2|NR3C1|PGR	progesterone receptor agonist	obstetrics/gynecology	spontaneous preterm birth
17-PA	C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@]34C)[C@@H]1CC=C2c1ccccc1 |c:21|	Preclinical		glucocorticoid receptor agonist		
2'-C-methylguanosine	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c1[nH]c(N)nc2=O	Preclinical		HCV inhibitor		
2'-MeCCPA	C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1cnc2c(NC3CCCC3)nc(Cl)nc12	Preclinical	ADORA1	adenosine receptor agonist		
2,3-cis/exo-camphanediol	CC1(C)[C@@H]2CC[C@@]1(C)[C@H](O)[C@@H]2O	Phase 1				
2,3-cis/exo-pinanediol	CC1(C)C2CC1[C@](C)(O)[C@H](O)C2	Phase 1				
2,3-DCPE	OCCNCCCOc1cccc(Cl)c1Cl	Preclinical	BCL2L1	BCL-XL downregulator		
2,4-dinitrochlorobenzene	[O-][N+](=O)c1ccc(Cl)c(c1)[N+]([O-])=O	Phase 2	TXN	thioredoxin inhibitor		
2,4-dinitrophenol	Oc1ccc(cc1[N+]([O-])=O)[N+]([O-])=O	Preclinical	APP	ATP synthase inhibitor		
2,5-furandimethanol	OCc1ccc(CO)o1	Phase 2	HBB	hemoglobin modulator		
2,6-dimethylpiperidine	C[C@H]1CCC[C@@H](C)N1 |&1:1	Preclinical				
2-(chloromethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4(3H)-one	ClC=C1Nc2sc3CCCCc3c2C(=O)N1	Preclinical				
2-(1-adamantylamino)benzoic-acid	OC(=O)c1ccccc1NC(=O)C12CC3CC(CC(C3)C1)C2	Preclinical				
2-(3-mercaptopropyl)pentanedioic-acid	OC(=O)CC[C@@H](CCCS)C(O)=O |&1:5	Phase 1	FOLH1	glutamate carboxypeptidase inhibitor		
2-[1-(4-piperonyl)piperazinyl]benzothiazole	C(N1CCN(CC1)c1nc2ccccc2s1)c1ccc2OCOc2c1	Preclinical	HTR4	serotonin receptor agonist		
2-aminobenzenesulfonamide	Nc1ccccc1S(N)(=O)=O	Preclinical	CA12|CA14|CA2|CA6|CA9	carbonic anhydrase inhibitor		
2-APB	NCCOB(c1ccccc1)c1ccccc1	Preclinical	TRPC1|TRPC3|TRPC4|TRPC5|TRPC6|TRPC7|TRPM2|TRPM3|TRPM6|TRPV1|TRPV6	1,4,5-trisphosphate inhibitor		
2-BFI	C1CN=C(N1)c1cc2ccccc2o1 |c:2|	Preclinical	ADRA2A|ADRA2B|ADRA2C|MAOA|MAOB	imidazoline receptor ligand		
2-chloro-N6-cyclopentyladenosine	OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(NC3CCCC3)nc(Cl)nc12	Preclinical	ADORA1|ADORA2A|ADORA2B|ADORA3	adenosine receptor agonist		
2-chloroadenosine	Nc1nc(Cl)nc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O	Preclinical	ADORA1|ADORA2A|ADORA2B	adenosine receptor agonist		
2-chloropyrazine	Clc1cnccn1	Preclinical				
2-CMDO	CN1CCN(CC1)C1=Cc2ccccc2Oc2ccc(Cl)cc12 |t:8|	Preclinical	DRD2|DRD4	dopamine receptor antagonist		
2-deoxy-2-([methyl(nitroso)carbamoyl]amino)hexose	CN([NH2+][O-])C(=O)N[C@@H](C=O)[C@@H](O)[C@@H](O)[C@@H](O)CO |&1:7	Preclinical			oncology, endocrinology	pancreatic cancer, hypoglycemia
2-deoxyglucose	OC[C@H]1O[C@H](O)C[C@@H](O)[C@@H]1O	Phase 2	SLC2A1|SLC2A2|SLC2A3|SLC2A4	glycolysis inhibitor		
2-ethoxybenzoic-acid	CCOc1ccccc1C(O)=O	Phase 1		analgesic agent		
2-ethyl-1,3-hexanediol	CCC[C@@H](O)[C@@H](CC)CO |&1:3	Preclinical				
2-fluoro-2-deoxy-D-galactose	OC[C@H]1O[C@@H](O)[C@@H](F)[C@@H](O)[C@@H]1O |&1:2	Phase 1	LCT			
2-fluorofucose	C[C@@H]1O[C@H](O)[C@@H](F)[C@H](O)[C@@H]1O |&1:3|	Phase 1				
2-hydroxy-4-((E)-3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)cyclohexane-1,3,5-trione	OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@H]1C(=O)C(=C(O)\C=C\c2ccc(O)cc2)C(=O)[C@@](O)([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C1=O |a:2	Preclinical				
2-hydroxyethyl-salicylate	OCCOC(=O)c1ccccc1O	Launched			neurology/psychiatry	pain relief
2-hydroxyflutamide	CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O	Phase 2	AR	androgen receptor antagonist		
2-hydroxysaclofen	NC[C@@](O)(CS(O)(=O)=O)c1ccc(Cl)cc1 |&1:2	Preclinical	GABBR1|GABBR2	GABA receptor antagonist		
2-iminobiotin	NC1=N[C@H]2CS[C@@H](CCCCC(O)=O)[C@H]2N1 |t:1|	Phase 2	NOS1|NOS2	nitric oxide synthase inhibitor		
2-iodohippuric-acid	OC(=O)CNC(=O)c1ccccc1I	Preclinical				
2-iodomelatonin	COc1ccc2[nH]c(I)c(CCNC(C)=O)c2c1	Preclinical	MTNR1A|MTNR1B|NQO2	melatonin receptor agonist		
2-methoxyestradiol	COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O	Phase 2	COMT|CYP19A1|CYP1A1|CYP1B1|HIF1A|TUBB	hypoxia inducible factor inhibitor		
2-methyl-5-hydroxytryptamine	Cc1[nH]c2ccc(O)cc2c1CCN	Preclinical	HTR1B|HTR1D|HTR1E|HTR1F|HTR3A|HTR3B|HTR6	serotonin receptor agonist		
2-methyl-5-nitrophenol	Cc1ccc(cc1O)[N+]([O-])=O	Preclinical				
2-methylimidazole	Cc1ncc[nH]1	Preclinical		cholesterol inhibitor		
2-octyldodecan-1-ol	CCCCCCCCCC[C@@H](CO)CCCCCCCC |&1:10	Preclinical				
2-oleoylglycerol	CCCCCCCC\C=C/CCCCCCCC(=O)OC(CO)CO	Phase 1	GPR119	glucose dependent insulinotropic receptor ligand		
2-oxoglutaric-acid	OC(=O)CCC(=O)C(O)=O	Preclinical	OXGR1			
2-oxopropanoate	OC(=C)C(O)=O	Preclinical	ABAT	pyruvate dehydrogenase kinase inhibitor		
2-phenylmelatonin	COc1ccc2[nH]c(c(CCNC(C)=O)c2c1)-c1ccccc1	Preclinical	MTNR1A|MTNR1B	melatonin receptor agonist		
2-PMDQ	O=C1Nc2ccccc2C2=N[C@@H](CN3CCN(CC3)c3ccccc3)CN12 |&1:11	Preclinical	ADRA1A	adrenergic receptor antagonist		
2-pyridylethylamine	NCCc1ccccn1	Preclinical	HRH1	histamine receptor agonist		
2-TEDC	Oc1ccc(\C=C(/C#N)C(=O)OCCc2cccs2)cc1O	Preclinical	ALOX12	lipoxygenase inhibitor		
2-thiouracil	O=c1cc[nH]c(=S)[nH]1	Preclinical				
20-HETE	OCCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O	Preclinical		ion channel antagonist		
20-hydroxyecdysone	CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@@H]3CC[C@]12C |t:16|	Phase 2		ecdysone receptor modulator		
3'-fluorobenzylspiperone	Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CN(Cc1cccc(F)c1)C2=O)c1ccccc1	Preclinical	DRD2	dopamine receptor ligand		
3,3'-dichlorobenzaldazine	Clc1cccc(\C=N\N=C\c2cccc(Cl)c2)c1	Preclinical	GRM5	glutamate receptor modulator		
3,3'-diindolylmethane	C(c1c[nH]c2ccccc12)c1c[nH]c2ccccc12	Phase 3	AR|HIF1A|IFNG|PI3	CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor		
3,4-DCPG-(+/-)	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O |&1:1	Preclinical	GRM8	glutamate receptor agonist		
3,4-DCPG-(R)	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	Preclinical		glutamate receptor antagonist		
3,4-DCPG-(S)	N[C@H](C(O)=O)c1ccc(C(O)=O)c(c1)C(O)=O	Preclinical	GRM8	glutamate receptor agonist		
3,4-methylenedioxy-beta-nitrostyrene	[O-][N+](=O)\C=C\c1ccc2OCOc2c1	Preclinical	SRC|SYK	SRC inhibitor, SYK inhibitor		
3,5-DHPG-(S)	N[C@H](C(O)=O)c1cc(O)cc(O)c1	Preclinical	GRM1	glutamate receptor agonist		
3-(4-methylbenzylidene)camphor	Cc1ccc(\C=C2\[C@H]3CC[C@@](C)(C2=O)C3(C)C)cc1 |&1:7	Launched		endocrine disruptor	dermatology	sunscreen lotion
3-alpha-bis-(4-fluorophenyl)-methoxytropane	CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(c1ccc(F)cc1)c1ccc(F)cc1 |&1:2	Preclinical	CHRM1|SLC6A2|SLC6A3|SLC6A4	dopamine uptake inhibitor		
3-alpha-hydroxy-5-beta-androstan-17-one	C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@H](O)CC[C@]34C)[C@@H]1CCC2=O |a:1	Preclinical	HSD17B11|IGHG2|SULT2A1			
3-amino-benzamide	NC(=O)c1cccc(N)c1	Phase 2	PARP1	PARP inhibitor		
3-anilinopropan-1-ol	OCCCNc1ccccc1	Preclinical				
3-AQC	C=CCN1CCN(CC1)c1nc2ccccc2nc1C#N	Preclinical	HTR3A	serotonin receptor agonist		
3-bromo-7-nitroindazole	[O-][N+](=O)c1cccc2c(Br)[nH]nc12	Preclinical	NOS1|NOS2|NOS3	nitric oxide synthase inhibitor		
3-bromocamphor	[H][C@]1(Br)[C@@H]2CC[C@@](C)(C1=O)C2(C)C |&1:1	Launched				
3-bromopyruvate	OC(=O)C(O)=CBr	Preclinical	HK2	hexokinase inhibitor		
3-carboxy-4-hydroxyphenylglycine-(R)	N[C@@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	Preclinical	GRIN1|GRIN2A|GRIN2B|GRIN2C	glutamate receptor antagonist		
3-carboxy-4-hydroxyphenylglycine-(S)	N[C@H](C(O)=O)c1ccc(O)c(c1)C(O)=O	Preclinical	GRM1|GRM5	glutamate receptor antagonist		
3-CPMT	CN1[C@H]2CC[C@@H]1C[C@@H](C2)O[C@H](c1ccccc1)c1ccc(Cl)cc1 |&1:2	Preclinical		dopamine reuptake inhibitor		
3-deazaadenosine	Nc1nccc2n(cnc12)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |a:10	Phase 2	AHCY	adenosylhomocysteinase inhibitor		
3-deazaneplanocin-A	Nc1nccc2n(cnc12)[C@@H]1C=C(CO)[C@@H](O)[C@H]1O |t:13|	Preclinical	EZH2	histone lysine methyltransferase inhibitor		
3-deazauridine	OC[C@H]1O[C@@H]([C@@H](O)[C@@H]1O)n1ccc(O)cc1=O |&1:2	Preclinical		cytidine deaminase inhibitor		
3-hydroxy-3-phenylpentanamide	CC[C@@](O)(CC(N)=O)c1ccccc1 |&1:2	Phase 1		GABA receptor modulator		
3-indolebutyric-acid	OC(=O)CCCc1c[nH]c2ccccc12	Preclinical	B2M|HLA-A|TRAC|TRBC1			
3-MATIDA	Cc1cc(sc1[C@@H](N)C(O)=O)C(O)=O |&1:6	Preclinical	GRM1	glutamate receptor antagonist		
3-methyl-GABA	C[C@@H](CN)CC(O)=O |&1:1|	Preclinical	ABAT	GABA aminotransferase activator		
3-methyladenine	Cn1cnc(=N)c2[nH]cnc12	Preclinical	PI3	PI3K inhibitor		
3-MPPI	COc1ccccc1N1CCN(CCn2c(=O)[nH]c3c4ccccc4[nH]c3c2=O)CC1	Preclinical	ADRA1A	adrenergic receptor ligand		
3PO	O=C(\C=C\c1cccnc1)c1ccncc1	Preclinical	PFKFB3	phosphofructokinase inhibitor		
4,4'-DDT	Clc1ccc(cc1)C(c1ccc(Cl)cc1)C(Cl)(Cl)Cl	Preclinical				
4,4-pentamethylenepiperidine	C1CCC2(CC1)CCNCC2	Preclinical		M2 channel blocker		
4,5,6,7-tetrabromobenzotriazole	Brc1c(Br)c(Br)c2n[nH]nc2c1Br	Preclinical	AKT1|CHEK1|CSNK2A1|GSK3B|LCK|MAP2K1|MAPK1|MAPK11|MAPK12|MAPK14|MAPK8|PRKCA|ROCK1|RPS6KB1|SGK1	casein kinase inhibitor		
4-(aminomethyl)benzoic-acid	NCc1ccc(cc1)C(O)=O	Preclinical		hemostatic agent		
4-(4-fluorobenzoyl)-1-(4-phenylbutyl)-piperidine	Fc1ccc(cc1)C(=O)C1CCN(CCCCc2ccccc2)CC1	Preclinical	HTR2A	serotonin receptor antagonist		
4-acetyl-1,1-dimethylpiperazinium	CC(=O)N1CC[N+](C)(C)CC1	Preclinical		acetylcholine receptor agonist		
4-aminohippuric-acid	Nc1ccc(cc1)C(=O)NCC(O)=O	Launched	SLC22A6		nephrology	renal diagnostic agent
4-carboxy-3-hydroxyphenylglycine-(RS)	N[C@@H](C(O)=O)c1ccc(C(O)=O)c(O)c1 |&1:1	Preclinical	GRM1	glutamate receptor agonist, glutamate receptor antagonist		
4-carboxy-3-hydroxyphenylglycine-(S)	N[C@H](C(O)=O)c1ccc(C(O)=O)c(O)c1	Preclinical	GRM1|GRM2	glutamate receptor agonist, glutamate receptor antagonist		
4-chlorophenylguanidine	NC(=N)Nc1ccc(Cl)cc1	Preclinical	PLAUR	urokinase inhibitor		
4-CMTB	CC(C)[C@@H](C(=O)Nc1nccs1)c1ccc(Cl)cc1 |&1:3	Preclinical	FFAR2	free fatty acid receptor agonist		
4-DAMP	C[N+]1(C)CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4|CHRM5	cholinergic receptor antagonist		
4-galactosyllactose	OC[C@H]1O[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O |a:2	Preclinical				
4-HQN	O=c1nc[nH]c2ccccc12	Preclinical	PARP1	PARP inhibitor		
4-hydroxy-phenazone	Cc1c(O)c(=O)n(-c2ccccc2)n1C	Preclinical				
4-IBP	Ic1ccc(cc1)C(=O)NC1CCN(Cc2ccccc2)CC1	Preclinical	SIGMAR1	sigma receptor agonist		
4-iodo-L-phenylalanine	N[C@H](Cc1ccc(I)cc1)C(O)=O	Preclinical	DPP4			
4-iodo-6-phenylpyrimidine	Ic1cc(ncn1)-c1ccccc1	Preclinical	MIF	macrophage migration inhibiting factor inhibitor		
4-methylgenistein	COc1ccc(cc1)-c1coc2cc(O)cc(O)c2c1=O	Preclinical	CYP19A1|ESRRA|ESRRB|ESRRG|FASN	protein tyrosine kinase inhibitor		
4-methylhistamine	Cc1nc[nH]c1CCN	Preclinical	HRH4	histamine receptor agonist		
4-mu-8C	Cc1cc(=O)oc2c(C=O)c(O)ccc12	Preclinical	ERN1	IRE1 inhibitor		
4-P-PDOT	CCC(=O)N[C@H]1C[C@@H](c2ccccc2)c2ccccc2C1 |&1:5	Preclinical	MTNR1A|MTNR1B	melatonin receptor antagonist		
4-phenolsulfonic-acid	Oc1ccc(cc1)S(O)(=O)=O	Preclinical				
4-phenyl-1,2,3,4-tetrahydroisoquinoline	C1NCc2ccccc2[C@@H]1c1ccccc1 |&1:9	Preclinical		dopamine release inhibitor		
4-PPBP	C(CCc1ccccc1)CN1CCC(CC1)c1ccccc1	Preclinical	SIGMAR1	sigma receptor ligand		
4-propylbenzoic-acid	CCCc1ccc(cc1)C(O)=O	Preclinical				
4-pyrimidinecarbonitrile	N#Cc1ccncn1	Preclinical				
4-tert-butylphenol	CC(C)(C)c1ccc(O)cc1	Preclinical				
4BP-TQS	NS(=O)(=O)c1ccc2N[C@@H]([C@H]3CC=C[C@@H]3c2c1)c1ccc(Br)cc1 |&1:9	Preclinical	CHRNA7	nicotinic receptor agonist		
4EGI-1	OC(=O)C(Cc1ccccc1[N+]([O-])=O)=NNc1nc(cs1)-c1ccc(Cl)c(Cl)c1	Preclinical	EIF4E	protein synthesis inhibitor		
4E1RCat	OC(=O)c1ccc(cc1)N1C(=O)\C(=C\c2ccc(o2)-c2ccc(cc2)[N+]([O-])=O)C=C1c1ccccc1 |c:31|	Preclinical	EIF4E|EIF4G1	protein synthesis inhibitor		
4SC-202	Cn1cc(cn1)-c1ccc(cc1)S(=O)(=O)n1ccc(\C=C\C(=O)Nc2ccccc2N)c1	Phase 1	HDAC1	HDAC inhibitor		
5'-chloro-5'-deoxy-ENBA-(+/-)	O[C@@H]1[C@@H](CCl)O[C@H]([C@@H]1O)n1cnc2c(N[C@H]3C[C@@H]4CC[C@H]3C4)ncnc12 |a:1	Preclinical	ADORA1	adenosine receptor agonist		
5,7-dichlorokynurenic-acid	OC(=O)c1cc(=O)c2c(Cl)cc(Cl)cc2[nH]1	Preclinical	GLRA2|GRIN1|GRIN2A|GRIN2B|GRIN2C|GRIN2D	glutamate receptor antagonist		
5-(4chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one	CCn1c(n[nH]c1=O)-c1ccc(Cl)cc1	Preclinical				
5-amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione	Nc1nc(=O)c2sc(=O)n([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2[nH]1	Preclinical	TLR7			
5-aminolevulinic-acid	NCC(=O)CCC(O)=O	Launched	ALAD	oxidizing agent	oncology, dermatology	glioma, actinic keratosis (AK)
5-BDBD	Brc1cccc(c1)C1=NCC(=O)Nc2c1oc1ccccc21 |t:8|	Preclinical	P2RX4	purinergic receptor antagonist		
5-carboxamidotryptamine	NCCc1c[nH]c2ccc(cc12)C(N)=O	Preclinical	HTR1A|HTR1B|HTR1D|HTR1E|HTR1F|HTR2A|HTR2B|HTR2C|HTR5A|HTR6|HTR7	serotonin receptor agonist		
5-fluoro-3-pyridyl-methanol	OCc1cncc(F)c1	Preclinical				
5-fluoropyrimidine	Fc1cncnc1	Phase 3		kinase inhibitor		
5-fluorouracil	Fc1c[nH]c(=O)[nH]c1=O	Launched	DPYD|TYMS	thymidylate synthase inhibitor	oncology	colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma
5-FP	Fc1cnc(=O)[nH]c1	Phase 1	TYMS	thymidylate synthase inhibitor		
5-HMF	OCc1ccc(C=O)o1	Phase 2				
5-hydroxydecanoic-acid	CCCCC[C@@H](O)CCCC(O)=O |&1:5|	Preclinical				
5-hydroxyectoine	CC1=NC[C@H](O)[C@H](N1)C(O)=O |t:1|	Preclinical				
5-hydroxymethyl-tolterodine	CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1O)C(C)C	Phase 1	CHRM3	acetylcholine receptor antagonist		
5-hydroxytryptophan	N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(O)=O |&1:1	Launched	SLC36A1|SLC36A2	neurotransmitter	neurology/psychiatry	insomnia
5-iodo-A-85380	Ic1cncc(OC[C@@H]2CCN2)c1	Phase 2		acetylcholine receptor agonist		
5-methylfurmethiodide	Cc1ccc(C[N+](C)(C)C)o1	Preclinical	CHRM1|CHRM2|CHRM3|CHRM4	acetylcholine receptor agonist		
5-methylhydantoin-(D)	C[C@H]1NC(=O)NC1=O	Preclinical				
5-methylhydantoin-(L)	C[C@@H]1NC(=O)NC1=O	Preclinical				
5-octanoylsalicylic-acid	CCCCCCCC(=O)c1ccc(O)c(c1)C(O)=O	Preclinical		protein kinase activator		
6,7-dehydro-17-acetoxy-progesterone	CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O |c:9	Preclinical		steroidal progestin		
6-aminochrysene	Nc1cc2c3ccccc3ccc2c2ccccc12	Phase 2		transferase inhibitor		
6-aminopenicillanic-acid	CC1(C)S[C@@H]2[C@H](N)C(=O)N2[C@H]1C(O)=O	Preclinical				
6-benzylaminopurine	C(Nc1ncnc2nc[nH]c12)c1ccccc1	Preclinical		purinergic receptor activator		
6-chloromelatonin	COc1cc2c(CCNC(C)=O)c[nH]c2cc1Cl	Preclinical	MTNR1A|MTNR1B	melatonin receptor agonist		
6-diazo-5-oxo-L-norleucine	N[C@@H](CCC(=O)C[N+]#N)C(O)=O	Preclinical		glutamate receptor antagonist, glutaminase inhibitor		
6-iodo-nordihydrocapsaicin	CCCCCCCCC(=O)NCc1cc(OC)c(O)cc1I	Preclinical	TRPV1	TRPV antagonist		
7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one	O=C1N2CCCCC=C2Nc2ccccc12 |c:7|	Preclinical				
7-aminocephalosporanic-acid	CC(=O)OCC1=C(N2[C@H](SC1)[C@H](N)C2=O)C(O)=O |t:5|	Preclinical		beta lactamase inhibitor		
7-chlorokynurenic-acid	OC(=O)c1cc(=O)c2ccc(Cl)cc2[nH]1	Preclinical	GRIN1|GRIN2A|GRIN2B|GRIN2C	glutamate receptor antagonist		
7-hydroxy-DPAT	CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1 |&1:7|	Preclinical	DRD2|DRD3	dopamine receptor agonist		
7-hydroxy-PIPAT	CCCN(C\C=C\I)[C@H]1CCc2ccc(O)cc2C1 |&1:8|	Preclinical	DRD3	dopamine receptor ligand		
7-hydroxystaurosporine	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4[C@H](O)NC(=O)c4c4c5ccccc5n2c4c13	Phase 2	CDK1|CHEK1|CHEK2|GSK3B|LCK|MAPK14|MARK1|MARK3|PDPK1|PRKCA|PRKCB|PRKCD|PRKCE|PRKCG	CDK inhibitor, CHK inhibitor, PKC inhibitor		
7-keto-DHEA	CC(=O)O[C@H]1CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CCC4=O)[C@@H]3C(=O)C=C2C1 |c:24|	Launched		steroid		
7-methoxytacrine	COc1ccc2nc3CCCCc3c(N)c2c1	Phase 2	ACHE	acetylcholinesterase inhibitor		
7-methylxanthine	Cn1cnc2[nH]c(=O)[nH]c(=O)c12	Phase 2		adenosine receptor antagonist		
7-nitroindazole	[O-][N+](=O)c1cccc2c[nH]nc12	Preclinical	NOS1|NOS2|NOS3	nitric oxide synthase inhibitor		
8-bromo-cAMP	Nc1ncnc2n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c(Br)nc12 |a:7	Preclinical		PKA activator		
8-bromo-cGMP	Nc1nc(=O)c2nc(Br)n([C@@H]3O[C@@H]4CO[P@](O)(=O)O[C@H]4[C@H]3O)c2[nH]1 |a:10	Preclinical	PRKG1	PKA activator		
8-hydroxy-DPAT	CCCN(CCC)[C@H]1CCc2cccc(O)c2C1 |&1:7|	Preclinical	HTR5A|HTR7	serotonin receptor agonist		
8-hydroxy-PIPAT	CCCN(C\C=C\I)[C@H]1CCc2cccc(O)c2C1 |&1:8|	Preclinical	DRD2|DRD3	dopamine receptor ligand		
8-M-PDOT	CCC(=O)N[C@H]1CCc2cccc(OC)c2C1 |&1:5	Preclinical	MTNR1A|MTNR1B	melatonin receptor agonist		
80841-78-7	Cc1oc(=O)oc1CCl	Preclinical				
9-aminoacridine	Nc1c2ccccc2nc2ccccc12	Preclinical				
9-aminocamptothecin	CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc(N)c4cc3Cn1c2=O	Phase 2	TOP1	topoisomerase inhibitor		
9-anthracenecarboxylic-acid	OC(=O)c1c2ccccc2cc2ccccc12	Preclinical	ANO1|CLCN1			
